PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Nightingale, SL				Nightingale, SL			Nicotine nasal spray approved for smoking cessation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1224	1224		10.1001/jama.275.16.1224	http://dx.doi.org/10.1001/jama.275.16.1224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF478	8601942				2022-12-28	WOS:A1996UF47800007
J	Hannah, ME; Ohlsson, A; Farine, D; Hewson, SA; Hodnett, ED; Myhr, TL; Wang, EEL; Weston, JA; Willan, AR				Hannah, ME; Ohlsson, A; Farine, D; Hewson, SA; Hodnett, ED; Myhr, TL; Wang, EEL; Weston, JA; Willan, AR			Induction of labor compared with expectant management for prelabor rupture of the membranes at term	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREMATURE RUPTURE; UNFAVORABLE CERVIX; PREGNANCY	Background. As the interval between rupture of the fetal membranes at term and delivery increases, so may the risk of fetal and maternal infection. It is not known whether inducing labor will reduce this risk or whether one method of induction is better than another. Methods. We studied 5041 women with prelabor rupture of the membranes at term. The women were randomly assigned to induction of labor with intravenous oxytocin; induction of labor with vaginal prostaglandin E(2) gel; or expectant management for up to four days, with labor induced with either intravenous oxytocin or vaginal prostaglandin E(2) gel if complications developed. The primary outcome was neonatal infection. Secondary outcomes were the need for cesarean section and women's evaluations of their treatment. Results. The rates of neonatal infection and cesarean section were not significantly different among the study groups. The rates of neonatal infection were 2.0 percent for the induction-with-oxytocin group, 3.0 percent for the induction-with-prostaglandin group, 2.8 percent for the expectant-management (oxytocin) group, and 2.7 percent for the expectant-management (prostaglandin) group. The rates of cesarean section ranged from 9.6 to 10.9 percent. Clinical chorioamnionitis was less likely to develop in the women in the induction-with-oxytocin group than in those in the expectant-management (oxytocin) group (4.0 percent vs. 8.6 percent, P<0.001), as was postpartum fever (1.9 percent vs. 3.6 percent, P=0.008). Women in the induction groups were less likely to say they liked ''nothing'' about their treatment than those in the expectant-management groups. Conclusions. In women with prelabor rupture of the membranes at term, induction of labor with oxytocin or prostaglandin E(2) and expectant management result in similar rates of neonatal infection and cesarean section. Induction of labor with intravenous oxytocin results in a lower risk of maternal infection than does expectant management. Women view induction of labor more positively than expectant management.	UNIV TORONTO,DEPT OBSTET & GYNAECOL,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PAEDIAT,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,FAC NURSING,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,WOMENS COLL HOSP,PERINATAL CLIN EPIDEMIOL UNIT,TORONTO,ON M5G 1N8,CANADA; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON,ON,CANADA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; McMaster University								CONWAY DI, 1984, AM J OBSTET GYNECOL, V150, P947, DOI 10.1016/0002-9378(84)90388-0; DUFF P, 1984, OBSTET GYNECOL, V63, P697; FAYEZ JA, 1978, OBSTET GYNECOL, V52, P17; Grant J, 1989, EFFECTIVE CARE PREGN, V2, P1112; GRANT JM, 1992, BRIT J OBSTET GYNAEC, V99, P557, DOI 10.1111/j.1471-0528.1992.tb13820.x; GUNN GC, 1970, AM J OBSTET GYNECOL, V106, P469, DOI 10.1016/0002-9378(70)90378-9; HANNAH ME, 1993, COCHRANE PREGNANCY C; HAUTH JC, 1977, OBSTET GYNECOL, V49, P523; MANROE BL, 1979, J PEDIATR-US, V95, P89, DOI 10.1016/S0022-3476(79)80096-7; MEINERT CL, 1986, MONOGRAPHS EPIDEMIOL, V8, P208; MORALES WJ, 1986, SOUTHERN MED J, V79, P955, DOI 10.1097/00007611-198608000-00010; Rydhstrom H, 1991, Acta Obstet Gynecol Scand, V70, P543, DOI 10.3109/00016349109007914; VANDERWALT D, 1989, S AFR MED J, V75, P54; WAGNER MV, 1989, OBSTET GYNECOL, V74, P93; ZAR JH, 1974, BIOSTAT ANAL, P59	15	281	299	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1996	334	16					1005	1010		10.1056/NEJM199604183341601	http://dx.doi.org/10.1056/NEJM199604183341601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE733	8598837				2022-12-28	WOS:A1996UE73300001
J	Wechsler, H; Levine, S; Idelson, RK; Schor, EL; Coakley, E				Wechsler, H; Levine, S; Idelson, RK; Schor, EL; Coakley, E			The physician's role in health promotion revisited - A survey of primary care practitioners	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									IOWA DEPT PUBL HLTH,DES MOINES,IA 50319		Wechsler, H (corresponding author), HARVARD UNIV,SCH PUBL HLTH,665 HUNTINGTON AVE,BOSTON,MA 02115, USA.							*US DHEW, 1979, DHEW PUBLICATION; WECHSLER H, 1983, NEW ENGL J MED, V308, P97, DOI 10.1056/NEJM198301133080211	2	132	132	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1996	334	15					996	998		10.1056/NEJM199604113341519	http://dx.doi.org/10.1056/NEJM199604113341519			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD596	8596615				2022-12-28	WOS:A1996UD59600034
J	Savin, VJ; Sharma, R; Sharma, M; McCarthy, ET; Swan, SK; Ellis, E; Lovell, H; Warady, B; Gunwar, S; Chonko, AM; Artero, M; Vincenti, F; Fine, R; Wood, E; Trachtman, H				Savin, VJ; Sharma, R; Sharma, M; McCarthy, ET; Swan, SK; Ellis, E; Lovell, H; Warady, B; Gunwar, S; Chonko, AM; Artero, M; Vincenti, F; Fine, R; Wood, E; Trachtman, H			Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHANGE NEPHROTIC SYNDROME; ISOLATED RAT GLOMERULI; RENAL-TRANSPLANTATION; LYMPHOCYTE-T; CHILDREN; SCLEROSIS; PLASMA; PROTEINURIA; ALLOGRAFTS; LESION	Background, Heavy proteinuria and progressive renal injury recur after transplantation in up to 40 percent of patients with renal failure caused by idiopathic focal segmental glomerulosclerosis. A circulating factor may be responsible for this recurrence. Methods. To determine whether patients with focal segmental glomerulosclerosis have a circulating factor capable of causing glomerular injury, we tested serum samples from 100 patients with the disorder in an in vitro assay of glomerular permeability to albumin. Of the 56 patients who had undergone renal transplantation, 33 had recurrences, Sixty-four patients, many of whom had undergone transplantation, were being treated with dialysis. Thirty-one patients with other renal diseases and nine normal subjects were also studied, Results. The 33 patients with recurrent focal segmental glomerulosclerosis after transplantation had a higher mean (+/-SE) value for permeability to albumin (0.47+/-0.06) than the normal subjects (0.06+/-0.07) or the patients who did not have recurrences (0.14+/-0.06), After plasmapheresis in six patients with recurrences, the permeability was reduced (from 0.79+/-0.06 to 0.10+/-0.05, P=0.008), and proteinuria was significantly decreased, Patients with corticosteroid-sensitive nephrotic syndrome or with membranous nephropathy after transplantation had low levels of serum activity. The circulating factor bound to protein A and hydrophobic-interaction columns and had an apparent molecular mass of about 50 kd. Conclusions, A circulating factor found in some patients with focal segmental glomerulosclerosis is associated with recurrent disease after renal transplantation and may be responsible for initiating the renal injury.	MED COLL WISCONSIN, DEPT MED, MILWAUKEE, WI 53226 USA; HENNEPIN CTY MED CTR, DEPT MED, MINNEAPOLIS, MN USA; ARKANSAS CHILDRENS HOSP, LITTLE ROCK, AR 72202 USA; UNIV NEBRASKA, MED CTR, DEPT PEDIAT, OMAHA, NE USA; CHILDRENS MERCY HOSP, KANSAS CITY, KS USA; UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, KANSAS CITY, KS 66103 USA; UNIV KANSAS, MED CTR, DEPT MED, KANSAS CITY, KS 66103 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA USA	Medical College of Wisconsin; Hennepin County Medical Center; Arkansas Children's Hospital; University of Nebraska System; University of Nebraska Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of California System; University of California San Francisco			Trachtman, Howard/GSE-2340-2022		NIDDK NIH HHS [DK 22040] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK022040] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARTERO M, 1992, AM J MED, V92, P375, DOI 10.1016/0002-9343(92)90267-F; ARTERO ML, 1994, AM J KIDNEY DIS, V23, P574, DOI 10.1016/S0272-6386(12)80381-7; BAKKER WW, 1986, KIDNEY INT, V30, P633; COCHAT P, 1993, PEDIATR NEPHROL, V7, P50, DOI 10.1007/BF00861567; DANTAL J, 1994, NEW ENGL J MED, V330, P7, DOI 10.1056/NEJM199401063300102; DILEEPAN KN, 1993, J LAB CLIN MED, V121, P797; HESLAN JM, 1986, NEPHRON, V42, P187, DOI 10.1159/000183664; HOYER JR, 1972, LANCET, V2, P343; INGULLI E, 1991, PEDIATR NEPHROL, V5, P393, DOI 10.1007/BF01453661; INGULLI E, 1991, TRANSPLANTATION, V51, P401, DOI 10.1097/00007890-199102000-00025; JONES JMB, 1983, CLIN NEPHROL, V20, P72; KOYAMA A, 1991, KIDNEY INT, V40, P453, DOI 10.1038/ki.1991.232; LAGRUE G, 1975, BIOMED EXPRESS, V23, P73; LAUFER J, 1988, TRANSPLANTATION, V46, P540, DOI 10.1097/00007890-198810000-00014; LEWIS EJ, 1982, KIDNEY INT, V22, P315, DOI 10.1038/ki.1982.173; LI JZ, 1994, KIDNEY INT, V46, P1025, DOI 10.1038/ki.1994.363; MALEKZADEH MH, 1979, J PEDIATR-US, V95, P249; MENDOZA SA, 1992, J AM SOC NEPHROL, V3, P889; MORALES JM, 1989, NEPHRON, V53, P283, DOI 10.1159/000185762; MORALES JM, 1988, NEPHRON, V48, P241, DOI 10.1159/000184924; SAVIN VJ, 1994, KIDNEY INT, V46, P382, DOI 10.1038/ki.1994.285; SAVIN VJ, 1981, KIDNEY INT, V20, P188, DOI 10.1038/ki.1981.121; SAVIN VJ, 1992, J AM SOC NEPHROL, V3, P1260; SAVIN VJ, 1993, AM J KIDNEY DIS, V21, P347, DOI 10.1016/S0272-6386(12)80260-5; SENGGUTUVAN P, 1990, PEDIATR NEPHROL, V4, P21, DOI 10.1007/BF00858431; SHALHOUB RJ, 1974, LANCET, V2, P556; SWAN SK, 1991, CLIN TRANSPLANT, V5, P90; TEJANI A, 1988, KIDNEY INT, V33, P729, DOI 10.1038/ki.1988.59; Tejani Amir, 1993, Journal of the American Society of Nephrology, V4, P289; TIBOR N, 1994, RENAL PAHTOLOGY CLIN, P330; TIEBOSCH ATMG, 1987, KIDNEY INT, V32, P112, DOI 10.1038/ki.1987.179; TOMIZAWA S, 1985, NEPHRON, V41, P157, DOI 10.1159/000183572; TRACHTMAN H, 1987, AM J NEPHROL, V7, P13, DOI 10.1159/000167422; VERANI RR, 1986, AM J NEPHROL, V6, P263, DOI 10.1159/000167173; WILKINSON AH, 1989, CLIN SCI, V77, P43, DOI 10.1042/cs0770043; WINETZ JA, 1981, AM J KIDNEY DIS, V1, P91, DOI 10.1016/S0272-6386(81)80035-2; Work T.S., 1969, LAB TECHNIQUES BIOCH; YOSHIZAWA N, 1989, NEPHRON, V51, P370, DOI 10.1159/000185325; ZIMMERMAN SW, 1985, NEPHRON, V40, P241, DOI 10.1159/000183469; ZIMMERMAN SW, 1984, CLIN NEPHROL, V22, P32	40	570	581	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	1996	334	14					878	883		10.1056/NEJM199604043341402	http://dx.doi.org/10.1056/NEJM199604043341402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD374	8596570	Bronze			2022-12-28	WOS:A1996UD37400002
J	Murphy, EL; Bryzman, S; Williams, AE; CoChien, H; Schreiber, GB; Ownby, HE; Gilcher, RO; Kleinman, SH; Matijas, L; Thomson, RA; Nemo, GJ				Murphy, EL; Bryzman, S; Williams, AE; CoChien, H; Schreiber, GB; Ownby, HE; Gilcher, RO; Kleinman, SH; Matijas, L; Thomson, RA; Nemo, GJ			Demographic determinants of hepatitis C virus seroprevalence among blood donors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; UNITED-STATES; INFECTION; ANTIBODIES; ASSOCIATION; SEROEPIDEMIOLOGY; EPIDEMIOLOGY; PREVALENCE; VIREMIA; DISEASE	Objective.-To measure demographic determinants of hepatitis C virus (HCV) seroprevalence among blood donors in the United States. Design.-Cross-sectional epidemiological study. Setting.-Five blood centers in different regions of the United States. Subjects.-A total of 862 398 consecutive volunteer blood donors with one or more nonautologous donations from March 1992 through December 1993. Methods.-Demographic data collection, serological screening with second-generation anti-HCV enzyme immunoassay, and confirmation with anti-HCV recombinant immunoblot. Results.-There were 3126 donors with at least one blood donation confirmed HCV-seropositive, for a crude prevalence of 3.6 per 1000. Age-specific HCV seroprevalence rose from 0.5 per 1000 in donors younger than 20 years to a maximum of 6.9 per 1000 in donors aged 30 to 39 years and declined in older age groups. There was interaction between age and educational attainment, with 30- to 49-year-olds with less than a high school diploma at highest risk of HCV infection (odds ratio [OR], 33.0; 95% confidence interval [CI], 23.0 to 47.2 compared with those younger than 30 years with a bachelor's degree or higher degree), Other independent risk factors for HCV seropositivity included male sex (OR, 1.9, 95% CI, 1.8 to 2.1), black race (OR, 1.7, 95% CI, 1.6 to 1.9), Hispanic ethnicity (OR, 1.3, 95% CI, 1.1 to 1.5), previous blood transfusion (OR, 2.8; 95% CI, 2.5 to 3.1), and first/only time donor status (OR, 4.2; 95% CI, 3.9 to 4.5, compared with repeat donors), Seropositivity for human T-lymphotropic virus types I and II, human immunodeficiency virus, or hepatitis B core antigen was highly associated with HCV seropositivity (OR, 10.4; 95% CI, 9.6 to 11.4 for one vs no marker). Conclusions.-Despite a low overall HCV prevalence in blood donors in the United States, there is marked variation in HCV seroprevalence by demographic subgroup, even after controlling for prior blood transfusion, a recognized risk factor for HCV. Further study of the prevalence of other parenteral risk factors such as past injection drug use among blood donors is needed.	HIGHLAND GEN HOSP,OAKLAND,CA; AMER RED CROSS,JEROME H HOLLAND LAB,ROCKVILLE,MD; WESTAT CORP,ROCKVILLE,MD; AMER RED CROSS,BLOOD SERV,DETROIT,MI; OKLAHOMA BLOOD INST,OKLAHOMA CITY,OK; UNIV CALIF LOS ANGELES,BLOOD & PLATELET CTR,LOS ANGELES,CA 90024; NHLBI,BETHESDA,MD 20892	American Red Cross; Westat; American Red Cross; University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Murphy, EL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT LAB MED,BOX 0884,SAN FRANCISCO,CA 94143, USA.				DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097078, N01HB097077, N01HB097079] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HB-97077, N01-HB-97079, N01-HB-97078] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AACH RD, 1991, NEW ENGL J MED, V325, P1328; ABDELAAL M, 1994, TRANSFUSION, V34, P135, DOI 10.1046/j.1537-2995.1994.34294143941.x; ALTER HJ, 1991, ANN INTERN MED, V115, P644, DOI 10.7326/0003-4819-115-8-644; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ARCHER GT, 1992, MED J AUSTRALIA, V157, P225, DOI 10.5694/j.1326-5377.1992.tb137122.x; CHIARAMONTE M, 1991, ITAL J GASTROENTEROL, V23, P555; *CTR BIOL EV RES, 1992, MEM REG BLOOD EST RE; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; ESTEBAN JI, 1989, LANCET, V2, P294; ESTEBAN R, 1993, J HEPATOL, V17, pS67, DOI 10.1016/S0168-8278(05)80427-1; GARSON JA, 1992, VOX SANG, V62, P218, DOI 10.1111/j.1423-0410.1992.tb01202.x; HOLSEN DS, 1993, EUR J CLIN MICROBIOL, V12, P673, DOI 10.1007/BF02009378; KALDOR JM, 1992, MED J AUSTRALIA, V157, P227, DOI 10.5694/j.1326-5377.1992.tb137123.x; KELEN GD, 1992, NEW ENGL J MED, V326, P1399, DOI 10.1056/NEJM199205213262105; KHAN M, 1993, GASTROENTEROL JPN, V28, P28, DOI 10.1007/BF02989200; LAI ME, 1993, J MED VIROL, V41, P282, DOI 10.1002/jmv.1890410405; LEE SD, 1991, HEPATOLOGY, V13, P830, DOI 10.1016/0270-9139(91)90249-U; LIN CK, 1992, VOX SANG, V62, P98, DOI 10.1111/j.1423-0410.1992.tb01178.x; MELE A, 1994, AM J PUBLIC HEALTH, V84, P1640, DOI 10.2105/AJPH.84.10.1640; MOORE SB, 1995, TRANSFUSION, V35, P308, DOI 10.1046/j.1537-2995.1995.35495216079.x; NAKAGIRI I, 1993, J CLIN MICROBIOL, V31, P2974, DOI 10.1128/JCM.31.11.2974-2980.1993; NEAL KR, 1994, EPIDEMIOL INFECT, V112, P595, DOI 10.1017/S0950268800051293; OSMOND DH, 1993, JAMA-J AM MED ASSOC, V269, P361, DOI 10.1001/jama.269.3.361; SCHOUB BD, 1992, T ROY SOC TROP MED H, V86, P431, DOI 10.1016/0035-9203(92)90255-B; STEVENS CE, 1990, JAMA-J AM MED ASSOC, V263, P49, DOI 10.1001/jama.263.1.49; THOMAS DL, 1993, ARCH INTERN MED, V153, P1705, DOI 10.1001/archinte.153.14.1705; *US BUR CENS, 1993, 1993 STAT ABSTR US; WATANABE J, 1993, VOX SANG, V65, P199, DOI 10.1111/j.1423-0410.1993.tb02148.x; WEINSTOCK HS, 1993, JAMA-J AM MED ASSOC, V269, P392; WILLIAMS A, 1993, TRANSFUSION, V33, pS59; Zuck TF, 1995, TRANSFUSION, V35, P944, DOI 10.1046/j.1537-2995.1995.351196110900.x	33	99	101	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					995	1000		10.1001/jama.275.13.995	http://dx.doi.org/10.1001/jama.275.13.995			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC123	8596257				2022-12-28	WOS:A1996UC12300026
J	Vladeck, BC				Vladeck, BC			New Medicare physician payment to reflect relative resources	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Vladeck, BC (corresponding author), US HLTH CARE FINANCING ADM,BALTIMORE,MD 21207, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					978	978						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC123	8596243				2022-12-28	WOS:A1996UC12300003
J	Gallagher, RB				Gallagher, RB			Enter Listeria, unruffled	SCIENCE			English	Editorial Material														Gallagher, Richard/0000-0001-5639-2187				Cossart P, 1996, SCIENCE, V271, P315, DOI 10.1126/science.271.5247.315; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3	4	3	3	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1825	1825		10.1126/science.271.5257.1825	http://dx.doi.org/10.1126/science.271.5257.1825			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596949				2022-12-28	WOS:A1996UC77800034
J	Fetters, MD; Fischer, G; Reed, BD				Fetters, MD; Fischer, G; Reed, BD			Effectiveness of vaginal Papanicolaou smear screening after total hysterectomy for benign disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN PAPILLOMAVIRUS INFECTION; PRIMARY INVASIVE-CARCINOMA; CLEAR-CELL ADENOCARCINOMA; INTRAEPITHELIAL NEOPLASIA; CERVICAL-CANCER; NATURAL-HISTORY; RISK FACTOR; INSITU; THERAPY; MALIGNANCIES	Objective.-Using literature review, we assessed (1) Papanicolaou smear screening recommendations after hysterectomy for benign disease, (2) total hysterectomy for benign disease as a risk for vaginal dysplasia dr carcinoma, and (3) effectiveness of screening for vaginal carcinoma after total hysterectomy for benign disease. Data Sources.-We considered (1) organizations' recommendations about screening, (2) references from major textbooks of gynecology, and (3) MEDLINE searches of English-language studies published from 1966 through 1995 using the search strategy (hysterectomy and vaginal smears) or (vaginal smears and vaginal neoplasms). Study Selection.-Published or verbal confirmations of screening recommendations were eligible. Criteria for assessing risk of vaginal dysplasia or carcinoma included original research, documented reports of hysterectomy as an exposure, and evidence of preinvasive vaginal disease or vaginal carcinoma outcomes. We sought data assessing burden of suffering, screening efficacy, and effectiveness of early detection. Data Extraction.-Descriptive and analytic data from each study were abstracted. Data Synthesis.-Screening recommendations were categorized by the organizations' positions: two opposed screening, two supported screening, and six lacked specific guidelines. Data on the risk between total hysterectomy for benign disease and subsequent vaginal carcinoma were organized by study design (three case control, two cohort, and 13 case series) and described. Data on screening effectiveness were organized to address the criteria advocated by the US Preventive Services Task Force. Conclusions.-There are conflicting guidelines on screening after hysterectomy and conflicting data on the risk of vaginal carcinoma after total hysterectomy for benign disease, though the best-designed research suggests no association. There is insufficient evidence to recommend routine vaginal smear screening in women after total hysterectomy for benign disease.			Fetters, MD (corresponding author), UNIV MICHIGAN,DEPT FAMILY PRACTICE,1018 FULLER ST,ANN ARBOR,MI 48109, USA.							AHO M, 1991, CANCER, V68, P195, DOI 10.1002/1097-0142(19910701)68:1<195::AID-CNCR2820680135>3.0.CO;2-L; Alexanian D., 1994, Journal of General Internal Medicine, V9, P84; *AM AC FAM PHYS, 1993, AGE CHARTS PER HLTH; *AM CANC SOC, 1991, CERV CANC DET; *AM COLL OBST GYN, 1995, REC FREQ PAP TEST SC, P152; American Cancer Society, 1991, PAP TEST; Baker H W, 1985, J Ky Med Assoc, V83, P355; BARCLAY DL, 1979, GYNECOL ONCOL, V8, P1, DOI 10.1016/0090-8258(79)90001-5; BELL J, 1984, OBSTET GYNECOL, V64, P699; BENEDET JL, 1984, AM J OBSTET GYNECOL, V148, P695, DOI 10.1016/0002-9378(84)90776-2; BENEDET JL, 1983, OBSTET GYNECOL, V62, P715; BEWTRA C, 1992, DIAGN CYTOPATHOL, V8, P342, DOI 10.1002/dc.2840080406; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BOWENSIMPKINS P, 1975, OBSTET GYNECOL, V46, P360; BRETT KM, 1994, AM J PUBLIC HEALTH, V84, P1653, DOI 10.2105/AJPH.84.10.1653; BRINTON LA, 1990, GYNECOL ONCOL, V38, P49, DOI 10.1016/0090-8258(90)90010-I; BRUDENELL M, 1973, J OBSTET GYN BR COMM, V80, P673; CAMPION MJ, 1987, OBSTET GYN CLIN N AM, V14, P363; CARLSON KJ, 1993, NEW ENGL J MED, V328, P856; CHOO YC, 1982, GYNECOL ONCOL, V14, P125, DOI 10.1016/0090-8258(82)90059-2; CRAMER DW, 1974, AM J OBSTET GYNECOL, V118, P443, DOI 10.1016/S0002-9378(16)33683-3; CZESNIN K, 1978, GYNECOL ONCOL, V6, P309, DOI 10.1016/0090-8258(78)90037-9; DAW E, 1971, J OBSTET GYN BR COMM, V78, P853; DUNCAN I, 1992, GUIDELINES CLIN PRAC; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; EDDY DM, 1991, COMMON SCREENING TES, P255; FAWDRY RDS, 1984, BRIT J OBSTET GYNAEC, V91, P67, DOI 10.1111/j.1471-0528.1984.tb05281.x; FERRIS DG, 1995, J FAM PRACTICE, V40, P81; FINK DJ, 1988, CA-CANCER J CLIN, V38, P127, DOI 10.3322/canjclin.38.2.127; FISCHER G, 1995, J FAM PRACTICE, V41, P16; FRABLE WJ, 1973, ACTA CYTOL, V17, P135; GALLUP DG, 1975, OBSTET GYNECOL, V46, P334; GALLUP DG, 1987, OBSTET GYNECOL, V69, P782; GEMMELL J, 1990, BRIT J OBSTET GYNAEC, V97, P58, DOI 10.1111/j.1471-0528.1990.tb01717.x; GRAVES E, 1992, VITAL HLTH STAT; GRAY LA, 1969, OBSTET GYNECOL, V34, P226; HALPERN J, 1995, J LAW MED ETHICS, V23, P75, DOI 10.1111/j.1748-720X.1995.tb01334.x; HERBST AL, 1970, AM J OBSTET GYNECOL, V106, P210, DOI 10.1016/0002-9378(70)90265-6; HERBST AL, 1986, AM J OBSTET GYNECOL, V154, P814, DOI 10.1016/0002-9378(86)90464-3; HERMAN JM, 1986, JAMA-J AM MED ASSOC, V256, P601, DOI 10.1001/jama.256.5.601; HERNANDEZLINARES W, 1980, OBSTET GYNECOL, V56, P356; HILBORNE LH, 1987, PATHOLOGY VULVA VAGI, P181; HOFFMAN MS, 1989, J REPROD MED, V34, P412; HUMMER WK, 1970, AM J OBSTET GYNECOL, V108, P1109, DOI 10.1016/0002-9378(70)90461-8; IRELAND D, 1988, BRIT J OBSTET GYNAEC, V95, P973, DOI 10.1111/j.1471-0528.1988.tb06499.x; IRWIN KL, 1990, J CLIN EPIDEMIOL, V43, P181, DOI 10.1016/0895-4356(90)90182-O; JIMERSON G K, 1976, Gynecologic Oncology, V4, P328, DOI 10.1016/0090-8258(76)90040-8; KAPP DS, 1982, GYNECOL ONCOL, V14, P271; KAU TY, 1994, RQ94350 MICH CANC F; Kvale K M, 1994, Wis Med J, V93, P275; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEE NC, 1984, AM J OBSTET GYNECOL, V150, P283, DOI 10.1016/S0002-9378(84)90366-1; LEE RA, 1976, OBSTET GYNECOL, V48, P61; Leininger L., 1994, Journal of General Internal Medicine, V9, P88; LENEHAN PM, 1986, OBSTET GYNECOL, V68, P333, DOI 10.1097/00006250-198609000-00008; Mack TM, 1992, GYNECOL ONCOL, P31; MANDELBLATT J, 1986, JAMA-J AM MED ASSOC, V256, P367, DOI 10.1001/jama.256.3.367; MANETTA A, 1990, OBSTET GYNECOL, V76, P639; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; MELNICK S, 1987, NEW ENGL J MED, V316, P514, DOI 10.1056/NEJM198702263160905; MILLER AB, 1991, CAN MED ASSOC J, V145, P1301; MILLER J, 1987, POSTGRAD MED, V82, P205; MILLER JM, 1987, POSTGRAD MED, V82, P200, DOI 10.1080/00325481.1987.11699908; MIYAZAKI K, 1991, OBSTET GYNECOL, V77, P107; MURAD TM, 1975, CANCER, V35, P787, DOI 10.1002/1097-0142(197503)35:3<787::AID-CNCR2820350334>3.0.CO;2-K; MURATA PJ, 1992, J FAM PRACTICE, V35, P644; NAIB ZM, 1966, CANCER, V19, P1026, DOI 10.1002/1097-0142(196607)19:7<1026::AID-CNCR2820190718>3.0.CO;2-#; *NAT CANC I BIOM B, 1975, NCI MON, V41; *NAT CANC I BIOM B, 1981, NCI MON, V57; *NAT HLTH SERV CER, 1993, HLTH SERV GUID NHS M; *NCI, 1991, WHAT YOU NEED KNOW C; Okagaki T, 1984, Pathol Annu, V19 Pt 2, P31; OLIVER JA, 1979, AM J OBSTET GYNECOL, V134, P133, DOI 10.1016/0002-9378(79)90876-7; Perez CA, 1992, PRINCIPLES PRACTICE, P567; PISCITELLI JT, 1995, AM J OBSTET GYNECOL, V173, P424, DOI 10.1016/0002-9378(95)90262-7; POKRAS R, 1988, AM J PUBLIC HEALTH, V78, P852, DOI 10.2105/AJPH.78.7.852; PRIDE GL, 1977, AM J OBSTET GYNECOL, V127, P513, DOI 10.1016/0002-9378(77)90445-8; RAWLS WE, 1976, CANCER RES, V36, P829; RUTLEDGE F, 1967, AM J OBSTET GYNECOL, V97, P635, DOI 10.1016/0002-9378(67)90451-6; SCHIFFER MA, 1972, SURG GYNECOL OBSTET, V134, P653; SCHNEIDER A, 1987, OBSTET GYNECOL, V70, P294; STUART GCE, 1981, AM J OBSTET GYNECOL, V139, P311, DOI 10.1016/0002-9378(81)90016-8; TIMONEN S, 1966, GYNAECOLOGIA, V162, P125, DOI 10.1159/000303007; UNDERWOOD PB, 1971, J AMER MED ASSOC, V217, P46, DOI 10.1001/jama.217.1.46; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P105; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, pR39; Vessey M P, 1989, IARC Sci Publ, P335; WIENER JJ, 1992, BRIT J OBSTET GYNAEC, V99, P907, DOI 10.1111/j.1471-0528.1992.tb14440.x; Williams W C, 1990, Fam Pract Res J, V10, P27; WOODMAN CBJ, 1984, BRIT J OBSTET GYNAEC, V91, P707, DOI 10.1111/j.1471-0528.1984.tb04835.x; 1984, ACOG TECH B, V81, P1	91	40	40	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					940	947		10.1001/jama.275.12.940	http://dx.doi.org/10.1001/jama.275.12.940			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA563	8598623				2022-12-28	WOS:A1996UA56300035
J	Sarzotti, M; Robbins, DS; Hoffman, PM				Sarzotti, M; Robbins, DS; Hoffman, PM			Induction of protective CTL responses in newborn mice by a murine retrovirus	SCIENCE			English	Article							CELL-MEDIATED-IMMUNITY; LEUKEMIA-VIRUS INFECTION; CYTOTOXIC T-CELL; INVIVO; TOLERANCE; LYMPHOCYTES; ONTOGENY; MATURATION; EXPRESSION; PARALYSIS	The susceptibility of neonates to virus-induced disease is thought to reflect, in part, the immaturity of their immune systems. However, inoculation of newborn mice with low doses of Cas-Br-M murine leukemia virus induced a protective cytotoxic T lymphocyte (CTL) response. The inability of neonates to develop a CTL response to high doses of virus was not the result of immunological immaturity but correlated with the induction of a nonprotective type 2 cytokine response. Thus, the initial viral dose is critical in the development of protective immunity in newborns.	UNIV MARYLAND, SCH MED, DEPT MICROBIOL & IMMUNOL, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT NEUROL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Sarzotti, M (corresponding author), VET AFFAIRS MED CTR, RES SERV, 10 N GREENE ST, BALTIMORE, MD 21201 USA.			Hoffman, Paul/0000-0003-2055-6455				ACTOR JK, 1993, P NATL ACAD SCI USA, V90, P948, DOI 10.1073/pnas.90.3.948; ADKINS B, 1994, J IMMUNOL, V153, P3378; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; CHEN NX, 1995, TRANSPLANTATION, V59, P933, DOI 10.1097/00007890-199504150-00002; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; FUCHS EJ, 1996, SCIENCE, V271, P1723; GARDNER MB, 1973, JNCI-J NATL CANCER I, V51, P1243, DOI 10.1093/jnci/51.4.1243; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HOFFMAN PM, 1991, J NEUROIMMUNOL, V33, P157, DOI 10.1016/0165-5728(91)90059-G; HOFFMAN PM, 1984, J VIROL, V52, P734, DOI 10.1128/JVI.52.3.734-738.1984; HOFFMAN PM, 1981, J NEUROIMMUNOL, V1, P275, DOI 10.1016/0165-5728(81)90031-X; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; HULI J, 1989, J IMMUNOL, V142, P800; JAMIESON BD, 1988, P NATL ACAD SCI USA, V85, P2265, DOI 10.1073/pnas.85.7.2265; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Lafferty K J, 1986, Prog Clin Biol Res, V224, P87; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; LU CY, 1980, P NATL ACAD SCI-BIOL, V77, P1597, DOI 10.1073/pnas.77.3.1597; LUKACHER AE, 1984, J EXP MED, V160, P814, DOI 10.1084/jem.160.3.814; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MOSIER DE, 1975, J EXP MED, V141, P216, DOI 10.1084/jem.141.1.216; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; OLIFF A, 1981, BLOOD, V58, P244; OTTEN GR, 1991, SCIENCE, V251, P1228, DOI 10.1126/science.1900952; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; PFEIFFER C, 1991, IMMUNOL REV, V123, P65, DOI 10.1111/j.1600-065X.1991.tb00606.x; PIGUET PF, 1981, J EXP MED, V154, P581, DOI 10.1084/jem.154.3.581; PILARSKI LM, 1977, J EXP MED, V146, P887, DOI 10.1084/jem.146.3.887; POWELL TJ, 1990, J IMMUNOL, V144, P854; ROBBINS DS, 1995, J VIROL, V69, P6847, DOI 10.1128/JVI.69.11.6847-6851.1995; ROBBINS DS, 1991, J NEUROIMMUNOL, V31, P9, DOI 10.1016/0165-5728(91)90081-H; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; SARZOTTI M, 1994, AIDS RES HUM RETROV, V10, P1695, DOI 10.1089/aid.1994.10.1695; SARZOTTI M, 1991, MODERN APPROACHES NE, P355; SARZOTTI M, UNPUB; Sarzotti Marcella, 1993, Viral Immunology, V6, P207, DOI 10.1089/vim.1993.6.207; SCHURMANS S, 1990, J IMMUNOL, V145, P2465; SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x; SPEAR PG, 1974, J EXP MED, V139, P249, DOI 10.1084/jem.139.2.249; ZAMOYSKA R, 1989, EUR J IMMUNOL, V19, P111, DOI 10.1002/eji.1830190118	43	367	376	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 22	1996	271	5256					1726	1728		10.1126/science.271.5256.1726	http://dx.doi.org/10.1126/science.271.5256.1726			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596933				2022-12-28	WOS:A1996UB15100046
J	Pellmyr, O; LeebensMack, J; Huth, CJ				Pellmyr, O; LeebensMack, J; Huth, CJ			Non-mutualistic yucca moths and their evolutionary consequences	NATURE			English	Article							SEQUENCE	Interspecific mutualisms are regarded as having evolved from antagonistic or commensalistic interactions, with most mutualisms remaining facultative but some having coevolved into obligate reciprocal dependency(1-4). Underlying mutualism is an intrinsic conflict between the parties, in that each is under selection for increased exploitation of the other(3-7). Theoretical models suggest that this conflict is a source of evolutionary instability, and that evolution of 'cheating' by one party may lead to reciprocal extinction(4,6,7). Here we present phylogenetic evidence for reversal of an obligate mutualism: within the yucca moth complex, distinct cheater species derived from obligate pollinators inflict a heavy cost on their yucca hosts by laying their eggs but not pollinating the yucca. Phylogenetic data show the cheaters to have existed for a long time. Coexisting pollinators and cheaters are not sister taxa, supporting predictions that evolution of cheating within a single pollinator is evolutionarily unstable. Several lines of evidence support a hypothesis that host shifts preceded the reversal of obligate mutualism. Host or partner shifts is a mechanism that can provide a route of evolutionary escape among obligate mutualists in general.			Pellmyr, O (corresponding author), VANDERBILT UNIV,DEPT BIOL,NASHVILLE,TN 37235, USA.		Leebens-Mack, James/AAF-6770-2019	Leebens-Mack, James/0000-0003-4811-2231				AXELROD R, 1988, SCIENCE, V242, P1385, DOI 10.1126/science.242.4884.1385; BROWN JL, ANN ENTOMOL SOC AM, V87, P795; BULL JJ, 1991, J THEOR BIOL, V149, P63, DOI 10.1016/S0022-5193(05)80072-4; CLARY DO, 1985, J MOL EVOL, V22, P252, DOI 10.1007/BF02099755; DAVIS DR, 1967, US NATIONAL MUSEUM B, V255, P1; Dawkins R, 1989, SELFISH GENE; FEIST MA, 1995, THESIS U CINCINNATI; Felsenstein J., 1993, PHYLOGENETIC INFEREN; GALIL J, 1969, Tijdschrift voor Entomologie, V112, P1; GARGAS A, 1995, SCIENCE, V268, P1492, DOI 10.1126/science.7770775; KEELEY JE, 1986, AM MIDL NAT, V115, P1, DOI 10.2307/2425831; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; MAINERO JS, 1985, BIOL MUTUALISM, P192; MCKELVEY S, 1947, YUCCAS SW US; MILES N J, 1983, Journal of the Lepidopterists' Society, V37, P207; PELLMYR O, 1994, NATURE, V372, P257, DOI 10.1038/372257a0; PELLMYR O, 1992, P NATL ACAD SCI USA, V89, P2927, DOI 10.1073/pnas.89.7.2927; POWELL JA, 1992, TRENDS ECOL EVOL, V7, P10, DOI 10.1016/0169-5347(92)90191-D; RICHTER KS, 1995, NATURE, V376, P557, DOI 10.1038/376557b0; Riley C.V., 1892, ANN REP MO BOT GARD, P99; Riley CV, 1881, P AM ASS ADV SCI, V29, P617; Swofford D.L., 1993, PHYLOGENETIC ANAL US; Thompson JD., 1994, COEVOLUTIONARY PROCE; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; TYRE AJ, 1993, OECOLOGIA, V94, P173, DOI 10.1007/BF00341314; VICKERY WL, 1991, AM NAT, V137, P847, DOI 10.1086/285197; WIEBES JT, 1994, P K NED AKAD WETENSC, V97, P491; Wright S., 1969, THEORY GENE FREQUENC, V2; YAMAUCHI A, 1995, AM NAT, V145, P434, DOI 10.1086/285748	30	152	158	1	109	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					155	156		10.1038/380155a0	http://dx.doi.org/10.1038/380155a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600388				2022-12-28	WOS:A1996TZ97800049
J	Metzker, ML; Lu, J; Gibbs, RA				Metzker, ML; Lu, J; Gibbs, RA			Electrophoretically uniform fluorescent dyes for automated DNA sequencing	SCIENCE			English	Article								A class of dyes, BODIPY fluorophores, has been identified for automated DNA sequencing that has improved spectral characteristics compared with conventional fluorescein and rhodamine dyes. Single and double BODIPY dye primers were characterized in commercially available DNA sequencers and showed uniform electrophoretic mobilities and high fluorescence intensities. The improved physical properties of BODIPY dye primers were demonstrated by direct base-calling from the unprocessed fluorescent signals and improved heterozygote analyses of mixed-base populations. The high sensitivity of BODIPY dye primers requires at least 33 percent less reagent consumed per reaction than conventional dye primers, which should affect the costs of large genome-sequencing efforts.			Metzker, ML (corresponding author), BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030, USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000823, P30HG000210] Funding Source: NIH RePORTER; NHGRI NIH HHS [1 RO1 HG00823, 1 P30 HG00210] Funding Source: Medline; NIAID NIH HHS [AI07483] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHAMBERLAIN JS, 1988, NUCLEIC ACIDS RES, V16, P11141, DOI 10.1093/nar/16.23.11141; FORESTER T, 1965, MODERN QUANTUM CHE 3, P93; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; JU JY, 1995, P NATL ACAD SCI USA, V92, P4347, DOI 10.1073/pnas.92.10.4347; LARDER BA, 1993, NATURE, V365, P671, DOI 10.1038/365671a0; METZKER ML, 1994, NUCLEIC ACIDS RES, V22, P4259, DOI 10.1093/nar/22.20.4259; METZKER ML, 1995, COMPUT APPL BIOSCI, V11, P187; METZKER ML, UNPUB; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339	13	129	147	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1420	1422		10.1126/science.271.5254.1420	http://dx.doi.org/10.1126/science.271.5254.1420			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596915				2022-12-28	WOS:A1996TY96100047
J	Warren, ST				Warren, ST			The expanding world of trinucleotide repeats	SCIENCE			English	Editorial Material							FRAGILE-X-SYNDROME; REGION; DNA		EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322	Emory University; Emory University	Warren, ST (corresponding author), EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,ATLANTA,GA 30322, USA.		Warren, Stephen T/A-2498-2012					Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GACY AM, 1995, CELL, V81, P533; HARDING A, 1984, HEREDITARY ATAXIAS R; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LOYD JE, 1995, AM J RESP CRIT CARE, V152, P93, DOI 10.1164/ajrccm.152.1.7599869; MARKOPOULOU K, 1995, ANN NEUROL, V38, P373, DOI 10.1002/ana.410380306; MCINNIS MG, 1993, AM J HUM GENET, V53, P385; MORRISON AW, 1995, J LARYNGOL OTOL, V109, P499, DOI 10.1017/S0022215100130567; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PETRONIS A, 1995, CLIN NEUROSCI, V3, P76; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WARREN ST, 1995, ANNU REV NEUROSCI, V18, P77, DOI 10.1146/annurev.neuro.18.1.77; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	16	134	198	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1374	1375		10.1126/science.271.5254.1374	http://dx.doi.org/10.1126/science.271.5254.1374			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596908				2022-12-28	WOS:A1996TY96100034
J	Nellen, JFJB; Smulders, YM; Frissen, PHJ; Slaats, EH; Silberbusch, J				Nellen, JFJB; Smulders, YM; Frissen, PHJ; Slaats, EH; Silberbusch, J			Lesson of the week - Hypovitaminosis D in immigrant women: Slow to be diagnosed	BRITISH MEDICAL JOURNAL			English	Article											Nellen, JFJB (corresponding author), ONZE LIEVE VROUW HOSP,DEPT INTERNAL MED,1E OOSTERPARKSTR 279,POB 95500,1090 HM AMSTERDAM,NETHERLANDS.		Smulders, YM/AAG-7506-2021					KRALL EA, 1989, NEW ENGL J MED, V321, P1777, DOI 10.1056/NEJM198912283212602; Parfitt AM, 1990, METABOLIC BONE DIS C, P329; PEACH H, 1983, LANCET, V2, P1347; PEACH H, 1982, J CLIN PATHOL, V35, P625, DOI 10.1136/jcp.35.6.625; PREECE MA, 1973, LANCET, V1, P907; THALASSINOS NC, 1970, BMJ-BRIT MED J, V1, P76, DOI 10.1136/bmj.1.5688.76	6	36	36	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					570	572		10.1136/bmj.312.7030.570	http://dx.doi.org/10.1136/bmj.312.7030.570			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595292	Green Published			2022-12-28	WOS:A1996TY88500036
J	GomezReino, JJ				GomezReino, JJ			Long-term therapy for rheumatoid arthritis	LANCET			English	Editorial Material							CLINICAL-TRIALS				GomezReino, JJ (corresponding author), HOSP UNIV DOCE OCTUBRE,RHEUMATOL RES UNIT,MADRID,SPAIN.		Gomez-Reino, Juan/ABI-2853-2020	Gomez-Reino, Juan/0000-0001-5229-6294				CASH JM, 1994, NEW ENGL J MED, V330, P1368; DELAMATA J, 1995, ANN RHEUM DIS, V54, P881, DOI 10.1136/ard.54.11.881; FELSON DT, 1992, ARTHRITIS RHEUM, V35, P1117, DOI 10.1002/art.1780351003; Hawley D J, 1992, Arthritis Care Res, V5, P130, DOI 10.1002/art.1790050304; HAWLEY DJ, 1991, J RHEUMATOL, V18, P1008; LEIGH JP, 1992, J RHEUMATOL, V19, P1906; PAULUS HE, 1994, J RHEUMATOL, V21, P8; PINCUS T, 1988, J CLIN EPIDEMIOL, V41, P1037, DOI 10.1016/0895-4356(88)90072-8; PINCUS T, 1995, RHEUM DIS CLIN N AM, V21, P619; PORTER DR, 1994, ANN RHEUM DIS, V53, P812, DOI 10.1136/ard.53.12.812; SCOTT DL, 1987, LANCET, V1, P1108; SCOTT DL, 1994, J RHEUMATOL, V21, P36	12	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					343	344		10.1016/S0140-6736(96)90531-0	http://dx.doi.org/10.1016/S0140-6736(96)90531-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598695				2022-12-28	WOS:A1996TU69500003
J	McGovern, PG; Pankow, JS; Shahar, E; Doliszny, KM; Folsom, AR; Blackburn, H; Luepker, RV				McGovern, PG; Pankow, JS; Shahar, E; Doliszny, KM; Folsom, AR; Blackburn, H; Luepker, RV			Recent trends in acute coronary heart disease - Mortality, morbidity, medical care, and risk factors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; SURVIVAL; RATES; CHOLESTEROL; DECLINE; DEATH	Background. Mortality from coronary heart disease (CHD) has declined in the United States since the late 1960s. To understand the reasons for the decline during the period from 1985 to 1990, we examined trends in mortality and morbidity due to CHD, medical care, and risk factors for CHD in a large metropolitan population, Methods. We identified all deaths from CHD in residents of the Minneapolis-St. Paul, Minnesota, metropolitan area who were 30 to 74 years old and classified the deaths according to whether they occurred in or out of the hospital, For 1985 and 1990, we obtained lists of patients in this age range who were discharged with a diagnosis of acute CHD from all area hospitals, and we selected the medical records of 50 percent of these patients for abstraction. Definite myocardial infarctions were identified with a standardized diagnostic algorithm, The 1985 and 1990 cohorts of patients hospitalized for myocardial infarction were followed for at least three years to identify those who died from any cause. Trends in risk factors for CHD were investigated through surveys of 25-to-74-year-olds that were conducted in 1985 through 1987 and 1990 through 1992. Results. Between 1985 and 1990, mortality from CHD fell by 25 percent for both men and women, and the decline in in-hospital mortality (41 percent) exceeded the decline in out-of-hospital mortality (17 percent) among men, The rates of hospitalization for acute myocardial infarction declined slightly, by 5 to 10 percent, between 1985 and 1990. Survival among patients hospitalized for acute myocardial infarction increased substantially during that period. After adjustment for age and previous myocardial infarction, the relative risk of dying within three years of hospitalization for a myocardial infarction (for the 1990 cohort as compared with the 1985 cohort) was 0.76 for men (95 percent confidence interval, 0.65 to 0.89) and 0.84 for women (95 percent confidence interval, 0.71 to 1.00). Substantial increases in the use of thrombolytic therapy, heparin, aspirin, and coronary angioplasty paralleled the survival trends, In general, the risk-factor profile of the area population with respect to CHD also improved considerably during that time, Conclusions. The recent decline in mortality due to CHD in the Minneapolis-St. Paul metropolitan area can be explained by both the declining incidence of myocardial infarction in the population and the improved survival of patients with myocardial infarction.			McGovern, PG (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.			Pankow, James/0000-0001-7076-483X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023727, T32HL007036] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07036, R01-HL-23727] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1988, LANCET, V2, P349; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; ASSAF AR, 1993, NEW ENGL J MED, V329, P931, DOI 10.1056/NEJM199309233291307; BURKE GL, 1991, NEW ENGL J MED, V324, P941, DOI 10.1056/NEJM199104043241402; BURKE GL, 1989, INT J EPIDEMIOL, V18, pS73; BURNAND B, 1992, J CLIN EPIDEMIOL, V45, P929, DOI 10.1016/0895-4356(92)90109-Z; BUTTS WC, 1974, CLIN CHEM, V20, P1344; DELLBORG M, 1994, EUR HEART J, V15, P5, DOI 10.1093/oxfordjournals.eurheartj.a060379; EDLAVITCH SA, 1988, AM J EPIDEMIOL, V127, P1164, DOI 10.1093/oxfordjournals.aje.a114910; EDLAVITCH SA, 1990, J CLIN EPIDEMIOL, V43, P93, DOI 10.1016/0895-4356(90)90061-S; Fibrinolytic Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; FOLSOM AR, 1987, AM J EPIDEMIOL, V125, P1012, DOI 10.1093/oxfordjournals.aje.a114617; FROME EL, 1985, AM J EPIDEMIOL, V121, P309, DOI 10.1093/oxfordjournals.aje.a114001; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GILLUM RF, 1994, J AM COLL CARDIOL, V23, P1273, DOI 10.1016/0735-1097(94)90367-0; GOLDBERG RJ, 1993, CIRCULATION, V87, P1947, DOI 10.1161/01.CIR.87.6.1947; GOMEZMARIN O, 1987, NEW ENGL J MED, V316, P1353, DOI 10.1056/NEJM198705283162201; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; *NAT CTR HLTH STAT, 1990, VITAL HLTH STATISTIC, V13; NAYLOR CD, 1994, J AM COLL CARDIOL, V24, P1431, DOI 10.1016/0735-1097(94)90136-8; PANKOW JS, 1994, J CLIN EPIDEMIOL, V47, P1051, DOI 10.1016/0895-4356(94)90121-X; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; PASHOS CL, 1994, J AM COLL CARDIOL, V23, P1023, DOI 10.1016/0735-1097(94)90585-1; RAPAPORT E, 1988, TRENDS CORONARY HEAR, P221; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; SPRAFKA JM, 1990, AM J EPIDEMIOL, V132, P489, DOI 10.1093/oxfordjournals.aje.a115685; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; TARONE RE, 1981, J CHRON DIS, V34, P463, DOI 10.1016/0021-9681(81)90006-0; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; THOM TJ, 1988, TRENDS CORONARY HEAR, P7; WEISFELDT ML, 1988, TRENDS CORONARY HEAR, P171; World Health Organization, 1980, INT CLASSIFICATION D; 1990, MON VITAL STAT REP S, V41	34	568	587	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	1996	334	14					884	890		10.1056/NEJM199604043341403	http://dx.doi.org/10.1056/NEJM199604043341403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD374	8596571				2022-12-28	WOS:A1996UD37400003
J	Spitz, AM; Velebil, P; Koonin, LM; Strauss, LT; Goodman, KA; Wingo, P; Wilson, JB; Morris, L; Marks, JS				Spitz, AM; Velebil, P; Koonin, LM; Strauss, LT; Goodman, KA; Wingo, P; Wilson, JB; Morris, L; Marks, JS			Pregnancy, abortion, and birth rates among US adolescents - 1980, 1985, and 1990	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To analyze pregnancy, abortion, and birth rates among US adolescent girls in 1980, 1985, and 1990. Design.-Retrospective analysis of trends in data on pregnancies, abortions, and births. Population.-US adolescent girls aged 13 to 19 years. Main Outcome Measures.-Pregnancy, abortion, and birth rates (with and without adjustment for sexual experience) among teenaged girls aged 15 to 19 years and girls under 15 years. Results.-Although pregnancy rates among all teenaged girls 15 to 19 years old remained fairly stable from 1980 to 1985, they increased by 9% during the last half of the decade, totaling 95.9 pregnancies per 1000 teenaged girls 15 to 19 years old by 1990. Because rates of sexual experience increased even faster, pregnancy rates among sexually experienced teens aged 15 to 19 actually declined between 1980 and 1990 by approximately 8%. Abortion rates among these teens remained stable during the 1980s, with 35.8 and 36.0 abortions per 1000 in 1980 and 1990, respectively. As with overall pregnancy rates, abortion rates among these sexually experienced teenaged girls declined during the 1980s. Between 1980 and 1985, birth rates among teenaged girls aged 15 to 19 years declined by 4%, but they increased by 18% during the latter half of the decade, totaling 59.9 births per 1000 in 1980. Among these sexually experienced teenagers, birth rates also declined between 1980 and 1985 and then increased over the next 5 years. In 1990, pregnancies and abortions among girls younger than 15 years accounted for only 3% of all adolescent pregnancies and abortions. However, the number of births among these younger adolescents increased by 15% over the decade. In that age group, trends in pregnancy, abortion, and birth rates over the decade were similar to those for older teens, However, during the late 1980s, the abortion rate declined and the pregnancy rate remained stable, resulting in a 26% increase in the birth rate. Conclusions.-Despite efforts to reduce adolescent pregnancy in the United States, pregnancy and birth rates for that group continue to be the highest among developed countries. Considering that 95% of adolescent pregnancies are unintended, increased efforts to prevent these pregnancies are warranted.	NATL CTR HLTH STAT, DIV VITAL STAT, HYATTSVILLE, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Spitz, AM (corresponding author), CTR DIS CONTROL & PREVENT, DIV REPROD HLTH, NATL CTR CHRON DIS PREVENT & HLTH PROMOT, ATLANTA, GA 30341 USA.							*A GUTTM I, 1994, SEX AM TEEN; ATRASH HK, 1990, CONT OB GYN, V35, P58; Brown S., 1995, BEST INTENTIONS; Burt M R, 1990, Adv Adolesc Mental Health, V4, P265; *CDC, 1983, AB SURV 1979 1980; DICLEMENTE RJ, 1992, PEDIATRICS, V89, P197; FRASER AM, 1995, NEW ENGL J MED, V332, P1113, DOI 10.1056/NEJM199504273321701; FROST JJ, 1995, FAM PLANN PERSPECT, V27, P188, DOI 10.2307/2136274; HENSHAW SK, 1990, FAM PLANN PERSPECT, V22, P76, DOI 10.2307/2135512; HENSHAW SK, 1992, US TEENAGE PREGNANCY; HENSHAW SK, 1988, INS OUTSJ HLTH POPUL, P46; Hofferth Sandra, 1987, RISKING FUTURE ADOLE, VII, P123; HOLLMAN FW, 1993, CURRENT POPULATION R; JAY MS, 1988, ADOLESCENT PEDIAT G, V1, P83, DOI 10.1016/S0932-8610(88)80029-X; Jones E.M., 1986, TEENAGE PREGNANCY IN; KOCHANEK KD, 1991, MONTHLY VITAL STAT S, V39, P1; Koonin L M, 1993, MMWR CDC Surveill Summ, V42, P29; Lawson H W, 1989, MMWR CDC Surveill Summ, V38, P11; MACIAK BJ, 1987, JAMA-J AM MED ASSOC, V258, P2069; MCANARNEY ER, 1989, JAMA-J AM MED ASSOC, V262, P74, DOI 10.1001/jama.262.1.74; MOORE KA, 1995, ADOLESCENT PREGNANCY; MOSHER WD, 1991, FAM PLANN PERSPECT, V23, P108, DOI 10.2307/2135822; ORR DP, 1988, J ADOLESCENT HEALTH, V9, P273, DOI 10.1016/0197-0070(88)90249-5; Peterson L., 1995, ADV DATA VITAL HLTH; PICCININO LJ, IN PRESS ADV DATA VI; PITTMAN K, 1988, TEENAGE PREGNANCY AD; *PUBL HLTH SERV, 1986, 1990 HLTH OBJ NAT MI; Spitz A M, 1993, MMWR CDC Surveill Summ, V42, P1; SPITZ AM, 1987, MMWR-MORBID MORTAL W, V36, P1; *US DEP HHS, 1991, US DHHS PUBL; VENTURA SJ, 1992, MONTHLY VITAL STAT S, V41, P1; ZUCKERMAN BS, 1994, J PEDIATR, V105, P857; 1995, MMWR-MORBID MORTAL W, V44, P131; 1992, TEENAGE PREGNANCY TO; 1993, MONTHLY VITAL STAT S, V42, P1; 1990, MONTHLY VITAL STAT S, V41, P1	36	47	49	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					989	994		10.1001/jama.275.13.989	http://dx.doi.org/10.1001/jama.275.13.989			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC123	8596256				2022-12-28	WOS:A1996UC12300025
J	Cha, K; Falk, RH				Cha, K; Falk, RH			Pulsus alternans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Cha, K (corresponding author), BOSTON UNIV,MED CTR,BOSTON,MA 02118, USA.								0	4	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1996	334	13					834	834		10.1056/NEJM199603283341305	http://dx.doi.org/10.1056/NEJM199603283341305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB950	8596550				2022-12-28	WOS:A1996UB95000005
J	Pardoll, D				Pardoll, D			Update - Releasing the brakes on antitumor immune response	SCIENCE			English	Editorial Material							CD28				Pardoll, D (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205, USA.							ALLISON JP, 1995, SCIENCE, V270, P932, DOI 10.1126/science.270.5238.932; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; HASKINS K, 1985, ANNU REV IMMUNOL, V2, P51; JENKINS MK, 1994, IMMUNITY, V1, P405; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; PARDOLL DM, 1994, NATURE, V369, P357, DOI 10.1038/369357a0; PHILLIPS JH, 1995, SCIENCE, V268, P403, DOI 10.1126/science.7716542; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; TOPALIAN SL, 1989, J IMMUNOL, V142, P3714; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985	15	16	18	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1691	1691		10.1126/science.271.5256.1691	http://dx.doi.org/10.1126/science.271.5256.1691			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596929				2022-12-28	WOS:A1996UB15100034
J	Schatz, G; Dobberstein, B				Schatz, G; Dobberstein, B			Common principles of protein translocation across membranes	SCIENCE			English	Review							REQUIRES NUCLEOSIDE TRIPHOSPHATES; MITOCHONDRIAL INNER MEMBRANE; IMMUNOGLOBULIN LIGHT-CHAINS; SIGNAL RECOGNITION PARTICLE; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; YEAST MITOCHONDRIA; INTERMEMBRANE SPACE; PRECURSOR PROTEINS; THYLAKOID MEMBRANE	Most major systems that transport proteins across a membrane share the following features: an amino-terminal transient signal sequence on the transported protein, a targeting system on the cis side of the membrane, a hetero-oligomeric transmembrane channel that is gated both across and within the plane of the membrane, a peripherally attached protein translocation motor that is powered by the hydrolysis of nucleoside triphosphate, and a protein folding system on the trans side of the membrane. These transport systems are divided into two families: export systems that export proteins out of the cytosol, and import systems that transport proteins into cytosol-like compartments.	UNIV HEIDELBERG, ZENTRUM MOLEK BIOL, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg	Schatz, G (corresponding author), UNIV BASEL, BIOCTR, KLINGELBERGSTR 70, CH-4056 BASEL, SWITZERLAND.							ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BAKER A, 1987, P NATL ACAD SCI USA, V84, P3117, DOI 10.1073/pnas.84.10.3117; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Blobel G., 1971, BIOMEMBRANE, P193; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; BRINKS S, 1994, J BIOL CHEM, V269, P16478; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CREISSEN G, 1995, PLANT J, V8, P167, DOI 10.1046/j.1365-313X.1995.08020167.x; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DIAMOND DL, 1995, PROTEIN SCI, V4, P1118, DOI 10.1002/pro.5560040610; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; ELGERSMA Y, 1995, THESIS U AMSTERDAM A; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; Gaut JR, 1993, CURR OPIN CELL BIOL, V5, P589, DOI 10.1016/0955-0674(93)90127-C; GILLHAM NW, 1994, ANNU REV GENET, V28, P71, DOI 10.1146/annurev.ge.28.120194.000443; GILMORE R, 1993, CELL, V75, P589, DOI 10.1016/0092-8674(93)90476-7; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HAHNE K, 1994, CELL, V79, P829, DOI 10.1016/0092-8674(94)90072-8; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HAUCKE V, IN PRESS EMBO J; HEINEMANN P, 1992, FEBS LETT, V300, P179, DOI 10.1016/0014-5793(92)80191-I; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HESTERKAMP T, IN PRESS P NATL ACAD; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; HUANG JT, 1990, PLANT CELL, V2, P1249, DOI 10.1105/tpc.2.12.1249; HUHSE S, 1996, COLD SPRING HARBOR S; HULTGREN SJ, 1993, ADV PROTEIN CHEM, V44, P99, DOI 10.1016/S0065-3233(08)60565-3; HURT EC, 1986, EMBO J, V5, P1343, DOI 10.1002/j.1460-2075.1986.tb04365.x; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; JOHNSON AE, 1993, TRENDS BIOCHEM SCI, V18, P456, DOI 10.1016/0968-0004(93)90002-5; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; JUNGNICKEL B, 1994, FEBS LETT, V346, P73, DOI 10.1016/0014-5793(94)00367-X; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; KIM YJ, 1994, CELL, V78, P845; KLEMM P, 1992, RES MICROBIOL, V143, P831, DOI 10.1016/0923-2508(92)90070-5; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; LAIDLER V, 1995, J BIOL CHEM, V270, P17664, DOI 10.1074/jbc.270.30.17664; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MANELLA CA, IN PRESS J BIOENERG; Margulis L, 1970, ORIGIN EUKARYOTIC CE; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MATOUSCHEK A, 1995, P NATL ACAD SCI USA, V92, P6319, DOI 10.1073/pnas.92.14.6319; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MILSTEIN C, 1972, NATURE-NEW BIOL, V239, P117, DOI 10.1038/newbio239117a0; NAKAI M, 1994, J BIOL CHEM, V269, P31338; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NGUYEN M, 1988, J CELL BIOL, V106, P1499, DOI 10.1083/jcb.106.5.1499; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; RACKER E, 1976, NEW LOOK MECHANISMS; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; RASSOW J, 1995, MOL CELL BIOL, V15, P2654; ROBINSON C, 1993, FEBS LETT, V325, P67, DOI 10.1016/0014-5793(93)81415-V; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; ROCHAIX JD, 1992, ANNU REV CELL BIOL, V8, P1, DOI 10.1146/annurev.cb.08.110192.000245; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; ROISE D, 1988, J BIOL CHEM, V263, P4509; ROSPERT S, IN PRESS EMBO J; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SAVITZ AJ, 1993, J CELL BIOL, V120, P853, DOI 10.1083/jcb.120.4.853; SCHATZ G, 1986, NATURE, V321, P108, DOI 10.1038/321108a0; SCHEKMAN R, 1994, CELL, V78, P911, DOI 10.1016/0092-8674(94)90265-8; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; SOLL J, 1995, BOT ACTA, V108, P277, DOI 10.1111/j.1438-8677.1995.tb00495.x; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; THEG SM, 1992, BIOCHEMISTRY-US, V31, P5053, DOI 10.1021/bi00136a018; TOKATLIDIS K, COMMUNICATION; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; VASSAROTTI A, 1987, EMBO J, V6, P705, DOI 10.1002/j.1460-2075.1987.tb04811.x; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VONHEIJNE G, 1986, J MOL BIOL, V189, P239, DOI 10.1016/0022-2836(86)90394-3; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; VOOS W, IN PRESS EMBO J; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WICKNER W, 1988, BIOCHEMISTRY-US, V27, P1081, DOI 10.1021/bi00404a001; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; WULFING C, 1994, MOL MICROBIOL, V12, P685, DOI 10.1111/j.1365-2958.1994.tb01056.x; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	131	911	935	1	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1996	271	5255					1519	1526		10.1126/science.271.5255.1519	http://dx.doi.org/10.1126/science.271.5255.1519			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599107				2022-12-28	WOS:A1996TZ98300027
J	Goonasekera, CDA; Shah, V; Wade, AM; Barratt, TM; Dillon, MJ				Goonasekera, CDA; Shah, V; Wade, AM; Barratt, TM; Dillon, MJ			15-year follow-up of renin and blood pressure in reflux nephropathy	LANCET			English	Article							VESICOURETERIC REFLUX; CHILDREN; PLASMA; HYPERTENSION	Background Beginning in 1978 a cohort of patients with reflux nephropathy first seen at a London Children's hospital have had 5-yearly follow-ups. This is the fourth (15-year) report from that series. Methods Of the original 100 normotensive children with reflux nephropathy 78 were traced for the 15-year study in 1994. Five patients were excluded because of nephrectomy, ten for other reasons, and eight refused to take part, leaving 55. 26 were on oral contraceptives. Supine blood pressure and plasma renin activity (PRA) were measured, and daily sodium excretion was assessed on a sample of overnight urine. Findings Of the 55 patients (15 male, 40 female, median age 27 years, range 20-31), five had systolic and two had diastolic hypertension. Compared with the 10-year (1988) follow-up there was no change in blood pressure standard deviation scores (SDS) in this cohort. PRA showed an increasing dissociation from controls after 15 years of age and was significantly above that of controls by age 25. Exclusion of the patients on oral contraceptives did not significantly alter the results. The PRA values in 1988 were not individually predictive of the development of hypertension over the ensuing 5 years. Interpretation Previously, in the long-term study of reflux nephropathy, blood pressure SDS had progressively increased with age. By 15 years blood pressure had levelled out and the PRA, though raised, did not predict the development of hypertension. Oral contraceptive use did not significantly modify the results.	INST CHILD HLTH, DIV CLIN SCI, LONDON WC1N 1EH, ENGLAND; INST CHILD HLTH, DIV BIOCHEM & GENET, LONDON WC1N 1EH, ENGLAND; INST CHILD HLTH, DIV EPIDEMIOL, LONDON WC1N 1EH, ENGLAND; INST CHILD HLTH, BIOSTAT UNIT, LONDON WC1N 1EH, ENGLAND; GREAT ORMOND ST HOSP CHILDREN NHS TRUST, RENAL UNIT, LONDON, ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust			Goonasekera, Chulananda/G-9327-2016	Goonasekera, Chulananda/0000-0002-9754-6477				[Anonymous], 1987, PEDIATRICS, V79, P1; BAILEY RR, 1984, CONTRIBUTIONS NEPRHO, P146; BRAREN V, 1988, UROLOGY, V32, P228, DOI 10.1016/0090-4295(88)90390-1; DERKX FHM, 1986, J CLIN ENDOCR METAB, V63, P1008, DOI 10.1210/jcem-63-4-1008; DILLON MJ, 1975, J CLIN PATHOL, V28, P625, DOI 10.1136/jcp.28.8.625; DILLON MJ, 1987, PEDIATR NEPHROL, V1, P59, DOI 10.1007/BF00866886; DILLON MJ, 1984, CONTRIBUTIONS NEPHRO, P68; GILL DG, 1976, ARCH DIS CHILD, V51, P951, DOI 10.1136/adc.51.12.951; Graystone JE, 1968, HUMAN GROWTH, P182; GUSMANO R, 1988, CONTRIB NEPHROL, V61, P201; JARDIM H, 1991, ARCH DIS CHILD, V66, P1213, DOI 10.1136/adc.66.10.1213; LINDEMAN RD, 1984, KIDNEY INT, V26, P861, DOI 10.1038/ki.1984.229; SAVAGE JM, 1987, ARCH DIS CHILD, V62, P678, DOI 10.1136/adc.62.7.678; SAVAGE JM, 1978, LANCET, V2, P441; SMELLIE JM, 1989, URINARY TRACT INFECT, P39; SMELLIE JM, 1979, REFLUX NEPHROPATHY, P14; STILL JL, 1967, ARCH DIS CHILD, V42, P34, DOI 10.1136/adc.42.221.34; The WHO multicentre trial of the vasopressor effects of combined oral contraceptives, 1989, CONTRACEPTION, V40, P129; WALLACE DMA, 1978, BRIT J UROL, V50, P479, DOI 10.1111/j.1464-410X.1978.tb06195.x; WOLFISH NM, 1993, J PEDIATR-US, V123, P559, DOI 10.1016/S0022-3476(05)80950-3	20	50	51	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	1996	347	9002					640	643		10.1016/S0140-6736(96)91201-5	http://dx.doi.org/10.1016/S0140-6736(96)91201-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596377				2022-12-28	WOS:A1996TZ28500009
J	Taylor, D				Taylor, D			Quality and professionalism in health care: A review of current initiatives in the NHS	BRITISH MEDICAL JOURNAL			English	Article								Since the start of the 1990s the NHS and the clinical professions have made significant investments in quality management in health care, and a plethora of initiatives has been aimed at service improvement. From a patient's perspective the extent to which these exercises have been cost effective is uncertain, although they have certainly involved great effort and enterprise on the part of many clinicians and managers, An important opportunity now exists to integrate this work into the mainstream of clinical and general service management. If clinicians can accept quality management concepts as central to their professional ethos and regulatory structures this could help them to maintain their professional authority and protect them and their patients from imposed decisions based on inadequate understanding of health care costs and benefits.	GJW HLTH AFFAIRS,LONDON,ENGLAND									Binney G., 1992, MAKING QUALITY WORK; *BRIT MED ASS ASS, 1995, CONS M SEP 1995; Foster A, 1994, Qual Health Care, V3 Suppl, P16, DOI 10.1136/qshc.3.Suppl.16; Freidson E., 1988, PROFESSION MED; MAXWELL RJ, 1984, BRIT MED J, V288, P1470, DOI 10.1136/bmj.288.6428.1470; *NHS MAN EX, 1993, A Z QUAL; RIBGY B, 1995, J ASS QUALITY HEALTH, V3, P3; SEN A, 1993, SCI AM, V268, P18	8	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					626	629						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595342				2022-12-28	WOS:A1996TZ84000033
J	Multhaup, G; Schlicksupp, A; Hesse, L; Beher, D; Ruppert, T; Masters, CL; Beyreuther, K				Multhaup, G; Schlicksupp, A; Hesse, L; Beher, D; Ruppert, T; Masters, CL; Beyreuther, K			The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I)	SCIENCE			English	Article							CEREBROSPINAL-FLUID; WILSON DISEASE; MENKES DISEASE; CANDIDATE GENE; CEREBRAL-HEMORRHAGE; TRANSPORTING ATPASE; SENILE PLAQUES; GROWTH-FACTOR; BETA-PROTEIN; MUTATION	The transition metal ion copper(II) has a critical role in chronic neurologic diseases. The amyloid precursor protein (APP) of Alzheimer's disease or a synthetic peptide representing its copper-binding site reduced bound copper(II) to copper(I). This copper ion-mediated redox reaction led to disulfide bond formation in APP, which indicated that free sulfhydryl groups of APP were involved. Neither superoxide nor hydrogen peroxide had an effect on the kinetics of copper(II) reduction. The reduction of copper(II) to copper(I) by APP involves an electron-transfer reaction and could enhance the production of hydroxyl radicals, which could then attack nearby sires. Thus, copper-mediated toxicity may contribute to neurodegeneration in Alzheimer's disease.	UNIV HEIDELBERG,DEPT VIROL,D-69120 HEIDELBERG,GERMANY; UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA; MENTAL HLTH RES INST VICTORIA,NEUROPATHOL LAB,PARKVILLE,VIC 3052,AUSTRALIA	Ruprecht Karls University Heidelberg; University of Melbourne	Multhaup, G (corresponding author), UNIV HEIDELBERG,ZMBH CTR MOLEC BIOL,NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.		Ruppert, Thomas/AAC-2467-2021	Ruppert, Thomas/0000-0001-9152-2266; Beher, Dirk/0000-0001-8005-5359				BASUN H, 1991, J NEURAL TRANSM, V4, P231; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BEYREUTHER K, 1993, ANN NY ACAD SCI, V695, P91, DOI 10.1111/j.1749-6632.1993.tb23035.x; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; BUSH AI, 1993, J BIOL CHEM, V268, P16109; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CORK LC, 1990, AM J PATHOL, V137, P1383; DYRKS T, 1993, FEBS LETT, V324, P231, DOI 10.1016/0014-5793(93)81399-K; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; FITZGERALD DJ, 1995, SCIENCE, V268, P1920, DOI 10.1126/science.7604269; GIACCONE G, 1989, NEUROSCI LETT, V97, P232, DOI 10.1016/0304-3940(89)90169-9; GILBERT HF, 1982, J BIOL CHEM, V257, P2086; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HARTMANN HA, 1992, MED HYPOTHESES, V38, P75, DOI 10.1016/0306-9877(92)90162-6; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HERSHEY CO, 1983, NEUROLOGY, V33, P1350, DOI 10.1212/WNL.33.10.1350; HESSE L, 1994, FEBS LETT, V349, P109, DOI 10.1016/0014-5793(94)00658-X; HYMAN BT, 1995, P NATL ACAD SCI USA, V92, P3586, DOI 10.1073/pnas.92.8.3586; JOSELOW M, 1951, J BIOL CHEM, V191, P11; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; LANDERS JW, 1958, AM J CLIN PATHOL, V29, P590; LANDGRAF W, 1991, J BIOL CHEM, V266, P16305; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LU HS, 1992, J BIOL CHEM, V267, P8770; LYNCH SM, 1993, J LIPID RES, V34, P1745; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARINDRASORASAK S, 1992, LAB INVEST, V67, P643; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; NULTHAUP G, 1994, FEBS LETT, V355, P151; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; PICKART L, 1987, METHOD ENZYMOL, V147, P314; PIKE CJ, 1993, NEUROSCIENCE, V56, P269, DOI 10.1016/0306-4522(93)90331-9; ROCH JM, 1992, J BIOL CHEM, V267, P2214; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SIMONS M, 1995, J NEUROSCI RES, V41, P121, DOI 10.1002/jnr.490410114; SMALL DH, 1994, J NEUROSCI, V14, P2117; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WANG D, 1995, J NEUROPATH EXP NEUR, V54, P548, DOI 10.1097/00005072-199507000-00009; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431	57	611	621	0	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1406	1409		10.1126/science.271.5254.1406	http://dx.doi.org/10.1126/science.271.5254.1406			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596911				2022-12-28	WOS:A1996TY96100043
J	Reichhardt, T				Reichhardt, T			Regulators face questioning on particulate rules	NATURE			English	Editorial Material																			0	4	4	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					11	12						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598893				2022-12-28	WOS:A1996TY87700017
J	Davenport, M				Davenport, M			ABC of general paediatric surgery - Inguinal hernia, hydrocele, and the undescended testis	BRITISH MEDICAL JOURNAL			English	Article											Davenport, M (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT PAEDIAT SURG,LONDON,ENGLAND.							CHILVERS C, 1989, UROLOGICAL GENITAL C, P306; *JOHN RADCL CRYPTO, 1986, BRIT MED J, V293, P1401; WOODHOUSE CRJ, 1992, BRIT J UROL, V70, P345	3	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					564	567		10.1136/bmj.312.7030.564	http://dx.doi.org/10.1136/bmj.312.7030.564			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595290	Green Published			2022-12-28	WOS:A1996TY88500034
J	Davenport, M				Davenport, M			ABC of general surgery in children - Acute abdominal pain in children	BRITISH MEDICAL JOURNAL			English	Article											Davenport, M (corresponding author), KINGS COLL HOSP,DEPT PAEDIAT SURG,LONDON,ENGLAND.							JONES PF, 1976, BRIT MED J, V2, P551, DOI 10.1136/bmj.2.6035.551	1	26	27	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					498	501		10.1136/bmj.312.7029.498	http://dx.doi.org/10.1136/bmj.312.7029.498			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597689	Green Published			2022-12-28	WOS:A1996TX38300036
J	Gliemroth, J; Heise, S; Missler, U				Gliemroth, J; Heise, S; Missler, U			A 64-year-old man with diabetes and ascending paraplegia	LANCET			English	Article							MENINGITIS		MED UNIV, NEUROCHIRURG KLIN, D-23538 LUBECK, GERMANY; MED UNIV, INST RADIOL, D-23538 LUBECK, GERMANY	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Lubeck; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Lubeck								COOPER EV, 1946, LANCET, V250, P459; GEHRZ RC, 1976, AM J DIS CHILD, V130, P877, DOI 10.1001/archpedi.1976.02120090087016; MACKAY NNS, 1971, BMJ-BRIT MED J, V1, P591, DOI 10.1136/bmj.1.5749.591; TOURAINE A, 1936, PRESSE MED, V44, P674; 1943, BRIT MED J, V1, P785	5	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 24	1996	347	9000					516	516		10.1016/S0140-6736(96)91142-3	http://dx.doi.org/10.1016/S0140-6736(96)91142-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596271				2022-12-28	WOS:A1996TW69700013
J	Irvine, S; Cawood, E; Richardson, D; MacDonald, E; Aitken, J				Irvine, S; Cawood, E; Richardson, D; MacDonald, E; Aitken, J			Evidence of deteriorating semen quality in the United Kingdom: Birth cohort study in 577 men in Scotland over 11 years	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MALE-FERTILITY; CHANGING PARAMETERS; TESTICULAR CANCER; SPERM COUNTS; EPIDEMIOLOGY; INFERTILITY; TERMS	Objective-To determine whether the quality of semen has changed in a group of over 500 Scottish men born between 1951 and 1973. Design-Retrospective review of data on semen quality collected in a single laboratory over 11 years and according to World Health Organisation guidelines. Setting-Programme of gamete biology research funded by Medical Research Council. Subjects-577 volunteer semen donors. Of these, 171 were born before 1959, 120 were born in 1960-4, 171 in 1965-9, and 115 in 1970-4. Main outcome measures-Conventional criteria of semen quality including semen volume (ml), sperm concentration (10(6)/ml), overall motility (% motile), total number of sperm in the ejaculate (10(6)), and total number of motile sperm in the ejaculate (10(6)). Results-When the four birth cohort groups were compared a later year of birth was associated with a lower sperm concentration, a lower total number of sperm in the ejaculate, and a lower number of motile sperm in the ejaculate. The median sperm concentration fell from 98 x 10(6)/ml among donors born before 1959 to 78 x 10(6)/ml among donors born after 1970 (P = 0.002). The total number of sperm in the ejaculate fell from 301 x 10(6) to 214 x 10(6) (P = 0.0005), and the total number of motile sperm in the ejaculate fell from 169.7 x 10(6) to 129.0 x 10(6) (P = 0.0065). Conclusion-This study provides direct evidence that semen quality is deteriorating, with a later year of birth being significantly associated with a reduced number of sperm in adult life.	UNIV EDINBURGH, CTR REPROD BIOL, REPROD MED LABS, EDINBURGH EH3 9EW, MIDLOTHIAN, SCOTLAND	University of Edinburgh	Irvine, S (corresponding author), MRC, CTR REPROD BIOL, REPROD BIOL UNIT, EDINBURGH EH3 9EW, MIDLOTHIAN, SCOTLAND.			Aitken, Robert John/0000-0002-9152-156X				AITKEN RJ, 1982, FERTIL STERIL, V38, P68; AITKEN RJ, 1991, AM J OBSTET GYNECOL, V164, P542, DOI 10.1016/S0002-9378(11)80017-7; [Anonymous], 1987, WHO LAB MANUAL EXAMI; [Anonymous], 1992, WHO LAB MANUAL EXAMI; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; Barratt C. L. R., 1993, Human Reproduction (Oxford), V8, P1521; BOSTOFTE E, 1983, INT J FERTIL, V28, P91; BOYLE P, 1987, EUR J CANCER CLIN ON, V23, P827, DOI 10.1016/0277-5379(87)90286-0; BOYLE P, 1985, LANCET, V1, P1311; BROMWICH P, 1994, BRIT MED J, V309, P19, DOI 10.1136/bmj.309.6946.19; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; GIWERCMAN A, 1992, INT J ANDROL, V15, P373, DOI 10.1111/j.1365-2605.1992.tb01351.x; IRVINE DS, 1995, HUM REPROD, V10, P2752, DOI 10.1093/oxfordjournals.humrep.a135786; IRVINE DS, 1994, ENDOCRIN METAB CLIN, V23, P725, DOI 10.1016/S0889-8529(18)30064-1; JACKSON MB, 1988, HORM RES, V30, P153, DOI 10.1159/000181052; JAMES WH, 1980, ANDROLOGIA, V12, P381; JOHNSON L, 1986, J ANDROL, V7, P331; LETO S, 1981, FERTIL STERIL, V36, P766; MACLEOD J, 1979, FERTIL STERIL, V31, P103; MACLEOD J, 1951, J UROLOGY, V66, P436, DOI 10.1016/S0022-5347(17)74358-3; MENKVELD R, 1986, ARCH ANDROLOGY, V17, P143, DOI 10.3109/01485018608990186; MORTIMER D, 1982, ARCH ANDROLOGY, V8, P251, DOI 10.3109/01485018208990205; NELSON CMK, 1974, FERTIL STERIL, V25, P503; OSSER S, 1984, ARCH ANDROLOGY, V12, P113, DOI 10.3109/01485018409161159; OSTERLIND A, 1986, BRIT J CANCER, V53, P501, DOI 10.1038/bjc.1986.79; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SHARPE RM, 1995, ENV HLTH PERSPECT, V103, P2; SHERINS RJ, 1995, NEW ENGL J MED, V332, P327, DOI 10.1056/NEJM199502023320510; TEMPLETON A, 1990, BRIT MED J, V301, P148, DOI 10.1136/bmj.301.6744.148; 1980, LAB MANUAL EXAMINATI; 1995, IEH ASSESSMENT ENV O; 1995, MALE REPROD HLTH ENV	32	336	352	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 24	1996	312	7029					467	471		10.1136/bmj.312.7029.467	http://dx.doi.org/10.1136/bmj.312.7029.467			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597676	Green Published			2022-12-28	WOS:A1996TX38300020
J	Bell, TW				Bell, TW			Molecular trees: A new branch of chemistry	SCIENCE			English	Editorial Material							SUPRAMOLECULAR CHEMISTRY; PERSPECTIVES; COMPLEXATION; DEVICES; GUESTS; HOSTS				Bell, TW (corresponding author), UNIV NEVADA,DEPT CHEM,RENO,NV 89557, USA.							ARDOIN N, 1995, B SOC CHIM FR, V132, P875; BELL TW, 1994, NATURE, V367, P441, DOI 10.1038/367441a0; BELL TW, 1995, SCIENCE, V269, P671, DOI 10.1126/science.7624796; BRANDA N, 1994, SCIENCE, V263, P1267, DOI 10.1126/science.8122107; CRAM DJ, 1988, SCIENCE, V240, P760, DOI 10.1126/science.3283937; FRECHET JMJ, 1994, SCIENCE, V263, P1710, DOI 10.1126/science.8134834; FRECHET JMJ, 1995, SCIENCE, V269, P1080, DOI 10.1126/science.269.5227.1080; Hamid A., 1991, Annals of Bangladesh Agriculture, V1, P1; KLUG A, 1983, ANGEW CHEM INT EDIT, V22, P565, DOI 10.1002/anie.198305653; Kolotuchin SV, 1995, ANGEW CHEM INT EDIT, V34, P2654; LEHN JM, 1988, ANGEW CHEM INT EDIT, V27, P89, DOI 10.1002/anie.198800891; LEHN JM, 1993, SCIENCE, V260, P1762, DOI 10.1126/science.8511582; LINDSEY JS, 1991, NEW J CHEM, V15, P153; MEISSNER RS, 1995, SCIENCE, V270, P1485, DOI 10.1126/science.270.5241.1485; NEWKOME GR, 1992, ALDRICHIM ACTA, V25, P31; PEDERSEN CJ, 1988, ANGEW CHEM INT EDIT, V27, P1021, DOI 10.1002/anie.198810211; PERCEC V, 1993, J CHEM SOC PERK T 2, P2381, DOI 10.1039/p29930002381; PHILP D, 1991, SYNLETT, P445; SAUVAGE JP, 1990, ACCOUNTS CHEM RES, V23, P319, DOI 10.1021/ar00178a001; SIMANEK EE, 1995, TETRAHEDRON, V51, P607, DOI 10.1016/0040-4020(94)00920-P; TOMALIA DA, 1990, ANGEW CHEM INT EDIT, V29, P138, DOI 10.1002/anie.199001381; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; XU X, 1993, ANGEW CHEM INT EDIT, V32, P1354; XU X, 1993, ANGEW CHEM INT EDIT, V32, P246; YANG J, 1995, SUPRAMOLECULAR STERE, P141; ZIMMERMAN SC, 1992, J ORG CHEM, V57, P2215, DOI 10.1021/jo00034a005; Zimmerman SC, 1996, SCIENCE, V271, P1095, DOI 10.1126/science.271.5252.1095; ZIMMERMAN SC, 1993, TOP CURR CHEM, V165, P71	28	32	37	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1077	1078		10.1126/science.271.5252.1077	http://dx.doi.org/10.1126/science.271.5252.1077			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599080				2022-12-28	WOS:A1996TW70100025
J	Smith, S; Robinson, J; Hollyer, J; Bhatt, R; Ash, S; Shaunak, S				Smith, S; Robinson, J; Hollyer, J; Bhatt, R; Ash, S; Shaunak, S			Combining specialist and primary health care teams for HIV positive patients: Retrospective and prospective studies	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS; FUNDING POLICIES; HOSPITAL DOCTORS; AIDS; COMMUNICATION; INFECTION	Objective-To develop and evaluate a model of health care for HIV positive patients involving specialist, hospital based teams and primary health care teams. Design-One year retrospective and 2 1/2 year prospective study. Setting-Two hospitals in west London and 88 general practitioners in 72 general practices. Subjects-209 adults with HIV infection. Intervention-General practitioners enrolled in the project were fared structured outpatient clinic summaries. When hospital inpatients were discharged, a brief discharge summary was fared. General practitioners had access to consultant physicians skilled in HIV medicine through a 24 hour mobile telephone service. An HIV/AIDS management and treatment guide containing relevant local information was produced. Quarterly discussion forums for general practitioners were held, and a regular newsletter was produced. Main outcome measures-Hospital attendance and general practitioner consultations; perceived benefits and problems of patients and general practitioners. Results-The average length of a hospital inpatient stay was halved for those patients who had participated in the project for two years, and the average number of visits to the outpatient clinic per month fell for patients with AIDS. There was a substantial increase in the number of visits to general practitioners by patients with AIDS and symptomatic HIV infection. Patients and general practitioners both felt that the standard of health care provided had improved. Conclusions-This model of health care efficiently and effectively utilised existing teams of hospital and primary health care professionals to provide care for HIV positive patients. Simple, prompt, and regular communication systems which provided information relevant to the needs of general practitioners were central to its success.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT INFECT DIS,LONDON W12 0NN,ENGLAND; ROYAL POSTGRAD MED SCH,MED STAT UNIT,LONDON W12 0NN,ENGLAND; GROVE MED PRACTICE,NORTHOLT,MIDDX,ENGLAND; EALING GEN HOSP,CAMERON CTR,LONDON,ENGLAND	Imperial College London; Imperial College London; Imperial College London								Butters E, 1991, Health Trends, V23, P59; COULTER A, 1995, BRIT MED J, V311, P1447, DOI 10.1136/bmj.311.7018.1447; COYLE A, 1995, BRIT MED J, V310, P1636, DOI 10.1136/bmj.310.6995.1636; GRUN L, 1994, BRIT MED J, V308, P538; GUTHRIE B, 1995, INT J STD AIDS, V6, P84, DOI 10.1177/095646249500600204; HICKMAN M, 1994, J PUBLIC HEALTH MED, V16, P447, DOI 10.1093/oxfordjournals.pubmed.a043026; HOCHULI V, 1993, BRIT MED J, V307, P801, DOI 10.1136/bmj.307.6907.801-b; HURWITZ B, 1993, BRIT MED J, V306, P624, DOI 10.1136/bmj.306.6878.624; LLOYD BW, 1993, BRIT MED J, V306, P247, DOI 10.1136/bmj.306.6872.247; Main J, 1993, Qual Health Care, V2, P53, DOI 10.1136/qshc.2.1.53; MANSFIELD S, 1993, LANCET, V342, P726; MCCARTHY M, 1993, BRIT MED J, V307, P367, DOI 10.1136/bmj.307.6900.367; MORLEY V, 1993, BMJ-BRIT MED J, V306, P112, DOI 10.1136/bmj.306.6870.112; NEWTON J, 1992, BRIT MED J, V304, P821, DOI 10.1136/bmj.304.6830.821; RAWAL J, 1993, BRIT MED J, V307, P1044, DOI 10.1136/bmj.307.6911.1044; REGNARD C, 1994, BRIT MED J, V308, P655, DOI 10.1136/bmj.308.6929.655d; SCHRODER F, 1995, BRIT MED J, V310, P142; SINGH S, 1994, BRIT MED J, V308, P539; SMITH S, 1993, BRIT MED J, V307, P801, DOI 10.1136/bmj.307.6907.801-c; SMITS A, 1990, BRIT MED J, V300, P241, DOI 10.1136/bmj.300.6719.241; VANDAMME R, 1994, BRIT J GEN PRACT, V44, P9; WADSWORTH E, 1992, BRIT J GEN PRACT, V42, P107; WILLIAMS H, 1993, BRIT MED J, V307, P802, DOI 10.1136/bmj.307.6907.802; 1994, BRIT MED J, V308, P559; 1994, BRIT MED J, V308, P1208	25	23	23	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	1996	312	7028					416	420						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601114	Green Published			2022-12-28	WOS:A1996TW56400024
J	Gunel, M; Awad, IA; Finberg, K; Anson, JA; Steinberg, GR; Batjer, PH; Kopitnik, TA; Morrison, L; Giannotta, SL; NelsonWilliams, C; Lifton, RP				Gunel, M; Awad, IA; Finberg, K; Anson, JA; Steinberg, GR; Batjer, PH; Kopitnik, TA; Morrison, L; Giannotta, SL; NelsonWilliams, C; Lifton, RP			A founder mutation as a cause of cerebral cavernous malformation in Hispanic Americans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-HISTORY; FAMILIAL OCCURRENCE; ANGIOMAS; BRAIN	Background. Cerebral cavernous malformation is a vascular disease of the brain causing headaches, seizures, and cerebral hemorrhage. Familial and sporadic cases are recognized, and a gene causing familial disease has been mapped to chromosome 7. Hispanic Americans have a higher prevalence of cavernous malformation than do other ethnic groups, raising the possibility that affected persons in this population have inherited the same mutation from a common ancestor. Methods. We compared the segregation of genetic markers and clinical cases of cavernous malformation in Hispanic-American kindreds with familial disease; we also compared the alleles for markers linked to cavernous malformation in patients with familial and sporadic cases. Results. All kindreds with familial disease showed linkage of cavernous malformation to a short segment of chromosome 7 (odds supporting linkage, 4x10(10):1), Forty-seven affected members of 14 kindreds shared identical alleles for up to 15 markers linked to the cavernous-malformation gene, demonstrating that they had inherited the same mutation from a common ancestor. Ten patients with sporadic cases also shared these same alleles, indicating that they too had inherited the same mutation. Thirty-three asymptomatic carriers of the disease gene were identified, demonstrating the variability and age dependence of the development of symptoms and explaining the appearance of apparently sporadic cases. Conclusions. Virtually all cases of familial and sporadic cavernous malformation among Hispanic Americans of Mexican descent are due to the inheritance of the same mutation from a common ancestor. (C) 1996, Massachusetts Medical Society.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,BOYER CTR MOLEC MED,NEW HAVEN,CT 06510; YALE UNIV,NEUROSURG SECT,NEW HAVEN,CT; YALE UNIV,DEPT CELL BIOL,NEW HAVEN,CT; YALE UNIV,DEPT MED & GENET,NEW HAVEN,CT; UNIV NEW MEXICO,DEPT NEUROSURG,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,DEPT NEUROL,ALBUQUERQUE,NM 87131; STANFORD UNIV,DEPT NEUROSURG,PALO ALTO,CA 94304; STANFORD UNIV,DEPT NEUROL,PALO ALTO,CA 94304; STANFORD UNIV,DEPT NEUROSURG,PALO ALTO,CA 94304; NORTHWESTERN UNIV,DEPT NEUROSURG,CHICAGO,IL 60611; UNIV TEXAS,SW MED CTR,DEPT NEUROSURG,DALLAS,TX 75235; UNIV SO CALIF,DEPT NEUROSURG,LOS ANGELES,CA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Yale University; University of New Mexico; University of New Mexico; Stanford University; Stanford University; Stanford University; Northwestern University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Southern California				Morrison, Leslie/0000-0002-0092-193X				Armitage P., 1987, STAT METHODS MED RES; Barrow D., 1993, CAVERNOUS MALFORMATI, P65; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BICKNELL JM, 1978, ARCH NEUROL-CHICAGO, V35, P746, DOI 10.1001/archneur.1978.00500350050010; CLARK JV, 1970, J NEUROL NEUROSUR PS, V33, P871, DOI 10.1136/jnnp.33.6.871; DELCURLING O, 1991, J NEUROSURG, V75, P702, DOI 10.3171/jns.1991.75.5.0702; DOBYNS WB, 1987, ANN NEUROL, V21, P578, DOI 10.1002/ana.410210609; DUBOVSKY J, 1995, HUM MOL GENET, V4, P453, DOI 10.1093/hmg/4.3.453; GANGEMI M, 1990, Neurological Research, V12, P131; GUNEL M, 1995, P NATL ACAD SCI USA, V92, P6620, DOI 10.1073/pnas.92.14.6620; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HASTBACKA J, 1992, NAT GENET, V2, P343; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; HAYMAN LA, 1982, AM J MED GENET, V11, P147, DOI 10.1002/ajmg.1320110205; HSU FPK, 1993, CAVERNOUS MALFORMATI, P13; HUHN SL, 1993, CAVERNOUS MALFORMATI, P87; JOHNSON PC, 1993, CAVERNOUS MALFORMATI, P1; KIDD HA, 1947, LANCET, V1, P747; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MASON I, 1988, NEUROLOGY, V38, P324, DOI 10.1212/WNL.38.2.324; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; Ojemann R G, 1993, Clin Neurosurg, V40, P98; OTTEN P, 1989, NEUROCHIRURGIE, V35, P82; PERL J, 1993, CAVERNOUS MALFORMATI, P37; RIGAMONTI D, 1987, J NEUROSURG, V67, P518, DOI 10.3171/jns.1987.67.4.0518; RIGAMONTI D, 1988, NEW ENGL J MED, V319, P343, DOI 10.1056/NEJM198808113190605; ROBINSON JR, 1993, NEUROSURGERY, V32, P730, DOI 10.1227/00006123-199305000-00005; ROBINSON JR, 1991, J NEUROSURG, V75, P709, DOI 10.3171/jns.1991.75.5.0709; Russell DS, 1989, PATHOLOGY TUMOURS NE, P730; SPENCER DD, 1984, NEUROLOGY, V34, P432, DOI 10.1212/WNL.34.4.432; STEICHENGERSDORF E, 1992, EUR J PEDIATR, V151, P861, DOI 10.1007/BF01957941; ZABRAMSKI JM, 1994, J NEUROSURG, V80, P422, DOI 10.3171/jns.1994.80.3.0422	32	172	179	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1996	334	15					946	951		10.1056/NEJM199604113341503	http://dx.doi.org/10.1056/NEJM199604113341503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD596	8596595				2022-12-28	WOS:A1996UD59600003
J	Maschio, G; Alberti, D; Janin, G; Locatelli, F; Mann, JFE; Motolese, M; Ponticelli, C; Ritz, E; Zucchelli, P; Marai, P; Marcelli, D; Tentori, F; Andriani, M; Drago, G; Meneghel, G; Oldrizzi, L; Rugiu, C; Salvadeo, A; Villa, G; Picardi, L; Borghi, M; Moriggi, M; Vendramin, G; Fusaroli, M; Esposti, ED; Fabbri, A; Koch, KM; Frey, U; Schaeffer, J; Mann, J; Schweitzer, C; Zuccala, A; Gaggi, R; Stahl, R; Blaser, C; Rivolta, E; Buccianti, G; Gastaldi, L; Baratelli, M; Ducret, F; Pointet, P; Sterzel, R; Oberdorf, E; Pedrini, L; Faranna, P; Cairo, G; Ferrari, L; Albertazzi, A; Cappelli, P; Cantu, P; Limido, A; Lachhein, L; Bosselmann, HP; Mioni, G; Montanaro, D; Sasdelli, M; Imperiali, P; Schmidt, R; Handschuck, I; Stein, G; Cagnoli, L; Rigotti, A; Grassi, G; Orazi, E; Borgatti, PP; Stefani, A; Nefti, H; Redaelli, B; Vigano, MR; Giangrande, A; Maret, J; Natusch, R; Laske, HR; Ramello, A; Cledes, J; Cordonnier, D; Sirajedine, K; Imbasciati, E; Palla, R; Sessa, A; Altieri, P; Aparicio, M; Verzetti, G; Baroni, C; Costanzo, R; Mery, JP; Idatte, JM; Bariety, J; Wolf, C; Bandiani, G; Marichal, JF; Menard, J; Bobrie, G; ElNahas, AM; Gretz, N; Marinoni, A; Maiocchi, G; DiMauro, R; Bodin, F; vonHahn, V; Heintzmann, F; Grun, A; Francucci, BM; Rainisio, M				Maschio, G; Alberti, D; Janin, G; Locatelli, F; Mann, JFE; Motolese, M; Ponticelli, C; Ritz, E; Zucchelli, P; Marai, P; Marcelli, D; Tentori, F; Andriani, M; Drago, G; Meneghel, G; Oldrizzi, L; Rugiu, C; Salvadeo, A; Villa, G; Picardi, L; Borghi, M; Moriggi, M; Vendramin, G; Fusaroli, M; Esposti, ED; Fabbri, A; Koch, KM; Frey, U; Schaeffer, J; Mann, J; Schweitzer, C; Zuccala, A; Gaggi, R; Stahl, R; Blaser, C; Rivolta, E; Buccianti, G; Gastaldi, L; Baratelli, M; Ducret, F; Pointet, P; Sterzel, R; Oberdorf, E; Pedrini, L; Faranna, P; Cairo, G; Ferrari, L; Albertazzi, A; Cappelli, P; Cantu, P; Limido, A; Lachhein, L; Bosselmann, HP; Mioni, G; Montanaro, D; Sasdelli, M; Imperiali, P; Schmidt, R; Handschuck, I; Stein, G; Cagnoli, L; Rigotti, A; Grassi, G; Orazi, E; Borgatti, PP; Stefani, A; Nefti, H; Redaelli, B; Vigano, MR; Giangrande, A; Maret, J; Natusch, R; Laske, HR; Ramello, A; Cledes, J; Cordonnier, D; Sirajedine, K; Imbasciati, E; Palla, R; Sessa, A; Altieri, P; Aparicio, M; Verzetti, G; Baroni, C; Costanzo, R; Mery, JP; Idatte, JM; Bariety, J; Wolf, C; Bandiani, G; Marichal, JF; Menard, J; Bobrie, G; ElNahas, AM; Gretz, N; Marinoni, A; Maiocchi, G; DiMauro, R; Bodin, F; vonHahn, V; Heintzmann, F; Grun, A; Francucci, BM; Rainisio, M			Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYSTEMIC HYPERTENSION; IGA NEPHROPATHY; FAILURE; PROTEINURIA; CREATININE; CAPTOPRIL; KIDNEY; TRIAL; RAT	Background. Drugs that inhibit angiotensin-converting enzyme slow the progression of renal insufficiency in patients with diabetic nephropathy. Whether these drugs have a similar action in patients with other renal diseases is not known, We conducted a study to determine the effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of renal insufficiency in patients with various underlying renal diseases. Methods. in a three-year trial involving 583 patients with renal insufficiency caused by various disorders, 300 patients received benazepril and 283 received placebo, The underlying diseases included glomerulopathies (in 192 patients), interstitial nephritis (in 105), nephrosclerosis (in 97), polycystic kidney disease (in 64), diabetic nephropathy (in 21), and miscellaneous or unknown disorders (in 104), The severity of renal insufficiency was classified according to the base-line creatinine clearance: 227 patients had mild insufficiency (creatinine clearance, 46 to 60 mi per minute), and 356 had moderate insufficiency (creatinine clearance, 30 to 45 mi per minute). The primary end point was a doubling of the base-line serum creatinine concentration or the need for dialysis. Results. At three years, 31 patients in the benazepril group and 57 in the placebo group had reached the primary end point (P<0.001), In the benazepril group, the reduction in the risk of reaching the end point was 53 percent overall (95 percent confidence interval, 27 to 70 percent), 71 percent (95 percent confidence interval, 21 to 90 percent) among the patients with mild renal insufficiency, and 46 percent (95 percent confidence interval, 12 to 67 percent) among those with moderate renal insufficiency, The reduction in risk was greatest among the male patients; those with glomerular diseases, diabetic nephropathy, or miscellaneous or unknown causes of renal disease; and those with base-line urinary protein excretion above 1 g per 24 hours, Benazepril was not effective in patients with polycystic disease, Diastolic pressure decreased by 3.5 to 5.0 mm Hg in the benazepril group and increased by 0.2 to 1.5 mm Hg in the placebo group. Conclusions. Benazepril provides protection against the progression of renal insufficiency in patients with various renal diseases. (C) 1996, Massachusetts Medical Society.	CIBA GEIGY SPA, DEPT MED, ORIGGIO, ITALY; HOP CHANAUX, SERV HEMODIALYSE, MACON, FRANCE; OSPED LECCO, DIV NEFROL, Lecce, ITALY; STAEDT KLINIKUM SCHWABING, MED ABT 6, MUNICH, GERMANY; GERMAN INST HIGH BLOOD PRESSURE RES, MUNICH, GERMANY; IST RICOVERO & CURA CARATTERE SCI, OSPED MAGGIORE POLICLIN, DIV NEFROL & DIALISI, MILAN, ITALY; UNIV KLIN HEIDELBERG, REHABIL ZENTRUM CHRON NIERENKRANKE, HEIDELBERG, GERMANY; SERV OSPED S ORSOLA, DIV NEFROL & DIALISI, BOLOGNA, ITALY	Munchen Klinik; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ruprecht Karls University Heidelberg; IRCCS Azienda Ospedaliero-Universitaria di Bologna	Maschio, G (corresponding author), OSPED CIVILE, DIV NEFROL, PIAZZALE STEFANI 1, I-37126 VERONA, ITALY.		Marinoni, Angela/AAK-9587-2021; Mann, Johannes/AAI-8803-2020; Marcelli, Daniele/J-3544-2016	Marinoni, Angela/0000-0002-6580-7126; Marcelli, Daniele/0000-0002-7650-8578				AGABITIROSEI E, 1990, INT C S SERIES ROYAL, V166, P59; AMBROSIONI E, 1995, NEW ENGL J MED, V332, P80, DOI 10.1056/NEJM199501123320203; ANDERSON S, 1986, J CLIN INVEST, V77, P1993, DOI 10.1172/JCI112528; BROWN JH, 1994, NEPHROL DIAL TRANSPL, V9, P1136, DOI 10.1093/ndt/9.8.1136; CARTWRIGHT ME, 1988, LAB INVEST, V59, P492; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; GANSEVOORT RT, 1994, J AM SOC NEPHROL, V5, P329; HANNEDOUCHE T, 1994, BRIT MED J, V309, P833, DOI 10.1136/bmj.309.6958.833; JACKSON B, 1988, J HYPERTENS, V6, P495, DOI 10.1097/00004872-198806000-00010; KAMPER AL, 1992, AM J HYPERTENS, V5, P423, DOI 10.1093/ajh/5.7.423; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LEWIS EJ, 1994, NEW ENGL J MED, V330, P152; LOCATELLI F, 1991, LANCET, V337, P1299, DOI 10.1016/0140-6736(91)92977-A; MANN JFE, 1990, NEPHRON, V55, P38; MASCHIO G, 1987, KIDNEY INT, V32, pS49; PETERSON JC, 1993, J AM SOC NEPHROL   S, V4, pA254; PRAGA M, 1992, AM J KIDNEY DIS, V20, P240, DOI 10.1016/S0272-6386(12)80696-2; RAINE AEG, 1992, NEPHROL DIAL TRANSPL, V7, P7; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; REKOLA S, 1991, NEPHRON, V59, P57, DOI 10.1159/000186518; REMUZZI A, 1991, KIDNEY INT, V39, P1267, DOI 10.1038/ki.1991.160; REMUZZI G, 1990, KIDNEY INT, V38, P384, DOI 10.1038/ki.1990.217; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; ZATZ R, 1987, KIDNEY INT, V31, pS123; ZUCCHELLI P, 1992, KIDNEY INT, V42, P452, DOI 10.1038/ki.1992.309	27	1516	1560	2	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 11	1996	334	15					939	945		10.1056/NEJM199604113341502	http://dx.doi.org/10.1056/NEJM199604113341502			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD596	8596594	Bronze			2022-12-28	WOS:A1996UD59600002
J	Testa, MA; Simonson, DC				Testa, MA; Simonson, DC			Current concepts - Assessment of quality-of-life outcomes	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							IMPACT MEASUREMENT SCALES; HEALTH-STATUS; CLINICAL-TRIALS; ANTIHYPERTENSIVE THERAPY; STATUS QUESTIONNAIRE; FUNCTIONAL STATUS; ARTHRITIS; DISEASE; CARE		BRIGHAM & WOMENS HOSP,JOSLIN DIABET CTR,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Testa, MA (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Testa, Marianna/L-9768-2019					AARONSON NK, 1992, EUR J CANCER, V28A, P1304, DOI 10.1016/0959-8049(92)90504-U; Anderson R. B., 1994, DRUG INF J, V28, P89; [Anonymous], 1995, LANCET, V1, P1; BERGNER M, 1989, MED CARE, V27, pS148, DOI 10.1097/00005650-198903001-00012; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERZON RA, 1995, QUAL LIFE RES, V4, P53, DOI 10.1007/BF00434384; BOMBARDIER C, 1986, AM J MED, V81, P565, DOI 10.1016/0002-9343(86)90539-5; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; Brook RH, 1979, RAND CORPORATION PUB; *CONST WHO, 1952, WHO HDB BAS DOC, P3; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; EPSTEIN RS, 1992, J CLIN EPIDEMIOL, V45, P1431, DOI 10.1016/0895-4356(92)90205-2; FEENY DH, 1989, MED CARE, V27, pS190, DOI 10.1097/00005650-198903001-00016; Feinstein AR, 1987, CLINIMETRICS; GOLDHIRSCH A, 1989, J CLIN ONCOL, V7, P36, DOI 10.1200/JCO.1989.7.1.36; GUYATT G, 1989, GASTROENTEROLOGY, V96, P804, DOI 10.1016/0016-5085(89)90905-0; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; HAMMOND GS, 1992, DIABETES CARE, V15, P469, DOI 10.2337/diacare.15.4.469; JETTE AM, 1986, J GEN INTERN MED, V1, P143, DOI 10.1007/BF02602324; JETTE AM, 1986, J GEN INTERN MED, V1, P427; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; KAPLAN RM, 1989, MED CARE, V27, pS27, DOI 10.1097/00005650-198903001-00003; KATZ JN, 1994, MED CARE, V32, P183, DOI 10.1097/00005650-199402000-00009; KATZ JN, 1992, MED CARE, V30, P917, DOI 10.1097/00005650-199210000-00004; LENDERKING WR, 1994, NEW ENGL J MED, V330, P738, DOI 10.1056/NEJM199403173301102; Levine S., 1984, ASSESSMENT QUALITY L, P46; LORD FM, 1980, APPLICATIONS ITEM RE; MEENAN RF, 1992, ARTHRITIS RHEUM, V35, P1, DOI 10.1002/art.1780350102; PARTICK DL, 1973, J HEALTH SOC BEHAV, V14, P6; Patrick DL, 1993, HLTH STATUS HLTH POL, P76; POCOCK SJ, 1987, BIOMETRICS, V43, P487, DOI 10.2307/2531989; SALSBURG DS, 1992, USE RESTRICTED SIGNI, P126; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; Testa M A, 1992, Pharmacoeconomics, V2, P107, DOI 10.2165/00019053-199202020-00004; TESTA MA, 1994, ANNU REV PUBL HEALTH, V15, P535; TESTA MA, 1991, AM J HYPERTENS, V4, P363, DOI 10.1093/ajh/4.4.363; TESTA MA, 1993, NEW ENGL J MED, V328, P907, DOI 10.1056/NEJM199304013281302; TESTA MA, 1987, J HYPERTENS, V5, pS9; TESTA MA, 1988, POSTGRAD MED J, V64, P50; TESTA MA, 1995, AIDS CLIN TRIALS, P213; THIER SO, 1992, MED CARE, V30, pMS15, DOI 10.1097/00005650-199205001-00002; Ware J.E, 1994, PHYS MENTAL HLTH SUM; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE, 1993, SF36 HLTH SURVEY MAN; WEINSTEIN MC, 1980, CLIN DECISION ANAL, P184; [No title captured]	46	1568	1639	2	60	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1996	334	13					835	840		10.1056/NEJM199603283341306	http://dx.doi.org/10.1056/NEJM199603283341306			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UB950	8596551				2022-12-28	WOS:A1996UB95000006
J	Back, AL; Wallace, JI; Starks, HE; Pearlman, RA				Back, AL; Wallace, JI; Starks, HE; Pearlman, RA			Physician-assisted suicide and euthanasia in Washington State - Patient requests and physician responses	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEATH; DECISIONS; LIFE	Objectives.-To estimate how often physicians receive requests for physician-assisted suicide and euthanasia and to describe a case series of patient requests for physician-assisted suicide and euthanasia, including physician responses to these requests. Design.-A mailed, anonymous two-part questionnaire. Participants.-A total of 828 physicians returned questionnaires sent to 1453 potential respondents, for a response rate of 57%. Questionnaires were mailed to a random sample (25%) of primary care physicians and all physicians in selected medical subspecialties in Washington State. Main Outcome Measures.-The frequency of explicit patient requests for physician-assisted suicide and euthanasia reported by physicians and individual case descriptions of patient characteristics, physician perceptions of patient concerns, and physician responses to patient requests. Results.-In the past year, 12% of responding physicians received one or more explicit requests for physician-assisted suicide, and 4% received one or more requests for euthanasia. These physicians provided 207 case descriptions. The diagnoses most often associated with requests were cancer, neurological disease, and the acquired immunodeficiency syndrome (AIDS). The patient concerns most often perceived by physicians were worries about loss of control, being a burden, being dependent on others for personal care, and loss of dignity, Physicians provided assistance more often to patients with physical symptoms. Physicians infrequently sought advice from colleagues, Of 156 patients who requested physician-assisted suicide, 38 (24%) received prescriptions, and 21 of these died as a result. Of 58 patients who requested euthanasia, 14 (24%) received parenteral medication and died. Conclusions.-Patient requests for physician-assisted suicide and euthanasia are not rare, As perceived by physicians, the most common patient concerns at the time these requests are made are nonphysical, Physicians occasionally provide these practices, even though they are currently illegal in Washington State. Physicians do not consult colleagues often about these requests. These findings raise the question of how to ensure quality in the evaluation of patient requests for physician-assisted death.	VET AFFAIRS PUGET SOUND HLTH CARE SYST, CTR GERIATR RES EDUC & CLIN, SEATTLE, WA 98108 USA; UNIV WASHINGTON, SCH MED, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT MED HIST & ETH, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH PUBL HLTH, DEPT HLTH SERV, SEATTLE, WA 98195 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Back, AL (corresponding author), VET AFFAIRS PUGET SOUND HLTH CARE SYST, MED SERV, 1660 S COLUMBIAN WAY, SEATTLE, WA 98108 USA.				NIA NIH HHS [AG00615-02] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BATTIN MP, 1991, J PAIN SYMPTOM MANAG, V6, P298, DOI 10.1016/0885-3924(91)90053-7; BATTIN MP, 1995, ACAD MED, V70, P583; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; CALLAHAN D, 1992, HASTINGS CENT REP, V22, P52, DOI 10.2307/3562566; CARSON R, 1992, HASTINGS CENT REP, V22, P7, DOI 10.2307/3562559; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CASSELL EJ, 1991, HASTINGS CENT REP, V21, P24, DOI 10.2307/3563319; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; DOUKAS DJ, 1995, J CLIN ONCOL, V13, P1055, DOI 10.1200/JCO.1995.13.5.1055; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; FINS JJ, 1995, J AM GERIATR SOC, V43, P563, DOI 10.1111/j.1532-5415.1995.tb06107.x; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; GIRSH FJ, 1992, WESTERN J MED, V157, P188; Humphry Derek, 1991, FINAL EXIT PRACTICAL; JECKER NS, 1994, J AM GERIATR SOC, V42, P672, DOI 10.1111/j.1532-5415.1994.tb06869.x; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; PEARLMAN RA, 1993, THEOR MED, V14, P197, DOI 10.1007/BF00995162; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; Pellegrino E D, 1992, J Clin Ethics, V3, P95; PELLEGRINO ED, 1995, J CLIN ETHIC, V6, P161; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; SACHS GA, 1995, J AM GERIATR SOC, V43, P553, DOI 10.1111/j.1532-5415.1995.tb06106.x; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; *WA STAT DEP HLTH, 1994, WASH STAT VIT STAT; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; 1995, J AM GERIATR SOC, V43, P579	37	259	259	1	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					919	925		10.1001/jama.275.12.919	http://dx.doi.org/10.1001/jama.275.12.919			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UA563	8598619				2022-12-28	WOS:A1996UA56300031
J	Friedman, E				Friedman, E			Capitation, integration, and managed care - Lessons from early experiments	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		*AM MED ASS, 1996, MED GROUPS US SURV P; BOO MR, 1991, HOUSE STONE DULUTH B; Foster Mark, 1989, HJ KAISER BUILDER MO; FRIEDMAN EA, 1993, ALOHA WAY HLTH CARE; *GROUP HLTH COOP P, 1983, WE KNEW WE COULD DO; *GROUP HLTH INC, 1993, END MISS STOR GROUP; Hendricks Rickey, 1993, MODEL NATL HLTH CARE; LASS W, 1983, MINNESOTA HIST; PAINTER PS, 1993, H FORD HLTH SYSTEM P; RODGERS C, 1991, HOSP OKLAHOMA HIST 1; RYAN JC, 1971, TIMBER PRODUCERS B, P8; SCOLLARD P, 1994, COMMUNICATION   0314; SHADID M, 1956, CRUSADING DOCTOR MY; Shadid Michael A., 1939, DOCTOR PEOPLE; SMILLIE JG, 1991, CAN PHYSICIANS MANAG; SOMERS AR, 1979, NEW ENGL J MED, V300, P977, DOI 10.1056/NEJM197904263001709; STEVENSON SB, 1987, ST PETER HOSP; WARBASSE JP, 1942, COOPERATIVE MED; WESCOTT LB, 1979, NEW ENGL J MED, V300, P952, DOI 10.1056/NEJM197904263001704; 1995, INTERSTUDY COMPETITI	20	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					957	962		10.1001/jama.275.12.957	http://dx.doi.org/10.1001/jama.275.12.957			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA563	8598625				2022-12-28	WOS:A1996UA56300039
J	Nightingale, SL				Nightingale, SL			National surveillance program for changes in antimicrobial susceptibilities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1996, MMWR-MORBID MORTAL W, V45, P110	1	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					902	902						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA563	8598604				2022-12-28	WOS:A1996UA56300011
J	Ogilvie, AD; Battersby, S; Bubb, VJ; Fink, G; Harmar, AJ; Goodwin, GM; Smith, CAD				Ogilvie, AD; Battersby, S; Bubb, VJ; Fink, G; Harmar, AJ; Goodwin, GM; Smith, CAD			Polymorphism in serotonin transporter gene associated with susceptibility to major depression	LANCET			English	Article							HYDROXYLASE GENE; DISORDERS	Background The serotonin transporter of the brain provides the primary target for the action of selective antidepressant drugs. We set out to identify polymorphisms of the serotonin transporter gene and to find out whether there was a relation between any such polymorphisms and the occurrence of affective disorder. Methods A comparison of a polymorphic region of the human serotonin transporter gene was carried out between two groups. The study group comprised 83 patients (39 unipolar depressive disorder, 44 bipolar disorder) with major affective disorder. The control group comprised 122 anonymous blood donors, and 71 volunteers who had been screened for psychiatric disorders. Findings We detected three novel alleles of the variable-number-tandem-repeat (VNTR) region (STin2.9, STin2.10, and STin2.12) containing nine, ten and 12 copies of the VNTR element, respectively. The frequencies of the different forms of the allele in the control group were compared with those in the affective disorder group. There was a significant difference between the control and affective disorder groups, largely explained by the excess of the STin2.9 allele in the unipolar group (chi(2)=10.05, p<0.004 [Bonferroni corrected]). The presence of the allele with nine copies of the repeat was significantly associated with risk of unipolar disorder (odds ratio=6.95 [95% CI 1.8-27.2]). Interpretation This association, for an obvious candidate gene, may provide a critical starting point for an understanding of the likely polygenic contributions towards susceptibility to affective disorder.	ROYAL EDINBURGH & ASSOCIATED HOSP,MRC,BRAIN METAB UNIT,EDINBURGH EH10 5HF,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,SCH MED,CRC LABS,EDINBURGH,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,SCH MED,DEPT PATHOL,EDINBURGH,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh				Fink, George/0000-0002-0713-527X; Harmar, Anthony/0000-0002-3838-9264				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDERSON IM, 1994, J PSYCHOPHARMACOL, V8, P238, DOI 10.1177/026988119400800407; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; BOYER WF, 1991, SEROTONIN HYPOTHESIS, P71; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; GOLTSOV AA, 1992, AM J HUM GENET, V51, P627; HUDSON JI, 1990, AM J PSYCHIAT, V147, P552; LESCH KP, 1994, J NEURAL TRANSM-GEN, V95, P157, DOI 10.1007/BF01276434; LESCH KP, 1995, BIOL PSYCHIAT, V37, P215, DOI 10.1016/0006-3223(94)00147-U; LESCH KP, 1993, J NEUROCHEM, V60, P2319, DOI 10.1111/j.1471-4159.1993.tb03522.x; LUCASSEN AM, 1995, HUM MOL GENET, V4, P501, DOI 10.1093/hmg/4.4.501; OWENS MJ, 1994, CLIN CHEM, V40, P288; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; SMITH CAD, 1992, LANCET, V339, P1375, DOI 10.1016/0140-6736(92)91196-F; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013	15	460	492	0	28	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					731	733		10.1016/S0140-6736(96)90079-3	http://dx.doi.org/10.1016/S0140-6736(96)90079-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8602004				2022-12-28	WOS:A1996TZ98200012
J	vanderVleuten, C				vanderVleuten, C			Making the best of the ''long case''	LANCET			English	Editorial Material											vanderVleuten, C (corresponding author), UNIV LIMBURG,DEPT EDUC DEV & RES,6200 MD MAASTRICHT,NETHERLANDS.							GLEESON DB, 1994, P 6 OTT C MED ED TOR, P412; Jolly B., 1993, TEACH LEARN MED, V5, P66; Muzzin LJ, 1995, EVALUATION METHODS R, P37; NEWBLE DI, 1983, MED EDUC, V17, P165, DOI 10.1111/j.1365-2923.1983.tb00657.x; SWANSON DB, 1987, FURTHER DEV ASSESSIN, P13; Swanson DB, 1995, ED RES, V24, P35; Swanson DB., 1995, EDUC RES-UK, V24, P5, DOI [DOI 10.3102/0013189X024005005, 10.3102/0013189X024005005]; van der Vleuten C.P., 1990, TEACH LEARN MED, V2, P58, DOI [https://doi.org/10.1080/10401339009539432, DOI 10.1080/10401339009539432]; Vu NV., 1994, ED RES, V23, P23	9	27	27	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					704	705		10.1016/S0140-6736(96)90069-0	http://dx.doi.org/10.1016/S0140-6736(96)90069-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TZ982	8601994				2022-12-28	WOS:A1996TZ98200002
J	Moore, ME				Moore, ME			Insight	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Moore, ME (corresponding author), ALBERT EINSTEIN MED CTR, DIV RHEUMATOL, 103 KORMAN BLDG, 5501 OLD YORK RD, PHILADELPHIA, PA 19141 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1996	124	6					609	610		10.7326/0003-4819-124-6-199603150-00012	http://dx.doi.org/10.7326/0003-4819-124-6-199603150-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ529	8597327				2022-12-28	WOS:A1996TZ52900013
J	Harada, K; Martin, SS; Frankel, AD				Harada, K; Martin, SS; Frankel, AD			Selection of RNA-binding peptides in vivo	NATURE			English	Article							BACTERIOPHAGE-LAMBDA; N-PROTEIN; RECOGNITION; ANTITERMINATION; REQUIRES; RESIDUES	Many principles of sequence-specific DNA recognition have been established over the past decade, largely from structural studies of protein-DNA and drug-DNA complexes. On the basis of these principles, it has been possible to design or select variants of known structural motifs, including zinc-fingers(1-3) and minor groove-binding drugs', that bind desired sequences. Here we describe a strategy, based on transcriptional termination in bacteria, to identify specific RNA-binding peptides using the arginine-rich RNA-binding motifs as a framework. Peptides were isolated from two combinatorial libraries that bind tightly and specifically to the Rev response element of HIV. It appears that a-helical peptides resembling Rev were selected from one library whereas new peptides that probably do not form helices were selected from the other, suggesting that the arginine-rich motif may be a particularly versatile framework for recognizing RNA structures.			Harada, K (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CHATTOPADHYAY S, 1995, P NATL ACAD SCI USA, V92, P4061, DOI 10.1073/pnas.92.9.4061; CHEN L, 1995, P NATL ACAD SCI USA, V92, P5077, DOI 10.1073/pnas.92.11.5077; CHEN L, 1994, BIOCHEMISTRY-US, V33, P2708, DOI 10.1021/bi00175a046; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; FRANKLIN NC, 1993, J MOL BIOL, V231, P343, DOI 10.1006/jmbi.1993.1287; FRANKLIN NC, 1989, J BACTERIOL, V171, P2513, DOI 10.1128/jb.171.5.2513-2522.1989; GEIERSTANGER BH, 1994, SCIENCE, V266, P646, DOI 10.1126/science.7939719; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; JONES KA, 1994, REV BICOH, V63, P717; KJERNS J, 1992, EMBO J, V11, P1119; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MOGRIDGE J, 1995, GENE DEV, V9, P2831, DOI 10.1101/gad.9.22.2831; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; Sambrook J., 1989, MOL CLONING; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; TAN RY, 1994, BIOCHEMISTRY-US, V33, P14579, DOI 10.1021/bi00252a025; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9	23	110	113	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					175	179		10.1038/380175a0	http://dx.doi.org/10.1038/380175a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600395				2022-12-28	WOS:A1996TZ97800056
J	Maxwell, JG				Maxwell, JG			Changes in Britain's health care - An American attempts to revisit 'from the London Post'	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV N CAROLINA,SCH MED,DEPT SURG,CHAPEL HILL,NC; NEW HANOVER REG MED CTR,DEPT SURG,WILMINGTON,NC	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Maxwell, JG (corresponding author), COASTAL AREA HLTH EDUC CTR,DEPT SURG,POB 9025,WILMINGTON,NC 28402, USA.							BEST G, 1994, BRIT MED J, V308, P842, DOI 10.1136/bmj.308.6932.842; *BRIT MED ASS, 1996, 1994 1995 BRIT MED A; *DEP HLTH, 1993, HOSP DOCT TRAIN FUT; DILLNER L, 1994, BRIT MED J, V308, P359, DOI 10.1136/bmj.308.6925.359a; DIXON J, 1994, BRIT MED J, V308, P772, DOI 10.1136/bmj.308.6931.772; HAM C, 1995, BRIT MED J, V310, P1150, DOI 10.1136/bmj.310.6988.1150; HERD B, 1995, BRIT MED J, V310, P1042, DOI 10.1136/bmj.310.6986.1042; JEFFREYS M, 1992, HLTH CARE SYSTEMS TH, P221; LISTER J, 1985, LONDON POST ESSAYS M; MACARA AW, 1994, BRIT MED J, V308, P848, DOI 10.1136/bmj.308.6932.848; *NAT HLTH SERV MAN, 1991, JUN DOCT NEW DEAL; SMITH R, 1994, BRIT MED J, V308, P1221, DOI 10.1136/bmj.308.6938.1221; STRACHAN CJL, 1993, POSITION PAPER JUNIO; 1995, BMA NEWS PREVIEW, V22, P22	14	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1996	275	10					789	793						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY886	8598596				2022-12-28	WOS:A1996TY88600027
J	Campuzano, V; Montermini, L; Molto, MD; Pianese, L; Cossee, M; Cavalcanti, F; Monros, E; Rodius, F; Duclos, F; Monticelli, A; Zara, F; Canizares, J; Koutnikova, H; Bidichandani, SI; Gellera, C; Brice, A; Trouillas, P; DeMichele, G; Filla, A; DeFrutos, R; Palau, F; Patel, PI; DiDonato, S; Mandel, JL; Cocozza, S; Koenig, M; Pandolfo, M				Campuzano, V; Montermini, L; Molto, MD; Pianese, L; Cossee, M; Cavalcanti, F; Monros, E; Rodius, F; Duclos, F; Monticelli, A; Zara, F; Canizares, J; Koutnikova, H; Bidichandani, SI; Gellera, C; Brice, A; Trouillas, P; DeMichele, G; Filla, A; DeFrutos, R; Palau, F; Patel, PI; DiDonato, S; Mandel, JL; Cocozza, S; Koenig, M; Pandolfo, M			Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion	SCIENCE			English	Article							MYOTONIC-DYSTROPHY; MUTATION; DNA; IDENTIFICATION; CHROMOSOME-9; LINKAGE; GENE	Friedreich's ataxia (FRDA) is an autosomal recessive, degenerative disease that involves the central and peripheral nervous systems and the heart. A gene, X25, was identified in the critical region for the FRDA locus on chromosome 9q13. The gene encodes a 210-amino acid protein, frataxin, that has homologs in distant species such as Caenorhabditis elegans and yeast. A few FRDA patients were found to have point mutations in X25, but the majority were homozygous for an unstable GAA trinucleotide expansion in the first X25 intron.	UNIV STRASBOURG 1,INST BIOL & BIOL MOLEC & CELLULAIRE,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE; CNRS,F-67404 ILLKIRCH GRAFFENS,FRANCE; CHU,F-67404 ILLKIRCH GRAFFENS,FRANCE; BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030; UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,I-80131 NAPLES,ITALY; CNR,CTR ENDOCRINOL ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; IST MEDITERRANEO NEUROSCI SANATRIX,I-86077 POZZILLI,ISERNIA,ITALY; UNIV HOSP LA FE,UNIDAD GENET,E-46006 VALENCIA,SPAIN; UNIV VALENCIA,DEPT GENET,E-46100 BURJASSOT,VALENCIA,SPAIN; IST NAZL NEUROL C BESTA,DIV BIOCHIM & GENET SISTEMA NERVOSO,I-20133 MILAN,ITALY; HOP LA PITIE SALPETRIERE,F-75651 PARIS 13,FRANCE; HOP NEUROL,F-69003 LYON,FRANCE; UNIV NAPLES FEDERICO II,DIV NEUROL 2,DIPARTIMENTO PATOL SISTEMA,I-80131 NAPLES,ITALY	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Baylor College of Medicine; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Valencia; IRCCS Istituto Neurologico Besta; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Lyon; University of Naples Federico II			Gellera, Cinzia/J-7887-2016; Cocozza, Sergio/F-6488-2010; Cavalcanti, Francesca/N-3901-2019; Canizares, Joaquin/X-9702-2019; Canizares, Joaquin/M-3255-2014; Pandolfo, Massimo/B-2853-2010; CAVALCANTI, FRANCESCA/I-3651-2014; Brice, Alexis/A-2170-2009; brice, alexis/AAE-8275-2019; Campuzano, Victoria/ABG-7429-2020; Palau, Francesc/A-9391-2014; Koutnikova, Hana/I-7758-2017; CAMPUZANO, VICTORIA/K-7883-2019; Campuzano, V/G-1826-2014; Zara, Federico/U-3477-2017; Di Donato, Stefano/B-9717-2012; Patel, Pragna/H-9129-2017	Gellera, Cinzia/0000-0002-3582-665X; Cavalcanti, Francesca/0000-0001-5769-4582; Canizares, Joaquin/0000-0001-9002-5516; Canizares, Joaquin/0000-0001-9002-5516; CAVALCANTI, FRANCESCA/0000-0001-5769-4582; brice, alexis/0000-0002-0941-3990; Campuzano, Victoria/0000-0001-8128-2641; Palau, Francesc/0000-0002-8635-5421; Campuzano, V/0000-0001-8128-2641; Zara, Federico/0000-0001-9744-5222; Molto, Maria Dolores/0000-0001-5219-2022; Bidichandani, Sanjay/0000-0001-6191-6475; Patel, Pragna/0000-0003-3584-1072; COSSEE, Mireille/0000-0002-5931-7454	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034192] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34192] Funding Source: Medline; Telethon [722] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BIDICHANDANI SI, UNPUB; CAMPUZANO V, UNPUB; CARVAJAL JJ, 1995, HUM MOL GENET, V4, P1411, DOI 10.1093/hmg/4.8.1411; CHAMBERLAIN S, 1988, NATURE, V334, P248, DOI 10.1038/334248a0; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; DUCLOS F, 1994, HUM MOL GENET, V3, P909, DOI 10.1093/hmg/3.6.909; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FINOCCHIARO G, 1988, NEUROLOGY, V38, P1292, DOI 10.1212/WNL.38.8.1292; Friedreich N, 1863, VIRCHOWS ARCH PATHOL, V26, P391, DOI 10.1515/9783112391280-017; FROHMAN MA, 1989, TECHNIQUE, V1, P165; FUJITA R, 1989, GENOMICS, V4, P110, DOI 10.1016/0888-7543(89)90323-6; GACY AM, 1995, CELL, V81, P533; GEOFFROY G, 1976, Canadian Journal of Neurological Sciences, V3, P279; GEOFFROY G, 1984, HEREDITARY ATAXIAS R; HANAUER A, 1990, AM J HUM GENET, V46, P133; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; HARDING AE, 1983, Q J MED, V52, P489; HEWER RL, 1968, BRIT MED J, V3, P649, DOI 10.1136/bmj.3.5619.649; HOFFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166; HUGHES JT, 1968, BRAIN, V91, P803, DOI 10.1093/brain/91.4.803; IMBERT G, 1993, NAT GENET, V4, P72, DOI 10.1038/ng0593-72; JITPIMOLMARD S, 1993, ACTA NEUROPATHOL, V86, P29, DOI 10.1007/BF00454895; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KLOCKGETHER T, 1990, J NEUROL NEUROSUR PS, V53, P297, DOI 10.1136/jnnp.53.4.297; KOCH KS, 1995, NUCLEIC ACIDS RES, V23, P1098, DOI 10.1093/nar/23.7.1098; LAMARCHE JB, 1984, CAN J NEUROL SCI, V11, P592, DOI 10.1017/S0317167100035113; MANDEL JL, 1994, NAT GENET, V7, P453, DOI 10.1038/ng0894-453; MONROS E, UNPUB; MONTERMINI L, 1995, AM J HUM GENET, V57, P1061; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; OHOY KL, 1993, SCIENCE, V259, P809, DOI 10.1126/science.8094260; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PANDOLFO M, 1994, BIOCHEM MED METAB B, V52, P115, DOI 10.1006/bmmb.1994.1041; PENTLAND B, 1983, J NEUROL NEUROSUR PS, V46, P1138, DOI 10.1136/jnnp.46.12.1138; ROMEO G, 1983, AM J HUM GENET, V35, P523; SAID G, 1986, NEUROLOGY, V36, P1292, DOI 10.1212/WNL.36.10.1292; Saleeba Jennifer A., 1992, Human Mutation, V1, P63, DOI 10.1002/humu.1380010110; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHELBOURNE P, 1992, HUM MOL GENET, V1, P467, DOI 10.1093/hmg/1.7.467; SKRE H, 1975, CLIN GENET, V7, P287; SOLOVYEV VV, 1994, COMPUT APPL BIOSCI, V10, P661; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WALDMANN TA, 1983, ANN INTERN MED, V99, P367, DOI 10.7326/0003-4819-99-3-367	49	2148	2220	3	126	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1423	1427		10.1126/science.271.5254.1423	http://dx.doi.org/10.1126/science.271.5254.1423			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596916				2022-12-28	WOS:A1996TY96100048
J	Mittal, R; Erickson, JW; Cerione, RA				Mittal, R; Erickson, JW; Cerione, RA			Uncoupling of GTP binding from target stimulation by a single mutation in the transducin alpha subunit	SCIENCE			English	Article							INTRINSIC FLUORESCENCE; REGULATORY PROTEINS; ACTIVATION; PHOSPHODIESTERASE; DEACTIVATION; KINETICS; CGMP	Glutamic acid-203 of the alpha subunit of transducin (alpha(T)) resides within a domain that undergoes a guanosine triphosphate (GTP)-induced conformational change that is essential for effector recognition. Changing the glutamic acid to an alanine in bovine alpha(T) yielded an alpha subunit (alpha(T)E203A) that was fully dependent on rhodopsin for GTP-guanosine diphosphate (GDP) exchange and showed GTP hydrolytic activity similar to that measured for wild-type alpha(T). However, unlike the wild-type protein, the GDP-bound form of alpha(T)E203A was constitutively active toward the effector of transducin, the cyclic guanosine monophosphate phosphodiesterase. Thus, the alpha(T)E203A mutant represents a short-circuited protein switch that no longer requires GTP for the activation of the effector target phosphodiesterase.	CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853	Cornell University								ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOSWAMI BB, 1991, BIOTECHNIQUES, V5, P626; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; MITTAL R, UNPUB; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; VANDOP C, 1984, J BIOL CHEM, V259, P23; YEE R, 1978, J BIOL CHEM, V253, P8902	16	19	19	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1413	1416		10.1126/science.271.5254.1413	http://dx.doi.org/10.1126/science.271.5254.1413			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596913				2022-12-28	WOS:A1996TY96100045
J	Verheij, M; Bose, R; Lin, XH; Yao, B; Jarvis, WD; Grant, S; Birrer, MJ; Szabo, E; Zon, LI; Kyriakis, JM; HaimovitzFriedman, A; Fuks, Z; Kolesnick, RN				Verheij, M; Bose, R; Lin, XH; Yao, B; Jarvis, WD; Grant, S; Birrer, MJ; Szabo, E; Zon, LI; Kyriakis, JM; HaimovitzFriedman, A; Fuks, Z; Kolesnick, RN			Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis	NATURE			English	Article							KINASE; DEATH	The induction of programmed cell death, or apoptosis, involves activation of a signalling system, many elements of which remain unknown(1). The sphingomyelin pathway, initiated by hydrolysis of the phospholipid sphingomyelin in the cell membrane to generate the second messenger ceramide(2,3), is thought to mediate apoptosis in response to tumour-necrosis factor (TNF)-alpha(2,3), to Fas ligand(4) and to X-rays(5). It is not known whether it plays a role in the stimulation of other forms of stress-induced apoptosis. Given that environmental stresses also stimulate a stress-activated protein kinase (SAPR/JNK)(6-12), the sphingomyelin and SAPK/ JNK signalling systems may be coordinated in induction of apoptosis. Here we report that ceramide initiates apoptosis through the SAPK cascade and provide evidence for a signalling mechanism that integrates cytokine- and stress-activated apoptosis.	MEM SLOAN KETTERING CANC CTR,LAB SIGNAL TRANSDUCT,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT RADIAT ONCOL,NEW YORK,NY 10021; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,DIV HEMATOL ONCOL,RICHMOND,VA 23298; NCI,DIV CANC PREVENT & CONTROL,BIOMARKERS & PREVENT RES BRANCH,ROCKVILLE,MD 20850; CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PEDIAT,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PEDIAT,DANA FARBER CANC INST,CHILDRENS HOSP,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP EAST,MED SERV,DIABET RES LAB,BOSTON,MA 02129	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital			Verheij, Marcel/O-9652-2018	Szabo, Eva/0000-0003-3891-0942				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; BROWN PH, 1994, ONCOGENE, V9, P791; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HAM J, 1995, CELL, V14, P927; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Martin Seamus J., 1993, Trends in Cell Biology, V3, P141, DOI 10.1016/0962-8924(93)90128-N; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	30	1696	1756	1	69	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					75	79		10.1038/380075a0	http://dx.doi.org/10.1038/380075a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598911				2022-12-28	WOS:A1996TY87700060
J	Greenberg, DS				Greenberg, DS			Washington - Cut immigration, medical schools say	LANCET			English	News Item																		Pew Health Professional Commission, CRIT CHALL REV HLTH	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					607	607		10.1016/S0140-6736(96)91297-0	http://dx.doi.org/10.1016/S0140-6736(96)91297-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596328				2022-12-28	WOS:A1996TX69400033
J	Hosking, D; Meunier, PJ; Ringe, JD; Reginster, JY; Gennari, C				Hosking, D; Meunier, PJ; Ringe, JD; Reginster, JY; Gennari, C			Fortnightly review - Paget's disease of bone: Diagnosis and management	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIPHOSPHONATE THERAPY; APD		HOP EDOUARD HERRIOT, SERV RHUMATOL & PATHOL OSSEUSE, LYON, FRANCE; UNIV COLOGNE, KLINIKUM LEVERKUSEN, LEVERKUSEN, GERMANY; UNIV LIEGE, CTR INVEST METAB OSSEUX & CARTILAGE ARTICULAIRE, LIEGE, BELGIUM; POLICLIN LE SCOTTO, INST PATOL MED, SIENA, ITALY	CHU Lyon; University of Cologne; University of Liege	Hosking, D (corresponding author), CITY HOSP, HUCKNALL RD, NOTTINGHAM NG5 1PB, ENGLAND.							ADAMI S, 1994, BONE, V15, P415, DOI 10.1016/8756-3282(94)90818-4; ALVAREZ L, 1995, J BONE MINER RES, V10, P458; BARKER DJP, 1980, BRIT MED J, V280, P1105, DOI 10.1136/bmj.280.6222.1105; CANFIELD R, 1977, J CLIN ENDOCR METAB, V44, P96, DOI 10.1210/jcem-44-1-96; CANTRILL JA, 1990, CLIN ENDOCRINOL, V32, P507, DOI 10.1111/j.1365-2265.1990.tb00892.x; CHAPMAN GK, 1992, AUST NZ J SURG, V62, P24, DOI 10.1111/j.1445-2197.1992.tb05350.x; COMPSTON JE, 1994, BRIT MED J, V309, P711, DOI 10.1136/bmj.309.6956.711; COULTON LA, 1988, ARTHRITIS RHEUM, V31, P1142, DOI 10.1002/art.1780310909; DELMAS PD, 1986, CALCIFIED TISSUE INT, V38, P60, DOI 10.1007/BF02556596; DEROSE J, 1974, AM J MED, V56, P858, DOI 10.1016/0002-9343(74)90815-8; DEVLIN RD, 1994, J BONE MINER RES, V9, P81; DODD GW, 1987, BRIT J RADIOL, V60, P849, DOI 10.1259/0007-1285-60-717-849; DOUGLAS DL, 1981, J BONE JOINT SURG BR, V63, P495, DOI 10.1302/0301-620X.63B4.6457839; ERIKSEN EF, 1993, J BONE MINER RES, V8, P127; FRANCK WA, 1974, AM J MED, V56, P592, DOI 10.1016/0002-9343(74)90629-9; GEBHARDT MC, 1990, METABOLIC BONE DIS C, P764; GOUTALLIER D, 1984, RHUMATOLOGIE, V36, P81; GRAY RES, 1987, Q J MED, V64, P755; HARINCK HIJ, 1987, CLIN ORTHOP RELAT R, P79; HOSKING DJ, 1990, DRUGS, V40, P829, DOI 10.2165/00003495-199040060-00005; KANIS JA, 1991, PATHOPHYSIOLOGY TREA, P47; KHAIRI MRA, 1974, JAMA-J AM MED ASSOC, V230, P562, DOI 10.1001/jama.230.4.562; LANDO M, 1988, ARCH OTOLARYNGOL, V114, P891; MAUTALEN CA, 1985, BONE, V6, P429, DOI 10.1016/8756-3282(85)90219-4; MEUNIER PJ, 1987, CLIN ORTHOP RELAT R, P37; MUNDY GR, 1995, BONE REMODELLING ITS, P32; PATEL S, 1993, DRUGS, V46, P594, DOI 10.2165/00003495-199346040-00003; PATEL S, 1995, ARTHRITIS RHEUM-US, V38, P1506, DOI 10.1002/art.1780381018; PATEL S, 1993, J BONE MINER RES, V8, P1467; ROUX C, 1995, ARTHRITIS RHEUM, V38, P851, DOI 10.1002/art.1780380620; STAUFFER RN, 1976, J BONE JOINT SURG AM, V58, P476, DOI 10.2106/00004623-197658040-00007; WALTON RJ, 1977, EUR J CLIN INVEST, V7, P37, DOI 10.1111/j.1365-2362.1977.tb01567.x; WOOTTON R, 1978, CLIN SCI MOL MED, V54, P69, DOI 10.1042/cs0540069	33	32	34	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 24	1996	312	7029					491	494		10.1136/bmj.312.7029.491	http://dx.doi.org/10.1136/bmj.312.7029.491			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597686	Green Published			2022-12-28	WOS:A1996TX38300031
J	Campisi, J				Campisi, J			Replicative senescence: An old lives' tale?	CELL			English	Review							HUMAN-FIBROBLASTS; AGE; CELLS				Campisi, J (corresponding author), UNIV CALIF BERKELEY,BERKELEY NATL LAB,DEPT CANC BIOL,DIV LIFE SCI,BERKELEY,CA 94720, USA.							ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Campisi Judith, 1996, P121; Carrel A, 1912, J EXP MED, V15, P516, DOI 10.1084/jem.15.5.516; CHOI HS, 1990, J BIOL CHEM, V265, P18005; CRISTOFALO VJ, 1993, PHYSIOL REV, V73, P617, DOI 10.1152/physrev.1993.73.3.617; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FAWCETT TW, 1994, J BIOL CHEM, V269, P32272; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HEYDARI AR, 1993, MOL CELL BIOL, V13, P2909, DOI 10.1128/MCB.13.5.2909; JAZWINSKI SM, 1993, GENETICA, V91, P35, DOI 10.1007/BF01435986; LINSKENS MHK, 1995, SCIENCE, V267, P17, DOI 10.1126/science.7848496; MARTIN GM, 1970, LAB INVEST, V23, P86; MARTIN GM, 1993, J GERONTOL, V48, P171; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; OSHIMA J, 1995, J CELL PHYSIOL, V162, P277, DOI 10.1002/jcp.1041620213; OSHIMA J, 1994, GENOMICS, V23, P100, DOI 10.1006/geno.1994.1464; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; STANULISPRAEGER BM, 1987, MECH AGEING DEV, V38, P1, DOI 10.1016/0047-6374(87)90109-6; WANG E, 1995, CANCER RES, V55, P2284; WARNER HR, 1995, J GERONTOL A-BIOL, V50, pB107, DOI 10.1093/gerona/50A.3.B107; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3	23	376	400	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					497	500		10.1016/S0092-8674(00)81023-5	http://dx.doi.org/10.1016/S0092-8674(00)81023-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598035	Bronze			2022-12-28	WOS:A1996TX17600001
J	Davenport, M				Davenport, M			ABC of general surgery in children - Acute problems of the scrotum	BRITISH MEDICAL JOURNAL			English	Article											Davenport, M (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT PAEDIAT SURG,LONDON,ENGLAND.								0	53	55	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	1996	312	7028					435	437						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601119				2022-12-28	WOS:A1996TW56400030
J	Seivewright, NA; Greenwood, J				Seivewright, NA; Greenwood, J			What is important in drug misuse treatment?	LANCET			English	Article							ADDICTS; FLUOXETINE; DEPENDENCE; DISORDERS; ABUSE		ROYAL EDINBURGH & ASSOCIATED HOSP, COMMUNITY DRUG PROBLEM SERV, EDINBURGH, MIDLOTHIAN, SCOTLAND	Royal Infirmary of Edinburgh	Seivewright, NA (corresponding author), COMMUNITY HLTH SHEFFIELD NHS TRUST, SUBST MISUSE SERV, 6 PEEL TERRACE, SHEFFIELD S10 2GU, S YORKSHIRE, ENGLAND.							AMIT Z, 1991, J CLIN PSYCHIAT, V52, P55; Ball J.C., 2012, EFFECTIVENESS METHAD; BATKI SL, 1993, J CLIN PSYCHOPHARM, V13, P243; Berridge V, 1996, LANCET, V347, P301, DOI 10.1016/S0140-6736(96)90471-7; Brewer C, 1995, ADDICT RES, V3, pR1; CROSBY RD, 1991, COCAINE AIDS INTRAVE; DEJONG CAJ, 1993, COMPR PSYCHIAT, V34, P87, DOI 10.1016/0010-440X(93)90052-6; DINWIDDIE SH, 1993, COMPR PSYCHIAT, V34, P235, DOI 10.1016/0010-440X(93)90004-N; FARRELL M, 1994, BMJ-BRIT MED J, V309, P997, DOI 10.1136/bmj.309.6960.997; GERRA G, 1995, J SUBST ABUSE TREAT, V12, P35, DOI 10.1016/0740-5472(94)00077-8; GOLD MS, 1981, DRUG ALCOHOL DEPEN, V8, P307, DOI 10.1016/0376-8716(81)90040-5; GOSSOP M, 1991, BRIT J PSYCHIAT, V158, P697, DOI 10.1192/bjp.158.5.697; GOSSOP M, 1989, BRIT J PSYCHIAT, V154, P348, DOI 10.1192/bjp.154.3.348; GREENWOOD J, 1996, PSYCHIAT B, V20, P8; KOSTEN TR, 1989, J NERV MENT DIS, V177, P379, DOI 10.1097/00005053-198907000-00001; Mattick RP, 1996, LANCET, V347, P97, DOI 10.1016/S0140-6736(96)90215-9; Meyer RE, 1996, LANCET, V347, P162, DOI 10.1016/S0140-6736(96)90345-1; NEELEMAN J, 1995, INT J DRUG POLICY, V6, P174; Nutt DJ, 1996, LANCET, V347, P31, DOI 10.1016/S0140-6736(96)91561-5; OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2; OHARE PA, 1992, REDUCTION DRUG RELAT; PARKER H, 1987, BRIT J ADDICT, V82, P147; POLSON RG, 1993, HUM PSYCHOPHARM CLIN, V8, P55, DOI 10.1002/hup.470080110; ROBINS LN, 1991, PSYCHIATRY, V54, P116; RUEGG R, 1995, PERSONALITY DIS, V91, P1; SEIVEWRIGHT N, 1994, J PSYCHOPHARMACOL, pA35; SEIVEWRIGHT N, 1993, INT J DRUG POLICY, V4, P42; VAILLANT GE, 1988, BRIT J ADDICT, V83, P1147; WASHTON AM, 1983, J CLIN PSYCHIAT, V44, P335; WITHERS NW, 1995, J CLIN PSYCHOPHARM, V15, P63, DOI 10.1097/00004714-199502000-00010; [No title captured]	31	15	15	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 10	1996	347	8998					373	376		10.1016/S0140-6736(96)90542-5	http://dx.doi.org/10.1016/S0140-6736(96)90542-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TU695	8598706				2022-12-28	WOS:A1996TU69500014
J	Longo, DR; Brownson, RC; Johnson, JC; Hewett, JE; Kruse, RL; Novotny, TE; Logan, RA				Longo, DR; Brownson, RC; Johnson, JC; Hewett, JE; Kruse, RL; Novotny, TE; Logan, RA			Hospital smoking bans and employee smoking behavior - Results of a national survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK FACTOR SURVEY; CIGARETTE CONSUMPTION; PASSIVE SMOKING; BIRTH-WEIGHT; HEALTH; WORKPLACE; CESSATION; POLICY; CHALLENGES; POPULATION	Objective.-To examine the impact of workplace smoking bans on smoking behavior of employees. Participants.-A total of 1469 current or former smokers (intervention group) employed in smoke-free hospitals and 920 current or former smokers (comparison group) employed in non-smoke-free workplaces were surveyed to determine smoking behavior. Design.-This cross-sectional study is part of a larger, ongoing prospective study, The study design was quasi-experimental. We randomly selected sites consisting of a hospital and a corresponding community. Furthermore, we randomly selected subjects from hospitals and their corresponding communities. Main Outcome Measures.-Postban quit ratio and progression along the stages-of-change continuum. Methods.-The Cox proportional hazards model was used to compare the postban quit ratio between the intervention and comparison groups. The Cochran-Mantel-Haenszel analysis of variance statistic was used to compare groups on the stages-of-change variables. Results.-Beginning with the smoking ban and continuing for 5 years after implementation, statistically significant differences in the postban quit ratio were observed between employees of smoke-free hospitals who were smokers and counterparts in the community (P<.001). Despite preban differences in smoking intensity, the overall difference in postban quit ratios remained significant even after multivariate adjustment for socioeconomic, demographic, and smoking intensity variables. For those sites that were 5 years postban, the quit ratio was 0.506 in smoke-free work-places compared with 0.377 in workplaces where smoking was permitted. In all but 1 category, the intervention group was further along the stages-of-change continuum toward quitting smoking than the comparison group (P<.001). Conclusion.-American hospitals' experiences with smoking bans, which directly affect more than 5 million workers, should be examined by other industries as a method of improving employee health. Workplace smoking bans could also be effective in saving lives, reducing health care costs, addressing safety concerns, and decreasing operating and maintenance expenses of employers.	UNIV MISSOURI,SCH MED,MED INFORMAT GRP,COLUMBIA,MO 65212; UNIV MISSOURI,COLL ARTS & SCI,DEPT STAT,COLUMBIA,MO 65212; UNIV MISSOURI,SCH JOURNALISM,COLUMBIA,MO 65212; ST LOUIS UNIV,SCH PUBL HLTH,DEPT COMMUNITY HLTH,ST LOUIS,MO; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341; UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; Saint Louis University; Centers for Disease Control & Prevention - USA; University of California System; University of California Berkeley	Longo, DR (corresponding author), UNIV MISSOURI,SCH MED,DEPT FAMILY & COMMUNITY MED,MA306 MED SCI BLDG,COLUMBIA,MO 65212, USA.			Kruse, Robin/0000-0001-9759-7218; Johnson, Jane/0000-0002-8825-5926				BARNES DE, 1995, JAMA-J AM MED ASSOC, V274, P278; BIENER L, 1989, AM J PUBLIC HEALTH, V79, P192, DOI 10.2105/AJPH.79.2.192; BORGATTA EF, 1968, SMOKING HLTH BEHAV, P31; BORLAND R, 1990, AM J PUBLIC HEALTH, V80, P178, DOI 10.2105/AJPH.80.2.178; BORLAND R, 1992, JAMA-J AM MED ASSOC, V268, P749, DOI 10.1001/jama.268.6.749; BORLAND R, 1991, AUST J PUBLIC HEALTH, V15, P130; BROWNSON RC, 1994, EPIDEMIOLOGY, V5, P545; BROWNSON RC, 1992, AM J PUBLIC HEALTH, V82, P99, DOI 10.2105/AJPH.82.1.99; Brownson RC, 1995, HEALTH EDUC QUART, V22, P478, DOI 10.1177/109019819502200406; *BUR LAB STAT, 1994, EMPLOY EARN, P41; *CDC, 1991, SURV TOB US 1991 SUM; *CDC, 1989, PUBL CDC; *CDCP, 1995, SMOK HLTH INF NAT HL; Chapman S, 1992, TOBACCO CONTROL S, V1, pS2; CNATTINGIUS S, 1985, OBSTET GYNECOL, V66, P449; CNATTINGIUS S, 1993, AM J OBSTET GYNECOL, V168, P16, DOI 10.1016/S0002-9378(12)90878-9; CNATTINGIUS S, 1988, BMJ-BRIT MED J, V297, P258, DOI 10.1136/bmj.297.6643.258; Cook T.C., 1979, QUASIEXPERIMENTATION; COTTON P, 1994, JAMA-J AM MED ASSOC, V271, P576, DOI 10.1001/jama.271.8.576; DAVIS JR, 1994, SAINT LOUIS U PUBLIC, V13, P749; DAVIS RM, 1990, JAMA-J AM MED ASSOC, V263, P3025; DAVIS RM, 1990, JAMA-J AM MED ASSOC, V263, P2208; DICLEMENTE CC, 1982, ADDICT BEHAV, V7, P133, DOI 10.1016/0306-4603(82)90038-7; DICLEMENTE CC, 1991, J CONSULT CLIN PSYCH, V59, P293; ELIOPOULOS C, 1994, JAMA-J AM MED ASSOC, V271, P621, DOI 10.1001/jama.271.8.621; EMONT SL, 1995, AM J HEALTH PROMOT, V9, P456, DOI 10.4278/0890-1171-9.6.456; EPA, 1992, PUBL EPA; *EPA, 1990, PUBL EPA; FIELDING JE, 1978, MILBANK FUND Q, V56, P274, DOI 10.2307/3349650; FLOYD RL, 1993, ANNU REV PUBL HEALTH, V14, P379, DOI 10.1146/annurev.pu.14.050193.002115; FONTHAM ETH, 1994, JAMA-J AM MED ASSOC, V271, P1752, DOI 10.1001/jama.271.22.1752; Fowler FJ., 2013, SURV RES METHODS-GER, V5; Frey J. H, 1989, SURVEY RES TELEPHONE, V150; GARFINKEL L, 1986, CA-CANCER J CLIN, V36, P2, DOI 10.3322/canjclin.36.1.2; Gentry E M, 1985, Am J Prev Med, V1, P9; Giovino Gary A., 1994, Morbidity and Mortality Weekly Report, V43, P1; GOLDSTEIN AO, 1992, J FAM PRACTICE, V34, P729; GOTTLIEB NH, 1990, J OCCUP ENVIRON MED, V32, P16, DOI 10.1097/00043764-199001000-00008; HUGHES PH, 1991, JAMA-J AM MED ASSOC, V265, P2069, DOI 10.1001/jama.265.16.2069; JACKSON C, 1992, AM J PUBLIC HEALTH, V82, P412, DOI 10.2105/AJPH.82.3.412; JCAHO, 1992, PAT RIGHTS SECT RI 1, P10; KALBFLEISCH JD, 1995, STAT AN FAIL TIM DAT; Kish L, 1965, SURVEY SAMPLING; KOEPSELL TD, 1991, J CLIN EPIDEMIOL, V44, P701, DOI 10.1016/0895-4356(91)90030-D; LANDIS RJ, 1978, INT STAT REV, V46, P237; LEFCOE NM, 1983, CHEST, V84, P90, DOI 10.1378/chest.84.1.90; LI CQ, 1992, AM J PREV MED, V8, P171, DOI 10.1016/S0749-3797(18)30827-4; LONGO DR, 1995, JAMA-J AM MED ASSOC, V274, P488, DOI 10.1001/jama.274.6.488; MCKINLAY JB, 1993, SOC SCI MED, V36, P109, DOI 10.1016/0277-9536(93)90202-F; MUDARRI DH, 1994, COSTS BENEFITS SMOKI; NELSON DE, 1994, JAMA-J AM MED ASSOC, V271, P1273, DOI 10.1001/jama.271.16.1273; NOVOTNY TE, 1992, CAN PREVEN       JUL, P1; Pierce JP, 1994, TOB CONTROL, V3, P15, DOI DOI 10.1136/TC.3.1.15; Prochaska J. O., 1984, TRANSTHEORETICAL APP; PROCHASKA JO, 1985, ADDICT BEHAV, V10, P395, DOI 10.1016/0306-4603(85)90036-X; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; Repace JL, 1994, ST LOUIS U PUB L REV, VXIII, P763; REPACE JL, 1992, TOB CONTROL, V1, P208; Rogers EM., 1983, DIFFUSION INNOVATION; SEXTON M, 1984, JAMA-J AM MED ASSOC, V251, P911, DOI 10.1001/jama.251.7.911; SHEA S, 1991, AM J EPIDEMIOL, V133, P489, DOI 10.1093/oxfordjournals.aje.a115916; Shiffman S, 1986, Health Psychol, V5 Suppl, P13, DOI 10.1037//0278-6133.5.Suppl.13; Stillman F A, 1994, Am J Health Promot, V9, P108; STILLMAN FA, 1990, JAMA-J AM MED ASSOC, V264, P1565, DOI 10.1001/jama.264.12.1565; *US DEP HHS, 1986, PUBL DHHS; *US DEPT HHS, 1990, PUBL CDC, P25; *US DEPT HHS, 1990, PUBL CDC; WAKEFIELD MA, 1992, J OCCUP ENVIRON MED, V34, P693; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WINETT RA, 1994, HLTH PSYCHOL PUBLIC; 1994, MMWR-MORBID MORTAL W, V43, P925; 1993, MMWR-MORBID MORTAL W, V42, P645; [No title captured]; 1994, PEDIATRICS, V93, P866; 1994, MMWR-MORBID MORTAL W, V43, P469	75	84	84	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1252	1257		10.1001/jama.275.16.1252	http://dx.doi.org/10.1001/jama.275.16.1252			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF478	8601957				2022-12-28	WOS:A1996UF47800029
J	Rothwell, PM; Wroe, SJ; Slattery, J; Warlow, CP				Rothwell, PM; Wroe, SJ; Slattery, J; Warlow, CP			Is stroke incidence related to season or temperature?	LANCET			English	Article							CEREBROVASCULAR-DISEASE; COMMUNITY; RATES	Background A winter excess of ischaemic stroke has been found in mortality and hospital-based studies. It is often assumed that this is due to seasonal variation in stroke incidence and several pathophysiological explanations have been proposed. We studied the incidence of stroke in relation to season and outside temperature. Methods The data came from a community-based study of first ever in a lifetime stroke in a defined population of about 105 000. 675 such strokes were registered over four years and the month of onset was analysed separately for cerebral infarction, primary intracerebral haemorrhage, and subarachnoid haemorrhage. Findings There was no significant seasonal variation. The incidence of primary intracerebral haemorrhage was increased at low temperatures, but there was no significant relation between the incidence of ischaemic stroke or subarachnoid haemorrhage and temperature. Interpretation The widely reported winter excess of ischaemic strokes may be an artifact due to referral bias in hospital-based studies and increased case fatality during the winter in mortality studies.	IPSWICH HOSP,DEPT NEUROL,IPSWICH,SUFFOLK,ENGLAND	Ipswich Hospital NHS Trust; Ipswich Hospital	Rothwell, PM (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211	Medical Research Council [G0500987] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALLEN CMC, 1983, Q J MED, V52, P515; BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; HABERMAN S, 1981, J NEUROL SCI, V52, P25, DOI 10.1016/0022-510X(81)90131-3; KELLYHAYES M, 1995, STROKE, V26, P1343, DOI 10.1161/01.STR.26.8.1343; PAN WH, 1995, LANCET, V345, P353, DOI 10.1016/S0140-6736(95)90341-0; RICCI S, 1992, NEUROEPIDEMIOLOGY, V11, P59, DOI 10.1159/000110913; ROTHWELL PM, 1994, LANCET, V344, P1161, DOI 10.1016/S0140-6736(94)90671-8; SOBEL E, 1987, STROKE, V18, P38, DOI 10.1161/01.STR.18.1.38; STOUT RW, 1991, LANCET, V338, P9, DOI 10.1016/0140-6736(91)90004-9; WALTER SD, 1975, BRIT J PREV SOC MED, V29, P18; *WHO, 1977, WHO MAN MORT AN, P212; WOODHOUSE PR, 1993, J HYPERTENS, V11, P1267; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	14	127	130	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1996	347	9006					934	936		10.1016/S0140-6736(96)91415-4	http://dx.doi.org/10.1016/S0140-6736(96)91415-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598757				2022-12-28	WOS:A1996UD59100010
J	Targarona, EM; Ayuso, RMP; Bordas, JM; Ros, E; Pros, I; Martinez, J; Teres, J; Trias, M				Targarona, EM; Ayuso, RMP; Bordas, JM; Ros, E; Pros, I; Martinez, J; Teres, J; Trias, M			Randomised trial of endoscopic sphincterotomy with gallbladder left in situ versus open surgery for common bileduct calculi in high-risk patients	LANCET			English	Article							DUCT STONES; MANAGEMENT; CHOLECYSTECTOMY; EXPLORATION; INSITU	Background Morbidity and mortality after surgical treatment of bileduct stones increase with age and associated diseases. A proposed alternative therapy is endoscopic sphincterotomy (ES) with the gallbladder left in situ, and we selected to compare this option with standard open surgery in high-risk patients. Methods 98 patients (mean age 80 years) with symptoms likely to be due to bileduct stones or a recent episode of biliary pancreatitis were randomised to be treated either by open cholecystectomy with operative cholangiography and (if necessary) bileduct exploration (n=48) or by endoscopic sphincterotomy alone (n=50). Findings The procedure was accomplished successfully in 94% of the surgery group and 88% of the ES group, and there were no significant differences in immediate morbidity (23% vs 16%) or mortality (4% vs 6%). During mean follow-up of 17 months biliary symptoms recurred in three surgical patients, none of whom underwent repeat surgery, and in 10 ES patients, seven of whom had biliary surgery. By multivariate regression analysis endoscopic sphincterotomy was an independent predictor of recurrent biliary symptoms (odds ratio 6.9; 95% Cl 1.46 to 32.54). Interpretation In elderly or high-risk patients, surgery is preferable to endoscopic sphincterotomy with the gallbladder left in situ as a definitive treatment for bileduct stones or non-severe biliary pancreatitis.	UNIV BARCELONA,HOSP CLIN,SERV GEN & DIGEST SURG,BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN,GASTROENTEROL SERV,BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN,ENDOSCOPY UNIT,BARCELONA,SPAIN	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona				Ros, Emilio/0000-0002-2573-1294; Targarona, Eduardo m/0000-0001-7557-6934				BENNY C, 1990, RADIOLOGY, V174, P127; DAVIDSON BR, 1988, GUT, V29, P114, DOI 10.1136/gut.29.1.114; ESCARCE JJ, 1995, SURGERY, V117, P156, DOI 10.1016/S0039-6060(05)80079-0; GINESTALCRUZ A, 1985, HEPATOLOGY, V5, P969; HILL J, 1991, BRIT J SURG, V78, P554, DOI 10.1002/bjs.1800780512; MANES G, 1994, INT J PANCREATOL, V16, P318; MERRIMAN R, 1989, GASTROENTEROLOGY A, V96, P698; MILLER BM, 1988, ANN SURG, V207, P135, DOI 10.1097/00000658-198802000-00004; MOREAUX J, 1995, AM J SURG, V169, P220, DOI 10.1016/S0002-9610(99)80141-X; NEOPTOLEMOS JP, 1984, BRIT J SURG, V71, P69, DOI 10.1002/bjs.1800710123; NEOPTOLEMOS JP, 1987, BRIT MED J, V294, P470, DOI 10.1136/bmj.294.6570.470; NEOPTOLEMOS JP, 1989, ANN SURG, V209, P157, DOI 10.1097/00000658-198902000-00004; NEOPTOLEMOS JP, 1987, BRIT J SURG, V74, P916, DOI 10.1002/bjs.1800741014; PANIS Y, 1995, GASTROENTEROLOGY, V108, pA431; PERISSAT J, 1994, BRIT J SURG, V81, P799, DOI 10.1002/bjs.1800810606; PERISSAT J, 1994, EUR J GASTROEN HEPAT, V6, P857, DOI 10.1097/00042737-199410000-00003; ROTHENBERG RE, 1991, AM SURGEON, V57, P306; STIEGMANN GV, 1992, AM J SURG, V163, P227, DOI 10.1016/0002-9610(92)90106-2; STRASBERG SM, 1995, GASTROENTEROLOGY, V109, P320, DOI 10.1016/0016-5085(95)90302-X; TARGARONA EM, 1992, MED CLIN-BARCELONA, V98, P69; TARGARONA EM, 1993, HPB SURG S, V6, pA5; Tierney S, 1995, Adv Surg, V28, P271; WELBOURN CRB, 1995, GUT, V37, P119, DOI 10.1136/gut.37.1.119; WINSLET MC, 1991, BAILLIERE CLIN GASTR, V5, P99, DOI 10.1016/0950-3528(91)90008-O	24	134	137	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1996	347	9006					926	929		10.1016/S0140-6736(96)91413-0	http://dx.doi.org/10.1016/S0140-6736(96)91413-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598755				2022-12-28	WOS:A1996UD59100008
J	Camins, BC; Bock, N; Watkins, DL; Blumberg, HM				Camins, BC; Bock, N; Watkins, DL; Blumberg, HM			Acceptance of isoniazid preventive therapy by health care workers after tuberculin skin test conversion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOSOCOMIAL TRANSMISSION; EPIDEMIOLOGY; INFECTION; OUTBREAK	Objective.-To examine health care workers' (HCWs') acceptance of and adherence to isoniazid preventive therapy in the setting of a comprehensive tuberculin skin-testing program. Design.-Descriptive case series. Setting.-University-affiliated inner-city public hospital in Atlanta, Ga. Participants.-A total of 125 HCWs (91 hospital employees and 34 house staff or medical students [the physician group]) who had a positive tuberculin skin test between July 1992 and January 1994 and were offered isoniazid preventive therapy. Interventions.-Health care workers with a recent tuberculin skin test conversion were required to have a chest x-ray performed and see a physician and were encouraged but not required to undergo preventive therapy. Main Outcome Measures.-Acceptance and initiation of preventive therapy with isoniazid by HCWs, completion of at least 6 months of preventive therapy, and differences between the employee and physician groups. Results.-All 125 HCWs with a recent positive tuberculin skin test had a chest radiograph performed, 123 (98.4%) saw a physician, and 105 (84%) initiated preventive therapy. Sixty-nine (66%) of the 105 HCWs who initiated preventive therapy (55% of the 125 total) completed at least 6 months of isoniazid therapy. More of the physician group than of the employee group completed preventive therapy (25 of 34 [74%] vs 44 of 91 [48%], respectively; P<.01). Of the 36 HCWs who started but did not complete preventive therapy, 12 discontinued therapy because of an adverse drug effect and 24 were nonadherent. Conclusions.-Acceptance of tuberculosis preventive therapy by HCWs was high in the setting of a comprehensive tuberculin skin-testing program, and completion of therapy was much higher in the physician group than in previously reported series.	EMORY UNIV,SCH MED,DEPT MED,DIV INFECT DIS,ATLANTA,GA 30303; GRADY MEM HOSP,ATLANTA,GA	Emory University			Blumberg, Henry/W-2156-2019	Blumberg, Henry/0000-0002-3110-2443	NHLBI NIH HHS [K07 HL03078-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL003078] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETTCONNOR E, 1979, JAMA-J AM MED ASSOC, V241, P33, DOI 10.1001/jama.241.1.33; BLUMBERG HM, 1995, ANN INTERN MED, V122, P658, DOI 10.7326/0003-4819-122-9-199505010-00003; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; CATANZARO A, 1995, LANCET, V345, P204, DOI 10.1016/S0140-6736(95)90216-3; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRASER VJ, 1994, INFECT CONT HOSP EP, V15, P95; GIESELER PJ, 1987, AM REV RESPIR DIS, V135, P3; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; JARVIS WR, 1993, RES MICROBIOL, V144, P117, DOI 10.1016/0923-2508(93)90025-W; LECOEUR HF, 1989, AM REV RESPIR DIS, V140, P1189, DOI 10.1164/ajrccm/140.5.1189; MCGOWAN JE, 1995, CLIN INFECT DIS, V21, P489, DOI 10.1093/clinids/21.3.489; SALPETER S, 1992, WESTERN J MED, V157, P421; SEPKOWITZ KA, 1994, ANN INTERN MED, V120, P71, DOI 10.7326/0003-4819-120-1-199401010-00012; WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7; ZAZA S, 1995, J INFECT DIS, V172, P1542, DOI 10.1093/infdis/172.6.1542; 1994, MMWR-MORBID MORTAL W, V43, P1; 1994, AM J RESP CRIT CARE, V149, P1359	19	26	27	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					1013	1015						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC123	8596233				2022-12-28	WOS:A1996UC12300029
J	Sengupta, P; Chou, JH; Bargmann, CI				Sengupta, P; Chou, JH; Bargmann, CI			odr-10 encodes a seven transmembrane domain olfactory receptor required for responses to the odorant diacetyl	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; SENSITIVE ADENYLATE-CYCLASE; C-ELEGANS; PROTEIN; EXPRESSION; EPITHELIUM; SEQUENCE; GENOME; SYSTEM; TRANSDUCTION	Olfactory signaling is initiated by interactions between odorants and olfactory receptors. We show that the C. elegans odr-10 gene is likely to encode a receptor for the odorant diacetyl. odr-10 mutants have a specific defect in chemotaxis to diacetyl, one of several odorants detected by the AWA olfactory neurons. odr-10 encodes a predicted seven transmembrane domain receptor; a green fluorescent protein-tagged Odr-10 protein is localized to the AWA sensory cilia. odr-10 expression is regulated by odr-7, a transcription factor implicated in AWA sensory specification. Expression of odr-10 from a heterologous promoter directs behavioral responses to diacetyl, but not to another odorant detected by the AWA neurons. These results provide functional evidence for a specific interaction between an olfactory receptor protein and its odorant ligand.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,GENET PROGRAM,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Cote, Rick H/G-3363-2013	Cote, Rick H/0000-0002-1573-6526; Chou, Joseph/0000-0002-3138-0777; Bargmann, Cornelia/0000-0002-8484-0618				AATSINKI JT, 1994, BIOTECHNIQUES, V16, P282; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BOEKHOFF I, 1994, J NEUROSCI, V14, P3304; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BRENNER S, 1974, GENETICS, V77, P71; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLARK SG, 1994, GENETICS, V137, P987; COLBERT HA, 1995, NEURON, V14, P803, DOI 10.1016/0896-6273(95)90224-4; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; FIRESTEIN S, 1991, J NEUROSCI, V11, P3565; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HIRAOKA Y, 1990, BIOPHYS J, V57, P325, DOI 10.1016/S0006-3495(90)82534-0; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; IVANOVA TT, 1993, J GEN PHYSIOL, V102, P1085, DOI 10.1085/jgp.102.6.1085; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KANG JS, 1995, J NEUROPHYSIOL, V73, P172, DOI 10.1152/jn.1995.73.1.172; KLEIN RD, 1993, CELL, V72, P349, DOI 10.1016/0092-8674(93)90113-5; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Sambrook J., 2002, MOL CLONING LAB MANU; SENGUPTA P, 1994, CELL, V79, P971, DOI 10.1016/0092-8674(94)90028-0; SIDDIQI O, 1987, TRENDS GENET, V3, P137, DOI 10.1016/0168-9525(87)90204-6; SINGER MS, 1995, NATURE, V377, P19, DOI 10.1038/377019b0; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; SULLIVAN SL, 1995, NEURON, V15, P779, DOI 10.1016/0896-6273(95)90170-1; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WARE RW, 1975, J COMP NEUROL, V162, P71, DOI 10.1002/cne.901620106; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILLIAMS BD, 1992, GENETICS, V131, P609; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	55	397	418	1	70	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					899	909		10.1016/S0092-8674(00)81068-5	http://dx.doi.org/10.1016/S0092-8674(00)81068-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601313	Bronze			2022-12-28	WOS:A1996UC38100011
J	Atri, J; Falshaw, M; Livingstone, A; Robson, J				Atri, J; Falshaw, M; Livingstone, A; Robson, J			Fair shares in health care? Ethnic and socioeconomic influences on recording of preventive care in selected inner London general practices	BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; NAME	Objective-To describe the association of ethnic and socioeconomic status with recording of preventive care information by selected general practitioners. Design-Random selection of people aged 20-64 registered with 43 general practitioners. Ethnic and social characteristics of stratified samples were determined at interview in the subject's home. Recording of preventive information was ascertained from general practitioners' medical records. Setting-Inner London borough of Tower Hamlets. Subjects-505 out of 739 people confirmed as resident at their home address (190 white, 86 black, 112 Bangladeshi, 105 Chinese or Vietnamese, 12 other). Main outcome measures-Socioeconomic characteristics, consultation with general practitioner, and recorded preventive activities for ethnic groups. Results-Minority ethnic groups were considerably more disadvantaged than white people and five times more likely to be overcrowded (31% v 6%), three times less likely to own their own home (11% v 37%), twice as likely to be in social classes IV and V (54% v 28%) and less likely to be employed (34% v 63%). There were no significant differences between white, black, Bangladeshi, and Chinese or Vietnamese subjects in recording of smoking, blood pressure, alcohol consumption, weight, and height in the general practitioners' medical records, White women were more Likely to have a record of mammography (46% v 20%; P = 0.03) and of cervical smears than women in minority ethnic groups. Conclusion-Despite major socioeconomic inequity, equitable recording of preventive activity for the major causes of death for white, black and Bangladeshi populations is possible. Chinese and Vietnamese people had lower levels of recording and consultation Mammography and, to a lesser extent, cervical cytology are inequitably recorded and require additional support at practice level.	UNIV LONDON QUEEN MARY & WESTFIELD COLL,MED COLL ST BARTHOLOMEWS & LONDON HOSP,LONDON E1 4NS,ENGLAND; UNIV LONDON QUEEN MARY & WESTFIELD COLL,LONDON HOSP MED COLL,DEPT MED STAT,LONDON E1 4NS,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London			Robson, John/H-3904-2014	Robson, John/0000-0001-6889-0415				AUSTOKER J, 1993, BREAST SCREENING ACC; BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; BALARAJAN R, 1993, ETHNICITY HLTH GUIDE; CHATURVEDI N, 1994, J EPIDEMIOL COMMUN H, V48, P107, DOI 10.1136/jech.48.2.107; COLDMAN AJ, 1988, J EPIDEMIOL COMMUN H, V42, P390, DOI 10.1136/jech.42.4.390; DOYLE Y, 1991, SOC SCI MED, V32, P953, DOI 10.1016/0277-9536(91)90250-G; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; *HLTH EAST PROJ, 1994, 1993 MAR WESTF COLL; HUGHES AO, 1995, J PUBLIC HEALTH MED, V17, P187, DOI 10.1093/oxfordjournals.pubmed.a043091; INKLEYLEITCH G, 1994, COLLABORATIVE DEV PL; JACOBSON B, 1994, 1994 5 E LON CIT HLT; Jones T., 1993, BRITAINS ETHNIC MINO; LEESE B, 1995, BRIT MED J, V311, P548; LORENTZON M, 1994, 66 ROYAL COLL GEN PR; MANT D, 1994, LANCET, V344, P1343, DOI 10.1016/S0140-6736(94)90698-X; MARSH GN, 1986, BRIT MED J, V292, P1173, DOI 10.1136/bmj.292.6529.1173; MCCORMICK A, 1990, 1981 1982 MORBID M85; MCKEIGUE P, 1991, LANCET, V377, P382; NAISH J, 1994, BRIT MED J, V309, P1126; *NAT HLTH SERV ETE, 1993, REP TASK FORC BLACK; NICOLL A, 1986, J EPIDEMIOL COMMUN H, V40, P364, DOI 10.1136/jech.40.4.364; *OFF POP CENS SURV, 1992, 1991 CENS DEF GREAT; *OFF POP CENS SURV, 1991, 1991 CENS INN LOND; Office of Population Censuses and Surveys, 1980, CLASS OCC 1980; Pilgrim S, 1993, BRISTOL BLACK ETHNIC; ROBSON J, 1995, BRIT J GEN PRACT, V45, P463; Rudat K., 1994, HLTH LIFESTYLES BLAC; TAYLOR V, 1992, BRIT J GEN PRACT, V42, P377; THOMPSON H, 1994, RESULTS HLTH SURVEY; WILMOTT P, 1992, URBAN TRENDS, V1	30	17	17	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					614	617						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595338				2022-12-28	WOS:A1996TZ84000028
J	Eriksson, BI; Ekman, S; Kalebo, P; Zachrisson, B; Bach, D; Close, P				Eriksson, BI; Ekman, S; Kalebo, P; Zachrisson, B; Bach, D; Close, P			Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393	LANCET			English	Article							MOLECULAR-WEIGHT HEPARIN; SUSPECTED PULMONARY-EMBOLISM; VENOUS THROMBOSIS; PERFUSION	Background The frequency of thromboembolism after major orthopaedic surgery continues to be high despite prophylaxis. New agents such as CGP 39393, a recombinant form of hirudin, may be more effective than existing therapies. Methods In this double-blind, multicentre, European study the efficacy of three doses of CGP 39393, in comparison with unfractionated heparin, were examined in 1119 patients undergoing elective hip surgery. Patients were randomly allocated to receive by subcutaneous injection either 10, 15, or 20 mg of CGP 39393 twice daily or 5000 IU of heparin three times daily. All treatments were started just before surgery and continued for 8-11 days, until bilateral venography was performed. Findings The occurrence of thromboembolism was significantly reduced in patients treated with CGP 39393 compared to heparin. The frequency of deep-vein thrombosis was 34.2% in the heparin group as compared to 23.9% (p=0.0113), 18.4% (p=0.0003), and 17.7% (p=0.0001) in the 10 mg, 15 mg, and 20 mg CGP 39393 groups, respectively. At all dose levels, CGP 39393 was more effective than heparin in preventing proximal deep-vein thrombosis. The frequency of proximal thrombosis was 19.6% in the heparin group as compared to 8.5% (p<0.001), 3.1% (p<0.001), and 2.4% (p<0.001) in the 10 mg, 15 mg, and 20 mg CGP 39393 groups, respectively. All treatments were well tolerated. Interpretation This study indicates that specific inhibition of thrombin by prophylactic CGP 39393 significantly reduces thromboembolic complications in patients undergoing total hip replacement.	GOTHENBURG UNIV,DEPT ORTHOPAED SURG,S-41685 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT RADIOL,S-41685 GOTHENBURG,SWEDEN; CIBA GEIGY LTD,BASEL,SWITZERLAND	University of Gothenburg; University of Gothenburg; Novartis				Eriksson, Bengt/0000-0001-6894-7434				BERGQVIST D, 1983, POSTOPERATIVE THROMB, P24; BIELLO DR, 1979, AM J ROENTGENOL, V133, P1033, DOI 10.2214/ajr.133.6.1033; CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; ERIKSSON BI, 1994, THROMB HAEMOSTASIS, V72, P227; ERIKSSON BI, 1991, J BONE JOINT SURG, V73, P479; HAUPTMANN J, 1987, HAEMOSTASIS, V17, P321; Havig O, 1977, Acta Chir Scand Suppl, V478, P1; HOLM S, 1979, SCAND J STAT, V6, P65; HULL R, 1993, NEW ENGL J MED, V329, P1370, DOI 10.1056/NEJM199311043291902; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; KAISER B, 1986, THROMB RES, V43, P613, DOI 10.1016/0049-3848(86)90098-8; KALEBO P, 1990, ACTA RADIOL, V31, P259, DOI 10.3109/02841859009171987; MARKWARDT F, 1982, THROMB HAEMOSTASIS, V47, P226; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; PLANES A, 1988, THROMB HAEMOSTASIS, V60, P407; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; TALBOT MD, 1990, INT S APP C, V1, P131; ZECHRISSON BE, 1973, ACTA RADIOL DIAGN, V14, P81	20	173	178	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					635	639		10.1016/S0140-6736(96)91200-3	http://dx.doi.org/10.1016/S0140-6736(96)91200-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596376				2022-12-28	WOS:A1996TZ28500008
J	Sinaiko, A; Michael, A				Sinaiko, A; Michael, A			Reflux nephropathy and hypertension: More whys and wherefores	LANCET			English	Editorial Material							PLASMA-RENIN ACTIVITY; CHILDREN; CAPTOPRIL				Sinaiko, A (corresponding author), UNIV MINNESOTA,UNIV VARIETY HOSP CHILDREN,DEPT PEDIAT,MINNEAPOLIS,MN 55455, USA.							BAILEY RR, 1978, J UROLOGY, V120, P21, DOI 10.1016/S0022-5347(17)57026-3; BURNS KD, 1993, SEMIN NEPHROL, V13, P13; DANSER AHJ, 1991, J HYPERTENS       S6, V9, P234; DILLON MJ, 1975, BMJ-BRIT MED J, V4, P316, DOI 10.1136/bmj.4.5992.316; GOMEZ RA, 1995, AM J KIDNEY DIS, V26, P409, DOI 10.1016/0272-6386(95)90487-5; GOMEZ RA, 1994, CANCER RES, V54, P2856; HAMED RMA, 1992, PEDIATR NEPHROL, V6, P33, DOI 10.1007/BF00856826; HICKS C C, 1976, Urology, V7, P587, DOI 10.1016/0090-4295(76)90082-0; HINER LB, 1976, J PEDIATR-US, V89, P258, DOI 10.1016/S0022-3476(76)80461-1; ODEA RF, 1988, J PEDIATR-US, V113, P403, DOI 10.1016/S0022-3476(88)80292-0; SEDMAN AB, 1995, PEDIATR NEPHROL, V9, P382, DOI 10.1007/BF02254221; SIEGLER R L, 1976, Urology, V7, P474, DOI 10.1016/0090-4295(76)90182-5; SINAIKO AR, 1989, J PEDIATR-US, V114, P664, DOI 10.1016/S0022-3476(89)80718-8; STALKER HP, 1976, J PEDIATR-US, V89, P256, DOI 10.1016/S0022-3476(76)80460-X; STECKER JF, 1977, J UROLOGY, V118, P644, DOI 10.1016/S0022-5347(17)58137-9	15	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					633	634		10.1016/S0140-6736(96)91198-8	http://dx.doi.org/10.1016/S0140-6736(96)91198-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596374				2022-12-28	WOS:A1996TZ28500006
J	Khachigian, LM; Lindner, V; Williams, AJ; Collins, T				Khachigian, LM; Lindner, V; Williams, AJ; Collins, T			Egr-1-induced endothelial gene expression: A common theme in vascular injury	SCIENCE			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; HUMAN ATHEROSCLEROTIC PLAQUES; SMOOTH-MUSCLE; TRANSCRIPTION FACTOR; ARTERIAL INJURY; BINDING; PROMOTER; EGR-1; SITE; ANGIOPLASTY	A number of pathophysiologically relevant genes, including platelet-derived growth factor B-chain (PDGF-B), are induced in the vasculature after acute mechanical injury. In rat aorta, the activated expression of these genes was preceded by a marked increase in the amount of the early-growth-response gene product Egr-1 at the endothelial wound edge. Egr-1 interacts with a novel element in the proximal PDGF-B promoter, as well as with consensus elements in the promoters of other genes induced by endothelial injury. This interaction is crucial for injury-induced PDGF-B promoter-dependent expression. Sp1, whose binding site in the PDGF-B promoter overlaps that of Egr-1, occupies this element in unstimulated cells and is displaced by increasing amounts of Egr-1. These findings implicate Egr-1 in the up-regulated expression of PDGF-B and other potent mediators in mechanically injured arterial endothelial cells.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV VASC RES,BOSTON,MA 02115; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	Harvard University; Brigham & Women's Hospital; University of Washington; University of Washington Seattle			Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; BARRETT TB, 1988, P NATL ACAD SCI USA, V85, P2810, DOI 10.1073/pnas.85.8.2810; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; CUI MZ, 1994, ARTERIOSCLER THROMB, V14, P807, DOI 10.1161/01.ATV.14.5.807; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DIRKS RPH, 1995, NUCLEIC ACIDS RES, V23, P1119, DOI 10.1093/nar/23.7.1119; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GIMBRONE MA, 1995, AM J CARDIOL, V75, pB67, DOI 10.1016/0002-9149(95)80016-L; HANCOCK WW, 1994, AM J PATHOL, V145, P1008; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P755; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KHACHIGIAN LM, UNPUB; KIM SJ, 1989, J BIOL CHEM, V264, P402; LINDNER V, 1995, AM J PATHOL, V146, P1488; Lindner V, 1996, AM J PATHOL, V148, P427; MACKMAN N, 1995, FASEB J, V9, P883, DOI 10.1096/fasebj.9.10.7615158; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MARMUR JD, 1993, J CLIN INVEST, V91, P2253, DOI 10.1172/JCI116452; MATTSSON E, 1995, TRENDS CARDIOVAS MED, V5, P200, DOI 10.1016/1050-1738(95)00075-K; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; REED MJ, 1995, AM J PATHOL, V147, P1068; REKHTER MD, 1994, CIRC RES, V75, P410, DOI 10.1161/01.RES.75.3.410; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671	35	476	491	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1427	1431		10.1126/science.271.5254.1427	http://dx.doi.org/10.1126/science.271.5254.1427			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596917				2022-12-28	WOS:A1996TY96100049
J	[Anonymous]				[Anonymous]			Infected blood in Japan	NATURE			English	Editorial Material																		1996, NATURE, V379, P663; 1996, NATURE, V379, P760	2	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1996	380	6569					1	1						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598891				2022-12-28	WOS:A1996TY87700002
J	Bourke, GJ				Bourke, GJ			Airbags and fatal injuries to children	LANCET			English	Editorial Material											Bourke, GJ (corresponding author), UNIV COLL DUBLIN,DEPT EPIDEMIOL & PUBL HLTH MED,DUBLIN,IRELAND.							HERBERT D C, 1964, Med J Aust, V1, P61; NORMAN LG, 1962, 12 WHO PUBL HLTH PAP; 1995, H9517 NAT TRANSP SAF; 1995, MMWR-MORBID MORTAL W, V44, P845; 1993, MMWR-MORBID MORTAL W, V42, P280; 1995, TRAFFIC SAFETY FACTS	6	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					560	560		10.1016/S0140-6736(96)91269-6	http://dx.doi.org/10.1016/S0140-6736(96)91269-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596316				2022-12-28	WOS:A1996TX69400007
J	Raiha, I; Kaprio, J; Koskenvuo, M; Rajala, T; Sourander, L				Raiha, I; Kaprio, J; Koskenvuo, M; Rajala, T; Sourander, L			Alzheimer's disease in Finnish twins	LANCET			English	Article							DEMENTIA; DIAGNOSIS; CONCORDANCE; ZYGOSITY; COHORT; PAIRS	Background The genetics of Alzheimer's disease (AD) are obscure. Although most cases are sporadic half the patients with sporadic AD have a positive family history. The mode of genetic transmission and the role of environmental factors are unknown. The purpose of this study was to examine the contribution of genetic factors to the pathogenesis of AD in a twin cohort. Methods The Finnish Twin Cohort consists of all Finnish same-sexed twin pairs born before 1958 with both co-twins alive in 1975. The total number of twin pairs is 13 888, of whom 4307 are monozygotic (MZ) and 9581 are dizygotic (DZ). These data were linked with the Hospital Discharge Register from 1972 to 1991 to identify twins who had dementia or related disease as a discharge diagnosis. The linkage of the registries yielded a total of 285 twin individuals. The medical records of these twins and their co-twins were reviewed to confirm and classify dementia (AD, vascular dementia, mixed dementia, and other dementia). The incidence, concordance, and age at onset of AD were examined. Findings The incidence of AD was significantly higher in MZ than in DZ twin individuals, with an adjusted MZ/DZ incidence ratio of 1.8 (95% confidence intervals 1.2 to 2.7). In contrast, the incidence of vascular or mixed dementia did not differ between MZ and DZ individuals (MZ/DZ ratio 0.6 [0.3 to 1.2]) for vascular and 1.0 [0.5 to 2.1] for mixed dementia). The pairwise concordance for AD was 18.6% in MZ pairs and 4.7% in DZ pairs and the corresponding probandwise concordance rates were 31.3% and 9.3%. The pairwise concordance for vascular dementia was 18.2% in MZ pairs and 6.7% in DZ pairs with corresponding probandwise rates of 30.8% and 12.5%. The onset age of AD in concordant MZ pairs was identical in two pairs and diverged by up to 15 years. Interpretation The higher incidence of AD in MZ individuals than in DZ individuals may provide a clue to the aetiology of AD. The higher concordance rate of MZ pairs confirms the contribution of the major genetic component while indicating the need to identify environmental triggers.	HELSINKI UNIV,DEPT PUBL HLTH,HELSINKI,FINLAND; UNIV TURKU,DEPT PUBL HLTH,SF-20700 TURKU,FINLAND	University of Helsinki; University of Turku	Raiha, I (corresponding author), UNIV TURKU,DEPT GERIATR,KUNNALLISSAIRAALANTIE 20,SF-20700 TURKU,FINLAND.		Kaprio, Jaakko/A-1820-2008	Kaprio, Jaakko/0000-0002-3716-2455				[Anonymous], 1987, DIAGNOSTIC STAT MANU; BERGEM ALM, 1992, NEUROBIOL AGING S1, V13, P66; BREITNER JCS, 1993, NEUROLOGY, V43, P261, DOI 10.1212/WNL.43.2.261; CEDERLOEF R, 1961, ACTA GENET STAT MED, V11, P338; CHRISTENSEN K, 1995, BRIT MED J, V310, P432, DOI 10.1136/bmj.310.6977.432; COOK RH, 1981, ARCH NEUROL-CHICAGO, V38, P300, DOI 10.1001/archneur.1981.00510050066011; EHNOLM C, 1986, J LIPID RES, V27, P227; Falconer D. S., 1981, INTRO QUANTITATIVE G; FROME EL, 1985, AM J EPIDEMIOL, V121, P309, DOI 10.1093/oxfordjournals.aje.a114001; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; HAGNELL O, 1983, ARCH PSYCHIAT NERVEN, V233, P423, DOI 10.1007/BF00342783; HARVALD B, 1965, DHEW PUBLICATION, V1163, P61; JABLON S, 1967, AM J HUM GENET, V19, P133; JARVINEN P, 1992, J INTERN MED, V231, P67; Kaprio J, 1978, Prog Clin Biol Res, V24 Pt B, P179; KAPRIO J, 1978, PUBLICATIONS PUBL M, V37; KASRIEL J, 1976, J BIOSOC SCI, V8, P263, DOI 10.1017/S0021932000010737; KERVINEN K, 1995, AM HEART ASS 68 SCI; KINNUNEN E, 1987, NEUROLOGY, V37, P1627, DOI 10.1212/WNL.37.10.1627; KOSKENVUE M, 1979, FINNISH TWIN REGISTR; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; MARTTILA RJ, 1988, NEUROLOGY, V38, P1217, DOI 10.1212/WNL.38.8.1217; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; NEE LE, 1987, NEUROLOGY, V37, P359, DOI 10.1212/WNL.37.3.359; OWEN M, 1994, BRIT MED J, V308, P672, DOI 10.1136/bmj.308.6930.672; PEDERSEN NL, 1991, GERONTOLOGIST, V31, P333; PHILLIPS DIW, 1993, LANCET, V341, P1008, DOI 10.1016/0140-6736(93)91086-2; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; RAPOPORT SI, 1991, NEUROLOGY, V41, P1549, DOI 10.1212/WNL.41.10.1549; Robinette C. D., 1990, Dementia and Geriatric Cognitive Disorders,, V1, P297, DOI [10.1159/000107157, DOI 10.1159/000107157]; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; ROMANOV K, 1990, ACTA GENET MED GEMEL, V39, P441, DOI 10.1017/S0001566000003664; SARNA S, 1978, HUM HERED, V28, P241, DOI 10.1159/000152964; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SLUSS TK, 1981, EPIDEMIOLOGY DEMENTI; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; SULKAVA R, 1985, NEUROLOGY, V35, P1035; VANDUIJN CM, 1994, GENET EPIDEMIOL, V11, P539, DOI 10.1002/gepi.1370110609	38	90	93	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					573	578		10.1016/S0140-6736(96)91272-6	http://dx.doi.org/10.1016/S0140-6736(96)91272-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596319				2022-12-28	WOS:A1996TX69400010
J	Andreae, M				Andreae, M			Confidentiality in medical telecommunication	LANCET			English	Editorial Material											Andreae, M (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,BAGRIT CTR BIOL & MED SYST,LONDON,ENGLAND.		Andreae, Michael/AAE-5558-2022	Andreae, Michael/0000-0002-9052-0936				ANDERSON R, 1995, BRIT MED J, V311, P5, DOI 10.1136/bmj.311.6996.5; Anderson R, 1996, BRIT MED J, V312, P109; BETH T, 1995, SCI AM, V273, P70; Coiera E, 1996, BMJ-BRIT MED J, V312, P3, DOI 10.1136/bmj.312.7022.3; Goodyear OM, 1996, BRIT MED J, V312, P185; RIVEST RL, 1978, COMMUN ACM, V21, P120, DOI [10.1145/359340.359342, 10.1145/357980.358017]; Sellu D, 1996, BRIT MED J, V312, P49, DOI 10.1136/bmj.312.7022.49a; WOODWARD B, 1995, NEW ENGL J MED, V333, P1419, DOI 10.1056/NEJM199511233332112; [No title captured]	9	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					487	488		10.1016/S0140-6736(96)91134-4	http://dx.doi.org/10.1016/S0140-6736(96)91134-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596263				2022-12-28	WOS:A1996TW69700005
J	Wolffenbuttel, BHR; Giordano, D; Founds, HW; Bucala, R				Wolffenbuttel, BHR; Giordano, D; Founds, HW; Bucala, R			Long-term assessment of glucose control by haemoglobin-AGE measurement	LANCET			English	Article							GLYCOSYLATION END-PRODUCTS; DIABETES-MELLITUS; HEMOGLOBIN-A; COMPLICATIONS; COLLAGEN; CELLS	Background Control of blood glucose is important in reducing both the incidence and the severity of complications in diabetes mellitus. One consequence of long-term. hyperglycaemia is the formation and accumulation of advanced glycation end-products (AGEs) on tissue macromolecules. An AGE-modified form of human haemoglobin (Hb-AGE), present at high levels in the red cells of diabetic patients, differs from the glucose-derived Amadori product HbA(1c) in being chemically irreversible and thus persisting for the circulating life of the red cell. We therefore compared Hb-AGE with HbA(1c) as indicators of long-term blood glucose control. Methods In an open study we measured circulating HbA(1c) and Hb-AGE concentrations in eight patients with poorly controlled non-insulin-dependent diabetes after a switch to subcutaneous insulin therapy and careful blood glucose monitoring. Results After 16 weeks of insulin therapy, the mean HbA(1c) had decreased from 13.3 (SD 1.2) to 7.3 (0.9)% and the mean Hb-AGE from 12.1 (1.5) to 7.3 (1.3) U/mg Hb. The rate of Hb-AGE decline was 23% slower than that of HbA(1c) (p=0.044). Interpretation The observation that Hb-AGE declines more slowly than HbA(1c) is consistent with the irreversible nature of the AGE product. Because of this property, Hb-AGE may prove superior to HbA(1c) as a long-term index of circulating glucose concentrations.	PICOWER INST MED RES,MANHASSET,NY 11030; UNIV LIMBURG HOSP,DIV ENDOCRINOL,MAASTRICHT,NETHERLANDS; ALTEON INC,RAMSEY,NJ 07446	Northwell Health; Maastricht University; Maastricht University Medical Centre (MUMC)			Wolffenbuttel, Bruce/A-8419-2011	Wolffenbuttel, Bruce/0000-0001-9262-6921	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019655] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19655-15] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEISSWENGER PJ, 1995, DIABETES, V44, P824, DOI 10.2337/diabetes.44.7.824; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; BUCALA R, 1994, DRUG DEVELOP RES, V32, P77, DOI 10.1002/ddr.430320204; BUCALA R, 1994, P NATL ACAD SCI USA, V91, P9441, DOI 10.1073/pnas.91.20.9441; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; DUNN PJ, 1979, DIABETOLOGIA, V17, P213, DOI 10.1007/BF01235857; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; KOENIG RJ, 1976, NEW ENGL J MED, V295, P417, DOI 10.1056/NEJM197608192950804; KOENIG RJ, 1975, P NATL ACAD SCI USA, V72, P3687, DOI 10.1073/pnas.72.9.3687; LARSEN ML, 1990, NEW ENGL J MED, V323, P1021, DOI 10.1056/NEJM199010113231503; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MAKITA Z, 1992, SCIENCE, V258, P651, DOI 10.1126/science.1411574; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; MORTENSEN HB, 1983, CLIN CHIM ACTA, V134, P317, DOI 10.1016/0009-8981(83)90370-4; NATHAN DM, 1984, NEW ENGL J MED, V310, P341, DOI 10.1056/NEJM198402093100602; Njoroge F G, 1989, Prog Clin Biol Res, V304, P85; PETERSON CM, 1977, ANN INTERN MED, V86, P425, DOI 10.7326/0003-4819-86-4-425; RAHBAR S, 1968, BIOCHEM BIOPH RES CO, V36, P838; TAHARA Y, 1995, DIABETES CARE, V18, P440, DOI 10.2337/diacare.18.4.440; WOLFFENBUTTEL BHR, 1990, DIABETES RES CLIN EX, V13, P79; WOLFFENBUTTEL BHR, 1991, DIABETES NUTR METAB, V4, P297; Zar JH., 1999, BIOSTAT ANAL; 1992, DIAMAT ANAL SYSTEM I; 1993, NEW ENGL J MED, V329, P977	26	86	86	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					513	515		10.1016/S0140-6736(96)91141-1	http://dx.doi.org/10.1016/S0140-6736(96)91141-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596270				2022-12-28	WOS:A1996TW69700012
J	Boivin, DB; Duffy, JF; Kronauer, RE; Czeisler, CA				Boivin, DB; Duffy, JF; Kronauer, RE; Czeisler, CA			Dose-response relationships for resetting of human circadian clock by light	NATURE			English	Article							MELATONIN SUPPRESSION; ENTRAINMENT; RHYTHMS; BRIGHT; SENSITIVITY; INTENSITY; PACEMAKER; AMPLITUDE; SYSTEM; PHASE	SINCE the first report in unicells(1), studies across diverse species have demonstrated that light is a powerful synchronizer which resets, in an intensity-dependent manner, endogenous circadian pacemakers(1-5). Although it is recognized that bright light (similar to 7,000 to 13,000 lux) is an effective circadian synchronizer in humans(6-10), it is widely believed that the human circadian pacemaker is insensitive to ordinary indoor illumination (similar to 50-300 lux)(11). It has been proposed that the relationship between the resetting effect of light and its intensity follows a compressive nonlinear function(12), such that exposure to lower illuminances still exerts a robust effect(13), We therefore undertook a series of experiments which support this hypothesis and report here that light of even relatively low intensity (similar to 180 lux) significantly phase-shifts the human circadian pacemaker. Our results clearly demonstrate that humans are much more sensitive to light than initially suspected and support the conclusion that they are not qualitatively different from other mammals in their mechanism of circadian entrainment(14).	HARVARD UNIV,SCH MED,BRIGHAM & WOMENS HOSP,DIV ENDOCRINOL,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,DIV APPL SCI,CAMBRIDGE,MA 02138	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University			Duffy, Jeanne F./AAJ-4845-2020	Duffy, Jeanne F./0000-0003-4177-4179				ALLAN JS, 1988, 154TH ANN AAA S M, V208, P101; BOIVIN DB, 1994, J BIOL RHYTHM, V9, P315, DOI 10.1177/074873049400900311; BOJKOWSKI CJ, 1987, HORM METAB RES, V19, P437, DOI 10.1055/s-2007-1011846; BROWN EN, 1992, J BIOL RHYTHM, V7, P177, DOI 10.1177/074873049200700301; CAMPBELL SS, 1993, SLEEP, V16, P638; CHANDRASHEKARAN MK, 1969, J EXP ZOOL, V172, P147, DOI 10.1002/jez.1401720203; Cole RJ, 1995, J BIOL RHYTHM, V10, P324, DOI 10.1177/074873049501000406; CZEISLER CA, 1989, SCIENCE, V244, P1328, DOI 10.1126/science.2734611; CZEISLER CA, 1981, PHOTOCHEM PHOTOBIOL, V34, P239; CZEISLER CA, 1995, CIBA F SYMP, V183, P254; CZEISLER CA, 1986, SCIENCE, V233, P667, DOI 10.1126/science.3726555; CZEISLER CA, 1995, SLEEP RES A, V24, P505; GADDY JR, 1993, J CLIN ENDOCR METAB, V77, P1398, DOI 10.1210/jc.77.5.1398; HASTINGS JW, 1958, BIOL BULL, V115, P440, DOI 10.2307/1539108; Honma K, 1988, JAPAN J PSYCHIAT NEU, V42, P167; HONMA KI, 1995, AM J PHYSIOL-REG I, V268, pR528, DOI 10.1152/ajpregu.1995.268.2.R528; JEWETT ME, 1994, J BIOL RHYTHM, V9, P295, DOI 10.1177/074873049400900310; JEWETT ME, 1991, NATURE, V350, P59, DOI 10.1038/350059a0; KLERMAN EB, 1996, AM J PHYSIOL, V39, pR271; KRONAUER RE, 1993, J BIOL RHYTHM, V8, P351, DOI 10.1177/074873049300800409; KRONAUER RE, 1993, SLEEP RES, V22, P626; KRONAUER RE, 1987, SLEEP RES, V16, P621; LAAKSO ML, 1993, J PINEAL RES, V15, P21, DOI 10.1111/j.1600-079X.1993.tb00505.x; MCGUIRE RA, 1973, SCIENCE, V181, P956, DOI 10.1126/science.181.4103.956; MCINTYRE IM, 1989, J PINEAL RES, V6, P149; MINORS DS, 1991, NEUROSCI LETT, V133, P36, DOI 10.1016/0304-3940(91)90051-T; NELSON DE, 1991, J PHYSIOL-LONDON, V439, P115, DOI 10.1113/jphysiol.1991.sp018660; TAKAHASHI JS, 1984, NATURE, V308, P186, DOI 10.1038/308186a0; VANCAUTER E, 1994, AM J PHYSIOL, V266, pE953, DOI 10.1152/ajpendo.1994.266.6.E953; Wehr TA, 1995, AM J PHYSIOL, V269, P173; WEVER RA, 1989, J BIOL RHYTHM, V4, P161; WINFREE AT, 1970, J THEOR BIOL, V28, P327, DOI 10.1016/0022-5193(70)90075-5	32	399	408	0	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					540	542		10.1038/379540a0	http://dx.doi.org/10.1038/379540a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596632				2022-12-28	WOS:A1996TU69300050
J	Hasan, MM				Hasan, MM			Sounding board - Let's end the nonprofit charade	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Hasan, MM (corresponding author), HLTH SYST INT,PUEBLO,CO 81003, USA.								0	50	50	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1996	334	16					1055	1057		10.1056/NEJM199604183341610	http://dx.doi.org/10.1056/NEJM199604183341610			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE733	8598846				2022-12-28	WOS:A1996UE73300010
J	Nader, S				Nader, S			Female judoists: Their hormones, muscles, and bones	LANCET			English	Editorial Material							EXERCISE; RUNNERS				Nader, S (corresponding author), UNIV TEXAS,SCH MED,DEPT OBSTET & GYNECOL,DIV REPROD ENDOCRINOL,HOUSTON,TX 77025, USA.							BARROW GW, 1988, AM J SPORT MED, V16, P209, DOI 10.1177/036354658801600302; BULLEN BA, 1985, NEW ENGL J MED, V312, P1349, DOI 10.1056/NEJM198505233122103; DE CREE C, 1995, J CLIN ENDOCR METAB, V80, P3639, DOI 10.1210/jc.80.12.3639; KEIZER HA, 1990, SPORTS MED, V10, P218, DOI 10.2165/00007256-199010040-00002; ROGOL AD, 1992, ENDOCRIN METAB CLIN, V21, P817, DOI 10.1016/S0889-8529(18)30190-7; SANBORN CF, 1982, AM J OBSTET GYNECOL, V143, P859, DOI 10.1016/0002-9378(82)90463-X; SCHACHTER M, 1994, FERTIL STERIL, V62, P1; YEN SSC, 1993, ENDOCRIN METAB CLIN, V22, P29, DOI 10.1016/S0889-8529(18)30179-8	8	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1996	347	9006					919	920		10.1016/S0140-6736(96)91411-7	http://dx.doi.org/10.1016/S0140-6736(96)91411-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598753				2022-12-28	WOS:A1996UD59100006
J	Steadman, K; Franks, A				Steadman, K; Franks, A			A woman with malignant bowel obstruction who did not want to die with tubes	LANCET			English	Article									LEICESTERSHIRE HOSPICE, LEICESTER LE3 9QE, LEICS, ENGLAND									BAINES M, 1995, PALLIATIVE CARE TODA, V4, P4; Fallon MT, 1994, EUR J PALLIAT CARE, V1, P20; JOHNSON IS, 1994, ARTICLES SOMATOSTATI; Mercadante Sebastiano, 1993, Palliative Medicine, V7, P295; RIPAMONTI C, 1994, EUR J PALLIATIVE CAR, V1, P1	5	13	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	1996	347	9006					944	944		10.1016/S0140-6736(96)91418-X	http://dx.doi.org/10.1016/S0140-6736(96)91418-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598760				2022-12-28	WOS:A1996UD59100013
J	Will, RG; Ironside, JW; Zeidler, M; Cousens, SN; Estibeiro, K; Alperovitch, A; Poser, S; Pocchiari, M; Hofman, A; Smith, PG				Will, RG; Ironside, JW; Zeidler, M; Cousens, SN; Estibeiro, K; Alperovitch, A; Poser, S; Pocchiari, M; Hofman, A; Smith, PG			A new variant of Creutzfeldt-Jakob disease in the UK	LANCET			English	Article								Background Epidemiological surveillance of Creutzfeldt-Jakob disease (CJD) was reinstituted in the UK in 1990 to identify any changes in the occurrence of this disease after the epidemic of bovine spongiform encephalopathy (BSE) in cattle. Methods Case ascertainment of CJD was mostly by direct referral from neurologists and neuropathologists. Death certificates on which CJD was mentioned were also obtained. Clinical details were obtained for all referred cases, and information on potential risk factors for CJD was obtained by a standard questionnaire administered to patients' relatives. Neuropathological examination was carried out on approximately 70% of suspect cases. Epidemiological studies of CJD using similar methodology to the UK study have been carried out in France, Germany, Italy, and the Netherlands between 1993 and 1995. Findings Ten cases of CJD have been identified in the UK in recent months with a new neuropathological profile. Other consistent features that are unusual include the young age of the cases, clinical findings, and the absence of the electroencephalogram features typical for CJD. Similar cases have not been identified in other countries in the European surveillance system. Interpretation These cases appear to represent a new variant of CJD, which may be unique to the UK. This raises the possibility that they are causally linked to BSE. Although this may be the most plausible explanation for this cluster of cases, a link with BSE cannot be confirmed on the basis of this evidence alone. It is essential to obtain further information on the current and past clinical and neuropathological profiles of CJD in the UK and elsewhere.	LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1,ENGLAND; HOP LA PITIE SALPETRIERE,INSERM,PARIS,FRANCE; UNIV GOTTINGEN,NEUROL KLIN & POLIKLIN,W-3400 GOTTINGEN,GERMANY; IST SUPER SANITA,VIROL LAB,I-00161 ROME,ITALY; ERASMUS UNIV ROTTERDAM,ROTTERDAM,NETHERLANDS	University of London; London School of Hygiene & Tropical Medicine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Gottingen; University of Hamburg; University Medical Center Hamburg-Eppendorf; Istituto Superiore di Sanita (ISS); Erasmus University Rotterdam	Will, RG (corresponding author), WESTERN GEN HOSP,NATL CJD SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Pocchiari, Maurizio/J-8443-2018	Pocchiari, Maurizio/0000-0002-7269-2486; Smith, Peter/0000-0003-0080-7560; Ironside, James/0000-0001-5869-2108				BATEMAN D, 1995, LANCET, V346, P1155, DOI 10.1016/S0140-6736(95)91828-0; BELL JE, 1993, BRIT MED BULL, V49, P738, DOI 10.1093/oxfordjournals.bmb.a072645; BERMAN PH, 1988, PEDIATR NEUROSCI, V14, P42, DOI 10.1159/000120361; BRITTON TC, 1995, LANCET, V346, P1155, DOI 10.1016/S0140-6736(95)91827-2; BROWN P, 1985, European Journal of Epidemiology, V1, P42, DOI 10.1007/BF00162311; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; BRUCE ME, 1991, J GEN VIROL, V72, P595, DOI 10.1099/0022-1317-72-3-595; BUDKA H, 1995, BRAIN PATHOL, V5, P459, DOI 10.1111/j.1750-3639.1995.tb00625.x; COUSENS SN, 1990, J NEUROL NEUROSUR PS, V53, P459, DOI 10.1136/jnnp.53.6.459; DELASNERIELAUPRETRE N, 1995, LANCET, V346, P898, DOI 10.1016/S0140-6736(95)92735-2; Fraser H., 1979, Aspects of slow and persistent virus infections, P30; GOODBRAND IA, 1995, NEUROSCI LETT, V183, P127, DOI 10.1016/0304-3940(94)11131-2; HOWARD RS, 1996, LANCET, V347, P945; KULCZYCKI J, 1991, EUR J EPIDEMIOL, V7, P501, DOI 10.1007/BF00143129; MONREAL J, 1981, J NEUROL SCI, V52, P341, DOI 10.1016/0022-510X(81)90015-0; *NAT CJD SURV UN D, 1995, 4 LOND SCH HYG TROP; PACKER RJ, 1980, NEUROLOGY, V30, P492, DOI 10.1212/WNL.30.5.492; WELLER RO, 1986, NEUROPATH APPL NEURO, V12, P117, DOI 10.1111/j.1365-2990.1986.tb00045.x	18	2040	2102	0	150	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1996	347	9006					921	925		10.1016/S0140-6736(96)91412-9	http://dx.doi.org/10.1016/S0140-6736(96)91412-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598754				2022-12-28	WOS:A1996UD59100007
J	Parham, P; Ohta, T				Parham, P; Ohta, T			Population biology of antigen presentation by MHC class I molecules	SCIENCE			English	Review							MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL RECOGNITION; HLA-B ALLELES; GENE CONVERSION; BALANCING SELECTION; NUCLEOTIDE SUBSTITUTION; OVERDOMINANT SELECTION; MULTIGENE FAMILIES; NATURAL-SELECTION; NEUTRAL THEORY	In principle, the function of major histocompatibility complex (MHC) molecules is simple: to bind a peptide and engage a T cell. In practice, placing this function within the context of the immune response begs questions of population biology: How does the immune response emerge from the interactions among populations of peptides, T cells, and MHC molecules? Within a population of vertebrates, how does MHC polymorphism stamp individuality on the response? Does polymorphism confer differential advantages in responding to parasites? How ale the pressures on the MHC reflected in turnover of alleles? The role of mutation, recombination, selection, and drift in the generation and maintenance of MHC class I polymorphism are considered.	GRAD UNIV ADV STUDIES, NATL INST GENET, MISHIMA, SHIZUOKA 411, JAPAN	Graduate University for Advanced Studies - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Parham, P (corresponding author), STANFORD UNIV, DEPT BIOL STRUCT, STANFORD, CA 94305 USA.							ARDEN B, 1982, P NATL ACAD SCI-BIOL, V79, P2342, DOI 10.1073/pnas.79.7.2342; ARNETT KL, UNPUB; AYALA FJ, 1995, SCIENCE, V270, P1930, DOI 10.1126/science.270.5244.1930; AYALA FJ, 1994, P NATL ACAD SCI USA, V91, P6787, DOI 10.1073/pnas.91.15.6787; BARBER LD, 1995, CURR BIOL, V5, P179, DOI 10.1016/S0960-9822(95)00039-X; BARBER LD, UNPUB; BELICH MP, 1992, NATURE, V357, P326, DOI 10.1038/357326a0; BIDWELL J, 1994, IMMUNOL TODAY, V15, P303, DOI 10.1016/0167-5699(94)90076-0; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLACK FL, 1981, AM J HUM GENET, V33, P894; BLACK FL, 1984, AM J HUM GENET, V36, P1318; BLACK FL, 1992, SCIENCE, V258, P1739, DOI 10.1126/science.1465610; Bodmer W. F., 1976, GENETICS EVOLUTION M; BODMER WF, 1972, NATURE, V237, P139, DOI 10.1038/237139a0; BODMER WF, 1967, HISTOCOMPATIBILITY T, P141; BODMER WF, 1990, HIST HLA 10 RECOLLEC; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BURNET FM, 1970, NATURE, V226, P123, DOI 10.1038/226123a0; BURNET FM, 1971, NATURE, V232, P230, DOI 10.1038/232230a0; CAMPBELL RD, 1993, IMMUNOL TODAY, V14, P349, DOI 10.1016/0167-5699(93)90234-C; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; CLARKE B, 1966, NATURE, V211, P999, DOI 10.1038/211999a0; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEGOS L, 1974, IMMUNOGENETICS, V1, P195, DOI 10.1007/BF01564062; DOHERTY PC, 1975, LANCET, V1, P1406, DOI 10.1016/S0140-6736(75)92610-0; DOHERTY PC, 1975, NATURE, V256, P50, DOI 10.1038/256050a0; DOMENA JD, 1993, TISSUE ANTIGENS, V42, P156, DOI 10.1111/j.1399-0039.1993.tb02186.x; DUNCAN WR, 1979, NATURE, V281, P603, DOI 10.1038/281603a0; ERLICH HA, 1991, IMMUNOL TODAY, V12, P411, DOI 10.1016/0167-5699(91)90143-H; ERLICH HA, 1991, HUM IMMUNOL, V30, P110, DOI 10.1016/0198-8859(91)90079-O; Fagan Brian M, 1987, GREAT JOURNEY PEOPLI; Falk K, 1993, Semin Immunol, V5, P81, DOI 10.1006/smim.1993.1012; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FLAVELL RA, 1986, SCIENCE, V233, P437, DOI 10.1126/science.3726537; FRANKLIN I, 1970, GENETICS, V65, P707; GARBER TL, 1995, IMMUNOGENETICS, V42, P19, DOI 10.1007/BF00164983; GELIEBTER J, 1987, TRENDS GENET, V3, P107, DOI 10.1016/0168-9525(87)90194-6; GIBBONS A, 1993, SCIENCE, V259, P312, DOI 10.1126/science.8420001; GIBBONS A, 1995, SCIENCE, V267, P35, DOI 10.1126/science.7809607; GREENBERG JH, 1986, CURR ANTHROPOL, V27, P477, DOI 10.1086/203472; GYLLENSTEN U, 1991, J IMMUNOL, V146, P4368; HASEGAWA M, 1987, J MOL EVOL, V26, P132, DOI 10.1007/BF02111287; HEDRICK PW, 1991, P NATL ACAD SCI USA, V88, P5897, DOI 10.1073/pnas.88.13.5897; HEDRICK PW, 1990, HUM HERED, V40, P213, DOI 10.1159/000153933; HEDRICK PW, 1983, GENETICS, V104, P449; HEDRICK PW, 1987, GENETICS, V65, P707; HEGLAND J, 1995, HUM IMMUNOL S1, V44, P126; HILDEBRAND WH, 1994, TISSUE ANTIGENS, V43, P209, DOI 10.1111/j.1399-0039.1994.tb02327.x; Hill A. V. S., 1992, HLA 1991, V2, P63; HILL AVS, 1994, PHILOS T R SOC B, V346, P379, DOI 10.1098/rstb.1994.0155; HILL AVS, 1992, NATURE, V355, P403, DOI 10.1038/355403a0; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HOFFECKER JF, 1993, SCIENCE, V259, P46, DOI 10.1126/science.259.5091.46; HUGHES AL, 1995, MOL BIOL EVOL, V12, P247; HUGHES AL, 1994, PHILOS T ROY SOC B, V346, P359, DOI 10.1098/rstb.1994.0153; HUGHES AL, 1995, IMMUNOGENETICS, V42, P233, DOI 10.1007/BF00176440; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; HUGHES AL, 1989, P NATL ACAD SCI USA, V86, P958, DOI 10.1073/pnas.86.3.958; HUGHES AL, 1995, IMMUNOGENETICS, V41, P257; HUGHES AL, 1993, IMMUNOGENETICS, V37, P337, DOI 10.1007/BF00216798; HUGHES AL, 1992, NATURE, V355, P402, DOI 10.1038/355402b0; HUGHES AL, 1993, GENETICS, V133, P669; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; Imanish T, 1992, HLA 1991, V1, P1065; JAULIN C, 1985, IMMUNOGENETICS, V22, P453, DOI 10.1007/BF00418091; KATO K, 1989, J IMMUNOL, V143, P3371; Kaufman J., 1988, Verhandlungen der Deutschen Zoologischen Gesellschaft, V81, P131; KIMURA M, 1968, NATURE, V217, P624, DOI 10.1038/217624a0; KIMURA M, 1977, NATURE, V267, P275, DOI 10.1038/267275a0; Kimura M., 1983, NEUTRAL THEORY MOL E; KLEIN J, 1994, PHILOS T R SOC B, V346, P351, DOI 10.1098/rstb.1994.0152; KLEIN J, 1993, CURR OPIN GENET DEV, V3, P923, DOI 10.1016/0959-437X(93)90015-H; KLEIN J, 1986, CRC CR REV IMMUNOL, V6, P295; KLEIN J, 1993, J MED PRIMATOL, V22, P57; KLEIN J, 1987, HUM IMMUNOL, V19, P155, DOI 10.1016/0198-8859(87)90066-8; KLEIN J, 1993, ANNU REV IMMUNOL, V11, P269, DOI 10.1146/annurev.immunol.11.1.269; KLEIN J, 1993, SCI AM, V269, P78, DOI 10.1038/scientificamerican1293-78; Klein J, 1980, IMMUNOLOGY, V80, P239; KLEIN J, 1975, BIOL MOUSE HISTOCOMP, V2; KOSTYU DD, 1981, TISSUE ANTIGENS, V17, P111; KUHNER MK, 1991, TISSUE ANTIGENS, V38, P152, DOI 10.1111/j.1399-0039.1991.tb01889.x; Kvist S, 1993, Semin Immunol, V5, P105, DOI 10.1006/smim.1993.1014; LAWLOR DA, 1990, IMMUNOL REV, V113, P147, DOI 10.1111/j.1600-065X.1990.tb00040.x; LAWLOR DA, 1988, NATURE, V335, P268, DOI 10.1038/335268a0; LAWLOR DA, 1990, ANNU REV IMMUNOL, V8, P23, DOI 10.1146/annurev.iy.08.040190.000323; LAWLOR DA, 1991, J EXP MED, V174, P1491, DOI 10.1084/jem.174.6.1491; LEONS FE, 1995, HUM IMMUNOL, V42, P348, DOI 10.1016/0198-8859(95)90009-8; LI WH, 1991, FUNDAMENTALS MOL EVO; LIENERT K, 1995, TISSUE ANTIGENS, V45, P12, DOI 10.1111/j.1399-0039.1995.tb02409.x; MARKOW T, 1993, AM J HUM GENET, V53, P943; MAY RM, 1995, NATURE, V374, P309, DOI 10.1038/374309a0; MAYER WE, 1988, EMBO J, V7, P2765, DOI 10.1002/j.1460-2075.1988.tb03131.x; Mayr E., 1942, P1; Mayr E., 1954, EVOLUTION PROCESS, P157; Mayr E, POPULATIONS SPECIES; MCADAM SN, 1994, P NATL ACAD SCI USA, V91, P5893, DOI 10.1073/pnas.91.13.5893; MCADAM SN, 1995, J IMMUNOL, V154, P6421; McNeill W.H., 1976, PLAGUES PEOPLES, V1st ed.; MOLLER G, 1995, IMMUNOL REV, V147; NATHENSON SG, 1986, ANNU REV IMMUNOL, V4, P471, DOI 10.1146/annurev.iy.04.040186.002351; NEEL JV, 1978, AM J HUM GENET, V30, P465; NGUYEN C, 1985, IMMUNOGENETICS, V21, P479, DOI 10.1007/BF00430931; OBRIEN SJ, 1994, P NATL ACAD SCI USA, V91, P5748, DOI 10.1073/pnas.91.13.5748; OBRIEN SJ, 1995, NAT MED, V1, P742, DOI 10.1038/nm0895-742; OBRIEN SJ, 1983, SCIENCE, V221, P459, DOI 10.1126/science.221.4609.459; OHTA T, 1992, ANNU REV ECOL SYST, V23, P263, DOI 10.1146/annurev.es.23.110192.001403; OHTA T, 1995, J MOL EVOL, V41, P115, DOI 10.1007/BF00170662; OHTA T, 1991, J MOL EVOL, V33, P34, DOI 10.1007/BF02100193; OHTA T, 1988, P NATL ACAD SCI USA, V85, P3509, DOI 10.1073/pnas.85.10.3509; OHTA T, 1991, EVOLUTION OF LIFE, P145; OHTA T, 1991, P NATL ACAD SCI USA, V88, P6716, DOI 10.1073/pnas.88.15.6716; OHTA T, 1990, THEOR POPUL BIOL, V37, P213, DOI 10.1016/0040-5809(90)90036-U; OHTA T, 1983, THEOR POPUL BIOL, V23, P216, DOI 10.1016/0040-5809(83)90015-1; OHTA T, 1992, HLA 1991, V2, P20; PARHAM P, 1988, P NATL ACAD SCI USA, V85, P4005, DOI 10.1073/pnas.85.11.4005; PARHAM P, 1995, IMMUNOL REV, V143, P141, DOI 10.1111/j.1600-065X.1995.tb00674.x; PARHAM P, 1989, J IMMUNOL, V142, P3937; PARHAM P, 1994, SEMIN IMMUNOL, V6, P1; Paul W., 1993, FUNDAMENTAL IMMUNOLO, P1211; PETZLERLER ML, 1993, TISSUE ANTIGENS, V41, P227; PIAZZA A, 1994, HUM IMMUNOL, V4, P297; ROGERS JH, 1985, EMBO J, V4, P749, DOI 10.1002/j.1460-2075.1985.tb03692.x; ROMER AS, 1968, PROCESSION LIFE; RUVOLO M, 1991, P NATL ACAD SCI USA, V88, P1570, DOI 10.1073/pnas.88.4.1570; Salzano FM, 1988, S AM INDIANS CASE ST; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SATTA Y, 1994, P NATL ACAD SCI USA, V91, P7184, DOI 10.1073/pnas.91.15.7184; SATTA Y, 1991, MOL EVOLUTION MAJOR, P51; SIBLEY CG, 1984, J MOL EVOL, V20, P2, DOI 10.1007/BF02101980; SNELL GD, 1968, FOLIA BIOL-PRAGUE, V14, P335; STEPHENS JC, 1985, MOL BIOL EVOL, V2, P539; STROYNOWSKI I, 1990, ANNU REV IMMUNOL, V8, P501, DOI 10.1146/annurev.iy.08.040190.002441; SZATHMARY EJE, 1993, AM J HUM GENET, V53, P793; TAKAHATA N, 1990, GENETICS, V124, P967; TAKAHATA N, 1993, MOL BIOL EVOL, V10, P2; TERASAKI PI, 1964, NATURE, V204, P998, DOI 10.1038/204998b0; TORONI A, 1992, GENETICS, V53, P563; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TROWSDALE J, 1995, IMMUNOGENETICS, V41, P1, DOI 10.1007/BF00188427; TROWSDALE J, 1989, IMMUNOGENETICS, V29, P19, DOI 10.1007/BF02341609; WALSH JB, 1987, GENETICS, V117, P543; WANG CR, 1991, CELL, V66, P335, DOI 10.1016/0092-8674(91)90623-7; WATKINS DI, 1991, IMMUNOGENETICS, V33, P79; WATKINS DI, 1992, NATURE, V357, P329, DOI 10.1038/357329a0; WATKINS DI, 1995, CRIT REV IMMUNOL, V15, P1; WILLIAMS RC, 1985, AM J PHYS ANTHROPOL, V66, P1, DOI 10.1002/ajpa.1330660102; WILLIAMS RC, 1992, HUM IMMUNOL, V33, P39, DOI 10.1016/0198-8859(92)90050-W; YUHKI N, 1990, J EXP MED, V172, P621, DOI 10.1084/jem.172.2.621; ZANGENBERG G, 1995, NAT GENET, V10, P407, DOI 10.1038/ng0895-407; ZEMMOUR J, 1992, J EXP MED, V176, P937, DOI 10.1084/jem.176.4.937; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173	154	527	548	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1996	272	5258					67	74		10.1126/science.272.5258.67	http://dx.doi.org/10.1126/science.272.5258.67			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600539				2022-12-28	WOS:A1996UD59700038
J	Bourne, Y; Watson, MH; Hickey, MJ; Holmes, W; Rocque, W; Reed, SI; Tainer, JA				Bourne, Y; Watson, MH; Hickey, MJ; Holmes, W; Rocque, W; Reed, SI; Tainer, JA			Crystal structure and mutational analysis the human CDK2 kinase complex with cell cycle-regulatory protein CksHs1	CELL			English	Article							FISSION YEAST; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; SCHIZOSACCHAROMYCES-POMBE; DIVISION CYCLE; CDC2; GENE; PHOSPHORYLATION; P34(CDC2); BINDING	The 2.6 Angstrom crystal structure for human cyclin-dependent kinase 2 (CDK2) in complex with CksHs1, a human homolog of essential yeast cell cycle-regulatory proteins suc1 and Cks1, reveals that CksHs1 binds via all four beta strands to the kinase C-terminal robe. This interface is biologically critical, based upon mutational analysis, but far from the CDK2 N-terminal lobe, cyclin, and regulatory phosphorylation sites. CDK2 binds the Cks single domain conformation and interacts with conserved hydrophobic residues plus His-60 and Glu-63 in their closed beta-hinge motif conformation. The beta hinge opening to form the Cks beta-interchanged dimer sterically precludes CDK2 binding, providing a possible mechanism regulating CDK2-Cks interactions. One face of the complex exposes the sequence-conserved phosphate-binding region on Cks and the ATP-binding site on CDK2, suggesting that Cks may target CDK2 to other phosphoproteins during the cell cycle.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; GLAXO WELLCOME, RES TRIANGLE PK, NC 27709 USA	Scripps Research Institute; GlaxoSmithKline			Bourne, Yves/AAC-4635-2022; Tainer, John/GWQ-4878-2022	Bourne, Yves/0000-0003-3850-0548; Tainer, John/0000-0003-1659-2429				ARVAI AS, 1995, PROTEINS, V21, P70, DOI 10.1002/prot.340210109; ARVAI AS, 1995, J MOL BIOL, V249, P835, DOI 10.1006/jmbi.1995.0341; AZZI L, 1994, J BIOL CHEM, V269, P13279; Boume Y., 1995, P NATL ACAD SCI USA, V92, P10232; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ENDICOTT JA, 1995, STRUCTURE, V3, P321, DOI 10.1016/S0969-2126(01)00162-9; ENDICOTT JA, 1995, EMBO J, V14, P1004, DOI 10.1002/j.1460-2075.1995.tb07081.x; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; KHATIB ZA, 1993, CANCER RES, V53, P5535; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TANG Y, 1993, GENE DEV, V7, P822, DOI 10.1101/gad.7.5.822; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	59	209	213	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					863	874		10.1016/S0092-8674(00)81065-X	http://dx.doi.org/10.1016/S0092-8674(00)81065-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601310	Bronze			2022-12-28	WOS:A1996UC38100008
J	Foucar, E				Foucar, E			Carcinoma-in-situ of the breast: Have pathologists run amok?	LANCET			English	Editorial Material							LESIONS				Foucar, E (corresponding author), PRESBYTERIAN HOSP,DEPT PATHOL,POB 26666,ALBUQUERQUE,NM 87125, USA.							Foote FW, 1941, AM J PATHOL, V17, P491; HAYAKAWA SI, 1990, LANGUAGE THOUGHT ACT, P111; HETELEKIDIS S, 1995, CA-CANCER J CLIN, V45, P244, DOI 10.3322/canjclin.45.4.244; MORROW M, 1994, ARCH SURG-CHICAGO, V129, P1091; Morrow M, 1996, JAMA-J AM MED ASSOC, V275, P61; PAGE DL, 1995, CANCER, V76, P1197, DOI 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0; ROSAI J, 1991, AM J SURG PATHOL, V15, P209, DOI 10.1097/00000478-199103000-00001; ROSAI J, 1996, BREAST ACKERMANS SUR, P1596; SCHNITT SJ, 1992, AM J SURG PATHOL, V16, P1133, DOI 10.1097/00000478-199212000-00001; SILVERSTEIN MJ, 1991, AM J CLIN ONCOL-CANC, V14, P534, DOI 10.1097/00000421-199112000-00014; SIMPSON JF, 1994, CANCER, V73, P2352, DOI 10.1002/1097-0142(19940501)73:9<2352::AID-CNCR2820730918>3.0.CO;2-X; STEWART FW, 1950, ATLAS TUMOUR PATHOL, P18; TAVASSOLI FA, 1994, MODERN PATHOL, V7, P813; WALT AJ, 1992, ARCH SURG-CHICAGO, V127, P904; WINCHESTER DP, 1995, ANN SURG ONCOL, V2, P207, DOI 10.1007/BF02307025	15	26	26	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					707	708		10.1016/S0140-6736(96)90073-2	http://dx.doi.org/10.1016/S0140-6736(96)90073-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8601998				2022-12-28	WOS:A1996TZ98200006
J	Finn, PJ; Plank, LD; Clark, MA; Connolly, AB; Hill, GL				Finn, PJ; Plank, LD; Clark, MA; Connolly, AB; Hill, GL			Progressive cellular dehydration and proteolysis in critically ill patients	LANCET			English	Article							BODY-WATER; NUTRITION; MUSCLE	Background According to a recent hypothesis, the profound loss of body protein that occurs in critically ill patients is triggered and maintained by cell shrinkage secondary to cellular dehydration. We tested this hypothesis by studying sequential changes in intracellular water, total body protein, total body potassium, and intracellular potassium in patients receiving intensive care for blunt trauma or sepsis. Methods Nine patients with multiple blunt trauma and 11 with severe sepsis were studied in an intensive care unit for 21 days. Intracellular water was measured in two ways--by subtraction of extracellular water (bromide dilution) from total body water (tritium dilution), and by bioimpedance spectroscopy. Total body protein was measured by whole-body neutron activation analysis and total body potassium by whole-body counting. Findings Over the study period intracellular water decreased by 15-20%, total body protein by 15%, and total body potassium by about 20%. Intracellular potassium concentration did not change, and was similar to that in healthy adult volunteers. In the trauma patients, sequential measurements of the ratio of potassium to protein In lost tissue indicated that cells were losing water in quantities greater than would be expected from protein losses. Interpretation The loss of protein and potassium from body stores in major trauma or sepsis is accompanied by progressive cellular dehydration. This insight opens up new therapeutic options for limiting the loss of body protein in critically ill patients.	UNIV AUCKLAND, DEPT SURG, AUCKLAND HOSP, AUCKLAND 3, NEW ZEALAND	Auckland City Hospital; University of Auckland				Plank, Lindsay/0000-0003-2737-0151				BAXTER CR, 1966, CARE TRAUMA PATIENT, P541; BERGSTROM J, 1979, ACTA CHIR SCAND    S, V494, P356; BERGSTROM JP, 1987, ACTA CHIR SCAND, V153, P261; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; CHANDRA RK, 1994, J NUTR, V124, pS1433, DOI 10.1093/jn/124.suppl_8.1433S; Cuthbertson DP, 1942, LANCET, V1, P433; ELWYN DH, 1975, ANN SURG, V182, P76, DOI 10.1097/00000658-197507000-00015; GATZEN C, 1992, SURGERY, V112, P181; HALLBRUCKER C, 1991, EUR J BIOCHEM, V197, P717, DOI 10.1111/j.1432-1033.1991.tb15963.x; HAUSSINGER D, 1993, LANCET, V341, P1330, DOI 10.1016/0140-6736(93)90828-5; HAUSSINGER O, 1995, CLIN NUTR, V14, P4, DOI 10.1016/S0261-5614(06)80003-8; HILL GL, 1992, JPEN-PARENTER ENTER, V16, P197, DOI 10.1177/0148607192016003197; Hill GL, 1993, METABOLIC SUPPORT CR, P3; *ICRP, 1975, 23 IRCP REP; KARNER J, 1981, J PARENT ENT NUTR, V5, P368; LINDSTEDT E, 1975, ANN SURG, V181, P842, DOI 10.1097/00000658-197506000-00014; LUCAS CE, 1983, SURG CLIN N AM, V63, P439; McGee JO, 1992, OXFORD TXB PATHOLOGY; MITRA S, 1989, PHYS MED BIOL, V34, P61, DOI 10.1088/0031-9155/34/1/006; MITRA S, 1993, PHYS MED BIOL, V38, P1971, DOI 10.1088/0031-9155/38/12/019; MONK DN, IN PRESS ANN SURG; ROTH E, 1985, CLIN CHEM, V31, P1305; STREAT SJ, 1985, METABOLISM, V34, P688, DOI 10.1016/0026-0495(85)90099-X; VANLOAN MD, 1993, BASIC LIFE SCI, P67; WINDSOR J A, 1988, Australian and New Zealand Journal of Surgery, V58, P711, DOI 10.1111/j.1445-2197.1988.tb01101.x; WINDSOR JA, 1988, ANN SURG, V207, P290, DOI 10.1097/00000658-198803000-00011; Ziegler T. R., 1993, Clinical Nutrition, V12, pS82, DOI 10.1016/S0261-5614(09)90014-0; [No title captured]	28	122	135	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	1996	347	9002					654	656		10.1016/S0140-6736(96)91204-0	http://dx.doi.org/10.1016/S0140-6736(96)91204-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596380				2022-12-28	WOS:A1996TZ28500012
J	Abramovitz, DL; Friedman, RA; Pyle, AM				Abramovitz, DL; Friedman, RA; Pyle, AM			Catalytic role of 2'-hydroxyl groups within a group II intron active site	SCIENCE			English	Article							TETRAHYMENA RIBOZYME; TERTIARY INTERACTIONS; MESSENGER-RNA; MECHANISM; BINDING; RIBOSE; SUBSTRATE; DOMAIN-5; CORE	Domain 5 is an essential active-site component of group II intron ribozymes. The role of backbone substituents in D5 function was explored through synthesis of a series of derivatives containing deoxynucleotides at each position along the D5 strand. Kinetic screens revealed that eight 2'-hydroxyl groups were likely to be critical for activity of D5. Through two separate methods, including competitive inhibition and direct kinetic analysis, effects on binding and chemistry were distinguished. Depending on their function, important 2'-hydroxyl groups lie on opposite faces of the molecule, defining distinct loci for molecular recognition and catalysis by D5.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University					NIGMS NIH HHS [GM41371, GM50313] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041371, R01GM050313] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITZ D, UNPUB; BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; BOULANGER SC, 1995, MOL CELL BIOL, V15, P4479; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHANFREAU G, 1994, SCIENCE, V266, P1383, DOI 10.1126/science.7973729; COSTA M, 1995, EMBO J, V14, P1276, DOI 10.1002/j.1460-2075.1995.tb07111.x; Daniels DL, 1996, J MOL BIOL, V256, P31, DOI 10.1006/jmbi.1996.0066; DOUDNA JA, 1995, RNA, V1, P36; FERSHT A, 1985, ENZYME STRUCTURE MEC, P102; FRANZEN JS, 1993, NUCLEIC ACIDS RES, V21, P627, DOI 10.1093/nar/21.3.627; FRIEDMAN RA, 1992, BIOPOLYMERS, V32, P145, DOI 10.1002/bip.360320205; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8299, DOI 10.1021/bi00083a034; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8312, DOI 10.1021/bi00083a035; JAEGER L, 1993, J MOL BIOL, V234, P331, DOI 10.1006/jmbi.1993.1590; JAEGER L, 1994, J MOL BIOL, V236, P1271, DOI 10.1016/0022-2836(94)90055-8; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KNITT DS, 1994, BIOCHEMISTRY-US, V33, P13864, DOI 10.1021/bi00250a041; KOCH JL, 1992, MOL CELL BIOL, V12, P1950, DOI 10.1128/MCB.12.5.1950; KWAKMAN JHJM, 1990, J BIOMOL STRUCT DYN, V8, P413, DOI 10.1080/07391102.1990.10507813; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MAJOR F, 1991, SCIENCE, V253, P1255, DOI 10.1126/science.1716375; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; MUSIERFORSYTH K, 1992, NATURE, V357, P513, DOI 10.1038/357513a0; PEEBLES CL, 1995, P NATL ACAD SCI USA, V92, P4422, DOI 10.1073/pnas.92.10.4422; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PODAR M, 1995, MOL CELL BIOL, V15, P4466; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P2716, DOI 10.1021/bi00175a047; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P13856, DOI 10.1021/bi00250a040; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; PYLE AM, 1995, CURR OPIN STRUC BIOL, V5, P303, DOI 10.1016/0959-440X(95)80091-3; PYLE AM, IN PRESS NUCLEIC ACI; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; STROBEL SA, 1993, BIOCHEMISTRY-US, V32, P13593, DOI 10.1021/bi00212a027; STROBEL SA, 1995, SCIENCE, V267, P675, DOI 10.1126/science.7839142; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; YU YT, 1995, RNA, V1, P46	41	99	117	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1410	1413		10.1126/science.271.5254.1410	http://dx.doi.org/10.1126/science.271.5254.1410			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596912				2022-12-28	WOS:A1996TY96100044
J	Roberts, J				Roberts, J			Light and dark in life and death	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					466	466		10.1136/bmj.312.7029.466a	http://dx.doi.org/10.1136/bmj.312.7029.466a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597675	Green Published			2022-12-28	WOS:A1996TX38300018
J	Jain, RK				Jain, RK			Delivery of molecular medicine to solid tumors	SCIENCE			English	Editorial Material									HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Harvard Medical School	Jain, RK (corresponding author), MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,EDWIN L STEELE LAB,BOSTON,MA 02114, USA.		Berk, David A/A-4863-2012; Jain, Rakesh K/I-1384-2017; Swartz, Melody A./F-9563-2011	Berk, David A/0000-0002-3855-6886; Jain, Rakesh K/0000-0001-7571-3548; 				[Anonymous], 1996, B MED ETHICS; BAXTER LT, 1995, CANCER RES, V55, P4611; Beardsley T, 1994, SCI AM, V270, P118; DEDRICK RL, 1973, J PHARMACOKINET BIOP, V1, P435, DOI 10.1007/BF01059667; GERLOWSKI LE, 1983, J PHARM SCI, V72, P1103, DOI 10.1002/jps.2600721003; GURA T, 1995, SCIENCE, V270, P575, DOI 10.1126/science.270.5236.575; HALL SS, 1995, SCIENCE, V270, P915, DOI 10.1126/science.270.5238.915; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; JAIN RK, IN PRESS ANN BIOMED; Jobe P C, 1994, Physiologist, V37, P79; MARSHALL E, 1995, SCIENCE, V269, P1050, DOI 10.1126/science.7652552; REESE DM, 1995, NATURE, V378, P532, DOI 10.1038/378532c0; WADMAN M, 1995, NATURE, V378, P655, DOI 10.1038/378655a0; WURTMAN RJ, 1995, NAT MED, V1, P1122, DOI 10.1038/nm1195-1122	14	270	315	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1079	1080		10.1126/science.271.5252.1079	http://dx.doi.org/10.1126/science.271.5252.1079			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599082				2022-12-28	WOS:A1996TW70100027
J	Hurt, RD; Offord, KP; Croghan, IT; GomezDahl, L; Kottke, TE; Morse, RM; Melton, LJ				Hurt, RD; Offord, KP; Croghan, IT; GomezDahl, L; Kottke, TE; Morse, RM; Melton, LJ			Mortality following inpatient addictions treatment - Role of tobacco use in a community-based cohort	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SMOKING; ALCOHOLICS; ABUSE; DEPENDENCE; DRINKING; SUICIDE	Objective.-To determine the impact of tobacco- and alcohol-related deaths on overall mortality following inpatient treatment for alcoholism and other nonnicotine drugs of dependence. Design.-Population-based retrospective cohort study. Setting.-Olmsted County, Minnesota (the Rochester Epidemiology Project), and the Inpatient Addiction Program (IAP) at Mayo Clinic, Rochester. Patients.-All 845 Olmsted County residents admitted to an inpatient addiction program for treatment of alcoholism and other nonnicotine drugs of dependence during the period 1972 through 1983. Methods.-Patients were followed up through the medical record linkage system of the Rochester Epidemiology Project through December 1994 to obtain vital status, and death certificates were obtained for those who died. The underlying cause of death was classified as alcohol related, tobacco related, both, or neither based on the classification from the Centers for Disease Control and Prevention. The observed number of deaths by underlying cause was compared with the expected number using cause-specific 1987 death rates for the white population of the United States. All-cause mortality was also compared with that expected for persons in the West North Central Region of the United States of like age, sex, and year of birth. Univariate and multivariate assessments were made to identify predictors of all-cause mortality from baseline demographic information. Results.-At admission, the mean (SD) age of the 845 patients was 41.4 (14.5) years, and 35% were women. Altogether, 78% had alcohol as their only nonnicotine drug of dependence and 18% had alcohol and other nonnicotine drugs of dependence, while 4% were classified as having a nonalcohol, nonnicotine drug dependence alone. At admission, 75% were current and 8% former cigarette smokers, 3% were current cigar or pipe smokers, and 2% were current users of smokeless tobacco. Follow-up after the index IAP admission totaled 8913 person-years (mean [SD] of 10.5 [5.6] years per patient). Death certificates were obtained for 96% (214) of the 222 patients who died. Of these 214 deaths, 50.9% (109) had a tobacco-related and 34.1% (73) had an alcohol-related underlying cause (P<.001). The cumulative mortality significantly exceeded that expected (P<.001); at 20 years, the observed mortality was 48.1% vs an expected 18.5%. Multivariate predictors of mortality, even after adjusting for expected mortality, were older age at admission (P<.001) and male sex (P<.001). Conclusions.-Patients previously treated for alcoholism and/or other nonnicotine drug dependence had an increased cumulative mortality that was due more to tobacco-related than to alcohol-related causes. Nicotine dependence treatment is imperative in such high-risk patients.	MAYO CLIN & MAYO FDN, BIOSTAT SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT PSYCHIAT & PSYCHOL, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Hurt, RD (corresponding author), MAYO CLIN & MAYO FDN, NICOTINE DEPENDENCE CTR, 200 1ST ST SW, ROCHESTER, MN 55905 USA.				NIAMS NIH HHS [AR30582] Funding Source: Medline; NIDA NIH HHS [DA 08039] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R03DA008039] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BARR HC, 1994, J STUD ALCOHOL, V45, P440; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; Bergstralh E, 1986, TECHNICAL REPORT SER, V31; BERGSTRALH EJ, 1988, TECHNICAL SUPPORT SE, V37; BULLOCK KD, 1992, JAMA-J AM MED ASSOC, V267, P668, DOI 10.1001/jama.267.5.668; BURLING TA, 1988, ADDICT BEHAV, V13, P185, DOI 10.1016/0306-4603(88)90010-X; COX DR, 1972, J R STAT SOC B, V34, P187; CRAIG TJ, 1977, J STUD ALCOHOL, V38, P1434, DOI 10.15288/jsa.1977.38.1434; Delaney G O, 1988, N J Med, V85, P131; DIETVORST TF, 1978, J CLIN PSYCHOL, V34, P244, DOI 10.1002/1097-4679(197801)34:1<244::AID-JCLP2270340150>3.0.CO;2-V; DIFRANZA JR, 1990, J STUD ALCOHOL, V51, P130, DOI 10.15288/jsa.1990.51.130; DORPAT TL, 1960, COMPR PSYCHIAT, V1, P349, DOI 10.1016/S0010-440X(60)80058-2; EDWARDS G, 1983, LANCET, V2, P269; FEUERLEIN W, 1994, ADDICTION, V89, P841, DOI 10.1111/j.1360-0443.1994.tb00987.x; FINNEY JW, 1992, J STUD ALCOHOL, V53, P142, DOI 10.15288/jsa.1992.53.142; FISHMAN ML, 1993, J SUBST ABUSE TREAT, V10, P133, DOI 10.1016/0740-5472(93)90037-3; FLEMING TR, 1981, COMMUN STAT A-THEOR, V10, P763, DOI 10.1080/03610928108828073; GILLIS L S, 1969, South African Medical Journal, V43, P230; GOLDSMITH JR, 1991, J ADDICT DIS, V11, P67; HOFFMAN AL, 1993, J SUBST ABUSE TREAT, V10, P153, DOI 10.1016/0740-5472(93)90040-9; HURT RD, 1994, ALCOHOL CLIN EXP RES, V18, P867, DOI 10.1111/j.1530-0277.1994.tb00052.x; JOSEPH AM, 1990, JAMA-J AM MED ASSOC, V263, P3043; KARAN LD, 1993, J SUBST ABUSE TREAT, V10, P101, DOI 10.1016/0740-5472(93)90032-W; KOZLOWSKI LT, 1989, ADDICT BEHAV, V14, P273, DOI 10.1016/0306-4603(89)90058-0; KOZLOWSKI LT, 1989, JAMA-J AM MED ASSOC, V261, P898; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; LAMBIE DG, 1982, NZ MED J, V96, P199; LEWIS CE, 1995, ALCOHOL CLIN EXP RES, V19, P984, DOI 10.1111/j.1530-0277.1995.tb00978.x; MALETZKY BM, 1974, AM J PSYCHIAT, V131, P445; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARSHALL EJ, 1994, ADDICTION, V89, P1293, DOI 10.1111/j.1360-0443.1994.tb03308.x; MCALPINE DE, 1990, MAYO CLIN PROC, V65, P13, DOI 10.1016/S0025-6196(12)62105-3; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996; MOOS RH, 1994, ALCOHOL CLIN EXP RES, V18, P187, DOI 10.1111/j.1530-0277.1994.tb00902.x; MORSE RM, 1991, PROFESSIONAL COU AUG, P33; National Center for Health Statistics, 1993, DHHS PUBL, V41; OCONNOR A, 1985, BRIT J PSYCHIAT, V146, P645, DOI 10.1192/bjp.146.6.645; OHARA K, 1989, BRIT J ADDICT, V84, P287; ORLEANS CT, 1993, J SUBST ABUSE TREAT, V10, P197, DOI 10.1016/0740-5472(93)90045-4; PUCKET CD, 1994, ED ANNOTATION ICD9CM; RAVENHOLT RT, 1984, POPUL DEV REV, V10, P697, DOI 10.2307/1973289; ROBINS E, 1959, AM J PUBLIC HEALTH N, V49, P888, DOI 10.2105/AJPH.49.7.888; ROSENGREN A, 1988, ACTA MED SCAND, V223, P111; SCHMIDT W, 1981, CANCER-AM CANCER SOC, V47, P1031, DOI 10.1002/1097-0142(19810301)47:5<1031::AID-CNCR2820470534>3.0.CO;2-C; TAYLOR JR, 1983, J STUD ALCOHOL, V44, P17, DOI 10.15288/jsa.1983.44.17; U. S. Department of Health and Human Services, 1990, DHHS PUBL; VAILLANT GE, 1991, J GEN INTERN MED, V6, P299, DOI 10.1007/BF02597425; 1995, MINN CANC SURVEI MAR, P2; 1993, MMWR-MORBID MORTAL W, V42, P645; 1990, MMWR-MORBID MORTAL W, V11, P172	51	514	517	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1996	275	14					1097	1103		10.1001/jama.275.14.1097	http://dx.doi.org/10.1001/jama.275.14.1097			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UD027	8601929				2022-12-28	WOS:A1996UD02700026
J	Butcher, EC; Picker, LJ				Butcher, EC; Picker, LJ			Lymphocyte homing and homeostasis	SCIENCE			English	Article							HIGH ENDOTHELIAL VENULES; HUMAN B-CELLS; L-SELECTIN; DIFFERENTIAL REGULATION; MOLECULAR MECHANISMS; T-CELLS; ADHESION; RECIRCULATION; MIGRATION; SPECIFICITY	The integration and control of systemic immune responses depends on the regulated trafficking of lymphocytes. This lymphocyte ''homing'' process disperses the immunologic repertoire, directs lymphocyte subsets to the specialized microenvironments that control their differentiation and regulate their survival, and targets immune effector cells to sites of antigenic or microbial invasion. Recent advances reveal that the exquisite specificity of lymphocyte homing is determined by combinatorial ''decision processes'' involving multistep sequential engagement of adhesion and signaling receptors. These homing-related interactions are seamlessly integrated into the overall interaction of the lymphocyte with its environment and participate directly in the control of lymphocyte function, life-span, and population dynamics. In this article a review of the molecular basis of lymphocyte homing is presented, and mechanisms by which homing physiology regulates the homeostasis of immunologic resources are proposed.	VET AFFAIRS PALO ALTO HLTH CARE SYST, CTR MOLEC BIOL & MED, PALO ALTO, CA 94304 USA; UNIV TEXAS, SW MED CTR, DEPT PATHOL, LAB MOL PATHOL, DALLAS, TX 75235 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Butcher, EC (corresponding author), STANFORD UNIV, SCH MED, DEPT PATHOL, LAB IMMUNOL & VASC BIOL, STANFORD, CA 94305 USA.							ADAMS DH, 1991, J IMMUNOL, V147, P609; ADAMS DH, 1994, P NATL ACAD SCI USA, V91, P7144, DOI 10.1073/pnas.91.15.7144; Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; ALON R, 1994, J CELL BIOL, V127, P1485, DOI 10.1083/jcb.127.5.1485; Bacon KB, 1996, INT ARCH ALLERGY IMM, V109, P97, DOI 10.1159/000237207; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; BUTCHER EC, 1980, EUR J IMMUNOL, V10, P556, DOI 10.1002/eji.1830100713; BUTCHER EC, 1986, CURR TOP MICROBIOL, V128, P85; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CAMPBELL JC, UNPUB; CARLOS TM, 1994, BLOOD, V84, P2068; CEPEK KL, 1993, J IMMUNOL, V150, P3459; Cyster JG, 1995, IMMUNITY, V3, P691, DOI 10.1016/1074-7613(95)90059-4; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; DEGRENDELE HC, IN PRESS J EXP MED; EERTWEGH VD, 1992, CRIT REV IMMUNOL, V11, P337; ERLANDSEN SL, 1993, J HISTOCHEM CYTOCHEM, V41, P327, DOI 10.1177/41.3.7679125; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; FIRRELL JC, 1989, AM J PHYSIOL, V256, pH1667, DOI 10.1152/ajpheart.1989.256.6.H1667; FORD WL, 1969, SEMIN HEMATOL, V6, P67; FRANCESCHI C, 1995, IMMUNOL TODAY, V16, P12, DOI 10.1016/0167-5699(95)80064-6; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; GILAT D, 1994, J IMMUNOL, V153, P4899; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; Glickstein Lisa J., 1994, P161; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HONDA S, 1994, J IMMUNOL, V152, P4026; HOOD L, 1977, J SUPRAMOL STR CELL, V7, P531, DOI 10.1002/jss.400070321; HORGAN KJ, 1992, CHEM IMMUNOL, V54, P72; Hu M C, 1993, Curr Top Microbiol Immunol, V184, P125; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMHOF BA, 1995, ADV IMMUNOL, V58, P345, DOI 10.1016/S0065-2776(08)60623-9; Jinquan Tan, 1995, Journal of Immunology, V154, P3742; JOHNSTON JA, 1994, J IMMUNOL, V153, P1762; JONES DA, 1994, J CLIN INVEST, V94, P2443, DOI 10.1172/JCI117612; KANSAS GS, 1991, J IMMUNOL, V147, P4094; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; KOOPMAN G, 1994, J IMMUNOL, V152, P3760; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; MACKALL CL, 1993, BLOOD, V82, P2585; MACKAY C, 1995, CURR BIOL, V5, P733, DOI 10.1016/S0960-9822(95)00147-3; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; OSMOND DG, 1986, IMMUNOL REV, V93, P103, DOI 10.1111/j.1600-065X.1986.tb01504.x; PALECANDA A, 1992, EUR J IMMUNOL, V22, P1279, DOI 10.1002/eji.1830220524; PARKMAN R, 1993, CURR OPIN IMMUNOL, V5, P800, DOI 10.1016/0952-7915(93)90140-N; PICKER LJ, 1994, CURR OPIN IMMUNOL, V6, P394, DOI 10.1016/0952-7915(94)90118-X; PICKER LJ, 1993, J IMMUNOL, V150, P1105; PICKER LJ, 1993, EUR J IMMUNOL, V23, P2751, DOI 10.1002/eji.1830231105; PICKER LJ, 1993, J IMMUNOL, V150, P1122; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; Picker Louis J., 1993, P145; QIN S, IN PRESS J IMMUNOL; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SALMI M, 1992, SCIENCE, V257, P1407, DOI 10.1126/science.1529341; SALMI M, IN PRESS J EXP MED; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; Smith M E, 1980, Monogr Allergy, V16, P203; SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282; Sprent J, 1980, Monogr Allergy, V16, P233; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; TAMATANI T, 1993, J IMMUNOL, V150, P1735; TAN JQ, 1993, J IMMUNOL, V151, P4545; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; TANAKA Y, 1992, ADV EXP MED BIOL, V323, P157; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Vestweber D, 1993, Curr Top Microbiol Immunol, V184, P65; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; WOLDEMARCARR M, 1996, IMMUNITY, V4, P179; WOODRUFF JJ, 1987, ANNU REV IMMUNOL, V5, P201, DOI 10.1146/annurev.immunol.5.1.201	80	2374	2454	5	122	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1996	272	5258					60	66		10.1126/science.272.5258.60	http://dx.doi.org/10.1126/science.272.5258.60			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600538				2022-12-28	WOS:A1996UD59700037
J	Linet, OI; Ogrinc, FG				Linet, OI; Ogrinc, FG			Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORPUS CAVERNOSUM; PEYRONIES DISEASE; NITRIC-OXIDE; IMPOTENT MEN; PROSTAGLANDIN-E1; RELAXATION; INJECTION	Background. Erectile dysfunction is a common medical problem affecting many men. Although several intracavernosal therapies are available, their efficacy and safety have not been studied systematically. Methods. We investigated the. efficacy and safety of alprostadil formulated for intracavernosal treatment in three separate multi-institutional, prospective studies in men with erectile dysfunction of vasculogenic, neurogenic, psychogenic, and mixed causes. Clinical and laboratory evaluations of erection and the feasibility and satisfactoriness of sexual activity as assessed both by the men and by their partners were the primary measures of efficacy. Results. In a dose-response study of 296 men, all doses of alprostadil were superior to placebo and there was a significant dose-response relation (P less than or equal to 0.001), resulting in higher response rates with increasing doses of alprostadil (from 2.5 to 20 mu g). In a dose-finding study of 201 men, the minimal effective dose was less than or equal to 2 mu g in 23, 20, 38, and 23 percent of men with erectile dysfunction of neurogenic, vasculogenic, psychogenic, or mixed causes, respectively. In a six-month self-injection study in 683 men, the participants reported being able to have sexual activity after 94 percent of the injections. The men and their partners rated the sexual activity as satisfactory after 87 and 86 percent of the injections, respectively. Penile pain, usually mild, occurred in 50 percent of the men at some time but after only II percent of the injections. Prolonged erections occurred in 5 percent of the men, priapism in 1 percent, penile fibrotic complications in 2 percent, and hematoma or ecchymosis in 8 percent. Conclusions. In men with erectile dysfunction, intracavernosal injection of alprostadil is an effective therapy with tolerable side effects.			Linet, OI (corresponding author), UPJOHN CO,CLIN DEV UNIT,7000 PORTAGE RD,KALAMAZOO,MI 49001, USA.							AMIN Z, 1993, BRIT J RADIOL, V66, P398, DOI 10.1259/0007-1285-66-785-398; BERRY DA, 1990, STATMETHODOLOGY PHAR, P402; CAPETOLA RJ, 1983, J CLIN PHARMACOL, V23, P545, DOI 10.1002/j.1552-4604.1983.tb01802.x; CHAN J C K, 1992, Journal of Urology, V147, p309A; DJAMILIAN M, 1993, J UROLOGY, V149, P1269, DOI 10.1016/S0022-5347(17)36364-4; EARLE CM, 1992, PARAPLEGIA, V30, P273, DOI 10.1038/sc.1992.68; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; GERBER GS, 1991, J UROLOGY, V146, P786, DOI 10.1016/S0022-5347(17)37921-1; GIESBERS AAGM, 1987, WORLD J UROL, V5, P173, DOI 10.1007/BF00326827; ISHII N, 1986, JAP J UROL, V77, P954; Jiinemann KP., 1989, INT J IMPOTENCE RES, V1, P71; KIM N, 1991, J CLIN INVEST, V88, P112, DOI 10.1172/JCI115266; KOLAJA GJ, 1993, ROLE ALPROSTADIL DIA, P40; KRANE RJ, 1989, NEW ENGL J MED, V321, P1648, DOI 10.1056/NEJM198912143212406; LINDSAY MB, 1991, J UROLOGY, V146, P1007, DOI 10.1016/S0022-5347(17)37988-0; LINET OI, 1994, CLIN INVESTIGATOR, V72, P139; Lue T F, 1990, Semin Urol, V8, P100; PORST H, 1989, UROLOGE A, V28, P94; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; SCHRAMEK P, 1989, BRIT J CLIN PHARMACO, V28, P567, DOI 10.1111/j.1365-2125.1989.tb03543.x; STACKL W, 1988, J UROLOGY, V140, P66, DOI 10.1016/S0022-5347(17)41488-1; VIRAG R, 1987, J UROLOGY, V137, P1010, DOI 10.1016/S0022-5347(17)44344-8; Virag Ronald, 1994, Journal of Urology, V151, p456A; VONHEYDEN B, 1993, J UROLOGY, V150, P1825, DOI 10.1016/S0022-5347(17)35906-2; ZENTGRAF M, 1989, EUR UROL, V16, P165; 1993, JAMA-J AM MED ASSOC, V270, P83	26	332	346	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	1996	334	14					873	877		10.1056/NEJM199604043341401	http://dx.doi.org/10.1056/NEJM199604043341401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD374	8596569				2022-12-28	WOS:A1996UD37400001
J	Rosencrance, G; Thistlewaite, T				Rosencrance, G; Thistlewaite, T			Thromboangiitis obliterans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Rosencrance, G (corresponding author), W VIRGINIA UNIV,ROBERT C BYRD HLTH SCI CTR,CHARLESTON,WV 25304, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	1996	334	14					891	891		10.1056/NEJM199604043341404	http://dx.doi.org/10.1056/NEJM199604043341404			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD374	8596572				2022-12-28	WOS:A1996UD37400004
J	Nagar, B; Overduin, M; Ikura, M; Rini, JM				Nagar, B; Overduin, M; Ikura, M; Rini, JM			Structural basis of calcium-induced E-cadherin rigidification and dimerization	NATURE			English	Article							CELL-ADHESION; PROTEIN	THE cadherins mediate cell adhesion and play a fundamental role in normal development(1). They participate in the maintenance of proper cell-cell contacts: for example, reduced levels of epithelial cadherin (E-cadherin) correlate with increased invasiveness in many human tumour cell types(2,3). The cadherins typically consist of five tandemly repeated extracellular domains, a single membrane-spanning segment and a cytoplasmic region(4-6). The N-terminal extracellular domains mediate cell-cell contact(7) while the cytoplasmic region interacts with the cytoskeleton through the catenins(8). Cadherins depend on calcium for their function: removal of calcium abolishes adhesive activity, renders cadherins vulnerable to proteases (reviewed in ref, 4) and, in E-cadherin, induces a dramatic reversible conformational change in the entire extracellular region(9). We report here the X-ray crystal structure at 2.0 Angstrom resolution of the two N-terminal extracellular domains of E-cadherin in the presence of calcium. The structure reveals a two-fold symmetric dimer, each molecule of which binds a contiguous array of three bridged calcium ions. Not only do the bound calcium ions linearize and rigidify the molecule, they promote dimerization. Although the N-terminal domain of each molecule in the dimer is aligned in a parallel orientation, the interactions between them differ significantly from those found in the neural cadherin (N-cadherin) N-terminal domain (NCD1) structure(10). The E-cadherin dual-domain structure reported here defines the role played by calcium in the cadherin-mediated formation and maintenance of solid tissues.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,ONTARIO CANC INST,DIV MOL & STRUCT BIOL,TORONTO,ON M5G 2M9,CANADA; UNIV TSUKUBA,CTR TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Tsukuba; University of Tsukuba			Nagar, Bhushan/C-1297-2010; Overduin, Michael/AAG-3632-2020	Overduin, Michael/0000-0002-3114-6585; Ikura, Mitsuhiko/0000-0002-9524-1303				BIRCHMEIER W, 1995, BIOESSAYS, V17, P97, DOI 10.1002/bies.950170203; Blaschuk O W, 1994, Can J Oncol, V4, P291; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BROWN EM, 1995, CELL, V83, P679, DOI 10.1016/0092-8674(95)90180-9; BRUNGER AT, 1992, XPLOR V 3 1 SYSTEM X; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUREY W, IN PRESS METH ENZYM; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MAREEL M, 1994, MOL BIOL REP, V19, P45, DOI 10.1007/BF00987321; NOSE A, 1990, CELL, V61, P17; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OVERDUIN M, IN PRESS J BIOMOL NM; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; RINGWALD M, 1987, EMBO J, V6, P3547; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TESMER JJG, 1994, PROTEINS, V18, P394, DOI 10.1002/prot.340180410; TONG KI, 1994, FEBS LETT, V352, P318; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832	28	547	561	1	38	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					360	364		10.1038/380360a0	http://dx.doi.org/10.1038/380360a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598933				2022-12-28	WOS:A1996UC37900064
J	Ernster, VL; Barclay, J; Kerlikowske, K; Grady, D; Henderson, IC				Ernster, VL; Barclay, J; Kerlikowske, K; Grady, D; Henderson, IC			Incidence of and treatment for ductal carcinoma in situ of the breast	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRADUCTAL CARCINOMA; SCREENING MAMMOGRAPHY; FEMALE BREAST; INSITU; CANCER; WOMEN; LESIONS; DCIS; PREVALENCE; MANAGEMENT	Objective.-To describe trends in incidence and treatment for ductal carcinoma in situ (DCIS) of the breast in the United States between 1973 and 1992 and to estimate total numbers of in situ cases diagnosed and numbers treated by mastectomy since 1983, when screening mammography for breast cancer began to become widespread. Design.-Analysis of population-based breast cancer incidence data collected by the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program since 1973 and treatment data collected by the SEER program since 1983. Study Population.-All women in the geographic areas of the United States included in the SEER program. Main Outcome Measures.-Annual age-adjusted and age-specific incidence rates for DCIS; time trends in distribution of cases by type of treatment; percentage of cases treated by mastectomy by geographic area; and estimated numbers for the entire United States of DCIS cases, mastectomies for DCIS, and cases attributable to mammography. Results.-There was a marked increase in DCIS incidence beginning in the early 1980s. Average annual increases in rates between 1973 and 1983 and between 1983 and 1992 changed from 0.3% to 12.0% among women aged 30 to 39 years, from 0.4% to 17.4% among women aged 40 to 49 years, and from 5.2% to 18.1% among women aged 50 years or older. The total estimated number of DCIS cases in the United States in 1992 (23 368) was 200% higher than expected based on 1983 rates and trends between 1973 and 1983, Between 1983 and 1992, there was a marked decline in the proportion of DCIS cases treated by mastectomy (from 71% to 43.8%) and an increase in those treated by lumpectomy (from 25.6% to 53.3%). In 1992, 23.3% of cases were treated by lumpectomy and radiation, 30.2% by lumpectomy alone, and 2.6% with no surgery, Treatment patterns varied substantially by geographic area, with 57.7% of cases in New Mexico treated by mastectomy in 1992 compared with 28.8% in Connecticut, Despite the decline in the proportion of cases treated by mastectomy, the increased DCIS incidence rates resulted in an increase in the absolute number of cases treated by mastectomy until 1990 (n=10 657); in 1992, there were an estimated 10 242 DCIS cases treated by mastectomy. Conclusions-Incidence rates of DCIS of the breast have increased dramatically since 1983. This increase correlates with the widespread adoption of modern mammographic screening. While early detection of invasive breast cancer is beneficial, the value of DCIS detection is currently unknown. There is cause for concern about the large number of DCIS cases that are being diagnosed as a consequence of screening mammography, most of which are treated; by some form of surgery. In addition, the proportion of cases treated by mastectomy may be inappropriately high, particularly in some areas of the United States.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143; VET ADM MED CTR,GEN INTERNAL MED SECT,SAN FRANCISCO,CA 94121; SEQUUS PHARMACEUT INC,MENLO PK,CA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ernster, VL (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOSTAT & EPIDEMIOL,BOX 0560,SAN FRANCISCO,CA 94143, USA.				NATIONAL CANCER INSTITUTE [U01CA063740, P50CA058207] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58207-03, U01 CA 63740] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ackermann S P, 1992, MMWR CDC Surveill Summ, V41, P17; ALPERS CE, 1985, HUM PATHOL, V16, P796, DOI 10.1016/S0046-8177(85)80251-3; BARTH A, 1995, WESTERN J MED, V163, P360; BARTOW SA, 1987, CANCER, V60, P2751, DOI 10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M; BASSETT LW, 1992, RADIOL CLIN N AM, V30, P93; BELLAMY COC, 1993, HUM PATHOL, V24, P16, DOI 10.1016/0046-8177(93)90057-N; BERG JW, 1995, CANCER, V75, P257, DOI 10.1002/1097-0142(19950101)75:1+<257::AID-CNCR2820751311>3.0.CO;2-Y; BHATHAL PS, 1985, BRIT J CANCER, V51, P271, DOI 10.1038/bjc.1985.39; BROWN ML, 1990, ANN INTERN MED, V113, P547, DOI 10.7326/0003-4819-113-7-547; CARPENTER R, 1989, BRIT J SURG, V76, P564, DOI 10.1002/bjs.1800760612; COLEMAN EA, 1992, AM J SURG, V164, P74, DOI 10.1016/S0002-9610(05)80652-X; FAGGIANO F, 1994, J EPIDEMIOL COMMUN H, V48, P447, DOI 10.1136/jech.48.5.447; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; FISHER ER, 1991, J SURG ONCOL, V47, P139, DOI 10.1002/jso.2930470302; FISHER ER, 1986, CANCER-AM CANCER SOC, V57, P197, DOI 10.1002/1097-0142(19860115)57:2<197::AID-CNCR2820570203>3.0.CO;2-N; FISHER ER, 1995, CANCER-AM CANCER SOC, V75, P1310, DOI 10.1002/1097-0142(19950315)75:6<1310::AID-CNCR2820750613>3.0.CO;2-G; GUMP FE, 1987, SURGERY, V102, P790; HETELEKIDIS S, 1995, CA-CANCER J CLIN, V45, P244, DOI 10.3322/canjclin.45.4.244; HOLLAND R, 1994, SEMIN DIAGN PATHOL, V11, P167; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; KRAMER WM, 1973, CANCER, V31, P130, DOI 10.1002/1097-0142(197301)31:1<130::AID-CNCR2820310117>3.0.CO;2-N; LAGIOS MD, 1990, SURG CLIN N AM, V70, P853; LYNDE JL, 1993, SOUTHERN MED J, V86, P338, DOI 10.1097/00007611-199303000-00018; MILLIKAN R, 1995, BREAST CANCER RES TR, V35, P65, DOI 10.1007/BF00694747; NATTINGER AB, 1992, NEW ENGL J MED, V326, P1102, DOI 10.1056/NEJM199204233261702; *NCI, 1995, SURV EP END RES SEER; NIELSEN M, 1984, CANCER-AM CANCER SOC, V54, P612, DOI 10.1002/1097-0142(1984)54:4<612::AID-CNCR2820540403>3.0.CO;2-B; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; OSTEEN RT, 1994, CANCER, V73, P1994, DOI 10.1002/1097-0142(19940401)73:7<1994::AID-CNCR2820730735>3.0.CO;2-O; OTTESEN GL, 1992, AM J SURG PATHOL, V16, P1183, DOI 10.1097/00000478-199212000-00005; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; PAGE DL, 1995, CANCER, V76, P1197, DOI 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0; Page DL, 1987, DIAGNOSTIC HISTOPATH, P157; POPE TL, 1988, RADIOLOGY, V168, P63, DOI 10.1148/radiology.168.1.3380984; REBNER M, 1994, RADIOLOGY, V190, P623, DOI 10.1148/radiology.190.3.8115600; Ries L, 1994, NIH PUBLICATION, V94-2789; ROSEN PP, 1980, CANCER, V46, P919, DOI 10.1002/1097-0142(19800815)46:4+<919::AID-CNCR2820461311>3.0.CO;2-Z; SCHWARTZ GF, 1992, CANCER, V70, P2468, DOI 10.1002/1097-0142(19921115)70:10<2468::AID-CNCR2820701013>3.0.CO;2-K; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; SILVERSTEIN MJ, 1992, EUR J CANCER, V28A, P630, DOI 10.1016/S0959-8049(05)80114-5; SOLIN LJ, 1993, CANCER-AM CANCER SOC, V71, P2532, DOI 10.1002/1097-0142(19930415)71:8<2532::AID-CNCR2820710817>3.0.CO;2-0; SONNENFIELD M, 1991, RADIOLOGY, V181, P623; SWANSON GM, 1993, CANCER, V72, P788, DOI 10.1002/1097-0142(19930801)72:3<788::AID-CNCR2820720326>3.0.CO;2-C; VANDONGEN JA, 1992, EUR J CANCER, V28A, P626, DOI 10.1016/S0959-8049(05)80113-3; ZAFRANI B, 1994, SEMIN DIAGN PATHOL, V11, P208; 1990, MMWR-MORBID MORTAL W, V39, P621; 1990, MMWR-MORBID MORTAL W, V39, P627	48	440	452	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					913	918		10.1001/jama.275.12.913	http://dx.doi.org/10.1001/jama.275.12.913			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA563	8598618				2022-12-28	WOS:A1996UA56300030
J	Balint, J; Shelton, W				Balint, J; Shelton, W			Regaining the initiative - Forging a new model of the patient physician relationship	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FINANCIAL INCENTIVES; REFORM				Balint, J (corresponding author), ALBANY MED COLL,CTR MED ETH EDUC & RES,DEPT MED,ALBANY,NY 12208, USA.							ANGELL M, 1993, NEW ENGL J MED, V328, P1778, DOI 10.1056/NEJM199306173282409; Angell M, 1993, Kennedy Inst Ethics J, V3, P279; Balint M., 1964, DOCTOR HIS PATIENT I; BEECHER HK, 1966, NEW ENGL J MED, V274, P1354, DOI 10.1056/NEJM196606162742405; BRENNAN TA, 1993, AM J LAW MED, V19, P37; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; EMANUEL EJ, 1995, JAMA-J AM MED ASSOC, V273, P323, DOI 10.1001/jama.273.4.323; ENGELHARDT HT, 1978, MED TREATMENT DYING, P9; ENGELHARDT HT, 1988, NEW ENGL J MED, V318, P1886; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; Jonsen A. R., 1992, CLIN ETHICS; MACINTYRE A, 1979, CHANGING VALUES MED, P83; *PC, 1983, PRES COMM STUD ETH P; Pellegrino E., 1988, PATIENTS GOOD RESTOR; PELLEGRINO ED, 1979, CHANGING VALUES MED, P97; RELMAN AS, 1993, NEW ENGL J MED, V328, P133, DOI 10.1056/NEJM199301143280212; ROTHMAN D, 1991, STRANGERS BEDSIDE; SIEGLER M, 1993, MAYO CLIN PROC, V68, P461, DOI 10.1016/S0025-6196(12)60195-5; SIEGLER M, 1982, ARCH INTERN MED, V142, P1899, DOI 10.1001/archinte.142.10.1899; SIEGLER M, 1981, B NEW YORK ACAD MED, V57, P56; Starr P, 1982, SOCIAL TRANSFORMATIO; SZASZ TS, 1956, ARCH INTERN MED, V97, P585, DOI 10.1001/archinte.1956.00250230079008; SZASZ TS, 1958, AM J PSYCHIAT, V115, P522, DOI 10.1176/ajp.115.6.522; Thomasma D C, 1994, Camb Q Healthc Ethics, V3, P10; TUMULTY PA, 1970, NEW ENGL J MED, V283, P20, DOI 10.1056/NEJM197007022830105; VEATCH RM, 1991, PATIENT PHYSICIAN RE; Wennberg J E, 1990, Qual Assur Health Care, V2, P21; WOLF SM, 1994, HASTINGS CENT REP, V24, P28, DOI 10.2307/3562181	30	106	106	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					887	891		10.1001/jama.275.11.887	http://dx.doi.org/10.1001/jama.275.11.887			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ971	8596230				2022-12-28	WOS:A1996TZ97100036
J	Yu, SF; Baldwin, DN; Gwynn, SR; Yendapalli, S; Linial, ML				Yu, SF; Baldwin, DN; Gwynn, SR; Yendapalli, S; Linial, ML			Human foamy virus replication: A pathway distinct from that of retroviruses and hepadnaviruses	SCIENCE			English	Article							HUMAN SPUMARETROVIRUS; HUMAN-IMMUNODEFICIENCY; GENE-PRODUCTS; GAG PROTEINS; IDENTIFICATION; EXPRESSION; VIRIONS; BINDING; GENOME; BEL	Human foamy virus (HFV) is the prototype of the Spumavirus genus of Retroviridae. In all other retroviruses, the pol gene products, including reverse transcriptase, are synthesized as Gag-Pol fusion proteins and are cleaved to functional enzymes during viral budding or release, In contrast, the Pol protein of HFV is translated from a spliced messenger RNA and lacks Gag domains, Infectious HFV particles contain double-stranded DNA similar in size to full-length provirus, suggesting that reverse transcription has taken place in viral particles before new rounds of infection, reminiscent of hepadnaviruses. These data suggest that foamy viruses possess a replication pathway containing features of both retroviruses and hepadnaviruses but distinct from both.	FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,INTERDISCIPLINARY PROGRAM MOLEC & CELLULAR BIOL,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NCI NIH HHS [CA18282, F32 CA60357] Funding Source: Medline; NHLBI NIH HHS [HL53762] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018282, F32CA060357] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053762] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDWIN D, UNPUB; BARTENSCHLAGER R, 1992, EMBO J, V11, P3413, DOI 10.1002/j.1460-2075.1992.tb05420.x; BARTHOLOMA A, 1992, VIRUS RES, V23, P27, DOI 10.1016/0168-1702(92)90065-H; Coffin J. M., 1990, VIROLOGY, P1437; FELSENSTEIN KM, 1988, J VIROL, V62, P2179, DOI 10.1128/JVI.62.6.2179-2182.1988; GANEM D, 1994, INFECT AGENT DIS, V3, P85; HAHN H, 1994, J GEN VIROL, V75, P2635, DOI 10.1099/0022-1317-75-10-2635; HATTON T, 1992, J VIROL, V66, P5232, DOI 10.1128/JVI.66.9.5232-5241.1992; HIRSCH RC, 1990, NATURE, V344, P552, DOI 10.1038/344552a0; KOGEL D, 1995, VIROLOGY, V213, P97, DOI 10.1006/viro.1995.1550; KONVALINKA J, 1995, J VIROL, V69, P7264, DOI 10.1128/JVI.69.11.7264-7268.1995; LOCHELT M, 1991, VIROLOGY, V184, P43, DOI 10.1016/0042-6822(91)90820-2; Lochelt M, 1996, J VIROL, V70, P1033; LORI F, 1992, J VIROL, V66, P5067, DOI 10.1128/JVI.66.8.5067-5074.1992; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; MAURER B, 1988, J VIROL, V62, P1590, DOI 10.1128/JVI.62.5.1590-1597.1988; MURANYI W, 1991, J VIROL, V65, P727, DOI 10.1128/JVI.65.2.727-735.1991; Nassal M, 1993, Trends Microbiol, V1, P221, DOI 10.1016/0966-842X(93)90136-F; NETZER KO, 1990, J GEN VIROL, V71, P1237, DOI 10.1099/0022-1317-71-5-1237; NETZER KO, 1993, VIROLOGY, V192, P336, DOI 10.1006/viro.1993.1039; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; RETHWILM A, 1991, P NATL ACAD SCI USA, V88, P941, DOI 10.1073/pnas.88.3.941; SCHLIEPHAKE AW, 1994, J VIROL, V68, P4946, DOI 10.1128/JVI.68.8.4946-4954.1994; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; Vogt P. K., 1990, CURR TOP MICROBIOL, V157, P93; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Yu SF, 1996, J VIROL, V70, P1250, DOI 10.1128/JVI.70.2.1250-1254.1996; YU SF, 1993, J VIROL, V67, P6618, DOI 10.1128/JVI.67.11.6618-6624.1993; [No title captured]	31	230	238	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1579	1582		10.1126/science.271.5255.1579	http://dx.doi.org/10.1126/science.271.5255.1579			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599113				2022-12-28	WOS:A1996TZ98300040
J	Lohr, KN; Vanselow, NA; Detmer, DE				Lohr, KN; Vanselow, NA; Detmer, DE			The nation's physician workforce: Options for balancing supply and requirements	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									TULANE UNIV,SCH MED,NEW ORLEANS,LA 70112; UNIV VIRGINIA,SCH MED,CHARLOTTESVILLE,VA 22908	Tulane University; University of Virginia	Lohr, KN (corresponding author), NATL ACAD SCI,INST MED,DIV HLTH CARE SERV,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418, USA.								0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1996	275	10					748	748						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY886	8598579				2022-12-28	WOS:A1996TY88600004
J	Davey, PG; Bax, RP; Newey, J; Reeves, D; Rutherford, D; Slack, R; Warren, RE; Watt, B; Wilson, J				Davey, PG; Bax, RP; Newey, J; Reeves, D; Rutherford, D; Slack, R; Warren, RE; Watt, B; Wilson, J			Growth in the use of antibiotics in the community in England and Scotland in 1980-93	BRITISH MEDICAL JOURNAL			English	Article									SMITHKLINE BEECHAM PHARMACEUT,HARLOW CM19 5AW,ESSEX,ENGLAND; HALLWOOD HLTH CTR,WEAVER VALE WA7 2OT,CHESHIRE,ENGLAND; SOUTHMEAD HOSP,DEPT MED MICROBIOL,BRISTOL BS10 5NB,AVON,ENGLAND; PIPELANDS HLTH CTR,ST ANDREWS KY16 8JZ,FIFE,SCOTLAND; PUBL HLTH LAB SERV LAB,NOTTINGHAM NG7 2UH,ENGLAND; PUBL HLTH LAB,SHREWSBURY SY3 8XQ,ENGLAND; CITY HOSP EDINBURGH,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; NOTTINGHAMSHIRE FAMILY HLTH SERV AUTHOR,NOTTINGHAM NG1 5EP,ENGLAND	GlaxoSmithKline; Southmead Hospital	Davey, PG (corresponding author), NINEWELLS HOSP,DEPT CLIN PHARMACOL,DUNDEE DD1 9SY,SCOTLAND.							BORDER P, 1994, DIS FIGHTING BACK GR, P1; Davey P G, 1992, Pharmacoeconomics, V1, P409; MCGAVOCK H, 1993, BRIT MED J, V307, P1118, DOI 10.1136/bmj.307.6912.1118; TABOULET F, 1990, J EC MED, V8, P37	4	68	71	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					613	613						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595337	Green Published			2022-12-28	WOS:A1996TZ84000027
J	McGrath, AM; Jackson, GA				McGrath, AM; Jackson, GA			Survey of neuroleptic prescribing in residents of nursing homes in Glasgow	BRITISH MEDICAL JOURNAL			English	Article							DRUG-USE		PARKHEAD HOSP,GLASGOW G31 5BA,LANARK,SCOTLAND; KNIGHTSWOOD HOSP,GLASGOW G13 2XF,LANARK,SCOTLAND					jackson, graham/0000-0002-0526-7084				BROWN JW, 1993, J NERV MENT DIS, V181, P695, DOI 10.1097/00005053-199311000-00008; JENCKS SF, 1991, JAMA-J AM MED ASSOC, V265, P502; MONANE M, 1993, ARCH INTERN MED, V153, P633, DOI 10.1001/archinte.153.5.633; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; SENLA TP, 1994, J AM GERIATR SOC, V42, P648	5	105	105	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					611	612						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TZ840	8595335				2022-12-28	WOS:A1996TZ84000025
J	Pantel, K; Izbicki, J; Passlick, B; Angstwurm, M; Haussinger, K; Thetter, O; Riethmuller, G				Pantel, K; Izbicki, J; Passlick, B; Angstwurm, M; Haussinger, K; Thetter, O; Riethmuller, G			Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases	LANCET			English	Article							MICROMETASTATIC CARCINOMA-CELLS; MONOCLONAL-ANTIBODIES; EXPRESSION; TISSUES; CYTOKERATIN; EPITHELIA; GENE	Background Metastasis is generally looked on as a late event in the natural history of epithelial tumours. However, the poor prognosis of patients with apparently localised lung cancer indicates that micrometastases occur often before diagnosis of the primary tumour. Methods At primary surgery, disseminated tumour cells were detected immunocytochemically in bone marrow of 139 patients with non-small-cell lung carcinomas without evidence of distant metastases (pT(1-4)pN(1-2)M(0)). Tumour cells in bone-marrow aspirates were detected with monoclonal antibody CK2 against cytokeratin polypeptide 18. Patients were followed up for a median of 39 months (range 14-52) after surgery. 215 patients without epithelial cancer (ie, with benign epithelial tumours, nonepithelial neoplasms, or inflammatory diseases) acted as controls. Findings In 83 of 139 (59.7%) patients cytokeratin-positive cells were detected at frequencies of 1 in 100 000 to 1 in 1 000 000. Even without histopathological involvement of lymph nodes (pN(0)), tumour cells were found in 38 of 70 (54.3%) patients. 1 positive cell was found in each of 6 out of 215 controls. Surgical manipulation during primary tumour resection did not affect the frequency of these cells. In Cox's regression analyses, the presence of such cells was a significant and independent predictor for a later clinical relapse in node-negative patients (p=0.028). Interpretation Early dissemination of isolated tumour cells is a frequent and intrinsic characteristic of non-small-cell lung carcinomas. The finding of these cells may help to decide whether adjuvant systemic therapy is required for the individual patient.	UNIV MUNICH, CHIRURG KLINIKUM INNENSTADT, D-80336 MUNICH, GERMANY; UNIV HAMBURG, KRANKENHAUS EPPENDORF, KLIN ALLGEMEINCHIRURG, HAMBURG, GERMANY; ZENT KRANKENHAUS GAUTING, ABT THORAXCHIRURG, GAUTING, GERMANY; ZENT KRANKENHAUS GAUTING, ABT PULMONOL, GAUTING, GERMANY	University of Munich; University of Hamburg	Pantel, K (corresponding author), UNIV MUNICH, INST IMMUNOL, D-80336 MUNICH, GERMANY.							BOS JL, 1989, CANCER RES, V49, P4682; BURKHARDT R, 1980, B CANCER, V67, P291; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DATTA YH, 1994, J CLIN ONCOL, V12, P475, DOI 10.1200/JCO.1994.12.3.475; DEBUS E, 1982, EMBO J, V1, P1641, DOI 10.1002/j.1460-2075.1982.tb01367.x; GOTTLINGER HG, 1986, INT J CANCER, V38, P47; GRUNOW N, 1991, PATHOLOGE, V12, P270; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARRISON WJ, 1962, J CLIN PATHOL, V15, P254, DOI 10.1136/jcp.15.3.254; HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2; IMMERMAN SC, 1981, ANN THORAC SURG, V32, P23, DOI 10.1016/S0003-4975(10)61368-9; KRISMANN M, 1995, J CLIN ONCOL, V13, P2769, DOI 10.1200/JCO.1995.13.11.2769; LATZA U, 1990, J CLIN PATHOL, V43, P213, DOI 10.1136/jcp.43.3.213; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Minna JD, 1989, CANCER PRINCIPLES PR, P591; MOMBURG F, 1987, CANCER RES, V47, P2883; PAGE A, 1987, CAN J SURG, V30, P96; Pantel K, 1994, J Hematother, V3, P165, DOI 10.1089/scd.1.1994.3.165; PANTEL K, 1991, CANCER RES, V51, P4712; PANTEL K, 1995, JNCI-J NATL CANCER I, V87, P1162, DOI 10.1093/jnci/87.15.1162; PANTEL K, 1993, CANCER RES, V53, P1027; PANTEL K, 1993, JNCI-J NATL CANCER I, V85, P1419, DOI 10.1093/jnci/85.17.1419; PASSLICK B, 1994, J CLIN ONCOL, V12, P1827, DOI 10.1200/JCO.1994.12.9.1827; RIETHMULLER G, 1994, LANCET, V343, P1177, DOI 10.1016/S0140-6736(94)92398-1; SCHLIMOK G, 1987, P NATL ACAD SCI USA, V84, P8672, DOI 10.1073/pnas.84.23.8672; TRAWEEK ST, 1993, AM J PATHOL, V142, P1111; WOOD DP, 1994, J UROLOGY, V151, P303	28	336	346	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	1996	347	9002					649	653		10.1016/S0140-6736(96)91203-9	http://dx.doi.org/10.1016/S0140-6736(96)91203-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596379				2022-12-28	WOS:A1996TZ28500011
J	Kataja, V; deBruijn, KM				Kataja, V; deBruijn, KM			Hypersensitivity reactions associated with 5-hydroxytryptamine(3)-receptor antagonists: A class effect?	LANCET			English	Article							ONDANSETRON	Background The 5-hydroxytryptamine (5-HT3)-receptor antagonists, granisetron, ondansetron, and tropisetron are effective anti-emetic medications for use during chemotherapy for cancer and they are generally well tolerated. Their adverse event profiles broadly overlap and include headache and gastrointestinal symptoms, especially constipation. Hypersensitivity reactions have been reported very rarely. Methods We describe two patients who developed severe hypersensitivity reactions following exposure to a 5-HT3 receptor antagonist after having experienced mild to moderate hypersensitivity symptoms following previous exposure to a different 5-HT3 receptor antagonist. Findings A literature search on hypersensitivity reactions associated with these drugs suggests that these are the first reported instances of cross-reactive hypersensitivity. Interpretation There may be a drug class effect, and we caution against switching to another 5-HT3 receptor antagonist in patients who have suffered even mild hypersensitivity reactions during previous therapy with 5HT(3) receptor antagonist.	SANDOZ CLIN DEV CTR,FRIMLEY,SURREY,ENGLAND; SANDOZ PHARMA LTD,CH-4002 BASEL,SWITZERLAND	Novartis; Sandoz; Novartis; Sandoz	Kataja, V (corresponding author), KUOPIO UNIV HOSP,DEPT ONCOL,POB 1777,SF-70211 KUOPIO,FINLAND.			Kataja, Vesa/0000-0003-4846-4843				CHEN M, 1993, ANN INTERN MED, V119, P862, DOI 10.7326/0003-4819-119-8-199310150-00026; GRUNBERG SM, 1989, J CLIN ONCOL, V7, P1137, DOI 10.1200/JCO.1989.7.8.1137; JONES AL, 1991, LANCET, V338, P483, DOI 10.1016/0140-6736(91)90554-3; KOSSEY JL, 1994, ANN PHARMACOTHER, V28, P1029, DOI 10.1177/106002809402800906; SORBE BG, 1994, CANCER, V73, P445, DOI 10.1002/1097-0142(19940115)73:2<445::AID-CNCR2820730233>3.0.CO;2-4; WARR D, 1993, EUR J CANCER, V29A, P33, DOI 10.1016/0959-8049(93)90572-W	6	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					584	585		10.1016/S0140-6736(96)91275-1	http://dx.doi.org/10.1016/S0140-6736(96)91275-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596322				2022-12-28	WOS:A1996TX69400013
J	Lee, N				Lee, N			South Africa's AIDS play provokes controversy	LANCET			English	News Item																			0	0	0	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					610	610		10.1016/S0140-6736(96)91306-9	http://dx.doi.org/10.1016/S0140-6736(96)91306-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596329				2022-12-28	WOS:A1996TX69400041
J	Gittoes, NJL; Miller, MR; Daykin, J; Sheppard, MC; Franklyn, JA				Gittoes, NJL; Miller, MR; Daykin, J; Sheppard, MC; Franklyn, JA			Upper airways obstruction in 153 consecutive patients presenting with thyroid enlargement	BRITISH MEDICAL JOURNAL			English	Article									UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham								Committee on Research into Chronic Bronchitis, 1966, QUESTIONNAIRE RESP S; COOPER JC, 1991, ANN ROY COLL SURG, V73, P32; EMPEY DW, 1972, BRIT MED J, V3, P503, DOI 10.1136/bmj.3.5825.503; MILLER MR, 1990, Q J MED, V74, P177; MILLER MR, 1988, THORAX, V43, P265, DOI 10.1136/thx.43.4.265	5	61	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					484	484		10.1136/bmj.312.7029.484	http://dx.doi.org/10.1136/bmj.312.7029.484			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597682	Green Published			2022-12-28	WOS:A1996TX38300027
J	Krueger, NX; VanVactor, D; Wan, HI; Gelbart, WM; Goodman, CS; Saito, H				Krueger, NX; VanVactor, D; Wan, HI; Gelbart, WM; Goodman, CS; Saito, H			The transmembrane tyrosine phosphatase DLAR controls motor axon guidance in Drosophila	CELL			English	Article							CELL-ADHESION MOLECULE; GROWTH CONE GUIDANCE; NERVOUS-SYSTEM AXONS; IMMUNOGLOBULIN SUPERFAMILY; CYTOPLASMIC REGION; GENETIC-ANALYSIS; FASCICLIN-II; C-ELEGANS; RECEPTOR; PROTEIN	DLAR is a receptor-like, transmembrane protein-tyrosine phosphatase in Drosophila that is expressed almost exclusively by developing neurons. Analysis of Dlar loss-of-function mutations shows that DLAR plays a key role during motoneuron growth cone guidance. Segmental nerve b (SNb) motor axons normally exit the common motor pathway, enter the ventral target region, and then synapse on specific ventral muscles. In Dlar mutant embryos, SNb axons bypass their normal target region and instead continue to extend along the common pathway. SNd motor axons also make pathfinding errors, while SNa and SNc axons appear normal. Thus, DLAR controls the ability of certain motor axons to navigate specific choice points in the developing Drosophila nervous system.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DIV NEUROBIOL,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of California System; University of California Berkeley; Harvard University			Saito, Haruo/AAF-6113-2019	Saito, Haruo/0000-0001-7891-1689; Van Vactor, Jr., David L./0000-0001-8156-9482	NIGMS NIH HHS [GM53415] Funding Source: Medline; PHS HHS [AL26598] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; AULD VJ, 1995, CELL, V81, P757, DOI 10.1016/0092-8674(95)90537-5; BARNES WM, 1987, METHOD ENZYMOL, V152, P538; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; BEIER DR, 1992, P NATL ACAD SCI USA, V89, P9102, DOI 10.1073/pnas.89.19.9102; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BIXBY JL, 1993, J NEUROSCI, V13, P3421; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DESAI CJ, 1996, CELL, V84; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOODMAN CS, 1996, IN PRESS ANN REV NEU, V19; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARIHARAN IK, 1991, P NATL ACAD SCI USA, V88, P11266, DOI 10.1073/pnas.88.24.11266; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KOPCZYNSKI CC, 1992, J CELL BIOL, V119, P503, DOI 10.1083/jcb.119.3.503; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LIN DM, 1995, NEURON, V14, P707, DOI 10.1016/0896-6273(95)90215-5; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; Maness P F, 1990, Adv Exp Med Biol, V265, P117; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; OGRADY P, 1994, J BIOL CHEM, V269, P25193; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PAN MG, 1993, J BIOL CHEM, V268, P19284; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PULIDO R, 1995, J BIOL CHEM, V270, P6722, DOI 10.1074/jbc.270.12.6722; RAMOS RGP, 1993, GENE DEV, V7, P2533, DOI 10.1101/gad.7.12b.2533; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER T, 1995, NEURON, V15, P259, DOI 10.1016/0896-6273(95)90032-2; Schultz Leonard D., 1993, Cell, V73, P1445; SPINARDI L, 1991, NUCLEIC ACIDS RES, V19, P4009, DOI 10.1093/nar/19.14.4009; STOKER AW, 1995, DEVELOPMENT, V121, P1833; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; YAN H, 1993, J BIOL CHEM, V268, P24880; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; Zinn Kai, 1993, Seminars in Cell Biology, V4, P397, DOI 10.1006/scel.1993.1047	62	293	297	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					611	622		10.1016/S0092-8674(00)81036-3	http://dx.doi.org/10.1016/S0092-8674(00)81036-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598047	Bronze			2022-12-28	WOS:A1996TX17600013
J	Cheng, EHY; Levine, B; Boise, LH; Thompson, CB; Hardwick, JM				Cheng, EHY; Levine, B; Boise, LH; Thompson, CB; Hardwick, JM			Bax-independent inhibition of apoptosis by Bcl-x(L)	NATURE			English	Article							SINDBIS VIRUS; MICE	THE Bcl-2-related protein, Bcl-x(L), has been shown to block apoptosis induced by a variety of stimuli(1-5) and to be a stronger protector against apoptosis than Bcl-2 under certain circumstances(2,5). Using site-specific mutagenesis, we show here that the amino-acid residues critical for protection of cells by Bcl-x(L) against Sindbis virus-induced apoptosis are clustered within the Bcl-2-homology regions 1 and 2 (BH1 and BH2 regions). The residues necessary for Bcl-x(L) function are not identical to those required for Bcl-2 function(6), Although it has been suggested that heterodimerization between Bcl-x(L) and Bax is essential for the anti death activity of Bcl-x(L) (refs 7, 8), our results suggest that the interaction with Bax is not required for Bcl-x(L) to exert its death-repressing activity, Specific mutations that disrupt the ability of Bcl-x(L) to interact with Bax or Bak still preserve 70-80% of the anti-death activity of wild-type Bcl-x(L).	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC GENET,CHICAGO,IL 60637; UNIV CHICAGO,DEPT CELL BIOL,CHICAGO,IL 60637	Columbia University; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago	Cheng, EHY (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,DEPT NEUROL,NEUROVIROL LABS,MEYER 6-181,BALTIMORE,MD 21287, USA.		Boise, Lawrence/AAD-2314-2019	Boise, Lawrence/0000-0001-9436-8815				BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOLSE LH, 1993, CELL, V74, P597; Bomer C, 1994, J CELL BIOL, V126, P1059; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; DOLE MG, 1995, CANCER RES, V55, P2576; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; GOTTSCHALK AR, IN PRESS CELL DEATH; HERTZ JM, 1992, J VIROL, V66, P857, DOI 10.1128/JVI.66.2.857-864.1992; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KAMADA S, 1995, CANCER RES, V55, P354; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; Lewis J, 1996, J VIROL, V70, P1828, DOI 10.1128/JVI.70.3.1828-1835.1996; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LUSTIG S, 1988, J VIROL, V62, P2329, DOI 10.1128/JVI.62.7.2329-2336.1988; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; TANAKA S, 1993, J BIOL CHEM, V268, P10920; UBOL S, 1994, P NATL ACAD SCI USA, V91, P5202, DOI 10.1073/pnas.91.11.5202; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	29	432	461	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					554	556		10.1038/379554a0	http://dx.doi.org/10.1038/379554a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596636				2022-12-28	WOS:A1996TU69300054
J	Goyal, RK; Hirano, I				Goyal, RK; Hirano, I			Mechanisms of disease - The enteric nervous system	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NITRIC-OXIDE SYNTHASE; MYENTERIC PLEXUS; SUBMUCOSAL ARTERIOLES; HIRSCHSPRUNG DISEASE; ULCERATIVE-COLITIS; SMALL-INTESTINE; SUBSTANCE-P; ACHALASIA; NEURONS; DISORDER		BROCKTON W ROXBURY VET AFFAIRS MED CTR, BOSTON, MA USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031092, R01DK031092] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31092] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANNEREN G, 1991, AM J MED GENET, V41, P251, DOI 10.1002/ajmg.1320410224; ATCHISON WD, 1978, AM J DIG DIS, V23, P513, DOI 10.1007/BF01072695; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; BEUBLER E, 1990, GASTROENTEROLOGY, V99, P83, DOI 10.1016/0016-5085(90)91233-V; BJORCK S, 1992, AGENTS ACTIONS, pC60; BUCK SH, 1986, PHARMACOL REV, V38, P179; CASTAGLIUOLO I, 1994, GASTROENTEROLOGY, V107, P657, DOI 10.1016/0016-5085(94)90112-0; COCKEL R, 1973, Q J MED, V42, P771; COOKE HJ, 1994, AM J PHYSIOL, V266, pG167, DOI 10.1152/ajpgi.1994.266.2.G167; COSTA M, 1994, AM J GASTROENTEROL, V89, pS129; CUBEDDU LX, 1990, NEW ENGL J MED, V322, P810, DOI 10.1056/NEJM199003223221204; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; EVANS RJ, 1992, BRIT J PHARMACOL, V106, P242, DOI 10.1111/j.1476-5381.1992.tb14323.x; FEINSTAT T, 1984, GASTROENTEROLOGY, V86, P1573; FOSTER PN, 1987, GUT, V28, P1522, DOI 10.1136/gut.28.11.1522; FURNESS JB, 1995, TXB GASTROENTEROLOGY, V1, P2; Furness JB., 1987, ENTERIC NERVOUS SYST; Gabella Giorgio, 1994, P751; Gershon Michael D., 1994, P381; GOYAL RK, 1989, HDB PHYSL GASTROINTE, V1, P865; HERMAN JR, 1989, FUND APPL TOXICOL, V13, P576, DOI 10.1016/0272-0590(89)90295-9; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; IKEDA SI, 1982, NEUROLOGY, V32, P1364, DOI 10.1212/WNL.32.12.1364; KHAN AH, 1987, J PEDIATR SURG, V22, P719, DOI 10.1016/S0022-3468(87)80612-7; KIRCHGESSNER AL, 1990, J NEUROSCI, V10, P1626; KIRCHGESSNER AL, 1989, J COMP NEUROL, V285, P38, DOI 10.1002/cne.902850105; KRISHNAMURTHY S, 1987, GASTROENTEROLOGY, V93, P610, DOI 10.1016/0016-5085(87)90926-7; KRUMINS SA, 1992, NEUROPEPTIDES, V21, P65, DOI 10.1016/0143-4179(92)90516-Y; KUROSE I, 1994, J CLIN INVEST, V94, P1919, DOI 10.1172/JCI117542; LEDOUARIN NM, 1994, CURR OPIN GENET DEV, V4, P685, DOI 10.1016/0959-437X(94)90135-P; LENNON VA, 1991, GASTROENTEROLOGY, V100, P137, DOI 10.1016/0016-5085(91)90593-A; LI Y, 1994, GASTROENTEROLOGY, V107, P525, DOI 10.1016/0016-5085(94)90180-5; LUNDGREN O, 1989, DIGEST DIS SCI, V34, P264, DOI 10.1007/BF01536062; MAEDA H, 1992, DEVELOPMENT, V116, P369; MANTYH CR, 1988, P NATL ACAD SCI USA, V85, P3235, DOI 10.1073/pnas.85.9.3235; MATHIAS JR, 1976, J CLIN INVEST, V58, P91, DOI 10.1172/JCI108464; MAY RJ, 1994, JOSLINS DIABETES MEL, P921; MAZUMDAR S, 1992, AM J GASTROENTEROL, V87, P176; MCCAFFERTY DM, 1994, AM J PHYSIOL, V266, pG560, DOI 10.1152/ajpgi.1994.266.4.G560; MEARIN F, 1993, EUR J CLIN INVEST, V23, P724, DOI 10.1111/j.1365-2362.1993.tb01292.x; MEI N, 1985, PHYSIOL REV, V65, P211, DOI 10.1152/physrev.1985.65.2.211; MONNIG PJ, 1990, ANN THORAC SURG, V49, P1019, DOI 10.1016/0003-4975(90)90897-F; MURPHY MS, 1989, AM J GASTROENTEROL, V84, P1329; NOCERINO A, 1995, GASTROENTEROLOGY, V108, P34, DOI 10.1016/0016-5085(95)90005-5; OBRIEN BD, 1982, GASTROENTEROLOGY, V82, P957; PASRICHA PJ, 1995, NEW ENGL J MED, V332, P774, DOI 10.1056/NEJM199503233321203; PASRICHA PJ, 1995, NEW ENGL J MED, V333, P75; POTHOULAKIS C, 1994, P NATL ACAD SCI USA, V91, P947, DOI 10.1073/pnas.91.3.947; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; QUALMAN SJ, 1984, GASTROENTEROLOGY, V87, P848; ROBERTSON CS, 1993, GUT, V34, P299, DOI 10.1136/gut.34.3.299; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; RUHL A, 1995, GASTROENTEROLOGY, V108, pA680, DOI 10.1016/0016-5085(95)27032-9; SANTOS H, 1988, J MED GENET, V25, P204, DOI 10.1136/jmg.25.3.204; SARNA SK, 1991, DIGEST DIS SCI, V36, P998, DOI 10.1007/BF01297155; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Sengupta J. N., 1994, P483; SHAH KN, 1981, J PEDIATR-US, V99, P432, DOI 10.1016/S0022-3476(81)80339-3; Shanahan Fergus, 1994, P643; SIMON LT, 1990, ANN NEUROL, V28, P349, DOI 10.1002/ana.410280308; SINGARAM C, 1995, GASTROENTEROLOGY, V109, P275, DOI 10.1016/0016-5085(95)90294-5; SMITH B, 1972, NEUROPATHOLOGY ALIME; SOUDAH HC, 1991, NEW ENGL J MED, V325, P1461, DOI 10.1056/NEJM199111213252102; STEAD RH, 1992, ANN NY ACAD SCI, V664, P443, DOI 10.1111/j.1749-6632.1992.tb39782.x; STUCKEY BG, 1987, ANN INTERN MED, V106, P62, DOI 10.7326/0003-4819-106-1-62; SURPRENANT A, 1994, ANNU REV PHYSIOL, V56, P117, DOI 10.1146/annurev.physiol.56.1.117; Szurszewski Joseph H., 1994, P795; TACHE Y, 1993, BASIC CLIN ASPECT CH, P141; TANNER MS, 1976, ARCH DIS CHILD, V51, P837, DOI 10.1136/adc.51.11.837; TANTISIRA MH, 1990, ACTA PHYSIOL SCAND, V138, P75, DOI 10.1111/j.1748-1716.1990.tb08814.x; VANDERWINDEN JM, 1992, NEW ENGL J MED, V327, P1252; VANDERWINDEN JM, 1993, GASTROENTEROLOGY, V105, P969, DOI 10.1016/0016-5085(93)90938-9; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; VANNER S, 1991, AM J PHYSIOL, V261, pG136, DOI 10.1152/ajpgi.1991.261.1.G136; VANNER S, 1993, AM J PHYSIOL, V264, pG202, DOI 10.1152/ajpgi.1993.264.2.G202; WOOD JD, 1972, AM J PHYSIOL, V222, P118, DOI 10.1152/ajplegacy.1972.222.1.118; WORL J, 1994, J AUTONOM NERV SYST, V49, P227, DOI 10.1016/0165-1838(94)90169-4; YAMATO S, 1992, LIFE SCI, V50, P1263, DOI 10.1016/0024-3205(92)90326-K; YAMATO S, 1992, GASTROENTEROLOGY, V103, P197, DOI 10.1016/0016-5085(92)91113-I; YOSHIDA MM, 1988, GASTROENTEROLOGY, V95, P820, DOI 10.1016/S0016-5085(88)80034-9	83	565	588	1	54	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 25	1996	334	17					1106	1115		10.1056/NEJM199604253341707	http://dx.doi.org/10.1056/NEJM199604253341707			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG457	8598871				2022-12-28	WOS:A1996UG45700007
J	Garner, DW				Garner, DW			Banning tobacco billboards - The case for municipal action	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								In 1994, Baltimore, Md, became the first city to generally prohibit billboards from displaying alcohol and tobacco advertisements. The owner of most of Baltimore's billboards, Penn Advertising, sued, but the federal district court rejected the billboard company's complaint and ruled that the First Amendment had not been violated and that the federal cigarette labeling acts had not preempted the ability of Baltimore to regulate and prohibit billboard cigarette advertising. In the fall of 1995, the federal district court's judgment was unanimously affirmed by the Fourth Circuit Court of Appeals in Richmond, Va. This article analyzes the constitutional and preemption issues and concludes that states and municipalities are on firm legal ground when they restrict the location or placement of publicly visible cigarette advertisements without attempting to regulate the advertisement's content or message. States and municipalities command broad authority to protect children and to shield the public from intrusive forms of advertisement that inflict their messages on a captive audience. A billboard ban thus offers local communities a legal avenue to help curb the rising tide of juvenile smoking without raising taxes, creating bureaucracy, or angering smokers.			Garner, DW (corresponding author), SO ILLINOIS UNIV,SCH LAW,CARBONDALE,IL 62901, USA.							AGUS C, 1990, NEWSDAY         0613, P4; EVANS N, 1995, J NATL CANCER I, V87, P1538, DOI 10.1093/jnci/87.20.1538; FISCHER PM, 1991, JAMA-J AM MED ASSOC, V266, P3145, DOI 10.1001/jama.266.22.3145; KIRBY J, 1990, NEWSDAY         0304, P4; PIERCE JP, 1994, JAMA-J AM MED ASSOC, V271, P608, DOI 10.1001/jama.271.8.608; ROEMER R, 1986, UNPUB NATL LEGISLATI, P66; RONSON J, 1992, WORLD SMOKING HLTH, V2, P25; RONSON J, 1992, WORLD SMOKING HLTH, V2, P24; ROTHSTEIN L, 1995, HLTH LAW NEWS    SEP, P4; *SMOK CONTR ADV RE, 1994, ISS STUD CORR ADV IN; *US DEPT HHS, 1989, HLTH CONS SMOK NIC A, P9; *US DEPT HHS, 1994, PREV TOB US YOUNG PE, P192; 1995, TOBOCCO FREE YOU FAL, P17; 1965, PUB L, V8992; 1994, MILFORD DAILY N 1118, P1; 1993, FED REGISTER, V58, P45156; 1995, FED REGISTER, V60, P41314; 1993, SCENIC AM, P16; 1995, FED REGISTER, V60, P41315; 1970, 91222 PUB L; 1993, FED REGISTER, V58, P45158	21	6	6	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1263	1269						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF478	8601959				2022-12-28	WOS:A1996UF47800031
J	Gerstein, HC; Yusuf, S				Gerstein, HC; Yusuf, S			Dysglycaemia and risk of cardiovascular disease	LANCET			English	Article							CORONARY-HEART-DISEASE; DEPENDENT DIABETES-MELLITUS; MORTALITY; HYPERGLYCEMIA; ASSOCIATION; WHITEHALL; NIDDM; DEATH; MEN		MCMASTER UNIV, CHEDOKE MCMASTER HOSP, DEPT MED, DIABET CARE & RES CTR, HAMILTON, ON L8N 3Z5, CANADA; HAMILTON CIV HOSP, RES CTR, PREVENT CARDIOL & THERAPEUT PROGRAMME, HAMILTON, ON, CANADA	McMaster University; McMaster University			Gerstein, Hertzel/ABB-8781-2020; Gerstein, Hertzel C/B-1235-2013	Gerstein, Hertzel/0000-0001-8072-2836; Gerstein, Hertzel C/0000-0001-8072-2836; Yusuf, Salim/0000-0003-4776-5601				BARRETTCONNOR E, 1984, J CHRON DIS, V37, P773, DOI 10.1016/0021-9681(84)90046-8; BURCHFIEL CM, 1994, STROKE, V25, P951, DOI 10.1161/01.STR.25.5.951; CURB JD, 1995, CIRCULATION, V91, P2591, DOI 10.1161/01.CIR.91.10.2591; DAMSGAARD EM, 1992, KIDNEY INT, V41, P731; Diabet Control Complications Trial DCCT Res Grp, 1995, AM J CARDIOL, V75, P894; DONAHUE RP, 1992, DIABETES CARE, V15, P1141, DOI 10.2337/diacare.15.9.1141; DONAHUE RP, 1987, DIABETES, V36, P689, DOI 10.2337/diabetes.36.6.689; FULLER JH, 1980, LANCET, V1, P1373; HARRIS MI, 1993, DIABETES CARE, V16, P642, DOI 10.2337/diacare.16.4.642; HERMAN JB, 1977, DIABETOLOGIA, V13, P229, DOI 10.1007/BF01219704; JARRETT RJ, 1984, DIABETOLOGIA, V26, P99; JARRETT RJ, 1988, DIABETOLOGIA, V31, P737, DOI 10.1007/BF00274775; Kenny S.J., 1995, NIH PUBLICATION, P47; KROLEWSKI AS, 1995, NEW ENGL J MED, V332, P1251, DOI 10.1056/NEJM199505113321902; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; LEONETTI F, 1993, J ENDOCRINOL INVEST, V16, P875, DOI 10.1007/BF03348949; MALBERG K, 1995, J AM COLL CARDIOL, V26, P57; MORRISH NJ, 1991, DIABETOLOGIA, V34, P584, DOI 10.1007/BF00400278; MOSS SE, 1994, ARCH INTERN MED, V154, P2473; NEIL A, 1993, DIABETES CARE, V16, P996, DOI 10.2337/diacare.16.7.996; REWERS M, 1995, NIH PUBLICATION, P179; SCHEIDTNAVE C, 1991, AM J EPIDEMIOL, V133, P565, DOI 10.1093/oxfordjournals.aje.a115928; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SINGER DE, 1992, DIABETES, V41, P202, DOI 10.2337/diabetes.41.2.202; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; VIBERTI G, 1995, NEW ENGL J MED, V332, P1293, DOI 10.1056/NEJM199505113321909; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; WINGARD DL, 1995, DIABETES CARE, V18, P1299, DOI 10.2337/diacare.18.9.1299; 1992, JAMA-J AM MED ASSOC, V266, P1292	29	138	143	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	1996	347	9006					949	950		10.1016/S0140-6736(96)91420-8	http://dx.doi.org/10.1016/S0140-6736(96)91420-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598762				2022-12-28	WOS:A1996UD59100015
J	Gregoire, AJP; Kumar, R; Everitt, B; Henderson, AF; Studd, JWW				Gregoire, AJP; Kumar, R; Everitt, B; Henderson, AF; Studd, JWW			Transdermal oestrogen for treatment of severe postnatal depression	LANCET			English	Article							CYCLICAL ORAL NORETHISTERONE; PREMENSTRUAL-SYNDROME; PSYCHIATRIC-DISORDER; CHILDBEARING; CHILDBIRTH; PREVALENCE; PATCHES; IMPACT; WOMEN	Background Postnatal depression can have long-term adverse consequences for the mother, for the marital relationship, and for the infant's psychological development. Such depressions can be severe and resistant to both support and counselling and to therapy with antidepressant drugs, We investigated the antidepressant efficacy of oestrogen given transdermally. Methods In a double-blind, placebo-controlled study, 61 women with major depression, which began within 3 months of childbirth and persisted for up to 18 months postnatally, were allocated randomly active treatment (n=34; 3 months of transdermal 17 beta-oestradiol 200 mu g daily alone, then 3 months with added cyclical dydrogesterone 10 mg daily for 12 days each month) or placebo (n=27; placebo patches and tablets according to the same regimen). The women were assessed monthly by self-ratings of depressive symptoms on the Edinburgh postnatal depression scale (EPDS) and by clinical psychiatric interview (schedule for affective disorders and schizophrenia [SADS]-change scale). Findings On pretreatment assessments the women in both groups were severely depressed (mean EPDS score 21.8 [SD 3.0] active group, 21.3 [2.9] placebo group; SADS scores, 66.3 [11.4] and 64.3 [10.7]). During the first month of therapy the women receiving oestrogen improved rapidly, and to a significantly greater extent than controls (mean EPDS scores 13.3 [SD 5.7] vs 16.5 [5.3]). Patients receiving placebo also improved over time but, on average, their scores did not fall below the screening threshold for major depression for at least 4 months. The estimated overall treatment effect of oestrogen on the EPDS was 4.38 points (95% Cl 1.89-6.87). None of a range of other factors (age, psychiatric, obstetric and gynaecological history, severity and duration of current episode of depression, and concurrent antidepressant medication), influenced the response to oestrogen. Interpretation This study has shown that transdermal oestrogen is an effective treatment for postnatal depression. Further studies are required to establish the minimum effective dose and shortest necessary duration of treatment as well as the mechanism of antidepressant action of oestrogen.	CHELSEA & WESTMINSTER HOSP, DEPT OBSTET & GYNAECOL, LONDON SW10 9NH, ENGLAND; SALISBURY HLTH CARE, MENTAL HLTH SERV, SALISBURY, WILTS, ENGLAND; INST PSYCHIAT, DEPT PERINATAL PSYCHIAT, LONDON, ENGLAND; INST PSYCHIAT, DEPT BEHAV SCI, LONDON, ENGLAND; ST GEORGE HOSP, DEPT OBSTET & GYNAECOL, LONDON, ENGLAND	Imperial College London; University of London; King's College London; University of London; King's College London; St Georges University London								BHUGRA D, 1993, PRINCIPLES SOCIAL PS, P424; BUIST A, 1990, J AFFECT DISORDERS, V19, P197, DOI 10.1016/0165-0327(90)90092-M; CAPLAN HL, 1989, BRIT J PSYCHIAT, V154, P818, DOI 10.1192/bjp.154.6.818; COGILL SR, 1986, BMJ-BRIT MED J, V292, P1165, DOI 10.1136/bmj.292.6529.1165; COOPER PJ, 1988, BRIT J PSYCHIAT, V152, P799, DOI 10.1192/bjp.152.6.799; COOPER PJ, 1994, 8 INT C MARC SOC; COX JL, 1982, BRIT J PSYCHIAT, V140, P111, DOI 10.1192/bjp.140.2.111; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; COX JL, 1993, BRIT J PSYCHIAT, V163, P27, DOI 10.1192/bjp.163.1.27; CUMMINGS EM, 1994, J CHILD PSYCHOL PSYC, V35, P73, DOI 10.1111/j.1469-7610.1994.tb01133.x; Dalton K., 1980, DEPRESSION CHILDBIRT; DALTON K, 1989, INT J PRENATAL PERIN, V1, P322; ENDICOTT J, 1986, ASSESSMENT DEPRESSIO, P316; EVERITT BS, 1995, J ROY STAT SOC D-STA, V44, P113, DOI 10.2307/2348622; FLEMING AS, 1992, J CHILD PSYCHOL PSYC, V33, P685, DOI 10.1111/j.1469-7610.1992.tb00905.x; FRISON L, 1992, STAT MED, V11, P1685, DOI 10.1002/sim.4780111304; HARRIS B, 1994, BRIT MED J, V308, P949, DOI 10.1136/bmj.308.6934.949; HARRIS B, 1993, BRIT J PSYCHIAT, V163, P403, DOI 10.1192/bjp.163.3.403; HENDERSON AF, 1991, LANCET, V338, P816, DOI 10.1016/0140-6736(91)90697-N; HOLDEN JM, 1989, BRIT MED J, V298, P223, DOI 10.1136/bmj.298.6668.223; KLAIBER EL, 1979, ARCH GEN PSYCHIAT, V36, P550; KUMAR R, 1994, SOC PSYCH PSYCH EPID, V29, P250, DOI 10.1007/BF00802048; KUMAR R, 1984, BRIT J PSYCHIAT, V144, P35, DOI 10.1192/bjp.144.1.35; MAGOS AL, 1986, BMJ-BRIT MED J, V292, P1629, DOI 10.1136/bmj.292.6536.1629; MONTGOMERY JC, 1987, LANCET, V1, P297; MURRAY L, 1992, J CHILD PSYCHOL PSYC, V33, P543, DOI 10.1111/j.1469-7610.1992.tb00890.x; OHARA MW, 1990, J ABNORM PSYCHOL, V99, P3, DOI 10.1037/0021-843X.99.1.3; OHARA MW, 1988, MOTHERHOOD MENTAL IL, P17; OKANO T, 1992, PROG NEURO-PSYCHOPH, V16, P921, DOI 10.1016/0278-5846(92)90110-Z; Sharp D, 1995, J CHILD PSYCHOL PSYC, V36, P1315, DOI 10.1111/j.1469-7610.1995.tb01666.x; Sherwin Barbara B., 1994, P119; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; STUDD JWW, 1994, MENOPAUSE, V1, P33; WATSON JP, 1984, BRIT J PSYCHIAT, V144, P453, DOI 10.1192/bjp.144.5.453; WATSON NR, 1989, LANCET, V2, P730, DOI 10.1016/S0140-6736(89)90784-8	36	391	402	2	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	1996	347	9006					930	933		10.1016/S0140-6736(96)91414-2	http://dx.doi.org/10.1016/S0140-6736(96)91414-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UD591	8598756				2022-12-28	WOS:A1996UD59100009
J	Francino, MP; Chao, L; Riley, MA; Ochman, H				Francino, MP; Chao, L; Riley, MA; Ochman, H			Asymmetries generated by transcription-coupled repair in enterobacterial genes	SCIENCE			English	Article							ESCHERICHIA-COLI; MUTATION-RATES; DNA-REPLICATION; LAGGING-STRAND; CODON USAGE; POPULATIONS; DEAMINATION; SALMONELLA; REGION; OPERON	Although certain replication errors occur at different frequencies on each of the complementary strands of DNA, it remains unclear whether this bias is prevalent enough during chromosome replication to affect sequence evolution. Here, nucleotide substitutions in enteric bacteria were examined, and no difference in mutation rates was detected between the leading and lagging strands, but in comparing the coding and noncoding strands, an excess of C-->T changes was observed on the coding strand. This asymmetry is best explained by transcription-coupled repair on the noncoding strand. Although the vast majority of mutations are thought to arise from spontaneous errors during replication, this result implicates DNA damage as a substantial source of mutations in the wild.	UNIV ROCHESTER, DEPT BIOL, ROCHESTER, NY 14627 USA; UNIV MARYLAND, DEPT ZOOL, COLLEGE PK, MD 20742 USA; YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06511 USA	University of Rochester; University System of Maryland; University of Maryland College Park; Yale University			Francino, M.Pilar/H-9090-2015; Riley, Margaret Ann/AAB-9743-2022	Francino, M.Pilar/0000-0002-4510-5653; 				BERG OG, 1995, J MOL EVOL, V41, P449, DOI 10.1007/BF00160316; BOYD EF, 1994, P NATL ACAD SCI USA, V91, P1280, DOI 10.1073/pnas.91.4.1280; BULMER M, 1991, J MOL EVOL, V33, P305, DOI 10.1007/BF02102861; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; DATTA A, 1995, SCIENCE, V268, P1616, DOI 10.1126/science.7777859; DOWNES CS, 1993, BIOESSAYS, V15, P209, DOI 10.1002/bies.950150311; DUBOSE RF, 1988, P NATL ACAD SCI USA, V85, P7036, DOI 10.1073/pnas.85.18.7036; EYREWALKER A, 1995, GENETICS, V140, P1407; FERSHT AR, 1981, P NATL ACAD SCI-BIOL, V78, P4251, DOI 10.1073/pnas.78.7.4251; FREDERICO LA, 1993, BIOCHEMISTRY-US, V32, P6523, DOI 10.1021/bi00077a005; HALL BG, 1992, MOL BIOL EVOL, V9, P654; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; IZUTA S, 1995, J BIOL CHEM, V270, P2595, DOI 10.1074/jbc.270.6.2595; Kornberg A., 1992, DNA REPLICATION; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; MADDISON WP, 1992, MACCLADE V 3 0 ANAL; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; NELSON K, 1994, P NATL ACAD SCI USA, V91, P10227, DOI 10.1073/pnas.91.21.10227; NELSON K, 1991, P NATL ACAD SCI USA, V88, P6667, DOI 10.1073/pnas.88.15.6667; NELSON K, 1992, J BACTERIOL, V174, P6886, DOI 10.1128/JB.174.21.6886-6895.1992; OLLER AR, 1992, P NATL ACAD SCI USA, V89, P11036, DOI 10.1073/pnas.89.22.11036; PHILLIPS GJ, 1987, NUCLEIC ACIDS RES, V15, P2611, DOI 10.1093/nar/15.6.2611; ROBERTS JD, 1994, J BIOL CHEM, V269, P1711; SELANDER RK, 1994, FEMS SYMP, P17; SHARP PM, 1987, MOL BIOL EVOL, V4, P222; SKANDALIS A, 1994, MUTAT RES, V314, P21, DOI 10.1016/0921-8777(94)90057-4; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; VEAUTE X, 1993, SCIENCE, V261, P598, DOI 10.1126/science.8342022; WU CI, 1991, NATURE, V352, P114, DOI 10.1038/352114b0; WU CI, 1987, NATURE, V327, P169, DOI 10.1038/327169a0; [No title captured]	31	109	113	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					107	109		10.1126/science.272.5258.107	http://dx.doi.org/10.1126/science.272.5258.107			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600517				2022-12-28	WOS:A1996UD59700049
J	Nehrbass, U; Blobel, G				Nehrbass, U; Blobel, G			Role of the nuclear transport factor p10 in nuclear import	SCIENCE			English	Article							PROTEIN RAN/TC4	The nuclear import factor p10 was cloned from Saccharomyces cerevisiae and found to be essential. The protein p10 can bind directly to several peptide repeat-containing nucleoporins. It also binds to the guanosine triphosphatase (GTPase) Ran in its guanosine diphosphate (GDP)-bound form and to karyopherin beta. Assembly of the karyopherin heterodimer on immobilized nucleoporin yielded cooperative binding of p10 and Ran-GDP. Addition of GTP to this pentameric complex led to dissociation of karyopherin alpha, presumably via in situ formation of Ran-GTP from Ran-GDP. Thus, p10 appears to coordinate the Ran-dependent association and dissociation reactions underlying nuclear import.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University				Vallar, Laurent/0000-0002-4404-1010; Nehrbass, Ulf/0000-0002-7028-8076				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DECASTILLIA CS, 1995, J CELL BIOL, V131, P19; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385	27	155	157	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1996	272	5258					120	122		10.1126/science.272.5258.120	http://dx.doi.org/10.1126/science.272.5258.120			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600522				2022-12-28	WOS:A1996UD59700054
J	Nowak, MA; Bangham, CRM				Nowak, MA; Bangham, CRM			Population dynamics of immune responses to persistent viruses	SCIENCE			English	Review							CYTOTOXIC LYMPHOCYTES-T; CENTRAL-NERVOUS-SYSTEM; EPSTEIN-BARR-VIRUS; GENETIC-VARIATION; CELL RECOGNITION; HIV-INFECTION; TYPE-1; INVIVO; INFLUENZA; CLEARANCE	Mathematical models, which are based on a firm understanding of biological interactions, can provide nonintuitive insights into the dynamics of host responses to infectious agents and can suggest new avenues for experimentation. Here, a simple mathematical approach is developed to explore the relation between antiviral immune responses, virus load, and virus diversity. The model results are compared to data on cytotoxic Tell responses and viral diversity in infections with the human T cell leukemia virus (HTLV-1) and the human immunodeficiency virus (HIV-1).	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP, SCH MED, LONDON W2 1PG, ENGLAND	Imperial College London	Nowak, MA (corresponding author), UNIV OXFORD, DEPT ZOOL, S PARKS RD, OXFORD OX1 3PS, ENGLAND.		Nowak, Martin A/A-6977-2008	Bangham, Charles/0000-0003-2624-3599	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUR Z, 1991, EXP HEMATOL, V19, P364; ALLISON AC, 1964, COLD SPRING HARB SYM, V29, P137, DOI 10.1101/SQB.1964.029.01.018; ANDERSON R M, 1991; ANDERSON RM, 1994, SCIENCE, V264, P1884, DOI 10.1126/science.8009218; ANDERSON RM, 1989, CELL TO CELL SIGNALLING : FROM EXPERIMENTS TO THEORETICAL MODELS, P335; Antia R, 1996, P NATL ACAD SCI USA, V93, P985, DOI 10.1073/pnas.93.3.985; ARIYOSHI K, 1995, AIDS, V9, P555, DOI 10.1097/00002030-199506000-00004; ASJO B, 1990, AIDS RES HUM RETROV, V6, P1177, DOI 10.1089/aid.1990.6.1177; BAIER M, 1995, NATURE, V378, P563, DOI 10.1038/378563a0; Bangham C R, 1993, Curr Opin Neurobiol, V3, P773, DOI 10.1016/0959-4388(93)90152-O; Bangham CRM, 1996, SEMIN VIROL, V7, P41, DOI 10.1006/smvy.1996.0006; BERTOLETTI A, 1994, J EXP MED, V180, P933, DOI 10.1084/jem.180.3.933; BONHOEFFER S, 1995, NATURE, V376, P125, DOI 10.1038/376125a0; BONHOEFFER S, 1995, IMMUNOL TODAY, V16, P131, DOI 10.1016/0167-5699(95)80129-4; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; BUREAU JF, 1993, NAT GENET, V5, P87, DOI 10.1038/ng0993-87; BURK RD, 1994, J INFECT DIS, V170, P1418, DOI 10.1093/infdis/170.6.1418; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; CANNON MJ, 1987, IMMUNOLOGY, V62, P133; CHEYNIER R, 1995, ADV EXP MED BIOL, V374, P173; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; Daenke S, 1996, VIROLOGY, V217, P139, DOI 10.1006/viro.1996.0101; DEBOER RJ, 1994, P NATL ACAD SCI USA, V91, P544, DOI 10.1073/pnas.91.2.544; DEBOER RJ, 1995, J THEOR BIOL, V175, P567, DOI 10.1006/jtbi.1995.0165; DECAMPOSLIMA PO, 1993, SCIENCE, V260, P98, DOI 10.1126/science.7682013; DELWART EL, 1994, J VIROL, V68, P6672, DOI 10.1128/JVI.68.10.6672-6683.1994; DIEHL LJ, 1995, J VIROL, V69, P2328, DOI 10.1128/JVI.69.4.2328-2332.1995; EIGEN M, 1977, NATURWISSENSCHAFTEN, V64, P541, DOI 10.1007/BF00450633; Ferrari C, 1996, SEMIN VIROL, V7, P23, DOI 10.1006/smvy.1996.0004; FONG TL, 1994, J MED VIROL, V43, P155, DOI 10.1002/jmv.1890430210; FOX JC, 1995, J GEN VIROL, V76, P309, DOI 10.1099/0022-1317-76-2-309; FROST SDW, 1994, AIDS, V8, P323, DOI 10.1097/00002030-199403000-00005; FURTADO MR, 1995, J VIROL, V69, P2092, DOI 10.1128/JVI.69.4.2092-2100.1995; GRAZIOSI C, 1993, P NATL ACAD SCI USA, V90, P6405, DOI 10.1073/pnas.90.14.6405; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HERZ AVM, IN PRESS P NATL ACAD; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HIRSCH VM, 1995, J VIROL, V69, P955, DOI 10.1128/JVI.69.2.955-967.1995; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOGERVORST E, 1995, J INFECT DIS, V171, P811, DOI 10.1093/infdis/171.4.811; HOLMES EC, 1992, P NATL ACAD SCI USA, V89, P4835, DOI 10.1073/pnas.89.11.4835; KHANNA R, 1993, J IMMUNOL, V150, P5154; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LIN YL, 1981, J EXP MED, V154, P225, DOI 10.1084/jem.154.2.225; MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104; MCELRATH MJ, 1994, J VIROL, V68, P5074, DOI 10.1128/JVI.68.8.5074-5083.1994; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; MCLEAN AR, 1992, J THEOR BIOL, V155, P69, DOI 10.1016/S0022-5193(05)80549-1; MCLEAN AR, 1992, AIDS, V6, P71, DOI 10.1097/00002030-199201000-00009; MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103; MCMICHAEL AJ, 1994, AIDS S1, V8, pS155; MEIER UC, 1995, SCIENCE, V270, P1360, DOI 10.1126/science.270.5240.1360; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MITTLER JE, J ACQUIRED IMMUNE DE; MOSKOPHIDIS D, 1994, J IMMUNOL, V152, P4976; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; MUNOZ A, 1992, J ACQ IMMUN DEF SYND, V5, P694; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; NIEWIESK S, 1995, J VIROL, V69, P2649, DOI 10.1128/JVI.69.4.2649-2653.1995; NIEWIESK S, 1994, J VIROL, V68, P6778, DOI 10.1128/JVI.68.10.6778-6781.1994; NIEWIESK S, IN PRESS J MOL EVOL; NOWAK MA, 1995, J THEOR BIOL, V175, P325, DOI 10.1006/jtbi.1995.0146; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; NOWAK MA, 1995, NATURE, V375, P193, DOI 10.1038/375193a0; NOWAK MA, 1995, SCI AM, V273, P58, DOI 10.1038/scientificamerican0895-58; NOWAK MA, IN PRESS P NATL ACAD; OLDSTONE MB, 1973, J EXP MED, V137, P1201, DOI 10.1084/jem.137.5.1201; OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; PARKER CE, 1992, VIROLOGY, V188, P628, DOI 10.1016/0042-6822(92)90517-S; PARKER CE, 1994, J VIROL, V68, P2860, DOI 10.1128/JVI.68.5.2860-2868.1994; PENNA A, 1991, J EXP MED, V174, P1565, DOI 10.1084/jem.174.6.1565; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PERELSON AS, 1993, MATH BIOSCI, V114, P81, DOI 10.1016/0025-5564(93)90043-A; Phillips AN, 1996, SCIENCE, V271, P497, DOI 10.1126/science.271.5248.497; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PLATAK M, 1993, SCIENCE, V259, P1749; REDDEHASE MJ, 1994, J EXP MED, V179, P185, DOI 10.1084/jem.179.1.185; REHERMANN B, 1995, J CLIN INVEST, V96, P1527, DOI 10.1172/JCI118191; RICKINSON AB, 1986, EPSTEINBARR VIRUS RE, P75; RIDDELL SR, 1992, SCIENCE, V257, P238; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; RINALDO CR, 1995, AIDS RES HUM RETROV, V11, P481, DOI 10.1089/aid.1995.11.481; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SASAKI A, 1994, J THEOR BIOL, V168, P291, DOI 10.1006/jtbi.1994.1110; SHANLEY JD, 1993, J INFECT DIS, V167, P264, DOI 10.1093/infdis/167.2.264; STEINHAUER DA, 1987, ANNU REV MICROBIOL, V41, P409, DOI 10.1146/annurev.mi.41.100187.002205; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; YAP KL, 1978, NATURE, V273, P238, DOI 10.1038/273238a0; ZINKERNAGEL RM, 1985, NATURE, V316, P814, DOI 10.1038/316814a0; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173	102	890	937	6	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1996	272	5258					74	79		10.1126/science.272.5258.74	http://dx.doi.org/10.1126/science.272.5258.74			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600540				2022-12-28	WOS:A1996UD59700039
J	Pasqualini, R; Ruoslahti, E				Pasqualini, R; Ruoslahti, E			Organ targeting in vivo using phage display peptide libraries	NATURE			English	Article							RECEPTOR; PROTEINS	PREFERENTIAL homing of tumour cells(1,2) and leukocytes(3,4) to specific organs indicates that tissues carry unique marker molecules accessible to circulating cells. Organ-selective address molecules on endothelial surfaces have been identified for lymphocyte homing to various lymphoid organs and to tissues undergoing inflammation(5-8), and an endothelial marker responsible for tumour homing to the lungs has also been identified(9). Here we report a new approach to studying organ-selective targeting based on in vivo screening of random peptide sequences. Peptides capable of mediating selective localization of phage to brain and kidney blood vessels were identified, and showed up to 13-fold selectivity for these organs. One of the peptides displayed by the brain-localizing phage mas synthesized and shown to specifically inhibit the localization of the homologous phage into the brain. When coated onto glutaraldehyde-fixed red blood cells, the peptide caused selective localization of intravenously injected cells into the brain, These peptide sequences represent the first step towards identifying selective endothelial markers, which may be useful in targeting cells, drugs and genes into selected tissues.	LA JOLLA CANC RES CTR,BURNHAM INST,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute								BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; JOHNSON RC, 1991, CANCER RES, V51, P394; JOHNSON RC, 1993, J CELL BIOL, V121, P1423, DOI 10.1083/jcb.121.6.1423; KOIVUNEN E, 1994, METHOD ENZYMOL, V245, P346; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; RAK JW, 1995, ANTI-CANCER DRUG, V6, P3, DOI 10.1097/00001813-199502000-00001; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SALMI M, 1992, P NATL ACAD SCI USA, V89, P11436, DOI 10.1073/pnas.89.23.11436; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9	15	973	1157	2	170	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					364	366		10.1038/380364a0	http://dx.doi.org/10.1038/380364a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598934				2022-12-28	WOS:A1996UC37900065
J	Brownell, JE; Zhou, JX; Ranalli, T; Kobayashi, R; Edmondson, DG; Roth, SY; Allis, CD				Brownell, JE; Zhou, JX; Ranalli, T; Kobayashi, R; Edmondson, DG; Roth, SY; Allis, CD			Tetrahymena histone acetyltransferase A: A homolog to yeast Gcn5p linking histone acetylation to gene activation	CELL			English	Article							TRANSCRIPTION; NUCLEOSOME; DNA; CHROMATIN; SNF2/SWI2; PROTEINS; SNF5; SWI1	We report the cloning of a transcription-associated histone acetyltransferase type A (HAT A). This Tetrahymena enzyme is strikingly homologous to the yeast protein Gcn5, a putative transcriptional adaptor, and we demonstrate that recombinant Gcn5p possesses HAT activity. Both the ciliate enzyme and Gcn5p contain potential active site residues found in other acetyltransferases and a highly conserved bromodomain. The presence of this domain in nuclear A-type HATs, but not in cytoplasmic B-type HATs, suggests a mechanism whereby HAT A is directed to chromatin to facilitate transcriptional activation. These findings shed light on the biochemical function of the evolutionarily conserved Gcn5p-Ada complex, directly linking histone acetylation to gene activation, and indicate that histone acetylation is a targeted phenomenon.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Rochester; Cold Spring Harbor Laboratory; University of Texas System; UTMD Anderson Cancer Center				Edmondson, Diane/0000-0003-3702-9715; Dent, Sharon/0000-0002-4824-3269	NATIONAL CANCER INSTITUTE [F32CA065098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM053512, R01GM053512] Funding Source: NIH RePORTER; NCI NIH HHS [F32CA65098] Funding Source: Medline; NIGMS NIH HHS [GM51189, GM53512] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1988, CURRENT PROTOCOLS MO, V1; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BELIKOFF E, 1980, J BIOL CHEM, V255, P1448; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Candau R, 1996, MOL CELL BIOL, V16, P593; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; FISHERADAMS G, 1995, EMBO J, V14, P1468, DOI 10.1002/j.1460-2075.1995.tb07133.x; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GAERTIG J, 1993, CELL MOTIL CYTOSKEL, V25, P243, DOI 10.1002/cm.970250305; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; HRUZ PW, 1992, BIOCHEMISTRY-US, V31, P6842, DOI 10.1021/bi00144a026; JOHNSON LM, 1990, P NATL ACAD SCI USA, V369, P245; JUAN LJ, 1994, EMBO J, V13, P6031, DOI 10.1002/j.1460-2075.1994.tb06949.x; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; KURIHARA T, 1992, EUR J BIOCHEM, V210, P999, DOI 10.1111/j.1432-1033.1992.tb17505.x; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; LOIDL P, 1994, CHROMOSOMA, V103, P441; MADIREDDI MT, 1994, DEV BIOL, V165, P418, DOI 10.1006/dbio.1994.1264; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; MARUYAMA IN, 1995, NUCLEIC ACIDS RES, V23, P3796, DOI 10.1093/nar/23.18.3796; MORIN PJ, 1995, CELL GROWTH DIFFER, V6, P789; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PRESCOTT DM, 1994, MICROBIOL REV, V58, P233, DOI 10.1128/MMBR.58.2.233-267.1994; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; SHAW WV, 1991, ANNU REV BIOPHYS BIO, V20, P363, DOI 10.1146/annurev.biophys.20.1.363; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TAVERNARAKIS N, 1995, MOL GEN GENET, V247, P571, DOI 10.1007/BF00290348; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; VAVRA KJ, 1982, J BIOL CHEM, V257, P2591; VETTESEDADEY M, 1994, MOL CELL BIOL, V14, P970, DOI 10.1128/MCB.14.2.970; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WINSTON F, 1992, TRENDS GENET, V8, P337; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	59	1248	1304	6	102	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					843	851		10.1016/S0092-8674(00)81063-6	http://dx.doi.org/10.1016/S0092-8674(00)81063-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601308	hybrid			2022-12-28	WOS:A1996UC38100006
J	Lansdown, ABG				Lansdown, ABG			Zinc in the healing wound	LANCET			English	Editorial Material							VENOUS LEG ULCERS; TISSUE				Lansdown, ABG (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT COMPARAT BIOL,LONDON,ENGLAND.							AGREN MS, 1993, BRIT J DERMATOL, V129, P221, DOI 10.1111/j.1365-2133.1993.tb03533.x; BARCIA PJ, 1970, ANN SURG, V172, P1048, DOI 10.1097/00000658-197012000-00019; ERIKSSON G, 1986, BRIT J DERMATOL, V114, P227, DOI 10.1111/j.1365-2133.1986.tb02801.x; HALLBOOK T, 1972, LANCET, V2, P780; HENG MK, 1993, BRIT J DERMATOL, V129, P280, DOI 10.1111/j.1365-2133.1993.tb11847.x; HENZEL JH, 1970, ARCH SURG-CHICAGO, V100, P349; Lansdown A. B. G., 1993, International Journal of Cosmetic Science, V15, P83, DOI 10.1111/j.1467-2494.1993.tb00072.x; LANSDOWN ABG, 1995, CRC CRIT R TOXICOL, V12, P397; OCCLESTON NL, 1995, 5 ANN M EUR TISS REP; PARISI AF, 1969, AM J CLIN NUTR, V22, P1222; PORIES WJ, 1967, ANN SURG, V165, P432; Raulin J., 1869, ANN SCI NAT BOT BIOL, V11, P93	12	64	65	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					706	707		10.1016/S0140-6736(96)90072-0	http://dx.doi.org/10.1016/S0140-6736(96)90072-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8601997	Bronze			2022-12-28	WOS:A1996TZ98200005
J	Marks, R				Marks, R			Squamous cell carcinoma	LANCET			English	Article							MELANOCYTIC SKIN-CANCER; SOLAR KERATOSES; TRANSPLANT RECIPIENTS; RETINOIDS; SUNLIGHT; LIP		SKIN & CANC FDN VICTORIA,MELBOURNE,VIC,AUSTRALIA	SKIN & CANCER FOUNDATION AUSTRALIA	Marks, R (corresponding author), UNIV MELBOURNE,ST VINCENTS HOSP,DEPT MED DERMATOL,FITZROY,VIC 3065,AUSTRALIA.							BAVINCK JNB, 1994, J NEPHROL, V7, P261; BERAL V, 1981, BRIT J CANCER, V44, P886, DOI 10.1038/bjc.1981.288; Bowen JT., 1912, J CUTAN DIS SYPH, V30, P241; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CHUANG TY, 1993, ARCH DERMATOL, V129, P317, DOI 10.1001/archderm.129.3.317; Cleaver J E, 1986, Basic Life Sci, V39, P425; DEGRUIJL FR, 1995, BIOESSAYS, V17, P651, DOI 10.1002/bies.950170711; EUVRARD S, 1993, CANCER, V72, P2198, DOI 10.1002/1097-0142(19931001)72:7<2198::AID-CNCR2820720722>3.0.CO;2-Q; FRANKEL DH, 1992, J AM ACAD DERMATOL, V26, P720, DOI 10.1016/0190-9622(92)70100-T; FROST CA, 1994, BRIT J DERMATOL, V131, P455; KELLY JW, 1991, LANCET, V338, P1407, DOI 10.1016/0140-6736(91)92292-A; KRAEMER KH, 1988, NEW ENGL J MED, V318, P1633, DOI 10.1056/NEJM198806233182501; LINDELOF B, 1991, LANCET, V338, P91, DOI 10.1016/0140-6736(91)90083-2; MAGNUS K, 1991, INT J CANCER, V47, P12, DOI 10.1002/ijc.2910470104; MARKS R, 1990, MED J AUSTRALIA, V152, P62, DOI 10.5694/j.1326-5377.1990.tb124456.x; MARKS R, 1993, INT J CANCER, V53, P585, DOI 10.1002/ijc.2910530410; MARKS R, 1988, LANCET, V1, P795, DOI 10.1016/s0140-6736(88)91658-3; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; NAYLOR MF, 1995, ARCH DERMATOL, V131, P170, DOI 10.1001/archderm.131.2.170; PETROVICH Z, 1987, RADIOTHER ONCOL, V8, P11, DOI 10.1016/S0167-8140(87)80017-8; ROSENBLATT L, IN PRESS AUSTRALAS J; ROWE DE, 1992, J AM ACAD DERMATOL, V26, P976, DOI 10.1016/0190-9622(92)70144-5; SCOTTO J, 1983, NIH PUBL; SPENCER JM, 1995, ARCH DERMATOL, V131, P796, DOI 10.1001/archderm.131.7.796; STREET ML, 1990, J AM ACAD DERMATOL, V23, P862, DOI 10.1016/0190-9622(90)70305-2; THOMPSON SC, 1993, NEW ENGL J MED, V329, P1147, DOI 10.1056/NEJM199310143291602; TIEBEN LM, 1994, BRIT J DERMATOL, V131, P226; WEINSTOCK M, 1994, J INVEST DERMATOL, V102, P65; WEINSTOCK MA, 1993, ARCH DERMATOL, V129, P1286, DOI 10.1001/archderm.129.10.1286; [No title captured]	30	95	98	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					735	738		10.1016/S0140-6736(96)90081-1	http://dx.doi.org/10.1016/S0140-6736(96)90081-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8602006	Bronze			2022-12-28	WOS:A1996TZ98200014
J	Berlowitz, DR; Ash, AS; Brandeis, GH; Brand, HK; Halpern, JL; Moskowitz, MA				Berlowitz, DR; Ash, AS; Brandeis, GH; Brand, HK; Halpern, JL; Moskowitz, MA			Rating long-term care facilities on pressure ulcer development: Importance of case-mix adjustment	ANNALS OF INTERNAL MEDICINE			English	Article							NURSING-HOMES; QUALITY; MORTALITY; SORES; RISK	Objective: To determine the importance of case-mix adjustment in interpreting differences in rates of pressure ulcer development in Department of Veterans Affairs long-term care facilities. Design: A sample assembled from the Patient Assessment File, a Veterans Affairs administrative database, was used to derive predictors of pressure ulcer development; the resulting model was validated in a separate sample. Facility-level rates of pressure ulcer development, both unadjusted long-term care and adjusted for case mix using the predictive model, were compared. Setting: Department of Veterans Affairs long-term care facilities. Patients: The derivation sample consisted of 31 150 intermediate medicine and nursing home residents who were initially free of pressure ulcers and were institutionalized between October 1991 and April 1993. The validation sample consisted of 17 946 residents institutionalized from April 1993 to October 1993. Measurement: Development of a stage 2 or greater pressure ulcer. Results: 11 factors predicted pressure ulcer development. Validated performance properties of the resulting model were good. Model-predicted rates of pressure ulcer development at individual long-term care facilities varied from 1.9% to 6.3%, and observed rates ranged from 0% to 10.9%. Case-mix-adjusted rates and ranks of facilities differed considerably from unadjusted ratings. For example, among five facilities that were identified as high outliers on the basis of unadjusted rates, two remained as outliers after adjustment for case mix. Conclusions: Gong-term care facilities differ in case mix. Adjustments for case mix result in different judgments about facility performance and should be used when facility incidence rates are compared.	BOSTON UNIV, MED CTR, GEN INTERNAL MED SECT, BOSTON, MA 02118 USA; DEPT VET AFFAIRS, WASHINGTON, DC USA	Boston University	Berlowitz, DR (corresponding author), VET AFFAIRS MED CTR, HLTH SERV RES & DEV FIELD PROGRAM, 200 SPRINGS RD, BEDFORD, MA 01730 USA.		Ash, Arlene/AAG-2914-2019	Ash, Arlene/0000-0002-8448-0253; Berlowitz, Dan/0000-0002-8783-5611				ALLMAN RM, 1986, ANN INTERN MED, V105, P337, DOI 10.7326/0003-4819-105-3-337; ALLMAN RM, 1995, JAMA-J AM MED ASSOC, V273, P865, DOI 10.1001/jama.273.11.865; ALLMAN RM, 1989, NEW ENGL J MED, V320, P850; ANDERSEN KE, 1982, BMJ-BRIT MED J, V284, P1370, DOI 10.1136/bmj.284.6326.1370; BERGSTROM N, 1992, J AM GERIATR SOC, V40, P747, DOI 10.1111/j.1532-5415.1992.tb01845.x; BERLOWITZ DR, 1989, J AM GERIATR SOC, V37, P1043, DOI 10.1111/j.1532-5415.1989.tb06918.x; BERLOWITZ DR, 1993, IMPROVING CARE NURSI; BLUMENTHAL D, 1993, JAMA-J AM MED ASSOC, V269, P2775, DOI 10.1001/jama.269.21.2775; BRANDEIS GH, 1994, J AM GERIATR SOC, V42, P388, DOI 10.1111/j.1532-5415.1994.tb07486.x; BRANDEIS GH, 1990, JAMA-J AM MED ASSOC, V264, P2905, DOI 10.1001/jama.264.22.2905; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; GERON SM, 1991, GERONTOLOGIST, V31, P292, DOI 10.1093/geront/31.3.292; GREEN J, 1991, JAMA-J AM MED ASSOC, V265, P1849; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; HOSMER EW, 1989, APPL LOGISTIC REGRES; Institute of Medicine (US) Committee on Nursing Home Regulation, 1986, IMPR QUAL CAR NURS H; KANE RA, 1988, INQUIRY-J HEALTH CAR, V25, P132; KANE RL, 1990, J AM GERIATR SOC, V38, P704, DOI 10.1111/j.1532-5415.1990.tb01432.x; KASSIRER JP, 1994, NEW ENGL J MED, V330, P634, DOI 10.1056/NEJM199403033300910; LOCALIO AR, 1995, ANN INTERN MED, V122, P125, DOI 10.7326/0003-4819-122-2-199501150-00009; MCNEIL BJ, 1992, INQUIRY-J HEALTH CAR, V29, P298; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; O'Leary D S, 1993, Jt Comm J Qual Improv, V19, P487; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; RUDMAN D, 1993, J AM GERIATR SOC, V41, P1317, DOI 10.1111/j.1532-5415.1993.tb06482.x; RUDMAN D, 1993, AM J PHYS MED REHAB, V72, P276, DOI 10.1097/00002060-199310000-00005; RUDMAN D, 1993, J GEN INTERN MED, V8, P653, DOI 10.1007/BF02598281; SCHNEIDER DP, 1988, HLTH CARE FINANC REV, V10, P39; SCHWARTZ M, 1994, RISK ADJUSTMENT MEAS; *US AG HLTH CAR PO, 1992, PRESS ULC AD PRED PR; *US HLTH CAR FIN A, 1987, HCFA PUBL; VERSLUYSEN M, 1986, BRIT MED J, V292, P1311, DOI 10.1136/bmj.292.6531.1311; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WILKING SV, 1990, ANN M AM GER SOC ATL; WU AW, 1995, ANN INTERN MED, V122, P149, DOI 10.7326/0003-4819-122-2-199501150-00013; ZINN JS, 1993, MED CARE, V31, P475, DOI 10.1097/00005650-199306000-00001; 1990, INT J TECHNOL ASSESS, V6, P181	37	73	73	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1996	124	6					557	+		10.7326/0003-4819-124-6-199603150-00003	http://dx.doi.org/10.7326/0003-4819-124-6-199603150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ529	8597318				2022-12-28	WOS:A1996TZ52900003
J	Knekt, P; Jarvinen, R; Reunanen, A; Maatela, J				Knekt, P; Jarvinen, R; Reunanen, A; Maatela, J			Flavonoid intake and coronary mortality in Finland: A cohort study	BRITISH MEDICAL JOURNAL			English	Article							LOW-DENSITY-LIPOPROTEIN; DISEASE; WINE; RISK	Objective-To study the association between dietary intake of flavonoids and subsequent coronary mortality. Design-A cohort study based on data collected at the Finnish mobile clinic health examination survey from 1967-72 and followed up until 1992. Settings-30 communities from different parts of Finland. Subjects-5133 Finnish men and women aged 30-69 years and free from heart disease at baseline. Main outcome measure-Dietary intake of flavonoids, total mortality, and coronary mortality. Results-In women a significant inverse gradient was observed between dietary intake of flavonoids and total and coronary mortality. The relative risks between highest and lowest quarters of flavonoid intake adjusted for age, smoking, serum cholesterol concentration, blood pressure, and body mass index were 0.69 (95% confidence interval 0.53 to 0.90) and 0.54 (0.33 to 0.87) for total and coronary mortality, respectively. The corresponding values for men were 0.76 (0.63 to 0.93) and 0.78 (0.56 to 1.08), respectively. Adjustment for intake of antioxidant vitamins and fatty acids weakened the associations for women; the relative risks for coronary heart disease were 0.73 (0.41 to 1.32) and 0.67 (0.44 to 1.00) in women and men, respectively. Intakes of onions and apples, the main dietary sources of flavonoids, presented similar associations. The relative risks for coronary mortality between highest and lowest quarters of apple intake were 0.57 (0.36 to 0.91) and 0.81 (0.61 to 1.09) for women and men, respectively. The corresponding values for onions were 0.50 (0.30 to 0.82) and 0.74 (0.53 to 1.02), respectively. Conclusion-The results suggest that people with very low intakes of flavonoids have higher risks of coronary disease.	SOCIAL INSURANCE INST,CTR RES & DEV,HELSINKI,FINLAND; SOCIAL INSURANCE INST,CTR RES & DEV,TURKU,FINLAND; KUOPIO UNIV,DEPT CLIN NUTR,KUOPIO,FINLAND	University of Eastern Finland	Knekt, P (corresponding author), NATL PUBL HLTH INST,MANNERHEIMINTIE 166,SF-00300 HELSINKI,FINLAND.							[Anonymous], 1975, APPL MULTIPLE REGRES, DOI 10.4324/9780203774441.; AROMAA A, 1981, SERIES AL, V17; COX DR, 1972, J R STAT SOC B, V34, P187; DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; GAZIANO JM, 1994, NATURAL ANTIOXIDANTS; GRYGLEWSKI RJ, 1987, BIOCHEM PHARMACOL, V36, P317, DOI 10.1016/0006-2952(87)90288-7; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; Herrmann K., 1976, Journal of Food Technology, V11, P433, DOI 10.1108/09566160010378107; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; HERTOG MGL, 1994, THESIS WAGENINGEN; HUANG TC, 1961, ANAL CHEM, V33, P1405, DOI 10.1021/ac60178a040; HUSSAIN SR, 1987, PHYTOCHEMISTRY, V26, P2489; JDRVINEN R, 1993, INT J EPIDEMIOL, V22, P520; KINSELLA JE, 1993, FOOD TECHNOL-CHICAGO, V47, P85; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; KNEKT P, 1990, AM J CLIN NUTR, V52, P903, DOI 10.1093/ajcn/52.5.903; KNEKT P, 1988, SERIES ML, V83; RANKIN SM, 1993, BIOCHEM PHARMACOL, V45, P67, DOI 10.1016/0006-2952(93)90378-A; REUNANEN A, 1983, ACTA MED SCAND S, V673, P1; STARKE H, 1976, Z LEBENSM UNTERS FOR, V161, P131, DOI 10.1007/BF01112856; Wildanger W., 1973, Zeitschrift fuer Lebensmittel-Untersuchung und -Forschung, V151, P103, DOI 10.1007/BF01842919; YUTING C, 1990, Free Radical Biology and Medicine, V9, P19	24	987	1026	1	46	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					478	481		10.1136/bmj.312.7029.478	http://dx.doi.org/10.1136/bmj.312.7029.478			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597679	Green Published			2022-12-28	WOS:A1996TX38300023
J	Cresswell, P				Cresswell, P			Invariant chain structure and MHC class II function	CELL			English	Review											Cresswell, P (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,333 CEDAR ST,NEW HAVEN,CT 06520, USA.							AMIGORENA S, 1995, J EXP MED, V181, P1729, DOI 10.1084/jem.181.5.1729; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; FALK K, 1994, IMMUNOGENETICS, V39, P230; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; JASANOFF A, 1995, P NATL ACAD SCI USA, V92, P9900, DOI 10.1073/pnas.92.21.9900; MORKOWSKI S, 1995, IN PRESS P NATL ACAD, V182, P1403; ROCHE PA, 1995, IMMUNITY, V3, P259, DOI 10.1016/1074-7613(95)90111-6; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; ROMAGNOLI P, 1994, J EXP MED, V180, P1107, DOI 10.1084/jem.180.3.1107; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SETTE A, 1995, J EXP MED, V181, P677, DOI 10.1084/jem.181.2.677; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0	13	283	313	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					505	507		10.1016/S0092-8674(00)81025-9	http://dx.doi.org/10.1016/S0092-8674(00)81025-9			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598037	hybrid			2022-12-28	WOS:A1996TX17600003
J	Cavill, I; Baddeley, PG; Barnes, RA; Finn, AHR; Hann, IM; Kelly, SJ; Leese, J; Lortan, JE; Spencer, J; Summerfield, GP; Whittaker, JA				Cavill, I; Baddeley, PG; Barnes, RA; Finn, AHR; Hann, IM; Kelly, SJ; Leese, J; Lortan, JE; Spencer, J; Summerfield, GP; Whittaker, JA			Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen	BRITISH MEDICAL JOURNAL			English	Article							BONE-MARROW TRANSPLANTATION; POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE; SICKLE-CELL DISEASE; POSTSPLENECTOMY SEPSIS; CONGENITAL ASPLENIA; SPLENECTOMY; PROPHYLAXIS; VACCINATION; CHILDREN; MANAGEMENT	Overwhelming postsplenectomy infection should be preventable if simple precautions are taken. An ad hoc working party of the British Committee for Standards in Haematology has reviewed recommendations for patients without a spleen and drawn up a consensus. Members of the working party were selected for their personal expertise and to represent relevant professional bodies. The guidelines, which are set out below, include and extend the chief medical officer's 1994 update.	ROYAL UNITED HOSP,BATH BA1 3NG,AVON,ENGLAND; ROYAL COLL GEN PRACTITIONERS,LONDON,ENGLAND; UNIV WALES COLL MED,CARDIFF CF4 4XN,S GLAM,WALES; SHEFFIELD CHILDRENS HOSP,SHEFFIELD,S YORKSHIRE,ENGLAND; BRITISH PAEDIAT ASSOC,LONDON,ENGLAND; HOSP SICK CHILDREN,LONDON WC1N 3JH,ENGLAND; WYCOMBE GEN HOSP,HIGH WYCOMBE,BUCKS,ENGLAND; DEPT HLTH,LONDON SE1 6TE,ENGLAND; ST MARYS HOSP,SCH MED,LONDON,ENGLAND; HAMMERSMITH HOSP,LONDON,ENGLAND; ROYAL COLL SURGEONS ENGLAND,LONDON,ENGLAND; MIDDLESBROUGH GEN HOSP,MIDDLESBROUGH TS5 5AZ,CLEVELAND,ENGLAND; UNIV WALES HOSP,CARDIFF CF4 4XW,S GLAM,WALES	Cardiff University; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Imperial College London; Imperial College London; Royal College of Surgeons of England; Cardiff University	Cavill, I (corresponding author), BRITISH COMM STAND HAEMATOL,CLIN HAEMATOL TASK FORCE,WORKING PARTY,2 CARLTON HOUSE TERRACE,LONDON SW1Y 5AF,ENGLAND.			Finn, Adam/0000-0003-1756-5668				AUCOUTURIER P, 1987, BLOOD, V70, P779; BUYUKUNAL C, 1987, BRIT J SURG, V74, P350, DOI 10.1002/bjs.1800740507; CHATTOPADHYAY B, 1989, BRIT J HOSP MED, V41, P172; CONLON CP, 1993, BRIT MED BULL, V49, P412, DOI 10.1093/oxfordjournals.bmb.a072618; CULLINGFORD GL, 1991, BRIT J SURG, V78, P716, DOI 10.1002/bjs.1800780626; CUMMINS D, 1991, BRIT MED J, V302, P989, DOI 10.1136/bmj.302.6783.989; DYKE MP, 1991, ARCH DIS CHILD, V66, P636, DOI 10.1136/adc.66.5.636; EDWARDS LD, 1976, SCAND J INFECT DIS, V8, P255, DOI 10.3109/inf.1976.8.issue-4.07; ELLISON FC, 1983, SURG CLIN N AM, V63, P1313; EVANS DIK, 1985, J CLIN PATHOL, V38, P309, DOI 10.1136/jcp.38.3.309; FIELDING AK, 1994, BLOOD REV, V8, P179, DOI 10.1016/0268-960X(94)90079-W; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; GIBB DM, 1993, GUIDELINES MANAGEMEN; GIEBINK GS, 1981, REV INFECT DIS S, V3, P168; GOWDA R, 1995, BRIT MED J, V311, P26, DOI 10.1136/bmj.311.6996.26; GRIMFORS G, 1989, EUR J HAEMATOL, V43, P404; HOFFBRAND AV, 1989, POSTGRADUATE HAEMATO, P20; HOLDSWORTH RJ, 1991, BRIT J SURG, V78, P1031, DOI 10.1002/bjs.1800780904; HOSEA SW, 1981, NEW ENGL J MED, V304, P246; JACKSON JW, 1983, ROB SMITHS OPERATIVE, V1, P177; JEWELL DP, 1987, OXFORD TXB MED, V12, P122; JONES DM, 1995, COMMUN DIS REP CDR W, V5, P125; KALHS P, 1988, ANN INTERN MED, V109, P461, DOI 10.7326/0003-4819-109-6-461; KELTON JG, 1981, JAMA-J AM MED ASSOC, V245, P369, DOI 10.1001/jama.245.4.369; KING H, 1952, ANN SURG, V136, P239, DOI 10.1097/00000658-195208000-00006; KLUGMAN KP, 1989, LANCET, V2, P444; LOSOWSKY MS, 1987, OXFORD TXB MED, V12, P106; MARSH GW, 1970, BRIT J HAEMATOL, V19, P445, DOI 10.1111/j.1365-2141.1970.tb06972.x; MCCARTHY M, 1988, BRIT MED J, V297, P135; MCMULLIN M, 1993, BRIT MED J, V307, P1372, DOI 10.1136/bmj.307.6916.1372; Newton J, 1992, Qual Health Care, V1, P256, DOI 10.1136/qshc.1.4.256; OSTER CN, 1980, AM J TROP MED HYG, V29, P1138, DOI 10.4269/ajtmh.1980.29.1138; ROBINETTE CD, 1977, LANCET, V2, P127; ROSNER F, 1984, AM J MED, V76, P696, DOI 10.1016/0002-9343(84)90298-5; ROSSE WF, 1987, NEW ENGL J MED, V317, P704, DOI 10.1056/NEJM198709103171110; RUBIN LG, 1992, AM J DIS CHILD, V146, P340, DOI 10.1001/archpedi.1992.02160150080026; SCOPES JW, 1991, ARCH DIS CHILD, V66, P750, DOI 10.1136/adc.66.6.750-b; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SHAW JHF, 1989, BRIT J SURG, V76, P1074, DOI 10.1002/bjs.1800761029; SHUTE PG, 1975, BMJ-BRIT MED J, V1, P516, DOI 10.1136/bmj.1.5956.516; SIBER GR, 1978, NEW ENGL J MED, V299, P442, DOI 10.1056/NEJM197808312990903; TEARE L, 1992, LANCET, V340, P1362, DOI 10.1016/0140-6736(92)92555-T; TRAUB A, 1987, NEW ENGL J MED, V317, P1559, DOI 10.1056/NEJM198712173172503; WAGHORN DJ, 1993, LANCET, V341, P248, DOI 10.1016/0140-6736(93)90119-2; WALKER G, 1995, ABPI DATA SHEET COMP, P986; WEINTRUB PS, 1984, J PEDIATR-US, V105, P261, DOI 10.1016/S0022-3476(84)80124-9; WINSTON DJ, 1979, ANN INTERN MED, V91, P835, DOI 10.7326/0003-4819-91-6-835; 1986, ANN INTERN MED, V104, P118; 1993, PLCMO9313; 1992, IMMUNISATION INFECT, P102; 1995, 26 ROYAL COLL GEN PR; 1994, EFFECTIVE HLTH CARE, V8; 1994, ASPLENIC PATIENTS IM, P3	53	162	169	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	1996	312	7028					430	434						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601117				2022-12-28	WOS:A1996TW56400028
J	Godfrey, K; Robinson, S; Barker, DJP; Osmond, C; Cox, V				Godfrey, K; Robinson, S; Barker, DJP; Osmond, C; Cox, V			Maternal nutrition in early and late pregnancy in relation to placental and fetal growth	BRITISH MEDICAL JOURNAL			English	Article							QUESTIONNAIRE; SIZE	Objective-To assess how nutrient intakes of mothers in early and late pregnancy influence placental and fetal growth. Design-Prospective observational study. Setting-Princess Anne Maternity Hospital, Southampton. Subjects-538 mothers who delivered at term. Main outcome measures-Placental and birth weights adjusted for the infant's sex and duration of gestation. Results-Mothers who had high carbohydrate intakes in early pregnancy had babies with lower placental and birth weights. Low maternal intakes of dairy and meat protein in late pregnancy were also associated with lower placental and birth weights. Placental weight fell by 49 g (95% confidence interval 16 g to 81 g; P=0.002) for each log g increase in intake of carbohydrate in early pregnancy and by 1.4 g (0.4 g to 2.4 g; P=0.005) for each g decrease in intake of dairy protein in late pregnancy. Birth weight fell by 165 g (49 g to 282 g; P=0.005) for each log g increase in carbohydrate intake in early pregnancy and by 3.1 g (0.3 g to 6.0 g; P=0.03) for each g decrease in meat protein intake in late pregnancy. These associations were independent of the mother's height and body mass index and of strong relations between the mother's birth weight and the placental and birth weights of her offspring. Conclusion-These findings suggest that a high carbohydrate intake in early pregnancy suppresses placental growth, especially if combined with a low dairy protein intake in late pregnancy. Such an effect could have long term consequences for the offspring's risk of cardiovascular disease.			Godfrey, K (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.			Osmond, Clive/0000-0002-9054-4655; Godfrey, Keith/0000-0002-4643-0618; Robinson, Sian/0000-0003-1766-7269				[Anonymous], 1980, CLASSIFICATION OCCUP; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARKER DJP, 1995, PLACENTA, V16, P317, DOI 10.1016/0143-4004(95)90118-3; Bingham S. A., 1987, Nutrition Abstracts and Reviews. Series A-Human and Experimental, V57, P705; BLOCK G, 1990, J CLIN EPIDEMIOL, V43, P1327, DOI 10.1016/0895-4356(90)90099-B; BOTTING B, 1993, POPULATION TRENDS, V74, P27; CAMPBELL D, IN PRESS BR J OBSTET; CRAWLEY H, 1988, FOOD PORTION SIZES; EMANUEL I, 1992, BRIT J OBSTET GYNAEC, V99, P67, DOI 10.1111/j.1471-0528.1992.tb14396.x; HEAP FC, 1967, J REPROD FERTIL, V13, P269, DOI 10.1530/jrf.0.0130269; HEMMINKI E, 1978, BRIT J OBSTET GYNAEC, V85, P404, DOI 10.1111/j.1471-0528.1978.tb14905.x; Holland B., 1991, MCCANCE WIDDOWSONS C, V5th; Holland B, 1991, MCCANCE WIDDOWSONS S; Holland B., 1989, MCCANCE WIDDOWSONS S; Holland B., 1988, MCCANCE WIDDOWSONS S; HOWE D, 1995, BRIT MED J, V310, P1601, DOI 10.1136/bmj.310.6994.1601b; HOWE DT, 1995, BRIT J OBSTET GYNAEC, V102, P213, DOI 10.1111/j.1471-0528.1995.tb09096.x; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; MAHOMED K, 1989, EFFECTIVE CARE PREGN, V1, P301; MARGETTS BM, 1989, INT J EPIDEMIOL, V18, P868, DOI 10.1093/ije/18.4.868; MCCRABB GJ, 1991, BRIT J NUTR, V65, P157, DOI 10.1079/BJN19910077; MCKEIGUE P, 1995, LANCET, V345, P269, DOI 10.1016/S0140-6736(95)90269-4; MCKEOWN T, 1953, J ENDOCRINOL, V10, P73, DOI 10.1677/joe.0.0100073; OUNSTED M, 1966, NATURE, V212, P687; OWENS JA, 1988, FETAL NEONATAL GROWT, P49; PRENTICE A, IN PRESS EUR J CLIN; Robinson JS, 1994, EARLY FETAL GROWTH D, P317; ROBINSON SM, IN PRESS EUR J CLIN; ROSSO P, 1990, NUTR METABOLISM PREG, P175; RUSH D, 1989, EFFECTIVE CARE PREGN, V1, P301; SLEN SB, 1969, NUTR ANIMALS AGR I 2, P827; THOMAS WJK, 1970, LOWLAND SHEEP PRODUC; WILLETT WC, 1994, AM J CLIN NUTR S, V59, P171	34	442	447	0	35	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	1996	312	7028					410	414						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601112	Green Published			2022-12-28	WOS:A1996TW56400021
J	Lithell, HO; McKeigue, PM; Berglund, L; Mohsen, R; Lithell, UB; Leon, DA				Lithell, HO; McKeigue, PM; Berglund, L; Mohsen, R; Lithell, UB; Leon, DA			Relation of size at birth to non-insulin dependent diabetes and insulin concentrations in men aged 50-60 years	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; BETA-CELL FUNCTION; FETAL GROWTH; RISK-FACTORS; FOLLOW-UP; HYPERTENSION; RESISTANCE; MELLITUS; UPPSALA; DISEASE	Objective-To establish whether the relation between size at birth and non-insulin dependent diabetes is mediated through impaired beta cell function or insulin resistance. Design-Cohort study. Setting-Uppsala, Sweden. Subjects-1333 men whose birth records were traced from a cohort of 2322 men born during 1920-4 and resident in Uppsala in 1970. Main outcome measures-Intravenous glucose tolerance test at age 50 years and non-insulin dependent diabetes at age 60 years. Results-There was a weak inverse correlation (r=-0.07, P=0.03) between ponderal index at birth and 60 minute insulin concentrations in the intravenous glucose tolerance test at age 50 years. This association was stronger (r=-0.19, P=0.001) in the highest third of the distribution of body mass index than in the other two thirds (P=0.01 for the interaction between ponderal index and body mass index). Prevalence of diabetes at age 60 years was 8% in men whose birth weight was less than 3250 g compared with 5% in men with birth weight 3250 g or more (P=0.08; 95% confidence interval for difference -0.3% to 6.8%). There was a stronger association between diabetes and ponderal index: prevalence of diabetes was 12% in the lowest fifth of ponderal index compared with 4% in the other four fifths (P=0.001; 3.0% to 12.6%). Conclusion-These results confirm that reduced fetal growth is associated with increased risk of diabetes and suggest a specific association with thinness at birth, This relation seems to be mediated through insulin resistance rather than through impaired beta cell function and to depend on an interaction with obesity in adult life.	UNIV LONDON LONDON SCH HYG & TROP MED, EPIDEMIOL UNIT, LONDON WC1E 7HT, ENGLAND; UNIV UPPSALA, DEPT GERIATR, S-75125 UPPSALA, SWEDEN	University of London; London School of Hygiene & Tropical Medicine; Uppsala University			Berglund, Lars/AAA-3188-2019; Berglund, Lars/AAD-3856-2019; Leon, David A/G-2195-2010	Berglund, Lars/0000-0002-7437-9047; Leon, David A/0000-0001-9747-1762				BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; COOK JTE, 1993, BRIT MED J, V306, P302, DOI 10.1136/bmj.306.6873.302; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DRAPER NR, 1966, APPL REGRESSION ANAL, P149; Gluckman P.D., 1986, OXF REV REPROD BIOL, V8, P1; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HARRIS M, 1979, DIABETES, V28, P1039; LITHELL H, 1984, ACTA MED SCAND, V215, P403; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; MILLER HC, 1973, PEDIATRICS, V52, P504; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P592; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SJOLIN S, 1975, HLTH CARE MOTHERS CH, P229; SKARFORS ET, 1991, J HYPERTENS, V9, P217, DOI 10.1097/00004872-199103000-00004; SKARFORS ET, 1991, BRIT MED J, V303, P755, DOI 10.1136/bmj.303.6805.755; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157	22	560	577	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 17	1996	312	7028					406	410						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601111				2022-12-28	WOS:A1996TW56400020
J	Cannistra, SA; Niloff, JM				Cannistra, SA; Niloff, JM			Medical progress - Cancer of the uterine cervix	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SQUAMOUS-CELL CARCINOMA; HUMAN PAPILLOMAVIRUS TYPE-16; GYNECOLOGIC-ONCOLOGY-GROUP; IMMUNODEFICIENCY-VIRUS INFECTION; TERM FOLLOW-UP; RADIATION-THERAPY; STAGE-IB; INTRAEPITHELIAL NEOPLASIA; RADICAL HYSTERECTOMY; PELVIC EXENTERATION		BETH ISRAEL HOSP, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, BOSTON, MA USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Cannistra, SA (corresponding author), DANA FARBER CANC INST, DEPT MED, DIV MED ONCOL, 44 BINNEY ST, BOSTON, MA 02115 USA.							ALLEN HH, 1977, AM J OBSTET GYNECOL, V127, P741, DOI 10.1016/0002-9378(77)90249-6; ARTMAN LE, 1987, GYNECOL ONCOL, V28, P8, DOI 10.1016/S0090-8258(87)80002-1; BARBER HRK, 1982, MODERN CONCEPTS GYNE, P11; BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BEAHRS OH, 1988, MANUAL STAGING CANCE; BENEDET JL, 1992, AM J OBSTET GYNECOL, V166, P1254, DOI 10.1016/S0002-9378(11)90618-8; BEREK JS, 1984, OBSTET GYNECOL, V63, P318; BONOMI P, 1985, J CLIN ONCOL, V3, P1079, DOI 10.1200/JCO.1985.3.8.1079; CHAUVERGNE J, 1988, P AN M AM SOC CLIN, V7, P136; CHEN L, 1992, J IMMUNOL, V148, P2617; CHRISTOPHERSON WM, 1965, NEW ENGL J MED, V273, P235, DOI 10.1056/NEJM196507292730502; COOK GA, 1984, BRIT J CANCER, V50, P367, DOI 10.1038/bjc.1984.185; CRAMER DW, 1974, AM J OBSTET GYNECOL, V118, P443, DOI 10.1016/S0002-9378(16)33683-3; CREASMAN WT, 1995, GYNECOL ONCOL, V58, P157, DOI 10.1006/gyno.1995.1203; CRUM CP, 1985, J VIROL, V54, P675, DOI 10.1128/JVI.54.3.675-681.1985; CRUM CP, 1984, INT J GYNECOL PATHOL, V3, P376; CRUM CP, 1984, NEW ENGL J MED, V310, P880, DOI 10.1056/NEJM198404053101403; DAY NE, 1984, OBSTET GYNECOL, V63, P714; DEVESA SS, 1987, J NATL CANCER I, V79, P701; DURRANCE FY, 1968, AMER J ROENTGENOL RA, V102, P165, DOI 10.2214/ajr.102.1.165; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FLETCHER GH, 1971, AMER J ROENTGENOL RA, V111, P225; FULLER AF, 1982, GYNECOL ONCOL, V13, P165, DOI 10.1016/0090-8258(82)90024-5; GALLION HH, 1985, CANCER, V56, P262, DOI 10.1002/1097-0142(19850715)56:2<262::AID-CNCR2820560210>3.0.CO;2-A; GRUSSENDORFCONEN EI, 1986, LANCET, V2, P1092; HALL JE, 1968, AM J OBSTET GYNECOL, V100, P662, DOI 10.1016/S0002-9378(15)33391-3; HALPERT R, 1986, OBSTET GYNECOL, V68, P251; HERBST AL, 1992, CLIN OBSTET GYNECOL, V35, P22, DOI 10.1097/00003081-199203000-00006; HERBST AL, 1991, INT J GYNECOL PATHOL, V10, P326, DOI 10.1097/00004347-199110000-00004; HOPKINS MP, 1991, CANCER-AM CANCER SOC, V68, P272, DOI 10.1002/1097-0142(19910715)68:2<272::AID-CNCR2820680210>3.0.CO;2-X; HOSKINS W J, 1976, Gynecologic Oncology, V4, P278, DOI 10.1016/0090-8258(76)90033-0; HOWLEY PM, 1991, CANCER RES, V51, pS5019; HRESHCHYSHYN MM, 1979, INT J RADIAT ONCOL, V5, P317, DOI 10.1016/0360-3016(79)91209-4; JOHANNESSON G, 1978, INT J CANCER, V21, P418, DOI 10.1002/ijc.2910210404; KATZ RL, 1987, ACTA CYTOL, V31, P845; KESSLER II, 1976, CANCER RES, V36, P783; KINNEY WK, 1989, GYNECOL ONCOL, V34, P258, DOI 10.1016/0090-8258(89)90156-X; KLEIN RS, 1994, J INFECT DIS, V170, P1404, DOI 10.1093/infdis/170.6.1404; KOLSTAD P, 1989, GYNECOL ONCOL, V33, P265, DOI 10.1016/0090-8258(89)90510-6; KOSS LG, 1989, JAMA-J AM MED ASSOC, V261, P737, DOI 10.1001/jama.261.5.737; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; KRAMER C, 1989, GYNECOL ONCOL, V32, P323, DOI 10.1016/0090-8258(89)90633-1; KUMAR L, 1994, GYNECOL ONCOL, V54, P307, DOI 10.1006/gyno.1994.1215; KURMAN RJ, 1983, AM J SURG PATHOL, V7, P39, DOI 10.1097/00000478-198301000-00004; KURMAN RJ, 1991, OBSTET GYNECOL, V77, P779; LERNER HM, 1980, OBSTET GYNECOL, V56, P413; LIPPMAN SM, 1992, JNCI-J NATL CANCER I, V84, P241, DOI 10.1093/jnci/84.4.241; LORINCZ AT, 1987, J NATL CANCER I, V79, P671; LOVECCHIO JL, 1989, GYNECOL ONCOL, V34, P43, DOI 10.1016/0090-8258(89)90103-0; LUNT R, 1984, OBSTET GYNECOL, V63, P708; MAIMAN M, 1990, GYNECOL ONCOL, V38, P377, DOI 10.1016/0090-8258(90)90077-X; MAIMAN M, 1993, CANCER-AM CANCER SOC, V71, P402, DOI 10.1002/1097-0142(19930115)71:2<402::AID-CNCR2820710222>3.0.CO;2-Y; MEISELS A, 1976, ACTA CYTOL, V20, P505; MONTANA GS, 1986, CANCER, V57, P148, DOI 10.1002/1097-0142(19860101)57:1<148::AID-CNCR2820570130>3.0.CO;2-7; MORLEY GW, 1989, OBSTET GYNECOL, V74, P934; MORLEY GW, 1976, AM J OBSTET GYNECOL, V126, P785, DOI 10.1016/0002-9378(76)90668-2; MORROW CP, 1980, GYNECOL ONCOL, V10, P105, DOI 10.1016/0090-8258(80)90071-2; MUNGER K, 1989, J VIROL, V63, P4417; NASIELL K, 1983, OBSTET GYNECOL, V61, P609; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; NELSON AJ, 1975, AM J ROENTGENOL, V123, P91, DOI 10.2214/ajr.123.1.91; Nelson J H Jr, 1975, CA Cancer J Clin, V25, P134, DOI 10.3322/canjclin.25.3.134; NEWTON M, 1975, AM J OBSTET GYNECOL, V123, P535, DOI 10.1016/0002-9378(75)90041-1; NILOFF J, 1995, REPROD HLTH CARE WOM, P11; OMURA GA, 1994, SEMIN ONCOL, V21, P54; OMURA GA, 1996, 27 ANN M SOC GYN ONC; PARK DJ, 1994, ONCOGENE, V9, P205; PENALVER MA, 1989, GYNECOL ONCOL, V34, P274, DOI 10.1016/0090-8258(89)90159-5; PEREZ CA, 1992, PRINCIPLES PRACTICE, P591; PODCZASKI E, 1990, CANCER, V66, P251, DOI 10.1002/1097-0142(19900715)66:2<251::AID-CNCR2820660210>3.0.CO;2-E; POTISH R, 1983, GYNECOL ONCOL, V15, P1, DOI 10.1016/0090-8258(83)90110-5; POTTER ME, 1989, CANCER, V63, P1283, DOI 10.1002/1097-0142(19890401)63:7<1283::AID-CNCR2820630709>3.0.CO;2-U; REID R, 1984, CANCER-AM CANCER SOC, V53, P943, DOI 10.1002/1097-0142(19840215)53:4<943::AID-CNCR2820530421>3.0.CO;2-X; Richart R M, 1973, Pathol Annu, V8, P301; ROTKIN ID, 1967, AM J PUBLIC HEALTH N, V57, P815, DOI 10.2105/AJPH.57.5.815; RUTLEDGE FN, 1977, AM J OBSTET GYNECOL, V129, P881, DOI 10.1016/0002-9378(77)90521-X; SARDI J, 1993, GYNECOL ONCOL, V49, P156, DOI 10.1006/gyno.1993.1100; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDER A, 1988, CONTEMP OBSTET GYNEC, V32, P131; SCHNEIDER V, 1983, ACTA CYTOL, V27, P220; SEDLIS A, 1979, AM J OBSTET GYNECOL, V133, P64, DOI 10.1016/0002-9378(79)90414-9; SESKI JC, 1977, OBSTET GYNECOL, V50, P410; SHERMAN ME, 1992, ARCH PATHOL LAB MED, V116, P1155; SHINGLETON HM, 1995, CA-CANCER J CLIN, V45, P305, DOI 10.3322/canjclin.45.5.305; SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931; SOUHAMI L, 1991, J CLIN ONCOL, V9, P970, DOI 10.1200/JCO.1991.9.6.970; STEHMAN FB, 1989, J CLIN ONCOL, V7, P1892, DOI 10.1200/JCO.1989.7.12.1892; SUTTON GP, 1993, AM J OBSTET GYNECOL, V168, P805, DOI 10.1016/S0002-9378(12)90824-8; TABBARA S, 1992, OBSTET GYNECOL, V79, P338, DOI 10.1097/00006250-199203000-00003; TATTERSALL MHN, 1995, J CLIN ONCOL, V13, P444, DOI 10.1200/JCO.1995.13.2.444; THIGPEN JT, 1989, GYNECOL ONCOL, V32, P198, DOI 10.1016/S0090-8258(89)80033-2; THIGPEN T, 1995, SEMIN ONCOL, V22, P67; TRELFORD JD, 1992, SURG GYNECOL OBSTET, V175, P126; VANDERGRAAF Y, 1987, ACTA CYTOL, V31, P434; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILLETT GD, 1989, INT J GYNECOL PATHOL, V8, P18, DOI 10.1097/00004347-198903000-00003; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; WINGO PA, 1995, CA-CANCER J CLIN, V45, P127; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; WORTH AJ, 1984, OBSTET GYNECOL, V63, P135; 1992, CA CANC J CLIN, V42, P4	101	234	261	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 18	1996	334	16					1030	1038		10.1056/NEJM199604183341606	http://dx.doi.org/10.1056/NEJM199604183341606			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE733	8598842				2022-12-28	WOS:A1996UE73300006
J	Nudelman, PM; Andrews, LM				Nudelman, PM; Andrews, LM			The ''value added'' of not-for-profit health plans	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Nudelman, PM (corresponding author), GRP HLTH COOPERAT PUGET SOUND,SEATTLE,WA 98121, USA.								0	43	43	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1996	334	16					1057	1059		10.1056/NEJM199604183341611	http://dx.doi.org/10.1056/NEJM199604183341611			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE733	8598847				2022-12-28	WOS:A1996UE73300011
J	Baker, LC				Baker, LC			Differences in earnings between male and female physicians	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							YOUNG PHYSICIANS; WOMEN; INCOMES; MEN	Background. Male physicians have long earned more than female physicians, even after differences in the number of hours worked, specialty, practice setting, and other characteristics are taken into account. Whether earnings patterns have changed recently is not known. Methods. I examined data on earnings from the 1991 Survey of Young Physicians, a nationwide survey of physicians under 45 years of age with two to nine years of practice experience. The results were compared with data from the 1987 Survey of Young Physicians and with data on the earnings of physicians with 10 or more years of experience from the American Medical Association's 1991 Socioeconomic Monitoring System survey. Results. In 1990, young male physicians earned 41 percent more per year than young female physicians (male:female earnings ratio, 1.41; 95 percent confidence interval, 1.34 to 1.49). Per hour, young men earned 14 percent more than young women (ratio, 1.14; 95 percent confidence interval, 1.09 to 1.20). However, after adjustment for differences in specialty, practice setting, and other characteristics, no earnings difference was evident (ratio, 1.00; 95 percent confidence interval, 0.96 to 1.04). In general practice and family practice, women earned more than men, after adjustment for differences in other characteristics (ratio, 0.87; 95 percent confidence interval, 0.78 to 0.97). In internal-medicine subspecialties and emergency medicine, men earned more than women (ratio, 1.26; 95 percent confidence interval, 1.10 to 1.44). Among physicians with 10 or more years of experience, men also earned more than women (ratio, 1.17; 95 percent confidence interval, 1.07 to 1.27). Conclusions. Young male and female physicians with similar characteristics earn equal amounts of money. However, differences in earnings between men and women remain among older physicians and in some specialties. (C) 1996, Massachusetts Medical Society.			Baker, LC (corresponding author), STANFORD UNIV,SCH MED,DEPT HLTH RES & POLICY,HRP REDWOOD BLDG,RM 253,STANFORD,CA 94305, USA.			Baker, Laurence/0000-0001-5032-794X				*AM MED ASS, 1991, WOM MED AM MAINSTR; Bobula J D, 1980, Profile Med Pract, P123; BOBULA JD, 1980, J MED EDUC, V55, P826; CANTOR JC, 1993, JAMA-J AM MED ASSOC, V270, P1035, DOI 10.1001/jama.270.9.1035; CARR P, 1992, J GEN INTERN MED, V7, P418, DOI 10.1007/BF02599159; COHEN AB, 1990, HEALTH AFFAIR, V9, P138, DOI 10.1377/hlthaff.9.4.138; COTTON P, 1992, JAMA-J AM MED ASSOC, V268, P173, DOI 10.1001/jama.268.2.173; DIAL TH, 1994, AM J PSYCHIAT, V151, P96; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; GONZALEZ ML, 1992, SOCIOECONOMIC CHARAC; KEHRER BH, 1976, J HUM RESOUR, V11, P526, DOI 10.2307/145430; KENNEDY PE, 1981, AM ECON REV, V71, P801; KOMAROMY M, 1993, NEW ENGL J MED, V328, P322, DOI 10.1056/NEJM199302043280507; LANGWELL KM, 1982, J HUM RESOUR, V17, P261, DOI 10.2307/145472; LEWIN T, 1992, NY TIMES        1018, P5; LEWIS TA, 1992, NATL WILDLIFE    OCT, P4; Oaxaca R., 1973, INT ECON REV, V14, P693, DOI DOI 10.2307/2525981; OGLE KS, 1986, J FAM PRACTICE, V23, P357; OHSFELDT RL, 1986, J HEALTH ECON, V5, P335, DOI 10.1016/0167-6296(86)90008-1; ROBACK G, 1993, PHYSICIAN CHARACTERI; SILBERGER AB, 1987, HEALTH AFFAIR, V6, P104, DOI 10.1377/hlthaff.6.4.104; TESCH BJ, 1995, JAMA-J AM MED ASSOC, V273, P1022, DOI 10.1001/jama.273.13.1022	22	119	120	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1996	334	15					960	964		10.1056/NEJM199604113341506	http://dx.doi.org/10.1056/NEJM199604113341506			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UD596	8596598	Bronze			2022-12-28	WOS:A1996UD59600006
J	Vathyam, S; Lee, S; Warren, WS				Vathyam, S; Lee, S; Warren, WS			Homogeneous NMR spectra in inhomogeneous fields	SCIENCE			English	Article							MULTIPLE SPIN ECHOES; NUCLEAR-MAGNETIC-RESONANCE; SPECTROSCOPY; LIQUIDS; WATER	Researchers interested in high-resolution nuclear magnetic resonance (NMR) spectroscopy have long sought higher magnetic fields to enhance resolution and simplify spectra. Magnets with substantially larger fields than those available in the best commercial spectrometers are available, but the inhomogeneity is unacceptable for high-resolution spectra. A detection method (termed HOMOGENIZED) is presented that removes inhomogeneity while retaining chemical shift differences and J couplings. With existing in-homogeneous homogeneous method could nearly double the largest resonance frequency available for high-resolution NMR. The HOMOGENIZED sequence is based on observations of intermolecular zero-quantum coherences between a solute molecule and solvent molecules that are micrometers away; as long as the field is homogeneous over this short distance, sharp resonances are recovered without echoes. Experimental demonstrations and a detailed density matrix theory to explain the effect are presented.	PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544	Princeton University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035253] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35253] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BARBARA TM, 1994, J MAGN RESON SER A, V109, P265, DOI 10.1006/jmra.1994.1168; BEDFORD AS, 1991, J MAGN RESON, V93, P516, DOI 10.1016/0022-2364(91)90080-D; BIRD MD, 1994, IEEE T MAGN, V30, P2220; BOWDEN GJ, 1995, CHEM PHYS LETT, V233, P639, DOI 10.1016/0009-2614(94)01502-M; BOWTELL R, 1990, J MAGN RESON, V88, P643, DOI 10.1016/0022-2364(90)90297-M; CARR HY, 1954, PHYS REV, V94, P630, DOI 10.1103/PhysRev.94.630; CROSS TA, COMMUNICATION; DEVILLE G, 1979, PHYS REV B, V19, P5666, DOI 10.1103/PhysRevB.19.5666; DURNEY CH, 1989, J MAGN RESON, V85, P554, DOI 10.1016/0022-2364(89)90245-X; EINZEL D, 1984, PHYS REV LETT, V53, P2312, DOI 10.1103/PhysRevLett.53.2312; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; HAHN EL, 1950, PHYS REV, V80, P580, DOI 10.1103/PhysRev.80.580; HE QH, 1993, J CHEM PHYS, V98, P6779, DOI 10.1063/1.464770; JEENER J, 1995, J CHEM PHYS, V103, P1309, DOI 10.1063/1.469808; KORBER H, 1991, J MAGN RESON, V93, P589, DOI 10.1016/0022-2364(91)90085-8; KUHNS PL, 1995, J MAGN RESON SER A, V115, P270, DOI 10.1006/jmra.1995.1178; LEE SD, IN PRESS J CHEM PHYS; MATTIELLO DL, UNPUB J AM CHEM SOC; MUNOWITZ M, 1986, SCIENCE, V233, P525, DOI 10.1126/science.233.4763.525; OLSON DL, 1995, SCIENCE, V270, P1967, DOI 10.1126/science.270.5244.1967; RICHTER W, 1995, SCIENCE, V267, P654, DOI 10.1126/science.7839140; Springer CS, 1994, NMR PHYSL BIOMEDICIN, P75; VANZIJL PCM, 1995, J MAGN RESON SER A, V113, P265, DOI 10.1006/jmra.1995.1092; VANZIJL PCM, 1990, J MAGN RESON, V87, P18, DOI 10.1016/0022-2364(90)90082-K; VATHYAM S, UNPUB; Warren WS, 1995, CHEM PHYS LETT, V247, P207, DOI 10.1016/0009-2614(95)01184-5	27	195	203	0	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					92	96		10.1126/science.272.5258.92	http://dx.doi.org/10.1126/science.272.5258.92			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600541				2022-12-28	WOS:A1996UD59700045
J	Kopczynski, CC; Davis, GW; Goodman, CS				Kopczynski, CC; Davis, GW; Goodman, CS			A neural tetraspanin, encoded by late bloomer, that facilitates synapse formation	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; NERVOUS-SYSTEM; INCLUDING CD9; ANTIGEN; DROSOPHILA; SUPERFAMILY; CD53; PROTEINS; MELANOMA; CD37	Upon contacting its postsynaptic target, a neuronal growth cone transforms into a presynaptic terminal. A membrane component on the growth cone that facilitates synapse formation was identified by means of a complementary DNA-based screen followed by genetic analysis. The late bloomer (lbl) gene in Drosophila encodes a member of the tetraspanin family of cell surface proteins. LBL protein is transiently expressed on motor axons, growth cones, and terminal arbors. In lbl mutant embryos, the growth cone of the RP3 motoneuron contacts its target muscles, but synapse formation is delayed and neighboring motoneurons display an increase in ectopic sprouting.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMIOT M, 1990, J IMMUNOL, V145, P4322; ANTON ES, 1995, J NEUROSCI, V15, P584; BATE M, 1995, NEURON, V15, P513, DOI 10.1016/0896-6273(95)90141-8; BELL GM, 1992, J EXP MED, V175, P527, DOI 10.1084/jem.175.2.527; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BOSCA L, 1994, J EXP MED, V179, P1119, DOI 10.1084/jem.179.4.1119; BROADIE K, 1993, DEVELOPMENT, P227; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CLASSON BJ, 1989, J EXP MED, V169, P1497, DOI 10.1084/jem.169.4.1497; DALBY B, 1995, GENETICS, V139, P757; DAVERN KM, 1991, MOL BIOCHEM PARASIT, V48, P67, DOI 10.1016/0166-6851(91)90165-3; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; EMI N, 1993, IMMUNOGENETICS, V37, P193; FITTER S, 1995, BLOOD, V86, P1348, DOI 10.1182/blood.V86.4.1348.bloodjournal8641348; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; GIL ML, 1992, J IMMUNOL, V148, P2826; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOODMAN CS, IN PRESS ANN REV NEU; HADJIARGYROU M, 1995, J NEUROSCI, V15, P574; HOREJSI V, 1991, FEBS LETT, V288, P1, DOI 10.1016/0014-5793(91)80988-F; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; IMAI T, 1992, J IMMUNOL, V149, P2879; IMAI T, 1995, J IMMUNOL, V155, P1229; Jarecki J, 1995, J NEUROSCI, V15, P8177; KAPRIELIAN Z, 1995, J NEUROSCI, V15, P562; KESHISHIAN H, 1993, J NEUROBIOL, V24, P757, DOI 10.1002/neu.480240606; KITANI S, 1991, J BIOL CHEM, V266, P1903; KOPCZYNSKI CC, UNPUB; LEBELBINAY S, 1995, J IMMUNOL, V155, P101; LEBELBINAY S, 1995, J LEUKOCYTE BIOL, V57, P956, DOI 10.1002/jlb.57.6.956; LITTLETON JT, 1993, DEVELOPMENT, V118, P1077; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; RASMUSSEN AM, 1994, J IMMUNOL, V153, P4997; ROBERTS JJ, 1995, BRIT J HAEMATOL, V89, P853; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; SI ZY, 1993, INT J CANCER, V54, P37, DOI 10.1002/ijc.2910540107; SINK H, 1991, DEVELOPMENT, V112, P307; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; TOLE S, 1993, DEV DYNAM, V197, P94, DOI 10.1002/aja.1001970203; TOMLINSON MG, 1993, EUR J IMMUNOL, V23, P136, DOI 10.1002/eji.1830230122; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5	44	147	149	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1867	1870		10.1126/science.271.5257.1867	http://dx.doi.org/10.1126/science.271.5257.1867			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596956				2022-12-28	WOS:A1996UC77800047
J	Welker, E; ArmstrongJames, M; Bronchti, G; Ourednik, W; GheorghitaBaechler, F; Dubois, R; Guernsey, DL; VanderLoos, H; Neumann, PE				Welker, E; ArmstrongJames, M; Bronchti, G; Ourednik, W; GheorghitaBaechler, F; Dubois, R; Guernsey, DL; VanderLoos, H; Neumann, PE			Altered sensory processing in the somatosensory cortex of the mouse mutant barrelless	SCIENCE			English	Article							OCULAR DOMINANCE COLUMNS; VISUAL-CORTEX; THALAMOCORTICAL AFFERENTS; STRUCTURAL ORGANIZATION; TERMINAL ARBORS; ADULT-RAT; LAYER-IV; MORPHOLOGY; VIBRISSAE; UNITS	Mice homozygous for the barrelless (brl) mutation, mapped here to chromosome 11, lack barrel-shaped arrays of cell clusters termed ''barrels'' in the primary somatosensory cortex. Deoxyglucose uptake demonstrated that the topology of the cortical whisker representation is nevertheless preserved. Anterograde tracers revealed a lack of spatial segregation of thalamic afferents into individual barrel territories, and single-cell recordings demonstrated a lack of temporal discrimination of center from surround information. Thus, structural segregation of thalamic inputs is not essential to generate topological order in the somatosensory cortex, but it is required for discrete spatiotemporal relay of sensory information to the cortex.	UNIV LONDON QUEEN MARY & WESTFIELD COLL, DEPT PHYSIOL, LONDON E1 4NS, ENGLAND; DALHOUSIE UNIV, DEPT ANAT & NEUROBIOL, HALIFAX, NS B3H 4H7, CANADA; DALHOUSIE UNIV, DEPT PATHOL, DIV MOL PATHOL & MOL GENET, HALIFAX, NS B3H 4H7, CANADA	University of London; Queen Mary University London; Dalhousie University; Dalhousie University	Welker, E (corresponding author), UNIV LAUSANNE, INST ANAT, RUE BUGNON 9, CH-1005 LAUSANNE, SWITZERLAND.			Neumann, Paul/0000-0002-8480-4799	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGMON A, 1993, J NEUROSCI, V13, P5365, DOI 10.1523/JNEUROSCI.13-12-05365.1993; ARMSTRONGJAMES M, 1991, J COMP NEUROL, V303, P193, DOI 10.1002/cne.903030203; ARMSTRONGJAMES M, 1987, J COMP NEUROL, V263, P265, DOI 10.1002/cne.902630209; BELFORD GR, 1979, J COMP NEUROL, V183, P305, DOI 10.1002/cne.901830207; Blue ME, 1991, CEREB CORTEX, V1, P380, DOI 10.1093/cercor/1.5.380; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; CATALANO SM, 1995, P NATL ACAD SCI USA, V92, P2549, DOI 10.1073/pnas.92.7.2549; COHENTANNOUDJI M, 1994, NATURE, V368, P460, DOI 10.1038/368460a0; de No RL, 1922, TRAB LAB BIOL U MADR, V20, P41; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DOLLEMANVANDERWEEL MJ, 1994, J NEUROSCI METH, V51, P9, DOI 10.1016/0165-0270(94)90021-3; DURHAM D, 1984, J COMP NEUROL, V223, P424, DOI 10.1002/cne.902230308; ERZURUMLU RS, 1990, DEV BRAIN RES, V56, P229; FOX K, 1994, J NEUROSCI, V14, P7665; GARRAGHTY PE, 1990, J COMP NEUROL, V294, P583, DOI 10.1002/cne.902940406; HUBEL DH, 1972, J COMP NEUROL, V146, P421, DOI 10.1002/cne.901460402; JENSEN KF, 1987, J NEUROSCI, V7, P3544; JENSEN KF, 1987, J NEUROSCI, V7, P3529; JHAVERI S, 1991, P NATL ACAD SCI USA, V88, P4489, DOI 10.1073/pnas.88.10.4489; LEVAY S, 1975, J COMP NEUROL, V159, P559, DOI 10.1002/cne.901590408; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; MA PM, 1991, J COMP NEUROL, V309, P161, DOI 10.1002/cne.903090202; SCHLAGGAR BL, 1994, J COMP NEUROL, V346, P80, DOI 10.1002/cne.903460106; Senft SL, 1991, CEREB CORTEX, V1, P308, DOI 10.1093/cercor/1.4.308; SIMONS DJ, 1985, J NEUROPHYSIOL, V54, P615, DOI 10.1152/jn.1985.54.3.615; STRYKER MP, 1986, J NEUROSCI, V6, P2117; VANDERLOOS H, 1976, NEUROSCI LETT, V2, P1, DOI 10.1016/0304-3940(76)90036-7; VANDERLOOS H, 1986, J HERED, V77, P66, DOI 10.1093/oxfordjournals.jhered.a110201; VONDERMALSBURG C, 1987, NEURAL MOL BASES LEA, P00411; WELKER E, 1993, EUR J NEUROSCI, V5, P691, DOI 10.1111/j.1460-9568.1993.tb00534.x; WELKER E, 1992, J NEUROSCI, V12, P153; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5; WOOLSEY TA, 1975, J COMP NEUROL, V164, P79, DOI 10.1002/cne.901640107; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X	34	124	126	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1996	271	5257					1864	1867		10.1126/science.271.5257.1864	http://dx.doi.org/10.1126/science.271.5257.1864			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596955				2022-12-28	WOS:A1996UC77800046
J	Israel, E; Cohn, J; Dube, L; Drazen, JM				Israel, E; Cohn, J; Dube, L; Drazen, JM			Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEUKOTRIENE-RECEPTOR ANTAGONIST; EXERCISE-INDUCED BRONCHOCONSTRICTION; SLOW-REACTING SUBSTANCES; ARACHIDONIC-ACID; AIRWAY RESPONSES; ATOPIC SUBJECTS; CHALLENGE; POTENT; SK-AND-F-104353; BRONCHODILATION	Objective.-To study the effect of 3 months of treatment with zileuton, an inhibitor of the enzymatic pathway (5-lipoxygenase) leading to leukotriene formation, on disease control in patients with mild to moderate asthma. Design.-Randomized, double-blind, parallel-group study in 401 patients. A 10-day placebo lead-in was followed by a double-blind treatment period of 13 weeks. Setting.-Asthma study clinics in university hospitals and private practices. Patients or Other Participants.-Patients with mild to moderate asthma (forced expiratory volume in the first second [FEV(1)], 40% to 80% of predicted) whose only treatment was inhaled p-agonists. Interventions.-Treatment with 600 mg or 400 mg of zileuton or placebo (each taken four times daily). Main Outcome Measures.-Frequency of asthma exacerbation requiring treatment with corticosteroids, use of inhaled beta-agonists, pulmonary function tests, asthma symptom assessment, and quality-of-life evaluation. Safety was evaluated by monitoring adverse events. Results.-Only eight (6.1%) of 132 patients receiving 600 mg of zileuton four times a day required corticosteroid treatment for asthma vs 21 (15.6%) of 135 patients receiving placebo (P=.02), giving a relative risk of 2.6. At the time of expected peak drug concentration, the average FEV(1) improved 15.7% in the 600-mg zileuton group vs 7.7% in the placebo group (P=.006). Quality-of-life assessments significantly improved in the 600-mg zileuton group and not in the placebo group (P=.007 for the overall score). Elevations in liver function tests (more than three times normal), all of which reversed with drug withdrawal, occurred in five patients (P=.03 vs placebo), three patients (P=.12 vs placebo), and no patients treated with 600 mg of zileuton, 400 mg of zileuton, or placebo, respectively. Conclusions.-Three months of 5-lipoxygenase inhibition produced a significant improvement in asthma control. These data indicate that g-lipoxygenase products of arachidonic acid metabolism are mediators of inflammation with an important role in the biology of asthma.	ABBOTT LABS,ABBOTT PK,IL 60064	Abbott Laboratories	Israel, E (corresponding author), BRIGHAM & WOMENS HOSP,DIV RESP & CRIT CARE,75 FRANCIS ST,BOSTON,MA 02115, USA.		Drazen, Jeffrey M/E-5841-2012					ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; BROWN GP, 1988, AM J PHYSIOL, V254, pC809, DOI 10.1152/ajpcell.1988.254.6.C809; CHAPMAN KR, 1991, NEW ENGL J MED, V324, P788, DOI 10.1056/NEJM199103213241202; CHRISTIE PE, 1991, AM REV RESPIR DIS, V144, P957, DOI 10.1164/ajrccm/144.4.957; CLOUD ML, 1989, AM REV RESPIR DIS, V140, P1336, DOI 10.1164/ajrccm/140.5.1336; DAHLEN B, 1993, EUR RESPIR J, V6, P1018; DAHLEN B, 1993, THORAX, V48, P1205, DOI 10.1136/thx.48.12.1205; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DRAZEN JM, 1986, CHEST, V89, P414, DOI 10.1378/chest.89.3.414; DYKEWICZ MS, 1986, ARCH INTERN MED, V146, P2369, DOI 10.1001/archinte.146.12.2369; FINDLAY SR, 1992, J ALLERGY CLIN IMMUN, V89, P1040, DOI 10.1016/0091-6749(92)90227-S; FRIEDMAN BS, 1993, AM REV RESPIR DIS, V147, P839, DOI 10.1164/ajrccm/147.4.839; FULLER RW, 1989, J ALLERGY CLIN IMMUN, V83, P939, DOI 10.1016/0091-6749(89)90109-7; GADDY JN, 1992, AM REV RESPIR DIS, V146, P358, DOI 10.1164/ajrccm/146.2.358; HUI KP, 1991, THORAX, V46, P184, DOI 10.1136/thx.46.3.184; HUI KP, 1991, LANCET, V337, P1062, DOI 10.1016/0140-6736(91)91709-4; IMPENS N, 1993, AM REV RESPIR DIS, V147, P1442, DOI 10.1164/ajrccm/147.6_Pt_1.1442; IRAEL E, 1993, AM REV RESPIR DIS, V148, P1447; ISRAEL E, 1989, AM REV RESPIR DIS, V140, P1348, DOI 10.1164/ajrccm/140.5.1348; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; ISRAEL E, 1994, TOPICS IN PHARMACEUTICAL SCIENCES 1993, P89; JOHNSON HM, 1986, J IMMUNOL, V137, P3053; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; KANE G, 1994, J ALLERGY CLIN IMMUN, V93, P184; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LEWIS RA, 1980, P NATL ACAD SCI-BIOL, V77, P3710, DOI 10.1073/pnas.77.6.3710; MAKKER HK, 1993, AM REV RESPIR DIS, V147, P1413, DOI 10.1164/ajrccm/147.6_Pt_1.1413; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; Nasser S. M. Shuaib, 1994, Thorax, V49, P749, DOI 10.1136/thx.49.8.749; OWEN WF, 1987, J IMMUNOL, V138, P532; ROBUSCHI M, 1992, AM REV RESPIR DIS, V145, P1285, DOI 10.1164/ajrccm/145.6.1285; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; 1991, J ALLERGY CLIN IMMUN, V88, P425; 1987, AM REV RESPIR DIS, V136, P225	39	239	248	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					931	936		10.1001/jama.275.12.931	http://dx.doi.org/10.1001/jama.275.12.931			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA563	8598621				2022-12-28	WOS:A1996UA56300033
J	Forsthuber, T; Yip, HC; Lehmann, PV				Forsthuber, T; Yip, HC; Lehmann, PV			Induction of T(H)1 and T(H)2 immunity in neonatal mice	SCIENCE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MEMORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; TOLERANCE INDUCTION; MIGRATION PATHWAYS; DETERMINANT; PEPTIDE; SPLEEN	The neonatal period has been thought of as a window in ontogeny, during which the developing immune system is particularly susceptible to tolerization. In the present study, the classic system for induction of neonatal tolerance to protein antigens was reexamined in mice. The presumably tolerogenic protocol was found to trigger a vigorous T helper cell type 2 (T(H)2) immune response. Thus, neonatal ''tolerization'' induces immune deviation, not tolerance in the immunological sense. Neonates are not immune privileged but generate T(H)2 or T(H)1 responses, depending on the mode of immunization.	CASE WESTERN RESERVE UNIV,DEPT PATHOL,CLEVELAND,OH 44106	Case Western Reserve University			Forsthuber, Thomas/AID-8080-2022	/0000-0003-0692-7125	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036219] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36219-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMOWICZ D, 1990, EUR J IMMUNOL, V20, P1647, DOI 10.1002/eji.1830200805; ASHERSON GL, 1965, IMMUNOLOGY, V9, P205; ASHERSON GL, 1967, BRIT MED BULL, V23, P24, DOI 10.1093/oxfordjournals.bmb.a070510; BERNARD CCA, 1977, CLIN EXP IMMUNOL, V29, P100; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BRADLEY LM, 1992, J IMMUNOL, V148, P324; Burnet FM, 1949, PRODUCTION ANTIBODIE, P102; CHEN H, 1995, TRANSPLANTATION, V60, P1182; Chen NX, 1995, TRANSPLANTATION, V60, P1187; CLAYTON JP, 1989, J EXP MED, V169, P1681, DOI 10.1084/jem.169.5.1681; DORSCH S, 1975, NATURE, V258, P233, DOI 10.1038/258233a0; EINSTEIN ER, 1968, IMMUNOCHEMISTRY, V5, P567, DOI 10.1016/0019-2791(68)90092-X; FALK GA, 1969, J IMMUNOL, V103, P1248; FORSTHUBER T, UNPUB; GAMMON G, 1986, NATURE, V319, P413, DOI 10.1038/319413a0; GAMMON GM, 1986, J EXP MED, V164, P667, DOI 10.1084/jem.164.2.667; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; JUNG TM, 1988, J IMMUNOL, V141, P4110; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MACKAY CR, 1992, EUR J IMMUNOL, V22, P887, DOI 10.1002/eji.1830220402; MACKAY CR, 1991, IMMUNOL TODAY, V12, P189, DOI 10.1016/0167-5699(91)90051-T; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Owen R. D., 1946, JOUR HEREDITY, V37, P291; OWEN RD, 1945, SCIENCE, V102, P400, DOI 10.1126/science.102.2651.400; PABST R, 1988, IMMUNOL TODAY, V9, P43, DOI 10.1016/0167-5699(88)91258-3; PABST R, 1989, IMMUNOL REV, V108, P83, DOI 10.1111/j.1600-065X.1989.tb00014.x; PATERSON PY, 1958, ANN NY ACAD SCI, V73, P811, DOI 10.1111/j.1749-6632.1959.tb40860.x; POWELL TJ, 1990, J IMMUNOL, V144, P854; QIN Y, 1989, EUR J IMMUNOL, V19, P373, DOI 10.1002/eji.1830190223; RIEGER M, 1977, J IMMUNOGENET, V4, P61; SWIERKOS.JE, 1974, FED PROC, V33, P814; SWIERKOSZ JE, 1975, J IMMUNOL, V115, P631; WELCH AM, 1976, EUR J IMMUNOL, V6, P910, DOI 10.1002/eji.1830061214	35	582	602	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1728	1730		10.1126/science.271.5256.1728	http://dx.doi.org/10.1126/science.271.5256.1728			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596934				2022-12-28	WOS:A1996UB15100047
J	Hochstrasser, M				Hochstrasser, M			Protein degradation or regulation: Ub the judge	CELL			English	Review											Hochstrasser, M (corresponding author), UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.			Hochstrasser, Mark/0000-0002-1131-5484				ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; BABOSHINA OV, 1996, IN PRESS J BIOL CHEM, V271; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Egner R, 1996, FEBS LETT, V378, P177, DOI 10.1016/0014-5793(95)01450-0; GOLDKNOPF IL, 1977, P NATL ACAD SCI USA, V74, P864, DOI 10.1073/pnas.74.3.864; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6	14	237	241	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					813	815		10.1016/S0092-8674(00)81058-2	http://dx.doi.org/10.1016/S0092-8674(00)81058-2			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601303	Bronze			2022-12-28	WOS:A1996UC38100001
J	Mount, SM				Mount, SM			AT-AC introns: An ATtACk on Dogma	SCIENCE			English	Editorial Material							RNA				Mount, SM (corresponding author), UNIV MARYLAND,DEPT ZOOL,ROOM 3202,COLLEGE PK,MD 20742, USA.			Mount, Steve/0000-0003-2748-8205				CAROTHERS AM, 1993, MOL CELL BIOL, V13, P5085, DOI 10.1128/MCB.13.8.5085; GESTELAND RF, 1993, RNA WORLD; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; Hall SL, 1996, SCIENCE, V271, P1716, DOI 10.1126/science.271.5256.1716; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KOHRMAN DC, UNPUB; LAMOND AI, 1995, PREMRNA PROCESSING; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; SPANA E, COMMUNICATION; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; TARN WY, 1995, RNA, V1, P644; Umen JG, 1995, RNA, V1, P869	12	48	50	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1690	1692		10.1126/science.271.5256.1690	http://dx.doi.org/10.1126/science.271.5256.1690			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596928				2022-12-28	WOS:A1996UB15100033
J	Myers, MP; WagerSmith, K; RothenfluhHilfiker, A; Young, MW				Myers, MP; WagerSmith, K; RothenfluhHilfiker, A; Young, MW			Light-induced degradation of TIMELESS and entrainment of the Drosophila circadian clock	SCIENCE			English	Article							PERIOD GENE-PRODUCT; VISUAL-SYSTEM; MELANOGASTER; RHYTHMS	Two genes, period (per) and timeless (tim), are required for production of circadian rhythms in Drosophila. The proteins encoded by these genes (PER and TIM) physically interact, and the timing of their association and nuclear localization is believed to promote cycles of per and tim transcription through an autoregulatory feedback loop. Here it is shown that TIM protein may also couple this molecular pacemaker to the environment, because TIM is rapidly degraded after exposure to light. TIM accumulated rhythmically in nuclei of eyes and in pacemaker cells of the brain. The phase of these rhythms was differentially advanced or delayed by light pulses delivered at different times of day, corresponding with phase shifts induced in the behavioral rhythms.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NSF,SCI & TECHNO CTR BIOL TRIMING,NEW YORK,NY 10021; ROCKEFELLER UNIV,LAB GENET,NEW YORK,NY 10021	Howard Hughes Medical Institute; National Science Foundation (NSF); Rockefeller University; Rockefeller University			, 机智的马小跳和机智的羊不愁/ABC-5169-2020	Rothenfluh, Adrian/0000-0002-3813-5723				ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BARGIELLO TA, 1984, P NATL ACAD SCI-BIOL, V81, P2142, DOI 10.1073/pnas.81.7.2142; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; DUSHAY MS, 1990, GENETICS, V125, P557; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EWER J, 1992, J NEUROSCI, V12, P3321; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; KAY SA, 1995, CELL, V83, P361, DOI 10.1016/0092-8674(95)90113-2; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LEVINE JD, 1994, NEURON, V13, P967, DOI 10.1016/0896-6273(94)90262-3; MATSUMOTO A, 1994, J NEUROGENET, V9, P141, DOI 10.3109/01677069409167276; MYERS M, UNPUB; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; PITTENDRIGH CS, 1981, HDB BEHAVIORAL NEURO, V4, P95; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; REDDY P, 1984, CELL, V38, P701, DOI 10.1016/0092-8674(84)90265-4; ROTHENFLUHHILFI.A, UNPUB; RUTILA J, COMMUNICATION; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SEHGAL A, UNPUB; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; WAGERSMITH K, UNPUB; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZERR DM, 1990, J NEUROSCI, V10, P2749	29	396	403	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1736	1740		10.1126/science.271.5256.1736	http://dx.doi.org/10.1126/science.271.5256.1736			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596937				2022-12-28	WOS:A1996UB15100050
J	Dawson, C; Whitfield, H				Dawson, C; Whitfield, H			ABC of urology - Urological evaluation	BRITISH MEDICAL JOURNAL			English	Article									CENT MIDDLESEX HOSP,LONDON NW10 7NS,ENGLAND; INST UROL & NEPHROL,LONDON,ENGLAND	Imperial College London; University of London; University College London	Dawson, C (corresponding author), EDITH CAVELL HOSP,PETERBOROUGH,ENGLAND.							MCANINCH JW, 1995, SMITHS GENERAL UROLO; MICHELL MJ, 1995, CURRENT OPINION UROL, V5, P79; PATEL MD, 1995, CURRENT OPINION UROL, V5, P67; TANAGHO EA, 1995, SMITHS GENERAL UROLO; WILLIAMS RD, 1995, SMITHS GENERAL UROLO	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					695	698						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597741				2022-12-28	WOS:A1996UB11000034
J	deSilva, M; MacArdle, B; McGowan, M; Hughes, E; Stewart, J; Neville, BGR; Johnson, AL; Reynolds, EH				deSilva, M; MacArdle, B; McGowan, M; Hughes, E; Stewart, J; Neville, BGR; Johnson, AL; Reynolds, EH			Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy	LANCET			English	Article							TONIC-CLONIC SEIZURES; REQUIRING PROLONGED OBSERVATION; PROGNOSIS; EFFICACY; THERAPY; PATIENT; ADULTS; DESIGN	Background The medical treatment of childhood epilepsy is largely influenced by clinical trials in adult patients. We know of only one randomised comparative trial (of two drugs) in newly diagnosed childhood epilepsy. We have undertaken a long-term, prospective, randomised, unmasked, pragmatic trial of the comparative efficacy and toxicity of four standard antiepileptic drugs used as monotherapy in children with newly diagnosed epilepsy. Methods Between 1981 and 1987, 167 children aged 3-16 years, who had had at least two previously untreated tonic-clonic or partial seizures, with or without secondary generalisation, were randomly allocated treatment with phenobarbitone, phenytoin, carbamazepine, or sodium valproate. The protocol was designed to conform to standard clinical practice. Efficacy was assessed by time to first seizure after the start of treatment and time to achieving 1-year remission. Findings The overall outcome with all four drugs was good. 20% of children remained free of seizures and 73% had achieved 1-year remission by 3 years of follow-up. We found no significant differences between the drugs for either measure of efficacy at 1, 2, or 3 years of follow-up. The overall frequency of unacceptable side-effects necessitating withdrawal of the randomised drug was 9%. This total included six of the first ten children assigned phenobarbitone; no further children were allocated this drug. Of the other three drugs, phenytoin (9%) was more likely to be withdrawn than carbamazepine (4%) or sodium valproate (4%). Interpretation Our data will inform choice of drug and outcome with four of the standard drugs available for newly diagnosed tonic-clonic or partial seizures with or without secondary generalisation in children.	UNIV LONDON KINGS COLL HOSP,INST EPILEPTOL,CTR EPILEPSY,LONDON SE5 8AZ,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT NEUROL,LONDON,ENGLAND; INST CHILD HLTH,NEUROSCI UNIT,LONDON,ENGLAND; GUYS HOSP,DEPT PAEDIAT NEUROL,LONDON SE1 9RT,ENGLAND; INST PUBL HLTH,MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of London; University College London; Guy's & St Thomas' NHS Foundation Trust; MRC Biostatistics Unit; University of Cambridge								Aicardi J., 1986, EPILEPSY CHILDREN; CALLAGHAN N, 1985, J NEUROL NEUROSUR PS, V48, P639, DOI 10.1136/jnnp.48.7.639; CAMFIELD CS, 1979, J PEDIATR-US, V95, P361, DOI 10.1016/S0022-3476(79)80507-7; CAMFIELD PR, 1985, NEUROLOGY, V35, P1657, DOI 10.1212/WNL.35.11.1657; CHADWICK D, 1985, J NEUROL NEUROSUR PS, V48, P1073, DOI 10.1136/jnnp.48.11.1073; ELWES RDC, 1984, NEW ENGL J MED, V311, P944, DOI 10.1056/NEJM198410113111503; ELWES RDC, 1988, BRIT MED J, V297, P948, DOI 10.1136/bmj.297.6654.948; FORSYTHE WI, 1984, DEV MED CHILD NEUROL, V26, P742; HELLER AJ, 1995, J NEUROL NEUROSUR PS, V58, P44, DOI 10.1136/jnnp.58.1.44; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; Machin D., 1987, STAT TABLES DESIGN C; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; O'Donohoe NV, 1985, EPILEPSIES CHILDHOOD; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; RAMSAY RE, 1983, NEUROLOGY, V33, P904, DOI 10.1212/WNL.33.7.904; RAMSAY RE, 1992, J EPILEPSY, V5, P55, DOI 10.1016/S0896-6974(05)80021-0; REYNOLDS EH, 1981, EPILEPSIA, V22, P1, DOI 10.1111/j.1528-1157.1981.tb04327.x; REYNOLDS EH, 1994, EPILEPSIE B, V22, P72; RICHENS A, 1994, J NEUROL NEUROSUR PS, V57, P682, DOI 10.1136/jnnp.57.6.682; SHORVON SD, 1977, BRIT MED J, V1, P1635, DOI 10.1136/bmj.1.6077.1635; SHORVON SD, 1984, J NEUROL NEUROSUR PS, V47, P1157, DOI 10.1136/jnnp.47.11.1157; TURNBULL DM, 1985, BRIT MED J, V290, P8150; VERITY CM, 1995, DEV MED CHILD NEUROL, V37, P97	25	217	221	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					709	713		10.1016/S0140-6736(96)90074-4	http://dx.doi.org/10.1016/S0140-6736(96)90074-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8601999				2022-12-28	WOS:A1996TZ98200007
J	Hodis, HN; Mack, WJ; LaBree, L; Selzer, RH; Liu, CR; Liu, CH; Alaupovic, P; KwongFu, H; Azen, SP				Hodis, HN; Mack, WJ; LaBree, L; Selzer, RH; Liu, CR; Liu, CH; Alaupovic, P; KwongFu, H; Azen, SP			Reduction in carotid arterial wall thickness using lovastatin and dietary therapy - A randomized, controlled clinical trial	ANNALS OF INTERNAL MEDICINE			English	Article							COLESTIPOL-NIACIN THERAPY; TRIGLYCERIDE-RICH LIPOPROTEINS; APOLIPOPROTEIN-C-III; CORONARY ATHEROSCLEROSIS; ELECTRO-IMMUNOASSAY; BYPASS GRAFTS; LOW-DENSITY; ULTRASOUND; RAT	Objective: To assess the effects of lipid-lowering therapy on the progression of early, preintrusive carotid arterial atherosclerosis. Design: Randomized, double-blind, placebo-controlled, serial carotid arterial imaging trial. Setting: University Atherosclerosis Research Unit. Patients: 188 patients from the Monitored Atherosclerosis Regression Study who were 37 to 67 years of age and had angiographically defined coronary artery disease. Intervention: Cholesterol-lowering diet plus placebo or lovastatin, 80 mg/d. Measurements: High-resolution B-mode ultrasonographic quantification of the combined thickness of the distal common carotid arterial far wall intima-media complex (carotid arterial intima-media thickness) at baseline and every 6 months for as long as 4 years. Results: The annual rate of change in carotid arterial intima-media thickness differed significantly between the lovastatin group and the placebo group at 2 and 4 years (P < 0.001). Patients receiving lovastatin had consistent reduction of the intima-media thickness (P < 0.001 as early as 1 year), whereas patients receiving placebo had consistent increase of the intima-media thickness at 2 and 4 years (P < 0.02). On-trial levels of low-density lipoprotein cholesterol, triglycerides, and apolipoproteins B, C-III, and E correlated significantly with the annual rate of change in carotid arterial intima-media thickness (P < 0.001). Conclusion: Lipid-lowering therapy reverses the progression of early, preintrusive atherosclerosis of the carotid artery. Both cholesterol-rich and triglyceride-rich lipoproteins correlate with the progression of early, pre-intrusive atherosclerosis of the carotid artery. These findings, together with earlier reports of the effects of lovastatin therapy on the progression of atherosclerosis of the coronary arteries, indicate that carotid arterial far wall intima-media thickness is a useful end point for anti-atherosclerosis trials.	OKLAHOMA MED RES FDN, OKLAHOMA CITY, OK 73104 USA; UNIV SO CALIF, SCH MED, DEPT PREVENT MED, LOS ANGELES, CA 90033 USA	Oklahoma Medical Research Foundation; University of Southern California	Hodis, HN (corresponding author), UNIV SO CALIF, SCH MED,DIV CARDIOL,ATHEROSCLEROSIS RES UNIT, 2250 ALCAZAR ST, CSC 132, LOS ANGELES, CA 90033 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL048399, R01HL045005, R01HL049885] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-49885, R01-HL-48399, R01-HL-45005] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MR, 1994, CIRCULATION, V90, P123; ALAUPOVIC P, 1981, CAN J BIOCHEM CELL B, V59, P565, DOI 10.1139/o81-079; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BLANKENHORN DH, 1990, CIRCULATION, V81, P470, DOI 10.1161/01.CIR.81.2.470; BLANKENHORN DH, 1992, CIRCULATION, V86, P1701, DOI 10.1161/01.CIR.86.6.1701; BLANKENHORN DH, 1994, ARTERIOSCLER THROMB, V14, P177, DOI 10.1161/01.ATV.14.2.177; BLANKENHORN DH, 1993, CIRCULATION, V88, P20, DOI 10.1161/01.CIR.88.1.20; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BLANKENHORN DH, 1991, CIRCULATION, V83, P438, DOI 10.1161/01.CIR.83.2.438; BLANKENHORN DH, 1987, CONTROL CLIN TRIALS, V8, P354, DOI 10.1016/0197-2456(87)90156-5; CASHINHEMPHILL L, 1990, JAMA-J AM MED ASSOC, V264, P3013, DOI 10.1001/jama.264.23.3013; CASHINHEMPHILL L, 1992, ONLINE J CURR C 1023; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; CURRY MD, 1976, BIOCHIM BIOPHYS ACTA, V439, P413, DOI 10.1016/0005-2795(76)90078-7; CURRY MD, 1978, CLIN CHEM, V24, P280; CURRY MD, 1976, CLIN CHEM, V22, P315; CURRY MD, 1980, BIOCHIM BIOPHYS ACTA, V617, P503, DOI 10.1016/0005-2760(80)90016-8; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; GEROULAKOS G, 1994, EUR HEART J, V15, P781, DOI 10.1093/oxfordjournals.eurheartj.a060585; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; HODIS HN, 1995, CURR OPIN LIPIDOL, V6, P209, DOI 10.1097/00041433-199508000-00004; HODIS HN, 1994, CIRCULATION, V90, P42, DOI 10.1161/01.CIR.90.1.42; HODIS HN, 1994, J INTERN MED, V236, P111, DOI 10.1111/j.1365-2796.1994.tb01272.x; MACK WJ, 1993, STROKE, V24, P1779, DOI 10.1161/01.STR.24.12.1779; PATSCH W, 1994, ARTERIOSCLER THROMB, V14, P874, DOI 10.1161/01.ATV.14.6.874; PERSSON J, 1994, ARTERIOSCLER THROMB, V14, P261, DOI 10.1161/01.ATV.14.2.261; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; RYU JE, 1992, STROKE, V23, P823, DOI 10.1161/01.STR.23.6.823; SALONEN R, 1994, CIRCULATION, V90, P127; SELZER RH, 1994, ATHEROSCLEROSIS, V111, P1, DOI 10.1016/0021-9150(94)90186-4; SHELBURNE F, 1980, J CLIN INVEST, V65, P652, DOI 10.1172/JCI109710; WANG CS, 1985, J CLIN INVEST, V75, P384, DOI 10.1172/JCI111711; WINDLER E, 1985, J LIPID RES, V26, P556	34	272	276	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1996	124	6					548	+		10.7326/0003-4819-124-6-199603150-00002	http://dx.doi.org/10.7326/0003-4819-124-6-199603150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ529	8597317				2022-12-28	WOS:A1996TZ52900002
J	Wadman, M				Wadman, M			US health politics may give insurers a respite on genetic information	NATURE			English	News Item																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					91	91		10.1038/380091a0	http://dx.doi.org/10.1038/380091a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600397	Bronze			2022-12-28	WOS:A1996TZ97800003
J	Takei, N				Takei, N			Funding of research in mental health care in Japan	LANCET			English	Editorial Material											Takei, N (corresponding author), INST PSYCHIAT,DEPT PSYCHOL MED,GENET SECT,DENMARK HILL,LONDON SE5 8AF,ENGLAND.		Takei, Nori/GWZ-7464-2022; Takei, Nori/AAC-8578-2019					ANDREWS G, 1985, ARCH GEN PSYCHIAT, V42, P537; Kakimoto Y, 1994, Seishin Shinkeigaku Zasshi, V96, P649; MACILWAIN C, 1994, NATURE, V367, P583, DOI 10.1038/367583b0; RICE DP, 1990, 901694 DHHS ADM NAT; Rose G., 1992, STRATEGY PREVENTIVE; SWINBANKS D, 1994, NATURE, V367, P670; Torrey E. F., 1995, SURVIVING SCHIZOPHRE; 1993, 1993 WORLD BANK; 1992, MONBUSHO KAGAKU KENK; 1994, LANCET, V344, P488; 1993, SCHIZOPHR B, V19, P651; 1993, SCHIZOPHR REV, V1, P1; 1995, 1994 WELLC TRUST; 1994, KAGAKU KENKYUHI HOJO	14	3	3	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					523	524		10.1016/S0140-6736(96)91145-9	http://dx.doi.org/10.1016/S0140-6736(96)91145-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TW697	8596274				2022-12-28	WOS:A1996TW69700016
J	Davis, MM				Davis, MM			Evolving catalysts in real time	SCIENCE			English	Editorial Material							PEPTIDE				Davis, MM (corresponding author), STANFORD UNIV, SCH MED, BECKMAN CTR, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA.			Davis, Mark/0000-0001-6868-657X				ABBAS AK, 1994, CELLULAR MOL IMMUNOL, P89; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; DINTZIS HM, 1976, P NATL ACAD SCI USA, V73, P3671, DOI 10.1073/pnas.73.10.3671; FOOTE J, 1994, P NATL ACAD SCI USA, V91, P10370, DOI 10.1073/pnas.91.22.10370; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; STRONG RK, 1991, BIOCHEMISTRY-US, V30, P3749, DOI 10.1021/bi00229a023; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; SYKULEV Y, 1994, P NATL ACAD SCI USA, V91, P12862; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	14	5	5	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1078	1079		10.1126/science.271.5252.1078	http://dx.doi.org/10.1126/science.271.5252.1078			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599081				2022-12-28	WOS:A1996TW70100026
J	Ohta, M; Inoue, H; Cotticelli, MG; Kastury, K; Baffa, R; Palazzo, J; Siprashvili, Z; Mori, M; McCue, P; Druck, T; Croce, CM; Huebner, K				Ohta, M; Inoue, H; Cotticelli, MG; Kastury, K; Baffa, R; Palazzo, J; Siprashvili, Z; Mori, M; McCue, P; Druck, T; Croce, CM; Huebner, K			The FHIT gene, spanning the chromosome 3p14.2 fragile site acid renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers	CELL			English	Article							PROTEIN-KINASE-C; ESOPHAGEAL CANCER; CGG REPEAT; TRANSLOCATION; REGION; INSTABILITY; DNA; SEQUENCE; CHINA	A 200-300 kb region of chromosome 3p14.2, including the fragile site locus FRA3B, is homozygously deleted in multiple tumor-derived cell lines. Exon amplification from cosmids covering this deleted region allowed identification of the human FHIT gene, a member of the histidine triad gene family, which encodes a protein with 69% similarity to an S. pombe enzyme, diadenosine 5', 5triple prime P-1, P-4-tetraphosphate asymmetrical hydrolase. The FHIT locus is composed of ten exons distributed over at least 500 kb, with three 5' untranslated exons centromeric to the renal carcinoma-associated 3p14.2 breakpoint, the remaining exons telomeric to this translocation breakpoint, and exon 5 within the homozygously deleted fragile region. aberrant transcripts of the FHIT locus were found in similar to 50% of esophageal, stomach, and colon carcinomas.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, KIMMEL CANC CTR, PHILADELPHIA, PA 19107 USA; KYUSHU UNIV, MED INST BIOREGULAT, DEPT SURG, BEPPU, OITA 874, JAPAN	Jefferson University; Kyushu University			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NCI NIH HHS [CA51083, CA21124, CA39860] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083, R35CA039860, P01CA021124] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLDOG FL, 1993, P NATL ACAD SCI USA, V90, P8509, DOI 10.1073/pnas.90.18.8509; BOLDOG FL, 1994, GENE CHROMOSOME CANC, V11, P216, DOI 10.1002/gcc.2870110403; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; DRUCK T, 1995, CANCER RES, V55, P5348; FONG LYY, 1978, J NATL CANCER I, V61, P145, DOI 10.1093/jnci/61.1.145; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GLOVER TW, 1988, CANCER GENET CYTOGEN, V31, P69, DOI 10.1016/0165-4608(88)90013-1; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Huang Y, 1995, BIOCHEM J, V312, P925, DOI 10.1042/bj3120925; JONES C, 1994, HUM MOL GENET, V3, P2123, DOI 10.1093/hmg/3.12.2123; KASTURY K, 1996, IN PRESS GENOMICS; KASTURY K, 1996, IN PRESS CANC RES; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LAFORGIA S, 1993, CANCER RES, V53, P3118; LI FP, 1993, ANN INTERN MED, V118, P106, DOI 10.7326/0003-4819-118-2-199301150-00005; LISITSYN NA, 1995, P NATL ACAD SCI USA, V92, P151, DOI 10.1073/pnas.92.1.151; LO KW, 1994, INT J ONCOL, V4, P1359; LUBINSKI J, 1994, CANCER RES, V54, P3710; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; MICHAELIS SC, 1995, CANCER GENET CYTOGEN, V81, P1, DOI 10.1016/0165-4608(94)00208-8; MOZIER NM, 1991, FEBS LETT, V279, P14, DOI 10.1016/0014-5793(91)80238-X; OHTA M, 1995, IN PRESS INT J CANC; PARADEE W, 1995, GENOMICS, V27, P358, DOI 10.1006/geno.1995.1057; PEARSON JD, 1990, J BIOL CHEM, V265, P4583; RASSOOL FV, 1992, AM J HUM GENET, V50, P1243; ROCHE J, 1994, HUM MOL GENET, V3, P215, DOI 10.1093/hmg/3.1.215; Seraphin B., 1992, DNA Sequence, V3, P177, DOI 10.3109/10425179209034013; SERAPHIN B, 1994, HUM MOL GENET, V3, P215; SUTHERLAND GR, 1991, GENET ANAL TECH APPL, V8, P1616; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WILKE CM, 1994, GENOMICS, V22, P319, DOI 10.1006/geno.1994.1390; YANG CS, 1980, CANCER RES, V40, P2633; YANG GC, 1987, J NATL CANCER I, V79, P1241; YOKOTA J, 1989, CANCER RES, V49, P3598; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	37	957	1133	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 23	1996	84	4					587	597		10.1016/S0092-8674(00)81034-X	http://dx.doi.org/10.1016/S0092-8674(00)81034-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598045	Bronze			2022-12-28	WOS:A1996TX17600011
J	Patten, PA; Gray, NS; Yang, PL; Marks, CB; Wedemayer, GJ; Boniface, JJ; Stevens, RC; Schultz, PG				Patten, PA; Gray, NS; Yang, PL; Marks, CB; Wedemayer, GJ; Boniface, JJ; Stevens, RC; Schultz, PG			The immunological evolution of catalysis	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; IMMUNE-RESPONSE; HYPERVARIABLE REGIONS; ANTIBODY DIVERSITY; SOMATIC MUTATION; MATURATION; BINDING; GENERATION; EXPRESSION; FRAGMENT	The germline genes used by the mouse to generate the esterolytic antibody 48G7 were cloned and expressed in an effort to increase our understanding of the detailed molecular mechanisms by which the immune system evolves catalytic function. The nine replacement mutations that were fixed during affinity maturation increased affinity for the transition state analogue by a factor of 10(4), primarily the result of a decrease in the dissociation rate of the hapten-antibody complex. There was a corresponding increase in the rate of reaction of antibody with substrate, k(cat)/K-m, from 1.7 x 10(2) M(-1) min(-1) to 1.4 x 10(4) M(-1) min-l The three-dimensional crystal structure of the 48G7-transition state analogue complex at 2.0 angstroms resolution indicates that none of the nine residues in which somatic mutations have been fixed directly contact the hapten. Thus, in the case of 48G7, affinity maturation appears to play a conformational role, either in reorganizing the active site geometry or limiting side-chain and backbone flexibility of the germline antibody. The crystal structure and analysis of somatic and directed active site mutants underscore the role of transition state stabilization in the evolution of this catalytic antibody.	UNIV CALIF BERKELEY,DEPT CHEM,HOWARD HUGHES MED INST,BERKELEY,CA 94720; STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,HOWARD HUGHES MED INST,STANFORD,CA 94305	Howard Hughes Medical Institute; University of California System; University of California Berkeley; Howard Hughes Medical Institute; Stanford University			Stevens, Raymond/K-7272-2015	Stevens, Raymond/0000-0002-4522-8725; Yang, Priscilla/0000-0001-7456-2557; Gray, Nathanael/0000-0001-5354-7403	PHS HHS [R01 AL24695] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALZARI PM, 1990, EMBO J, V9, P3807, DOI 10.1002/j.1460-2075.1990.tb07598.x; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BRAISTED AC, 1994, J AM CHEM SOC, V116, P2211, DOI 10.1021/ja00084a098; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; CHEN C, 1995, EMBO J, V14, P2784, DOI 10.1002/j.1460-2075.1995.tb07278.x; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; COCHRAN AG, 1990, SCIENCE, V249, P781, DOI 10.1126/science.2389144; EIGENBROT C, 1993, J MOL BIOL, V229, P969, DOI 10.1006/jmbi.1993.1099; EISEN HN, 1964, BIOCHEMISTRY-US, V3, P996, DOI 10.1021/bi00895a027; FOOTE J, 1991, NATURE, V352, P530, DOI 10.1038/352530a0; FOOTE J, 1994, P NATL ACAD SCI USA, V91, P10370, DOI 10.1073/pnas.91.22.10370; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GOLINELLIPIMPAN.B, 1994, CURR BIOL, V2, P175; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; Haldane JBS, 1930, ENZYMES; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; JACOBS JW, 1989, THESIS U CALIFORNIA; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JESKE DJ, 1984, J IMMUNOL, V133, P1090; JONES TA, O COMPUTER GRAPHICS; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; Kabat EA, 1991, SEQUENCES PROTEINS I; KAUFFMAN SA, 1988, MATURATION IMMUNE RE, V2, P349; KIM S, 1981, CELL, V27, P573, DOI 10.1016/0092-8674(81)90399-8; LASCOMBE MB, 1989, P NATL ACAD SCI USA, V86, P607, DOI 10.1073/pnas.86.2.607; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LESLEY SA, 1993, P NATL ACAD SCI USA, V90, P1160, DOI 10.1073/pnas.90.4.1160; MALMBORG AC, 1992, SCAND J IMMUNOL, V35, P643, DOI 10.1111/j.1365-3083.1992.tb02970.x; PADLAN EA, 1985, ANN INST PASTEUR IMM, VC136, P271, DOI 10.1016/S0769-2625(85)80058-1; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; ROBERTS VA, 1994, J MOL BIOL, V235, P1098, DOI 10.1006/jmbi.1994.1060; SCHIFF C, 1986, J EXP MED, V163, P573, DOI 10.1084/jem.163.3.573; SCHULTZ PG, 1995, SCIENCE, V269, P835; Siskind G W, 1969, Adv Immunol, V10, P1, DOI 10.1016/S0065-2776(08)60414-9; SMILEY JA, 1994, P NATL ACAD SCI USA, V91, P8319, DOI 10.1073/pnas.91.18.8319; STEINER LA, 1967, J EXP MED, V126, P1143, DOI 10.1084/jem.126.6.1143; STRONG RK, 1991, BIOCHEMISTRY-US, V30, P3749, DOI 10.1021/bi00229a023; THERIAULT TP, 1991, J MOL BIOL, V221, P257; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; ULRICH HD, 1995, P NATL ACAD SCI USA, V92, P11907, DOI 10.1073/pnas.92.25.11907; VANVRANKEN DL, 1994, TETRAHEDRON LETT, V35, P3873, DOI 10.1016/S0040-4039(00)76689-5; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444; [No title captured]	47	198	205	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1086	1091		10.1126/science.271.5252.1086	http://dx.doi.org/10.1126/science.271.5252.1086			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599084	Green Submitted			2022-12-28	WOS:A1996TW70100029
J	Kenyon, TA; Valway, SE; Ihle, WW; Onorato, IM; Castro, KG				Kenyon, TA; Valway, SE; Ihle, WW; Onorato, IM; Castro, KG			Transmission of multidrug-resistant Mycobacterium tuberculosis during a long airplane flight	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. In April 1994, a passenger with infectious multidrug-resistant tuberculosis traveled on commercial-airline flights from Honolulu to Chicago and from Chicago to Baltimore and returned one month later, We sought to determine whether she had infected any of her contacts on this extensive trip. Methods. Passengers and crew were identified from airline records and were notified of their exposure, asked to complete a questionnaire, and screened by tuberculin skin tests. Results. Of the 925 people on the airplanes, 802 (86.7 percent) responded. All 11 contacts with positive tuberculin skin tests who were on the April flights and 2 of 3 contacts with positive tests who were on the Baltimore-to-Chicago flight in May had other risk factors for tuberculosis, More contacts on the final, 8.75-hour flight from Chicago to Honolulu had positive skin tests than those on the other three flights (6 percent, as compared with 2.3, 3.8, and 2.8 percent). Of 15 contacts with positive tests on the May flight from Chicago to Honolulu, 6 (4 with skin-test conversions) had no other risk factors; all 6 had sat in the same section of the plane as the index patient (P = 0.001). Passengers seated within two rows of the index patient were more likely to have positive tuberculin skin tests than those in the rest of the section (4 of 13, or 30.8 percent, vs. 2 of 55, or 3.6 percent; rate ratio, 8.5; 95 percent confidence interval, 7.7 to 41.3; P = 0.01). Conclusions. The transmission of Mycobacterium tuberculosis that we describe aboard a commercial aircraft involved a highly infectious passenger, a long flight, and close proximity of contacts to the index patient. (C) 1996, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,NATL CTR HIV STD & TB PREVENT,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA			Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				AMLER RW, 1982, JAMA-J AM MED ASSOC, V248, P2129, DOI 10.1001/jama.248.17.2129; BRADEN CR, 1995, CLIN INFECT DIS, V21, P565, DOI 10.1093/clinids/21.3.565; *CDC, 1987, DHHS PUBL, P95; Dean A.G., 1994, EPI INFO VERSION 6 W; DRIVER CR, 1994, JAMA-J AM MED ASSOC, V272, P1031, DOI 10.1001/jama.272.13.1031; HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P26, DOI 10.1080/00039896.1968.10665011; HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968; *IMM NAT SERV, 1994, STAT YB IMM NAT SERV; MCFARLAND JW, 1993, LANCET, V342, P112, DOI 10.1016/0140-6736(93)91311-9; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; MENZIES R, 1994, ANN INTERN MED, V120, P190, DOI 10.7326/0003-4819-120-3-199402010-00003; MILLER MA, 1993, M AM PUBL HLTH ASS E; MOSER MR, 1979, AM J EPIDEMIOL, V110, P1; *PHS, 1991, TECHN INSTR MED EX A; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; RITZINGER FR, 1965, AEROMED REV, V4, P1; ROSE CE, 1979, AM REV RESPIR DIS, V119, P603; THOMPSON NJ, 1979, AM REV RESPIR DIS, V119, P587; WILSON RA, 1994, TRANSPORTATION AM ST; 1995, MMWR-MORBID MORTAL W, V44, P387; 1992, AM REV RESPIR DIS, V146, P1623; 1995, MMWR-MORBID MORTAL W, V44, P137; 1992, MMWR-MORBID MORTAL W, V41, P59	23	263	271	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1996	334	15					933	938		10.1056/NEJM199604113341501	http://dx.doi.org/10.1056/NEJM199604113341501			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD596	8596593				2022-12-28	WOS:A1996UD59600001
J	Strick, TR; Allemand, JF; Bensimon, D; Bensimon, A; Croquette, V				Strick, TR; Allemand, JF; Bensimon, D; Bensimon, A; Croquette, V			The elasticity of a single supercoiled DNA molecule	SCIENCE			English	Article							TORSIONAL RIGIDITY; DEPOLARIZATION; MACROMOLECULES; FLUORESCENCE; ENERGETICS; DYNAMICS	Single linear DNA molecules were bound at multiple sites at one extremity to a treated glass cover slip and at the other to a magnetic bead. The DNA was therefore torsionally constrained, A magnetic field was used to rotate the beads and thus to coil and pull the DNA. The stretching force was determined by analysis of the Brownian fluctuations of the bead. Here, the elastic behavior of individual lambda DNA molecules over- and underwound by up to 500 turns was studied, A sharp transition was discovered from a low to a high extension state at a force of similar to 0.45 piconewtons for underwound molecules and at a force of similar to 3 piconewtons for overwound ones. These transitions, probably reflecting the formation of alternative structures in stretched coiled DNA molecules, might be relevant for DNA transcription and replication.	UNIV PARIS 07,ENS,PHYS STAT LAB,F-75231 PARIS 05,FRANCE; INST PASTEUR,ADN,BIOPHYS LAB,F-75015 PARIS,FRANCE	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Strick, TR (corresponding author), UNIV PARIS 06,ENS,PHYS STAT LAB,24 RUE LHOMOND,F-75231 PARIS 05,FRANCE.		Strick, Terence R/J-1886-2012; Bensimon, David/E-7768-2015	Bensimon, David/0000-0003-1971-9907; Allemand, Jean - Francois/0000-0001-7496-0977; Croquette, Vincent/0000-0003-1400-0039; Strick, Terence/0000-0003-1744-3679				ADRIAN M, 1990, EMBO J, V9, P4551, DOI 10.1002/j.1460-2075.1990.tb07907.x; ALLISON SA, 1979, CHEM PHYS, V41, P35, DOI 10.1016/0301-0104(79)80131-7; BARKLEY MD, 1979, J CHEM PHYS, V70, P2991, DOI 10.1063/1.437838; BEDNAR J, 1994, J MOL BIOL, V235, P825, DOI 10.1006/jmbi.1994.1042; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; FULLER FB, 1971, P NATL ACAD SCI USA, V68, P815, DOI 10.1073/pnas.68.4.815; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; KLENIN KV, 1995, BIOPHYS J, V68, P81, DOI 10.1016/S0006-3495(95)80161-X; Kornberg A., 1992, DNA REPLICATION; LANGOWSKI J, 1994, BIOPOLYMERS, V34, P639, DOI 10.1002/bip.360340506; MARKO JF, 1994, SCIENCE, V265, P506, DOI 10.1126/science.8036491; MARKO JF, 1995, PHYS REV E, V52, P2912, DOI 10.1103/PhysRevE.52.2912; MARKO JF, COMMUNICATION; MCCLELLAN JA, 1991, J MOL BIOL, V219, P145, DOI 10.1016/0022-2836(91)90555-K; MORSE RH, 1988, CELL, V54, P285, DOI 10.1016/0092-8674(88)90190-0; MURCHIE AIH, 1992, BIOCHIM BIOPHYS ACTA, V1131, P1, DOI 10.1016/0167-4781(92)90091-D; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SCHLICK T, 1992, J MOL BIOL, V223, P1089, DOI 10.1016/0022-2836(92)90263-J; SELVIN PR, 1992, SCIENCE, V255, P82, DOI 10.1126/science.1553534; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SIMON A, 1995, P INSTRUMENTATION PH, P93; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; VINOGRAD J, 1965, P NATL ACAD SCI USA, V53, P1104, DOI 10.1073/pnas.53.5.1104; VOLOGODSKII A, 1994, MACROMOLECULES, V27, P5623, DOI 10.1021/ma00098a016; VOLOGODSKII AV, 1992, J MOL BIOL, V227, P1224, DOI 10.1016/0022-2836(92)90533-P; VOLOGODSKII AV, 1994, ANNU REV BIOPH BIOM, V23, P609, DOI 10.1146/annurev.bb.23.060194.003141; WHITE JH, 1969, AM J MATH, V91, P693, DOI 10.2307/2373348; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653	34	1001	1030	4	164	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1835	1837		10.1126/science.271.5257.1835	http://dx.doi.org/10.1126/science.271.5257.1835			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596951				2022-12-28	WOS:A1996UC77800037
J	Hall, SL; Padgett, RA				Hall, SL; Padgett, RA			Requirement of U12 snRNA for in vivo splicing of a minor class of eukaryotic nuclear pre-mRNA introns	SCIENCE			English	Article							COMPENSATORY BASE CHANGE; MESSENGER-RNA; SITE SELECTION; U6 SNRNA; PAIRING INTERACTION; U2 SNRNP; YEAST; RIBONUCLEOPROTEINS; INVITRO; SPLICEOSOME	A conserved sequence element in a minor class of eukaryotic pre-messenger RNA (pre-mRNA) introns was previously proposed to base pair with a complementary sequence in the U12 small nuclear RNA (snRNA) in a manner analogous to the pairing of U2 snRNA with the branch site sequence of the major class of introns. Here, mutations generated in this conserved sequence element block the splicing of a member of this minor intron class in vivo. This block was relieved by coexpression of a U12 snRNA containing compensatory mutations that restore the proposed base pairing interaction, These results show that this minor class of pre-mRNA introns is a distinct class existing alongside the major class of introns in animal genomes, and these results also establish an in vivo function for U12 snRNA.	CLEVELAND CLIN FDN,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045371] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM45371] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Baserga S., 1993, RNA WORLD, P359; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; MADHANI HD, 1994, GENE DEV, V8, P1071, DOI 10.1101/gad.8.9.1071; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MATERA AG, 1993, J CELL BIOL, V121, P715, DOI 10.1083/jcb.121.4.715; MONTZKA KA, 1988, P NATL ACAD SCI USA, V85, P8885, DOI 10.1073/pnas.85.23.8885; NELSON KK, 1989, GENE DEV, V3, P1562, DOI 10.1101/gad.3.10.1562; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PADGETT RA, 1985, P NATL ACAD SCI USA, V82, P8349, DOI 10.1073/pnas.82.24.8349; PADGETT RA, 1984, SCIENCE, V225, P898, DOI 10.1126/science.6206566; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; QUERY CC, 1994, GENE DEV, V8, P587, DOI 10.1101/gad.8.5.587; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; RUSKIN B, 1985, CELL, V41, P833, DOI 10.1016/S0092-8674(85)80064-7; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SUN JS, 1995, GENE DEV, V9, P843, DOI 10.1101/gad.9.7.843; TARN WY, 1995, RNA, V1, P644; TARN WY, IN PRESS CELL; WASSARMAN KM, 1992, MOL CELL BIOL, V12, P1276, DOI 10.1128/MCB.12.3.1276; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	29	169	170	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1716	1718		10.1126/science.271.5256.1716	http://dx.doi.org/10.1126/science.271.5256.1716			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596930				2022-12-28	WOS:A1996UB15100043
J	Mebatsion, T; Konig, M; Conzelmann, KK				Mebatsion, T; Konig, M; Conzelmann, KK			Budding of rabies virus particles in the absence of the spike glycoprotein	CELL			English	Article							VESICULAR STOMATITIS-VIRUS; MATRIX PROTEIN; INSECT CELLS; MEMBRANE; GENE; PRECURSOR; SEQUENCES; RNA	Budding of enveloped viruses from cellular membranes is believed to depend on the presence of transmembrane spike proteins interacting with cytoplasmic virus components. To address the mechanism of rhabdovirus budding, we generated rabies virus mutants deficient for the glycoprotein G or the G cytoplasmic tail. We found that spikeless rhabdovirus particles were released from cells infected with the G-deficient mutant, demonstrating that a viral surface protein is not required to drive the budding process. However, particle production is enhanced approximately B-fold and 30-fold in the presence of tailless G or G, respectively. This reveals that G also possesses an intrinsic and independent exocytosis activity. We propose a model according to which efficient budding of rhabdoviruses is achieved by a concerted action of both core and spike proteins.	UNIV GIESSEN,INST VIROL,D-35392 GIESSEN,GERMANY	Justus Liebig University Giessen	Mebatsion, T (corresponding author), FED RES CTR VIRUS DIS ANIM,INST CLIN VIROL,PAUL EHRLICH STR 28,D-72076 TUBINGEN,GERMANY.		Conzelmann, Karl-Klaus/L-7239-2013	Conzelmann, Karl-Klaus/0000-0002-8614-3656				ANILIONIS A, 1981, NATURE, V294, P275, DOI 10.1038/294275a0; BRUSS V, 1991, P NATL ACAD SCI USA, V88, P1059, DOI 10.1073/pnas.88.3.1059; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CHONG LD, 1994, J VIROL, V68, P441, DOI 10.1128/JVI.68.1.441-447.1994; CHONG LD, 1993, J VIROL, V67, P407, DOI 10.1128/JVI.67.1.407-414.1993; CONZELMANN KK, 1991, VIROLOGY, V184, P655, DOI 10.1016/0042-6822(91)90435-E; CONZELMANN KK, 1994, J VIROL, V68, P713, DOI 10.1128/JVI.68.2.713-719.1994; CONZELMANN KK, 1990, VIROLOGY, V175, P485, DOI 10.1016/0042-6822(90)90433-R; DELCHAMBRE M, 1989, EMBO J, V8, P2653, DOI 10.1002/j.1460-2075.1989.tb08405.x; DONG JY, 1992, J VIROL, V66, P7374, DOI 10.1128/JVI.66.12.7374-7382.1992; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAUDIN Y, 1991, VIROLOGY, V184, P441, DOI 10.1016/0042-6822(91)90866-A; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; HUNTER E, 1994, SEMIN VIROL, V5, P71, DOI 10.1006/smvy.1994.1008; JIN H, 1994, EMBO J, V13, P5504, DOI 10.1002/j.1460-2075.1994.tb06885.x; JUSTICE PA, 1995, J VIROL, V69, P3156, DOI 10.1128/JVI.69.5.3156-3160.1995; Kessler S W, 1981, Methods Enzymol, V73, P442; LAWSON ND, 1995, P NATL ACAD SCI USA, V92, P4477, DOI 10.1073/pnas.92.10.4477; LI Y, 1993, J VIROL, V67, P4415, DOI 10.1128/JVI.67.7.4415-4420.1993; MEBATSION T, 1995, J VIROL, V69, P1444, DOI 10.1128/JVI.69.3.1444-1451.1995; METSIKKO K, 1986, EMBO J, V5, P1913, DOI 10.1002/j.1460-2075.1986.tb04444.x; OWENS RJ, 1993, J VIROL, V67, P360, DOI 10.1128/JVI.67.1.360-365.1993; RHEE SS, 1990, J VIROL, V64, P3844, DOI 10.1128/JVI.64.8.3844-3852.1990; ROLLS MM, 1994, CELL, V79, P497, DOI 10.1016/0092-8674(94)90258-5; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; SCHNEIDER LG, 1981, REPLICATION NEGATIVE, P947; SCHNELL MJ, 1994, EMBO J, V13, P4195, DOI 10.1002/j.1460-2075.1994.tb06739.x; SIMONS K, 1980, J GEN VIROL, V50, P1, DOI 10.1099/0022-1317-50-1-1; SOKOL F, 1968, J VIROL, V2, P836, DOI 10.1128/JVI.2.8.836-849.1968; SUOMALAINEN M, 1992, J VIROL, V66, P4737, DOI 10.1128/JVI.66.8.4737-4747.1992; WHELAN SPJ, 1995, P NATL ACAD SCI USA, V92, P8388, DOI 10.1073/pnas.92.18.8388; WHITT MA, 1989, J VIROL, V63, P3569, DOI 10.1128/JVI.63.9.3569-3578.1989; WHITT MA, 1991, VIROLOGY, V185, P681, DOI 10.1016/0042-6822(91)90539-N; WUNNER WH, 1985, ANN INST PASTEUR VIR, V136E, P353, DOI 10.1016/S0769-2617(85)80127-1; ZAVADA J, 1982, J GEN VIROL, V63, P15, DOI 10.1099/0022-1317-63-1-15; ZHAO HX, 1994, EMBO J, V13, P4204, DOI 10.1002/j.1460-2075.1994.tb06740.x	37	216	249	2	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					941	951		10.1016/S0092-8674(00)81072-7	http://dx.doi.org/10.1016/S0092-8674(00)81072-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601317	Bronze			2022-12-28	WOS:A1996UC38100015
J	Self, DW; Barnhart, WJ; Lehman, DA; Nestler, EJ				Self, DW; Barnhart, WJ; Lehman, DA; Nestler, EJ			Opposite modulation of cocaine-seeking behavior by D-1- and D-2-like dopamine receptor agonists	SCIENCE			English	Article							SELF-ADMINISTRATION BEHAVIOR; VENTRAL TEGMENTAL AREA; RHESUS-MONKEYS; RAT; REINSTATEMENT; BROMOCRIPTINE; HEROIN; AMPHETAMINE; INVOLVEMENT; INJECTIONS	Activation of the mesolimbic dopamine system is known to trigger relapse in animal models of cocaine-seeking behavior. We found that this ''priming'' effect was selectively induced by D-2-like, and not by D-1-like, dopamine receptor agonists in rats. Moreover, D-1-like receptor agonists prevented cocaine-seeking behavior induced by cocaine itself, whereas D-1-like receptor agonists enhanced this behavior, These results demonstrate an important dissociation between D-1- and D-2-like receptor processes in cocaine-seeking behavior and support further evaluation of D-1-like receptor agonists as a possible pharmacotherapy for cocaine addiction.	YALE UNIV, SCH MED, CONNECTICUT MENTAL HLTH CTR, DEPT PHARMACOL, NEW HAVEN, CT 06508 USA	Yale University	Self, DW (corresponding author), YALE UNIV, SCH MED, CONNECTICUT MENTAL HLTH CTR, DEPT PSYCHIAT, LAB MOLEC PSYCHIAT, NEW HAVEN, CT 06508 USA.							ANDERSEN PH, 1990, EUR J PHARM-MOLEC PH, V188, P335, DOI 10.1016/0922-4106(90)90194-3; BELMAKER RH, 1977, BRIT J PSYCHIAT, V131, P222, DOI 10.1192/bjp.131.2.222b; CAINE SB, 1993, SCIENCE, V260, P1814, DOI 10.1126/science.8099761; CALLAHAN PM, 1991, PSYCHOPHARMACOLOGY, V103, P50, DOI 10.1007/BF02244073; CHILDRESS AR, 1988, NIDA RES MONOGR, P137; DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175; EHRMAN RN, 1992, PSYCHOPHARMACOLOGY, V107, P523, DOI 10.1007/BF02245266; FREEDMAN JE, 1995, TRENDS PHARMACOL SCI, V272, pR1; GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GOEDERS NE, 1983, SCIENCE, V221, P773, DOI 10.1126/science.6879176; HUBNER CB, 1990, NEUROPSYCHOPHARMACOL, V3, P101; JAFFE JH, 1989, PSYCHOPHARMACOLOGY, V97, P59, DOI 10.1007/BF00443414; JOHANSON C, 1995, PSYCHOPHARMACOLOGY 4; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KLEVEN MS, 1990, PSYCHOPHARMACOLOGY, V101, P208, DOI 10.1007/BF02244128; LARGE CH, 1994, TRENDS PHARMACOL SCI, V15, P46, DOI 10.1016/0165-6147(94)90108-2; LEVESQUE D, 1992, P NATL ACAD SCI USA, V89, P8155, DOI 10.1073/pnas.89.17.8155; MISERENDINO MJD, 1993, MOL CELL NEUROSCI, V4, P440, DOI 10.1006/mcne.1993.1055; PRESTON KL, 1992, J PHARMACOL EXP THER, V262, P279; ROBERTS DCS, 1977, PHARMACOL BIOCHEM BE, V6, P615, DOI 10.1016/0091-3057(77)90084-3; ROBERTS DCS, 1980, PHARMACOL BIOCHEM BE, V12, P781, DOI 10.1016/0091-3057(80)90166-5; SATEL S, 1992, CLIN GUIDE COCAINE A, P172; SELF DW, 1995, SYNAPSE, V21, P312, DOI 10.1002/syn.890210405; SELF DW, 1992, BRAIN RES, V582, P349, DOI 10.1016/0006-8993(92)90155-3; SHIPPENBERG TS, 1991, PSYCHOPHARMACOLOGY, V103, P209, DOI 10.1007/BF02244205; SHIPPENBERG TS, 1987, BRAIN RES, V436; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SIRIS SG, 1991, SCHIZOPHRENIA BULL, V17, P75, DOI 10.1093/schbul/17.1.75; SNYDER SH, 1981, P NATL ACAD SCI-BIOL, V78, P3260, DOI 10.1073/pnas.78.5.3260; SPEALMAN RD, 1991, J PHARMACOL EXP THER, V258, P945; STEWART J, 1988, BRAIN RES, V457, P287, DOI 10.1016/0006-8993(88)90698-1; STEWART J, 1984, PHARMACOL BIOCHEM BE, V20, P917, DOI 10.1016/0091-3057(84)90017-0; TSURUTA K, 1981, NATURE, V292, P463, DOI 10.1038/292463a0; WEED MR, 1993, PSYCHOPHARMACOLOGY, V113, P51, DOI 10.1007/BF02244333; WISE RA, 1990, PSYCHOPHARMACOLOGY, V100, P355, DOI 10.1007/BF02244606; WITKIN JM, 1991, J PHARMACOL EXP THER, V257, P706	37	418	424	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1996	271	5255					1586	1589		10.1126/science.271.5255.1586	http://dx.doi.org/10.1126/science.271.5255.1586			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599115				2022-12-28	WOS:A1996TZ98300042
J	Sherertz, RJ; Reagan, DR; Hampton, KD; Robertson, KL; Streed, SA; Hoen, HM; Thomas, R; Gwaltney, JM				Sherertz, RJ; Reagan, DR; Hampton, KD; Robertson, KL; Streed, SA; Hoen, HM; Thomas, R; Gwaltney, JM			A cloud adult: The Staphylococcus aureus - Virus interaction revisited	ANNALS OF INTERNAL MEDICINE			English	Article							NEWBORN NURSERY; MOLECULAR EPIDEMIOLOGY; BACTERIAL ADHERENCE; GEL-ELECTROPHORESIS; NASAL CARRIAGE; CARE UNIT; OUTBREAK; INFECTION; SPREAD; COLDS	Background: Nasal carriage of Staphylococcus aureus is common among health care workers, but outbreaks caused by such carriers are relatively uncommon. We previously reported outbreaks of S. aureus skin infections that affected newborn infants and were attributed to an S. aureus nasa I carrier who had had an associated upper respiratory tract infection (URI) during the outbreak period. Objective: To investigate the contribution of a nasal methicillin-resistant S. aureus (MRSA) carrier (physician 4) who contracted a URI to an outbreak of MRSA infections that involved 8 of 43 patients in a surgical intensive care unit during a 3-week period. Design: An epidemiologic study of an outbreak of MRSA infections and a quantitative investigation of airborne dispersal of S. aureus associated with an experimentally induced rhinoviral Infection. Setting: A university hospital. Participants: 43 patients in a surgical intensive care unit and 1 physician. Measurements: Molecular typing was done, and risk factors for MRSA colonization were analyzed. Agar settle plates and volumetric air cultures were used to evaluate the airborne dispersal of S. aureus by physician 4 before and after a rhinoviral infection and with or without a surgical mask. Results: A search for nasal carriers of MRSA identified a single physician (physician 4); molecular typing showed that the MRSA strain from physician 4 and those from the patients were identical. Multivariate logistic regression analysis identified exposure to physician 4 and duration of ventilation as independent risk factors for colonization with MRSA (P less than or equal to 0.008). Air cultures showed that physician 4 dispersed little S. aureus in the absence of a URI. After experimental induction of a rhinovirus URI, physician 4's airborne dispersal of S. aureus without a surgical mask increased 40-fold; dispersal was significantly reduced when physician 4 wore a mask (P less than or equal to 0.015). Conclusions: Physician 4 became a ''cloud adult,'' analogous to the ''cloud babies'' described by Eichenwald and coworkers who shed S. aureus into the air in association with viral URIs. Airborne dispersal of S. aureus in association with a URI may be an important mechanism of transmission of S. aureus.	E TENNESSEE STATE UNIV, JAMES H QUILLEN COLL MED, JOHNSON CITY, TN 37614 USA; N CAROLINA BAPTIST HOSP INC, WINSTON SALEM, NC USA; UNIV VIRGINIA, SCH MED, CHARLOTTESVILLE, VA USA	East Tennessee State University; Wake Forest University; Wake Forest Baptist Medical Center; University of Virginia	Sherertz, RJ (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.							BACK NA, 1993, JAMA-J AM MED ASSOC, V270, P1329, DOI 10.1001/jama.270.11.1329; BARRY AL, 1991, AM SOC MICROBIOLOGY, V11, P17; BELANI A, 1986, INFECT CONT HOSP EP, V7, P487, DOI 10.1017/S0195941700065097; BETHUNE DW, 1965, LANCET, V1, P480; BIBEL DJ, 1982, J INVEST DERMATOL, V79, P250, DOI 10.1111/1523-1747.ep12500072; BOYCE JM, 1993, CLIN INFECT DIS, V17, P496, DOI 10.1093/clinids/17.3.496; BOYCE JM, 1983, JAMA-J AM MED ASSOC, V249, P2803, DOI 10.1001/jama.249.20.2803; CHOWDHURY MNH, 1992, J HOSP INFECT, V22, P299, DOI 10.1016/0195-6701(92)90015-E; COOVADIA YM, 1989, J HOSP INFECT, V14, P303, DOI 10.1016/0195-6701(89)90070-4; DANCER SJ, 1988, J INFECTION, V16, P87, DOI 10.1016/S0163-4453(88)96249-4; DANCER SJ, 1990, J INFECTION, V20, P73, DOI 10.1016/S0163-4453(90)92434-M; DUNKLE LM, 1981, AM J MED, V70, P455, DOI 10.1016/0002-9343(81)90787-7; EICHENWALD HF, 1960, AM J DIS CHILD, V100, P161, DOI 10.1001/archpedi.1960.04020040163003; Fa W., 1995, PRINCIPLES PRACTICES, V4, P1754; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GAYNES R, 1991, J INFECT DIS, V163, P117, DOI 10.1093/infdis/163.1.117; GOERING RV, 1990, J CLIN MICROBIOL, V28, P426, DOI 10.1128/JCM.28.3.426-429.1990; GOERING RV, 1993, INFECT CONT HOSP EP, V14, P595; GWALTNEY JM, 1978, ANN INTERN MED, V88, P463, DOI 10.7326/0003-4819-88-4-463; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; GWALTNEY JM, 1975, J INFECT DIS, V132, P62, DOI 10.1093/infdis/132.1.62; GWALTNEY JM, 1982, UPPER AIRWAY PHYSL A, P399; HALEY RW, 1982, J INFECT DIS, V145, P875, DOI 10.1093/infdis/145.6.875; HAMRE D, 1966, AM J EPIDEMIOL, V83, P238, DOI 10.1093/oxfordjournals.aje.a120579; HARE R, 1956, BMJ-BRIT MED J, V2, P840, DOI 10.1136/bmj.2.4997.840; HEDBERG K, 1990, PEDIATR INFECT DIS J, V9, P268, DOI 10.1097/00006454-199004000-00009; HOEGER PH, 1988, PEDIATR INFECT DIS J, V7, P340, DOI 10.1097/00006454-198805000-00010; HUIJSMANSEVERS AGM, 1978, ARCH CHIR NEERL, V30, P141; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; KINSMAN OS, 1983, J MED MICROBIOL, V16, P215, DOI 10.1099/00222615-16-2-215; KNIGHT V, 1964, PROG MED VIROL, V6, P1; LIANOU P, 1989, ACTA DERM-VENEREOL, V69, P330; LIPSKY BA, 1987, DIABETES CARE, V10, P483, DOI 10.2337/diacare.10.4.483; MULLIGAN ME, 1993, AM J MED, V94, P313, DOI 10.1016/0002-9343(93)90063-U; NAHMIAS AJ, 1960, JAMA-J AM MED ASSOC, V174, P1269, DOI 10.1001/jama.1960.03030100037009; NAKASHIMA AK, 1984, INFECT CONT HOSP EP, V5, P326, DOI 10.1017/S0195941700060513; NICHOL KP, 1967, NEW ENGL J MED, V277, P667, DOI 10.1056/NEJM196709282771301; PEACOCK JE, 1980, ANN INTERN MED, V93, P526, DOI 10.7326/0003-4819-93-4-526; REAGAN DR, 1991, ANN INTERN MED, V114, P101, DOI 10.7326/0003-4819-114-2-101; RICHARDSON JF, 1990, J HOSP INFECT, V16, P109, DOI 10.1016/0195-6701(90)90055-S; Sahm D.H., 1991, MANUAL CLIN MICROBIO; SANFORD BA, 1987, P SOC EXP BIOL MED, V185, P120; SINGH G, 1978, DERMATOLOGICA, V157, P21, DOI 10.1159/000250804; STONE AA, 1992, BEHAV MED, V18, P115, DOI 10.1080/08964289.1992.9936961; TANNER EI, 1980, J HYG-CAMBRIDGE, V85, P219, DOI 10.1017/S0022172400063257; THOMPSON RL, 1982, ANN INTERN MED, V97, P309, DOI 10.7326/0003-4819-97-3-309; WHITE A, 1961, J LAB CLIN MED, V58, P273; WILLIAMS RE, 1963, BACTERIOL REV, V27, P56, DOI 10.1128/MMBR.27.1.56-71.1963; WINKLER J, 1990, J INFECT DIS, V162, P1400, DOI 10.1093/infdis/162.6.1400	49	149	159	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1996	124	6					539	+		10.7326/0003-4819-124-6-199603150-00001	http://dx.doi.org/10.7326/0003-4819-124-6-199603150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ529	8597316				2022-12-28	WOS:A1996TZ52900001
J	Dib, C; Faure, S; Fizames, C; Samson, D; Drouot, N; Vignal, A; Millasseau, P; Marc, S; Hazan, J; Seboun, E; Lathrop, M; Gyapay, G; Morissette, J; Weissenbach, J				Dib, C; Faure, S; Fizames, C; Samson, D; Drouot, N; Vignal, A; Millasseau, P; Marc, S; Hazan, J; Seboun, E; Lathrop, M; Gyapay, G; Morissette, J; Weissenbach, J			A comprehensive genetic map of the human genome based on 5,264 microsatellites	NATURE			English	Article								The great increase in successful linkage studies in a number of higher eukaryotes during recent years has essentially resulted from major improvements in reference genetic linkage maps(1-6), which at present consist of short tandem repeat polymorphisms of simple sequences or microsatellites(7,8). We report here the last version of the Genethon human linkage map(6). This map consists of 5,264 short tandem (AC/TG)(n) repeat polymorphisms with a mean heterozygosity of 70%. The map spans a sex-averaged genetic distance of 3,699 cM and comprises 2,335 positions, of which 2,032 could be ordered with an odds ratio of at least 1,000:1 against alternative orders. The average interval size is 1.6 cM; 59% of the map is covered by intervals of 2 cM at most and 1% remains in intervals above 10 cM.	GENETHON SA,F-91000 EVRY,FRANCE; CNRS,URA 1922,F-91000 EVRY,FRANCE; HOP ST LOUIS,INSERM,U358,PARIS,FRANCE; CHU LAVAL,CTR RECH,QUEBEC CITY,PQ G1V 4G2,CANADA	Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Laval University			Vignal, Alain/I-6253-2017	Vignal, Alain/0000-0002-6797-2125; Hazan, Jamile/0000-0001-8119-0325; Fizames, Cecile/0000-0002-0551-8250; Steinbach, Delphine/0000-0001-7144-7908				BARENDSE W, 1994, NAT GENET, V6, P227, DOI 10.1038/ng0394-227; CHUMAKOV IM, 1995, NATURE, V377, P175; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; ELSNER TI, 1995, AM J HUM GENET, V56, P500; GERKEN SC, 1995, AM J HUM GENET, V56, P484; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JACOB HJ, 1995, NAT GENET, V9, P63, DOI 10.1038/ng0195-63; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LATHROP GM, 1988, GENOMICS, V2, P157; LITT M, 1989, AM J HUM GENET, V44, P397; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; PLAETKE R, 1995, AM J HUM GENET, V56, P508; Spurr N. K., 1994, European Journal of Human Genetics, V2, P193; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; 1995, AM J HUM GENET, V57, P619	21	2675	2781	1	51	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					152	154		10.1038/380152a0	http://dx.doi.org/10.1038/380152a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600387				2022-12-28	WOS:A1996TZ97800048
J	Weaver, WD; White, HD; Wilcox, RG; Aylward, PE; Morris, D; Guerci, A; Ohman, M; Barbash, GI; Betriu, A; Sadowski, Z; Topol, EJ; Califf, RM				Weaver, WD; White, HD; Wilcox, RG; Aylward, PE; Morris, D; Guerci, A; Ohman, M; Barbash, GI; Betriu, A; Sadowski, Z; Topol, EJ; Califf, RM			Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEX-RELATED DIFFERENCES; GENDER DIFFERENCES; MORTALITY; PROGNOSIS; MORBIDITY; SURVIVAL; DISEASE; STROKE	Objective.-To compare baseline characteristics, complications, and treatment-specific outcomes of women and men with acute myocardial infarction treated with thrombolytic therapy. Design.-Randomized controlled trial. Patients and Setting.-A total of 10 315 women and 30 706 men with acute myocardial infarction treated in 1081 hospitals in 15 countries as part of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I). Intervention.-One of four thrombolytic regimens: (1) streptokinase with subcutaneous heparin; (2) streptokinase with intravenous heparin; (3) streptokinase plus alteplase (tissue-type plasminogen activator) with intravenous heparin; or (4) accelerated alteplase with intravenous heparin. Main Outcome Measures.-Mortality, stroke, and nonfatal complications during 30-day follow-up. Results.-Women were on average 7 years older than men and delayed 18 minutes (median) longer after symptom onset before presenting to the hospital. After adjustment for age, women more often had a history of diabetes, hypertension, and smoking than men. Time to treatment was significantly longer in women (1.2 vs 1.0 hours; P<.001). Women had more nonfatal complications after treatment, including shock (9% vs 5%; P<.001), congestive heart failure (22% vs 14%; P<.001), serious bleeding (15% vs 7%; P<.001), and reinfarction (5.1% vs 3.6%; P<.001). Women had twice as many total strokes as men (2.1% vs 1.2%; P<.001), secondary to their older age at presentation. The unadjusted mortality rate was twice as high in women as men (11.3% vs 5.5%; P<.001); the relative risk (RR) of death was greater among women than men after adjustment for differences in baseline characteristics (RR=1.15; 95% confidence interval, 1.0 to 1.31). Although women and men underwent angiography at similar rates, there were small but significant differences in their rates of revascularization procedures (angioplasty: 35% of women and 32% of men; bypass surgery: 7% of women and 9% of men; P<.001 for both). The higher rate of stroke in women after treatment with alteplase (2.0% vs 1.9% with streptokinase and intravenous heparin) was offset by a greater relative reduction in mortality (10.3% vs 11.1%). Conclusion.-Women who received thrombolytic therapy for treatment of acute myocardial infarction were at greater risk for both fatal and nonfatal complications than men.	GREEN LANE HOSP, DEPT CARDIOL, AUCKLAND 3, NEW ZEALAND; QUEENS MED CTR, DEPT MED, NOTTINGHAM NG7 2UH, ENGLAND; FLINDERS CARDIOVASC CTR, DEPT CARDIOVASC MED, ADELAIDE, SA, AUSTRALIA; EMORY UNIV, EMORY CLIN, ATLANTA, GA 30322 USA; ST FRANCIS HOSP, DEPT MED, ROSLYN, NY USA; DUKE UNIV, MED CTR, DIV CARDIOL, DURHAM, NC 27710 USA; TEL AVIV SOURASKY UNIV, MED CTR, DEPT MED, TEL AVIV, ISRAEL; HOSP CLIN 1, BARCELONA, SPAIN; INST KARDIOL, ISCHEM HEART DIS DEPT, WARSAW, POLAND; CLEVELAND CLIN FDN, DEPT CARDIOL, CLEVELAND, OH 44195 USA	University of Nottingham; Emory University; Duke University; Tel Aviv University; Sackler Faculty of Medicine; Institute of Cardiology - Poland; Cleveland Clinic Foundation	Weaver, WD (corresponding author), UNIV WASHINGTON, MITI COORDINATING CTR, DIV CARDIOL RG22, 1910 FAIRVIEW AVE E, SUITE 205, SEATTLE, WA 98102 USA.			Aylward, Philip/0000-0002-5358-8552; Topol, Eric/0000-0002-1478-4729; Wilcox, Robert/0000-0001-9911-8743				APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BEHAR S, 1992, EUR HEART J, V13, P45, DOI 10.1093/oxfordjournals.eurheartj.a060046; CHIRIBOGA DE, 1993, AM J CARDIOL, V71, P268, DOI 10.1016/0002-9149(93)90789-F; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; GOMEZMARIN O, 1987, NEW ENGL J MED, V316, P1353, DOI 10.1056/NEJM198705283162201; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HIGGINBOTHAM MB, 1984, CIRCULATION, V70, P357, DOI 10.1161/01.CIR.70.3.357; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LINCOFF AM, 1993, J AM COLL CARDIOL, V22, P1780, DOI 10.1016/0735-1097(93)90757-R; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MAYNARD C, 1993, CARDIOL ELDER, V1, P121; MAYNARD C, 1992, J MYOCARD ISCHEMIA, V4, P27; MAZEIKA PK, 1994, EUR HEART J, V15, P17, DOI 10.1093/oxfordjournals.eurheartj.a060373; MUELLER HS, 1992, CIRCULATION, V85, P1254, DOI 10.1161/01.CIR.85.4.1254; PULETTI M, 1984, AM HEART J, V108, P63, DOI 10.1016/0002-8703(84)90545-3; Ridolfo Buno, 1993, Journal of the American College of Cardiology, V21, p238A; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOFLER GH, 1989, AM J CARDIOL, V64, P256, DOI 10.1016/0002-9149(89)90476-1; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VASAN RS, 1995, J AM COLL CARDIOL, V26, P1565, DOI 10.1016/0735-1097(95)00381-9; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WEAVER WD, 1992, CIRCULATION, V86, P16; WHITE HD, 1993, CIRCULATION, V88, P2097, DOI 10.1161/01.CIR.88.5.2097	29	206	213	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1996	275	10					777	782		10.1001/jama.275.10.777	http://dx.doi.org/10.1001/jama.275.10.777			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY886	8598594				2022-12-28	WOS:A1996TY88600025
J	vanderWal, G; OnwuteakaPhilipsen, BD				vanderWal, G; OnwuteakaPhilipsen, BD			Cases of euthanasia and assisted suicide reported to the public prosecutor in North Holland over 10 years	BRITISH MEDICAL JOURNAL			English	Article									VRIJE UNIV AMSTERDAM,INST RES EXTRAMURAL MED,1081 BT AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam								VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; VANDERWAL G, 1992, EUTHANASIA ASSISTED	2	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					612	613						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595336				2022-12-28	WOS:A1996TZ84000026
J	Tishkoff, SA; Dietzsch, E; Speed, W; Pakstis, AJ; Kidd, JR; Cheung, K; BonneTamir, B; SantachiaraBenerecetti, AS; Moral, P; Krings, M; Paabo, S; Watson, E; Risch, N; Jenkins, T; Kidd, KK				Tishkoff, SA; Dietzsch, E; Speed, W; Pakstis, AJ; Kidd, JR; Cheung, K; BonneTamir, B; SantachiaraBenerecetti, AS; Moral, P; Krings, M; Paabo, S; Watson, E; Risch, N; Jenkins, T; Kidd, KK			Global patterns of linkage disequilibrium at the CD4 locus and modern human origins	SCIENCE			English	Article							HUMAN MITOCHONDRIAL-DNA; STEPWISE MUTATION MODEL; HUMAN-EVOLUTION; HUMAN-POPULATIONS; TRANSGENIC MICE; CONTROL REGION; SEQUENCES; POLYMORPHISMS; EXPRESSION; SCALE	Haplotypes consisting of alleles at a short tandem repeat polymorphism (STRP) and an Alu deletion polymorphism at the CD4 locus on chromosome 12 were analyzed in more than 1600 individuals sampled from 42 geographically dispersed populations (13 African, 2 Middle Eastern, 7 European, 9 Asian, 3 Pacific, and 8 Amerindian). Sub-Saharan African populations had more haplotypes and exhibited more variability in frequencies of haplotypes than the Northeast African or non-African populations. The Alu deletion was nearly always associated with a single STRP allele in non-African and Northeast African populations but was associated with a wide range of STRP alleles in the sub-Saharan African populations. This global pattern of haplotype variation and linkage disequilibrium suggests a common and recent African origin for all non-African human populations.	S AFRICAN INST MED RES,SCH PATHOL,DEPT HUMAN GENET,JOHANNESBURG 2000,SOUTH AFRICA; UNIV WITWATERSRAND,JOHANNESBURG 2000,SOUTH AFRICA; TEL AVIV UNIV,SACKLER FAC MED,DEPT HUMAN GENET,IL-69978 RAMAT AVIV,ISRAEL; UNIV PAVIA,DIPARTIMENTO GENET & MICROBIOL A BUZZATI TRAVERSO,I-27100 PAVIA,ITALY; UNIV BARCELONA,DEPT ANIM BIOL,E-08028 BARCELONA,SPAIN; UNIV MUNICH,INST ZOOL,D-80021 MUNICH,GERMANY; MASSEY UNIV,SCH BIOL SCI,PALMERSTON NORTH,NEW ZEALAND; UNIV MUNICH,INST ZOOL,D-80333 MUNICH 2,GERMANY; STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305	University of Witwatersrand; Tel Aviv University; Sackler Faculty of Medicine; University of Pavia; University of Barcelona; University of Munich; Massey University; University of Munich; Stanford University	Tishkoff, SA (corresponding author), YALE UNIV,SCH MED,DEPT GENET,333 CEDAR ST,NEW HAVEN,CT 06520, USA.		Klein, Richard G/B-5910-2009; Moral, Pedro/K-9587-2014	Moral, Pedro/0000-0001-5072-5892	NHGRI NIH HHS [HG00348] Funding Source: Medline; NIAAA NIH HHS [AA09379] Funding Source: Medline; NIMH NIH HHS [MH39239] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039239, R01MH039239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009379] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AYALA FJ, 1994, P NATL ACAD SCI USA, V91, P6787, DOI 10.1073/pnas.91.15.6787; BATZER MA, 1994, P NATL ACAD SCI USA, V91, P12288, DOI 10.1073/pnas.91.25.12288; BENGTSSON BO, 1981, TISSUE ANTIGENS, V18, P356, DOI 10.1111/j.1399-0039.1981.tb01404.x; BLUM MD, 1993, J EXP MED, V177, P1343, DOI 10.1084/jem.177.5.1343; Bowcock A M, 1991, Gene Geogr, V5, P151; BOWCOCK AM, 1991, P NATL ACAD SCI USA, V88, P839, DOI 10.1073/pnas.88.3.839; BOWCOCK AM, 1994, NATURE, V368, P455, DOI 10.1038/368455a0; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CASTIGLIONE CM, 1995, AM J HUM GENET, V57, P1445; CAVALLISFORZA LL, 1988, P NATL ACAD SCI USA, V85, P6002, DOI 10.1073/pnas.85.16.6002; DEKA R, 1995, AM J HUM GENET, V56, P461; DIRIENZO A, 1991, P NATL ACAD SCI USA, V88, P1597, DOI 10.1073/pnas.88.5.1597; DIRIENZO A, 1994, P NATL ACAD SCI USA, V91, P3166, DOI 10.1073/pnas.91.8.3166; DORIT RL, 1995, SCIENCE, V268, P1183, DOI 10.1126/science.7761836; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; EDWARDS MC, 1991, NUCLEIC ACIDS RES, V19, P4791, DOI 10.1093/nar/19.17.4791-a; EDWARDS MC, 1992, GENOMICS, V14, P590, DOI 10.1016/S0888-7543(05)80156-9; GILLESPIE FP, 1993, MOL CELL BIOL, V13, P2952, DOI 10.1128/MCB.13.5.2952; GOLDSTEIN DB, 1995, P NATL ACAD SCI USA, V92, P6723, DOI 10.1073/pnas.92.15.6723; GOLDSTEIN DB, 1995, GENETICS, V139, P463; GOODFELLOW PN, 1995, NATURE, V378, P379; HAKIM I, 1990, PLURIDISCIPLINARY AP, P43; HAMMER MF, 1995, NATURE, V378, P376, DOI 10.1038/378376a0; HARPENDING HC, 1993, CURR ANTHROPOL, V34, P483, DOI 10.1086/204195; HASEGAWA M, 1993, J MOL EVOL, V37, P347, DOI 10.1007/BF00178865; HAWLEY ME, 1995, J HERED, V86, P409, DOI 10.1093/oxfordjournals.jhered.a111613; HEDGES SB, 1992, SCIENCE, V255, P737, DOI 10.1126/science.1738849; Hill A., 1994, INTEGRATIVE PATHS PA, P123; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; JONES JS, 1986, NATURE, V319, P449, DOI 10.1038/319449b0; JORDE LB, 1995, AM J HUM GENET, V57, P523; KIDD KK, IN PRESS ALCOHOLISM; LAHR MM, 1995, EVOL ANTHR, V3, P48; MADDISON DR, 1992, SYST BIOL, V41, P111, DOI 10.2307/2992510; MAHTANI MM, 1993, HUM MOL GENET, V2, P431, DOI 10.1093/hmg/2.4.431; MARTINSON JJ, 1995, AM J HUM GENET, V57, P1186; MCNEMAR Q, 1969, PSYCHOL STATISTICS; MERRIWETHER DA, 1991, J MOL EVOL, V33, P543, DOI 10.1007/BF02102807; MICHALATOSBELOI.S, UNPUB; NEI M, 1989, HUM HERED, V39, P276, DOI 10.1159/000153872; NEI M, 1993, MOL BIOL EVOL, V10, P927; Nei M., 1987, MOL EVOLUTIONARY GEN; PENNY D, 1995, MOL BIOL EVOL, V12, P863; REYNOLDS J, 1983, GENETICS, V105, P767; RISCH N, 1995, NAT GENET, V9, P152, DOI 10.1038/ng0295-152; RITTE U, 1993, HUM BIOL, V65, P359; ROGERS AR, 1995, HUM BIOL, V67, P1; RUVOLO M, 1991, P NATL ACAD SCI USA, V88, P1570, DOI 10.1073/pnas.88.4.1570; SATTA Y, 1994, P NATL ACAD SCI USA, V91, P7184, DOI 10.1073/pnas.91.15.7184; SHEBA C, 1962, AM J PHYS ANTHROPOL, V20, P167, DOI 10.1002/ajpa.1330200218; SHRIVER MD, 1993, GENETICS, V134, P983; SLATKIN M, 1995, MOL BIOL EVOL, V12, P473; SLATKIN M, 1995, GENETICS, V139, P457; SLATKIN M, 1994, GENETICS, V137, P331; STRINGER CB, 1993, ORIGIN AND EVOLUTION OF HUMANS AND HUMANNESS, P75; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; STRINGER CB, 1992, HOMO SAPIENS EVOLUTI, P9; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; TAUTZ D, 1994, CURR OPIN GENET DEV, V4, P832, DOI 10.1016/0959-437X(94)90067-1; TEMPLETON AR, 1993, AM ANTHROPOL, V95, P51, DOI 10.1525/aa.1993.95.1.02a00030; TEMPLETON AR, 1992, SCIENCE, V255, P737, DOI 10.1126/science.1590849; Tishkoff S. A., 1995, American Journal of Human Genetics, V57, pA42; TISHKOFF SA, 1995, AM J PHYS ANTHR S, V20, P211; VALDES AM, 1993, GENETICS, V133, P737; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WAINSCOAT JS, 1986, NATURE, V319, P491, DOI 10.1038/319491a0; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; WILSON AC, 1969, P NATL ACAD SCI USA, V63, P1088, DOI 10.1073/pnas.63.4.1088; WOLPOFF M, 1989, HUMAN REVOLUTION BEH, V1, P62; WOLPOFF MH, 1992, HOMO SAPIENS EVOLUTI, P25; WORKMAN PL, 1970, AM J HUM GENET, V22, P24; ZISCHLER H, 1995, NATURE, V378, P489, DOI 10.1038/378489a0; ZOOSSMANNDISKIN A, 1991, ISRAEL J MED SCI, V27, P245	74	485	491	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1380	1387		10.1126/science.271.5254.1380	http://dx.doi.org/10.1126/science.271.5254.1380			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596909				2022-12-28	WOS:A1996TY96100036
J	Nakai, J; Dirksen, RT; Nguyen, HT; Pessah, IN; Beam, KG; Allen, PD				Nakai, J; Dirksen, RT; Nguyen, HT; Pessah, IN; Beam, KG; Allen, PD			Enhanced dihydropyridine receptor channel activity in the presence of ryanodine receptor	NATURE			English	Article							DYSGENIC SKELETAL-MUSCLE; STEM-CELL LINES; COMPLEMENTARY-DNA; RELEASE CHANNEL; CALCIUM CURRENT; PERCHLORATE; EXPRESSION	Excitation-contraction coupling in skeletal muscle involves a voltage sensor in the plasma membrane which, in response to depolarization, causes an intracellular calcium-release channel to open. The skeletal isoform of the ryanodine receptor (RyR-1) functions as the Ca2+-release channel(1-3) and the dihydropyridine receptor (DHPR) functions as the voltage sensor and also as an L-type Ca2+ channel(4,5). Here we examine the possibility that there is a retrograde signal from RyR-1 to the DHPR, using myotubes from mice homozygous for a disrupted RyR-1 gene (dyspedic mice)(3). As expected, we find that there is no excitation-contraction coupling in dyspedic myotubes, but we also find that they have a roughly 30-fold reduction in L-type Ca2+-current density. Injection of dyspedic myotubes with RyR-1 complementary DNA restores excitation-contraction coupling and causes the density of L-type Ca2+ current to rise towards normal. Despite the differences in Ca2+-current magnitude, measurements of charge movement indicate that the density of DHPRs is similar in dyspedic and RyR-1-expressing myotubes. Our results support the possibility of a retrograde signal hy which RyR-1 enhances the function of DHPRs as Ca2+ channels.	CHILDRENS HOSP,DEPT CARDIOL,MOLEC CARDIOL LAB,BOSTON,MA 02115; KYOTO UNIV,FAC MED,DEPT MED CHEM,KYOTO 60601,JAPAN; COLORADO STATE UNIV,COLL VET MED & BIOMED SCI,DEPT ANAT & NEUROBIOL,FT COLLINS,CO 80523; UNIV CALIF DAVIS,SCH VET MED,DEPT MOLEC BIOSCI,DAVIS,CA 95616; BRIGHAM & WOMENS HOSP,DEPT ANESTHESIOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Kyoto University; Colorado State University; University of California System; University of California Davis; Harvard University; Brigham & Women's Hospital			Nakai, Junichi/GQZ-6415-2022; Tuluc, Petronel/C-2527-2011; Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X				ADAMS BA, 1989, J GEN PHYSIOL, V94, P429, DOI 10.1085/jgp.94.3.429; ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; BUCK R, 1992, J BIOL CHEM, V287, P23560; CAFFREY JM, 1987, SCIENCE, V236, P570, DOI 10.1126/science.2437651; DIRKSEN RT, 1995, J GEN PHYSIOL, V105, P227, DOI 10.1085/jgp.105.2.227; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FELDMEYER D, 1993, PFLUG ARCH EUR J PHY, V425, P54, DOI 10.1007/BF00374503; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GARCIA J, 1994, J GEN PHYSIOL, V103, P125, DOI 10.1085/jgp.103.1.125; GARCIA J, 1994, J GEN PHYSIOL, V103, P107, DOI 10.1085/jgp.103.1.107; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GONZALEZ A, 1993, J GEN PHYSIOL, V102, P373, DOI 10.1085/jgp.102.3.373; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; MA J, 1993, J GEN PHYSIOL, V102, P423, DOI 10.1085/jgp.102.3.423; MA J, 1991, Biophysical Journal, V59, p201A; MA JJ, 1988, BIOPHYS J, V53, P387, DOI 10.1016/S0006-3495(88)83115-1; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEJIAALVAREZ R, 1991, J GEN PHYSIOL, V97, P393, DOI 10.1085/jgp.97.2.393; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; TAKEKURA H, 1994, BIOPHYS J, V67, P793, DOI 10.1016/S0006-3495(94)80539-9; TAKEKURA H, 1995, P NATL ACAD SCI USA, V92, P3381, DOI 10.1073/pnas.92.8.3381; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; TANABE T, 1991, NATURE, V352, P800, DOI 10.1038/352800a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; WINGER DB, 1990, J PHYSIOL-LONDON, V425, P563; YATANI A, 1988, J BIOL CHEM, V263, P9887	30	386	389	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					72	75		10.1038/380072a0	http://dx.doi.org/10.1038/380072a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598910				2022-12-28	WOS:A1996TY87700059
J	Logan, RL; Scott, PJ				Logan, RL; Scott, PJ			Uncertainty in clinical practice: Implications for quality and costs of health care	LANCET			English	Article							PROBABILITY		UNIV AUCKLAND,MIDDLEMORE HOSP,AUCKLAND,NEW ZEALAND	University of Auckland	Logan, RL (corresponding author), HUTT VALLEY HLTH CORP LTD,PRIVATE BAG 31-907,LOWER HUTT,NEW ZEALAND.							ANNAS GJ, 1995, NEW ENGL J MED, V332, P744; Bono Edward de, 1990, LATERAL THINKING CRE; BRYANT GD, 1980, NEW ENGL J MED, V302, P411; BUCHER HC, 1994, BRIT MED J, V309, P761, DOI 10.1136/bmj.309.6957.761; Charlton J., 1993, POPULATION TRENDS, V71, P34; COPE H, 1994, LANCET, V344, P864, DOI 10.1016/S0140-6736(94)92833-9; DEBONO E, 1994, PARALLEL THINKING; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; DONER D, 1990, PHIL T R SOC LOND, V327, P463; EDDY DM, 1993, MED AUDIT NEWS, V8, P115; GARRUD P, 1990, BRIT MED J, V300, P445, DOI 10.1136/bmj.300.6722.445; Gleick J., 1988, CHAOS MAKING NEW SCI; HEIM E, 1991, PSYCHOTHER PSYCHOSOM, V55, P90, DOI 10.1159/000288414; HERMAN J, 1990, J CLIN EPIDEMIOL, V43, P1001, DOI 10.1016/0895-4356(90)90084-3; JOHNSON N, 1991, J MED ETHICS, V17, P30, DOI 10.1136/jme.17.1.30; KATZ J, 1984, HASTINGS CENT REP, V14, P35, DOI 10.2307/3560848; MARINKER M, 1994, BMJ; MCKEE M, 1995, BRIT MED J, V310, P111; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; Payne R, 1987, STRESS HLTH PROFESSI; Popper Karl R., 1990, WORLD PROPENSITIES; Russell B, 1948, PROBLEMS PHILOS; SIMPSON J, 1994, BRIT MED J, V309, P1505, DOI 10.1136/bmj.309.6967.1505; THIBAULT GE, 1994, NEW ENGL J MED, V331, P1216, DOI 10.1056/NEJM199411033311809; WERKO L, 1995, J INTERN MED, V237, P507, DOI 10.1111/j.1365-2796.1995.tb00877.x; 1994, BRIT MED J, V306, P1677; 1995, LANCET, V345, P1449	27	90	91	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					595	598		10.1016/S0140-6736(96)91284-2	http://dx.doi.org/10.1016/S0140-6736(96)91284-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596325				2022-12-28	WOS:A1996TX69400022
J	Whynes, DK; Baines, DL; Tolley, KH				Whynes, DK; Baines, DL; Tolley, KH			Explaining variations in general practice prescribing costs per ASTRO-PU (age, sex, and temporary resident originated prescribing unit)	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM,SCH MED,SCH PUBL HLTH,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham	Whynes, DK (corresponding author), UNIV NOTTINGHAM,DEPT ECON,NOTTINGHAM NG7 2RD,ENGLAND.		Baines, Darrin/ABI-5893-2020	Baines, Darrin/0000-0001-9502-4678				BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; CARLISLE RD, 1993, BRIT MED J, V306, P1383, DOI 10.1136/bmj.306.6889.1383; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; 1994, PRESCRIPTION IMPROVE; 1994, EL942 NHS MAN EX DEP	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					488	489		10.1136/bmj.312.7029.488	http://dx.doi.org/10.1136/bmj.312.7029.488			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597684	Green Published			2022-12-28	WOS:A1996TX38300029
J	Zimmerman, SC; Zeng, FW; Reichert, DEC; Kolotuchin, SV				Zimmerman, SC; Zeng, FW; Reichert, DEC; Kolotuchin, SV			Self-assembling dendrimers	SCIENCE			English	Article							CASCADE	Hydrogen bond-mediated self-assembly is a powerful strategy for generating large structures from smaller subunits. The synthesis of molecules containing two isophthalic acid units covalently attached to a rigid aromatic spacer is described. By normal pairing of carboxylic acids into hydrogen-bonded dimers, these molecules self-assemble in organic solvents to form either a series of linear aggregates or a cyclic hexamer. These molecules were linked to the core of a family of polyether dendrimers, which caused the hexamer to be formed preferentially. The stability of the hexamer depended on the generation number of the dendrimer. The largest of these hydrogen-bonded macromolecular assemblies is roughly disk-shaped with a 9-nanometer diameter and a 2-nanometer thickness. Its size and molecular mass (34,000 daltons) are comparable to that of small proteins.			Zimmerman, SC (corresponding author), UNIV ILLINOIS,DEPT CHEM,600 S MATHEWS AVE,URBANA,IL 61801, USA.		Reichert, David/B-3281-2009; Reichert, David/AAS-4442-2020; Zimmerman, Steven C. C/E-4244-2010	Reichert, David/0000-0003-3432-8998; Reichert, David/0000-0003-3432-8998; Zimmerman, Steven C. C/0000-0002-5333-3437	NIGMS NIH HHS [GM39782] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039782] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTHONSEN MW, 1994, CARBOHYD POLYM, V25, P13, DOI 10.1016/0144-8617(94)90157-0; BARTH HG, 1994, ANAL CHEM, V66, pR595, DOI 10.1021/ac00084a022; CHAPMAN TM, 1994, J AM CHEM SOC, V116, P11195, DOI 10.1021/ja00103a060; FRECHET JMJ, 1994, SCIENCE, V263, P1710, DOI 10.1126/science.8134834; HAWKER CJ, 1993, J CHEM SOC PERK T 1, P1287, DOI 10.1039/p19930001287; LAWRENCE DS, 1995, CHEM REV, V95, P2229, DOI 10.1021/cr00038a018; LEHN JM, 1994, PURE APPL CHEM, V66, P1961, DOI 10.1351/pac199466101961; MATHIAS JP, 1994, J AM CHEM SOC, V116, P4326, DOI 10.1021/ja00089a022; MATHIAS JP, 1994, J AM CHEM SOC, V116, P1725, DOI 10.1021/ja00084a013; MHATRE R, 1994, CHROMATOGRAPHIA, V38, P349, DOI 10.1007/BF02269779; NEWKOME GR, 1993, J ORG CHEM, V58, P3123, DOI 10.1021/jo00063a036; NEWKOME GR, 1995, POLYM PREPRINTS, V36, P609; NEWKOME GR, 1992, ALDRICHIM ACTA, V25, P31; ROGER P, 1993, CARBOHYD POLYM, V21, P83, DOI 10.1016/0144-8617(93)90002-L; TOMALIA DA, 1993, TOP CURR CHEM, V165, P193; VANHEST JCM, 1995, SCIENCE, V268, P1592, DOI 10.1126/science.268.5217.1592; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; XU ZF, 1994, ADV DENDR MACROMOL, V1, P69; ZERKOWSKI JA, 1992, J AM CHEM SOC, V114, P5473, DOI 10.1021/ja00039a096; ZIMMERMAN SC, 1993, P NATL ACAD SCI USA, V90, P1190, DOI 10.1073/pnas.90.4.1190	20	567	591	1	165	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1095	1098		10.1126/science.271.5252.1095	http://dx.doi.org/10.1126/science.271.5252.1095			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599085				2022-12-28	WOS:A1996TW70100031
J	Shan, SO; Loh, S; Herschlag, D				Shan, SO; Loh, S; Herschlag, D			The energetics of hydrogen bonds in model systems: Implications for enzymatic catalysis	SCIENCE			English	Article							DIMETHYL-SULFOXIDE SOLUTION; PROTON-TRANSFER REACTIONS; GENERAL ACID CATALYSIS; CARBON ACIDS; GAS-PHASE; EQUILIBRIUM ACIDITIES; EXCHANGE EQUILIBRIA; ION SOLVATION; ANIONS; SOLVENT	Low-barrier or short, strong hydrogen bonds have been proposed to contribute 10 to 20 kilocalories per mole to transition-state stabilization in enzymatic catalysis. The proposal invokes a large increase in hydrogen bond energy when the pK(a) values of the donor and acceptor (where K-a is the acid constant) become matched in the transition state (Delta pK(a) = 0). This hypothesis was tested by investigating the energetics of hydrogen bonds as a function of Delta pK(a) for homologous series of compounds under nonaqueous conditions that are conducive to the formation of low-barrier hydrogen bonds. In all cases, there was a linear correlation between the increase in hydrogen-bond energy and the decrease in Delta pK(a), as expected from simple electrostatic effects. However, no additional energetic contribution to the hydrogen bond was observed at Delta pK(a) = 0. These results and those of other model studies suggest alternative mechanisms by which hydrogen bonds can contribute to enzymatic catalysis, in accord with conventional electrcstatic considerations.	STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University								ALBRECHT G, 1984, Z NATURFORSCH A, V39, P986; ALBRECHT G, 1983, J CHEM SOC F1, V80, P553; ALLERHAND A, 1963, J AM CHEM SOC, V85, P371, DOI 10.1021/ja00887a001; ALTMAN LJ, 1978, J AM CHEM SOC, V100, P8264, DOI 10.1021/ja00494a040; BARTL H, 1980, Z KRISTALLOGR, V152, P161, DOI 10.1524/zkri.1980.152.3-4.161; BEESON C, 1993, J AM CHEM SOC, V115, P10275, DOI 10.1021/ja00075a049; BIAGINICINGI M, 1977, ACTA CRYSTALLOGR B, V33, P3772; BORDWELL FG, 1988, ACCOUNTS CHEM RES, V21, P456, DOI 10.1021/ar00156a004; BORDWELL FG, 1984, J ORG CHEM, V49, P1424, DOI 10.1021/jo00182a020; BORDWELL FG, 1980, J ORG CHEM, V45, P3305, DOI 10.1021/jo01304a034; BORS DA, 1985, J AM CHEM SOC, V107, P6975, DOI 10.1021/ja00310a038; CALDWELL G, 1984, J AM CHEM SOC, V106, P4660, DOI 10.1021/ja00329a002; CLELAND WW, 1992, BIOCHEMISTRY-US, V31, P317, DOI 10.1021/bi00117a001; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; DIXON HP, 1972, J CHEM PHYS, V57, P4388, DOI 10.1063/1.1678079; EXNER O, 1988, CORRELATION ANAL CHE, P439; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; FUNDERBURK LH, 1978, J AM CHEM SOC, V100, P6708, DOI 10.1021/ja00489a026; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; GERLT JA, 1993, J AM CHEM SOC, V115, P11552, DOI 10.1021/ja00077a062; GILLI P, 1994, J AM CHEM SOC, V116, P909, DOI 10.1021/ja00082a011; GILSON MK, 1989, P NATL ACAD SCI USA, V86, P1524, DOI 10.1073/pnas.86.5.1524; GORDON JE, 1961, J ORG CHEM, V26, P738, DOI 10.1021/jo01062a024; GUNNARSSON G, 1976, CHEM PHYS LETT, V38, P96, DOI 10.1016/0009-2614(76)80264-3; GUTHRIE JP, 1993, J AM CHEM SOC, V115, P11569, DOI 10.1021/ja00077a063; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8312, DOI 10.1021/bi00083a035; Hibbert F., 1990, ADV PHYS ORG CHEM, V26, P255, DOI DOI 10.1016/S0065-3160(08)60047-7; HINE J, 1972, J AM CHEM SOC, V94, P5766, DOI 10.1021/ja00771a038; HINE J, 1962, PHYSICAL ORGANIC CHE, pCH4; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, pCH6; KASENDE O, 1984, J PHYS CHEM-US, V88, P2636, DOI 10.1021/j150656a042; KOLTHOFF IM, 1971, J AM CHEM SOC, V93, P3843, DOI 10.1021/ja00745a001; Kortum G., 1961, DISSOCIATION CONSTAN; KREEVOY MM, 1980, J AM CHEM SOC, V102, P3315, DOI 10.1021/ja00530a002; KRYGOWSKI TM, 1975, J AM CHEM SOC, V97, P2143, DOI 10.1021/ja00841a026; LARSON JW, 1983, J AM CHEM SOC, V105, P2944, DOI 10.1021/ja00348a003; MATTHEWS WS, 1975, J AM CHEM SOC, V97, P7006, DOI 10.1021/ja00857a010; MEOTNER M, 1984, J AM CHEM SOC, V106, P1257, DOI 10.1021/ja00317a015; MEOTNER M, 1986, J PHYS CHEM-US, V90, P6687, DOI 10.1021/j100283a019; MEOTNER M, 1986, J AM CHEM SOC, V108, P7525, DOI 10.1021/ja00284a014; MIHALICK JE, UNPUB; NADLER EB, 1989, J AM CHEM SOC, V111, P213, DOI 10.1021/ja00183a033; PAWLAK Z, 1984, ELECTROCHIM ACTA, V29, P391, DOI 10.1016/0013-4686(84)87080-2; PERRIN CL, 1989, J AM CHEM SOC, V111, P8010, DOI 10.1021/ja00202a050; PERRIN CL, 1992, J AM CHEM SOC, V114, P8559, DOI 10.1021/ja00048a031; PERRIN CL, 1994, SCIENCE, V266, P1665, DOI 10.1126/science.266.5191.1665; RAO SN, 1987, NATURE, V328, P551, DOI 10.1038/328551a0; ROTHENBERG ME, 1985, J AM CHEM SOC, V107, P1340, DOI 10.1021/ja00291a038; RUBIN J, 1965, J PHYS CHEM-US, V69, P3089, DOI 10.1021/j100893a045; SAUNDERS M, 1984, J AM CHEM SOC, V106, P3098, DOI 10.1021/ja00323a005; SCHEINER S, 1995, J AM CHEM SOC, V117, P6970, DOI 10.1021/ja00131a020; SCHMIDEDER H, 1987, J MOL STRUCT, V161, P87, DOI 10.1016/0022-2860(87)85064-0; SCHWARTZ B, 1995, J AM CHEM SOC, V117, P11902, DOI 10.1021/ja00153a011; SCHWARTZ B, 1995, BIOCHEMISTRY-US, V34, P15459, DOI 10.1021/bi00047a010; SHAN S, UNPUB; SHERRY AD, 1970, J PHYS CHEM-US, V74, P3535, DOI 10.1021/j100713a017; STAHL N, 1986, J AM CHEM SOC, V108, P4196, DOI 10.1021/ja00274a058; TAFT RW, 1969, J AM CHEM SOC, V91, P4801, DOI 10.1021/ja01045a038; TONG HX, 1995, BIOCHEMISTRY-US, V34, P3362, DOI 10.1021/bi00010a027; USHER KC, 1994, BIOCHEMISTRY-US, V33, P7753, DOI 10.1021/bi00191a002; WALDBURGER CD, 1995, NAT STRUCT BIOL, V2, P122, DOI 10.1038/nsb0295-122; WARSHEL A, 1978, P NATL ACAD SCI USA, V75, P5250, DOI 10.1073/pnas.75.11.5250; WARSHEL A, 1981, BIOCHEMISTRY-US, V20, P3167, DOI 10.1021/bi00514a028; WILCOX CS, 1995, TETRAHEDRON, V51, P621, DOI 10.1016/0040-4020(94)00921-G; YAMDAGNI R, 1971, J AM CHEM SOC, V93, P7139, DOI 10.1021/ja00755a003	67	252	254	2	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					97	101		10.1126/science.272.5258.97	http://dx.doi.org/10.1126/science.272.5258.97			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600542				2022-12-28	WOS:A1996UD59700046
J	Ades, PA; Ballor, DL; Ashikaga, T; Utton, JL; Nair, KS				Ades, PA; Ballor, DL; Ashikaga, T; Utton, JL; Nair, KS			Weight training improves walking endurance in healthy elderly persons	ANNALS OF INTERNAL MEDICINE			English	Article							FRAMINGHAM DISABILITY; SKELETAL-MUSCLE; STRENGTH	Objective: To determine the effect of a resistance-training program on walking endurance in a healthy, community-dwelling elderly population. Design: 12-week randomized, controlled trial comparing a resistance-training group with a nonexercising control group. Setting: Hospital-affiliated outpatient exercise facility. Patients: 24 healthy men and women who were 65 years of age or older (mean age +/- SD, 70.4 +/- 4 years; range, 65 to 79 years). Measurements: The primary outcome variable was exhaustive submaximal walking time measured at an intensity of 80% of baseline peak aerobic capacity. Results: Participants in the resistance-training program increased submaximal walking endurance by 9 minutes (from 25 +/- 4 minutes to 34 +/- 9 minutes; P = 0.001), a 38% increase, whereas no change was seen in controls (20 +/- 5 minutes to 19 +/- 10 minutes; P > 0.2; P = 0.005 between groups). The relation between change in leg strength and change in walking endurance was significant (r = 0.48; P = 0.02). Neither group showed a change in peak aerobic capacity or in whole-body composition, although fat-free mass of the leg increased in the exercise group. Conclusions: Resistance training for 3 months improves both leg strength and walking endurance in healthy, community-dwelling elderly persons. This finding is relevant to older persons at risk for disability, because walking endurance and leg strength are important components of physical functioning.	UNIV VERMONT, COLL MED, BURLINGTON, VT 05405 USA; MAYO CLIN, DIV ENDOCRINOL, ROCHESTER, MN 55905 USA	University of Vermont; Mayo Clinic					NATIONAL INSTITUTE ON AGING [R01AG009531] Funding Source: NIH RePORTER; NCRR NIH HHS [RR209] Funding Source: Medline; NIAMS NIH HHS [AR1964] Funding Source: Medline; NIA NIH HHS [R01-AG09531-01A2] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADES PA, 1993, CIRCULATION, V88, P572, DOI 10.1161/01.CIR.88.2.572; BORG GAV, 1973, MED SCI SPORT EXER, V5, P90; BROZEK J, 1963, ANN NY ACAD SCI, V110, P113, DOI 10.1111/j.1749-6632.1963.tb17079.x; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FRONTERA WR, 1988, J APPL PHYSIOL, V64, P1038, DOI 10.1152/jappl.1988.64.3.1038; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; IKEGAMI N, 1995, NEW ENGL J MED, V332, P598, DOI 10.1056/NEJM199503023320910; JENSEN MD, 1993, MAYO CLIN PROC, V68, P867, DOI 10.1016/S0025-6196(12)60695-8; JETTE AM, 1981, AM J PUBLIC HEALTH, V71, P1211, DOI 10.2105/AJPH.71.11.1211; MARCINIK EJ, 1991, MED SCI SPORT EXER, V23, P739; Maxwell S.E., 2018, DESIGNING EXPT ANAL, V3rd edition, DOI 10.4324/9781315642956; PINSKY JL, 1990, AM J PUBLIC HEALTH, V80, P1363, DOI 10.2105/AJPH.80.11.1363; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335	14	179	185	1	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1996	124	6					568	572		10.7326/0003-4819-124-6-199603150-00005	http://dx.doi.org/10.7326/0003-4819-124-6-199603150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ529	8597320				2022-12-28	WOS:A1996TZ52900005
J	Lanker, S; Valdivieso, MH; Wittenberg, C				Lanker, S; Valdivieso, MH; Wittenberg, C			Rapid degradation of the G(1) cyclin Cln2 induced by CDK-dependent phosphorylation	SCIENCE			English	Article							YEAST-CELL CYCLE; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; G1 CYCLINS; GENE; CDC28; ASSOCIATION; ACTIVATOR; DIVISION; COMPLEX	Cyclins regulate the major cell cycle transitions in eukaryotes through association with cyclin-dependent protein kinases (CDKs). In yeast, G(1) cyclins are essential, rate-limiting activators of cell cycle initiation. G(1)-specific accumulation of one G(1) cyclin, Cln2, results from periodic gene expression coupled with rapid protein turnover. Site-directed mutagenesis of CLN2 revealed that its phosphorylation provides a signal that promotes rapid degradation. Cln2 phosphorylation is dependent on the Cdc28 protein kinase, the CDK that it activates, These findings suggest that Cln2 is rendered self-limiting by virtue of its ability to activate its cognate CDK subunit.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; EDIFICIO DEPT MICROBIOL BIOL, E-37007 SALAMANCA, SPAIN	Scripps Research Institute; Scripps Research Institute			Valdivieso, M.-Henar/B-5199-2017	Valdivieso, M.-Henar/0000-0002-6857-7493	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043487] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43487] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1993, MOL CELL BIOL, V13, P3266, DOI 10.1128/MCB.13.6.3266; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; LANKER S, UNPUB; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; LITTLEFIELD R, UNPUB; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; VALDIVIESO M, UNPUB; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WITTENBERG C, 1987, J CELL BIOL, V105, P1527, DOI 10.1083/jcb.105.4.1527; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; WITTENBERG C, UNPUB; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	32	195	196	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1996	271	5255					1597	1601		10.1126/science.271.5255.1597	http://dx.doi.org/10.1126/science.271.5255.1597			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599119				2022-12-28	WOS:A1996TZ98300046
J	Hirsch, E; Iglesias, A; Potocnik, AJ; Hartmann, U; Fassler, R				Hirsch, E; Iglesias, A; Potocnik, AJ; Hartmann, U; Fassler, R			Impaired migration but not differentiation of haematopoietic stem cells in the absence of beta(1) integrins	NATURE			English	Article							GENE REARRANGEMENT; FETAL LIVER; ADHESION; HEMATOPOIESIS; TRANSCRIPTION; PRECURSORS; ACTIVATION; RECEPTOR; CHAIN	Adhesive interactions mediated by integrins of the beta(1) subfamily(1) are thought to be critical in controlling differentiation and migration of blood cell precursors(2-7). Here we report that chimaeric mice generated with beta(1)-integrin-deficient embryonic stem (ES) cells(8,9) lack beta(1)(-/-) cells in blood and in haematopoietic organs such as spleen, thymus and bone marrow. Chimaeric embryos contain beta(1)-null haematopoietic cells in the yolk sac and in fetal blood but not in fetal liver. We show that such beta(1)(-/-) haematopoietic stem cells derived from yolk sac of 10.5-day-old chimaeric embryos readily generate erythroid and myeloid colonies and that beta(1)(-/-) ES cells can differentiate into mature B lymphocytes in vitro. Our results indicate that haematopoietic stem cells lacking beta(1) integrins can form and differentiate into different lineages but cannot colonize the fetal liver.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; MAX PLANCK INST PSYCHIAT,D-82152 MARTINSRIED,GERMANY; MAX PLANCK INST IMMUNBIOL,D-79108 FREIBURG,GERMANY	Max Planck Society; Max Planck Society; Max Planck Society			Hirsch, Emilio/F-4848-2013	Hirsch, Emilio/0000-0002-9073-6024; Potocnik, Alexandre/0000-0002-4730-8593				ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; BOTTGER BA, 1989, DIFFERENTIATION, V41, P158, DOI 10.1111/j.1432-0436.1989.tb00743.x; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CUMANO A, 1992, EMBO J, V11, P593, DOI 10.1002/j.1460-2075.1992.tb05091.x; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; GIANCOTTI FG, 1986, J CELL BIOL, V103, P429, DOI 10.1083/jcb.103.2.429; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGLESIAS A, 1992, EUR J IMMUNOL, V22, P335, DOI 10.1002/eji.1830220208; JOHNSON GR, 1975, NATURE, V258, P726, DOI 10.1038/258726a0; LABOW MA, 1994, IMMUNITY, V1, P709, DOI 10.1016/1074-7613(94)90041-8; LEPTIN M, 1984, EUR J IMMUNOL, V14, P534, DOI 10.1002/eji.1830140610; Moore K. A., 1993, Gene targeting: a practical approach., P63; PAPAYANNOPOULOU T, 1992, BLOOD, V79, P1686; PARDANAUD L, 1989, DEVELOPMENT, V105, P473; PATEL VP, 1987, J CELL BIOL, V105, P3105, DOI 10.1083/jcb.105.6.3105; PATEL VP, 1986, J CELL BIOL, V102, P449, DOI 10.1083/jcb.102.2.449; PEVNY L, 1995, DEVELOPMENT, V121, P163; POTOCNIK AJ, 1994, EMBO J, V13, P5274, DOI 10.1002/j.1460-2075.1994.tb06861.x; RUIZ P, 1995, EUR J IMMUNOL, V25, P2034, DOI 10.1002/eji.1830250735; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUBRAMANIAM M, 1995, J EXP MED, V181, P2277, DOI 10.1084/jem.181.6.2277; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0; WILT FH, 1965, SCIENCE, V147, P1588, DOI 10.1126/science.147.3665.1588; YANG JT, 1995, DEVELOPMENT, V121, P549	28	291	301	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					171	175		10.1038/380171a0	http://dx.doi.org/10.1038/380171a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600394				2022-12-28	WOS:A1996TZ97800055
J	Davidson, AC; Emberlin, J; Cook, AD; Venables, KM; Wallis, DN; Webb, J; Brooke, D; Brookes, B; Brown, R; Findlay, A; Harris, M; Hulbert, D; Little, G; Nonoo, C; ODonnell, C; Park, G; Soorma, A				Davidson, AC; Emberlin, J; Cook, AD; Venables, KM; Wallis, DN; Webb, J; Brooke, D; Brookes, B; Brown, R; Findlay, A; Harris, M; Hulbert, D; Little, G; Nonoo, C; ODonnell, C; Park, G; Soorma, A			A major outbreak of asthma associated with a thunderstorm: Experience of accident and emergency departments and patients' characteristics	BRITISH MEDICAL JOURNAL			English	Article							GRASS-POLLEN; MECHANISM	Objective-To investigate the time course of an epidemic of asthma after a thunderstorm, characteristics of patients affected, and the demand on emergency medical resources. Design-study of registers and records in accident and emergency departments and questionnaire to staff. Setting-London area. Subjects-All patients presenting at 12 accident and emergency departments with asthma or other airways disease. Main outcome measures-Numbers of patients, clinical features, information on shortage of resources-equipment, drugs, and staff. Results-The epidemic had a sudden onset on 24 June 1994; 640 patients with asthma or other airways disease attended during 30 hours from 1800 on 24 June, nearly 10 times the expected number. Over half (365) the patients were aged 21 to 40 years. A history of hay fever was recorded in 403 patients; for 283 patients this was the first known attack of asthma; a history of chronic obstructive airways disease was recorded in 12 patients. In all, 104 patients were admitted (including five to an intensive care unit). Several departments ran out of equipment or drugs, called in additional doctors, or both. Conclusions-This study supports the view that this epidemic was larger than previously reported epidemics and the hypothesis that ''thunderstorm associated asthma'' is related to aeroallergens. Demands on resources were considerable; a larger proportion of patients needing intensive care would have caused greater problems.	NEWHAM GEN HOSP,DEPT ACCID & EMERGENCY,LONDON E13 8RU,ENGLAND; POLLEN RES UNIT,WORCESTER WR2 6AJ,ENGLAND; NATL HEART & LUNG INST,DEPT OCCUPAT & ENVIRONM MED,LONDON SW3 6LR,ENGLAND	University of Worcester; Imperial College London								Alderman P M, 1986, Arch Emerg Med, V3, P260; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834, DOI 10.5694/j.1326-5377.1992.tb136994.x; CAMPBELLHEWSON G, 1994, BRIT MED J, V309, P1086, DOI 10.1136/bmj.309.6961.1086a; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1983, LANCET, V2, P253; *DEP HLTH ADV GROU, 1995, 4 DEP HLTH ADV GROUP; EGAN P, 1985, MED J AUSTRALIA, V142, P330, DOI 10.5694/j.1326-5377.1985.tb113389.x; HABENICHT HA, 1984, J ALLERGY CLIN IMMUN, V74, P64, DOI 10.1016/0091-6749(84)90088-5; HIGHAM JH, 1994, BRIT MED J, V309, P604; KNOX RB, 1993, CLIN EXP ALLERGY, V23, P354, DOI 10.1111/j.1365-2222.1993.tb00339.x; MURRAY V, 1994, BRIT MED J, V309, P131, DOI 10.1136/bmj.309.6947.131c; Norris-Hill J, 1993, AEROBIOLOGIA, V9, P27, DOI DOI 10.1007/BF02311367; PACKE GE, 1985, LANCET, V2, P199; PACKE GE, 1986, LANCET, V1, P850; PREMARATNE UN, IN PRESS RESPIR MED; RODRIGO MJ, 1990, J ALLERGY CLIN IMMUN, V85, P778, DOI 10.1016/0091-6749(90)90198-D; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; 1985, LANCET, V1, P1079	18	94	95	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					601	604						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595332				2022-12-28	WOS:A1996TZ84000022
J	Dias, R; Robbins, TW; Roberts, AC				Dias, R; Robbins, TW; Roberts, AC			Dissociation in prefrontal cortex of affective and attentional shifts	NATURE			English	Article							FRONTAL-CORTEX; LOBE	The prefrontal cortex is implicated in such human characteristics as volition, planning, abstract reasoning and affect(1-6). Frontal-lobe damage can cause disinhibition such that the behaviour of a subject is guided by previously acquired responses that are inappropriate to the current situation(7-9). Here we demonstrate that disinhibition, or a loss of inhibitory control, can be selective for particular cognitive functions and that different regions of the prefrontal cortex provide inhibitory control in different aspects of cognitive processing. Thus, whereas damage to the lateral prefrontal cortex (Brodmann's area 9) in monkeys causes a loss of inhibitory control in attentional selection, damage to the orbito-frontal cortex in monkeys causes a loss of inhibitory control in 'affective' processing, thereby impairing the ability to alter behaviour in response to fluctuations in the emotional significance of stimuli. These findings not only support the view that the prefrontal cortex has multiple functions, but also provide evidence for the distribution of different cognitive functions within specific regions of prefrontal cortex.	UNIV CAMBRIDGE,DEPT EXPTL PSYCHOL,CAMBRIDGE CB2 3EB,ENGLAND	University of Cambridge			Roberts, Angela C/C-1313-2012; Robbins, Trevor W/A-7551-2008	Roberts, Angela C/0000-0003-2873-157X; Robbins, Trevor/0000-0003-0642-5977	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMARAL DG, 1993, AMYGDALA NEUROBIOLOG, P1; Brodmann K, 1909, VERGLEICHENDE LOKALI; Damasio A.R., 2005, DESCARTES ERROR EMOT; Fuster J.M., 1989, PREFRONTAL CORTEX; Goldman-Rakic P.S., 2011, HDB PHYSL, P373, DOI DOI 10.1002/CPHY.CP010509; IVERSEN SD, 1970, EXP BRAIN RES, V11, P376; Milner B., 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI DOI 10.1001/ARCHNEUR.1963.00460070100010; Mishkin M., 1964, FRONTAL GRANULAR COR, P219; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; OWEN AM, 1993, BRAIN, V116, P1159, DOI 10.1093/brain/116.5.1159; Passingham RE., 1993, FRONTAL LOBES VOLUNT; PETRIDES M, 1991, P ROY SOC B-BIOL SCI, V246, P293, DOI 10.1098/rspb.1991.0157; PREUSS TM, 1991, J COMP NEUROL, V310, P429, DOI 10.1002/cne.903100402; ROBERTS AC, 1994, J NEUROSCI, V14, P2531; ROBERTS AC, 1988, Q J EXP PSYCHOL-B, V40, P321; Shallice T, 1988, NEUROPSYCHOLOGY MENT, P328; SUTHERLAND NS, 1971, MECHANISMS ANIMAL DI; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	18	1197	1210	0	99	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					69	72		10.1038/380069a0	http://dx.doi.org/10.1038/380069a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598908				2022-12-28	WOS:A1996TY87700058
J	Klingelhutz, AJ; Foster, SA; McDougall, JK				Klingelhutz, AJ; Foster, SA; McDougall, JK			Telomerase activation by the E6 gene product of human papillomavirus type 16	NATURE			English	Article							TERMINAL TRANSFERASE; HUMAN FIBROBLASTS; RIBONUCLEOPROTEIN; ONCOPROTEIN; REPEATS; ENZYME; CELLS; P53	Activation of telomerase, a ribonucleoprotein complex that synthesizes telomere repeat sequences(1-4), is linked to cell immortalization and is characteristic of most cell lines and tumours(4,5-8) Here we show that expression of the human papillomavirus type 16 (HPV-16) E6 protein activates telomerase in early-passage human keratinocytes and mammary epithelial cells. This activation was observed in cells pre-crisis, that is, before they became immortal, and occurred within one passage of retroviral infection with vectors expressing HPV-16 E6. Studies using HPV-16 E6 mutants showed that there was no correlation between the ability of the mutants to activate telomerase and their ability to target p53 for degradation, suggesting that telomerase activation by HPV-16 E6 is p53 independent. Keratinocytes expressing wild-type HPV-16 E6 have an extended lifespan, but do not become immortal(9), indicating that telomerase activation and E6-mediated degradation of p53 are insufficient for their immortalization. These results show that telomerase activation is an intrinsic, but insufficient, component of transformation by HPV.	UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	Klingelhutz, AJ (corresponding author), FRED HUTCHINSON CANC RES CTR,PROGRAM CANC BIOL,SEATTLE,WA 98104, USA.		Klingelhutz, Aloysius/L-9081-2018	Klingelhutz, Aloysius/0000-0003-4258-5046				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; CHADENEAU C, 1995, CANCER RES, V55, P2533; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; MILLER AD, 1988, J VIROL, V62, P4337, DOI 10.1128/JVI.62.11.4337-4345.1988; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8	21	651	679	1	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					79	82		10.1038/380079a0	http://dx.doi.org/10.1038/380079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598912				2022-12-28	WOS:A1996TY87700061
J	Evans, JA; Hamerton, JL				Evans, JA; Hamerton, JL			Limb defects and chorionic villus sampling	LANCET			English	Editorial Material							PRENATAL-DIAGNOSIS; MALFORMATIONS; POPULATION; ANOMALIES; ABNORMALITIES; AMNIOCENTESIS; CVS				Evans, JA (corresponding author), UNIV MANITOBA,DEPT HUMAN GENET,WINNIPEG,MB,CANADA.							[Anonymous], 1991, LANCET, V337, P1491; BURTON BK, 1992, OBSTET GYNECOL, V79, P726; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; FROSTER UG, 1993, AM J MED GENET, V45, P60, DOI 10.1002/ajmg.1320450116; FROSTER UG, 1992, AM J MED GENET, V44, P767, DOI 10.1002/ajmg.1320440611; FROSTERISKENIUS UG, 1990, TERATOLOGY, V41, P23, DOI 10.1002/tera.1420410104; FROSTERISKENIUS UG, 1989, TERATOLOGY, V39, P127, DOI 10.1002/tera.1420390205; KAPLAN P, 1990, AM J MED GENET, V37, P366, DOI 10.1002/ajmg.1320370315; KULIEV AM, 1992, J ASSIST REPROD GEN, V9, P299, DOI 10.1007/BF01203947; LIPPMAN A, 1992, PRENATAL DIAG, V12, P385, DOI 10.1002/pd.1970120508; MASTROIACOVO P, 1992, AM J MED GENET, V44, P856, DOI 10.1002/ajmg.1320440639; OLNEY RS, 1995, TERATOLOGY, V51, P20, DOI 10.1002/tera.1420510104; RHOADS GG, 1989, NEW ENGL J MED, V320, P609, DOI 10.1056/NEJM198903093201001; SMIDTJENSEN S, 1991, ULTRASOUND OBST GYN, V1, P86, DOI 10.1046/j.1469-0705.1991.01020086.x	14	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					484	485		10.1016/S0140-6736(96)91131-9	http://dx.doi.org/10.1016/S0140-6736(96)91131-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596260				2022-12-28	WOS:A1996TW69700002
J	Belmont, LD; Mitchison, TJ				Belmont, LD; Mitchison, TJ			Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules	CELL			English	Article							DYNAMIC INSTABILITY; TRANSITION FREQUENCIES; CYTOPLASMIC EXTRACTS; XENOPUS; KINASE; STATHMIN; CELLS; PHOSPHORYLATION; INTERPHASE; LEUKEMIA	Using a polymerization inhibition assay, we have purified a small, heat stable protein that physically interacts with tubulin dimers and increases the catastrophe rate of microtubules. Sequence analysis identified this protein as oncoprotein 18 (Op18)/stathmin, a conserved phosphoprotein that is highly expressed in leukemia cells. Immunodepletion experiments in Xenopus egg extracts showed that Op18/stathmin is involved in physiological regulation of mitotic microtubule dynamics. Op18/stathmin is a microtubule regulator that preferentially interacts with unpolymerized subunits. It is a candidate for increasing the microtubule catastrophe rate in mitosis and might also regulate microtubule dynamics in response to external signals.	UNIV CALIF SAN FRANCISCO,DEPT MOLEC & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Belmont, LD (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM039565, R01GM039565] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39565-07] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN SSL, 1994, J CELL BIOL, V127, P1289, DOI 10.1083/jcb.127.5.1289; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BERETTA L, 1993, J BIOL CHEM, V268, P20076; BRAVERMAN R, 1986, J BIOL CHEM, V261, P14342; CASSIMERIS L, 1993, CELL MOTIL CYTOSKEL, V26, P275, DOI 10.1002/cm.970260402; CURMI PA, 1994, BIOCHEM J, V300, P331, DOI 10.1042/bj3000331; GARD DL, 1987, J CELL BIOL, V105, P2191, DOI 10.1083/jcb.105.5.2191; GLIKSMAN NR, 1992, J CELL BIOL, V119, P1271, DOI 10.1083/jcb.119.5.1271; GLIKSMAN NR, 1993, MOL BIOL CELL, V4, P1035, DOI 10.1091/mbc.4.10.1035; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; LUO XN, 1994, J BIOL CHEM, V269, P10312; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; MARKLUND U, 1994, J BIOL CHEM, V269, P30626; MAUCUER A, 1993, J BIOL CHEM, V268, P16420; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; ROWLANDS DC, 1995, LAB INVEST, V72, P100; SALMON ED, 1984, J CELL BIOL, V99, P2165, DOI 10.1083/jcb.99.6.2165; SAWIN KE, 1992, J CELL SCI, V101, P303; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SCHUBART UK, 1987, J BIOL CHEM, V262, P11871; SIMON JR, 1992, CELL MOTIL CYTOSKEL, V21, P1, DOI 10.1002/cm.970210102; SOBEL A, 1989, J BIOL CHEM, V264, P3765; VANDRE DD, 1991, J CELL SCI, V98, P577; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; VERLHAC MH, 1994, DEVELOPMENT, V120, P1017; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WILSON L, 1995, CHEM BIOL, V2, P569, DOI 10.1016/1074-5521(95)90119-1	37	572	589	3	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					623	631		10.1016/S0092-8674(00)81037-5	http://dx.doi.org/10.1016/S0092-8674(00)81037-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598048	Bronze			2022-12-28	WOS:A1996TX17600014
J	Daub, H; Weiss, FU; Wallasch, C; Ullrich, A				Daub, H; Weiss, FU; Wallasch, C; Ullrich, A			Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors	NATURE			English	Article							SWISS 3T3 CELLS; TYROSINE PHOSPHORYLATION; KINASE; GROWTH; FIBROBLASTS; ACTIVATION; TRANSDUCTION; MECHANISM; STIMULATE	TRANSDUCTION of a mitogenic signal from the cell membrane to the nucleus involves the adapter proteins SHC and Grb2, which mediate activation of the Ras/mitogen-activated protein (MAP) kinase pathway(1-5). In contrast to receptor tyrosine kinases (RTKs), the signalling steps leading to Ras/MAP kinase activation by G-protein-coupled receptors (GPCRs) are still poorly characterized but appear to include beta gamma subunits of heterotrimeric G-proteins and as-yet unidentified tyrosine kinases(6-8). We report here that the epidermal growth factor receptor (EGFR) and the neu oncoprotein become rapidly tyrosine-phosphorylated upon stimulation of Rat-1 cells with the GPCR agonists endothelin-1, lysophosphatic acid and thrombin, suggesting that there is an intracellular mechanism for transactivation. Specific inhibition of EGFR function by either the selective tyrphostin AG1478 or a dominant-negative EGFR mutant suppressed MAP kinase activation and strongly inhibited induction of fos gene expression and DNA synthesis, Our results demonstrate a role for RTKs as downstream mediators in GPCR mitogenic signalling and suggest a ligand-independent mechanism of RTK activation through intracellular signal crosstalk.			Daub, H (corresponding author), MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,AM KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.		Weiss, Frank Ulrich/A-6386-2009	Weiss, Frank Ulrich/0000-0003-3369-6369				AMBAR I, 1993, EUR J PHARM-MOLEC PH, V245, P31, DOI 10.1016/0922-4106(93)90166-7; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MULDOON LL, 1990, CELL REGUL, V1, P379, DOI 10.1091/mbc.1.4.379; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERGEER P, 1994, REV CELL BIOL, V10, P251; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	29	1272	1301	1	77	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					557	560		10.1038/379557a0	http://dx.doi.org/10.1038/379557a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596637				2022-12-28	WOS:A1996TU69300055
J	Fiscella, K; Franks, P				Fiscella, K; Franks, P			Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENERAL-PRACTITIONERS ADVICE; CHEWING-GUM; CONTROLLED TRIAL; CIGARETTE-SMOKING; SMOKERS; EXPENDITURES; WITHDRAWAL; IMPACT	Objective.-To determine the incremental cost-effectiveness of the transdermal nicotine patch. Design.-Decision analytic model that evaluated the incremental cost-effectiveness of the addition of the nicotine patch to smoking cessation counseling. Costs were based on physician time and the retail cost of the nicotine patch, and benefits were based on quality-adjusted life years (QALYs) saved. Patients.-Male and female smokers aged 25 to 69 years receiving primary care. Intervention.-Addition of the nicotine patch to physician-based smoking cessation counseling. Main Outcome Measure.-Costs (1995 dollars) per QALYs saved discounted by 3% annually. Results.-The use of the patch produced 1 additional lifetime quitter at a cost of $7332. The incremental cost-effectiveness of the nicotine patch by age group ranged from $4390 to $10943 per QALY for men and $4955 to $6983 per QALY for women. A clinical strategy involving limiting prescription renewals to patients successfully abstaining for the first 2 weeks improved the cost-effectiveness of the patch by 25%. Conclusions.-The findings provide support both for the routine use of the nicotine patch as an adjunct to physicians' smoking cessation counseling and for health insurance coverage of nicotine patch therapy.			Fiscella, K (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT FAMILY MED,HIGHLAND HOSP,PRIMARY CARE INST,ROCHESTER,NY 14642, USA.							ABELIN T, 1989, METHOD FIND EXP CLIN, V11, P205; ABELIN T, 1989, LANCET, V1, P7; ADAMS PF, 1992, VIT HLTH STAT, V184; BENITOCEPEDA A, 1993, J CONSULT CLIN PSYCH, V61, P822; BLONDAL T, 1989, ARCH INTERN MED, V149, P1818, DOI 10.1001/archinte.149.8.1818; BUCHKREMER G, 1989, ADDICT BEHAV, V14, P229, DOI 10.1016/0306-4603(89)90054-3; *CDC, 1989, CDC PUBL; Cummings K M, 1994, Arch Fam Med, V3, P682, DOI 10.1001/archfami.3.8.682; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; FAGERSTROM KO, 1982, J BEHAV MED, V5, P343, DOI 10.1007/BF00846161; FEE WM, 1982, PRACTITIONER, V226, P148; FIORE MC, 1992, JAMA-J AM MED ASSOC, V268, P2687, DOI 10.1001/jama.268.19.2687; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; Gold MR, 1996, COST EFFECTIVENESS H; GOLD MR, 1994, MED DECIS MAKING, V14, P431; GOURLAY SG, 1994, BRIT MED J, V309, P842, DOI 10.1136/bmj.309.6958.842; HJALMARSON AIM, 1984, JAMA-J AM MED ASSOC, V252, P2835, DOI 10.1001/jama.252.20.2835; HODGSON TA, 1992, MILBANK Q, V70, P81, DOI 10.2307/3350086; HUGHES JR, 1991, PREV MED, V20, P486, DOI 10.1016/0091-7435(91)90046-7; HURT RD, 1994, JAMA-J AM MED ASSOC, V271, P595, DOI 10.1001/jama.271.8.595; JAMROZIK K, 1984, BRIT MED J, V288, P1499, DOI 10.1136/bmj.288.6429.1499; JARVIK ME, 1984, AM J PSYCHIAT, V141, P790; JARVIS MJ, 1982, BRIT MED J, V285, P537, DOI 10.1136/bmj.285.6341.537; JOHNSON RE, 1992, J FAM PRACTICE, V34, P61; KENFORD SL, 1994, JAMA-J AM MED ASSOC, V271, P589, DOI 10.1001/jama.271.8.589; LAM W, 1987, LANCET, V2, P27; LAW M, 1995, ARCH INTERN MED, V155, P1933, DOI 10.1001/archinte.155.18.1933; LEU RE, 1983, SOC SCI MED, V17, P1907, DOI 10.1016/0277-9536(83)90168-5; LEU RE, 1985, SOC SCI MED, V21, P825, DOI 10.1016/0277-9536(85)90131-5; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; MANNING W, 1991, COSTS POOR HLTH HABI; NORREGAARD J, 1993, PREV MED, V22, P261, DOI 10.1006/pmed.1993.1021; ORLEANS CT, 1994, JAMA-J AM MED ASSOC, V271, P601, DOI 10.1001/jama.271.8.601; OSTER G, 1984, PREV MED, V13, P377, DOI 10.1016/0091-7435(84)90029-X; OSTER G, 1986, JAMA-J AM MED ASSOC, V256, P1315, DOI 10.1001/jama.256.10.1315; PIERCE JP, 1995, J NATL CANCER I, V87, P87, DOI 10.1093/jnci/87.2.87; ROGERS RG, 1991, SOC SCI MED, V32, P1151, DOI 10.1016/0277-9536(91)90092-Q; RUSSELL MAH, 1983, BRIT MED J, V287, P1782, DOI 10.1136/bmj.287.6407.1782; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; SACHS DPL, 1993, ARCH INTERN MED, V153, P1881, DOI 10.1001/archinte.153.16.1881; SACHS DPL, 1995, ARCH INTERN MED, V155, P1973, DOI 10.1001/archinte.155.18.1973; SCHAUFFLER HH, 1993, HEALTH EDUC QUART, V20, P185, DOI 10.1177/109019819302000211; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; STAPLETON JA, 1995, ADDICTION, V90, P31, DOI 10.1046/j.1360-0443.1995.901316.x; STEWART PJ, 1982, CAN MED ASSOC J, V126, P1051; TANG JL, 1994, BRIT MED J, V308, P21, DOI 10.1136/bmj.308.6920.21; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; Torrance GW, 1987, METHODS EC EVALUATIO; *TREEAG SOFTW INC, 1995, DATA VERS 2 6; 1995, MED LETT DRUGS THER, V37, P6; [No title captured]; 1993, MMWR-MORBID MORTAL W, V42, P504; 1995, STAT NOTES, V7, P1	53	160	161	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1247	1251		10.1001/jama.275.16.1247	http://dx.doi.org/10.1001/jama.275.16.1247			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF478	8601956				2022-12-28	WOS:A1996UF47800028
J	Moore, MS				Moore, MS			Generation of GTP-Ran for nuclear protein import	SCIENCE			English	Editorial Material											Moore, MS (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.							Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120	2	7	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					47	47		10.1126/science.272.5258.47	http://dx.doi.org/10.1126/science.272.5258.47			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600534				2022-12-28	WOS:A1996UD59700033
J	Todo, T; Ryo, H; Yamamoto, K; Toh, H; Inui, T; Ayaki, H; Nomura, T; Ikenaga, M				Todo, T; Ryo, H; Yamamoto, K; Toh, H; Inui, T; Ayaki, H; Nomura, T; Ikenaga, M			Similarity among the Drosophila (6-4)photolyase, a human photolyase homolog, and the DNA photolyase-blue-light photoreceptor family	SCIENCE			English	Article							(6-4)PHOTOPRODUCTS; PROTEIN	Ultraviolet light (UV)-induced DNA damage can be repaired by DNA photolyase in a light-dependent manner. Two types of photolyase are known, one specific for cyclobutane pyrimidine dimers (CPD photolyase) and another specific for pyrimidine (6-4) pyrimidone photoproducts [(6-4)photolyase]. In contrast to the CPD photolyase, which has been detected in a wide variety of organisms, the (6-4)photolyase has been found only in Drosophila melanogaster. In the present study a gene encoding the Drosophila (6-4)photolyase was cloned, and the deduced amino acid sequence of the product was found to be similar to the CPD photolyase and to the blue-light photoreceptor of plants. A homolog of the Drosophila (6-4)photolyase gene was also cloned from human cells.	OSAKA UNIV, FAC MED, DEPT RADIAT BIOL, SUITA, OSAKA 565, JAPAN; TOHOKU UNIV, FAC SCI, DEPT BIOL, AOBA KU, SENDAI, MIYAGI 98077, JAPAN; KYUSHU INST TECHNOL, FAC COMP SCI & SYST ENGN, DEPT BIOCHEM ENGN & SCI, IIZUKA, FUKUOKA 820, JAPAN	Osaka University; Tohoku University; Kyushu Institute of Technology	Todo, T (corresponding author), KYOTO UNIV, CTR RADIAT BIOL, SAKYO KU, YOSHIDA KONECHO, KYOTO 60601, JAPAN.							AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; BARTON GJ, 1987, J MOL BIOL, V198, P327, DOI 10.1016/0022-2836(87)90316-0; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; FRIEDBERG EC, 1995, DNA REPAIR; Harm W, 1980, BIOL EFFECTS ULTRAVI; KATO T, 1994, NUCLEIC ACIDS RES, V22, P4119, DOI 10.1093/nar/22.20.4119; KIM ST, 1994, J BIOL CHEM, V269, P8535; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; MALHOTRA K, 1994, BIOCHEMISTRY-US, V33, P8712, DOI 10.1021/bi00195a012; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; MATSUNAGA T, 1993, PHOTOCHEM PHOTOBIOL, V57, P934, DOI 10.1111/j.1751-1097.1993.tb02952.x; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; SMALL GD, 1995, PLANT MOL BIOL, V28, P443, DOI 10.1007/BF00020393; TODO T, 1994, MUTAT RES-DNA REPAIR, V315, P213, DOI 10.1016/0921-8777(94)90033-7; TODO T, 1993, NATURE, V361, P371, DOI 10.1038/361371a0; TODO T, 1992, MUTAT RES, V273, P85, DOI 10.1016/0921-8777(92)90052-5; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x	21	219	227	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					109	112		10.1126/science.272.5258.109	http://dx.doi.org/10.1126/science.272.5258.109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600518				2022-12-28	WOS:A1996UD59700050
J	Bernhard, JD				Bernhard, JD			Mastocytosis: For better and worse	LANCET			English	Editorial Material							SYSTEMIC MASTOCYTOSIS				Bernhard, JD (corresponding author), UNIV MASSACHUSETTS,MED CTR,DIV DERMATOL,WORCESTER,MA 01605, USA.							AUSTEN KF, 1992, NEW ENGL J MED, V326, P639, DOI 10.1056/NEJM199202273260912; BERNHARD JD, 1994, ITCH MECHANISMS MANA, P251; DUFFY TP, 1993, NEW ENGL J MED, V328, P1333, DOI 10.1056/NEJM199305063281809; FRIEDMAN BS, 1994, J ALLERGY CLIN IMMUN, V93, P53, DOI 10.1016/0091-6749(94)90232-1; KENDALL ME, 1984, J AM ACAD DERMATOL, V10, P903, DOI 10.1016/S0190-9622(84)80443-0; Kors JW, 1996, J INTERN MED, V239, P157, DOI 10.1046/j.1365-2796.1996.440787000.x; KUTER I, 1992, NEW ENGL J MED, V326, P472; LEGRAIN V, 1994, ANN DERMATOL VENER, V121, P561; LONGLEY J, 1995, J AM ACAD DERMATOL, V32, P545, DOI 10.1016/0190-9622(95)90336-4; MAHOOD JM, 1982, ACTA DERM-VENEREOL, V62, P264; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS2, DOI 10.1111/1523-1747.ep12468882; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; TUR E, 1990, DERMATOLOGICA, V181, P5, DOI 10.1159/000247849	13	2	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					705	705		10.1016/S0140-6736(96)90070-7	http://dx.doi.org/10.1016/S0140-6736(96)90070-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8601995	Bronze			2022-12-28	WOS:A1996TZ98200003
J	Stearman, R; Yuan, DS; YamaguchiIwai, Y; Klausner, RD; Dancis, A				Stearman, R; Yuan, DS; YamaguchiIwai, Y; Klausner, RD; Dancis, A			A permease-oxidase complex involved in high-affinity iron uptake in yeast	SCIENCE			English	Article							WILSON DISEASE GENE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; FERRIC REDUCTASE; PROTEIN; ATPASE	Iron must cross biological membranes to reach essential intracellular enzymes. Two proteins in the plasma membrane of yeast-a multicopper oxidase, encoded by the FET3 gene, and a permease, encoded by the FTR1 gene-were shown to mediate high-affinity iron uptake. FET3 expression was required for FTR1 protein to be transported to the plasma membrane. FTR1 expression was required for apo-FET3 protein to be loaded with copper and thus acquire oxidase activity. FTR1 protein also played a direct role in iron transport. Mutations in a conserved sequence motif of FTR1 specifically blocked iron transport.	NICHHD, CELL BIOL & METAB BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BAGG A, 1987, BIOCHEMISTRY-US, V26, P5471, DOI 10.1021/bi00391a039; BOMFORD A, 1976, Q J MED, V45, P611; BOTHWELL TH, 1995, METABOLIC MOL BASES, P2237; Brittenham Gary M., 1995, P492; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Cammack R, 1990, IRON TRANSPORT STORA, P17; CHANEY RL, 1988, J PLANT NUTR, V11, P1033, DOI 10.1080/01904168809363867; CONRAD ME, 1993, BLOOD, V81, P517; CRICHTON RR, 1991, INORGANIC BIOCH IRON, P144; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DIX DR, 1994, J BIOL CHEM, V269, P26092; DOOLING EC, 1974, ARCH NEUROL-CHICAGO, V30, P770; DOOLING EC, 1995, NEUROLOGY, V45, P1138; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; *GEN COMP GROUP, 1994, PROGRMA MANUAL WISCO; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; HALLERVORDENSPA.EC, 1980, NEUROLOGY, V30, P1128; Halliwell B., 1991, FREE RADICALS BIOL M; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; KAMMLER M, 1993, J BACTERIOL, V175, P6212, DOI 10.1128/JB.175.19.6212-6219.1993; KARLIN KD, 1993, SCIENCE, V261, P701, DOI 10.1126/science.7688141; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LEE GR, 1968, J CLIN INVEST, V47, P2058, DOI 10.1172/JCI105891; LESUISSE E, 1987, J GEN MICROBIOL, V133, P3229; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; LI CY, 1994, J BIOL CHEM, V269, P10242; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P125; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; NIELANDS JB, 1981, ANNU REV NUTR, V1, P27; OREILLY S, 1968, NEUROLOGY, V18, P634, DOI 10.1212/WNL.18.7.634; OSAKI S, 1966, J BIOL CHEM, V241, P2746; RINE J, 1991, METHOD ENZYMOL, V194, P239; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROESER HP, 1970, J CLIN INVEST, V49, P2408, DOI 10.1172/JCI106460; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SMITH C, 1992, BIOCHEM J, V286, P901, DOI 10.1042/bj2860901; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TRIKHA J, 1995, J MOL BIOL, V248, P949, DOI 10.1006/jmbi.1995.0274; WANG X, 1995, J NEUROCHEM, V74, P1868; WEINBERG ED, 1985, J PHARMACOL-PARIS, V16, P358; WILLIAMS RJP, 1990, IRON TRANSPORT STORA, P2; Winkelmann G, 1987, IRON TRANSPORT MICRO; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YAMAGUCHIIWAI Y, UNPUB; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; YUAN DS, UNPUB	57	561	575	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1996	271	5255					1552	1557		10.1126/science.271.5255.1552	http://dx.doi.org/10.1126/science.271.5255.1552			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599111				2022-12-28	WOS:A1996TZ98300032
J	Blendy, JA; Kaestner, KH; Weinbauer, GF; Nieschlag, E; Schutz, G				Blendy, JA; Kaestner, KH; Weinbauer, GF; Nieschlag, E; Schutz, G			Severe impairment of spermatogenesis in mice lacking the CREM gene	NATURE			English	Article							MAJOR CHROMOSOMAL PROTEIN; CDNA CLONE; MITOCHONDRIAL CAPSULE; MAMMALIAN SPERMATIDS; TRANSITION PROTEIN-1; NUCLEOTIDE-SEQUENCE; MOUSE PROTAMINE-1; MESSENGER-RNAS; SELENO-PROTEIN; EXPRESSION	Spermatogenesis is a complex developmental process that occurs in several phases. A large number of genes have been identified that are expressed during spermatogenesis(1,2), but the biological significance of many of these is not yet known. We have used gene targeting to selectively eliminate the transcription factor CREM (cyclic AMP-responsive element modulator), which is thought to be important for mammalian spermatogenesis(3-5). Male mice deficient for all CREM proteins are sterile, as their developing spermatids fail to differentiate into sperm, and postmeiotic gene expression in the testis declines dramatically. The cessation of sperm development is not accompanied by decreases in the levels of follicle-stimulating hormone or testosterone. Our findings indicate that the CREM gene is essential for spermatogenesis, and mice deficient for this transcription factor could serve as a model system for the study of idiopathic infertility in men.	GERMAN CANC RES CTR,MOL BIOL CELL DIV 1,D-69120 HEIDELBERG,GERMANY; UNIV MUNSTER,INST REPROD MED,D-48149 MUNSTER,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); University of Munster								ADHAM IM, IN PRESS DNA CELL BI; ANAKWE OO, 1991, MOL REPROD DEV, V29, P172, DOI 10.1002/mrd.1080290213; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; CHANDOLIA RK, 1991, ACTA ENDOCRINOL-COP, V125, P547, DOI 10.1530/acta.0.1250547; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; ERIKSON RP, 1990, TRENDS GENET, V6, P264; ESCALIER D, 1991, DEVELOPMENT, V1133, P779; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; HEIDARAN MA, 1987, GENE, V54, P281, DOI 10.1016/0378-1119(87)90498-7; HEIDARAN MA, 1988, J CELL BIOL, V106, P1427, DOI 10.1083/jcb.106.5.1427; HURST HC, 1995, PROTEIN PROFILE, V2, P105; KAESTNER KH, 1994, GENE, V148, P67, DOI 10.1016/0378-1119(94)90234-8; KASHIWABARA S, 1990, BIOCHEM BIOPH RES CO, V173, P240, DOI 10.1016/S0006-291X(05)81047-2; KISTLE RMK, 1994, BIOL REPROD, V51, P1322; KLEENE KC, 1985, BIOCHEMISTRY-US, V24, P719, DOI 10.1021/bi00324a027; KLEENE KC, 1988, BIOCHIM BIOPHYS ACTA, V950, P215, DOI 10.1016/0167-4781(88)90013-9; KLEENE KC, 1989, DEVELOPMENT, V106, P367; KLEENE KC, 1990, DEV BIOL, V137, P395, DOI 10.1016/0012-1606(90)90263-I; KLEMM U, 1990, DIFFERENTIATION, V42, P160, DOI 10.1111/j.1432-0436.1990.tb00757.x; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; NIESCHLAG E, 1993, CLIN ENDOCRINOL, V38, P123, DOI 10.1111/j.1365-2265.1993.tb00983.x; Russell L.D., 1990, HISTOLOGICAL HISTOPA, P119; SHIH DM, 1992, MOL REPROD DEV, V33, P222, DOI 10.1002/mrd.1080330216; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; VANDERHOORN FA, 1992, P NATL ACAD SCI USA, V89, P703, DOI 10.1073/pnas.89.2.703; WEINBAUER GF, 1993, MOL BIOL MALE REPROD, P99; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071	31	422	447	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					162	165		10.1038/380162a0	http://dx.doi.org/10.1038/380162a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600391				2022-12-28	WOS:A1996TZ97800052
J	Mason, BJ; Kocsis, JH; Ritvo, EC; Cutler, RB				Mason, BJ; Kocsis, JH; Ritvo, EC; Cutler, RB			A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PSYCHIATRIC-DISORDERS; CONSUMMATORY BEHAVIORS; CLINICAL IMPLICATIONS; DIAGNOSTIC CRITERIA; ETHANOL INTAKE; DRUG-ABUSE; FLUOXETINE; COMORBIDITY; NALTREXONE; POPULATION	Objective.-To assess the use of desipramine for secondary depression in primary alcohol dependence and its effect on abstinence. Design.-Randomized, double-blind, placebo-controlled trial, with stratification on the presence of secondary depression. Subjects.-Seventy-one volunteer and referred patients with primary alcohol dependence, abstinent a median of 8 days before randomization. A subset of 28 patients had major depression secondary to alcoholism. Setting.-The outpatient psychiatry departments of two urban medical centers. Intervention.-Six months of a clinically determined dose of desipramine. Main Outcome Measures.-Hamilton Depression Rating Scale, and Time Line Follow Back Interview, with breath alcohol concentrations and collateral verification. Results.-Hamilton Depression scores of desipramine-treated depressed alcoholics decreased significantly, controlling for baseline Hamilton Depression scores (P=.04). Overall, patients were abstinent significantly longer when receiving desipramine (P=.03). Rates of relapse of depressed vs nondepressed patients, analyzed separately, were not significant, although the survival function approached significance for the depressed Subgroup (P=.09). Desipramine-treated depressed patients were more satisfied and were rated as more improved. Conclusions.-Major depression secondary to alcohol dependence that is diagnosed after at least 1 week of abstinence can remain stable in some placebo-treated alcoholics and can respond to desipramine. Treating depression secondary to alcoholism may reduce risk for drinking relapse in some patients. Use of desipramine to reduce relapse in nondepressed alcoholics is not supported.	CORNELL UNIV,COLL MED,DEPT PSYCHIAT,NEW YORK,NY	Cornell University	Mason, BJ (corresponding author), UNIV MIAMI,SCH MED,DEPT PSYCHIAT & BEHAV SCI,1400 NW 10 AVE,SUITE 307,MIAMI,FL 33136, USA.		Mason, Barbara J/P-6604-2016		NIAAA NIH HHS [AA08111, AA06866] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R23AA006866, R01AA008111] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; BERGLUND M, 1984, ARCH GEN PSYCHIAT, V41, P888; BERKSON J, 1988, ARCH GEN PSYCHIAT, V45, P1023; BROWN SA, 1995, AM J PSYCHIAT, V152, P45; BROWN SA, 1988, J STUD ALCOHOL, V49, P41; CIRAULO DA, 1981, J CLIN PSYCHOPHARM, V1, P146, DOI 10.1097/00004714-198105000-00006; CIRAULO DA, 1981, J CLIN PSYCHOPHARM, V68, P819; CORNELIUS JR, 1993, PSYCHOPHARMACOL BULL, V29, P195; DVOREDSKY AE, 1986, PSYCHOSOMATICS, V27, P625, DOI 10.1016/S0033-3182(86)72631-5; FEIGHNER JP, 1972, ARCH GEN PSYCHIAT, V26, P57, DOI 10.1001/archpsyc.1972.01750190059011; FOLSTEIN MF, 1983, ASSESSMENT GERIATRIC, P46; FULLER MG, 1994, HEALTH CARE MANAGE R, V19, P20; FULOP G, 1987, AM J PSYCHIAT, V144, P878; Gordis E., 1989, ALCOHOL ALERT, V6, P3; GORELICK DA, 1992, ALCOHOL CLIN EXP RES, V16, P261, DOI 10.1111/j.1530-0277.1992.tb01373.x; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P405; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HATSUKAMI D, 1982, AM J PSYCHIAT, V139, P1563; HELZER JE, 1988, J STUD ALCOHOL, V49, P219, DOI 10.15288/jsa.1988.49.219; Holder H D, 1986, Adv Alcohol Subst Abuse, V6, P1; HOLDER HD, 1986, JAMA-J AM MED ASSOC, V256, P1456, DOI 10.1001/jama.256.11.1456; Kissin B, 1968, Psychiatr Res Rep Am Psychiatr Assoc, V24, P44; KLERMAN GL, 1974, AM J PSYCHIAT, V131, P186, DOI 10.1176/ajp.131.2.186; KRANZLER HR, 1995, AM J PSYCHIAT, V152, P391; Litten RZ, 1995, EXP CLIN PSYCHOPHARM, V3, P87; MALKA R, 1992, BRIT J PSYCHIAT, V15, P66; MASON BJ, 1994, ALCOHOL CLIN EXP RES, V18, P1162, DOI 10.1111/j.1530-0277.1994.tb00098.x; MASON BJ, 1991, PSYCHOPHARMACOL BULL, V27, P155; MASON BJ, 1992, NEW CLIN DRUG EV UN; MCBRIDE WJ, 1988, PHARMACOL BIOCHEM BE, V30, P1045, DOI 10.1016/0091-3057(88)90137-2; MINDHAM RHS, 1973, PSYCHOL MED, V3, P5, DOI 10.1017/S0033291700046304; NARANJO CA, 1987, CLIN PHARMACOL THER, V41, P266, DOI 10.1038/clpt.1987.27; NARANJO CA, 1989, CLIN PHARMACOL THER, V46, P301, DOI 10.1038/clpt.1989.142; NARANJO CA, 1986, J CLIN PSYCHIAT, V47, P16; NARANJO CA, 1984, CLIN PHARMACOL THER, V35, P374, DOI 10.1038/clpt.1984.46; NARANJO CA, 1990, CLIN PHARMACOL THER, V47, P490, DOI 10.1038/clpt.1990.62; NELSON JC, 1982, ARCH GEN PSYCHIAT, V39, P1419; NUNES EV, 1993, AM J PSYCHIAT, V150, P963; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; Polich J. M., 1981, COURSE ALCOHOLISM 4, P159; POTTENGER M, 1978, J NERV MENT DIS, V166, P562, DOI 10.1097/00005053-197808000-00003; Puri Madan Lal, 1971, WILEY PUBLICATION MA; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; ROSS HE, 1988, ARCH GEN PSYCHIAT, V45, P1023; SARAVAY SM, 1991, AM J PSYCHIAT, V148, P324; SCHUCKIT MA, 1985, ARCH GEN PSYCHIAT, V42, P1043; SCHUCKIT MA, 1986, AM J PSYCHIAT, V143, P140; SCHUCKIT MA, 1983, HOSP COMMUNITY PSYCH, V34, P1022; SHAW GK, 1987, BRIT J PSYCHIAT, V150, P164, DOI 10.1192/bjp.150.2.164; SKINNER HA, 1982, J ABNORM PSYCHOL, V91, P199, DOI 10.1037/0021-843X.91.3.199; SOBELL LC, 1980, EVALUATING ALCOHOL D, P129; *SPSS INC, 1990, SPSS PC PLUS; SUCKOW RF, 1981, J PHARM SCI, V70, P257, DOI 10.1002/jps.2600700307; VOLMOT R, 1981, J CLIN PHARMACOL, V24, P615; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; ZOOK CJ, 1980, NEW ENGL J MED, V302, P996, DOI 10.1056/NEJM198005013021804; 1985, PSYCHOPHARMACOL B, V0021, P01069	59	178	180	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1996	275	10					761	767		10.1001/jama.275.10.761	http://dx.doi.org/10.1001/jama.275.10.761			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TY886	8598592				2022-12-28	WOS:A1996TY88600023
J	Treasure, T				Treasure, T			Do whatever works in your hands	LANCET			English	Editorial Material											Treasure, T (corresponding author), UNIV LONDON ST GEORGES HOSP,REG CARDIOTHORAC UNIT,LONDON,ENGLAND.							ANDERSON JR, 1994, ANN THORAC SURG, V58, P768, DOI 10.1016/0003-4975(94)90745-5; GRANSHAW L, 1967, MED INNOVATIONS HIST; Pye D., 1968, NATURE ART WORKMANSH; TREASURE T, 1990, LANCET, V336, P1115, DOI 10.1016/0140-6736(90)92583-4; WILSON SJ, 1996, ANN R COLL SURG, V18, P20	5	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					559	560		10.1016/S0140-6736(96)91268-4	http://dx.doi.org/10.1016/S0140-6736(96)91268-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596315				2022-12-28	WOS:A1996TX69400006
J	Jernigan, DB; Hofmann, J; Cetron, MS; Genese, CA; Nuorti, JP; Fields, BS; Benson, RF; Carter, RJ; Edelstein, PH; Guerrero, IC; Paul, SM; Lipman, HB; Breiman, RF				Jernigan, DB; Hofmann, J; Cetron, MS; Genese, CA; Nuorti, JP; Fields, BS; Benson, RF; Carter, RJ; Edelstein, PH; Guerrero, IC; Paul, SM; Lipman, HB; Breiman, RF			Outbreak of Legionnaires' disease among cruise ship passengers exposed to a contaminated whirlpool spa	LANCET			English	Article							LEGIONELLA-PNEUMOPHILA SEROGROUP-1; POLYMERASE CHAIN-REACTION; PONTIAC FEVER; PNEUMONIA	Background Outbreaks of travel-related Legionnaires' disease present a public-health challenge since rapid, sensitive, and specific diagnostic tests are not widely used and because detection of clusters of disease among travellers is difficult. We report an outbreak of Legionnaires' disease among cruise ship passengers that occurred in April, 1994, but that went unrecognised until July, 1994. Methods After rapid diagnosis of Legionnaires' disease in three passengers by urine antigen testing, we searched for additional cases of either confirmed (laboratory evidence of infection) or probable Legionnaires' disease (pneumonia of undetermined cause). A case-control study was conducted to compare exposures and activities on the ship and in ports of call between each case-passenger and two or three matched control-passengers. Water samples from the ship, from sites on Bermuda, and from the ship's water source in New York City were cultured for legionellae and examined with PCR. Findings 50 passengers with Legionnaires' disease (16 confirmed, 34 probable) were identified from nine cruises embarking between April 30 and July 9, 1994. Exposure to whirlpool spas was strongly associated with disease (odds ratio 16.2, 95% CI 2.8-351.7); risk of acquiring Legionnaires' disease increased by 64% (95% CI 12-140) for every hour spent in the spa water. Passengers spending time around the whirlpool spas, but not in the water, were also significantly more likely to have acquired infection. Legionella pneumophila serogroup 1 was isolated only from the sand filter in the ship's whirlpool spa. This isolate matched a clinical isolate from the respiratory secretions of a case-passenger as judged by monoclonal antibody subtyping and by arbitrarily primed PCR. Interpretation This investigation shows the benefit of obtaining a recent travel history, the usefulness or urine antigen testing for rapid diagnosis of legionella infection, and the need for improved surveillance for travel-related Legionnaires' disease. New strategies for whirlpool spa maintenance and decontamination may help to minimise transmission of legionellae from these aerosol-producing devices.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,BIOSTAT & INFORMAT MANAGEMENT BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,DIV FIELD EPIDEMIOL,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30333; NEW JERSEY STATE DEPT HLTH,DIV EPIDEMIOL,TRENTON,NJ; HOSP UNIV PENN,PHILADELPHIA,PA 19104; TOMS RIVER COMMUNITY MED CTR,TOMS RIVER,NJ	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; New Jersey Department of Health & Senior Services; University of Pennsylvania; Pennsylvania Medicine	Jernigan, DB (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,CHILDHOOD & RESP DIS BRANCH,MS CO9,1600 CLIFTON RD,ATLANTA,GA 30333, USA.		Paul, Steve/ABE-5400-2020; Edelstein, Paul/I-5527-2019	Edelstein, Paul/0000-0002-4069-5279				AGUEROROSENFELD ME, 1988, J CLIN MICROBIOL, V26, P1775, DOI 10.1128/JCM.26.9.1775-1778.1988; BARON PA, 1986, ENVIRON RES, V39, P8, DOI 10.1016/S0013-9351(86)80003-2; EDELSTEIN PH, 1985, MANUAL CLIN MICROBIO, P373; EDELSTEIN PH, 1992, MANUAL CLIN LAB IMMU, P459; GOLDBERG DJ, 1989, LANCET, V1, P316; GOMEZLUS P, 1993, J CLIN MICROBIOL, V31, P1940, DOI 10.1128/JCM.31.7.1940-1942.1993; GRIST NR, 1979, ANN INTERN MED, V90, P563, DOI 10.7326/0003-4819-90-4-563; HOGE CW, 1991, EPIDEMIOL REV, V13, P329, DOI 10.1093/oxfordjournals.epirev.a036076; JOLY JR, 1986, J CLIN MICROBIOL, V23, P768, DOI 10.1128/JCM.23.4.768-771.1986; Joseph C A, 1994, Commun Dis Rep CDR Rev, V4, pR109; Joseph C A, 1993, Commun Dis Rep CDR Rev, V3, pR124; KALLINGS I, 1991, TRAVEL MED, V2, P228; KAUFMANN AF, 1981, AM J EPIDEMIOL, V114, P337, DOI 10.1093/oxfordjournals.aje.a113200; KOHLER RB, 1986, DIAGN MICR INFEC DIS, V4, pS47, DOI 10.1016/S0732-8893(86)80042-6; MANGIONE EJ, 1985, JAMA-J AM MED ASSOC, V253, P535; MARSTON BJ, 1994, ARCH INTERN MED, V154, P2417, DOI 10.1001/archinte.154.21.2417; MILLER LA, 1993, J INFECT DIS, V168, P769, DOI 10.1093/infdis/168.3.769; PLOUFFE JF, 1995, CLIN INFECT DIS, V20, P1286, DOI 10.1093/clinids/20.5.1286; REINGOLD AL, 1984, J INFECT DIS, V149, P819, DOI 10.1093/infdis/149.5.819; SANDEN GN, 1993, J CLIN MICROBIOL, V31, P170, DOI 10.1128/JCM.31.1.170-172.1993; SPITALNY KC, 1984, AM J EPIDEMIOL, V120, P809, DOI 10.1093/oxfordjournals.aje.a113953; THOMAS DL, 1993, ARCH INTERN MED, V153, P2597, DOI 10.1001/archinte.153.22.2597; VOGT RL, 1987, ANN INTERN MED, V107, P596, DOI 10.7326/0003-4819-107-4-596_1; 1994, CRUISE IND OVERVIEW; 1985, US DEP HLTH HUMAN SE; 1994, COMMUNICAB DIS REP, V4, P25; 1989, US DEP HLTH HUMAN SE, P12; 1991, COMMUNICAB DIS REP, V1, P157; 1994, MMWR-MORBID MORTAL W, V43, P521; 1992, PROCEDURES RECOVERY	30	134	143	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					494	499		10.1016/S0140-6736(96)91137-X	http://dx.doi.org/10.1016/S0140-6736(96)91137-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596266	hybrid			2022-12-28	WOS:A1996TW69700008
J	Frenette, PS; Mayadas, TN; Rayburn, H; Hynes, RO; Wagner, DD				Frenette, PS; Mayadas, TN; Rayburn, H; Hynes, RO; Wagner, DD			Susceptibility to infection and altered hematopoiesis in mice deficient in both P- and E-selectins	CELL			English	Article							LEUKOCYTE ADHESION DEFICIENCY; MOUSE; EXPRESSION; MOLECULE-1; CLONING; INVIVO; RATS	We describe the phenotype of mice lacking both endothelial selectins after sequential ablation of the genes encoding P- and E-selectins. In contrast with the rather mild phenotypes observed in mice deficient in a single selectin gene, the doubly deficient mice present extreme leukocytosis, elevated cytokine levels, and alterations in hematopoiesis. Granulocytopoiesis is increased both in bone marrow and spleen, while erythropoiesis is partially translocated to the spleen. Virtual lack of leukocyte rolling and low extravasation at sites of inflammation make these animals susceptible to opportunistic bacterial infections, to which they succumb. Our results show that the absence of endothelial selectins severely affects leukocyte homeostasis and indicate that these two selectins are as important for normal leukocyte function as are the leukocyte beta 2 integrins.	HARVARD UNIV,SCH MED,CTR BLOOD RES,DEPT PATHOL,BOSTON,MA 02115; MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard Medical School			Frenette, Paul S/J-8272-2012	Frenette, Paul S/0000-0003-0862-9922	NHLBI NIH HHS [P01 HL41484, HL53756, HL41002] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL041002, R01HL053756, R01HL041002, P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; BAKER M, 1974, MICROVASC RES, V7, P131, DOI 10.1016/0026-2862(74)90043-0; BARTOCCI A, 1987, P NATL ACAD SCI USA, V84, P6179, DOI 10.1073/pnas.84.17.6179; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FRIES JWU, 1993, AM J PATHOL, V143, P725; FRYDMAN M, 1992, AM J MED GENET, V44, P297, DOI 10.1002/ajmg.1320440307; JOHNSON RC, 1995, BLOOD, V86, P1106; LABOW MA, 1994, IMMUNITY, V1, P709, DOI 10.1016/1074-7613(94)90041-8; LEY K, 1991, BLOOD, V77, P2553; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MOLINEUX G, 1990, BLOOD, V75, P563; ODELL TT, 1979, P SOC EXP BIOL MED, V160, P263; OLOFSSON AM, 1994, BLOOD, V84, P2749, DOI 10.1182/blood.V84.8.2749.bloodjournal8482749; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; SANDERS WE, 1992, BLOOD, V80, P795; SAWAI S, 1991, NEW BIOL, V3, P861; SCHOOLEY JC, 1972, BLOOD-J HEMATOL, V40, P662, DOI 10.1182/blood.V40.5.662.662; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; WELLER A, 1992, J BIOL CHEM, V267, P15176; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; WILSON RW, 1993, J IMMUNOL, V151, P1571; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95; YAMADA S, 1995, BLOOD, V86, P3487, DOI 10.1182/blood.V86.9.3487.bloodjournal8693487; ZANNETTINO ACW, 1995, BLOOD, V85, P3466, DOI 10.1182/blood.V85.12.3466.bloodjournal85123466	32	450	459	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					563	574		10.1016/S0092-8674(00)81032-6	http://dx.doi.org/10.1016/S0092-8674(00)81032-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598043	Bronze			2022-12-28	WOS:A1996TX17600009
J	Leon, DA; Koupilova, I; Lithell, HO; Berglund, L; Mohsen, R; Vagero, D; Lithell, UB; McKeigue, PM				Leon, DA; Koupilova, I; Lithell, HO; Berglund, L; Mohsen, R; Vagero, D; Lithell, UB; McKeigue, PM			Failure to realise growth potential in utero and adult obesity in relation to blood pressure in 50 year old Swedish men	BRITISH MEDICAL JOURNAL			English	Article							NATIONAL BIRTH COHORT; HYPERTENSION; FETAL; RISK; LIFE; ENVIRONMENT; CHILDHOOD; INUTERO; AGE	Objectives-To clarify the type of fetal growth impairment associated with increased blood pressure in adult life, and to establish whether this association is influenced by obesity and is mediated through impairment of insulin action. Design-Cross sectional survey with retrospective ascertainment of size at birth from obstetric archives. Subjects-1333 men resident in Uppsala, Sweden, who took part in a 1970 study of coronary risk factors at age 50 and for whom birth weight was traced. Main outcome measures-Systolic and diastolic blood pressure at age 50. Results-In the full study population for a 1000 g increase in birth weight there was a small change in systolic blood pressure of -2.2 mm Hg (95% confidence interval -4.2 to -0.3 mm Hg) and in diastolic blood pressure of -1.0 mm Hg (-2.2 to 0.1 mm Hg). Much stronger effects were observed among men who were born at term and were in the top third of body mass index at age 50, for whom a 1000 g increase in birth weight was associated with a change of -9.1 mm Hg (-16.4 to -1.9 mm Hg) systolic and -4.2 mm Hg (-8.3 to -0.1 mm Hg) diastolic blood pressure. Men who were light at birth (< 3250 g) but were of above median adult height had particularly high blood pressure. Adjustment for insulin concentrations reduced the associations of birth weight with systolic and diastolic blood pressure. Conclusions-A failure to realise growth potential in utero (as indicated by being light at birth but tall as an adult) is associated with raised adult blood pressure. Impaired fetal growth may lead to substantial increases in adult blood pressure among only those who become obese. Metabolic disturbances, possibly related to insulin resistance, may provide a pathway through which fetal growth affects blood pressure.	UNIV UPPSALA,INST GERIATR,S-75125 UPPSALA,SWEDEN; UNIV STOCKHOLM,SWEDISH INST SOCIAL RES,S-10691 STOCKHOLM,SWEDEN	Uppsala University; Stockholm University	Leon, DA (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,EPIDEMIOL UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Koupil, Ilona/AAC-9067-2020; Berglund, Lars/AAD-3856-2019; Leon, David A/G-2195-2010; Berglund, Lars/AAA-3188-2019	Koupil, Ilona/0000-0002-7034-1922; Berglund, Lars/0000-0002-7437-9047; Leon, David A/0000-0001-9747-1762; 				ANDERSON EA, 1993, HYPERTENSION, V21, P136, DOI 10.1161/01.HYP.21.2.136; BAKKETEIG L, 1989, EFFECTIVE CARE PREGN, P765; Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BRENNER BM, 1994, AM J KIDNEY DIS, V23, P171, DOI 10.1016/S0272-6386(12)80967-X; COHEN MP, 1988, DIABETES, V37, P824, DOI 10.2337/diabetes.37.6.824; EDWARDS CRW, 1993, LANCET, V341, P355, DOI 10.1016/0140-6736(93)90148-A; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; Gruenwald P, 1974, CIBA F S, V27, P3; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HALES CN, 1994, SCI AM           JUL, P54; HEDSTRAND H, 1976, ACTA MED SCAND, V199, P281; HOLLAND FJ, 1993, J EPIDEMIOL COMMUN H, V47, P432, DOI 10.1136/jech.47.6.432; KUH D, 1989, INT J EPIDEMIOL, V18, P663, DOI 10.1093/ije/18.3.663; LAW CM, 1994, J HYPERTENS, V12, P1329; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; MARTYN CN, 1995, BRIT HEART J, V73, P116; OUNSTED MK, 1985, ARCH DIS CHILD, V60, P631, DOI 10.1136/adc.60.7.631; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PETTITT DJ, 1988, DIABETES, V37, P622, DOI 10.2337/diabetes.37.5.622; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; SEIDMAN DS, 1993, ISRAEL J MED SCI, V29, P772; SKARFORS ET, 1991, J HYPERTENS, V9, P217, DOI 10.1097/00004872-199103000-00004; Stein Z., 1975, FAMINE HUM DEV DUTCH; WADSWORTH MEJ, 1985, BRIT MED J, V291, P1534, DOI 10.1136/bmj.291.6508.1534; 1993, STATA REFERENCE MANU	29	332	340	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	1996	312	7028					401	406						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601110	Green Published			2022-12-28	WOS:A1996TW56400019
J	Hadjivassiliou, M; Gibson, A; DaviesJones, GAB; Lobo, AJ; Stephenson, TJ; MilfordWard, A				Hadjivassiliou, M; Gibson, A; DaviesJones, GAB; Lobo, AJ; Stephenson, TJ; MilfordWard, A			Does cryptic gluten sensitivity play a part in neurological illness?	LANCET			English	Article							CELIAC-DISEASE; ANTIGLIADIN ANTIBODIES; FREE DIET; MALIGNANCY	Background Antigliadin antibodies are a marker of untreated coeliac disease but can also be foun in individuals with normal small-bowel mucosa. Because neurological dysfunction is a known complication of coeliac disease we have investigated the frequency of antigliadin antibodies, as a measure of cryptic gluten sensitivity, and coeliac disease in neurological patients. Methods Using ELISA, we estimated serum IgG and IgA antigliadin antibodies in 147 neurological patients who were divided into two groups. There were 53 patients with neurological dysfunction of unknown cause despite full investigation (25 ataxia, 20 peripheral neuropathy, 5 mononeuritis multiplex, 4 myopathy, 3 motor neuropathy, 2 myelopathy). The remaining 94 patients were found to have a specific neurological diagnosis (16 stroke, 12 multiple sclerosis, 10 Parkinson's disease, 56 other diagnoses) and formed the neurological control group. 50 healthy blood donors formed a third group. Findings The proportions of individuals with positive titres for antigliadin antibodies in the three groups were 30/53, 5/94, and 6/50 respectively (57, 5, and 12%). The difference in proportion between group 1 and the combined control groups was 0.49 (95% CI 0.35-0.63). Distal duodenal biopsies in 26 out of 30 antigliadin-positive patients from group 1 revealed histological evidence of coeliac disease in nine (35%), non-specific duodenitis in ten (38%), and no lesion in seven (26%) individuals. Interpretation Our data suggest that gluten sensitivity is common in patients with neurological disease of unknown cause and may have aetiological significance.	ROYAL HALLAMSHIRE HOSP,DEPT GASTROENTEROL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND; ROYAL HALLAMSHIRE HOSP,DEPT HISTOPATHOL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND; NO GEN HOSP,DEPT IMMUNOL,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND; ROYAL HALLAMSHIRE HOSP,DEPT NEUROL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield; University of Sheffield; Northern General Hospital; University of Sheffield								CATASSI C, 1994, LANCET, V343, P200, DOI 10.1016/S0140-6736(94)90989-X; COOKE WT, 1984, COELIAC DIS, P197; COOKE WT, 1976, HDB CLIN NEUROLOGY, V28, P225; COOPER BT, 1980, MEDICINE, V59, P249, DOI 10.1097/00005792-198007000-00002; GRODZINSKY E, 1992, ANN ALLERGY, V69, P66; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; LEE FD, 1980, BIOPSY PATHOLOGY SMA, P97; MAKI M, 1990, ARCH DIS CHILD, V65, P1137, DOI 10.1136/adc.65.10.1137; MARSH MN, 1995, Q J MED, V85, P9; MAYER M, 1991, GUT, V32, P881, DOI 10.1136/gut.32.8.881; TRONCONE R, 1991, J PEDIATR GASTR NUTR, V12, P150, DOI 10.1097/00005176-199102000-00002	11	335	369	0	22	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					369	371		10.1016/S0140-6736(96)90540-1	http://dx.doi.org/10.1016/S0140-6736(96)90540-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598704				2022-12-28	WOS:A1996TU69500012
J	HolgadoMadruga, M; Emlet, DR; Moscatello, DK; Godwin, AK; Wong, AJ				HolgadoMadruga, M; Emlet, DR; Moscatello, DK; Godwin, AK; Wong, AJ			A Grb2-associated docking protein in EGF- and insulin-receptor signalling	NATURE			English	Article							SUBSTRATE-1; DOMAIN; IRS-1; SH2; GRB2	THE protein Grb2 plays a central role in signalling by receptor protein-tyrosine kinases(1,2), where its SH2 domain binds to the receptor and its two SH3 domains link to effecters. One target effector is Sos, so Grb2 links receptor protein-tyrosine kinases with the Ras signalling pathway. The SH3 domains can also couple to other signalling proteins, including Vav(3), c-AbI(4) and dynamin(5), We have identified several bands in glial and medulloblastoma tumours that are recognized by Grb2 but these did not correspond to any known protein. Here we use recombinant Grb2 to isolate a complementary DNA called Gab1 (for Grb2-associated binder-1). Gab1 shares amino-acid homology and several structural features with IRS-1 (insulin-receptor substrate-1; refs 6,7), is a substate of the EGF and insulin receptors, and can act as a docking protein for several SH2-containing proteins, Overexpression of Gab1 enhances cell growth and results in transformation. We conclude that Gab1 is a new protein in EGF and insulin receptor signalling which could integrate signals from different systems.	JEFFERSON CANC INST, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19107 USA; JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA; FOX CHASE CANC CTR, DEPT MED ONCOL, PHILADELPHIA, PA 19111 USA	Jefferson University; Jefferson University; Fox Chase Cancer Center								ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CHEN DI, 1995, MOL CELL BIOL, V15, P4711; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; LAMPHERE L, 1994, AM J PHYSIOL, V266, pE486, DOI 10.1152/ajpendo.1994.266.3.E486; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RON D, 1992, BIOTECHNIQUES, V13, P866; SCHLAEPFER DD, 1994, NATURE, V372, P786; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	30	581	589	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 8	1996	379	6565					560	564		10.1038/379560a0	http://dx.doi.org/10.1038/379560a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596638				2022-12-28	WOS:A1996TU69300056
J	Schroeder, SA				Schroeder, SA			The medically uninsured - Will they always be with us?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH-INSURANCE; COVERAGE				Schroeder, SA (corresponding author), ROBERT WOOD JOHNSON FDN, PRINCETON, NJ 08543 USA.							AYANIAN JZ, 1993, NEW ENGL J MED, V329, P326, DOI 10.1056/NEJM199307293290507; BERK ML, 1995, HEALTH AFFAIR, V14, P139, DOI 10.1377/hlthaff.14.3.139; BLENDON RJ, 1995, HEALTH AFFAIR, V14, P7, DOI 10.1377/hlthaff.14.2.7; Burner S T, 1995, Health Care Financ Rev, V16, P221; *EMPL BEN RES I, 1996, EBRI ED RES FUND, V17, P1; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P737, DOI 10.1001/jama.270.6.737; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HOLAHAN J, 1995, CHANGING COMPOSITION; HUGHES RG, 1995, HEALTH AFFAIR, V14, P158, DOI 10.1377/hlthaff.14.2.158; LONG SH, 1993, HEALTH AFFAIR, V12, P282, DOI 10.1377/hlthaff.12.suppl_1.282; LONG SH, 1994, HEALTH AFFAIR, V13, P211, DOI 10.1377/hlthaff.13.2.211; *OFF TECHN ASS, 1992, DOES HLTH INS MAK DI; Rowland D, 1994, Health Aff (Millwood), V13, P283, DOI 10.1377/hlthaff.13.2.283; SHORT PF, 1995, JAMA-J AM MED ASSOC, V274, P1302; SWARTZ K, 1994, JAMA J AM MED ASS, V0271; THORPE KE, 1995, COUNC EC IMP HLTH CA; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WINTERBOTTOM C, 1995, STATE LEVEL DATA BOO; WINTERBOTTOM C, 1993, TRENDS HLTH INSURANC	19	59	59	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 25	1996	334	17					1130	1133		10.1056/NEJM199604253341713	http://dx.doi.org/10.1056/NEJM199604253341713			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG457	8598876				2022-12-28	WOS:A1996UG45700012
J	Collier, AC; Coombs, RW; Schoenfeld, DA; Bassett, RL; Timpone, J; Baruch, A; Jones, M; Facey, K; Whitacre, C; McAuliffe, VJ; Friedman, HM; Merigan, TC; Reichman, RC; Hooper, C; Corey, L				Collier, AC; Coombs, RW; Schoenfeld, DA; Bassett, RL; Timpone, J; Baruch, A; Jones, M; Facey, K; Whitacre, C; McAuliffe, VJ; Friedman, HM; Merigan, TC; Reichman, RC; Hooper, C; Corey, L			Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; REVERSE-TRANSCRIPTASE; AZIDOTHYMIDINE AZT; PROTEASE INHIBITOR; NATURAL-HISTORY; HIV PROTEINASE; DOUBLE-BLIND; RO 31-8959; RESISTANCE	Background. In patients with human immunodeficiency virus (HIV) infection, combined treatment with several agents may increase the effectiveness of antiviral therapy. We studied the safety and efficacy of saquinavir, an HIV-protease inhibitor, given with one or two nucleoside antiretroviral agents, as compared with the safety and efficacy of a combination of two nucleosides alone. Methods. In this double-blind trial, patients with HIV infection were randomly assigned to receive either saquinavir (1800 mg per day) plus both zidovudine (600 mg per day) and zalcitabine (2.25 mg per day) or zidovudine plus either saquinavir or zalcitabine. The 302 patients enrolled had CD4+ counts of 50 to 300 cells per cubic millimeter and had previously received zidovudine for a median of 27 months. The study lasted 24 weeks, with an optional double-blind extension period of an additional 12 to 32 weeks. Results. Ninety-six percent of the patients completed the 24-week study. In all three treatment groups, CD4+ cell counts rose at first and then fell gradually. The normalized area under the curve for the CD4+ cell count was greater with the three-drug combination than with either saquinavir and zidovudine (P=0.017) or zalcitabine and zidovudine (P<0.001). There were significantly greater reductions in plasma HIV with the three-drug combination than with the other regimens when peripheral-blood mononuclear cells were cultured for HIV and HIV RNA was assessed, and there were greater decreases in serum neopterin and beta(2)-microglobulin levels. There were no major differences in toxic effects among the three treatments. Conclusions. Treatment with saquinavir, zalcitabine, and zidovudine was well tolerated. This drug combination reduced HIV-1 replication, increased CD4+ cell counts, and decreased levels of activation markers in serum more than did treatment with zidovudine and either saquinavir or zalcitabine. Studies are warranted to evaluate whether the three-drug combination will reduce morbidity and mortality.	UNIV WASHINGTON,SCH MED,SEATTLE,WA; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; NIAID,BETHESDA,MD 20892; HOFFMANN LA ROCHE INC,NUTLEY,NJ 07110; ROCHE PROD,WELWYN GARDEN CIT,HERTS,ENGLAND; OHIO STATE UNIV,COLUMBUS,OH 43210; NYU,NEW YORK,NY; UNIV PENN,PHILADELPHIA,PA 19104; STANFORD UNIV,PALO ALTO,CA 94304; UNIV ROCHESTER,ROCHESTER,NY	University of Washington; University of Washington Seattle; Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Roche Holding; Roche Holding; University System of Ohio; Ohio State University; New York University; University of Pennsylvania; Stanford University; University of Rochester			Merigan, Thomas/AGQ-7464-2022; Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027664, U01AI027658] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00044] Funding Source: Medline; NIAID NIH HHS [AI-27658, AI-27664] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMS DI, 1994, NEW ENGL J MED, V330, P657, DOI 10.1056/NEJM199403103301001; ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; CAO YZ, 1995, AIDS RES HUM RETROV, V11, P353, DOI 10.1089/aid.1995.11.353; CRAIG JC, 1994, ANTIVIR CHEM CHEMOTH, V5, P380, DOI 10.1177/095632029400500605; CRAIG JC, 1991, ANTIVIR RES, V16, P295, DOI 10.1016/0166-3542(91)90045-S; CRAIG JC, 1993, ANTIVIR CHEM CHEMOTH, V4, P161, DOI 10.1177/095632029300400305; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172; EDLIN BR, 1992, ANN INTERN MED, V117, P457, DOI 10.7326/0003-4819-117-6-457; EDLIN BR, 1992, ANN INTERN MED, V117, P879, DOI 10.7326/0003-4819-117-10-879_2; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; FISCHL MA, 1995, ANN INTERN MED, V122, P24, DOI 10.7326/0003-4819-122-1-199501010-00004; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCUS SA, 1995, J INFECT DIS, V171, P305, DOI 10.1093/infdis/171.2.305; HOLLINGER FB, 1992, J CLIN MICROBIOL, V30, P1787, DOI 10.1128/JCM.30.7.1787-1794.1992; HOOPER C, 1994, P 3 INT HIV DRUG RES; JOHNSON VA, 1992, J INFECT DIS, V166, P1143, DOI 10.1093/infdis/166.5.1143; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KITCHEN VS, 1995, LANCET, V345, P952, DOI 10.1016/S0140-6736(95)90699-1; KRAMER RA, 1986, SCIENCE, V231, P1580, DOI 10.1126/science.2420008; LAMBERT DM, 1992, ANTIMICROB AGENTS CH, V36, P982, DOI 10.1128/AAC.36.5.982; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LIN HJ, 1994, J INFECT DIS, V170, P553, DOI 10.1093/infdis/170.3.553; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEHTA CR, 1984, BIOMETRICS, V40, P819, DOI 10.2307/2530927; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOORE RD, 1992, AIDS, V6, P671, DOI 10.1097/00002030-199207000-00009; MUIRHEAD GJ, 1992, BR J CLIN PHARM, V34, pP170; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; *SAS I, 1989, SAS STAT US GUID VER, V6, P997; SCHOENFELD DA, 1993, AIDS, V7, P955, DOI 10.1097/00002030-199307000-00008; SPRUANCE SL, 1994, ANN INTERN MED, V120, P360, DOI 10.7326/0003-4819-120-5-199403010-00002; TODD J, 1994, SERODIAGN IMMUNOTHER, V6, P233; VELLA S, 1992, JAMA-J AM MED ASSOC, V267, P1232, DOI 10.1001/jama.267.9.1232; VELLA S, 1994, AIDS, V8, pS25, DOI 10.1097/00002030-199409001-00006; Williams PEO, 1992, BR J CLIN PHARM, V34, p155P; YERLY S, 1995, AIDS, V9, P159, DOI 10.1097/00002030-199509020-00007; 1992, MMWR-MORBID MORTAL W, V41, P1	42	606	618	1	30	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1996	334	16					1011	1017		10.1056/NEJM199604183341602	http://dx.doi.org/10.1056/NEJM199604183341602			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE733	8598838	Bronze			2022-12-28	WOS:A1996UE73300002
J	Rettig, RA				Rettig, RA			The social contract and the treatment of permanent kidney failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Rettig, RA (corresponding author), RAND CORP, 2100 M ST NW, WASHINGTON, DC 20037 USA.							BRADSHER K, 1995, NY TIMES        0417, pA1; BURTON TM, 1996, WALL STREET J   0205, pA3; DAMICO G, 1995, AM J KIDNEY DIS, V25, P113, DOI 10.1016/0272-6386(95)90637-1; EICHENWALD K, 1996, NY TIMES        1116, pA1; EICHENWALD K, 1995, NY TIMES        1204, pA1; FARLEY DO, 1994, DESIGNING CAPITATION; Friedman E, 1993, Nephrol News Issues, V7, P41; Friedman EA, 1996, JAMA-J AM MED ASSOC, V275, P1118, DOI 10.1001/jama.275.14.1118; HAKIM RM, 1992, AM J KIDNEY DIS, V20, P107, DOI 10.1016/S0272-6386(12)80538-5; HELD PJ, 1990, AM J KIDNEY DIS, V15, P451, DOI 10.1016/S0272-6386(12)70363-3; HELD PJ, 1994, DEV NEPHROL, V35, P13; HELD PJ, 1992, KIDNEY INT, V42, pS16; *HLTH CAR FIN ADM, 1994, HLTH CAR FIN RES REP; KJELLSTRAND CM, 1994, DEV NEPHROL, V35, P55; KOPPLE JD, 1994, AM J KIDNEY DIS, V24, P968, DOI 10.1016/S0272-6386(12)81071-7; LIPIN S, 1996, WALL STREET J   0202, pA3; MALLICK MB, 1995, AM J KIDNEY DIS, V25, P176; MCCLELLAN WM, 1992, ANN INTERN MED, V117, P332, DOI 10.7326/0003-4819-117-4-332; Moss A H, 1995, Adv Ren Replace Ther, V2, P175; PARKER TF, 1994, AM J KIDNEY DIS, V24, P981, DOI 10.1016/S0272-6386(12)81073-0; RETTIG RA, 1991, DECISION MAKING SCI; Rettig RA, 1991, KIDNEY FAILURE FEDER; *US GEN ACC OFF, 1995, MED ENR GROWTH PAYM; *US REN DAT SYST, 1991, 1991 USRDS NIH NAT I; *US REN DAT SYST, 1990, 1990 USRDS NIH NAT I; *US REN DAT SYST, 1992, 1992 USRDS NIH NAT I; *US REN DAT SYST, 1993, 1993 USRDS NIH NAT I; *US REN DAT SYST, 1989, 1989 USRDS NIH NAT I; *US REN DAT SYST, 1995, 1995 USRDS NIH NAT I; *US REN DAT SYST, 1994, 1994 USRDS NIH NAT I; WOLFE RA, 1991, KIDNEY FAILURE FEDER, P353	31	30	30	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1996	275	14					1123	1126		10.1001/jama.275.14.1123	http://dx.doi.org/10.1001/jama.275.14.1123			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD027	8601933				2022-12-28	WOS:A1996UD02700030
J	Werler, MM; Louik, C; Shapiro, S; Mitchell, AA				Werler, MM; Louik, C; Shapiro, S; Mitchell, AA			Prepregnant weight in relation to risk of neural tube defects	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To examine the relation between prepregnant weight and the risk of neural tube defects (NTDs). Design.-Data were collected from 1988 to 1994 in a case-control surveillance program of birth defects. Setting.-Study subjects were ascertained at tertiary care centers and birth hospitals in the greater metropolitan areas of Boston, Mass, and Philadelphia, Pa, and in southeastern Ontario. Participants.-Cases were 604 fetuses or infants with an NTD identified within 6 months of delivery. Controls were 1658 fetuses or infants with other major malformations identified within 6 months of delivery. For 1992 to 1994, there were 93 control infants without major malformations. Main Outcome Measure.-Relative risk of NTDs in infants or fetuses for different maternal weights. Results.-Relative to women who weighed 50 to 59 kg, risk of NTDs increased from 1.9 (95% confidence interval [CI], 1.2 to 2.9) for women weighing 80 to 89 kg to 4.0 (95% CI, 1.6 to 9.9) for women weighing 110 kg or more. When women were classified according to daily intake above or below the recommended level of 400 mu g of folate, approximate threefold increases in risk were estimated for the heaviest weights in both groups. Intakes of 400 mu g of folate or more reduced risk of NTDs by 40% among women weighing less than 70 kg, but no risk reduction was observed among heavier women. Conclusion.-The risk of NTDs increased with increasing prepregnant weight, independent of the effects of folate intake.			Werler, MM (corresponding author), BOSTON UNIV,SCH PUBL HLTH,SLONE EPIDEMIOL UNIT,1371 BEACON ST,BROOKLINE,MA 02146, USA.			Werler, Martha/0000-0003-3392-6814; Mitchell, Allen/0000-0003-0950-6799; Louik, Carol/0000-0001-5429-5084	NICHD NIH HHS [R01-HD27697] Funding Source: Medline; PHS HHS [MCJ-2505667] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027697] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMITAGE P, 1971, STAT ASPECTS MED RES; CZEIZEL AE, 1993, BRIT MED J, V306, P1645, DOI 10.1136/bmj.306.6893.1645; GOLDENBERG RL, 1995, JAMA-J AM MED ASSOC, V274, P463, DOI 10.1001/jama.274.6.463; HADDOW JE, 1995, AM J OBSTET GYNECOL, V172, P245, DOI 10.1016/0002-9378(95)90139-6; HADDOW JE, 1981, CLIN CHEM, V27, P133; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LEMIRE RJ, 1988, JAMA-J AM MED ASSOC, V259, P558, DOI 10.1001/jama.259.4.558; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; *NAT AC SCI, 1990, NUTR PREGN, P5; Shaw G. M., 1995, Teratology, V51, P196; SHAW GM, 1995, LANCET, V345, P393; STEWART AW, 1987, AM J EPIDEMIOL, V125, P122, DOI 10.1093/oxfordjournals.aje.a114494; WALLER DK, 1994, AM J OBSTET GYNECOL, V170, P541, DOI 10.1016/S0002-9378(94)70224-1; WATKINS M, 1994, AM J EPIDEMIOL, V139, pS11; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; WOLFE HM, 1990, OBSTET GYNECOL, V76, P339; 1992, MMWR-MORBID MORTAL W, V41, P1	17	249	250	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1996	275	14					1089	1092		10.1001/jama.275.14.1089	http://dx.doi.org/10.1001/jama.275.14.1089			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD027	8601927				2022-12-28	WOS:A1996UD02700024
J	Delbanco, TL; Daley, J; Walzer, J				Delbanco, TL; Daley, J; Walzer, J			A man with alcoholism and HIV infection, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		HYMAN SE, 1995, JAMA-J AM MED ASSOC, V274, P837, DOI 10.1001/jama.274.10.837	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					1029	1029						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC123	8596236				2022-12-28	WOS:A1996UC12300032
J	Smith, A; Nutt, D				Smith, A; Nutt, D			Noradrenaline and attention lapses	NATURE			English	Letter									UNIV BRISTOL,DEPT PSYCHOPHARMACOL,BRISTOL BS8 1TN,AVON,ENGLAND	University of Bristol	Smith, A (corresponding author), UNIV BRISTOL,DEPT PSYCHOL,8 WOODLAND RD,BRISTOL BS8 1TN,AVON,ENGLAND.		Smith, Andrew P/B-2192-2010	Smith, Andrew/0000-0001-8805-8028				ASTONJONES G, 1994, J NEUROSCI, V14, P4467; BROADBENT DE, 1989, EUROPEAN J COGNITIVE, V1, P69, DOI DOI 10.1080/09541448908403072; CLIFFORD JM, 1982, BRIT J CLIN PHARMACO, V14, P99, DOI 10.1111/j.1365-2125.1982.tb04941.x; CORCORAN DWJ, 1962, Q J EXP PSYCHOL, V14, P178, DOI 10.1080/17470216208416533; Everitt BJ, 1990, PHARM NORADRENALINE, P349; Glue P, 1988, J Psychopharmacol, V2, P119, DOI 10.1177/026988118800200302; MIDDLETON HC, 1994, J PSYCHOPHARMACOL, V8, P1, DOI 10.1177/026988119400800101; ROBBINS TW, 1987, COGNITIVE NEUROCHEMI, P135	8	138	141	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					291	291		10.1038/380291a0	http://dx.doi.org/10.1038/380291a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598925	Bronze			2022-12-28	WOS:A1996UC37900028
J	Pennacchio, LA; Lehesjoki, AE; Stone, NE; Willour, VL; Virtaneva, K; Miao, JM; DAmato, E; Ramirez, L; Faham, M; Koskiniemi, M; Warrington, JA; Norio, R; delaChapelle, A; Cox, DR; Myers, RM				Pennacchio, LA; Lehesjoki, AE; Stone, NE; Willour, VL; Virtaneva, K; Miao, JM; DAmato, E; Ramirez, L; Faham, M; Koskiniemi, M; Warrington, JA; Norio, R; delaChapelle, A; Cox, DR; Myers, RM			Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1)	SCIENCE			English	Article							FAMILIAL NEONATAL CONVULSIONS; CYSTEINE-PROTEINASE-INHIBITOR; CHROMOSOME-20; LOCALIZATION; EXPRESSION; LINKAGE	Progressive myoclonus epilepsy of the Unverricht-Lundborg type (EPM1) is an autosomal recessive inherited form of epilepsy, previously linked to human chromosome 21q22.3. The gene encoding cystatin B was shown to be localized to this region, and levels of messenger RNA encoded by this gene were found to be decreased in cells from affected individuals. Two mutations, a 3' splice site mutation and a stop codon mutation, were identified in the gene encoding cystatin B in EPM1 patients but were not present in unaffected individuals. These results provide evidence that mutations in the gene encoding cystatin B are responsible for the primary defect in patients with EPM1.	STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305; STANFORD UNIV,DEPT BIOL,STANFORD,CA 94305; UNIV HELSINKI,DEPT MED GENET,SF-00290 HELSINKI,FINLAND; UNIV HELSINKI,DEPT VIROL,SF-00290 HELSINKI,FINLAND; FINNISH POPULAT & FAMILY WELF FEDERAT,DEPT MED GENET,SF-00100 HELSINKI,FINLAND	Stanford University; Stanford University; University of Helsinki; University of Helsinki; Family Federation of Finland				Pennacchio, Len/0000-0002-8748-3732; Willour, Virginia/0000-0002-6639-487X	NHGRI NIH HHS [P50 HG-00206] Funding Source: Medline; NICHD NIH HHS [HD-24610] Funding Source: Medline; NIGMS NIH HHS [IF32GM17502] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024610] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG000206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017502] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSON M, 1989, HUM GENET, V82, P223, DOI 10.1007/BF00291159; BERKOVIC SF, 1986, NEW ENGL J MED, V315, P296, DOI 10.1056/NEJM198607313150506; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; ELDRIDGE R, 1983, LANCET, V2, P838, DOI 10.1016/s0140-6736(83)90749-3; FAHAM M, UNPUB; GHISO J, 1986, P NATL ACAD SCI USA, V83, P2974, DOI 10.1073/pnas.83.9.2974; GREENBERG DA, 1988, AM J MED GENET, V31, P185, DOI 10.1002/ajmg.1320310125; JARVINEN M, 1982, BIOCHIM BIOPHYS ACTA, V708, P210, DOI 10.1016/0167-4838(82)90222-9; JERALA R, 1988, FEBS LETT, V239, P41, DOI 10.1016/0014-5793(88)80541-6; JOU YS, 1994, GENOMICS, V24, P410, DOI 10.1006/geno.1994.1643; KOSKINIEMI M, 1974, EPILEPSIA, V15, P537, DOI 10.1111/j.1528-1157.1974.tb04027.x; KOSKINIEMI M, 1974, ACTA NEUROL SCAND, V50, P333; KOSKINIEMI M, 1974, ACTA NEUROL SCAND, V50, P307; LEHESJOKI AE, 1992, NEUROLOGY, V42, P1545, DOI 10.1212/WNL.42.8.1545; LEHESJOKI AE, 1993, HUM MOL GENET, V2, P1229, DOI 10.1093/hmg/2.8.1229; LEHESJOKI AE, 1991, P NATL ACAD SCI USA, V88, P3696, DOI 10.1073/pnas.88.9.3696; LEPPERT M, 1989, NATURE, V337, P647, DOI 10.1038/337647a0; LEWIS TB, 1993, AM J HUM GENET, V53, P670; LIU AW, 1995, AM J HUM GENET, V57, P68; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; LUNDBORG H, 1903, PROGR MYOCLONUS EPIL, P1; NAKAI K, 1994, GENE, V141, P171, DOI 10.1016/0378-1119(94)90567-3; NORIO R, 1979, CLIN GENET, V15, P382; OTTMAN R, 1995, NAT GENET, V10, P56, DOI 10.1038/ng0595-56; PENNACCHIO LA, UNPUB; RITONJA A, 1985, BIOCHEM BIOPH RES CO, V131, P1187, DOI 10.1016/0006-291X(85)90216-5; SCHEUER ML, 1990, NEW ENGL J MED, V323, P1468; SERRATOSA JM, 1995, HUM MOL GENET, V4, P1657; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; Stone NE, 1996, GENOME RES, V6, P218, DOI 10.1101/gr.6.3.218; TAHVANAINEN E, 1994, P NATL ACAD SCI USA, V91, P7267, DOI 10.1073/pnas.91.15.7267; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; UNVERRICHT H, 1891, MYOCLONIE, P1; Unverricht H., 1891, DTSCH Z NERVENHEILKD, V7, P32, DOI [10.1007/BF01833165, DOI 10.1007/BF01833165]; VIRTANEVA K, UNPUB	35	460	473	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1731	1734		10.1126/science.271.5256.1731	http://dx.doi.org/10.1126/science.271.5256.1731			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596935				2022-12-28	WOS:A1996UB15100048
J	Wolffe, AP; Pruss, D				Wolffe, AP; Pruss, D			Targeting chromatin disruption: Transcription regulators that acetylate histones	CELL			English	Review							YEAST				Wolffe, AP (corresponding author), NICHHD,MOLEC EMBRYOL LAB,NIH,BLDG 6,RM B1A-13,BETHESDA,MD 20892, USA.							BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Grunstein M., 1992, TRANSCRIPTIONAL REGU, P1295; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2	14	341	349	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					817	819		10.1016/S0092-8674(00)81059-4	http://dx.doi.org/10.1016/S0092-8674(00)81059-4			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601304	Bronze			2022-12-28	WOS:A1996UC38100002
J	Eckford, SD; Westgate, J				Eckford, SD; Westgate, J			A cure for pneumothorax during menstruation	LANCET			English	Article							CATAMENIAL PNEUMOTHORAX; ENDOMETRIOSIS				Eckford, SD (corresponding author), UNIV AUCKLAND,MIDDLEMORE HOSP,DEPT OBSTET & GYNAECOL,AUCKLAND,NEW ZEALAND.							ESPAULELLA J, 1991, OBSTET GYNECOL, V78, P535; LILLINGTON GA, 1972, J AMER MED ASSOC, V219, P1328, DOI 10.1001/jama.219.10.1328; MULLER NL, 1986, AM REV RESPIR DIS, V134, P803; ROSS J, 1952, AM REV TUBERC, V63, P67; STERN H, 1980, CHEST, V78, P480, DOI 10.1378/chest.78.3.480	5	5	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					734	734		10.1016/S0140-6736(96)90080-X	http://dx.doi.org/10.1016/S0140-6736(96)90080-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8602005	Bronze			2022-12-28	WOS:A1996TZ98200013
J	Kaplan, J; OHalloran, TV				Kaplan, J; OHalloran, TV			Iron metabolism in eukaryotes: Mars and Venus at it again	SCIENCE			English	Editorial Material							ACHROMOBACTER-CYCLOCLASTES; ASCORBATE OXIDASE; NITRITE REDUCTASE; CRYSTAL-STRUCTURE		NORTHWESTERN UNIV,DEPT CHEM,EVANSTON,IL 60208	Northwestern University	Kaplan, J (corresponding author), UNIV UTAH,SCH MED,DEPT PATHOL,SALT LAKE CITY,UT 84132, USA.		O'Halloran, Thomas/ABE-6125-2021	O'Halloran, Thomas/0000-0001-8732-5059	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038784] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM038784] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Bryson J. W., 1993, BIOINORGANIC CHEM CO, P101; COLLYER CA, 1990, J MOL BIOL, V211, P617, DOI 10.1016/0022-2836(90)90269-R; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DIX DR, 1994, J BIOL CHEM, V269, P26092; FENDERSON FF, 1991, BIOCHEMISTRY-US, V30, P7180, DOI 10.1021/bi00243a020; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; HARRIS Z, IN PRESS MULTICOPPER; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; KAMMLER M, 1993, J BACTERIOL, V175, P6212, DOI 10.1128/JB.175.19.6212-6219.1993; LANGEN R, 1995, SCIENCE, V268, P1733, DOI 10.1126/science.7792598; LEE GR, 1968, J CLIN INVEST, V47, P2058, DOI 10.1172/JCI105891; LINDLEY PF, COMMUNICATION; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; MUNSON GM, UNPUB; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; OSAKI S, 1966, J BIOL CHEM, V241, P2746; PAN Y, 1995, NAT STRUCT BIOL, V2, P740, DOI 10.1038/nsb0995-740; SAENKO EL, 1994, J TRACE ELEM EXP MED, V7, P69; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	24	110	112	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1510	1512		10.1126/science.271.5255.1510	http://dx.doi.org/10.1126/science.271.5255.1510			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599104				2022-12-28	WOS:A1996TZ98300024
J	Schekman, R; Orci, L				Schekman, R; Orci, L			Coat proteins and vesicle budding	SCIENCE			English	Review							GTP-BINDING PROTEIN; GOLGI TRANSPORT VESICLES; ADP-RIBOSYLATION FACTOR; ENDOPLASMIC-RETICULUM; BREFELDIN-A; VESICULAR TRANSPORT; GUANINE-NUCLEOTIDE; MEMBRANE-PROTEIN; SECRETORY PATHWAY; CELL-SURFACE	The trafficking of proteins within eukaryotic cells is achieved by the capture of cargo and targeting molecules into vesicles that bud from a donor membrane and deliver their contents to a receiving compartment. This process is bidirectional and may involve multiple organelles within a cell. Distinct coat proteins mediate each budding event, serving both to shape the transport vesicle and to select by direct or indirect interaction the desired set of cargo molecules. Secretion, which has been viewed as a default pathway, may require sorting and packaging signals on transported molecules to ensure their rapid delivery to the cell surface.	UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA; UNIV GENEVA, FAC MED, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Geneva	Schekman, R (corresponding author), UNIV CALIF BERKELEY, DEPT CELL & MOLEC BIOL, BERKELEY, CA 94720 USA.							Anderson R G, 1993, Trends Cell Biol, V3, P177, DOI 10.1016/0962-8924(93)90205-F; ANDERSON RGW, 1978, CELL, V15, P919, DOI 10.1016/0092-8674(78)90276-3; ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1993, J BIOL CHEM, V268, P873; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BRION C, 1992, J BIOL CHEM, V267, P1477; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DENFERT C, 1991, MOL CELL BIOL, V11, P5727, DOI 10.1128/MCB.11.11.5727; Doering TL, 1996, EMBO J, V15, P182, DOI 10.1002/j.1460-2075.1996.tb00346.x; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUDEN R, 1994, J BIOL CHEM, V269, P24486; DUL JL, 1990, P NATL ACAD SCI USA, V87, P8135, DOI 10.1073/pnas.87.20.8135; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; FRANZUSOFF A, 1992, NATURE, V355, P173, DOI 10.1038/355173a0; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; GIMENO RE, 1995, J CELL BIOL, V131, P325, DOI 10.1083/jcb.131.2.325; GUGLIATTI TA, 1973, MOL GENET, V120, P107; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KTISTAKIS NT, 1995, MOL BIOL CELL, V6, P688; KUEHN M, UNPUB; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LADINSKY MS, 1994, J CELL BIOL, V127, P29, DOI 10.1083/jcb.127.1.29; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LIPOWSKY R, 1993, BIOPHYS J, V64, P1133, DOI 10.1016/S0006-3495(93)81479-6; LIPOWSKY R, 1991, NATURE, V349, P475, DOI 10.1038/349475a0; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NARULA N, 1995, P NATL ACAD SCI USA, V92, P2874, DOI 10.1073/pnas.92.7.2874; NEWMAN AP, 1992, MOL CELL BIOL, V12, P3663, DOI 10.1128/MCB.12.8.3663; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; ORCI L, 1994, P NATL ACAD SCI USA, V91, P11924, DOI 10.1073/pnas.91.25.11924; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PACCAUD JP, UNPUB; PAYNE GS, 1987, MOL CELL BIOL, V7, P3888, DOI 10.1128/MCB.7.11.3888; PAYNE GS, 1985, SCIENCE, V230, P1009, DOI 10.1126/science.2865811; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SALAMA N, 1992, EMBO J, V122, P667; SCHAUER I, 1985, J CELL BIOL, V100, P1664, DOI 10.1083/jcb.100.5.1664; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SIMONS K, 1987, BIOL ORG MACROMOLECU, P139; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TAYLOR TC, 1994, MOL BIOL CELL, V5, P237, DOI 10.1091/mbc.5.2.237; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TOWNSLEY FM, 1994, J CELL BIOL, V127, P21, DOI 10.1083/jcb.127.1.21; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WHITNEY JA, 1995, CELL, V83, P703; Yeung T, 1995, J BIOL CHEM, V270, P30567, DOI 10.1074/jbc.270.51.30567; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	118	805	818	3	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1996	271	5255					1526	1533		10.1126/science.271.5255.1526	http://dx.doi.org/10.1126/science.271.5255.1526			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599108				2022-12-28	WOS:A1996TZ98300028
J	Trapnell, CB; Narang, PK; Li, R; Lavelle, JP				Trapnell, CB; Narang, PK; Li, R; Lavelle, JP			Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients	ANNALS OF INTERNAL MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; AEROSOLIZED PENTAMIDINE; PROPHYLAXIS; TRIALS; AGENT; AIDS	Objective: To determine the effect of fluconazole on rifabutin pharmacokinetics. Design: An open-label, crossover, phase 1 trial. Setting: Outpatient clinical research center at a university medical center in Washington, D.C. Patients: 12 persons with human immunodeficiency virus (HIV) infection whose CD4 lymphocyte counts were between 200 and 500 cells/mm(3) and who were receiving maintenance therapy with zidovudine. Intervention: Fluconazole, 200 mg/d for 2 weeks; then a combination of fluconazole, 200 mg/d, and rifabutin, 300 mg/d, for 2 weeks; and then rifabutin, 300 mg/d, for the final 2 weeks of the study. Measurements: Blood and urine samples were obtained at regular intervals for 24 hours at the end of each 2-week dosing period to ascertain concentrations of fluconazole and rifabutin and the 25-desacetyl metabolite of rifabutin, LM565. Results: Fluconazole significantly increased the plasma concentrations of both rifabutin and LM565. Mean increases in the area under the plasma concentration curve compared with the time curve over a 24-hour dosing interval were 82% (5442 +/- 2404 ng . h/mL compared with 3025 +/- 1117 ng . h/mL; P less than or equal to 0.05) for rifabutin and 216% (959 +/- 529 ng . h/mL compared with 244 +/- 141 ng . h/mL; P less than or equal to 0.05) for LM565. Conclusions: Fluconazole significantly increases the systemic exposure of both rifabutin and LM565. This pharmacokinetic interaction offers a mechanism that may explain the changes reported in both the efficacy and toxicity of rifabutin with concomitant fluconazole therapy.	GEORGETOWN UNIV, MED CTR, WASHINGTON, DC 20007 USA; PHARMACIA INC, COLUMBUS, OH 43216 USA	Georgetown University; Pfizer	Trapnell, CB (corresponding author), US FDA, CTR DRUG EVALUAT & RES, 5600 FISHERS LANE, HFD-900, ROOM 13B-16, ROCKVILLE, MD 20857 USA.							BOZZETTE SA, 1995, NEW ENGL J MED, V332, P693, DOI 10.1056/NEJM199503163321101; COCCHIARA G, 1989, XENOBIOTICA, V19, P769, DOI 10.3109/00498258909042314; FOULDS G, 1988, J CLIN PHARMACOL, V28, P363, DOI 10.1002/j.1552-4604.1988.tb03159.x; FRANK MO, 1994, NEW ENGL J MED, V330, P868, DOI 10.1056/NEJM199403243301218; FULLER JD, 1994, NEW ENGL J MED, V330, P1315, DOI 10.1056/NEJM199405053301816; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; HAVLIR D, 1994, ANN INTERN MED, V121, P510, DOI 10.7326/0003-4819-121-7-199410010-00006; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; LEWIS RC, 1991, PHARMACEUT RES, V8, P1434, DOI 10.1023/A:1015865526655; MAURICE M, 1992, FASEB J, V6, P752, DOI 10.1096/fasebj.6.2.1371482; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; MORROW JD, 1991, AM J MED SCI, V302, P129, DOI 10.1097/00000441-199108000-00012; NARANG PK, 1994, NEW ENGL J MED, V330, P1316, DOI 10.1056/NEJM199405053301817; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; POWDERLY WG, 1995, NEW ENGL J MED, V332, P700, DOI 10.1056/NEJM199503163321102; SHAFRAN SD, 1994, NEW ENGL J MED, V330, P438, DOI 10.1056/NEJM199402103300616; SPECTOR SA, 1995, 2 NAT C HUM RETR, V1, P55; SWARBRICK J, 1982, PHARMACOKINETICS, P409	19	48	48	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1996	124	6					573	576		10.7326/0003-4819-124-6-199603150-00006	http://dx.doi.org/10.7326/0003-4819-124-6-199603150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ529	8597321				2022-12-28	WOS:A1996TZ52900007
J	Bach, JF; Chalons, S; Forier, E; Elana, G; Jouanelle, J; Kayemba, S; Delbois, D; Mosser, A; SaintAime, C; Berchel, C				Bach, JF; Chalons, S; Forier, E; Elana, G; Jouanelle, J; Kayemba, S; Delbois, D; Mosser, A; SaintAime, C; Berchel, C			10-year educational programme aimed at rheumatic fever in two French Caribbean islands	LANCET			English	Article							UNITED-STATES; RESURGENCE; DISEASE	Background In less developed countries, rheumatic fever still occurs. We started a long-term educational programme in two French Caribbean islands that was directed at the public and at health-care workers to see whether we could reduce the incidence of rheumatic fever. Methods Our 10-year programme started in 1981 in Martinique and Guadeloupe, and was based in the community and in clinics and hospitals. The programme established a registry of all cases of primary and secondary rheumatic fever (diagnosed by Jones' modified criteria), with systematic hospital admission of children. We graded carditis as severe, mild, or subclinical, and acute glomerulonephritis was defined by oedema, proteinuria, and haematuria for less than 3 months. The educational part of the programme targeted the public and healthcare workers, including doctors, with written information distributed in schools or via radio and television broadcasts or videotapes. For the public, the benign clinical presentation of the initial streptococcal infection was contrasted with the severity of later heart disease. Findings The first months of the programme led to a 10-20% increase in the number of rheumatic fever cases admitted to hospital, because of the renewed attention paid to the disease. Therefore we took 1982 as the baseline year. In 1982-83 the incidence of rheumatic fever was 19.6 per 100 000 inhabitants aged under 20 in Martinique, and 17.4 per 100 000 in Guadeloupe. In 100 Martinique children and 97 Guadeloupe children in 1982-83, 40 and 71% had carditis, respectively (severe in 10 and 32%). Rheumatic fever was preceded by symptomatic sore throat in 52 and 41% of cases, respectively. The disease was not seen in children with active streptococcal cutaneous infections. Disease frequency was highest in the poorest areas and families, a finding that persisted over time. The programme was associated with a progressive decline in the frequency of rheumatic fever: final reduction of 78% in Martinique and 74% in Guadeloupe. The frequency of carditis also fell. Apart from two outbreaks in one hospital, the frequency of acute glomerulonephritis also declined; 31% of cases had had sore throat, while 56% had shin infections, The cost of the programme during the 4 most intensive years was FFr 250 000 (US$ 44 500) in each island. The cost of childhood rheumatic fever, excluding late sequelae, was initially (in 1982) about FFr 7.8 million (US$ 1 426 000). The cost fell to an average of FFr 550 000 (US$ 100 000) per year in 1991-92. Interpretation A rapid decline in rheumatic fever incidence was achieved at modest cost. Such a programme needs to be continued because of the risk of disease resurgence.	DDASS, FORT DE FRANCE, Martinique, FRANCE; DASD, PMI, JARRYBALE MANHAULT, Guadeloupe, FRANCE; HOP PIERRE ZOBDA QUITMAN, MICROBIOL LAB, FORT DE FRANCE, Martinique, FRANCE; HOP LOUIS DOMMERGUE, LA TRINITE, Martinique, FRANCE; HOP REDOURTE, FORT DE FRANCE, Martinique, FRANCE; CHU POINTE PITRE, SERV PEDIAT, POINTE A PITRE, Guadeloupe, FRANCE	CHU Martinique; CHU Guadeloupe	Bach, JF (corresponding author), HOP NECKER ENFANTS MALAD, INSERM, U25, F-75743 PARIS 15, FRANCE.		KAYEMBA-KAY'S, SIMON/F-3503-2012; KAYEMBA-KAY'S, KABANGU/AAE-4573-2021	KAYEMBA-KAY'S, SIMON/0000-0002-5239-844X; 				AGIS F, 1985, THESIS U PARIS 5; AYOUB EM, 1992, POSTGRAD MED, V92, P133; Canterin A A, 1978, Arch Sci Med (Torino), V135, P623; CARDONA PN, 1988, REV CUBANA PEDIATR, V60, P32; DEWALS P, 1983, MED MALADIES INFECT, V13, P420, DOI 10.1016/S0399-077X(83)80022-5; DODU S R A, 1989, World Health Forum, V10, P203; EISENBERG MJ, 1993, EUR HEART J, V14, P122, DOI 10.1093/eurheartj/14.1.122; Gharagozloo R A, 1976, Acta Trop, V33, P215; GORDIS L, 1969, J CHRON DIS, V21, P655, DOI 10.1016/0021-9681(69)90037-X; KASSEM AS, 1992, PEDIATR ANN, V21, P835, DOI 10.3928/0090-4481-19921201-10; MARKOWITZ M, 1991, PEDIATR INFECT DIS J, V10, pS11, DOI 10.1097/00006454-199110001-00003; MARKOWITZ M, 1980, STREPTOCOCCAL DIS IM, P741; MASSELL BF, 1988, NEW ENGL J MED, V318, P280, DOI 10.1056/NEJM198802043180504; MONPLAISIR N, 1986, TISSUE ANTIGENS, V28, P209, DOI 10.1111/j.1399-0039.1986.tb00484.x; PATARROYO ME, 1979, NATURE, V278, P173, DOI 10.1038/278173a0; POONKING T, 1980, STREPTOCOCCAL DISEAS, P523; QUINN RW, 1978, SOUTHERN MED J, V71, P242, DOI 10.1097/00007611-197803000-00006; QUINN RW, 1980, SOUTHERN MED J, V73, P288, DOI 10.1097/00007611-198003000-00007; ROTTA J, 1980, STREPTOCOCCAL DIS IM, P751; RUTSTEIN DD, 1956, CIRCULATION, V13, P617, DOI 10.1161/01.CIR.13.4.617; Svartman M, 1980, STREPTOCOCCAL DIS IM, P669; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; VLAJINAC H, 1989, MICROBIOL IMMUNOL, V3, P471	23	85	85	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	1996	347	9002					644	648		10.1016/S0140-6736(96)91202-7	http://dx.doi.org/10.1016/S0140-6736(96)91202-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596378				2022-12-28	WOS:A1996TZ28500010
J	Blenkinsopp, A; Bradley, C				Blenkinsopp, A; Bradley, C			Over the counter drugs: Patients, society, and the increase in self medication	BRITISH MEDICAL JOURNAL			English	Article								Self medication with over the counter medicines has long been a feature of the lay health system. With the reclassification of certain drugs, the public can buy preparations that were previously available only on prescription. Sales of over the counter medicines are now equivalent to a third of the NHS drugs bill; governments throughout the world see self medication as a way of shifting some of the cost of health care onto consumers. The trend towards increased self care and with it the increasing empowerment of patients has many potential benefits; collaboration between doctors and pharmacists will be critical.	UNIV BIRMINGHAM,SCH MED,DEPT GEN PRACTICE,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	Blenkinsopp, A (corresponding author), KEELE UNIV,DEPT PHARM POLICY & PRACTICE,KEELE ST5 5BG,STAFFS,ENGLAND.			Blenkinsopp, Alison/0000-0001-8872-2769				ANDERSEN M, 1994, BRIT MED J, V309, P494; BLENKINSOPP A, 1991, BR J GEN PRACT, V41, P16; BRADLEY B, 1994, J CLIN PHARM THER, V19, P7, DOI 10.1111/j.1365-2710.1994.tb00802.x; BRANSTAD JO, 1994, SOC SCI MED, V39, P207, DOI 10.1016/0277-9536(94)90329-8; Emmerton L, 1994, INT J PHARM PRACT, V3, P27; GIBSON P, 1993, BRIT MED J, V306, P1514, DOI 10.1136/bmj.306.6891.1514; HANNAY DR, 1989, SYMPTOM ICEBERG STUD; HEATH I, 1994, BRIT MED J, V309, P623, DOI 10.1136/bmj.309.6955.623; HERXHEIMER A, 1994, BRIT J GEN PRACT, V44, P339; LAWSON D, 1995, OTC DIRECTORY 1995 9; MORLEY A, 1983, PHARM J, V231, P387; *NUFF FDN, 1986, PHARM COMM INQ APP N; PLATTEN A, 1994, MODEL STANDARDS SELF, V9; *PROPR ASS GREAT B, 1995, ANN REP; *PROPR ASS GREAT B, 1987, EVER HLTH CAR CONS S; *PROPR ASS GREAT B, 1995, OTC DIR 1995 96; RAITH H, 1992, SCRIP MAGAZINE   MAR, P20; *ROYAL PHARM SOC G, 1995, MED ETH PRACT; SMITH FJ., 1993, INT J PHARM PRACT, V2, P86; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; WHITAKER MJ, 1994, PHARM J, V253, P867; Wilson M., 1992, INT J PHARM PRACT, V1, P152; 1994, LANCET, V343, P1374	23	137	143	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					629	632						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595343				2022-12-28	WOS:A1996TZ84000034
J	Frankel, DH				Frankel, DH			Skin cancer	LANCET			English	Editorial Material																		HEANEY S, 1969, DOOR DARK, P47	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					634	634		10.1016/S0140-6736(96)91199-X	http://dx.doi.org/10.1016/S0140-6736(96)91199-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596375				2022-12-28	WOS:A1996TZ28500007
J	Goldberg, LH				Goldberg, LH			Basal cell carcinoma	LANCET			English	Article							CANCER				Goldberg, LH (corresponding author), BAYLOR COLL MED,DEPT DERMATOL,HOUSTON,TX 77030, USA.		Goldberg, Leonard/AGR-0657-2022					BLACK HS, 1995, INT J CANCER, V62, P165, DOI 10.1002/ijc.2910620210; CORNELL RC, 1990, J AM ACAD DERMATOL, V23, P694, DOI 10.1016/0190-9622(90)70276-N; DAWBER R, 1992, CUTANEOUS CRYOSURGER, P95; FIDLER IJ, 1978, CANCER RES, V38, P2651; GAILAIN MR, 1969, CELL, V69, P111; GORLIN RJ, 1995, DERMATOL CLIN, V13, P113, DOI 10.1016/S0733-8635(18)30114-1; GRANSTEIN RD, 1995, ARCH DERMATOL, V131, P1201; HOWELL JB, 1984, J AM ACAD DERMATOL, V11, P98, DOI 10.1016/S0190-9622(84)70141-1; JACKSON A, 1995, BRIT J GEN PRACT, V45, P97; KO CB, 1994, BRIT J DERMATOL, V130, P269, DOI 10.1111/j.1365-2133.1994.tb02920.x; Kripke M L, 1981, Adv Cancer Res, V34, P69, DOI 10.1016/S0065-230X(08)60239-0; LIGHTSTONE AC, 1965, ARCH DERMATOL, V191, P497; MARGHOOB AA, 1995, CANCER-AM CANCER SOC, V75, P707, DOI 10.1002/1097-0142(19950115)75:2+<707::AID-CNCR2820751415>3.0.CO;2-W; MARKS R, 1987, INT J DERMATOL, V26, P201, DOI 10.1111/j.1365-4362.1987.tb00900.x; Mohs FE, 1941, ARCH SURG, V42, P279, DOI [DOI 10.1001/ARCHSURG.1941.01210080079004, 10.1001/archsurg.1941.01210080079004]; MOTLEY RJ, 1995, BRIT J DERMATOL, V132, P437, DOI 10.1111/j.1365-2133.1995.tb08679.x; NAYLOR MF, 1995, ARCH DERMATOL, V131, P170, DOI 10.1001/archderm.131.2.170; PARK AJ, 1994, J ROY COLL SURG EDIN, V39, P209; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; POINSFORD MW, 1983, AUST J DERMATOL, V24, P153; REES J, 1994, J INVEST DERMATOL, V103, P747, DOI 10.1111/1523-1747.ep12412256; ROBINSON JK, 1987, CANCER, V60, P118, DOI 10.1002/1097-0142(19870701)60:1<118::AID-CNCR2820600122>3.0.CO;2-1; ROWE DE, 1989, J DERMATOL SURG ONC, V15, P424, DOI 10.1111/j.1524-4725.1989.tb03249.x; SIEGLE RJ, 1986, J DERMATOL SURG ONC, V12, P830, DOI 10.1111/j.1524-4725.1986.tb01990.x; SPILLER WF, 1985, CRYOSURGERY SKIN CAN, P187; SVANBERG K, 1994, BRIT J DERMATOL, V130, P743, DOI 10.1111/j.1365-2133.1994.tb03412.x; TROMOVITCH TA, 1978, CANCER-AM CANCER SOC, V41, P653, DOI 10.1002/1097-0142(197802)41:2<653::AID-CNCR2820410232>3.0.CO;2-X; WEI QY, 1993, P NATL ACAD SCI USA, V90, P1614, DOI 10.1073/pnas.90.4.1614; WEI QY, 1994, J CLIN EPIDEMIOL, V47, P829, DOI 10.1016/0895-4356(94)90185-6	29	96	99	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					663	667		10.1016/S0140-6736(96)91208-8	http://dx.doi.org/10.1016/S0140-6736(96)91208-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596384				2022-12-28	WOS:A1996TZ28500016
J	Ramirez, VD				Ramirez, VD			How do steroids act?	LANCET			English	Editorial Material							RAT				Ramirez, VD (corresponding author), UNIV ILLINOIS,DEPT MOLEC & INTEGRAT PHYSIOL,URBANA,IL 61801, USA.							BLACKMORE PF, 1993, CELL SIGNAL, V5, P531, DOI 10.1016/0898-6568(93)90048-Q; BRESSION D, 1986, ENDOCRINOLOGY, V119, P1048, DOI 10.1210/endo-119-3-1048; KOENIG H, 1989, CIRC RES, V64, P415, DOI 10.1161/01.RES.64.3.415; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; MCENERY MW, 1989, J BIOL CHEM, V264, P12029; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; RAMIREZ VD, IN PRESS FRONTIERS N; RAMIREZ VD, IN PRESS CELL MOL NE; SZEGO CM, 1984, INT REV CYTOL, V88, P1, DOI 10.1016/S0074-7696(08)62759-X; WEHLING M, 1995, STEROIDS, V60, P153, DOI 10.1016/0039-128X(94)00027-A; WEHLING M, 1995, GENOMIC NON GENOMIC	11	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					630	631		10.1016/S0140-6736(96)91195-2	http://dx.doi.org/10.1016/S0140-6736(96)91195-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596371				2022-12-28	WOS:A1996TZ28500003
J	Halfen, JA; Mahapatra, S; Wilkinson, EC; Kaderli, S; Young, VG; Que, L; Zuberbuhler, AD; Tolman, WB				Halfen, JA; Mahapatra, S; Wilkinson, EC; Kaderli, S; Young, VG; Que, L; Zuberbuhler, AD; Tolman, WB			Reversible cleavage and formation of the dioxygen O-O band within a dicopper complex	SCIENCE			English	Article							MONOOXYGENASE CATALYTIC CYCLE; WATER-OXIDATION; RIBONUCLEOTIDE REDUCTASE; COPPER(II) COMPLEXES; OXYGEN EVOLUTION; ACTIVE-SITES; METHANE; MODEL; HEMOCYANIN; REACTIVITY	A key step in dioxygen evolution during photosynthesis is the oxidative generation of the O-O bond from water by a manganese cluster consisting of M(2)(mu-O)(2) units (where M is manganese). The reverse reaction, reductive cleavage of the dioxygen O-O bond, is performed at a variety of dicopper and di-iron active sites in enzymes that catalyze important organic oxidations. Both processes can be envisioned to involve the interconversion of dimetal-dioxygen adducts, M(2)(O-2), and isomers having M(2)(mu-O)(2) cores. The viability of this notion has been demonstrated by the identification of an equilibrium between synthetic complexes having [Cu-2(mu-eta(2):eta(2)-O-2)](2+) and [Cu-2(mu-O)(2)](2+) cores through kinetic, spectroscopic, and crystallographic studies.	UNIV MINNESOTA, DEPT CHEM, MINNEAPOLIS, MN 55455 USA; UNIV BASEL, INST ORGAN CHEM, CH-4056 BASEL, SWITZERLAND	University of Minnesota System; University of Minnesota Twin Cities; University of Basel					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047365, R37GM047365, R01GM033162, R37GM033162] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33162, GM47365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8024, DOI 10.1021/ja00097a009; de Montellano P. R. Ortiz, 1986, CYTOCHROME P 450 STR; DONG YH, 1995, J AM CHEM SOC, V117, P2778, DOI 10.1021/ja00115a013; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; GESELOWITZ D, 1990, INORG CHEM, V29, P3894, DOI 10.1021/ic00344a048; GILBERT JA, 1985, J AM CHEM SOC, V107, P3855, DOI 10.1021/ja00299a017; Hodgson D. J., 1975, PROG INORG CHEM, V19, P173; HOUSER RP, 1995, J AM CHEM SOC, V117, P10745, DOI 10.1021/ja00148a018; KARLIN KD, 1993, J AM CHEM SOC, V115, P9506, DOI 10.1021/ja00074a015; KARLIN KD, 1988, J AM CHEM SOC, V110, P1196, DOI 10.1021/ja00212a031; KARLIN KD, 1991, J AM CHEM SOC, V113, P5868, DOI 10.1021/ja00015a054; KITAJIMA N, 1992, J AM CHEM SOC, V114, P1277, DOI 10.1021/ja00030a025; LEE SC, 1993, INORG CHEM, V32, P4745, DOI 10.1021/ic00074a016; LEE SK, 1993, J BIOL CHEM, V268, P21569; LEE SK, 1993, J AM CHEM SOC, V115, P6450, DOI 10.1021/ja00067a086; LIU KE, 1994, J AM CHEM SOC, V116, P7465, DOI 10.1021/ja00095a083; LIU KE, 1995, J AM CHEM SOC, V117, P4997, DOI 10.1021/ja00122a032; MAGNUS KA, 1994, PROTEINS, V19, P302, DOI 10.1002/prot.340190405; MAHAPATRA S, 1995, J AM CHEM SOC, V117, P8865, DOI 10.1021/ja00139a026; MAHAPATRA S, 1994, J AM CHEM SOC, V116, P9785, DOI 10.1021/ja00100a068; NARUTA Y, 1994, ANGEW CHEM INT EDIT, V33, P1839, DOI 10.1002/anie.199418391; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; PECORARO VL, 1994, CHEM REV, V94, P807, DOI 10.1021/cr00027a012; PROSERPIO DM, 1992, J AM CHEM SOC, V114, P4374, DOI 10.1021/ja00037a052; QUE L, 1990, PROG INORG CHEM, V38, P97; RAMARAJ R, 1986, ANGEW CHEM INT EDIT, V25, P825, DOI 10.1002/anie.198608252; REINAUD OM, 1994, J AM CHEM SOC, V116, P6979, DOI 10.1021/ja00094a080; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; SANCHEZFERRER A, 1995, BBA-PROTEIN STRUCT M, V1247, P1; SAUER K, 1992, MANGANESE REDOX ENZY, P141; SOLOMON EI, 1992, CHEM REV, V92, P521, DOI 10.1021/cr00012a003; SOLOMON EI, 1994, CHEM REV, V94, P827, DOI 10.1021/cr00027a013; WATKINSON M, 1994, J CHEM SOC CHEM COMM, P2141, DOI 10.1039/c39940002141; WIEGHARDT K, 1989, ANGEW CHEM INT EDIT, V28, P1153, DOI 10.1002/anie.198911531; YACHANDRA VK, 1993, SCIENCE, V260, P675, DOI 10.1126/science.8480177; ZANG Y, 1995, J AM CHEM SOC, V117, P1169, DOI 10.1021/ja00108a050	37	463	464	1	123	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 8	1996	271	5254					1397	1400		10.1126/science.271.5254.1397	http://dx.doi.org/10.1126/science.271.5254.1397			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596910				2022-12-28	WOS:A1996TY96100040
J	Smeal, T; Claus, J; Kennedy, B; Cole, F; Guarente, L				Smeal, T; Claus, J; Kennedy, B; Cole, F; Guarente, L			Loss of transcriptional silencing causes sterility in old mother cells of S-cerevisiae	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; TELOMERE LENGTH; HUMAN FIBROBLASTS; DNA-REPLICATION; LIFE-SPAN; GENE; ACTIVATION; AGE; RECOMBINATION; INHERITANCE	We show that sterility is an aging-specific phenotype in S. cerevisiae and, by genetic and physical means, demonstrate that this phenotype results from a loss of silencing in most old cells by the SIR complex at the HM loci. This loss of silencing is specific because transcription of genes, such as MEI4 and DCM1, normally induced by sporulation, is not observed, while transcription of HMRa is observed. These findings pinpoint the molecular cause of an aging-specific phenotype in yeast. Further, they provide direct evidence for a breakdown of silencing in old cells, as predicted from earlier findings that SIR4 is a determinant of life span in this organism.			Smeal, T (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Cole, Francesca/0000-0001-6391-2363	NATIONAL INSTITUTE ON AGING [R37AG011119, R01AG011119] Funding Source: NIH RePORTER; NIA NIH HHS [AG11119] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Ballou CE, 1982, MOL BIOL YEAST SACCH; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BERTRAND H, 1985, CELL, V41, P877, DOI 10.1016/S0092-8674(85)80068-4; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; CABIB E, 1971, J BIOL CHEM, V246, P152; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; DMELLO NP, 1991, J BACTERIOL, V173, P6709, DOI 10.1128/jb.173.21.6709-6713.1991; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; EGLIMEZ NK, 1990, J GERONTOL, V45, pB9; Finch CE, 1990, LONGEVITY SENESCENCE; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GILLEY D, 1994, P NATL ACAD SCI USA, V91, P1955, DOI 10.1073/pnas.91.5.1955; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; JAZWINSKI SM, 1989, EXP GERONTOL, V24, P423; KENNEDY BK, 1994, J CELL BIOL, V127, P1985, DOI 10.1083/jcb.127.6.1985; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; MENEES TM, 1992, MOL CELL BIOL, V12, P1340, DOI 10.1128/MCB.12.3.1340; MILLER AM, 1984, EMBO J, V3, P1061, DOI 10.1002/j.1460-2075.1984.tb01927.x; MOLNAR JA, 1986, BIOCHEM J, V240, P431, DOI 10.1042/bj2400431; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MULLER I, 1985, A VAN LEEUW J MICROB, V51, P1, DOI 10.1007/BF00444223; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; POHLEY HJ, 1987, MECH AGEING DEV, V38, P231, DOI 10.1016/0047-6374(87)90092-3; REISER KM, 1987, BIOCHIM BIOPHYS ACTA, V926, P339, DOI 10.1016/0304-4165(87)90220-0; RINE J, 1987, GENETICS, V116, P9; SCHEKMAN R, 1982, MOL BIOL YEAST SACCH; SCHWARTZ HS, 1993, CANCER GENET CYTOGEN, V71, P132, DOI 10.1016/0165-4608(93)90018-H; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; VAZIRI H, 1993, AM J HUM GENET, V52, P661; WAREHAM KA, 1987, NATURE, V327, P725, DOI 10.1038/327725a0; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WOLDRINGH CL, 1995, YEAST, V11, P361, DOI 10.1002/yea.320110409; WRIGHT RM, 1982, CELL, V29, P505, DOI 10.1016/0092-8674(82)90167-2; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	45	211	219	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					633	642		10.1016/S0092-8674(00)81038-7	http://dx.doi.org/10.1016/S0092-8674(00)81038-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598049	Bronze			2022-12-28	WOS:A1996TX17600015
J	Zhao, FZ; Murray, C; Spinaci, S; Styblo, K; Broekmans, J; Zou, JQ; Dai, YS; Chi, YH; Du, X; Cao, JP; Chen, YL; Li, LM; Li, NW; Liu, CJ; Liu, HQ; Lu, Q; Tang, DR; Wang, PF; Wang, ZH; Wu, PE; Zhang, FD; Zhang, FS; Zhu, GL				Zhao, FZ; Murray, C; Spinaci, S; Styblo, K; Broekmans, J; Zou, JQ; Dai, YS; Chi, YH; Du, X; Cao, JP; Chen, YL; Li, LM; Li, NW; Liu, CJ; Liu, HQ; Lu, Q; Tang, DR; Wang, PF; Wang, ZH; Wu, PE; Zhang, FD; Zhang, FS; Zhu, GL			Results of directly observed short-course chemotherapy in 112842 Chinese patients with smear-positive tuberculosis	LANCET			English	Article							PROGRAM	Background Tuberculosis remains a substantial public health burden in China. The cure rate in treatment programmes has been about 50%. In 1991, a new project based on directly observed short-course chemotherapy was introduced. We report the results of the first 112 842 patients treated. Methods Patients with symptoms suggesting tuberculosis are referred by general health services to the tuberculosis county dispensary for physical examination and fluoroscopy. Those with suspicious findings submit three sputum samples for smear examination. Village doctors deliver free, directly observed therapy to ail smear-positive patients on an outpatient basis. New cases are treated with streptomycin (750 mg), isoniazid (600 mg), pyrazinamide (2000 mg), and rifampicin (600 mg) every other day for 2 months, followed by 4 months of alternate-day isoniazid plus rifampicin. Previously treated patients receive streptomycin, isoniazid, pyrazinamide, rifampicin, and ethambutol (1250 mg) every other day for 2 months, followed by 6 months of isoniazid, rifampicin. and ethambutol. Patients are re-examined and smears are repeated at 2 months (then 3 months if still positive) and at 5 and 6 months (new cases) or 5 and 8 months (previously treated cases). Findings Nearly 1.6 million patients with suspected tuberculosis were referred for fluoroscopy between 1991 and 1994. 48% had suspicious findings on fluoroscopy and underwent sputum examination. 104 444 new smear positive cases and 95616 previously treated smear positive cases have been diagnosed. Results of treatment for those enrolled up to the first quarter of 1994 show cure rates of 89.7% among new cases (55 213) and 81.1% among those previously treated (57 629). The failure rate in previously treated cases, an indicator of drug resistance, fell from 17.6% among 437 patients enrolled in 1991 to 62% among 7822 patients enrolled in the first quarter of 1994. Interpretation Our experience shows that high rates of compliance and cure can be achieved on a mass scale and in a short time by means of directly observed short-course chemotherapy and the WHO technical strategy for effective tuberculosis control.	HARVARD UNIV,CTR POPULAT & DEV STUDIES,CAMBRIDGE,MA 02138	Harvard University								BELL J, 1988, S AFR MED J, V73, P31; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BROEKMANS JF, 1994, TUBERCULOSIS BACK FU, P171; CHEUNG R, 1988, EUR J CLIN PHARMACOL, V35, P401, DOI 10.1007/BF00561372; Farmer P, 1991, Semin Respir Infect, V6, P254; MANOLO F, 1990, AM REV RESPIR DIS, V142, P1301; MILES SH, 1984, AM REV RESPIR DIS, V130, P827; MORISKY DE, 1990, HEALTH EDUC QUART, V17, P253, DOI 10.1177/109019819001700303; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P447; MURRAY CJL, 1990, B INT UNION TUBERC, V65, P2; VALEZA FS, 1990, LANCET, V335, P473, DOI 10.1016/0140-6736(90)90705-A; WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9; 1990, 1989 NAT TUB I ANN R; WHOTB9417; 1988, NATIONWIDE RANDOM SU; 1981, NATIONWIDE RANDOM SU; 1995, WHOGTBCARG959 MIN PU; 1992, NATIONWIDE RANDOM SU	19	129	133	2	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					358	362						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598701				2022-12-28	WOS:A1996TU69500009
J	Stoller, J				Stoller, J			New surgery: Sense and sensibility	LANCET			English	Editorial Material											Stoller, J (corresponding author), UNIV BRITISH COLUMBIA,DEPT SURG,VANCOUVER,BC V6T 1W5,CANADA.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1996	347	9006					919	919		10.1016/S0140-6736(96)91410-5	http://dx.doi.org/10.1016/S0140-6736(96)91410-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598752				2022-12-28	WOS:A1996UD59100005
J	Brown, DR; Schmidt, B; Kretzschmar, HA				Brown, DR; Schmidt, B; Kretzschmar, HA			Role of microglia and host prion protein in neurotoxicity of a prion protein fragment	NATURE			English	Article							SCRAPIE PRION; NITRIC-OXIDE; BRAIN; PRP; SUPEROXIDE; RESISTANT	THE prion protein PrPc is a glycoprotein of unknown function(1) normally found in neurons(2) and glia(3). It is involved in diseases such as bovine spongiform encephalopathy (BSE), scrapie and Creutzfeldt-Jakob disease(4). PrPSc, an altered isoform of PrPc that is associated with disease, shows greater protease resistance and is part of the infectious agent, the prion(5,6). Prion diseases are characterized by neuronal degeneration, gliosis and accumulation of PrPSc (ref. 7). Mice devoid of PrPc are resistant to scrapie(8). A fragment of human PrP consisting of amino acids 106-126 that forms fibrils in vitro is toxic to cultured neurons(9-11). Here we show that this toxic effect requires the presence of microglia which respond to PrP106-126 by increasing their oxygen radical production, The combined direct and microglia-mediated effects of PrP106-126 are toxic to normal neurons but are insufficient to destroy neurons from mice not expressing PrPc.	UNIV GOTTINGEN,INST NEUROPATHOL,D-37075 GOTTINGEN,GERMANY; UNIV GOTTINGEN,ZENTRUM BIOCHEM & MOL ZELLBIOL,D-37075 GOTTINGEN,GERMANY	University of Gottingen; University of Gottingen			Brown, David/A-4083-2008					BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BROWN DR, 1994, NEUROREPORT, V5, P2057, DOI 10.1097/00001756-199410270-00017; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CORRADIN SB, 1993, GLIA, V7, P255, DOI 10.1002/glia.440070309; DEARMOND SJ, 1987, NEUROLOGY, V37, P1271, DOI 10.1212/WNL.37.8.1271; ELSTNER EF, 1976, ANAL BIOCHEM, V70, P616, DOI 10.1016/0003-2697(76)90488-7; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; GIESE A, 1995, BRAIN PATHOL, V5, P213, DOI 10.1111/j.1750-3639.1995.tb00597.x; GIULIAN D, 1988, J NEUROSCI, V8, P709; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Herms JW, 1995, EUR J NEUROSCI, V7, P2508, DOI 10.1111/j.1460-9568.1995.tb01049.x; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MOSER M, 1995, NEURON, V14, P509, DOI 10.1016/0896-6273(95)90307-0; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; SELVAGGINI C, 1993, BIOCHEM BIOPH RES CO, V194, P1380, DOI 10.1006/bbrc.1993.1977; WILLIAMS AE, 1994, NEUROPATH APPL NEURO, V20, P47, DOI 10.1111/j.1365-2990.1994.tb00956.x	22	485	497	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					345	347		10.1038/380345a0	http://dx.doi.org/10.1038/380345a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598929				2022-12-28	WOS:A1996UC37900060
J	Dobrowolski, JM; Sibley, LD				Dobrowolski, JM; Sibley, LD			Toxoplasma invasion of mammalian cells is powered by the actin cytoskeleton of the parasite	CELL			English	Article							CYTOCHALASIN-B; COCCIDIAN SPOROZOITES; MALARIAL PARASITES; GONDII; MOTILITY; EXPRESSION; RESISTANT; JUNCTION; VACUOLES; FUSION	Toxoplasma gondii is an obligate intracellular parasite that invades a wide range of vertebrate host cells. We demonstrate that invasion is critically dependent on actin filaments in the parasite, but not the host cell. Invasion into cytochalasin D (CD)-resistant host cells was blocked by CD, while parasite mutants invaded wild-type host cells in the presence of drug. CD resistance in Toxoplasma was mediated by a point mutation in the single-copy actin gene ACT1. Transfection of the mutant act1 allele into wild-type Toxoplasma conferred motility and invasion in the presence of CD. We conclude that host cell invasion by Toxoplasma, and likely by related Apicomplexans, is actively powered by an actin-based contractile system in the parasite.	WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Sibley, L. David/C-4616-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034036, T32AI007172] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI034036, AI34036, AI07172] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKAWA M, 1978, J CELL BIOL, V77, P72, DOI 10.1083/jcb.77.1.72; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; Dubey J.P., 1988, TOXOPLASMOSIS ANIMAL; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FALKOW S, 1992, ANNU REV CELL BIOL, V8, P333, DOI 10.1146/annurev.cb.08.110192.002001; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; JONES TC, 1972, J EXP MED, V136, P1173, DOI 10.1084/jem.136.5.1173; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE CA, 1990, P NATL ACAD SCI USA, V87, P4304, DOI 10.1073/pnas.87.11.4304; LESSARD JL, 1988, CELL MOTIL CYTOSKEL, V10, P349, DOI 10.1002/cm.970100302; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; MILLER LH, 1979, J EXP MED, V149, P172, DOI 10.1084/jem.149.1.172; MORISAKI JH, 1995, J CELL SCI, V108, P2457; NICHOLS BA, 1981, LAB INVEST, V44, P324; OHMORI H, 1992, J CELL BIOL, V116, P933, DOI 10.1083/jcb.116.4.933; PFEFFERKORN ER, 1977, J PROTOZOOL, V24, P449, DOI 10.1111/j.1550-7408.1977.tb04774.x; RUSSELL DG, 1983, PARASITOLOGY, V87, P199, DOI 10.1017/S0031182000052562; RUSSELL DG, 1981, J CELL SCI, V50, P345; RUSSELL DG, 1984, J CELL SCI, V65, P193; RYNING FW, 1978, INFECT IMMUN, V20, P739, DOI 10.1128/IAI.20.3.739-743.1978; SCHWARTZMAN JD, 1983, J PROTOZOOL, V30, P657, DOI 10.1111/j.1550-7408.1983.tb05339.x; SIBLEY LD, 1985, NATURE, V315, P416, DOI 10.1038/315416a0; SIBLEY LD, 1995, TRENDS CELL BIOL, V5, P129, DOI 10.1016/S0962-8924(00)88964-3; SOLDATI D, 1993, SCIENCE, V260, P349, DOI 10.1126/science.8469986; STEWART MJ, 1988, J PROTOZOOL, V35, P389, DOI 10.1111/j.1550-7408.1988.tb04115.x; TOYAMA S, 1984, CELL, V37, P609, DOI 10.1016/0092-8674(84)90391-X; TOYAMA S, 1988, J CELL BIOL, V107, P1499, DOI 10.1083/jcb.107.4.1499; WANG FW, 1990, GENE, V100, P195	31	504	527	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					933	939		10.1016/S0092-8674(00)81071-5	http://dx.doi.org/10.1016/S0092-8674(00)81071-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601316	Bronze			2022-12-28	WOS:A1996UC38100014
J	Hamblin, TJ				Hamblin, TJ			From dendritic cells to tumour vaccines	LANCET			English	Editorial Material							ANTI-IDIOTYPE ANTIBODY; LYMPHOMA				Hamblin, TJ (corresponding author), ROYAL BOURNEMOUTH HOSP,DEPT HAEMATOL & ONCOL,BOURNEMOUTH,DORSET,ENGLAND.							CHEN TT, 1994, J IMMUNOL, V153, P4775; FLAMAND V, 1994, EUR J IMMUNOL, V24, P605, DOI 10.1002/eji.1830240317; GEORGE AJT, 1988, J IMMUNOL, V141, P2168; HAMBLIN TJ, 1987, BLOOD, V69, P790; HAWKINS RE, 1994, BLOOD, V83, P3279; HSU FJ, 1993, ANN NY ACAD SCI, V690, P385; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; KOTERA Y, 1994, CANCER RES, V54, P2856; MARCHAND M, 1993, DERMATOLOGY, V186, P278, DOI 10.1159/000247375; MCCABE BJ, 1995, CANCER RES, V55, P1741; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; TAKAMIZAWA M, 1995, J CLIN INVEST, V95, P296, DOI 10.1172/JCI117654; TAO MH, 1993, NATURE, V362, P755, DOI 10.1038/362755a0	15	11	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					705	706		10.1016/S0140-6736(96)90071-9	http://dx.doi.org/10.1016/S0140-6736(96)90071-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8601996				2022-12-28	WOS:A1996TZ98200004
J	Livingstone, AE; Shaddick, G; Grundy, C; Elliott, P				Livingstone, AE; Shaddick, G; Grundy, C; Elliott, P			Do people living near inner city main roads have more asthma needing treatment? Case-control study	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON LONDON SCH HYG & TROP MED,ENVIRONM EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	Livingstone, AE (corresponding author), GILL ST HLTH CTR,LIMEHOUSE PRACTICE,LONDON E14 8HQ,ENGLAND.		Shaddick, Gavin B/B-3344-2011					DIGGLE PJ, 1994, J ROY STAT SOC A STA, V157, P433, DOI 10.2307/2983529; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223, DOI 10.1080/00039896.1994.9937471; WALDRON G, 1995, J PUBLIC HEALTH MED, V17, P85; WEILAND SK, 1994, ANN EPIDEMIOL, V4, P79; WJST M, 1993, BRIT MED J, V307, P596, DOI 10.1136/bmj.307.6904.596	5	65	66	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					676	677						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597735				2022-12-28	WOS:A1996UB11000025
J	Klauck, TM; Faux, MC; Labudda, K; Langeberg, LK; Jaken, S; Scott, JD				Klauck, TM; Faux, MC; Labudda, K; Langeberg, LK; Jaken, S; Scott, JD			Coordination of three signaling enzymes by AKAP79, a mammalian scaffold protein	SCIENCE			English	Article							KINASE-C; POSTSYNAPTIC DENSITIES; REGULATORY SUBUNIT; PHOSPHATIDYLSERINE	Multivalent binding proteins, such as the yeast scaffold protein Sterile-5, coordinate the location of kinases by serving as platforms for the assembly of signaling units. Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79. Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN. The subcellular distributions of PKC and AKAP79 were similar in neurons. Thus, AKAP79 appears to function as a scaffold protein for three multifunctional enzymes.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946	Oregon Health & Science University					NCI NIH HHS [CA538841] Funding Source: Medline; NIGMS NIH HHS [GM50152, GM48231] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048231, R01GM048231] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARR DW, 1992, J BIOL CHEM, V267, P16816; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CHOI KY, 1994, CELL, V78, P499; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; COGHLAN VM, 1995, ADV PROTEIN PHOSPHAT, V8, P51; Corbin J D, 1974, Methods Enzymol, V38, P287; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; FAUX MC, UNPUB; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; HYATT SL, 1994, CELL GROWTH DIFFER, V5, P495; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KLAUCK T, UNPUB; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; LEACH KL, 1988, J BIOL CHEM, V263, P13223; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LIEBERMAN DN, 1994, SCIENCE, V369, P235; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; ORR JW, 1992, J BIOL CHEM, V267, P15263; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POTTER RL, 1978, ARCH BIOCHEM BIOPHYS, V190, P174, DOI 10.1016/0003-9861(78)90265-5; PRINTEN JA, 1994, GENETICS, V138, P609; RICH DP, 1989, J NEUROCHEM, V53, P807, DOI 10.1111/j.1471-4159.1989.tb11777.x; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; SARKAR D, 1984, J BIOL CHEM, V259, P9840; Scott J. I., UNPUB; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; WOLF M, 1986, J BIOL CHEM, V261, P3327; WOLF M, 1986, BIOCHEM BIOPH RES CO, V140, P691, DOI 10.1016/0006-291X(86)90787-4	33	469	485	2	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1589	1592		10.1126/science.271.5255.1589	http://dx.doi.org/10.1126/science.271.5255.1589			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599116				2022-12-28	WOS:A1996TZ98300043
J	Altman, DG; Bland, JM				Altman, DG; Bland, JM			Statistics notes - Presentation of numerical data .15.	BMJ-BRITISH MEDICAL JOURNAL			English	Article									ST GEORGE HOSP, SCH MED,DEPT PUBL HLTH SCI, LONDON SW17 0RE, ENGLAND	St Georges University London	Altman, DG (corresponding author), INST HLTH SCI, CTR STAT MED, IRCF MED STAT GRP, POB 777, OXFORD OX3 7LF, ENGLAND.							BHARGAVA SK, 1985, BMJ-BRIT MED J, V291, P1617, DOI 10.1136/bmj.291.6509.1617; MOSTELLER F, 1992, MED USES STAT, P375	2	29	31	1	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 2	1996	312	7030					572	572		10.1136/bmj.312.7030.572	http://dx.doi.org/10.1136/bmj.312.7030.572			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595293	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1996TY88500037
J	Pickering, WG				Pickering, WG			Does medical treatment mean patient benefit?	LANCET			English	Article																		BERN JL, 1988, BR J CLIN PHARM, V26, P679; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; Marinker M, 1973, J R Coll Gen Pract, V23 Suppl 2, P26; MEDAWAR C, 1992, POWER DEPENDENCE; PICKERING W, 1992, BRIT MED J, V304, P1516; Pickering W G, 1993, J Med Ethics, V19, P121, DOI 10.1136/jme.19.2.121-a; 1995, BRIT NATIONAL FORMUL, P219; 1994, PRESCRIPTION IMPROVE	8	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					379	380		10.1016/S0140-6736(96)90544-9	http://dx.doi.org/10.1016/S0140-6736(96)90544-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598708				2022-12-28	WOS:A1996TU69500016
J	Sumarsono, SH; Wilson, TJ; Tymms, MJ; Venter, DJ; Corrick, CM; Kola, R; Lahoud, MH; Papas, TS; Seth, A; Kola, I				Sumarsono, SH; Wilson, TJ; Tymms, MJ; Venter, DJ; Corrick, CM; Kola, R; Lahoud, MH; Papas, TS; Seth, A; Kola, I			Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice	NATURE			English	Article							BINDING; MOUSE	EXPRESSION of Ets2, a proto-oncogene(1) and transcription factor(2-5), occurs in a variety of cell types(6), During murine development it is highly expressed in newly forming cartilage, including In the skull precursor cells and vertebral primordia(7), Ets(2) is located on human chromosome 21 (ref. 8) and is overexpressed in Down's syndrome (trisomy 21)(9), Here we generate transgenic mice to Investigate the consequences of overexpression of Ets2, We find that mice with less than 2-fold Ets2 overexpression in particular organs develop neurocranial, viscerocranial and cervical skeletal abnormalities, These abnormalities have similarities with the skeletal anomalies found in trisomy-16 mice and humans with Down's syndrome, in which the gene dosage of Ets2 is increased(10,12), Our results indicate that Ets2 has a role in skeletal development and implicate the overexpression of Ets2 in the genesis of some skeletal abnormalities that occur in Down's syndrome.	MONASH UNIV,MONASH MED CTR,INST REPROD & DEV,MOLEC GENET & DEV GRP,CLAYTON,VIC 3168,AUSTRALIA; PETER MACCALLUM CANC INST,MELBOURNE,VIC 3002,AUSTRALIA; MED UNIV S CAROLINA,HOLLINGS CANC CTR,CTR MOLEC & STRUCT BIOL,CHARLESTON,SC 29425; UNIV TORONTO,FAC MED,DEPT PATHOL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,FAC DENT,TORONTO,ON M5S 1A8,CANADA; WOMENS COLL HOSP,TORONTO,ON M5S 1A8,CANADA	Monash University; Peter Maccallum Cancer Center; Medical University of South Carolina; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital			Lahoud, Mireille/F-1299-2013; Kola, Ismail/C-5254-2013	Lahoud, Mireille/0000-0001-8472-6201; 				ASCIONE R, 1992, INT J ONCOL, V1, P631; AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1; Bancroft JD, 1984, J PATH, V145, P355; CAFFEY J, 1978, PAEDIATRIC XRAY DIAG, V1, P155; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; DAVISSON MT, 1990, CYTOGENET CELL GENET, V55, P434, DOI 10.1159/000133026; Epstein L B, 1980, Ann N Y Acad Sci, V350, P171, DOI 10.1111/j.1749-6632.1980.tb20618.x; GRAUSZ H, 1991, MORPHOGENESIS DOWN S, P169; HART AH, 1995, ONCOGENE, V10, P1423; IANNELLO RC, 1994, REPROD FERT DEVELOP, V6, P599, DOI 10.1071/RD9940599; KAUFMAN MH, 1990, ATLAS MOUSE DEV, P495; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KOLA I, 1995, ADV HUMAN REPROD, P309; KORENBERG JR, 1991, MORPHOGENESIS DOWN S, P43; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; PATTERSON D, 1987, SCI AM, V257, P42; REEVES RH, 1987, MOL BRAIN RES, V2, P215, DOI 10.1016/0169-328X(87)90028-3; REEVES RH, 1985, NAT GENET, V111, P177; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; THOMAS RS, 1995, ONCOGENE, V11, P2135; Tymms M J, 1995, Methods Mol Biol, V37, P31; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0	23	168	169	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					534	537						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596630				2022-12-28	WOS:A1996TU69300048
J	Schomig, A; Neumann, FJ; Kastrati, A; Schuhlen, H; Blasini, R; Hadamitzky, M; Walter, H; ZitzmannRoth, EM; Richardt, G; Alt, E; Schmitt, C; Ulm, K				Schomig, A; Neumann, FJ; Kastrati, A; Schuhlen, H; Blasini, R; Hadamitzky, M; Walter, H; ZitzmannRoth, EM; Richardt, G; Alt, E; Schmitt, C; Ulm, K			A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANGIOPLASTY; MULTICENTER; TICLOPIDINE; STROKE	Background. The clinical benefit of coronary-artery stenting performed in conjunction with coronary angioplasty is limited by the risk of thrombotic occlusion of the stent as well as hemorrhagic and vascular complications of intensive anticoagulation. We compared antiplatelet therapy with conventional anticoagulant therapy with respect to clinical outcomes 30 days after coronary-artery stenting. Methods. After successful placement of Palmaz-Schatz coronary-artery stents, 257 patients were randomly assigned to receive antiplatelet therapy (ticlopidine plus aspirin) and 260 to receive anticoagulant therapy (intravenous heparin, phenprocoumon, and aspirin), The primary cardiac end point was a composite measure reflecting death from cardiac causes or the occurrence of myocardial infarction, aortocoronary bypass surgery, or repeated angioplasty. The primary noncardiac end point comprised death from noncardiac causes, cerebrovascular accident, severe hemorrhage, and peripheral vascular events. Results. Of the patients assigned to antiplatelet therapy, 1.6 percent reached a primary cardiac end point, as did 6.2 percent of those assigned to anticoagulant therapy (relative risk, 0.25; 95 percent confidence interval, 0.06 to 0.77), With antiplatelet therapy, there was an 82 percent lower risk of myocardial infarction than in the anticoagulant-therapy group, and a 78 percent lower need for repeated interventions. Occlusion of the stented vessel occurred in 0.8 percent of the antiplatelet-therapy group and in 5.4 percent of the anticoagulant-therapy group (relative risk, 0.14; 95 percent confidence interval, 0.02 to 0.62), A primary noncardiac end point was reached by 1.2 percent of the antiplatelet-therapy group and 12.3 percent of the anticoagulant-therapy group (relative risk, 0.09; 95 percent confidence interval, 0.02 to 0.31), Hemorrhagic complications occurred only in the anticoagulant-therapy group (in 6.5 percent), An 87 percent reduction in the risk of peripheral vascular events was observed with antiplatelet therapy. Conclusions. As compared with conventional anticoagulant therapy, combined antiplatelet therapy after the placement of coronary-artery stents reduces the incidence of both cardiac events and hemorrhagic and vascular complications. (C) 1996, Massachusetts Medical Society.	TECH UNIV MUNICH,KLINIKUM RECHTS ISAR,INST MED STAT & EPIDEMIOL,D-81675 MUNICH,GERMANY	Technical University of Munich	Schomig, A (corresponding author), TECH UNIV MUNICH,KLINIKUM RECHTS ISAR,MED KLIN 1,ISMANINGER STR 22,D-81675 MUNICH,GERMANY.		, Kastrati/Y-2389-2019	Schuhlen, Helmut/0000-0001-8630-4264				Breslow N. E., 1980, IARC SCI PUBLICATION, V32; COLLER BS, 1990, NEW ENGL J MED, V322, P33, DOI 10.1056/NEJM199001043220107; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; ELLIS SG, 1990, CIRCULATION, V82, P1193, DOI 10.1161/01.CIR.82.4.1193; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Fleiss JL, 1981, STAT METHODS RATES P; Freedman JE, 1994, THROMBOSIS HEMORRHAG, P1155; GAWAZ M, IN PRES CIRCULATION; GENT M, 1989, LANCET, V1, P1215, DOI 10.1016/S0140-6736(89)92327-1; GEORGE BS, 1993, J AM COLL CARDIOL, V22, P135, DOI 10.1016/0735-1097(93)90827-N; HARKER LA, 1993, TICLOPIDINE PLATELET, P41; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; Neumann FJ, 1996, J AM COLL CARDIOL, V27, P15, DOI 10.1016/0735-1097(95)00433-5; SCHATZ RA, 1991, CIRCULATION, V83, P148, DOI 10.1161/01.CIR.83.1.148; SCHAUB F, 1994, CIRCULATION, V90, P1861, DOI 10.1161/01.CIR.90.4.1861; SCHOMIG A, 1994, CIRCULATION, V90, P2716, DOI 10.1161/01.CIR.90.6.2716; SCHUHLEN H, 1995, J AM COLL CARDIOL, pA123; Serruys PW, 1996, CIRCULATION, V93, P412, DOI 10.1161/01.CIR.93.3.412; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; TOPOL EJ, 1994, NEW ENGL J MED, V331, P539, DOI 10.1056/NEJM199408253310811; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; XIAO X, 1995, J AM COLL CARDIOL A, V117	23	1645	1672	0	33	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	1996	334	17					1084	1089		10.1056/NEJM199604253341702	http://dx.doi.org/10.1056/NEJM199604253341702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG457	8598866				2022-12-28	WOS:A1996UG45700002
J	Weiss, EJ; Bray, PF; Tayback, M; Schulman, SP; Kickler, TS; Becker, LC; Weiss, JL; Gerstenblith, G; GoldschmidtClermont, PJ				Weiss, EJ; Bray, PF; Tayback, M; Schulman, SP; Kickler, TS; Becker, LC; Weiss, JL; Gerstenblith, G; GoldschmidtClermont, PJ			A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DOSE ASPIRIN; ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; GPIIB-IIIA; TRIAL; REINFARCTION; PREVENTION; DISEASE; THERAPY; PECTORIS	Background. Platelet glycoprotein IIb/IIIa is a membrane receptor for fibrinogen and von Willebrand factor, and it has an important role in platelet aggregation, It is known to be involved in the pathogenesis of acute coronary syndromes, Previously, we found a high frequency of a particular polymorphism, Pl(A2), of the gene encoding glycoprotein IIIa in kindreds with a high prevalence of premature myocardial infarction. Methods. To investigate the relation between the Pl(A2) polymorphism and acute coronary syndromes, we conducted a case-control study of 71 case patients with myocardial infarction or unstable angina and 68 inpatient controls without known heart disease, The groups were matched for age, race, and sex, We used two methods to determine the Pl(A2) genotype, reverse dot blot hybridization and allele-specific restriction digestion. Results. The prevalence of Pl(A2) was 2.1 times higher among the case patients than among the controls (39.4 percent vs, 19.1 percent, P=0.01), In a subgroup of patients whose disease began before the age of 60 years, the prevalence of Pl(A2) was 50 percent, a value that was 3.6 times that among control subjects under 60 years of age (13.9 percent, P=0.002), Among subjects with the Pl(A2) polymorphism, the odds ratio for having a coronary event was 2.8 (95 percent confidence interval, 1.2 to 6.4). In the patients less than 60 years of age at the onset of disease, the odds ratio was 6.2 (95 percent confidence interval, 1.8 to 22.4). Conclusions. We observed a strong association between the Pl(A2) polymorphism of the glycoprotein IIIa gene and acute coronary thrombosis, and this association was strongest in patients who had had coronary events before the age of 60 years. (C) 1996, Massachusetts Medical Society.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CARDIOL, BERNARD LAB, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DIV HEMATOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NHLBI NIH HHS [HL49762] Funding Source: Medline; NINR NIH HHS [NR02241] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR002241] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1980, CIRCULATION, V62, P449; BORNE AEGV, 1990, TRANSFUSION, V30, P477, DOI 10.1046/j.1537-2995.1990.30590296385.x; BRAY PF, 1994, BLOOD, V84, P4361, DOI 10.1182/blood.V84.12.4361.bloodjournal84124361; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Chandler A B, 1974, Am J Cardiol, V34, P823; COLLER BS, 1995, CIRCULATION, V92, P2373, DOI 10.1161/01.CIR.92.9.2373; COLLER BS, 1990, NEW ENGL J MED, V322, P33, DOI 10.1056/NEJM199001043220107; DAVIES MJ, 1990, CIRCULATION, V82, P38; DEWOOD MA, 1986, NEW ENGL J MED, V315, P417, DOI 10.1056/NEJM198608143150703; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GOLD HK, 1990, J CLIN INVEST, V86, P651, DOI 10.1172/JCI114757; HOFFMAN W, 1991, PROSTAG LEUKOTR ESS, V44, P159, DOI 10.1016/0952-3278(91)90051-6; JANG YS, 1994, J AM COLL CARDIOL, V24, P1591, DOI 10.1016/0735-1097(94)90162-7; JIN Y, 1993, BLOOD, V82, P2281; JUULMOLLER S, 1992, LANCET, V340, P1421, DOI 10.1016/0140-6736(92)92619-Q; KICKLER TS, 1994, SCI BASIS TRANSFUSIO, P304; KIM HO, 1995, TRANSFUSION, V35, P863, DOI 10.1046/j.1537-2995.1995.351096026369.x; KLIMT CR, 1986, J AM COLL CARDIOL, V7, P251, DOI 10.1016/S0735-1097(86)80489-2; KUNICKI TJ, 1979, MOL IMMUNOL, V16, P353, DOI 10.1016/0161-5890(79)90100-7; LAM JYT, 1986, J AM COLL CARDIOL, V8, P1380, DOI 10.1016/S0735-1097(86)80311-4; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; MICKELSON JK, 1989, J MOL CELL CARDIOL, V21, P393, DOI 10.1016/0022-2828(89)90650-0; NEWMAN PJ, 1989, J CLIN INVEST, V83, P1778, DOI 10.1172/JCI114082; NEWMAN PJ, 1994, THROMBOSIS HEMORRHAG, P529; NYMAN I, 1992, LANCET, V340, P497, DOI 10.1016/0140-6736(92)91706-E; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; RAMSEY G, 1986, TRANSFUSION, V26, P531, DOI 10.1046/j.1537-2995.1986.26687043619.x; RIDKER PM, 1991, ANN INTERN MED, V114, P835, DOI 10.7326/0003-4819-114-10-835; RIDKER PM, 1990, CIRCULATION, V82, P897, DOI 10.1161/01.CIR.82.3.897; RIDKER PM, 1991, CIRCULATION, V84, P708, DOI 10.1161/01.CIR.84.2.708; SHULMAN NR, 1961, J CLIN INVEST, V40, P1597, DOI 10.1172/JCI104383; TRIP MD, 1990, NEW ENGL J MED, V322, P1549, DOI 10.1056/NEJM199005313222201; VAN LOGHEM JJ J, 1959, Vox Sang, V4, P161; VERHEUGT FWA, 1990, AM J CARDIOL, V66, P267, DOI 10.1016/0002-9149(90)90833-M; WALLENTIN L, 1990, LANCET, V336, P827; Weiss EJ, 1995, TISSUE ANTIGENS, V46, P374, DOI 10.1111/j.1399-0039.1995.tb03129.x; ZIMRIN AB, 1990, J BIOL CHEM, V265, P8590	41	625	651	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 25	1996	334	17					1090	1094		10.1056/NEJM199604253341703	http://dx.doi.org/10.1056/NEJM199604253341703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG457	8598867	Green Published			2022-12-28	WOS:A1996UG45700003
J	Lindpaintner, K; Lee, MA; Larson, MG; Rao, VS; Pfeffer, MA; Ordovas, JM; Schaefer, EJ; Wilson, AF; Wilson, PWF; Vasan, RS; Myers, RH; Levy, D				Lindpaintner, K; Lee, MA; Larson, MG; Rao, VS; Pfeffer, MA; Ordovas, JM; Schaefer, EJ; Wilson, AF; Wilson, PWF; Vasan, RS; Myers, RH; Levy, D			Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-FAILURE; HYPERTROPHY; TWINS; CELLS; CAPTOPRIL; RATS; POLYMORPHISM; HYPERTENSION; DYSFUNCTION; EXPRESSION	Background. Homozygous carriers of the D allele of the angiotensin-converting-enzyme (ACE) gene have been reported to be at increased risk for various cardiovascular disorders, including left ventricular hypertrophy. We investigated the potential role of the ACE gene in influencing left ventricular mass. Methods. Quantitative echocardiographic data and DNA samples were available for 2439 subjects from the Framingham Heart Study. ACE genotypes were determined by an assay based on the polymerase chain reaction. (The D allele of the ACE gene contains a deletion, whereas the I [insertion] allele does not.) Left ventricular mass and the prevalence of left ventricular hypertrophy, adjusted for clinical covariates, were analyzed according to genotype, Genetic linkage between the ACE locus and left ventricular mass was evaluated by quantitative analysis of pairs of siblings. Results. The ACE genotype was associated neither with left ventricular mass nor with the prevalence of left ventricular hypertrophy. Mean (+/-SE) left ventricular mass (adjusted for sex) among subjects carrying the DD, DI, and II genotypes was 165+/-1.6, 165+/-1.3, and 166+/-2.0 g, respectively (P=0.90). The prevalence of left ventricular hypertrophy among the three genotype groups was 15.6 percent, 13.6 percent, and 15.6 percent, respectively (P=0.36), and the adjusted relative risk of left ventricular hypertrophy associated with the DD genotype was 1.10 (95 percent confidence interval, 0.86 to 1.19). Linkage analysis in 759 pairs of siblings using both the ACE D/I marker and a microsatellite polymorphism at the neighboring locus for the human growth hormone gene failed to support any role of ACE in influencing left ventricular mass. Conclusions. The ACE genotype showed no association with echocardiographically determined left ventricular mass, nor did it confer an increased risk of left ventricular hypertrophy. We found no appreciable role of the ACE gene in influencing left ventricular mass.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT CARDIOL, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV CARDIOL, BOSTON, MA USA; HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED, DIV CLIN EPIDEMIOL, BOSTON, MA USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DIV EPIDEMIOL, BOSTON, MA USA; BOSTON UNIV, SCH MED, DEPT MED, DIV PREVENT MED, BOSTON, MA 02118 USA; TUFTS UNIV, SCH MED,HUMAN NUTR RES CTR AGING,USDA, LIPID METAB LAB, BOSTON, MA USA; FRAMINGHAM HEART DIS EPIDEMIOL STUDY, FRAMINGHAM, MA USA; LOUISIANA STATE UNIV, MED CTR, DEPT BIOMETRY & GENET, NEW ORLEANS, LA 70112 USA; NHLBI, BETHESDA, MD 20892 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University; Boston University; Boston University; Tufts University; United States Department of Agriculture (USDA); Framingham Heart Study; Louisiana State University System; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lindpaintner, K (corresponding author), HARVARD UNIV, DIV CARDIOVASC DIS,DEPT MED,BRIGHAM & WOMENS HOSP, SCH MED, 75 FRANCIS ST, BOSTON, MA 02115 USA.		Ramachandran, Vasan/Y-2527-2019; Wilson, Alexander/C-2320-2009; Lee-Kirsch, Min Ae/C-5769-2018; Levy, Daniel/ABF-6873-2021; Wilson, Peter W.F./J-2455-2016; Wilson, Alexander F./Q-6910-2019; Levy, Daniel/ABB-2752-2021; Ordovas, Jose/B-8727-2013	Ramachandran, Vasan/0000-0001-7357-5970; Levy, Daniel/0000-0003-1843-8724; Myers, Richard/0000-0002-8365-2674; Larson, Martin/0000-0002-9631-1254; Ordovas, Jose/0000-0002-7581-5680	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003655] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL003138] Funding Source: NIH RePORTER; NCRR NIH HHS [RR03655] Funding Source: Medline; NHLBI NIH HHS [K04-HL03138-01] Funding Source: Medline; PHS HHS [N01-38038] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMOS CI, 1989, GENET EPIDEMIOL, V6, P349, DOI 10.1002/gepi.1370060205; AMOS CI, 1989, GENET EPIDEMIOL, V6, P435, DOI 10.1002/gepi.1370060306; AMOS CL, 1989, GENET EPIDEMIOL, V6, P727; BAKER KM, 1990, AM J PHYSIOL, V259, pH324, DOI 10.1152/ajpheart.1990.259.2.H324; BAKER KM, 1990, AM J PHYSIOL, V259, pH610, DOI 10.1152/ajpheart.1990.259.2.H610; BIELEN E, 1990, EUR HEART J, V11, P7, DOI 10.1093/oxfordjournals.eurheartj.a059595; BOEHNKE M, 1991, AM J HUM GENET, V48, P22; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; FABRIS B, 1990, CLIN EXP PHARMACOL P, V17, P309, DOI 10.1111/j.1440-1681.1990.tb01326.x; FAGARD R, 1987, AM J CARDIOL, V60, P1362, DOI 10.1016/0002-9149(87)90620-5; GANAU A, 1990, CIRCULATION, V81, P25, DOI 10.1161/01.CIR.81.1.25; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HARSHFIELD GA, 1990, AM J HYPERTENS, V3, P538, DOI 10.1093/ajh/3.7.538; HIRSCH AT, 1991, CIRC RES, V69, P475, DOI 10.1161/01.RES.69.2.475; HOSMER DW, 1989, APPL LOGISTIC REGRES; IWAI N, 1994, CIRCULATION, V90, P2622, DOI 10.1161/01.CIR.90.6.2622; IWAI N, 1992, J HYPERTENS, V10, P1155, DOI 10.1097/00004872-199210000-00007; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; JULIEN J, 1990, J AM COLL CARDIOL, V16, P137, DOI 10.1016/0735-1097(90)90470-A; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; KUPARI M, 1994, AM J PHYSIOL, V267, pH1107, DOI 10.1152/ajpheart.1994.267.3.H1107; LANDRY F, 1985, JAMA-J AM MED ASSOC, V254, P77, DOI 10.1001/jama.254.1.77; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LAUER MS, 1994, AM J CARDIOL, V74, P487, DOI 10.1016/0002-9149(94)90909-1; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; LINDPAINTNER K, 1993, J MOL CELL CARDIOL, V25, P133, DOI 10.1006/jmcc.1993.1017; LINDPAINTNER K, 1995, NEW ENGL J MED, V332, P706, DOI 10.1056/NEJM199503163321103; *LOU STAT U CTR, 1991, SAGE STAT AN GEN EP; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PFEFFER JM, 1982, P NATL ACAD SCI-BIOL, V79, P3310, DOI 10.1073/pnas.79.10.3310; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; POST WS, IN PRESS J AM COLL C; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; RUTHERFORD JD, 1994, CIRCULATION, V90, P1731, DOI 10.1161/01.CIR.90.4.1731; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; *SAS I, 1979, SAS STAT US GUID VER, P891; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302; SCHWARTZ K, 1995, CIRCULATION, V91, P532, DOI 10.1161/01.CIR.91.2.532; SHURTLEFF D, 1974, NIH PUBLICATION; Sullivan JM, 1993, J AM COLL CARDIOL, V22, P508, DOI 10.1016/0735-1097(93)90057-8; TIRET L, 1992, AM J HUM GENET, V51, P197; VERHAAREN HA, 1991, AM J CARDIOL, V68, P661, DOI 10.1016/0002-9149(91)90361-N; 1992, NEW ENGL J MED, V327, P1768	52	228	234	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 18	1996	334	16					1023	1028		10.1056/NEJM199604183341604	http://dx.doi.org/10.1056/NEJM199604183341604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE733	8598840	Bronze			2022-12-28	WOS:A1996UE73300004
J	Shaw, GM; Velie, EM; Schaffer, D				Shaw, GM; Velie, EM; Schaffer, D			Risk of neural tube defect-affected pregnancies among obese women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALPHA-FETOPROTEIN LEVELS; MATERNAL WEIGHT	Objective.-To investigate the risk for neural tube defect (NTD)-affected pregnancies among obese women (ie, women with a body mass index [BMI] >29 kg/m(2)) compared with women of average prepregnancy weight. Design.-Population-based case-control study. Setting.-All hospitals in 55 of 58 counties in California. Participants.-In-person interviews were conducted with mothers of 538 (88% of eligible) NTD cases (including fetuses and infants electively terminated, stillborn, or born alive) and with mothers of 539 nonmalformed controls (88%) within an average of 5 months from the term delivery date. Main Outcome Measures.-The risk of an NTD-affected pregnancy among obese women. Results.-Compared with women whose BMI was less than or equal to 29 kg/m(2), an increased risk for NTD-affected pregnancy was observed among obese women (odds ratio, 1.9; 95% confidence interval, 1.3 to 2.9). The increased risk was not attributable to maternal nonuse of a vitamin containing folic acid, diabetes, use of diet pills, lower dietary folate intake, or an NTD-pregnancy history. Adjustment for maternal age, education, gravidity, use of vitamins, and use of alcohol did not change the odds ratio. The risk associated with maternal obesity was greater for spina bifida and for other less prevalent NTDs than for anencephaly. Conclusion.-Because as many as 10% of women maybe obese periconceptionally, the observed twofold increased risk is relevant to the population burden of NTDs.	KAISER PERMANENTE,DIV RES,OAKLAND,CA	Kaiser Permanente	Shaw, GM (corresponding author), MARCH DIMES BIRTH DEFECTS FDN,CALIF BIRTH DEFECTS MONITORING PROGRAM,1900 POWELL ST,SUITE 1050,EMERYVILLE,CA 94608, USA.		Velie, Ellen/AAF-3493-2020	Shaw, Gary/0000-0001-7438-4914				BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; CAVDAR AO, 1980, TERATOLOGY, V22, P141, DOI 10.1002/tera.1420220116; Croen L A, 1991, Paediatr Perinat Epidemiol, V5, P423, DOI 10.1111/j.1365-3016.1991.tb00728.x; EANDERSON WJF, 1958, LANCET, V1, P1305; Elwood JM, 1992, EPIDEMIOLOGY CONTROL, P521; FRIEL JK, 1995, AM J MED GENET, V55, P195, DOI 10.1002/ajmg.1320550209; HADDOW JE, 1982, BRIT J OBSTET GYNAEC, V89, P93, DOI 10.1111/j.1471-0528.1982.tb04646.x; JOHNSON AM, 1990, AM J OBSTET GYNECOL, V163, P9, DOI 10.1016/S0002-9378(11)90655-3; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; MARTIN L, 1988, LANCET, V1, P640; NAEYE RL, 1990, AM J CLIN NUTR, V52, P273, DOI 10.1093/ajcn/52.2.273; *NAT AC SCI, 1990, NUTR PREGN, P5; PERRY GS, 1995, EPIDEMIOLOGY, V6, P61, DOI 10.1097/00001648-199501000-00012; RICHARDS ID, 1969, BRIT J PREV SOC MED, V23, P218; ROBERT E, 1995, REPROD TOXICOL, V9, P57, DOI 10.1016/0890-6238(94)00056-3; Ruge S, 1985, Obstet Gynecol Surv, V40, P57, DOI 10.1097/00006254-198502000-00001; SHAW GM, 1995, EPIDEMIOLOGY, V6, P219, DOI 10.1097/00001648-199505000-00005; *STAT EP RES CORP, 1991, EGRET VERS 0256; WALD N, 1981, BRIT J OBSTET GYNAEC, V88, P1094, DOI 10.1111/j.1471-0528.1981.tb01759.x; WALLER DK, 1994, AM J OBSTET GYNECOL, V170, P541, DOI 10.1016/S0002-9378(94)70224-1; WALLER DK, 1995, AM J OBSTET GYNECOL, V172, P246, DOI 10.1016/0002-9378(95)90140-X; WATKINS M, 1994, AM J EPIDEMIOL, V139, pS11; WOLFE HM, 1990, OBSTET GYNECOL, V76, P339	23	273	274	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1996	275	14					1093	1096		10.1001/jama.275.14.1093	http://dx.doi.org/10.1001/jama.275.14.1093			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD027	8601928				2022-12-28	WOS:A1996UD02700025
J	Szarewski, A; Jarvis, MJ; Sasieni, P; Anderson, M; Edwards, R; Steele, SJ; Guillebaud, J; Cuzick, J				Szarewski, A; Jarvis, MJ; Sasieni, P; Anderson, M; Edwards, R; Steele, SJ; Guillebaud, J; Cuzick, J			Effect of smoking cessation on cervical lesion size	LANCET			English	Article							COTININE; NONSMOKERS; NICOTINE; SMOKERS; NEOPLASIA; CANCER; FLUIDS; MUCUS	Background Cigarette smoking has been postulated as a cofactor in the aetiology of cervical cancer, but a causal role is difficult to establish because of potential confounding by sexual behaviour. We have investigated the effect of cessation or reduction in cigarette smoking on the course of minor-grade cervical lesions. Methods In this intervention study 82 women volunteers with minor-grade lesions on colposcopy (cervical intraepithelial neoplasia grade 1 or less) attempted to give up smoking for 6 months. Smoking histories were taken at 3-monthly clinic visits and verified by measurement of salivary cotinine concentrations. At each clinic visit, a photograph of the cervix was taken; the image was digitised and computer-aided image analysis was used to assess lesion size, by investigators unaware of smoking status. Findings Of the 82 women, 17 stopped smoking completely for at least 6 months and 11 others reduced their smoking consumption by more than 75%. Of these 28 women, 23 (82%) showed a reduction in lesion size of at least 20% or 4 mm(2) compared with 13 (28%) of the 47 non-quitters (odds ratio 12.0 [95% CI 3.9-32.7]). The remaining seven women had unconfirmed smoking histories. There was a significant correlation between the extent of smoking reduction and the change in lesion size (chi(2) for trend=31.55, p<0.0001). Adjustment for social class, method of contraception, and stage of menstrual cycle did not affect the results. Interpretation Our findings support a link between smoking and cervical disease and suggest that smoking cessation could have a beneficial effect on early cervical abnormalities.	IMPERIAL CANC RES FUND, HLTH BEHAV UNIT, LONDON WC2A 3PX, ENGLAND; UNIV HOSP, DEPT HISTOPATHOL, NOTTINGHAM, ENGLAND; UCL HOSP TRUST, DEPT OBSTET & GYNAECOL, LONDON, ENGLAND; MARGARET PYKE CTR RES & TRAINING FAMILY PLANNING, LONDON, ENGLAND	Cancer Research UK; Nottingham University Hospital NHS Trust; University of Nottingham; University College London Hospitals NHS Foundation Trust; University of London; University College London	Szarewski, A (corresponding author), IMPERIAL CANC RES FUND, DEPT MATH STAT & EPIDEMIOL, POB 123, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.		Ruiz, Emilia Sanchez/K-3013-2013; Jarvis, Martin J/B-1034-2008	Ruiz, Emilia Sanchez/0000-0003-0522-8007; Jarvis, Martin J/0000-0001-9238-8038; Sasieni, Peter/0000-0003-1509-8744				BARTON SE, 1988, LANCET, V2, P652; BUXTON EJ, 1991, BRIT J OBSTET GYNAEC, V98, P1273, DOI 10.1111/j.1471-0528.1991.tb15401.x; CAMPION MJ, 1986, LANCET, V2, P237; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; FAIRLEY CK, 1995, AUST NZ J OBSTET GYN, V35, P181, DOI 10.1111/j.1479-828X.1995.tb01865.x; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; HELLBERG D, 1988, AM J OBSTET GYNECOL, V158, P910, DOI 10.1016/0002-9378(88)90093-2; IARC, 1995, IARC MON EV CARC RIS, P64; JARVIS MJ, 1987, AM J PUBLIC HEALTH, V77, P1435, DOI 10.2105/AJPH.77.11.1435; JARVIS MJ, 1988, AM J PUBLIC HEALTH, V78, P696, DOI 10.2105/AJPH.78.6.696; LUESLEY D, 1994, BRIT J OBSTET GYNAEC, V101, P49, DOI 10.1111/j.1471-0528.1994.tb13009.x; MCCANN MF, 1992, CANCER EPIDEM BIOMAR, V1, P125; POPPE WAJ, 1995, GYNECOL OBSTET INVES, V39, P34, DOI 10.1159/000292372; SCHIFFMAN MH, 1987, CANCER RES, V47, P3886; SHAFI MI, 1994, BRIT J OBSTET GYNAEC, V101, P234, DOI 10.1111/j.1471-0528.1994.tb13116.x; STAFL A, 1981, AM J OBSTET GYNECOL, V139, P815, DOI 10.1016/0002-9378(81)90549-4; TERRY G, 1994, LANCET, V344, P1096, DOI 10.1016/S0140-6736(94)91757-4; WINKELSTEIN W, 1977, AM J EPIDEMIOL, V106, P257, DOI 10.1093/oxfordjournals.aje.a112460; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; Zur Hausen H, 1982, LANCET, V2, P1370, DOI DOI 10.1016/S0140-6736(82)91273-9	20	80	90	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	1996	347	9006					941	943		10.1016/S0140-6736(96)91417-8	http://dx.doi.org/10.1016/S0140-6736(96)91417-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598759				2022-12-28	WOS:A1996UD59100012
J	Blair, SS				Blair, SS			Notch and wingless signals collide	SCIENCE			English	Editorial Material							CELL-FATE; DROSOPHILA; RECEPTOR				Blair, SS (corresponding author), UNIV WISCONSIN, DEPT ZOOL, MADISON, WI 53706 USA.							ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; BLAIR SS, 1994, DEV BIOL, V162, P229, DOI 10.1006/dbio.1994.1081; BLAIR SS, 1992, DEV BIOL, V152, P263, DOI 10.1016/0012-1606(92)90134-3; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; COUSO JP, 1994, CELL, V79, P259, DOI 10.1016/0092-8674(94)90195-3; COUSO JP, 1994, DEVELOPMENT, V120, P621; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HING HK, 1994, MECH DEVELOP, V47, P261, DOI 10.1016/0925-4773(94)90044-2; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1994, DEV BIOL, V135, P287; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; THEISEN H, 1994, DEVELOPMENT, V120, P347; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087	28	15	15	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1996	271	5257					1822	1823		10.1126/science.271.5257.1822	http://dx.doi.org/10.1126/science.271.5257.1822			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596948				2022-12-28	WOS:A1996UC77800032
J	Hoffmann, A; Chiang, CM; Oelgeschlager, T; Xie, XL; Burley, SK; Nakatani, Y; Roeder, RG				Hoffmann, A; Chiang, CM; Oelgeschlager, T; Xie, XL; Burley, SK; Nakatani, Y; Roeder, RG			A histone octamer-like structure within TFIID	NATURE			English	Article							IMMEDIATE EARLY PROTEIN; RNA POLYMERASE-II; TATA BOX; PROMOTER INTERACTIONS; PREINITIATION COMPLEX; TRANSCRIPTION FACTOR; INITIATION; BINDING	THE general transcription factor TFIID nucleates initiation complex formation through direct core promoter binding(1,2), commits promoters within chromatin to transcription(3), and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced TFIID recruitment(4-7) or conformational changes in TFIID-promoter complexes(8,9). Molecular studies of the multiprotein TFIID complex have identified a primary TATA binding subunit (TBP)(2), TBP-associated factors (TAFs) that interact with and mediate the function of activators(2,7,10,11) and intersubunit interactions(2) but have yielded relatively little insight into the structural organization of the complete or the actual mechanism of transcriptional activation. Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15. Together with analyses of native TFIID complexes and accompanying crystallographic studies(12), the results suggest that there is a histone octamer-like TAF complex within TFIID.	ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,LABS MOL BIOPHYS,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; NINCDS,NIH,BETHESDA,MD 20892; NICHHD,NIH,BETHESDA,MD 20892	Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Oelgeschlager, Thomas/0000-0002-4086-719X; Burley, Stephen K./0000-0002-2487-9713				ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; BURLEY SK, IN PRESS REV BIOCH; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; GILMOUR DS, 1990, MOL CELL BIOL, V10, P4233, DOI 10.1128/MCB.10.8.4233; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; MARTINEZ E, 1995, P NATL ACAD SCI USA, V92, P11864, DOI 10.1073/pnas.92.25.11864; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; PRUSS D, 1995, BIOESSAYS, V17, P1; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZHONG R, 1983, NUCLEIC ACIDS RES, V11, P7409, DOI 10.1093/nar/11.21.7409	30	159	162	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					356	359		10.1038/380356a0	http://dx.doi.org/10.1038/380356a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598932				2022-12-28	WOS:A1996UC37900063
J	Haas, GG				Haas, GG			Antisperm antibodies in infertile men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							SPERM-ASSOCIATED IMMUNOGLOBULINS; PENETRATION; BINDING; PLACEBO				Haas, GG (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT OBSTET & GYNECOL,SECT REPROD ENDOCRINOL INFERTIL,OKLAHOMA CITY,OK 73190, USA.							ACOSTA AA, 1994, FERTIL STERIL, V62, P826; ADEGHE AJH, 1989, INT J ANDROL, V12, P281, DOI 10.1111/j.1365-2605.1989.tb01315.x; ASCH RH, 1977, FERTIL STERIL, V28, P671; BRONSON RA, 1987, FERTIL STERIL, V48, P505; HAAS GG, 1987, FERTIL STERIL, V47, P295; HAAS GG, 1985, AM J REPROD IM MIC, V7, P109; HAAS GG, 1988, J ANDROL, V9, P190; HAAS GG, 1986, FERTIL STERIL, V46, P334; HAMILTON F, 1989, J IN VITRO FERTIL EM, V6, P342, DOI 10.1007/BF01138774; HENDRY WF, 1990, LANCET, V335, P85, DOI 10.1016/0140-6736(90)90548-J; LANSFORD B, 1990, J ANDROL, V11, P532; MAHONY MC, 1991, J REPROD IMMUNOL, V19, P287, DOI 10.1016/0165-0378(91)90041-N	12	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					885	886		10.1001/jama.275.11.885	http://dx.doi.org/10.1001/jama.275.11.885			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ971	8596228				2022-12-28	WOS:A1996TZ97100034
J	Shelhamer, JH; Gill, VJ; Quinn, TC; Crawford, SW; Kovacs, JA; Masur, H; Ognibene, FP				Shelhamer, JH; Gill, VJ; Quinn, TC; Crawford, SW; Kovacs, JA; Masur, H; Ognibene, FP			The laboratory evaluation of opportunistic pulmonary infections	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							POLYMERASE CHAIN-REACTION; PNEUMOCYSTIS-CARINII PNEUMONIA; BONE-MARROW TRANSPLANTATION; ACQUIRED IMMUNODEFICIENCY SYNDROME; BRONCHOALVEOLAR LAVAGE FLUID; PERIPHERAL-BLOOD LEUKOCYTES; HUMAN CYTOMEGALOVIRUS-INFECTION; RESPIRATORY SYNCYTIAL VIRUS; RAPID DETECTION; MONOCLONAL-ANTIBODY	The patient population at risk for opportunistic pulmonary infections has increased during the last decade. The spectrum of organisms causing opportunistic infections has also grown. With an ever broader list of potential therapeutic options and a growing differential diagnosis, a specific diagnosis of the cause of pulmonary disease becomes more important. Recent microbiologic advances have helped to facilitate the laboratory diagnosis of some of these agents. Immunoassays are available for the detection of antigen in nasopharyngeal secretions (respiratory syncytial virus, influenza), in serum (Cryptococcus species), and in urine (Legionella or Histoplasma species). Rapid-culture techniques are available for the culture a nd detection of various viruses, including cytomegalovirus. Molecular probes can now assist in the rapid identification of Mycobacterium tuberculosis and some fungi. In the near future, polymerase chain reaction-based techniques may assist in the detection of Pneumocystis carinii and Legionella, Chlamydia, Mycoplasma, and Mycobacteria species. An expeditious evaluation of pulmonary disease requires an understanding of the differential diagnosis of likely causes of pulmonary disease in specific immunosuppressed patient populations, an understanding of the most appropriate specimens to process for these diagnoses, and an understanding of the limitations (sensitivity and specificity) of these diagnostic tests. An understanding of the most appropriate specimens and tests in a given institution should allow for early, relatively specific treatment of many potentially life-threatening infections.	NIH, CTR CLIN, DEPT CLIN PATHOL, BETHESDA, MD 20892 USA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Fred Hutchinson Cancer Center	Shelhamer, JH (corresponding author), NIH, CTR CLIN, DEPT CRIT CARE MED, BLDG 10, ROOM 7-D-43, BETHESDA, MD 20892 USA.		Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880				ABE C, 1993, J CLIN MICROBIOL, V31, P3270, DOI 10.1128/JCM.31.12.3270-3274.1993; AGUEROROSENFELD ME, 1988, J CLIN MICROBIOL, V26, P1775, DOI 10.1128/JCM.26.9.1775-1778.1988; ANAISSIE E, 1992, CLIN INFECT DIS, V14, pS43, DOI 10.1093/clinids/14.Supplement_1.S43; [Anonymous], 1979, Ann Intern Med, V90, P489; BEIN G, 1993, TRANSPLANT INT, V6, P185, DOI 10.1007/BF00337097; BEJ AK, 1991, APPL ENVIRON MICROB, V57, P597, DOI 10.1128/AEM.57.2.597-600.1991; BENNETT JE, 1987, REV INFECT DIS, V9, P398; BIGBY TD, 1986, AM REV RESPIR DIS, V133, P515; BITSCH A, 1993, TRANSPLANTATION, V56, P108, DOI 10.1097/00007890-199307000-00020; BOECKH M, 1992, BLOOD, V80, P1358; BUCK GE, 1992, J CLIN MICROBIOL, V125, P680; CARTWRIGHT CP, 1994, J CLIN MICROBIOL, V32, P1634, DOI 10.1128/JCM.32.7.1634-1638.1994; CHMEL H, 1993, FUNGAL INFECTIONS IM, P405; CLES LD, 1990, J CLIN MICROBIOL, V28, P938, DOI 10.1128/JCM.28.5.938-940.1990; CRAWFORD SW, 1988, ANN INTERN MED, V108, P180, DOI 10.7326/0003-4819-108-2-180; DEGAST GC, 1992, BONE MARROW TRANSPL, V9, P221; Edelstein Paul H., 1994, P455; EDELSTEIN PH, 1985, J CLIN MICROBIOL, V22, P419, DOI 10.1128/JCM.22.3.419-421.1985; EDELSTEIN PH, 1992, MANUAL CLIN LAB IMMU, V10, P685; EINSELE H, 1991, BLOOD, V77, P1104; EINSELE H, 1993, BLOOD, V82, P1672; EMANUEL D, 1986, ANN INTERN MED, V104, P476, DOI 10.7326/0003-4819-104-4-476; ENGLAND AC, 1981, ANN INTERN MED, V94, P164, DOI 10.7326/0003-4819-94-2-164; ERICE A, 1992, J CLIN MICROBIOL, V30, P2822, DOI 10.1128/JCM.30.11.2822-2825.1992; Fanta Christopher H., 1994, P275; FISHMAN JA, 1994, J CLIN MICROBIOL, V32, P131, DOI 10.1128/JCM.32.1.131-134.1994; FORTUN J, 1992, EUR RESPIR J, V5, P665; GAYDOS CA, 1992, J CLIN MICROBIOL, V30, P796, DOI 10.1128/JCM.30.4.796-800.1992; GAYDOS CA, 1993, CLIN INFECT DIS, V17, P718, DOI 10.1093/clinids/17.4.718; GLEAVES CA, 1985, J CLIN MICROBIOL, V21, P217, DOI 10.1128/JCM.21.2.217-221.1985; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; GRAYSTON JT, 1990, J INFECT DIS, V161, P618, DOI 10.1093/infdis/161.4.618; HACKMAN RC, 1985, J INFECT DIS, V151, P325, DOI 10.1093/infdis/151.2.325; HALWACHS G, 1993, TRANSPLANTATION, V56, P338, DOI 10.1097/00007890-199308000-00016; HELMS CM, 1983, ANN INTERN MED, V99, P172, DOI 10.7326/0003-4819-99-2-172; JAULHAC B, 1992, J CLIN MICROBIOL, V30, P920, DOI 10.1128/JCM.30.4.920-924.1992; JIWA NM, 1989, TRANSPLANTATION, V48, P72, DOI 10.1097/00007890-198907000-00017; JONES BE, 1993, AM REV RESPIR DIS, V148, P1292, DOI 10.1164/ajrccm/148.5.1292; JULESELYSEE KM, 1990, ANN INTERN MED, V112, P750, DOI 10.7326/0003-4819-112-10-750; KENNY GE, 1990, J CLIN MICROBIOL, V28, P2087, DOI 10.1128/JCM.28.9.2087-2093.1990; KENNY GE, 1986, MANUAL CLIN LABORATO, P440; Kenny GE, 1991, MANUAL CLIN MICROBIO, P478; KIRBY BD, 1980, MEDICINE, V59, P188; KLOTZ SA, 1987, AM REV RESPIR DIS, V136, P1197, DOI 10.1164/ajrccm/136.5.1197; KOVACS JA, 1988, NEW ENGL J MED, V318, P589, DOI 10.1056/NEJM198803103181001; LEVINE SJ, 1992, AM REV RESPIR DIS, V146, P838, DOI 10.1164/ajrccm/146.4.838; LEVINE SJ, 1991, AM REV RESPIR DIS, V144, P760, DOI 10.1164/ajrccm/144.4.760; LIPSCHIK GY, 1992, LANCET, V340, P203, DOI 10.1016/0140-6736(92)90469-J; LJUNGMAN P, 1989, BONE MARROW TRANSPL, V4, P35; MARTIN WJ, 1986, J CLIN MICROBIOL, V23, P1006, DOI 10.1128/JCM.23.6.1006-1008.1986; MAZZULLI T, 1993, J CLIN MICROBIOL, V31, P2824, DOI 10.1128/JCM.31.10.2824-2827.1993; MEYERS JD, 1982, REV INFECT DIS, V4, P1119; MICHAELS MG, 1992, PEDIATR INFECT DIS J, V11, P613; MIDGLEY J, 1989, LANCET, V2, P1523, DOI 10.1016/S0140-6736(89)92964-4; MILES PR, 1990, CHEST, V97, P1072, DOI 10.1378/chest.97.5.1072; MILLAR AB, 1990, AM REV RESPIR DIS, V141, P1474, DOI 10.1164/ajrccm/141.6.1474; MONES JM, 1986, CHEST, V89, P522, DOI 10.1378/chest.89.4.522; MYERSON D, 1984, HUM PATHOL, V15, P430, DOI 10.1016/S0046-8177(84)80076-3; NG VL, 1990, J CLIN MICROBIOL, V28, P2228, DOI 10.1128/JCM.28.10.2228-2233.1990; NOORDHOEK GT, 1994, J CLIN MICROBIOL, V32, P277, DOI 10.1128/JCM.32.2.277-284.1994; OGNIBENE FP, 1984, AM REV RESPIR DIS, V129, P929; PARADIS IL, 1988, AM REV RESPIR DIS, V138, P697, DOI 10.1164/ajrccm/138.3.697; QUINN TC, 1991, RESPIRATORY DIS IMMU, P298; RABALAIS GP, 1992, J CLIN MICROBIOL, V30, P1505, DOI 10.1128/JCM.30.6.1505-1508.1992; RAVIGLIONE MC, 1990, REV INFECT DIS, V12, P1127; RICHARDSON SE, 1988, REV INFECT DIS, V10, P1171; ROBLIN PM, 1992, J CLIN MICROBIOL, V30, P1968, DOI 10.1128/JCM.30.8.1968-1971.1992; RUCHEL R, 1993, ANN HEMATOL, V67, P1, DOI 10.1007/BF01709659; RUUTU P, 1990, ANN INTERN MED, V112, P913, DOI 10.7326/0003-4819-112-12-913; SCHLUGER NW, 1994, CHEST, V105, P1116, DOI 10.1378/chest.105.4.1116; SCHMIDT CA, 1994, BONE MARROW TRANSPL, V13, P71; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; SHAMI MJ, 1991, AM J OPHTHALMOL, V112, P15, DOI 10.1016/S0002-9394(14)76206-3; SLAVIN MA, 1992, J CLIN MICROBIOL, V30, P2776, DOI 10.1128/JCM.30.11.2776-2779.1992; Smith J W, 1982, Clin Lab Med, V2, P393; STOVER DE, 1984, AM REV RESPIR DIS, V130, P659; SUMMERSGILL J, 1994, INT C ANT AG CHEM OR, P165; THE TH, 1992, TRANSPLANTATION, V54, P193, DOI 10.1097/00007890-199208000-00001; THOMAS EE, 1991, J CLIN MICROBIOL, V29, P632, DOI 10.1128/JCM.29.3.632-635.1991; THORPE JE, 1987, J INFECT DIS, V155, P855, DOI 10.1093/infdis/155.5.855; VANDENBERG AP, 1993, TRANSPLANTATION, V55, P847, DOI 10.1097/00007890-199304000-00031; VANDERBIJ W, 1988, J CLIN MICROBIOL, V26, P2531, DOI 10.1128/JCM.26.12.2531-2535.1988; VANDORP WT, 1992, TRANSPLANTATION, V54, P661, DOI 10.1097/00007890-199210000-00019; VANKUPPEVELD FJ, 1994, EUR J CLIN MICROBIOL, V13, P401; WAKEFIELD AE, 1990, LANCET, V336, P451, DOI 10.1016/0140-6736(90)92008-6; WEINBERGER M, 1992, MEDICINE, V71, P24, DOI 10.1097/00005792-199201000-00003; Wheat L. Joseph, 1993, P29; WHEAT LJ, 1986, NEW ENGL J MED, V314, P83, DOI 10.1056/NEJM198601093140205; WOLINSKY E, 1994, CLIN INFECT DIS, V19, P396, DOI 10.1093/clinids/19.3.396; WOODS GL, 1993, ARCH PATHOL LAB MED, V117, P876; XAUBET A, 1989, CHEST, V95, P130, DOI 10.1378/chest.95.1.130; YU VL, 1986, AM J MED, V81, P249, DOI 10.1016/0002-9343(86)90259-7; YUNG RC, 1993, AM REV RESPIR DIS, V148, P1563, DOI 10.1164/ajrccm/148.6_Pt_1.1563	93	51	53	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1996	124	6					585	599		10.7326/0003-4819-124-6-199603150-00008	http://dx.doi.org/10.7326/0003-4819-124-6-199603150-00008			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ529	8597323				2022-12-28	WOS:A1996TZ52900009
J	Zwicker, J; Liu, NS; Engeland, K; Lucibello, FC; Muller, R				Zwicker, J; Liu, NS; Engeland, K; Lucibello, FC; Muller, R			Cell cycle regulation of E2F site occupation in vivo	SCIENCE			English	Article							TRANSCRIPTION FACTOR; RETINOBLASTOMA GENE; BINDING PROTEIN; EXPRESSION; PRODUCT; CDNA; CLONING	DNA-binding E2F complexes have been identified throughout the mammalian cell cycle, including the transcriptionally inactive complexes with pocket proteins, which occur early in the prereplicative G(1) phase of the cycle, and the transactivating free E2F, which increases in late G(1). Here, a regulatory B-myb promoter site was shown to bind with high affinity to free E2F and to E2F-pocket protein complexes in an indistinguishable way in vitro. In contrast, in vivo footprinting with NIH 3T3 cells demonstrated E2F site occupation specifically in early G(1), when the B-myb promoter is inactive. These observations indicate that a novel mechanism governs E2F-DNA interactions during the cell cycle and emphasize the relevance of E2F site-directed transcriptional repression.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,D-35033 MARBURG,GERMANY	Philipps University Marburg			Engeland, Kurt/AAW-9965-2020; Müller, Rolf/L-4997-2016	Engeland, Kurt/0000-0003-3525-0440; Müller, Rolf/0000-0003-3339-4248				BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ENGELAND K, 1995, J BIOL CHEM, V270, P24572, DOI 10.1074/jbc.270.41.24572; ENGELAND K, UNPUB; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LIU N, UNPUB; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NEVINS JR, 1992, SCIENCE, V258, P424; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x; ZWICKER J, UNPUB	29	149	151	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1595	1597		10.1126/science.271.5255.1595	http://dx.doi.org/10.1126/science.271.5255.1595			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599118				2022-12-28	WOS:A1996TZ98300045
J	Gareau, R; Audran, M; Baynes, RD; Flowers, CH; Duvallet, A; Senecal, L; Brisson, GR				Gareau, R; Audran, M; Baynes, RD; Flowers, CH; Duvallet, A; Senecal, L; Brisson, GR			Erythropoietin abuse in athletes	NATURE			English	Letter							BLOOD		UNIV MONTPELLIER 1,DEPT PHARM,BIOPHYS LAB,F-34060 MONTPELLIER,FRANCE; UNIV KANSAS,MED CTR,DEPT INTERNAL MED,DIV HEMATOL,KANSAS CITY,KS 66160; UNIV PARIS 05,FAC MED COCHIN PORT ROYAL,F-75014 PARIS,FRANCE; INST NATL RECH SCI SANTE,MONTREAL ANTIDOPING LAB,POINTE CLAIRE,PQ H9R 1G6,CANADA	Universite de Montpellier; University of Kansas; University of Kansas Medical Center; UDICE-French Research Universities; Universite Paris Cite; University of Quebec	Gareau, R (corresponding author), UNIV QUEBEC,DEPT BIOL CHEM,POB 500,TROIS RIVIERES,PQ G9A 5H7,CANADA.							BERGLUND B, 1987, INT J SPORTS MED, V8, P66, DOI 10.1055/s-2008-1025643; BRUGGER W, 1993, BLOOD, V81, P2579; CASONI I, 1993, INT J SPORTS MED, V14, P307, DOI 10.1055/s-2007-1021183; FLOWERS CH, 1989, J LAB CLIN MED, V114, P368; GAREAU R, 1994, BLOOD SAMPLES DOPING; WIDE L, 1995, MED SCI SPORT EXER, V27, P1569; 1991, MONDE CYCLISTE, V23, P10	7	66	68	1	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					113	113		10.1038/380113a0	http://dx.doi.org/10.1038/380113a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600382	Bronze			2022-12-28	WOS:A1996TZ97800029
J	Ferradini, L; Gu, H; DeSmet, A; Rajewsky, K; Reynaud, CA; Weill, JC				Ferradini, L; Gu, H; DeSmet, A; Rajewsky, K; Reynaud, CA; Weill, JC			Rearrangement-enhancing element upstream of the mouse immunoglobulin kappa chain J cluster	SCIENCE			English	Article							REGION GENE SEGMENTS; B-CELL; V(D)J RECOMBINATION; INTRON ENHANCER; TRANSCRIPTION; MICE; EXPRESSION; HEAVY; LOCUS; DISRUPTION	Transcriptional regulatory elements have been shown to be necessary but not sufficient for the developmental regulation of immunoglobulin gene rearrangement in mouse precursor B cells. In the chicken lambda light chain locus, additional elements in the V-J intervening sequence are involved in negative and positive regulation of rearrangement. Here, mutation of the mouse homolog of a chicken element, located in the V-kappa-J(kappa) intervening sequence upstream of the J(kappa) duster, was shown to significantly decrease rearrangement. This cis-acting recombination-enhancing element affects the rearrangement process without being involved in regulating transcription.	UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY	University of Cologne	Ferradini, L (corresponding author), UNIV PARIS 05, FAC MED NECKER ENFANT MALAD,INST NECKER,INSERM, U373, 156 RUE VAUGIRARD, F-75730 PARIS 05, FRANCE.			Rajewsky, Klaus/0000-0002-6633-6370				ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; ARTELT P, 1991, GENE, V99, P249, DOI 10.1016/0378-1119(91)90134-W; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BUCCHINI D, 1987, NATURE, V326, P409, DOI 10.1038/326409a0; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; DENG CX, 1993, MOL CELL BIOL, V13, P2134, DOI 10.1128/MCB.13.4.2134; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; Ferradini L, 1994, Semin Immunol, V6, P165, DOI 10.1006/smim.1994.1022; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; Grutzmann R., 1981, THESIS U COLOGNE COL; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LAUSTER R, 1993, EMBO J, V12, P4615, DOI 10.1002/j.1460-2075.1993.tb06150.x; LECLERCQ L, 1989, NUCLEIC ACIDS RES, V17, P6809, DOI 10.1093/nar/17.17.6809; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN DJ, 1990, MOL CELL BIOL, V10, P1950, DOI 10.1128/MCB.10.5.1950; MEDINA CA, 1993, J EXP MED, V177, P1317, DOI 10.1084/jem.177.5.1317; NELSON KJ, 1984, NUCLEIC ACIDS RES, V12, P1911, DOI 10.1093/nar/12.4.1911; NISHI M, 1985, P NATL ACAD SCI USA, V82, P6399, DOI 10.1073/pnas.82.19.6399; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; OPITZ HG, 1982, IMMUNOBIOLOGY, V160, P438, DOI 10.1016/S0171-2985(82)80007-7; RETH M, 1981, THESIS U COLOGNE COL; SAUER B, 1990, New Biologist, V2, P441; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SERWE M, 1993, EMBO J, V12, P2321, DOI 10.1002/j.1460-2075.1993.tb05886.x; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; STORB U, 1983, P NATL ACAD SCI-BIOL, V80, P6642, DOI 10.1073/pnas.80.21.6642; TAKEDA S, 1993, EMBO J, V12, P2329, DOI 10.1002/j.1460-2075.1993.tb05887.x; VANNESS BG, 1981, CELL, V27, P593, DOI 10.1016/0092-8674(81)90401-3; WEAVER D, 1987, P NATL ACAD SCI USA, V84, P1516, DOI 10.1073/pnas.84.6.1516; WOOD DL, 1984, P NATL ACAD SCI-BIOL, V81, P4756, DOI 10.1073/pnas.81.15.4756; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	41	64	66	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 8	1996	271	5254					1416	1420		10.1126/science.271.5254.1416	http://dx.doi.org/10.1126/science.271.5254.1416			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596914				2022-12-28	WOS:A1996TY96100046
J	Eastman, QM; Leu, TMJ; Schatz, DG				Eastman, QM; Leu, TMJ; Schatz, DG			Initiation of V(D)J recombination in vitro obeying the 12/23 rule	NATURE			English	Article							MOUSE THYMOCYTES; DNA-SYNTHESIS; SIGNALS; INVITRO; BREAKS	V(D)J recombination the process that assembles antigen-receptor genes, is directed by signal sequences flanking the DNA segments to be joined. Signals consist of a conserved heptamer and nonamer separated by a spacer of either 12 or 23 base pairs. Recombination occurs almost exclusively between two signals with spacers of different lengths. This restriction, called the '12/ 23 rule', governs the organization and pattern of rearrangement of antigen-receptor loci(1,2). In vitro work demonstrating the direct roles of the Rag proteins in the initiation of V(D)J recombination did not recreate the 12/23 rule(3,4). Instead, double-strand breaks were formed efficiently at isolated signals. Here we show that extracts made from a lymphoid cell line that expresses truncated forms of the Rag1 and Rag2 proteins have a signal-cutting activity that obeys the 12/23 rule. Cleavage at the two signals is concerted and requires their synapsis, and mutations of one signal prevent cleavage at both.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; UNIV ZURICH IRCHEL,CH-8057 ZURICH,SWITZERLAND	Howard Hughes Medical Institute; Yale University; Yale University; University of Zurich			Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176				BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; COPELAND WC, 1993, J BIOL CHEM, V268, P11041; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; HANIFORD D, 1994, EMBO J, V13, P3401, DOI 10.1002/j.1460-2075.1994.tb06643.x; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; KULKOSKY J, 1990, J ACQ IMMUN DEF SYND, V3, P852; LEE YMH, 1991, MOL CELL BIOL, V11, P1419, DOI 10.1128/MCB.11.3.1419; LEU TMJ, 1995, MOL CELL BIOL, V15, P5657; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P5644; SHEEHAN KM, 1993, MOL CELL BIOL, V13, P1363, DOI 10.1128/MCB.13.3.1363; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6082, DOI 10.1021/bi00141a018; VORA AC, 1990, J VIROL, V64, P5656, DOI 10.1128/JVI.64.11.5656-5659.1990; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	20	202	204	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					85	88		10.1038/380085a0	http://dx.doi.org/10.1038/380085a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598914				2022-12-28	WOS:A1996TY87700063
J	Altman, DG; Bland, JM				Altman, DG; Bland, JM			Calculating correlation coefficients with repeated observations .2. Correlation between subjects (vol 310, pg 633, 195)	BRITISH MEDICAL JOURNAL			English	Correction, Addition																		ALTMAN, 1995, BRIT MED J, V310, P633	1	29	31	1	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					572	572		10.1136/bmj.312.7030.572	http://dx.doi.org/10.1136/bmj.312.7030.572			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595293	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1996TY88500038
J	Sewry, CA; Philpot, J; Sorokin, LM; Wilson, LA; Naom, I; Goodwin, F; DAlessandro, M; Dubowitz, V; Muntoni, F				Sewry, CA; Philpot, J; Sorokin, LM; Wilson, LA; Naom, I; Goodwin, F; DAlessandro, M; Dubowitz, V; Muntoni, F			Diagnosis of merosin (laminin-2) deficient congenital muscular dystrophy by skin biopsy	LANCET			English	Article								Background The alpha 2 chain of laminin-2 (merosin), encoded by a gene on chromosome 6q22, is deficient in about half the cases of congenital muscular dystrophy. Diagnosis of this condition has relied on immunocytochemical analysis of the alpha 2 chain in muscle biopsy specimens. We have observed that normal skin also expresses laminin alpha 2 in the basement membrane at the junction of the dermis and epidermis. Here we have investigated laminin alpha 2 deficiency in skin biopsy specimens from two patients with congenital muscular dystrophy. Participants Two patients with severe congenital muscular dystrophy gave informed consent to a shin biopsy. The girl was aged 10 and the boy was aged 7. The specimens were labelled with a commercially available mouse monoclonal antibody and a rat monoclonal antibody (4H8-2), which recognise an 80 and a 380 kDa fragment of the alpha 2 chain, respectively. The antibodies were visualised by standard methods. A muscle biopsy specimen was available for each case, and was processed with the skin biopsy samples (from the girl a few months previously, from the boy at age 14 days). Skin biopsies were done on four controls with normal expression of laminin alpha 2 on their skeletal muscle fibres. Findings We did not detect laminin alpha 2 in skin specimens from either case, although the controls were positive. The muscle biopsy specimens from the girl showed a few fibres, with traces of laminin alpha 2; those from the boy showed no laminin alpha 2. Interpretation Skin biopsy specimens will provide a useful alternative to muscle biopsy samples for the assessment of laminin-2 (merosin) status in congenital muscular dystrophy.	ROYAL POSTGRAD MED SCH,MUSCLE CELL BIOL GRP,MRC,CTR CLIN SCI,LONDON W12 0NN,ENGLAND; UNIV ERLANGEN NURNBERG,INST EXPT MED,W-8520 ERLANGEN,GERMANY	Imperial College London; University of Erlangen Nuremberg	Sewry, CA (corresponding author), ROYAL POSTGRAD MED SCH,DEPT PAEDIAT & NEONATAL MED,NEUROMUSCULAR UNIT,LONDON W12 0NN,ENGLAND.			Sorokin, Lydia/0000-0001-7704-7921				BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; DUBOWITZ V, 1985, MUSCLE BIOPSY MODERN; Dubowitz V., 1995, MUSCLE DISORDERS CHI; ENGVALL E, 1993, KIDNEY INT, V43, P2, DOI 10.1038/ki.1993.2; HELBLINGLECLERC, 1995, CR ACAD SCI PARIS LI, V318, P1245; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; HILLAIRE D, 1994, HUM MOL GENET, V3, P1657, DOI 10.1093/hmg/3.9.1657; MERCURI E, 1995, NEUROPEDIATRICS, V26, P156, DOI 10.1055/s-2007-979746; MERCURI E, 1995, NEUROPEDIATRICS, V26, P3, DOI 10.1055/s-2007-979711; MUNTONI F, 1995, LANCET, V345, P591, DOI 10.1016/S0140-6736(95)90504-9; PHILPOT J, 1995, NEUROMUSCULAR DISORD, V5, P301, DOI 10.1016/0960-8966(94)00069-L; SCHULER F, 1995, J CELL SCI, V108, P3795; SEWRY CA, 1995, NEUROMUSCULAR DISORD, V5, P307, DOI 10.1016/0960-8966(94)00072-H; SHORER Z, 1995, J CHILD NEUROL, V10, P472, DOI 10.1177/088307389501000610; TODA T, 1993, NAT GENET, V5, P283, DOI 10.1038/ng1193-283; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351	16	72	74	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					582	584		10.1016/S0140-6736(96)91274-X	http://dx.doi.org/10.1016/S0140-6736(96)91274-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596321				2022-12-28	WOS:A1996TX69400012
J	Lascaratos, J; Damanakis, A				Lascaratos, J; Damanakis, A			Ocular torticollis: A new explanation for the abnormal head-posture of Alexander the Great	LANCET			English	Review											Lascaratos, J (corresponding author), UNIV ATHENS,HIPPOCRATOUS 164B ST,GR-11471 ATHENS,GREECE.							ANDRONICOS M, 1993, VERGINA ROYAL TOMBS, P125; BIEBER M, 1964, ALEXANDER GREAT GREE, P25; BOUTROS GS, 1995, AM ORTHOPT J, V45, P68; DECHAMBRE A, 1851, GAZETTE MED PARIS, V18, P745; DECHAMBRE A, 1851, GAZETTE MED PARIS, V18, P717; DUKEELDER S, 1973, SYSTEM OPHTHALMOLOGY, P696; EDMONDSON A, 1980, CAMPBELLS OPERATIVE, V2, P1909; HEINEMANN W, 1962, PLUTARCHS MORALIA FO, V4, P430; HEINEMANN W, 1971, PLUTARCHS LIVES, V7, P230; KIESSLINGIUS T, 1826, IOANNIS TZETZAE HIST, P298; KIILERICH B, 1988, SYMBOLAE OSLOENSES, V63, P52; LASCARATOS J, 1995, ALEXANDER GREAT, P79; LEIMBACH R, 1979, ARCHAOLOGISCHER ANZE, V94, P213; LEONE P, 1972, IOANNIS TZETZAE EPIS, P112; PATON W, 1953, GREEK ANTHOLOGY, V5, P226; PAYSEE EA, 1995, J PEDIATR OPHTHALMOL, V32, P158; Robb R M, 1983, J Pediatr Ophthalmol Strabismus, V20, P58; SCHACHERMAYER F, 1973, ALEXANDER GROSSE PRO, P95; SCHREIBER T, 1903, STUDIEN BILDNISS ALE, P13; SCHWARZENBERG E, 1975, ALEXANDRE GRAND IMAG, P227; STEWART A, 1993, FACES POWER ALEXANDE, P73	21	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					521	523		10.1016/S0140-6736(96)91144-7	http://dx.doi.org/10.1016/S0140-6736(96)91144-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596273				2022-12-28	WOS:A1996TW69700015
J	Cao, ZD; Henzel, WJ; Gao, XO				Cao, ZD; Henzel, WJ; Gao, XO			IRAK: A kinase associated with the interleukin-1 receptor	SCIENCE			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE; DROSOPHILA EMBRYO; TRANSMEMBRANE PROTEIN; DORSOVENTRAL POLARITY; ARABIDOPSIS-THALIANA; GENE; TOLL; ACTIVATION	The pleiotropic biological activities of interleukin-1 (IL-1) are mediated by its type I receptor (IL-1RI). When the ligand binds, IL-1RI initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B (NF-kappa B). A protein kinase designated IRAK (IL-1 receptor-associated kinase) was purified, and its complementary DNA was molecularly cloned. When human embryonic kidney cells (cell line 293) overexpressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated. The primary amino acid sequence of IRAK shares similarity with that of Pelle, a protein kinase that is essential for the activation of a NF-kappa B homolog in Drosophila.	GENENTECH INC, DEPT PROT CHEM, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech	Cao, ZD (corresponding author), TULARIK INC, DEPT MOLEC BIOL, S SAN FRANCISCO, CA 94080 USA.			Henzel, William/0000-0003-2940-3797				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; COLOTTA F, 1994, IMMUNOL TODAY, V15, P562, DOI 10.1016/0167-5699(94)90217-8; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GRILLI M, 1993, INT REV CYTOL, V143, P1; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HIRAYAMA T, 1992, PLANT MOL BIOL, V20, P653, DOI 10.1007/BF00046450; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; ING YL, 1994, ONCOGENE, V9, P1745; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KRASNOW SW, 1991, CYTOKINE, V3, P372, DOI 10.1016/1043-4666(91)90040-K; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MORAN TV, 1993, BIOCHIM BIOPHYS ACTA, V1216, P9, DOI 10.1016/0167-4781(93)90031-8; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; STJOHNSTON D, 1992, CELL, V68, P201; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5	33	757	826	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 23	1996	271	5252					1128	1131		10.1126/science.271.5252.1128	http://dx.doi.org/10.1126/science.271.5252.1128			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599092				2022-12-28	WOS:A1996TW70100042
J	Pontoglio, M; Barra, J; Hadchouel, M; Doyen, A; Kress, C; Bach, JP; Babinet, C; Yaniv, M				Pontoglio, M; Barra, J; Hadchouel, M; Doyen, A; Kress, C; Bach, JP; Babinet, C; Yaniv, M			Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome	CELL			English	Article							ENRICHED TRANSCRIPTION FACTOR; DNA-BINDING; ALBUMIN GENE; EXPRESSION; PROTEIN; MOUSE; CELLS; HOMEODOMAIN; DOMAIN; HOMEOPROTEINS	HNF1 is a transcriptional activator of many hepatic genes including albumin, alpha 1-antitrypsin, and alpha- and beta-fibrinogen. It is related to the homeobox gene family and is predominantly expressed in liver and kidney. Mice lacking HNF1 fail to thrive and die around weaning after a progressive wasting syndrome with a marked liver enlargement. The transcription rate of genes like albumin and alpha 1-antitrypsin is reduced, while the gene coding for phenylalanine hydroxylase is totally silent, giving rise to phenylketonuria. Mutant mice also suffer from severe Fanconi syndrome caused by renal proximal tubular dysfunction. The resulting massive urinary glucose loss leads to energy and water wasting. HNF1-deficient mice may provide a model for human renal Fanconi syndrome.	INST PASTEUR,CTR NATL RECH SCI,URA 1960,UNITE BIOL DEV,F-75724 PARIS 15,FRANCE; HOP KREMLIN BICETRE,INSERM,U347,F-94276 LE KREMLIN BICETR,FRANCE; HOP KREMLIN BICETRE,BIOCHIM LAB,F-94276 LE KREMLIN BICETR,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP	Pontoglio, M (corresponding author), INST PASTEUR,DEPT BIOTECHNOL,CTR NATL RECH SCI,URA 1644,UNITE VIRUS ONCOGENES,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BESMOND C, 1983, BIOCHEM BIOPH RES CO, V117, P601, DOI 10.1016/0006-291X(83)91243-3; BLUMENFELD M, 1991, DEVELOPMENT, V113, P589; BRADLEY A, 1987, TETATOCARCINOMAS EMB; BRENNER BM, 1991, KIDNEY; CAMPOS JR, 1991, EMBO J, V10, P1445; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CEREGHINI S, 1992, DEVELOPMENT, V116, P783; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P120; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; CITRON BA, 1992, P NATL ACAD SCI USA, V89, P11891, DOI 10.1073/pnas.89.24.11891; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KESNER L, 1975, CLIN CHEM, V21, P353; KOEPSELL H, 1990, J MEMBRANE BIOL, V114, P113, DOI 10.1007/BF01869093; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LAZZARO D, 1992, DEVELOPMENT, V114, P469; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LONE YC, 1986, FEBS LETT, V195, P97, DOI 10.1016/0014-5793(86)80138-7; MALATHI P, 1979, BIOCHIM BIOPHYS ACTA, V554, P259, DOI 10.1016/0005-2736(79)90023-3; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCDONALD JD, 1988, J NEUROCHEM, V50, P655, DOI 10.1111/j.1471-4159.1988.tb02961.x; MCDONALD JD, 1990, P NATL ACAD SCI USA, V87, P1965, DOI 10.1073/pnas.87.5.1965; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; OTT MO, 1991, MECH DEVELOP, V36, P47, DOI 10.1016/0925-4773(91)90071-D; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROYER P, 1983, MOL CLONING; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TRONCHE F, 1989, MOL CELL BIOL, V9, P4759, DOI 10.1128/MCB.9.11.4759; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WANG YB, 1994, J BIOL CHEM, V269, P9137; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; [No title captured]	44	480	496	0	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					575	585		10.1016/S0092-8674(00)81033-8	http://dx.doi.org/10.1016/S0092-8674(00)81033-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598044	Bronze			2022-12-28	WOS:A1996TX17600010
J	Beare, S; Steward, WP				Beare, S; Steward, WP			Plasma free iron and chemotherapy toxicity	LANCET			English	Editorial Material							DEFEROXAMINE				Beare, S (corresponding author), QUEENS UNIV,NATL CANC INST CANADA,CLIN TRIALS GRP,KINGSTON,ON,CANADA.							AISEN P, 1992, ANN NEUROL, V32, pS62, DOI 10.1002/ana.410320711; BUSS JL, 1993, AGENTS ACTIONS, V40, P86, DOI 10.1007/BF01976756; CARMINE TC, 1995, CANCER LETT, V94, P219, DOI 10.1016/0304-3835(95)03852-N; DONFRANCESCO A, 1992, AM J CLIN ONCOL-CANC, V15, P319, DOI 10.1097/00000421-199208000-00009; EHLERS KH, 1991, J PEDIATR-US, V118, P540, DOI 10.1016/S0022-3476(05)83374-8; GORDEUK VR, 1992, FEBS LETT, V308, P4, DOI 10.1016/0014-5793(92)81037-M; HAY J, 1991, ARCH TOXICOL, V65, P81, DOI 10.1007/BF02034932; KONTOGHIORGHES GJ, 1995, ANALYST, V120, P845, DOI 10.1039/an9952000845; MALISZA KL, 1995, ARCH BIOCHEM BIOPHYS, V316, P680, DOI 10.1006/abbi.1995.1091; MARCIANI MG, 1991, HAEMATOLOGICA, V76, P131; SOBEL MM, 1991, MOL PHARMACOL, V41, P8; SPEYER JL, 1992, J CLIN ONCOL, V10, P117, DOI 10.1200/JCO.1992.10.1.117	12	19	20	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					342	343		10.1016/S0140-6736(96)90530-9	http://dx.doi.org/10.1016/S0140-6736(96)90530-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598694				2022-12-28	WOS:A1996TU69500002
J	Liberthson, RR				Liberthson, RR			Current concepts - Sudden death from cardiac causes in children and young adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MITRAL-VALVE PROLAPSE; CARDIOVASCULAR-DISEASE; UNEXPECTED DEATH; KAWASAKI DISEASE; NATURAL DEATH; CARDIOMYOPATHY; CHILDHOOD; ADOLESCENCE; PROGNOSIS; ANEURYSMS		HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	Liberthson, RR (corresponding author), MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114, USA.							ADELSON L, 1956, PEDIATRICS, V17, P663; BENDAVID J, 1993, LANCET, V341, P1578, DOI 10.1016/0140-6736(93)90708-O; BJORNSSON J, 1985, MAYO CLIN PROC, V60, P16, DOI 10.1016/S0025-6196(12)65277-X; BURCH M, 1994, BRIT HEART J, V72, P246; CHEITLIN MD, 1974, CIRCULATION, V50, P780, DOI 10.1161/01.CIR.50.4.780; CORRADO D, 1994, CIRCULATION, V90, P2315, DOI 10.1161/01.CIR.90.5.2315; CORRADO D, 1990, AM J MED, V89, P588, DOI 10.1016/0002-9343(90)90176-E; DENFIELD SW, 1990, PEDIATR CLIN N AM, V37, P215; DRISCOLL DJ, 1985, J AM COLL CARDIOL, V5, pB118, DOI 10.1016/S0735-1097(85)80540-4; DRORY Y, 1991, AM J CARDIOL, V68, P1388, DOI 10.1016/0002-9149(91)90251-F; EPSTEIN SE, 1986, J AM COLL CARDIOL, V7, P220, DOI 10.1016/S0735-1097(86)80285-6; GARSON A, 1985, J AM COLL CARDIOL, V5, pB134, DOI 10.1016/S0735-1097(85)80543-X; GARSON A, 1985, J AM COLL CARDIOL, V5, pB130, DOI 10.1016/S0735-1097(85)80542-8; Gilbert E M, 1991, Heart Vessels Suppl, V6, P29, DOI 10.1007/BF01752533; ISNER JM, 1985, ANN INTERN MED, V102, P49, DOI 10.7326/0003-4819-102-1-49; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; JERESATY RM, 1986, J AM COLL CARDIOL, V7, P231, DOI 10.1016/S0735-1097(86)80286-8; KAMIYA T, 1985, JPN J PEDIAT MED, V17, P765; KATO H, 1982, AM J CARDIOL, V49, P1758, DOI 10.1016/0002-9149(82)90256-9; KELLY DH, 1977, CIRCULATION, V56, P633; KENNEDY HL, 1984, J AM COLL CARDIOL, V3, P485; KRAMER MR, 1989, ISRAEL J MED SCI, V25, P620; LAMBERT EC, 1974, AM J CARDIOL, V34, P89, DOI 10.1016/0002-9149(74)90098-8; LIBERTHSON RR, 1974, NEW ENGL J MED, V291, P317, DOI 10.1056/NEJM197408152910701; LIBERTHSON RR, 1974, CIRCULATION, V49, P790, DOI 10.1161/01.CIR.49.5.790; LIBERTHSON RR, 1979, CIRCULATION, V59, P748, DOI 10.1161/01.CIR.59.4.748; LIBERTHSON RR, 1985, CIRCULATION, V72, P197; LIBERTHSON RR, 1982, AM J CARDIOL, V49, P1018, DOI 10.1016/0002-9149(82)92478-X; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; Maron BJ, 1994, J AM COLL CARDIOL, V24, P845; MCCAFFREY FM, 1991, AM J DIS CHILD, V145, P177, DOI 10.1001/archpedi.1991.02160020069020; MCKENNA W, 1981, AM J CARDIOL, V47, P532, DOI 10.1016/0002-9149(81)90535-X; MOLANDER N, 1982, ARCH DIS CHILD, V57, P572, DOI 10.1136/adc.57.8.572; MURDOCH JL, 1972, NEW ENGL J MED, V286, P804, DOI 10.1056/NEJM197204132861502; NEUSPIEL DR, 1985, JAMA-J AM MED ASSOC, V254, P1321, DOI 10.1001/jama.254.10.1321; PHILLIPS M, 1986, JAMA-J AM MED ASSOC, V256, P2696, DOI 10.1001/jama.256.19.2696; POCOCK WA, 1984, AM HEART J, V107, P378, DOI 10.1016/0002-8703(84)90389-2; RAGOSTA M, 1984, MED SCI SPORT EXER, V16, P339; RAYMOND JR, 1988, ARCH INTERN MED, V148, P303, DOI 10.1001/archinte.148.2.303; RICH BSE, 1994, MED CLIN N AM, V78, P267, DOI 10.1016/S0025-7125(16)30159-6; ROWLEY AH, 1988, J PEDIATR-US, V113, P290, DOI 10.1016/S0022-3476(88)80267-1; SCHOELLER R, 1993, AM J CARDIOL, V71, P720, DOI 10.1016/0002-9149(93)91017-C; SCHWARTZ PJ, 1991, CIRCULATION, V84, P503, DOI 10.1161/01.CIR.84.2.503; SILKA MJ, 1991, PEDIATR ANN, V20, P360, DOI 10.3928/0090-4481-19910701-09; SILKA MJ, 1991, PEDIATR ANN, V20, P362; TAYLOR AJ, 1992, J AM COLL CARDIOL, V20, P640, DOI 10.1016/0735-1097(92)90019-J; THIENE G, 1988, NEW ENGL J MED, V318, P129, DOI 10.1056/NEJM198801213180301; TOPAZ O, 1985, CHEST, V87, P476, DOI 10.1378/chest.87.4.476; TSUNG SH, 1982, ARCH PATHOL LAB MED, V106, P168; VALDESDAPENA M, 1985, J AM COLL CARDIOL, V5, pB113, DOI 10.1016/S0735-1097(85)80539-8; VANCAMP SP, 1992, CLIN SPORT MED, V11, P273; YOUNG D, 1971, AM J CARDIOL, V28, P658, DOI 10.1016/0002-9149(71)90054-3	53	348	364	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1996	334	16					1039	1044		10.1056/NEJM199604183341607	http://dx.doi.org/10.1056/NEJM199604183341607			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE733	8598843				2022-12-28	WOS:A1996UE73300007
J	Blackburn, H				Blackburn, H			Olestra and the FDA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Blackburn, H (corresponding author), UNIV MINNESOTA,MINNEAPOLIS,MN 55455, USA.								0	24	24	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1996	334	15					984	986		10.1056/NEJM199604113341511	http://dx.doi.org/10.1056/NEJM199604113341511			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD596	8596603				2022-12-28	WOS:A1996UD59600011
J	Bucher, HC; Guyatt, GH; Cook, RJ; Hatala, R; Cook, DJ; Lang, JD; Hunt, D				Bucher, HC; Guyatt, GH; Cook, RJ; Hatala, R; Cook, DJ; Lang, JD; Hunt, D			Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia - A meta-analysis of randomized controlled trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							BLOOD-PRESSURE; WOMEN; ECLAMPSIA; PROGNOSIS	Objective.-To review the effect of calcium supplementation during pregnancy on blood pressure, preeclampsia, and adverse outcomes of pregnancy. Data Source.-We searched MEDLINE and EMBASE for 1966 to May 1994. We contacted authors of eligible trials to ensure accuracy and completeness of data and to identify unpublished trials. Study Selection.-Fourteen randomized trials involving 2459 women were eligible. Data Extraction.-Reviewers working independently in pairs abstracted data and assessed validity according to six quality criteria. Data Synthesis.-Each trial yielded differences in blood pressure change between calcium supplementation and control groups that we weighted by the inverse of the variance. The pooled analysis showed a reduction in systolic blood pressure of -5.40 mm Hg (95% confidence interval [CI], -7.81 to -3.00 mm Hg; P<.001) and in diastolic blood pressure of -3.44 mm Hg (95% CI, -5.20 to -1.68 mm Hg; P<.001). The odds ratio for preeclampsia in women with calcium supplementation compared with placebo was 0.38 (95% CI, 0.22 to 0.65). Conclusions.-Calcium supplementation during pregnancy leads to an important reduction in systolic and diastolic blood pressure and preeclampsia. While pregnant women at risk of preeclampsia should consider taking calcium, many more patient events are needed to confirm calcium's impact on maternal and fetal morbidity.	MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON,ON L8N 3Z5,CANADA; MCMASTER UNIV,DEPT MED,HAMILTON,ON L8N 3Z5,CANADA; UNIV WATERLOO,FAC APPL HLTH SCI,DEPT HLTH STUDIES & GERONTOL,KITCHENER,ON,CANADA	McMaster University; McMaster University; University of Waterloo				Cook, Richard/0000-0002-1414-4908				BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BELIZAN JM, 1980, AM J CLIN NUTR, V33, P2202, DOI 10.1093/ajcn/33.10.2202; BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002; BELIZAN JM, 1983, AM J OBSTET GYNECOL, V146, P175, DOI 10.1016/0002-9378(83)91049-9; Bucher HC, 1996, JAMA-J AM MED ASSOC, V275, P1016, DOI 10.1001/jama.275.13.1016; CARROLI G, 1994, BRIT J OBSTET GYNAEC, V101, P753, DOI 10.1111/j.1471-0528.1994.tb11940.x; CONG KJ, 1993, AM J OBSTET GYNECOL, V28, P1; CONG KJ, 1992, BEIJING MED J, V5, P1; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; FELIX C, 1991, Journal of Obstetrics and Gynaecology (Abingdon), V11, P93, DOI 10.3109/01443619109013523; FERRIS TF, 1991, NEW ENGL J MED, V325, P1439, DOI 10.1056/NEJM199111143252009; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; KAUNITZ AM, 1985, OBSTET GYNECOL, V65, P605; KNIGHT KB, 1992, AM J CLIN NUTR, V55, P891, DOI 10.1093/ajcn/55.4.891; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LEVINE RJ, 1992, 8 WORLD C HYP PREGN; LOPEZJARAMILLO P, 1987, AM J OBSTET GYNECOL, V156, P261, DOI 10.1016/0002-9378(87)90259-6; LOPEZJARAMILLO P, 1989, BRIT J OBSTET GYNAEC, V96, P648, DOI 10.1111/j.1471-0528.1989.tb03278.x; LOPEZJARAMILLO P, 1990, LANCET, V335, P293, DOI 10.1016/0140-6736(90)90112-I; MABIE WC, 1986, OBSTET GYNECOL, V67, P197, DOI 10.1097/00006250-198602000-00008; MARYA RK, 1987, GYNECOL OBSTET INVES, V24, P38, DOI 10.1159/000298772; MCGARVEY ST, 1991, HYPERTENSION, V17, P218, DOI 10.1161/01.HYP.17.2.218; MIONTANARO D, 1987, 10 INT C NEPHR MIL; MONTANARO D, 1990, 7 WORLD C HYP PREGN; MOUTQUIN JM, 1985, AM J OBSTET GYNECOL, V151, P191, DOI 10.1016/0002-9378(85)90010-9; PRADA JA, 1992, HYPERTENSION, V20, P620, DOI 10.1161/01.HYP.20.5.620; REPKE JT, 1989, AM J OBSTET GYNECOL, V160, P684, DOI 10.1016/S0002-9378(89)80059-6; REY E, 1994, AM J OBSTET GYNECOL, V171, P410, DOI 10.1016/0002-9378(94)90276-3; Sanchez-Ramos L., 1993, American Journal of Obstetrics and Gynecology, V168, P385; SANCHEZRAMOS L, 1994, OBSTET GYNECOL, V84, P349; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SIBAI BM, 1992, AM J OBSTET GYNECOL, V166, P1757, DOI 10.1016/0002-9378(92)91566-S; SIBAI BM, 1986, AM J OBSTET GYNECOL, V155, P1011, DOI 10.1016/0002-9378(86)90336-4; VILLAR J, 1987, OBSTET GYNECOL, V70, P317; VILLAR J, 1983, INT J GYNECOL OBSTET, V21, P271, DOI 10.1016/0020-7292(83)90016-4; VILLAR J, 1990, AM J OBSTET GYNECOL, V163, P124; 1994, LANCET, V242, P619	37	151	159	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1996	275	14					1113	1117		10.1001/jama.275.14.1113	http://dx.doi.org/10.1001/jama.275.14.1113			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD027	8601931				2022-12-28	WOS:A1996UD02700028
J	Hanauer, SB				Hanauer, SB			Drug therapy - Inflammatory bowel disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							COOPERATIVE CROHNS-DISEASE; RANDOMIZED CONTROLLED TRIAL; DISTAL ULCERATIVE-COLITIS; CORTICOSTEROID-THERAPY; ACTIVITY INDEX; DOUBLE-BLIND; FISH OIL; SULFASALAZINE; METRONIDAZOLE; AZATHIOPRINE				Hanauer, SB (corresponding author), UNIV CHICAGO, PRITZKER SCH MED, MED CTR, 5841 S MARYLAND AVE, CHICAGO, IL 60637 USA.							ACTIS GC, 1993, J CLIN GASTROENTEROL, V17, P10, DOI 10.1097/00004836-199307000-00004; ALLGAYER H, 1992, GASTROENTEROL CLIN N, V21, P643; ALSTEAD EM, 1990, GASTROENTEROLOGY, V99, P443, DOI 10.1016/0016-5085(90)91027-4; AZADKHAN AK, 1977, LANCET, V2, P892; BARON JH, 1962, BRIT MED J, P441; BAYLESS TM, 1990, MED CLIN N AM, V74, P21, DOI 10.1016/S0025-7125(16)30583-1; BECK IT, 1987, DIGEST DIS SCI, V32, pS26, DOI 10.1007/BF01312461; BERNSTEIN CN, 1994, DIGEST DIS SCI, V39, P1638, DOI 10.1007/BF02087769; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BJARNASON I, 1993, GASTROENTEROLOGY, V104, P1832, DOI 10.1016/0016-5085(93)90667-2; BOUMPAS DT, 1993, ANN INTERN MED, V119, P1198, DOI 10.7326/0003-4819-119-12-199312150-00007; BRANDT LJ, 1982, GASTROENTEROLOGY, V83, P383; BRIGNOLA C, 1986, GASTROENTEROLOGY, V91, P1490, DOI 10.1016/0016-5085(86)90206-4; BRYNSKOV J, 1989, NEW ENGL J MED, V321, P845, DOI 10.1056/NEJM198909283211301; CHAPMAN RW, 1986, GUT, V27, P1210, DOI 10.1136/gut.27.10.1210; CHOI PM, 1994, DIGEST DIS SCI, V39, P1885, DOI 10.1007/BF02088121; COHEN RD, 1995, CURR OPIN GASTROEN, V11, P321, DOI 10.1097/00001574-199507000-00007; CONNELL WR, 1994, LANCET, V343, P1249, DOI 10.1016/S0140-6736(94)92150-4; CONNELL WR, 1993, GUT, V34, P1081, DOI 10.1136/gut.34.8.1081; DANIELSSON A, 1992, SCAND J GASTROENTERO, V27, P9, DOI 10.3109/00365529209011158; DERKX B, 1993, LANCET, V342, P173, DOI 10.1016/0140-6736(93)91375-V; DWARAKANATH AD, 1994, GUT, V35, P1141, DOI 10.1136/gut.35.8.1141; Eliakim R, 1992, GASTROENTEROL INT, V5, P48; EMMRICH J, 1991, LANCET, V338, P570, DOI 10.1016/0140-6736(91)91133-F; EWE K, 1993, GASTROENTEROLOGY, V105, P367, DOI 10.1016/0016-5085(93)90709-L; FEAGAN BG, 1994, NEW ENGL J MED, V330, P1846, DOI 10.1056/NEJM199406303302602; FEAGAN BG, 1995, NEW ENGL J MED, V332, P292, DOI 10.1056/NEJM199502023320503; FELDER JB, 1991, AM J GASTROENTEROL, V86, P1450; FREEMAN HJ, 1993, NEW ENGL J MED, V329, P1314, DOI 10.1056/NEJM199310283291805; GAGINELLA TS, 1992, DIGEST DIS SCI, V37, P801, DOI 10.1007/BF01300376; GOMES P, 1986, GUT, V27, P92, DOI 10.1136/gut.27.1.92; GREENBERG GR, 1994, NEW ENGL J MED, V331, P836, DOI 10.1056/NEJM199409293311303; GREENFIELD SM, 1993, ALIMENT PHARM THER, V7, P369; GRIFFITHS AM, 1995, GASTROENTEROLOGY, V108, P1056, DOI 10.1016/0016-5085(95)90203-1; GRISHAM MB, 1994, LANCET, V344, P859, DOI 10.1016/S0140-6736(94)92831-2; HABER CJ, 1986, GASTROENTEROLOGY, V91, P982, DOI 10.1016/0016-5085(86)90703-1; Hanan Ira M., 1993, Comprehensive Therapy, V19, P91; HANAUER SB, 1993, AM J GASTROENTEROL, V88, P646; HANAUER SB, 1993, LANCET, V342, P412, DOI 10.1016/0140-6736(93)92819-F; HANAUER SB, 1995, GASTROENTEROL CLIN N, V24, P523; HANAUER SB, 1991, DRUG SAFETY, V6, P192, DOI 10.2165/00002018-199106030-00005; HANAUER SB, 1995, INFLAMM BOWEL DIS, P664; HANAUER SB, 1994, INFLAMM BOWEL DIS, P429; HANAUER SB, 1995, INFLAMM BOWEL DIS, P643; HANAUER SB, 1991, FED REGISTER, V56, P27519; HAWTHORNE AB, 1992, BRIT MED J, V305, P20, DOI 10.1136/bmj.305.6844.20; HAWTHORNE AB, 1992, GUT, V33, P922, DOI 10.1136/gut.33.7.922; HAWTHORNE AB, 1989, DRUGS, V38, P267, DOI 10.2165/00003495-198938020-00007; HODGSON HJF, 1991, ALIMENT PHARM THERAP, V5, P555; HYAMS JS, 1991, J PEDIATR GASTR NUTR, V12, P439, DOI 10.1097/00005176-199105000-00005; IRVINE EJ, 1994, GASTROENTEROLOGY, V106, P287, DOI 10.1016/0016-5085(94)90585-1; IRVINE EJ, 1995, J CLIN GASTROENTEROL, V20, P27; JARNEROT G, 1985, GASTROENTEROLOGY, V89, P1005; JEEJEEBHOY KN, 1995, INFLAMM BOWEL DIS, P734; KAPLAN MA, 1988, J CLIN GASTROENTEROL, V10, P275, DOI 10.1097/00004836-198806000-00010; KIRSCHNER BS, 1995, GASTROENTEROL CLIN N, V24, P99; KJELDSEN J, 1993, SCAND J GASTROENTERO, V28, P1, DOI 10.3109/00365529309096037; KLOTZ U, 1980, NEW ENGL J MED, V303, P1499, DOI 10.1056/NEJM198012253032602; KORNBLUTH AA, 1993, J CLIN GASTROENTEROL, V16, P215, DOI 10.1097/00004836-199304000-00010; LAURITSEN K, 1989, INT J COLORECTAL DIS, V4, P75, DOI 10.1007/BF01646865; LENNARDJONES JE, 1983, GUT, V24, P177, DOI 10.1136/gut.24.3.177; LEREBOURS E, 1994, GASTROENTEROLOGY, V107, P357, DOI 10.1016/0016-5085(94)90159-7; LEWIS JD, 1994, MED CLIN N AM, V78, P1443, DOI 10.1016/S0025-7125(16)30110-9; LICHTIGER S, 1994, NEW ENGL J MED, V330, P1841, DOI 10.1056/NEJM199406303302601; Lofberg R, 1995, Inflamm Bowel Dis, V1, P135; MACDERMOTT RP, 1994, MED CLIN N AM, V78, P1207, DOI 10.1016/S0025-7125(16)30096-7; MALCHOW H, 1984, GASTROENTEROLOGY, V86, P249; MARGOLIN ML, 1988, AM J GASTROENTEROL, V83, P227; MARSHALL JK, 1995, ALIMENT PHARM THERAP, V9, P293; MARY JY, 1989, GUT, V30, P983, DOI 10.1136/gut.30.7.983; MEYERS S, 1985, GASTROENTEROLOGY, V89, P1189, DOI 10.1016/0016-5085(85)90226-4; Meyers S, 1995, INFLAMM BOWEL DIS, P695; MODIGLIANI R, 1990, GASTROENTEROLOGY, V98, P811, DOI 10.1016/0016-5085(90)90002-I; MORGAN SL, 1994, ANN INTERN MED, V121, P833, DOI 10.7326/0003-4819-121-11-199412010-00002; MULDER CJJ, 1993, ALIMENT PHARM THERAP, V7, P125; MUNKHOLM P, 1994, GUT, V35, P360, DOI 10.1136/gut.35.3.360; PEARSON DC, 1995, ANN INTERN MED, V123, P132, DOI 10.7326/0003-4819-123-2-199507150-00009; PEPPERCORN MA, 1993, J CLIN GASTROENTEROL, V17, P235, DOI 10.1097/00004836-199310000-00013; PEPPERCORN MA, 1993, J CLIN GASTROENTEROL, V17, P14, DOI 10.1097/00004836-199307000-00005; PIGOT F, 1992, DIGEST DIS SCI, V37, P1396, DOI 10.1007/BF01296010; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P1008, DOI 10.1056/NEJM199110033251406; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; PRESENT DH, 1980, NEW ENGL J MED, V302, P981, DOI 10.1056/NEJM198005013021801; PRESENT DH, 1994, DIGEST DIS SCI, V39, P374, DOI 10.1007/BF02090211; PRESENT DH, 1989, ANN INTERN MED, V111, P641, DOI 10.7326/0003-4819-111-8-641; PULLAN RD, 1994, NEW ENGL J MED, V330, P811, DOI 10.1056/NEJM199403243301202; RAMCHANDANI D, 1994, MED CLIN N AM, V78, P1321, DOI 10.1016/S0025-7125(16)30103-1; RIJK MCM, 1992, SCAND J GASTROENTERO, V27, P863, DOI 10.3109/00365529209000155; RILEY SA, 1991, GUT, V32, P174, DOI 10.1136/gut.32.2.174; RUTGEERTS P, 1995, GASTROENTEROLOGY, V108, P1617, DOI 10.1016/0016-5085(95)90121-3; RUTGEERTS P, 1994, NEW ENGL J MED, V331, P842, DOI 10.1056/NEJM199409293311304; SACHAR DB, 1994, NEW ENGL J MED, V331, P873, DOI 10.1056/NEJM199409293311311; SACHAR DB, 1995, J CLIN GASTROENTEROL, V20, P117, DOI 10.1097/00004836-199503000-00009; SALOMON P, 1992, J CLIN GASTROENTEROL, V14, P211, DOI 10.1097/00004836-199204000-00006; SANDBORN WJ, 1994, GASTROENTEROLOGY, V107, P1856, DOI 10.1016/0016-5085(94)90832-X; SANDBORN WJ, 1995, INFLAMM BOWEL DIS, V1, P48; SARTOR RB, 1995, INFLAMM BOWEL DIS, P96; SCHEPPACH W, 1992, GASTROENTEROLOGY, V103, P51, DOI 10.1016/0016-5085(92)91094-K; SCHUMACHER G, 1994, SCAND J GASTROENTERO, V29, P265, DOI 10.3109/00365529409090475; SINGLETON JW, 1993, GASTROENTEROLOGY, V104, P1293, DOI 10.1016/0016-5085(93)90337-C; SPIRT MJ, 1994, AM J GASTROENTEROL, V89, P974; STENSON WF, 1992, ANN INTERN MED, V116, P609, DOI 10.7326/0003-4819-116-8-609; STERNBERG EM, 1992, ANN INTERN MED, V117, P854, DOI 10.7326/0003-4819-117-10-854; SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847; SUTHERLAND L, 1991, GUT, V32, P1071, DOI 10.1136/gut.32.9.1071; SUTHERLAND LR, 1993, ANN INTERN MED, V118, P540, DOI 10.7326/0003-4819-118-7-199304010-00009; SUTHERLAND LR, 1990, MED CLIN N AM, V74, P119, DOI 10.1016/S0025-7125(16)30590-9; SVARTZ N, 1988, AM J GASTROENTEROL, V83, P497; TRUELOVE SC, 1955, BRIT MED J, V2, P1041, DOI 10.1136/bmj.2.4947.1041; URSING B, 1982, GASTROENTEROLOGY, V83, P550; WADWORTH AN, 1991, DRUGS, V41, P647, DOI 10.2165/00003495-199141040-00009; WEINBLATT ME, 1995, NEW ENGL J MED, V332, P330, DOI 10.1056/NEJM199502023320512	112	360	380	1	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1996	334	13					841	848		10.1056/NEJM199603283341307	http://dx.doi.org/10.1056/NEJM199603283341307			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB950	8596552				2022-12-28	WOS:A1996UB95000007
J	vanGent, DC; Mizuuchi, K; Gellert, M				vanGent, DC; Mizuuchi, K; Gellert, M			Similarities between initiation of V(D)J recombination and retroviral integration	SCIENCE			English	Article							DNA STRAND TRANSFER; MECHANISM; SITE; PROTEIN	In the first step of V(D)J recombination, the RAG1 and RAG2 proteins cleave DNA between a signal sequence and the adjacent coding sequence, generating a blunt signal end and a coding end with a closed hairpin structure. These hairpins are intermediates leading to the formation of assembled antigen receptor genes. It is shown here that the hairpins are formed by a chemical mechanism of direct trans-esterification, very similar to the early steps of transpositional recombination and retroviral integration. A minor variation in the reaction is sufficient to divert the process from transposition to hairpin formation.	NIDDKD,NIH,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BURGERS PMJ, 1979, J BIOL CHEM, V254, P6889; CHOW SA, 1994, J VIROL, V68, P7869, DOI 10.1128/JVI.68.12.7869-7878.1994; CRAIG NL, 1988, ANNU REV GENET, V22, P77; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; KLECKNER N, 1995, CURR TOP MICROBIOL I, V204, P49; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MAY EW, IN PRESS SCIENCE; MAZUMDER A, 1994, NUCLEIC ACIDS RES, V22, P1037, DOI 10.1093/nar/22.6.1037; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; RICE PR, UNPUB; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; VANDENENT FMI, 1994, J VIROL, V68, P7825, DOI 10.1128/JVI.68.12.7825-7832.1994; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; VINK C, 1993, TRENDS GENET, V9, P433, DOI 10.1016/0168-9525(93)90107-S	23	224	228	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1592	1594		10.1126/science.271.5255.1592	http://dx.doi.org/10.1126/science.271.5255.1592			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599117				2022-12-28	WOS:A1996TZ98300044
J	McLoone, P				McLoone, P			Suicide and deprivation in Scotland	BRITISH MEDICAL JOURNAL			English	Article											McLoone, P (corresponding author), UNIV GLASGOW,PUBL HLTH RES UNIT,GLASGOW G12 8RZ,LANARK,SCOTLAND.		McLoone, Philip/H-2353-2017	McLoone, Philip/0000-0003-0002-8700				Charlton J., 1993, POPULATION TRENDS, V71, P34; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; GUNNELL DJ, 1995, BRIT MED J, V311, P226, DOI 10.1136/bmj.311.6999.226; MCLOONE P, 1994, BRIT MED J, V309, P1465, DOI 10.1136/bmj.309.6967.1465; McLoone P., 1994, CARSTAIRS SCORES SCO	5	31	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					543	544		10.1136/bmj.312.7030.543	http://dx.doi.org/10.1136/bmj.312.7030.543			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595284	Green Published			2022-12-28	WOS:A1996TY88500024
J	Kandela, P				Kandela, P			Exposing the abuse of Chinese orphans	BRITISH MEDICAL JOURNAL			English	Article																		1996, DEATH DEFAULT POLICY	1	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					495	496		10.1136/bmj.312.7029.495	http://dx.doi.org/10.1136/bmj.312.7029.495			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TX383	8597687	Green Published			2022-12-28	WOS:A1996TX38300033
J	Sciurba, FC; Rogers, RM; Keenan, RJ; Slivka, WA; Gorcsan, J; Ferson, PF; Holbert, JM; Brown, ML; Landreneau, RJ				Sciurba, FC; Rogers, RM; Keenan, RJ; Slivka, WA; Gorcsan, J; Ferson, PF; Holbert, JM; Brown, ML; Landreneau, RJ			Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISEASE	Background. Pulmonary function may improve after surgical resection of the most severely affected lung tissue (lung-reduction surgery) in patients with diffuse emphysema, The basic mechanisms responsible for the improvement, however, are not known. Methods. We studied 20 patients with diffuse emphysema before and at least three months after either a unilateral or a bilateral lung-reduction procedure. Clinical benefit was assessed by measurement of the six-minute walking distance and the transitional-dyspnea index, which is a subjective rating of the change from base line in functional impairment and the threshold for effort- and task-dependent dyspnea, Pressure-volume relations in the lungs were measured with static expiratory esophageal-balloon techniques, and right ventricular systolic function was assessed by echocardiography. Results. The patients had significant improvement in the transitional-dyspnea index after surgery (P<0.001), The mean (+/-SD) coefficient of retraction, an indicator of elastic recoil of the lung, improved (from 1.3+/-0.6 cm of water per liter before surgery to 1.8+/-0.8 after, P<0.001), Sixteen patients with increased elastic recoil had a greater increase in the distance walked in six minutes than the other four patients, in whom recoil did not increase (P=0.02), The improved lung recoil led to disproportionate decreases in residual volume as compared with total lung capacity (16 percent vs. 6 percent), but the decreases in both values were significant (P<0.001), Forced expiratory volume in one second increased (from 0.87+/-0.36 to 1.11+/-0.45 liters, P<0.001), End-expiratory esophageal pressure also decreased (P=0.002), These improvements in lung mechanics led to a decrease in the partial pressure of arterial carbon dioxide from 42+/-6 to 38+/-5 mm Hg (P=0.006). Furthermore, the fractional change in right ventricular area, an indicator of systolic function, increased from 0.33+/-0.11 to 0.38+/-0.10 (P=0.02). Conclusions. Lung-reduction surgery can increase the elastic recoil of the lung in patients with diffuse emphysema, leading to short-term improvement in dyspnea and exercise tolerance. (C) 1996, Massachusetts Medical Society.	UNIV PITTSBURGH, MED CTR, DIV PULM ALLERGY & CRIT CARE MED, PITTSBURGH, PA USA; UNIV PITTSBURGH, MED CTR, DIV CARDIOL, PITTSBURGH, PA USA; UNIV PITTSBURGH, MED CTR, DEPT MED, PITTSBURGH, PA USA; UNIV PITTSBURGH, MED CTR, DEPT SURG, DIV THORAC SURG, PITTSBURGH, PA USA; UNIV PITTSBURGH, MED CTR, DEPT RADIOL, PITTSBURGH, PA USA; UNIV PITTSBURGH, SCH MED, PITTSBURGH, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Sciurba, Frank/AAZ-9339-2021	sciurba, frank/0000-0001-7468-2225				[Anonymous], 1980, Ann Intern Med, V93, P391; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; BENDITT JO, 1995, CHEST, V107, P297, DOI 10.1378/chest.107.2.297; BOUSHY SF, 1969, AM J MED, V47, P916, DOI 10.1016/0002-9343(69)90205-8; BRANTIGAN OC, 1959, AM REV RESPIR DIS, V80, P194; BURROWS B, 1961, AM REV RESPIR DIS, V84, P789; Christie RV, 1934, J CLIN INVEST, V13, P295, DOI 10.1172/JCI100588; COLTON T, 1974, STAT MED, P131; COOPER JD, 1995, J THORAC CARDIOV SUR, V109, P106, DOI 10.1016/S0022-5223(95)70426-4; DERENNE JP, 1978, AM REV RESPIR DIS, V118, P581; FRY DL, 1960, AM J MED, V29, P672, DOI 10.1016/0002-9343(60)90100-5; Gaensler E A, 1986, J Thorac Imaging, V1, P75, DOI 10.1097/00005382-198603000-00009; GELB AF, 1973, AM REV RESPIR DIS, V107, P571, DOI 10.1164/arrd.1973.107.4.571; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; HALUSZKA J, 1990, AM REV RESPIR DIS, V141, P1194, DOI 10.1164/ajrccm/141.5_Pt_1.1194; HARRIS P, 1968, CARDIOVASC RES, V2, P84, DOI 10.1093/cvr/2.1.84; ITING EY, 1963, AM REV RESPIR DIS, V87, P538, DOI 10.1164/arrd.1963.87.4.538; Keenan RJ, 1996, J THORAC CARDIOV SUR, V111, P308, DOI 10.1016/S0022-5223(96)70439-7; KNUDSON R J, 1965, Ann Thorac Surg, V1, P332; KNUDSON RJ, 1977, J APPL PHYSIOL, V43, P1054, DOI 10.1152/jappl.1977.43.6.1054; MACKLEM PT, 1963, AM REV RESPIR DIS, V87, P47; MAHLER DA, 1984, CHEST, V85, P751, DOI 10.1378/chest.85.6.751; MEAD J, 1967, J APPL PHYSIOL, V22, P95, DOI 10.1152/jappl.1967.22.1.95; MILICEMILI J, 1964, J APPL PHYSIOL, V19, P207, DOI 10.1152/jappl.1964.19.2.207; MORRIS JF, 1976, WESTERN J MED, V125, P110; OE M, 1995, CIRCULATION, V92, P1026, DOI 10.1161/01.CIR.92.4.1026; PIERCE JA, 1962, NEW ENGL J MED, V267, P169, DOI 10.1056/NEJM196207262670402; PRIDE NB, 1967, J APPL PHYSIOL, V23, P646, DOI 10.1152/jappl.1967.23.5.646; PRIDE NB, 1973, AM REV RESPIR DIS, V107, P83; ROGERS RM, 1970, AM REV RESPIR DIS, V101, P452; ROGERS RM, 1968, J CLIN INVEST, V47, P2569, DOI 10.1172/JCI105939; SCHLUETER DP, 1967, AM REV RESPIR DIS, V96, P656; STEAD WW, 1952, J LAB CLIN MED, V40, P674; WAKABAYASHI A, 1991, LANCET, V337, P881, DOI 10.1016/0140-6736(91)90206-5	35	352	365	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 25	1996	334	17					1095	1099		10.1056/NEJM199604253341704	http://dx.doi.org/10.1056/NEJM199604253341704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG457	8598868				2022-12-28	WOS:A1996UG45700004
J	Rivo, ML; Kindig, DA				Rivo, ML; Kindig, DA			A report card on the physician work force in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WORKFORCE REFORM; HEALTH-CARE		UNIV WISCONSIN, SCH MED, DEPT PREVENT MED, MADISON, WI USA	University of Wisconsin System; University of Wisconsin Madison	Rivo, ML (corresponding author), PCA HLTH PLANS FLORIDA, 5959 BLUE LAGOON DR, MIAMI, FL 33126 USA.							*AM AC FAM PHYS, 1995, 1994 DIR FAM PRACT R; *AM AC FAM PHYS, 1994, SURV GRAD FAM PRACT; *ASS AM MED COLL, 1993, US MED SCH FACULTY; *ASS AM MED COLL, 1995, GRADUATE STUDENT QUE; *BUR HLTH PROF, 1993, AR RES FIL TAB OST P; *BUR HLTH PROF, 1994, 1992 STAT RES SUPPL; CANTOR JC, 1993, JAMA-J AM MED ASSOC, V270, P1035, DOI 10.1001/jama.270.9.1035; COHEN JJ, 1993, NEW ENGL J MED, V329, P1810, DOI 10.1056/NEJM199312093292412; *COUNC GRAD MED ED, 8TH HLTH RES SERV AD; Council on Graduate Medical Education, 1992, 3 HLTH RES SERV ADM; Council on Graduate Medical Education, 1995, 7 HLTH RES SERV ADM; Council on Graduate Medical Education, 1994, 4 HLTH RES SERV ADM; EISENBERG JM, 1994, INQUIRY-J HEALTH CAR, V31, P241; EPSTEIN AM, 1995, JAMA-J AM MED ASSOC, V273, P1203, DOI 10.1001/jama.273.15.1203; GAMLIEL S, 1995, HEALTH AFFAIR, V14, P131, DOI 10.1377/hlthaff.14.2.131; IGLEHART JK, 1994, NEW ENGL J MED, V331, P63, DOI 10.1056/NEJM199407073310129; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1391, DOI 10.1056/NEJM199411173312025; IGLEHART JK, 1995, NEW ENGL J MED, V332, P407, DOI 10.1056/NEJM199502093320624; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1370, DOI 10.1056/NEJM199411173312010; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1535; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1151, DOI 10.1056/NEJM199410273311709; KINDIG D, 1994, WASHINGTON POST 0907, P14; KINDIG DA, 1993, JAMA-J AM MED ASSOC, V270, P1069; KONRAD R, 1995, COUNC GRAD MED ED GE; MULLAN F, 1995, JAMA-J AM MED ASSOC, V273, P1521, DOI 10.1001/jama.273.19.1521; *NAT HLTH SERV COR, 1995, NHSC SCHOL PROGR ANN; PALSBO SE, 1993, RECRUITMENT EXPERIEN; *PHS, 1994, TRENDS PRIMARY CARE; REINHARDT UE, 1994, INQUIRY-J HEALTH CAR, V31, P250; RELMAN AS, 1994, NEW ENGL J MED, V331, P471, DOI 10.1056/NEJM199408183310711; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1083, DOI 10.1001/jama.270.9.1083; STODDARD JJ, 1994, JAMA-J AM MED ASSOC, V272, P1256; Weinber JP, 1994, JAMA-J AM MED ASSOC, V272, P222	35	69	69	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	1996	334	14					892	896		10.1056/NEJM199604043341405	http://dx.doi.org/10.1056/NEJM199604043341405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD374	8596573				2022-12-28	WOS:A1996UD37400005
J	Sirmon, M; Kreisberg, R				Sirmon, M; Kreisberg, R			The invisible patient	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									BAPTIST HLTH SYST,BIRMINGHAM,AL		Sirmon, M (corresponding author), UNIV SO ALABAMA,SCH MED,DEPT MED,MOBILE,AL 36688, USA.							*AM MED ASS, 1848, COD ETH AM MED ASS; AMERICAN HOSPITAL ASSOCIATION, 1973, PAT BILL RIGHTS; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; CARRESE JA, 1995, JAMA-J AM MED ASSOC, V274, P826, DOI 10.1001/jama.274.10.826; *COUNC ETH JUD AFF, 1995, COD MED ETH 1994 95; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; FEINBERG WM, 1990, ARCH INTERN MED, V150, P2340, DOI 10.1001/archinte.150.11.2340; RADOVSKY SS, 1985, NEW ENGL J MED, V313, P586, DOI 10.1056/NEJM198508293130922	8	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	1996	334	14					908	911		10.1056/NEJM199604043341408	http://dx.doi.org/10.1056/NEJM199604043341408			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD374	8596576				2022-12-28	WOS:A1996UD37400008
J	Schumacher, TNM; Mayr, LM; Minor, DL; Milhollen, MA; Burgess, MW; Kim, PS				Schumacher, TNM; Mayr, LM; Minor, DL; Milhollen, MA; Burgess, MW; Kim, PS			Identification of D-peptide ligands through mirror-image phage display	SCIENCE			English	Article							EPITOPE LIBRARY; N-15 NMR; PROTEINS; MOLECULES; SELECTION; DOMAIN; BIND; SRC; H-1	Genetically encoded libraries of peptides and oligonucleotides are well suited for the identification of ligands for many macromolecules. A major drawback of these techniques is that the resultant ligands are subject to degradation by naturally occurring enzymes. Here, a method is described that uses a biologically encoded library for the identification of D-peptide ligands, which should be resistant to proteolytic degradation, In this approach, a protein is synthesized in the D-amino acid configuration and used to select peptides from a phage display library expressing random L-amino acid peptides, For reasons of symmetry, the mirror images of these phage-displayed peptides interact with the target protein of the natural handedness, The value of this approach was demonstrated by the identification of a cyclic D-peptide that interacts with the Src homology 3 domain of c-Src. Nuclear magnetic resonance studies indicate that the binding site for this D-peptide partially overlaps the site for the physiological ligands of this domain.	MIT, HOWARD HUGHES MED INST, WHITEHEAD INST BIOMED RES, DEPT CHEM, CAMBRIDGE, MA 02142 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	Schumacher, TNM (corresponding author), MIT, HOWARD HUGHES MED INST, WHITEHEAD INST BIOMED RES, DEPT BIOL, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Schumacher, Ton/Y-2432-2019; Ueno, Hiroshi/C-3301-2009	Schumacher, Ton/0000-0003-0517-8804; 				BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BOREK F, 1965, BIOCHEM J, V96, P577, DOI 10.1042/bj0960577; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BUNIN BA, 1994, P NATL ACAD SCI USA, V91, P4708, DOI 10.1073/pnas.91.11.4708; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DINTZIS HM, 1993, PROTEINS, V16, P306, DOI 10.1002/prot.340160309; DOOLEY CT, 1994, SCIENCE, V266, P2019, DOI 10.1126/science.7801131; DOOLITTLE RF, 1993, SCI AM, V269, P50, DOI 10.1038/scientificamerican1093-50; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EFIMOV AV, 1994, FEBS LETT, V355, P213, DOI 10.1016/0014-5793(94)01194-X; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; GILL TJ, 1963, NATURE, V197, P746, DOI 10.1038/197746a0; GOMEZ FA, 1994, J ORG CHEM, V59, P2885, DOI 10.1021/jo00089a038; GORDON EM, 1994, J MED CHEM, V37, P1385, DOI 10.1021/jm00036a001; JANEWAY CA, 1967, IMMUNOLOGY, V13, P29; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; MATTHEAKIS LC, 1994, P NATL ACAD SCI USA, V91, P9022, DOI 10.1073/pnas.91.19.9022; MAUER PH, 1965, J EXP MED, V121, P339; MCINTOSH LP, 1990, BIOCHEMISTRY-US, V29, P6341, DOI 10.1021/bi00479a003; MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MUIR TW, 1995, STRUCTURE, V3, P649, DOI 10.1016/S0969-2126(01)00200-3; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; PASTEUR ML, 1860, RECHERCHES DISSYMETR; PRELOG V, 1976, SCIENCE, V193, P17, DOI 10.1126/science.935852; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHUMACHER TNM, UNPUB; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SEYMOUR JF, 1995, SCI MED, V2, P48; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; STALEY JP, 1994, PROTEIN SCI, V3, P1822, DOI 10.1002/pro.5560031021; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YU H, 1993, FEBS LETT, V324, P87, DOI 10.1016/0014-5793(93)81538-B; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZAWADZKE LE, 1993, PROTEINS, V16, P301, DOI 10.1002/prot.340160308; ZAWADZKE LE, 1992, J AM CHEM SOC, V114, P4002, DOI 10.1021/ja00036a073	51	283	328	3	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1996	271	5257					1854	1857		10.1126/science.271.5257.1854	http://dx.doi.org/10.1126/science.271.5257.1854			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596952				2022-12-28	WOS:A1996UC77800043
J	Friedman, LN; Williams, MT; Singh, TP; Frieden, TR				Friedman, LN; Williams, MT; Singh, TP; Frieden, TR			Tuberculosis, aids, and death among substance abusers on welfare in New York City	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MENS SHELTER; INFECTION; RISK; HIV; PROGRESSION	Background. In New York City, the incidence of tuberculosis has more than doubled during the past decade. We examined the incidence of tuberculosis and the acquired immunodeficiency syndrome (AIDS) and the rate of death from all causes in a very-high-risk group - indigent subjects who abuse drugs, alcohol, or both. Methods. In 1984 we began to study prospectively a cohort of welfare applicants and recipients 18 to 64 years of age who abused drugs or alcohol. The incidence rates of tuberculosis, AIDS, and death for this group were ascertained through vital records and New York City's tuberculosis and AIDS registries. Results. The cohort was followed for eight years. Of the 858 subjects, tuberculosis developed in 47 (5.5 percent), 84 (9.8 percent) were given a diagnosis of AIDS, and 183 (21.3 percent) died. The rates of incidence per 100,000 person-years were 744 for tuberculosis, 1323 for AIDS, and 2842 for death. In this group of welfare clients, the rate of newly diagnosed tuberculosis was 14.8 times that of the age-matched general population of New York City; the rate of AIDS was 10.0 times as high; and the death rate was 5.2 times as high. There was no significant difference in the rate of new cases of tuberculosis between subjects with positive skin tests and those with negative skin tests at examination in 1984. Conclusions. Among indigent alcohol and drug abusers in New York City, the rates of tuberculosis, AIDS, and death are extremely high. In this population, a single positive or negative skin test does not predict the development of tuberculosis, probably because both anergy and new infections are common. If programs to control tuberculosis and AIDS are to be effective in groups of indigent substance abusers, health services must be integrated into the welfare delivery system. (C) 1996, Massachusetts Medical Society.	MILFORD HOSP,DEPT QUAL MANAGEMENT,MILFORD,CT 06460; YALE UNIV,SCH MED,PULM & CRIT CARE SECT,NEW HAVEN,CT; NEW YORK CITY DEPT HLTH,BUR TB CONTROL,NEW YORK,NY 10013; NEW YORK CITY DEPT HLTH,OFF AIDS SURVEILLANCE,NEW YORK,NY 10013; CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,ATLANTA,GA 30341	Yale University; New York City Department of Health & Mental Hygiene; New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA	Friedman, LN (corresponding author), MILFORD HOSP,DEPT INTENS CARE,2047 BRIDGEPORT AVE,MILFORD,CT 06460, USA.							ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; AVINS AL, 1994, JAMA-J AM MED ASSOC, V271, P515, DOI 10.1001/jama.271.7.515; BALLA AK, 1994, ALCOHOL, V11, P99, DOI 10.1016/0741-8329(94)90050-7; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; *BUR TUB CONTR, 1993, TUB NEW YORK CIT 199; CONCATO J, 1994, ARCH INTERN MED, V154, P2069, DOI 10.1001/archinte.154.18.2069; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; *DEP HLTH HUM SERV, 1994, REP TUB US 1993; Diem K., 1970, SCI TABLES, VSeventh; *DIV SUBST AB SERV, 1985, STAT COMPR 5 YEAR PL; FONG IW, 1994, CLIN INFECT DIS, V19, P337, DOI 10.1093/clinids/19.2.337; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDMAN LN, 1987, AM REV RESPIR DIS, V136, P1188, DOI 10.1164/ajrccm/136.5.1188; *HUM RES ADM, 1984, 9 HUM RES ADM MONTHL, V45; *HUM RES ADM CIT N, 1994, HRA FACTS DEC 1994; JORDAN TJ, 1991, JAMA-J AM MED ASSOC, V265, P2987, DOI 10.1001/jama.265.22.2987; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P104; MAHLER J, 1994, AM J PSYCHIAT, V151, P439; MCADAM JM, 1991, CHEST, V99, P792, DOI 10.1378/chest.99.3.792-c; MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003; *OFF VIT STAT EP, 1990, SUMM VIT STAT 1990 C; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PAUL EA, 1993, AM J PUBLIC HEALTH, V83, P1743, DOI 10.2105/AJPH.83.12.1743; REICHMAN LB, 1991, AM REV RESPIR DIS, V144, P741, DOI 10.1164/ajrccm/144.4.741; REICHMAN LB, 1979, ARCH INTERN MED, V139, P337, DOI 10.1001/archinte.139.3.337; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P3434; ZOLOPA AR, 1994, JAMA-J AM MED ASSOC, V272, P455, DOI 10.1001/jama.272.6.455; 1992, MMWR-MORBID MORTAL W, V41, P13; 1990, MMWR-MORBID MORTAL W, V39, P561; 1987, MMWR MORB MORTAL S1S, V36, pS3; 1986, MMWR-MORBID MORTAL W, V35, P74; 1991, MMWR-MORBID MORTAL W, V40, P485; 1987, MMWR-MORBID MORTAL W, V36, P785; 1992, MMWR-MORBID MORTAL W, V41, P1	38	92	95	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1996	334	13					828	833		10.1056/NEJM199603283341304	http://dx.doi.org/10.1056/NEJM199603283341304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB950	8596549				2022-12-28	WOS:A1996UB95000004
J	Rensch, MJ; Merenich, JA; Lieberman, M; Long, BD; Davis, DR; McNally, PR				Rensch, MJ; Merenich, JA; Lieberman, M; Long, BD; Davis, DR; McNally, PR			Gluten-sensitive enteropathy in patients with insulin-dependent diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article							CELIAC-DISEASE; ANTIBODIES; RELATIVES; CHILDREN; GLIADIN	Objective: To determine the prevalence of celiac disease in a cohort of patients with insulin-dependent diabetes mellitus and to describe the clinical characteristics of patients with coexistent disease. Design: Prospective cohort study. Setting: U.S. Army medical center. Patients: 47 patients with insulin-dependent diabetes mellitus. Measurements: Antiendomysial antibody testing was used to screen for celiac disease. The diagnosis of celiac disease required histologic evidence of villous atrophy and crypt hyperplasia and a positive antiendomysial antibody test result. In patients identified as having coexistent disease, complete blood counts, multiphasic biochemical testing, D-xylose absorption testing, and bone mineral density estimates were done. Results: 3 of 47 patients with insulin-dependent diabetes mellitus (6.4%; 95% Cl, 1.4% to 17.5%) had positive antiendomysial antibody test results and small-bowel biopsy specimens consistent with celiac disease. The 95% Ci lies entirely above the estimated prevalence of celiac disease expected in the general U.S. population, which ranges from 0.02% to 0.1%. Mean bone mineral densities were 0.8 and 1.1 SD below age-, ethnicity-, and sex matched controls in each of the 2 antiendomysial anti body-positive patients tested. Small-bowel absorption was abnormal in 1 of the 2 patients tested by D-xylose. Anemia and hypoalbuminemia were not detected in any of the patients with coexistent disease. Only 1 of the 3 patients had symptoms of diarrhea. All patients were at or above their ideal body weights. Conclusions: Celiac disease appears to be more common among patients with insulin-dependent diabetes mellitus than in the general U.S. population (P < 0.001). Two of the three patients with coexistent disease in this study had subclinical or latent celiac disease.	FITZSIMONS ARMY MED CTR, DEPT MED, SERV GASTROENTEROL, AURORA, CO 80045 USA; FITZSIMONS ARMY MED CTR, DEPT CLIN INVEST, AURORA, CO 80045 USA; UNIV COLORADO, HLTH SCI CTR, DENVER, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BARERA G, 1991, ARCH DIS CHILD, V66, P491, DOI 10.1136/adc.66.4.491; CATASSI C, 1994, LANCET, V343, P200, DOI 10.1016/S0140-6736(94)90989-X; COLLIN P, 1989, SCAND J GASTROENTERO, V24, P81, DOI 10.3109/00365528909092243; CONGIA M, 1994, HUM IMMUNOL, V40, P138, DOI 10.1016/0198-8859(94)90059-0; CORAZZA G, 1992, GASTROENTEROLOGY, V103, P1517, DOI 10.1016/0016-5085(92)91172-Z; FERREIRA M, 1992, GUT, V33, P1633, DOI 10.1136/gut.33.12.1633; Kahn CR, 1994, JOSLINS DIABETES MEL; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KNUDTZON J, 1991, J PEDIATR GASTR NUTR, V12, P190, DOI 10.1097/00005176-199102000-00009; LINDH E, 1992, J INTERN MED, V231, P403, DOI 10.1111/j.1365-2796.1992.tb00951.x; MAKI M, 1995, GUT, V36, P239, DOI 10.1136/gut.36.2.239; MAKI M, 1991, LANCET, V337, P763, DOI 10.1016/0140-6736(91)91375-5; RUBIN CE, 1960, GASTROENTEROLOGY, V38, P28; SAVILAHTI E, 1986, J PEDIATR-US, V108, P690, DOI 10.1016/S0022-3476(86)81042-3; STROBER W, 1992, OXFORD MONOGRAPHS ME, V20, P279; TALLEY NJ, 1994, AM J GASTROENTEROL, V89, P843; VOLTA U, 1991, DIGEST DIS SCI, V36, P752, DOI 10.1007/BF01311232; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909; WATSON RG, 1994, GUT, V35, pW14	19	77	77	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1996	124	6					564	567		10.7326/0003-4819-124-6-199603150-00004	http://dx.doi.org/10.7326/0003-4819-124-6-199603150-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ529	8597319				2022-12-28	WOS:A1996TZ52900004
J	Celenza, A; Fothergill, J; Kupek, E; Shaw, RJ				Celenza, A; Fothergill, J; Kupek, E; Shaw, RJ			Thunderstorm associated asthma: A detailed analysis of environmental factors	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SOYBEAN DUST; WEATHER; POLLEN	Objectives-To seek meteorological factors, pollutants or pollen, and an asthma epidemic which occurred in London on 24 and 25 June 1994 after a thunderstorm. Design-Retrospective study of patients' accident and emergency department records, with bivariate and multivariate analysis of environmental factors and data collection for the two months surrounding the epidemic. Setting-The accident and emergency department of St Mary's Hospital in west central London. Subjects-148 patients presenting with asthma between 1 June and 31 July 1994, of whom 40 presented in the 24 hours after the storm. Results-The asthma epidemic was significantly associated with a drop in air temperature six hours previously and a high grass pollen concentration nine hours previously. Non-epidemic asthma was significantly associated with lightning strikes, increase in humidity or sulphur dioxide concentration, a drop in temperature or high rainfall the previous day, and a decrease in maximum air pressure or changes in grass pollen counts over the previous two days. Conclusions-New episodes of asthma during the epidemic on 24 and 25 June 1994 were associated with a fall in air temperature and a rise in grass pollen concentration. Non-epidemic asthma was significantly associated with a greater number of environmental changes. This may indicate that the patients with thunderstorm associated asthma were a separate population, sensitive to different environmental stimuli.	ST MARYS HOSP, LONDON W2 1NY, ENGLAND	Imperial College London								ACEVES M, 1991, J ALLERGY CLIN IMMUN, V88, P124, DOI 10.1016/0091-6749(91)90309-C; ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; AYRES J, 1994, BRIT MED J, V309, P619, DOI 10.1136/bmj.309.6955.619; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834, DOI 10.5694/j.1326-5377.1992.tb136994.x; BROWN HM, 1983, LANCET, V2, P630; CAMPBELLHEWSON G, 1994, BRIT MED J, V309, P1086, DOI 10.1136/bmj.309.6961.1086a; EGAN P, 1985, MED J AUSTRALIA, V142, P330, DOI 10.5694/j.1326-5377.1985.tb113389.x; Ito S, 1989, Arerugi, V38, P1077; Lim T O, 1991, Med J Malaysia, V46, P230; LOGAN WPD, 1953, LANCET, V264, P336; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MONTEALEGRE F, 1993, J ASTHMA, V30, P219, DOI 10.3109/02770909309054520; MORRISON I, 1960, Med J Aust, V47(1), P850; MURRAY V, 1994, BRIT MED J, V309, P131, DOI 10.1136/bmj.309.6947.131c; PACKE GE, 1985, LANCET, V2, P199; ROSSI OVJ, 1993, THORAX, V48, P244, DOI 10.1136/thx.48.3.244; *SAS I, 1995, P243 SAS I; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; WALTERS S, 1994, THORAX, V49, P133, DOI 10.1136/thx.49.2.133	19	151	154	1	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 9	1996	312	7031					604	607						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595333				2022-12-28	WOS:A1996TZ84000023
J	Zuckerman, AJ				Zuckerman, AJ			Alphabet of hepatitis viruses	LANCET			English	Editorial Material											Zuckerman, AJ (corresponding author), ROYAL FREE HOSP, SCH MED, WHO, COLLABORATING CTR REFERENCE & RES VIRAL DIS, LONDON, ENGLAND.							Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; MUERHOFF AS, 1995, J VIROL, V69, P5621, DOI 10.1128/JVI.69.9.5621-5630.1995; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7; ZUCKERMAN AJ, 1995, LANCET, V345, P1453, DOI 10.1016/S0140-6736(95)91032-8	7	173	174	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 2	1996	347	9001					558	559		10.1016/S0140-6736(96)91267-2	http://dx.doi.org/10.1016/S0140-6736(96)91267-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596314				2022-12-28	WOS:A1996TX69400005
J	Wragg, M; Hutton, M; Talbot, C; Busfield, F; Han, SW; Lendon, C; Clark, RF; Morris, JC; Edwards, D; Goate, A; Pfeiffer, E; Crook, R; Prihar, G; Phillips, H; Baker, M; Hardy, J; Rossor, M; Houlden, H; Karran, E; Roberts, G; Craddock, N				Wragg, M; Hutton, M; Talbot, C; Busfield, F; Han, SW; Lendon, C; Clark, RF; Morris, JC; Edwards, D; Goate, A; Pfeiffer, E; Crook, R; Prihar, G; Phillips, H; Baker, M; Hardy, J; Rossor, M; Houlden, H; Karran, E; Roberts, G; Craddock, N			Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease	LANCET			English	Article								Background Mutations in the presenilin-1 (PS-1) gene are associated with early-onset Alzheimer's disease. 40-50% of the risk for late-onset disease has been attributed to alleles at the apolipoprotein E (ApoE) locus. We have looked for an association between PS-1 and late-onset disease. Methods We collected blood samples from 208 white cases of dementia of the Alzheimer type and from 185 age matched controls (mean ages 76.9 and 76.2 years, respectively; 58% female in each series). Clinical diagnostic accuracy for Alzheimer's disease in our patients is 96%. We also studied 29 African-American patients with dementia of the Alzheimer type and 50 age-matched controls (cases vs controls, 77.2 vs 72.0 years; 72 vs 77% female). We used PCR to test for an association between Alzheimer's disease and a polymorphism within the intron 3' to exon 8 of the PS-1 gene. The ApoE genotype of most of the cases and controls was known from previous investigations. Findings Homozygosity of the 1 allele in the PS-1 gene was associated with a doubling of the risk for late-onset Alzheimer's disease compared with the [12]/[22] genotype (odds ratio 1.97, 95% CI 1.29-3.00). The proportion of Alzheimer's disease cases in the white population that could be attributed to homozygosity at this locus, as estimated by the attributable fraction, was 0.22. This compares with 0.35 for a single copy of ApoE4 and 0.15 for two copies. The smaller African-American series showed similar distribution of PS-1 genotype between cases and controls. Interpretation In our white series of cases, PS-1 accounted for about half as much of the risk for late-onset Alzheimer's disease as did ApoE4.	WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63100; UNIV S FLORIDA,GERONTOL CTR,TAMPA,FL; WASHINGTON UNIV,SCH MED,DEPT NEUROL & OCCUPAT THERAPY,ST LOUIS,MO 63100; UNIV S FLORIDA,SUNCOAST ALZHEIMERS DIS LABS,DEPT PSYCHIAT,TAMPA,FL; UNIV S FLORIDA,SUNCOAST ALZHEIMERS DIS LABS,DEPT PHARMACOL,TAMPA,FL; UNIV S FLORIDA,SUNCOAST ALZHEIMERS DIS LABS,DEPT BIOCHEM,TAMPA,FL; UNIV S FLORIDA,SUNCOAST ALZHEIMERS DIS LABS,DEPT NEUROL,TAMPA,FL; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT NEUROL,LONDON W2,ENGLAND; SMITHKLINE BEECHAM,DEPT MOL NEUROPATHOL,HARLOW,ESSEX,ENGLAND; UNIV WALES COLL CARDIFF,COLL MED,DEPT PSYCHOL MED,CARDIFF,S GLAM,WALES	Washington University (WUSTL); State University System of Florida; University of South Florida; Washington University (WUSTL); State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Imperial College London; GlaxoSmithKline; Cardiff University			Morris, John C/A-1686-2012; Rossor, Martin/C-1598-2008; Hardy, John/C-2451-2009; Houlden, Henry J/C-1532-2008	Hardy, John/0000-0002-3122-0423; Houlden, Henry J/0000-0002-2866-7777; Phillips, Helen Margaret/0000-0003-4513-9148; Rossor, Martin/0000-0001-8215-3120; Clark, Robert/0000-0001-5091-8280; Goate, Alison/0000-0002-0576-2472; Talbot, Christopher/0000-0001-7406-8962	NIA NIH HHS [AG00634, AG11871, AG12028] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012028, R01AG011871] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berg Leonard, 1994, P9; CLARK RF, 1995, NAT GENET, V11, P219, DOI 10.1038/ng1095-219; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CRUTS M, 1995, HUM MOL GENET, V4, P2363, DOI 10.1093/hmg/4.12.2363; HOULDEN H, 1993, NEURODEGENERATION, V2, P283; HUTTON M, IN PRESS NEUROREPORT; KAMBOH MI, 1995, NAT GENET, V10, P486, DOI 10.1038/ng0895-486; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; PEREZTUR J, IN PRESS NEUROREPORT; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SCHELLENBERG GD, 1993, AM J HUM GENET, V53, P619; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; TALBOT C, 1994, LANCET, V343, P1432, DOI 10.1016/S0140-6736(94)92557-7; TALBOT CJ, IN PRESS NEUROREPORT; WASCO W, 1995, NAT MED, V1, P848, DOI 10.1038/nm0995-848a; WISNIEWSKI T, 1995, LANCET, V346, P1366, DOI 10.1016/S0140-6736(95)92379-9	17	230	242	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					509	512		10.1016/S0140-6736(96)91140-X	http://dx.doi.org/10.1016/S0140-6736(96)91140-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596269				2022-12-28	WOS:A1996TW69700011
J	Cochran, AG; Kim, PS				Cochran, AG; Kim, PS			Imitation of Escherichia coli aspartate receptor signaling in engineered dimers of the cytoplasmic domain	SCIENCE			English	Article							LIGAND-BINDING DOMAIN; BACTERIAL CHEMOTAXIS; LEUCINE ZIPPER; COVALENT MODIFICATION; COILED-COILS; CRYSTAL-STRUCTURE; SENSORY RECEPTOR; KINASE CHEA; TRANSDUCTION; COMPLEX	Transmembrane signaling by bacterial chemotaxis receptors appears to require a conformational change within a receptor dimer. Dimers were engineered of the cytoplasmic domain of the Escherichia coli aspartate receptor that stimulated the kinase CheA in vitro. The folding free energy of the leucine-zipper dimerization domain was harnessed to twist the dimer interface of the receptor, which markedly affected the extent of CheA activation. Response to this twist was attenuated by modification of receptor regulatory sites, in the same manner as adaptation resets sensitivity to ligand in vivo. These results suggest that the normal allosteric activation of the chemotaxis receptor has been mimicked in a system that lacks both ligand-binding and transmembrane domains. The most stimulatory receptor dimer formed a species of tetrameric size.			Cochran, AG (corresponding author), MIT, WHITEHEAD INST BIOMED RES, HOWARD HUGHES MED INST, DEPT BIOL, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Cochran, Andrea/0000-0001-6469-795X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007348] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI07348-07] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BAUMGARTNER JW, 1994, J BACTERIOL, V176, P1157, DOI 10.1128/JB.176.4.1157-1163.1994; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1991, METHOD ENZYMOL, V200, P205; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BOWIE JU, 1995, ACTA CRYSTALLOGR D, V51, P145, DOI 10.1107/S0907444994010498; CARR CM, 1995, THESIS MIT; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; CHERVITZ SA, 1995, BIOCHEMISTRY-US, V34, P9722, DOI 10.1021/bi00030a010; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COLLINS LA, 1992, J BACTERIOL, V174, P3667, DOI 10.1128/JB.174.11.3667-3675.1992; DANIELSON MA, 1994, BIOCHEMISTRY-US, V33, P6100, DOI 10.1021/bi00186a009; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOERING D, 1992, THESIS MIT; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HESS JF, 1991, METHOD ENZYMOL, V200, P188; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JIN T, 1994, J MOL BIOL, V244, P477, DOI 10.1006/jmbi.1994.1746; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KAPLAN N, 1988, J BACTERIOL, V170, P5134, DOI 10.1128/jb.170.11.5134-5140.1988; KRIKOS A, 1983, CELL, V33, P615, DOI 10.1016/0092-8674(83)90442-7; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEE GF, 1995, P NATL ACAD SCI USA, V92, P3391, DOI 10.1073/pnas.92.8.3391; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; LUMB KJ, 1994, BIOCHEMISTRY-US, V33, P7361, DOI 10.1021/bi00189a042; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MADDOCK JR, 1993, SCIENCE, V259, P1717; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; MUTOH N, 1986, J BACTERIOL, V167, P992, DOI 10.1128/jb.167.3.992-998.1986; NINFA EG, 1991, J BIOL CHEM, V266, P9764; OOSAWA K, 1988, J BACTERIOL, V170, P2521, DOI 10.1128/jb.170.6.2521-2526.1988; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PARK CY, 1990, J BACTERIOL, V172, P7179, DOI 10.1128/jb.172.12.7179-7187.1990; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PU WT, 1991, P NATL ACAD SCI USA, V88, P6901, DOI 10.1073/pnas.88.16.6901; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SCOTT WG, 1993, J MOL BIOL, V232, P555, DOI 10.1006/jmbi.1993.1411; SCOTT WG, 1994, STRUCTURE, V2, P877, DOI 10.1016/S0969-2126(94)00088-3; SMITH RA, 1980, P NATL ACAD SCI-BIOL, V77, P5370, DOI 10.1073/pnas.77.9.5370; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; STEWART RC, 1987, CHEM REV, V87, P997, DOI 10.1021/cr00081a007; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; STOCK JB, 1992, J BIOL CHEM, V267, P19753; WU ZN, 1994, PROTEIN ENG, V7, P1137, DOI 10.1093/protein/7.9.1137; YEH JI, 1993, J BIOL CHEM, V268, P8789; ZITZEWITZ JA, 1995, BIOCHEMISTRY-US, V34, P12812, DOI 10.1021/bi00039a042	62	99	100	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 23	1996	271	5252					1113	1116		10.1126/science.271.5252.1113	http://dx.doi.org/10.1126/science.271.5252.1113			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599087				2022-12-28	WOS:A1996TW70100037
J	Paulusma, CC; Bosma, PJ; Zaman, GJR; Bakker, CTM; Otter, M; Scheffer, GL; Scheper, RJ; Borst, P; Elferink, RPJO				Paulusma, CC; Bosma, PJ; Zaman, GJR; Bakker, CTM; Otter, M; Scheffer, GL; Scheper, RJ; Borst, P; Elferink, RPJO			Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene	SCIENCE			English	Article							HEREDITARY-CONJUGATED HYPERBILIRUBINEMIA; ATP-DEPENDENT TRANSPORT; MUTANT RATS; CANALICULAR TRANSPORT; MEMBRANE-VESICLES; ORGANIC-ANIONS; EXCRETION; LIVER; TR	The human Dubin-Johnson syndrome and its animal model, the TR(-) rat, are characterized by a chronic conjugated hyperbilirubinemia. TR(-) rats are defective in the canalicular multispecific organic anion transporter (cMOAT), which mediates hepatobiliary excretion of numerous organic anions. The complementary DNA for rat cmoat, a homolog of the human multidrug resistance gene (hMRP1), was isolated and shown to be expressed in the canalicular membrane of hepatocytes. In the TR(-) rat, a single-nucleotide deletion in this gene resulted in a reduced messenger RNA level and absence of the protein. It is likely that this mutation accounts for the TR(-) phenotype.	NETHERLANDS CANC INST,DIV MOLEC BIOL,1066 CX AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM,1105 AZ AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT PATHOL,1080 HV AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Paulusma, CC (corresponding author), UNIV AMSTERDAM,ACAD MED CTR FO116,DEPT GASTROINTESTINAL & LIVER DIS,CTR LIVER & INTESTINAL RES,1105 AZ AMSTERDAM,NETHERLANDS.		Paulusma, Coen/AAR-7943-2021	Paulusma, Coen/0000-0001-7284-1974				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V8, P148; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; CRAWFORD JM, 1993, DISEASE LIVER, V1, P42; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVRIES MH, 1989, N-S ARCH PHARMACOL, V340, P588, DOI 10.1007/BF00260615; ELFERINK RPJO, 1987, HEPATOLOGY, V7, P1109; ELFERINK RPJO, 1990, AM J PHYSIOL, V258, pG699, DOI 10.1152/ajpgi.1990.258.5.G699; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; EVERS R, IN PRESS J CLIN INVE; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HUBER M, 1987, HEPATOLOGY, V7, P224, DOI 10.1002/hep.1840070204; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; JANSEN PLM, 1987, GASTROENTEROLOGY, V93, P1094, DOI 10.1016/0016-5085(87)90574-9; JANSEN PLM, 1985, HEPATOLOGY, V5, P573, DOI 10.1002/hep.1840050408; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; KUIPERS F, 1989, J LIPID RES, V30, P1835; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MAYER R, 1995, J CELL BIOL, V131, P137, DOI 10.1083/jcb.131.1.137; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NISHIDA T, 1992, J CLIN INVEST, V90, P2130, DOI 10.1172/JCI116098; Otter M, 1995, BIOCHEM MOL BIOL INT, V37, P563; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P463; SMIT JJM, 1994, LAB INVEST, V71, P638; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; ZAMAN GJR, 1993, CANCER RES, V53, P1747	36	755	765	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1126	1128		10.1126/science.271.5252.1126	http://dx.doi.org/10.1126/science.271.5252.1126			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599091				2022-12-28	WOS:A1996TW70100041
J	Rothwell, P				Rothwell, P			Multicentre Acute Stroke Trial - Italy	LANCET			English	Letter											Rothwell, P (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,NEUROSCI TRIALS UNIT,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				Multicentre Acute Stroke Trial-Italy Group, 1995, LANCET, V346, P1509; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; SANDERCOCK P, 1995, LANCET, V346, P1504, DOI 10.1016/S0140-6736(95)92044-7; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; 1995, NEW ENGL J MED, V333, P1581	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					392	393						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598714				2022-12-28	WOS:A1996TU69500041
J	Barker, FG; Jannetta, PJ; Bissonette, DJ; Larkins, MV; Jho, HD				Barker, FG; Jannetta, PJ; Bissonette, DJ; Larkins, MV; Jho, HD			The long-term outcome of microvascular decompression for trigeminal neuralgia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RETROGASSERIAN GLYCEROL RHIZOTOMY; PARTIAL SENSORY RHIZOTOMY; HEMIFACIAL SPASM; MANAGEMENT; EXPERIENCE; INJECTION; GANGLION	Background. Several surgical procedures to treat trigeminal neuralgia (tic douloureux) are available, but most reports provide only short-term follow-up information. Methods. We describe the long-term results of surgery in 1185 patients who underwent microvascular decompression of the trigeminal nerve for medically intractable trigeminal neuralgia, The outcome of the procedure was assessed prospectively with annual questionnaires. Results. Of the 1185 patients who underwent microvascular decompression during the 20-year study period, 1155 were followed for 1 year or more after the operation, The median follow-up period was 6.2 years, Most postoperative recurrences of tic took place in the first two years after surgery, Thirty percent of the patients had recurrences of tie during the study period, and 11 percent underwent second operations for the recurrences. Ten years after surgery, 70 percent of the patients (as determined by Kaplan-Meier analysis) had excellent final results - that is, they were free of pain without medication for tie. An additional 4 percent had occasional pain that did not require long-term medication, Ten years after the procedure, the annual rate of the recurrence of tic was less than 1 percent, Female sex, symptoms lasting more than eight years, venous compression of the trigeminal-root entry zone, and the lack of immediate postoperative cessation of tic were significant predictors of eventual recurrence, Having undergone a previous ablative procedure did not lessen a patient's likelihood of having a cessation of tic after microvascular decompression, but the rates of burning and aching facial pain, as reported on the last follow-up questionnaire, were higher if a trigeminal-ganglion lesion had been created with radiofrequency current before microvascular decompression. Major complications included two deaths shortly after the operation (0.2 percent) and one brain-stem infarction (0.1 percent), Sixteen patients (1 percent) had ipsilateral hearing loss. Conclusions. Microvascular decompression is a safe and effective treatment for trigeminal neuralgia, with a high rate of long-term success. (C) 1996, Massachusetts Medical Society.	MASSACHUSETTS GEN HOSP, NEUROL SERV, BOSTON, MA 02114 USA; UNIV PITTSBURGH, DEPT NEUROL SURG, PITTSBURGH, PA 15260 USA; SW OHIO NEUROSURG, PIQUA, OH USA	Harvard University; Massachusetts General Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								Apfelbaum R I, 1983, Clin Neurosurg, V31, P351; BARBA D, 1984, J NEUROSURG, V60, P104, DOI 10.3171/jns.1984.60.1.0104; BARKER FG, 1995, J NEUROSURG, V82, P201, DOI 10.3171/jns.1995.82.2.0201; BEDERSON JB, 1989, J NEUROSURG, V71, P359, DOI 10.3171/jns.1989.71.3.0359; BERGENHEIM AT, 1991, ACTA NEUROCHIR, V111, P114, DOI 10.1007/BF01400498; BRISMAN R, 1987, J NEUROSURG, V67, P44, DOI 10.3171/jns.1987.67.1.0044; BROGGI G, 1990, NEUROSURGERY, V26, P783, DOI 10.1227/00006123-199005000-00008; BURCHIEL KJ, 1988, J NEUROSURG, V69, P35, DOI 10.3171/jns.1988.69.1.0035; BURCHIEL KJ, 1988, J NEUROSURG, V69, P361, DOI 10.3171/jns.1988.69.3.0361; CUTBUSH K, 1964, AUST N Z J SURG, V64, P173; FUJIMAKI T, 1990, J NEUROSURG, V73, P212, DOI 10.3171/jns.1990.73.2.0212; GEHAN EA, 1969, J CHRON DIS, V21, P629, DOI 10.1016/0021-9681(69)90035-6; HAKANSON S, 1981, NEUROSURGERY, V9, P638, DOI 10.1227/00006123-198112000-00005; HAMLYN PJ, 1992, J NEUROSURG, V76, P948, DOI 10.3171/jns.1992.76.6.0948; Jannetta P J, 1979, Clin Neurosurg, V26, P607; JANNETTA PJ, 1977, NEUROCHIRURGIA, V20, P145; JANNETTA PJ, 1967, J NEUROSURG, V26, P159, DOI 10.3171/jns.1967.26.1part2.0159; Jannetta PJ, 1990, TRIGEMINAL NEURALGIA, P201; KATUSIC S, 1990, ANN NEUROL, V27, P89, DOI 10.1002/ana.410270114; KLUN B, 1992, NEUROSURGERY, V30, P49, DOI 10.1227/00006123-199201000-00009; KOLLURI S, 1984, SURG NEUROL, V22, P235, DOI 10.1016/0090-3019(84)90005-3; Lee E.T., 1992, STATISTICAL METHODS; LINSKEY ME, 1994, J NEUROSURG, V81, P1, DOI 10.3171/jns.1994.81.1.0001; MENDOZA N, 1995, BRIT J NEUROSURG, V9, P13, DOI 10.1080/02688699550041692; MULLAN S, 1983, J NEUROSURG, V59, P1007, DOI 10.3171/jns.1983.59.6.1007; *NAT CTR HLTH STAT, 1989, VIT STAT US, V2; PIATT JH, 1984, NEUROSURGERY, V14, P462, DOI 10.1227/00006123-198404000-00012; POLLACK IF, 1988, J NEUROSURG, V68, P559, DOI 10.3171/jns.1988.68.4.0559; PUCA A, 1993, ACTA NEUROCHIR, P165; SLETTEBO H, 1993, ACTA NEUROCHIR, V122, P231, DOI 10.1007/BF01405534; SUN T, 1994, ACTA NEUROCHIR, V126, P144, DOI 10.1007/BF01476425; SWEET WH, 1974, J NEUROSURG, V40, P143, DOI 10.3171/jns.1974.40.2.0143; Sweet WH, 1993, BRAIN SURG COMPLICAT, V2, P2053; SZAPIRO J, 1985, NEUROSURGERY, V17, P920, DOI 10.1227/00006123-198512000-00009; TAARNHOJ P, 1952, J NEUROSURG, V9, P288, DOI 10.3171/jns.1952.9.3.0288; TAHA JM, 1995, J NEUROSURG, V83, P989, DOI 10.3171/jns.1995.83.6.0989; TAYLOR JC, 1981, POSTGRAD MED J, V57, P16, DOI 10.1136/pgmj.57.663.16; TURNBULL BW, 1976, J R STAT SOC B, V38, P290; ZAKRZEWSKA JM, 1993, ACTA NEUROCHIR, V122, P225, DOI 10.1007/BF01405533	39	914	971	3	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 25	1996	334	17					1077	1083		10.1056/NEJM199604253341701	http://dx.doi.org/10.1056/NEJM199604253341701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG457	8598865				2022-12-28	WOS:A1996UG45700001
J	Kreuder, J; Borkhardt, A; Repp, R; Pekrun, A; Gottsche, B; Gottschalk, U; Reichmann, H; Schachenmayr, W; Schlegel, K; Lampert, F				Kreuder, J; Borkhardt, A; Repp, R; Pekrun, A; Gottsche, B; Gottschalk, U; Reichmann, H; Schachenmayr, W; Schlegel, K; Lampert, F			Brief report: Inherited metabolic myopathy and hemolysis due to a mutation in aldolase A	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMMENDED METHODS; ANEMIA; DEFICIENCY		UNIV GIESSEN,ZENTRUM KINDERHEILKUNDE,ABT ALLGEMEINE PADIAT HAMATOL & ONKOL,DEPT PEDIAT,D-35385 GIESSEN,GERMANY; UNIV GIESSEN,INST NEUROPATHOL,D-35385 GIESSEN,GERMANY; UNIV GIESSEN,INST CLIN CHEM,D-35385 GIESSEN,GERMANY; UNIV GOTTINGEN,DEPT PEDIAT,W-3400 GOTTINGEN,GERMANY; UNIV WURZBURG,DEPT NEUROL,W-8700 WURZBURG,GERMANY	Justus Liebig University Giessen; Justus Liebig University Giessen; Justus Liebig University Giessen; University of Gottingen; University of Wurzburg								BEERNINK PT, 1994, PROTEIN SCI, V3, P1383, DOI 10.1002/pro.5560030904; Beutler E, 1973, Trans Assoc Am Physicians, V86, P154; BEUTLER E, 1977, BRIT J HAEMATOL, V35, P331, DOI 10.1111/j.1365-2141.1977.tb00589.x; BEUTLER E, 1957, J LAB CLIN MED, V49, P84; BORKHARDT A, 1994, LEUKEMIA, V8, P549; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P456; DiMauro S, 1994, MYOLOGY, P1554; DUBOWITZ V, 1985, MUSCLE BIOPSY PRACTI, P28; GAMBLIN SJ, 1991, J MOL BIOL, V219, P573, DOI 10.1016/0022-2836(91)90650-U; GAMBLIN SJ, 1990, FEBS LETT, V264, P159; GAMBLIN SJ, 1990, FEBS LETT, V262, P282, DOI 10.1016/0014-5793(90)80211-Z; KISHI H, 1987, P NATL ACAD SCI USA, V84, P8623, DOI 10.1073/pnas.84.23.8623; KUKITA A, 1987, HUM GENET, V76, P20; LAKOMEK M, 1989, BRIT J HAEMATOL, V72, P445, DOI 10.1111/j.1365-2141.1989.tb07730.x; MALEK AA, 1988, ARCH BIOCHEM BIOPHYS, V266, P10, DOI 10.1016/0003-9861(88)90232-9; MILLER DR, 1989, BLOOD DIS INFANCY CH, P294; MIWA S, 1981, AM J HEMATOL, V11, P425, DOI 10.1002/ajh.2830110412; MIWA S, 1989, CLIN LAB HAEMATOL, V11, P131; REICHMANN H, 1983, PFLUG ARCH EUR J PHY, V397, P202, DOI 10.1007/BF00584358; ROSA R, 1982, BLOOD, V60, P84; SAKAKIBARA M, 1985, BIOCHEM BIOPH RES CO, V131, P413, DOI 10.1016/0006-291X(85)91818-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHROTER W, 1971, BRIT J HAEMATOL, V20, P249, DOI 10.1111/j.1365-2141.1971.tb07036.x; Susor W A, 1975, Methods Enzymol, V41, P66; TANAKA KR, 1995, METABOLIC MOL BASES, V3, P3485; VALENTINE WN, 1984, BLOOD, V64, P583	26	56	57	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	1996	334	17					1100	1104		10.1056/NEJM199604253341705	http://dx.doi.org/10.1056/NEJM199604253341705			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG457	8598869				2022-12-28	WOS:A1996UG45700005
J	Kizer, KW				Kizer, KW			Transforming the veterans health care system - The 'new VA'	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Kizer, KW (corresponding author), HLTH DEPT VET AFFAIRS,WASHINGTON,DC, USA.								0	46	46	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1996	275	14					1069	1069		10.1001/jama.275.14.1069	http://dx.doi.org/10.1001/jama.275.14.1069			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD027	8601910				2022-12-28	WOS:A1996UD02700004
J	Stone, PH; Thompson, B; Anderson, V; Kronenberg, MW; Gibson, RS; Rogers, WJ; Diver, DJ; Theroux, P; Warnica, JW; Nasmith, JB; Kells, C; Kleiman, N; McCabe, CH; Schactman, M; Knatterud, GL; Braunwald, E				Stone, PH; Thompson, B; Anderson, V; Kronenberg, MW; Gibson, RS; Rogers, WJ; Diver, DJ; Theroux, P; Warnica, JW; Nasmith, JB; Kells, C; Kleiman, N; McCabe, CH; Schactman, M; Knatterud, GL; Braunwald, E			Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction - The TIMI III Registry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; BYPASS-SURGERY; HEART-DISEASE; INTERVENTION-REGISTRY; ADVERSE PROGNOSIS; MORTALITY-RATES; WOMEN; GENDER; PATTERNS; BLACK	Objective.-To investigate the natural history and response to treatment of patients with unstable angina or non-Q-wave myocardial infarction (MI). Design.-Inception cohort. Setting.-Patients in general community, primary care, or referral hospitals. Patients.-All patients with an episode of unstable exertional chest pain or chest pain at rest presumed to be ischemic in origin lasting 5 minutes or more but without persisting ST-segment elevation greater than 30 minutes or the development of Q-waves were identified and enumerated in 18 participating hospitals. A subset of enumerated patients was selected to be followed prospectively using specific sampling strategies that would provide adequate numbers of black, women, and elderly (aged greater than or equal to 75 years) patients for comparison with their respective counterparts. Main Outcome Measures.-The primary analysis compared the incidence of death or MI at 42 days after entry into the prospective study according to race, sex, and age. Other outcomes considered were recurrent ischemia and the combined outcomes of death, MI, or recurrent ischemia by 42 days after entry. Results.-A total of 8676 admissions with unstable angina or non-Q-wave MI were enumerated and, of these, 3318 patients were selected for the prospective study. The direct adjusted mean age of the 3318 patients was 63.8 years. There were 943 blacks and 2375 nonblacks. Compared with nonblacks, blacks were less likely to be treated with intensive anti-ischemic therapy for their qualifying anginal episode and less likely to undergo invasive procedures (risk ratio [RR], 0.65; 95% confidence interval [CI], 0.58 to 0.72; P<.001). However, of those who underwent angiography (45% of blacks and 61% of nonblacks), blacks had less extensive and severe coronary stenoses than nonblacks. The incidence of death and MI was similar for blacks and nonblacks, but blacks had a lower incidence of recurrent ischemia. There were 1678 men and 1640 women. Women were less likely than men to receive intensive anti-ischemic therapy and less likely to undergo coronary angiography (RR, 0.71; 95% CI, 0.65 to 0.78; P<.001). Women had less severe and extensive coronary disease and were less likely to undergo revascularization, yet had a similar risk of experiencing an adverse cardiac event by 6 weeks. There were 2490 patients aged 75 years or less and 828 patients aged more than 75 years. Elderly patients received less aggressive anti-ischemic therapy and were less likely to undergo coronary angiography than their younger counterparts. Elderly patients had more severe and extensive coronary disease but fewer revascularization procedures than younger patients and experienced a much higher incidence of adverse cardiac events both in hospital and by 6 weeks. Conclusions.-Among patients presenting with acute ischemic chest pain without persistent ST-segment elevation, blacks appeared to have less severe coronary disease, received revascularization less frequently, and had less recurrent ischemia compared with nonblacks. Women also were found to have less severe coronary disease and were treated less intensely than men, but experienced similar outcomes. Elderly patients had more severe coronary disease than younger patients on coronary angiography, but were more likely to be treated medically, and they experienced far more adverse outcomes. These data suggest that more aggressive strategies should be directed to those patients with the greatest likelihood of adverse outcomes.	MARYLAND MED RES INST, TIMI III REGISTRY DATA COORDINATING CTR, BALTIMORE, MD 21210 USA; BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, TIMI III REGISTRY STUDY CHAIRMANS OFF, BOSTON, MA 02115 USA; BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA; HARVARD UNIV, BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02215 USA; HOP SACRE COEUR, DEPT MED, MONTREAL, PQ H4J 1C5, CANADA; INST CARDIOL, DEPT MED, MONTREAL, PQ, CANADA; UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA; UNIV CALGARY, FOOTHILLS PROV GEN HOSP, DEPT MED, CALGARY, AB, CANADA; UNIV TEXAS, HLTH SCI CTR, DEPT MED, HOUSTON, TX USA; UNIV TEXAS, MED BRANCH, DEPT MED, GALVESTON, TX 77550 USA; UNIV VIRGINIA, DEPT MED, CHARLOTTESVILLE, VA USA; VICTORIA GEN HOSP, DEPT MED, HALIFAX, NS B3H 2Y9, CANADA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Baylor College of Medicine; Harvard University; Beth Israel Deaconess Medical Center; Universite de Montreal; Universite de Montreal; Institut de Cardiologie de Montreal; University of Alabama System; University of Alabama Birmingham; University of Calgary; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Medical Branch Galveston; University of Virginia; Dalhousie University; University of Victoria					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042311, R01HL042428] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-42428, R01-HL-42311] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1994, Circulation, V89, P1545; [Anonymous], 1988, LANCET, V2, P349; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BECKER RC, 1994, ANN INTERN MED, V120, P638, DOI 10.7326/0003-4819-120-8-199404150-00003; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; COX DR, 1972, J R STAT SOC B, V34, P187; CROWLEY MJ, 1985, CIRCULATION, V71, P90; DIVER DJ, 1994, AM J CARDIOL, V74, P531, DOI 10.1016/0002-9149(94)90739-0; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; GOLDBERG RJ, 1993, CIRCULATION, V87, P1947, DOI 10.1161/01.CIR.87.6.1947; GRAYBILL FA, 1976, THEORY APPLICATION L; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; JECKER NS, 1991, JAMA-J AM MED ASSOC, V266, P3012, DOI 10.1001/jama.266.21.3012; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KARLSON BW, 1993, CLIN CARDIOL, V16, P397, DOI 10.1002/clc.4960160506; KEIL JE, 1993, NEW ENGL J MED, V329, P73, DOI 10.1056/NEJM199307083290201; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARK DB, 1994, NEW ENGL J MED, V330, P1101, DOI 10.1056/NEJM199404213301601; MAYNARD C, 1991, AM J CARDIOL, V67, P18, DOI 10.1016/0002-9149(91)90092-Y; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MONTAGUE TJ, 1991, AM J CARDIOL, V68, P843, DOI 10.1016/0002-9149(91)90397-4; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V266, P559; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; PETERSON ED, 1994, ANN INTERN MED, V121, P919, DOI 10.7326/0003-4819-121-12-199412150-00003; ROIG E, 1987, CIRCULATION, V76, P280, DOI 10.1161/01.CIR.76.2.280; Scheffe H, 1959, ANAL VARIANCE; SHRYOCK HS, 1975, METHODS MAT DEMOGRAP, P419; SMITH SC, 1990, J AM COLL CARDIOL, V16, P784, DOI 10.1016/S0735-1097(10)80322-5; Snedecor GW, 1967, STATISTICAL METHODS, P199; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; STONE PH, 1989, J AM COLL CARDIOL, V14, P49, DOI 10.1016/0735-1097(89)90053-3; TAYLOR HA, 1993, CIRCULATION, V88, P1484, DOI 10.1161/01.CIR.88.4.1484; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1988, AM J CARDIOL, V62, P860, DOI 10.1016/0002-9149(88)90882-X; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WENGER NK, 1990, ANN INTERN MED, V112, P557, DOI 10.7326/0003-4819-112-8-557	42	285	298	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1996	275	14					1104	1112		10.1001/jama.275.14.1104	http://dx.doi.org/10.1001/jama.275.14.1104			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD027	8601930				2022-12-28	WOS:A1996UD02700027
J	Murray, D				Murray, D			Oestrogen and postnatal depression	LANCET			English	Editorial Material											Murray, D (corresponding author), ST ITAS HOSP,PORTRAINE,DUBLIN,IRELAND.							HOLDEN J, 1994, PERINATAL PSYCHIATRY, P125; KENDELL RE, 1987, BRIT J PSYCHIAT, V150, P662, DOI 10.1192/bjp.150.5.662; MURRAY L, 1991, BRIT MED J, V302, P978, DOI 10.1136/bmj.302.6783.978; OBRIEN S, 1994, PERINATAL PSYCHIATRY, P103; OHARA MW, 1988, MOTHERHOOD MENTAL IL, P17; PAYKEL ES, 1991, BRIT J PSYCHIAT, V158, P22, DOI 10.1192/S0007125000291952; World Health Organisation, 1993, ICD 10 CLASSIFICATIO	7	7	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1996	347	9006					918	919		10.1016/S0140-6736(96)91409-9	http://dx.doi.org/10.1016/S0140-6736(96)91409-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598751				2022-12-28	WOS:A1996UD59100004
J	Fearon, DT; Locksley, RM				Fearon, DT; Locksley, RM			Elements of immunity - The instructive role of innate immunity in the acquired immune response	SCIENCE			English	Article							COMPLEMENT; RECEPTOR; IMMUNOLOGY; RESISTANCE; INFECTION; PROTEINS; ANTIGEN; CELLS	Innate immunity has been considered only to provide rapid, incomplete antimicrobial host defense until the slower, more definitive acquired immune response develops. However, innate immunity may have an additional role in determining which antigens the acquired immune system responds to and the nature of that response. Knowledge of the molecules and pathways involved may create new therapeutic options for infectious and autoimmune diseases.	UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	Fearon, DT (corresponding author), UNIV CAMBRIDGE, SCH CLIN MED, DEPT MED, WELLCOME TRUST IMMUNOL UNIT, CAMBRIDGE CB2 2SP, ENGLAND.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI026918, R01AI026918, R01AI030663] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26918, AI30663] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAM R, 1995, J IMMUNOL, V154, P1; AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BARTON CH, 1994, J EXP MED, V179, P1683, DOI 10.1084/jem.179.5.1683; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BEVERLEY PCL, 1990, CURR TOP MICROBIOL, V159, P111; BLUESTONE JA, 1995, IMMUNITY, V2, P555, DOI 10.1016/1074-7613(95)90000-4; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; Carson WE, 1995, J CLIN INVEST, V96, P2578, DOI 10.1172/JCI118321; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; CONSTANT P, 1995, IMMUNITY, V3, P495; COOPER NR, 1991, IMMUNOL TODAY, V12, P327, DOI 10.1016/0167-5699(91)90010-Q; CRESSWELL P, 1994, CURR BIOL, V4, P541, DOI 10.1016/S0960-9822(00)00119-6; CROFT M, 1994, J EXP MED, V180, P1715, DOI 10.1084/jem.180.5.1715; DAVIES KA, 1994, SPRINGER SEMIN IMMUN, V15, P397, DOI 10.1007/BF01837367; DELLABONA P, 1994, J EXP MED, V180, P1171, DOI 10.1084/jem.180.3.1171; DELPRETE G, 1995, J EXP MED, V182, P1655, DOI 10.1084/jem.182.6.1655; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; DIGHE AS, 1995, IMMUNITY, V3, P657, DOI 10.1016/1074-7613(95)90136-1; Dodds AW, 1996, NATURE, V379, P177, DOI 10.1038/379177a0; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; ENGELHARD VH, 1994, CURR OPIN IMMUNOL, V6, P13, DOI 10.1016/0952-7915(94)90028-0; FEARON DT, 1980, NEW ENGL J MED, V303, P259, DOI 10.1056/NEJM198007313030505; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0; FLESCH IEA, 1995, J EXP MED, V181, P1615, DOI 10.1084/jem.181.5.1615; FREEMAN GJ, 1995, IMMUNITY, V2, P523, DOI 10.1016/1074-7613(95)90032-2; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GOODING LR, 1992, CELL, V71, P5; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; HOWARD JC, 1995, CURR OPIN IMMUNOL, V7, P69, DOI 10.1016/0952-7915(95)80031-X; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KATZ JD, 1995, SCIENCE, V268, P1185, DOI 10.1126/science.7761837; KOSEKI H, 1990, P NATL ACAD SCI USA, V87, P5248, DOI 10.1073/pnas.87.14.5248; KOTWAL GJ, 1988, NATURE, V335, P176, DOI 10.1038/335176a0; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LOCKSLEY RM, 1994, J EXP MED, V179, P1405, DOI 10.1084/jem.179.5.1405; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MCHEYZERWILLIAMS MG, 1995, SCIENCE, V268, P106, DOI 10.1126/science.7535476; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MOUGNEAU E, 1995, SCIENCE, V268, P563, DOI 10.1126/science.7725103; NATHAN C, 1995, CELL, V82, P873, DOI 10.1016/0092-8674(95)90019-5; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; PARIZADE M, 1994, J EXP MED, V179, P1625, DOI 10.1084/jem.179.5.1625; PENNINGER JM, 1995, NATURE, V375, P241, DOI 10.1038/375241a0; PORCELLI SA, 1995, J IMMUNOL, V155, P3709; POWRIE F, 1994, J EXP MED, V179, P589, DOI 10.1084/jem.179.2.589; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; RHODES J, 1995, NATURE, V377, P71, DOI 10.1038/377071a0; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; SAD S, 1995, IMMUNITY, V2, P271, DOI 10.1016/1074-7613(95)90051-9; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SCHIFFERLI JA, 1983, LANCET, V2, P957; SCOTT B, 1994, IMMUNITY, V1, P73, DOI 10.1016/1074-7613(94)90011-6; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SKELKY YAW, 1995, J EXP MED, V181, P1527; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; STAHL PD, 1992, CURR OPIN IMMUNOL, V4, P49, DOI 10.1016/0952-7915(92)90123-V; STEINMAN RM, 1995, J EXP MED, V182, P283, DOI 10.1084/jem.182.2.283; Stout RD, 1996, J IMMUNOL, V156, P8; SUDA T, 1995, J IMMUNOL, V154, P3806; SUMIDA T, 1995, J EXP MED, V182, P1163, DOI 10.1084/jem.182.4.1163; SYMONS JA, 1995, CELL, V81, P551, DOI 10.1016/0092-8674(95)90076-4; TEDDER TE, 1994, IMMUNOL TODAY, V15, P437, DOI 10.1016/0167-5699(94)90274-7; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; THOMPSON CB, 1995, CELL, V81, P979, DOI 10.1016/S0092-8674(05)80001-7; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WENG WK, 1994, J BIOL CHEM, V269, P32514; WYNN TA, 1995, NATURE, V376, P594, DOI 10.1038/376594a0; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; YOSHIMOTO T, 1995, SCIENCE, V270, P1845, DOI 10.1126/science.270.5243.1845	85	1332	1433	1	136	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1996	272	5258					50	54		10.1126/science.272.5258.50	http://dx.doi.org/10.1126/science.272.5258.50			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600536				2022-12-28	WOS:A1996UD59700035
J	Guerette, PA; Ginzinger, DG; Weber, BHF; Gosline, JM				Guerette, PA; Ginzinger, DG; Weber, BHF; Gosline, JM			Silk properties determined by gland-specific expression of a spider fibroin gene family	SCIENCE			English	Article								Spiders produce a variety of silks that range from Lycra-like elastic fibers to Kevlar-like superfibers. A gene family from the spider Araneus diadematus was found to encode silk-forming proteins (fibroins) with different proportions of amorphous glycine-rich domains and crystal domains built from poly(alanine) and poly(glycine-alanine) repeat motifs. Spiders produce silks of different composition by gland-specific expression of this gene family, which allows for a range of mechanical properties according to the crystal-forming potential of the constituent fibroins. These principles of fiber property control may be important in the development of genetically engineered structural proteins.	UNIV BRITISH COLUMBIA,DEPT ZOOL,VANCOUVER,BC V6T 1Z4,CANADA; UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER,BC V6T 1Z4,CANADA	University of British Columbia; University of British Columbia				Weber, Bernhard H.F./0000-0002-8808-7723				ANDERSEN SO, 1970, COMP BIOCHEM PHYSIOL, V35, P705, DOI 10.1016/0010-406X(70)90988-6; BECKWITT R, 1994, J BIOL CHEM, V269, P6661; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENNY M, 1980, MECHANICAL PROPERTIE, P475; FRASER RDB, 1972, CONFORMATION FIBROUS; GOSLINE J, 1995, BIOMIMETICS DESIGN P, P237; GOSLINE JM, 1986, ENDEAVOUR, V10, P37, DOI 10.1016/0160-9327(86)90049-9; GOSLINE JM, 1994, MAT SCI BIOTECHNOLOG, P328; HINMAN MB, 1994, MAT SCI BIOTECHNOLOG, P222; JACKSON C, 1995, MACROMOLECULES, V28, P5975, DOI 10.1021/ma00121a042; KERKAM K, 1991, NATURE, V349, P596, DOI 10.1038/349596a0; LEWIS RV, 1992, ACCOUNTS CHEM RES, V25, P392, DOI 10.1021/ar00021a002; ROBSON P, 1993, J BIOL CHEM, V268, P1440; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; Simmons AH, 1996, SCIENCE, V271, P84, DOI 10.1126/science.271.5245.84; VOLLRATH F, 1992, SCI AM, V266, P70, DOI 10.1038/scientificamerican0392-70	16	345	389	2	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					112	115		10.1126/science.272.5258.112	http://dx.doi.org/10.1126/science.272.5258.112			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600519				2022-12-28	WOS:A1996UD59700051
J	Krawitt, EL				Krawitt, EL			Medical progress - Autoimmune hepatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC ACTIVE HEPATITIS; MICROSOME ANTIBODY TYPE-1; SOLUBLE LIVER ANTIGEN; C VIRUS-ANTIBODIES; ULCERATIVE-COLITIS; DISEASE; AUTOANTIBODIES; THERAPY; TRANSPLANTATION; IDENTIFICATION				Krawitt, EL (corresponding author), UNIV VERMONT, COLL MED, GASTROENTEROL UNIT, C-317 GIVEN BLDG, BURLINGTON, VT 05405 USA.							ABAUF N, 1991, AUTOIMMUNE LIVER DIS, P93; ABUAF N, 1992, HEPATOLOGY, V16, P892, DOI 10.1002/hep.1840160407; Batts KP, 1991, AUTOIMMUNE LIVER DIS, P75; BELLARY S, 1995, ANN INTERN MED, V123, P32, DOI 10.7326/0003-4819-123-1-199507010-00004; BENARI Z, 1993, HEPATOLOGY, V18, P10, DOI 10.1016/0270-9139(93)90499-D; BIANCHI FB, 1993, J HEPATOL, V18, P273, DOI 10.1016/S0168-8278(05)80268-5; CIANCIARA J, 1995, DIGEST DIS SCI, V40, P1842, DOI 10.1007/BF02212711; CLIFFORD BD, 1995, HEPATOLOGY, V21, P613, DOI 10.1016/0270-9139(95)90507-3; CZAJA AJ, 1993, GASTROENTEROLOGY, V104, P1755, DOI 10.1016/0016-5085(93)90656-W; CZAJA AJ, 1993, GASTROENTEROLOGY, V105, P1502, DOI 10.1016/0016-5085(93)90157-8; CZAJA AJ, 1995, AM J GASTROENTEROL, V90, P1206; CZAJA AJ, 1993, GASTROENTEROLOGY, V105, P1522, DOI 10.1016/0016-5085(93)90160-E; CZAJA AJ, 1993, J HEPATOL, V17, P180, DOI 10.1016/S0168-8278(05)80035-2; CZAJA AJ, 1990, HEPATOLOGY, V11, P1044, DOI 10.1002/hep.1840110621; Czaja Albert J., 1994, P283; DAVIS PA, 1992, HEPATOLOGY, V16, P1128, DOI 10.1016/0270-9139(92)90004-S; Devlin J, 1995, Liver Transpl Surg, V1, P162, DOI 10.1002/lt.500010305; DOHERTY DG, 1994, HEPATOLOGY, V19, P609, DOI 10.1002/hep.1840190311; DONALDSON PT, 1991, HEPATOLOGY, V13, P701, DOI 10.1016/0270-9139(91)92567-R; DUCLOSVALLEE JC, 1995, GASTROENTEROLOGY, V108, P470, DOI 10.1016/0016-5085(95)90076-4; ESTEBAN JI, 1989, LANCET, V2, P294; GARCIABUEY L, 1995, GASTROENTEROLOGY, V108, P1770, DOI 10.1016/0016-5085(95)90139-6; GORDON SC, 1995, GASTROENTEROLOGY, V108, P1802, DOI 10.1016/0016-5085(95)90143-4; HAN SH, 1995, HEPATOLOGY, V21, P58, DOI 10.1002/hep.1840210111; HARDARSON S, 1993, AM J CLIN PATHOL, V99, P277, DOI 10.1093/ajcp/99.3.277; HOMBERG JC, 1987, HEPATOLOGY, V7, P1333, DOI 10.1002/hep.1840070626; HYAMS JS, 1987, GASTROENTEROLOGY, V93, P890, DOI 10.1016/0016-5085(87)90454-9; JOHNSON PJ, 1995, NEW ENGL J MED, V333, P958, DOI 10.1056/NEJM199510123331502; JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435; KNOX TA, 1991, AUTOIMMUNE LIVER DIS, P167; KRAWITT EL, 1987, HEPATOLOGY, V7, P1305, DOI 10.1002/hep.1840070621; KRAWITT EL, 1993, IMMUNOLOGY LIVER, P240; Kuroki Tetsuo, 1994, P305; LACERDA MA, 1995, AM J GASTROENTEROL, V90, P247; LASHNER BA, 1988, AM J MED, V85, P609; LEE YM, 1995, NEW ENGL J MED, V332, P924, DOI 10.1056/NEJM199504063321406; LOHR H, 1992, CLIN EXP IMMUNOL, V88, P45; LOHSE AW, 1995, HEPATOLOGY, V22, P381, DOI 10.1016/0270-9139(95)90554-5; LUNEL F, 1992, HEPATOLOGY, V16, P630, DOI 10.1002/hep.1840160304; MACKAY IR, 1972, LANCET, V2, P793; MANABE K, 1994, GASTROENTEROLOGY, V106, P1321, DOI 10.1016/0016-5085(94)90025-6; MANNS M, 1987, LANCET, V1, P292; MARTINI E, 1988, HEPATOLOGY, V8, P1662, DOI 10.1002/hep.1840080632; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MICHEL G, 1992, LANCET, V339, P267, DOI 10.1016/0140-6736(92)91332-3; MICHIRO S, 1991, LANCET, V337, P252; MISHIRO S, 1990, LANCET, V336, P1400, DOI 10.1016/0140-6736(90)93101-T; MISTILIS SP, 1985, MED J AUSTRALIA, V143, P463, DOI 10.5694/j.1326-5377.1985.tb123140.x; MULDER AHL, 1993, HEPATOLOGY, V17, P411; NEUBERGER J, 1984, TRANSPLANTATION, V37, P363, DOI 10.1097/00007890-198404000-00009; NOURIARIA KT, 1982, NEW ENGL J MED, V307, P1301, DOI 10.1056/NEJM198211183072102; PERDIGOTO R, 1992, J HEPATOL, V14, P325, DOI 10.1016/0168-8278(92)90178-R; PHILIPP T, 1994, LANCET, V344, P578, DOI 10.1016/S0140-6736(94)91966-6; RAHAMAN SM, 1994, AM J GASTROENTEROL, V89, P106; RATZIU V, 1994, HEPATOLOGY, V20, pA120; REDDY KR, 1995, J VIRAL HEPATITIS, V2, P175, DOI 10.1111/j.1365-2893.1995.tb00026.x; Roberts S., 1995, Hepatology, V22, p215A; ROBERTSON DAF, 1987, LANCET, V2, P9; ROITT IM, 1994, ESSENTIAL IMMUNOLOGY, P384; RYDER SD, 1995, HEPATOLOGY, V22, P718, DOI 10.1016/0270-9139(95)90288-0; SANCHEZURDAZPAL L, 1992, HEPATOLOGY, V15, P215, DOI 10.1002/hep.1840150208; SHERMAN KE, 1994, J HEPATOL, V21, P1040, DOI 10.1016/S0168-8278(05)80615-4; STECHEMESSER E, 1993, HEPATOLOGY, V18, P1; STELLON AJ, 1988, HEPATOLOGY, V8, P781, DOI 10.1002/hep.1840080414; TAGEJENSEN U, 1987, LIVER, V7, P81; TARGAN SR, 1995, GASTROENTEROLOGY, V108, P1159, DOI 10.1016/0016-5085(95)90215-5; TODA G, 1990, HEPATOLOGY, V12, P664, DOI 10.1002/hep.1840120408; TREICHEL U, 1994, GASTROENTEROLOGY, V107, P799, DOI 10.1016/0016-5085(94)90129-5; VANTHIEL DH, 1995, AM J GASTROENTEROL, V90, P771; VENTO S, 1995, LANCET, V346, P608, DOI 10.1016/S0140-6736(95)91438-2; VENTO S, 1991, LANCET, V337, P1183, DOI 10.1016/0140-6736(91)92858-Y; WACHTER B, 1990, J HEPATOL, V11, P232, DOI 10.1016/0168-8278(90)90119-C; WANG KK, 1988, HEPATOLOGY, V8, P1679, DOI 10.1002/hep.1840080635; WANG KK, 1989, HEPATOLOGY, V10, P39, DOI 10.1002/hep.1840100110; WEN L, 1990, LANCET, V336, P1527, DOI 10.1016/0140-6736(90)93306-A; WESIERSKAGADEK J, 1988, CLIN IMMUNOL IMMUNOP, V49, P107, DOI 10.1016/0090-1229(88)90100-6; WORMAN HJ, 1991, HEPATOLOGY, V14, P1269, DOI 10.1016/0270-9139(91)90159-S; WRIGHT HL, 1992, TRANSPLANTATION, V53, P136, DOI 10.1097/00007890-199201000-00027; ZENIYA M, 1994, LIVER, V14, P206; ZUMBUSCHENFELDE KHM, 1990, HEPATOLOGY, V12, P354, DOI 10.1002/hep.1840120225	80	218	226	2	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	1996	334	14					897	903		10.1056/NEJM199604043341406	http://dx.doi.org/10.1056/NEJM199604043341406			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD374	8596574				2022-12-28	WOS:A1996UD37400006
J	Bevec, D; Jaksche, H; Oft, M; Wohl, T; Himmelspach, M; Pacher, A; Schebesta, M; Koettnitz, K; Dobrovnik, M; Csonga, R; Lottspeich, F; Hauber, J				Bevec, D; Jaksche, H; Oft, M; Wohl, T; Himmelspach, M; Pacher, A; Schebesta, M; Koettnitz, K; Dobrovnik, M; Csonga, R; Lottspeich, F; Hauber, J			Inhibition of HIV-1 replication in lymphocytes by mutants of the Rev cofactor eIF-5A	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; EUKARYOTIC INITIATION FACTOR-5A; GENE-EXPRESSION REQUIRES; HUMAN T-CELLS; TRANS-ACTIVATOR; RESPONSIVE ELEMENT; REGULATORY GENES; CARBOXY-TERMINUS; TARGET SEQUENCE; MESSENGER-RNA	Eukaryotic initiation factor 5A (eIF-5A) is a cellular cofactor required for the function of the human immunodeficiency virus type-1 (HIV-1) Rev trans-activator protein. The majority of a set of eIF-5A mutants did not support growth of yeast cells having an inactivated genomic copy of eIF-5A, indicating that the introduced mutation eliminated eIF-5A activity. Two nonfunctional mutants, eIF-5AM13 and eIF-5AM14, retained their binding capacity for the HIV-1 Rev response element:Rev complex. Both mutants were constitutively expressed in human T cells. When these T cells were infected with replication-competent HIV-1, virus replication was inhibited. The eIF-5AM13 and eIF-5AM14 proteins blocked Rev trans-activation and Rev-mediated nuclear export.	SANDOZ GMBH,RES INST,DEPT IMMUNODERMATOL,A-1235 VIENNA,AUSTRIA; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Novartis; Sandoz; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Max Planck Society			Schebesta, Michael/B-5891-2008					ANSORGE W, 1982, EXP CELL RES, V140, P31, DOI 10.1016/0014-4827(82)90152-5; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BEVEC D, 1992, P NATL ACAD SCI USA, V89, P9870, DOI 10.1073/pnas.89.20.9870; BEVEC D, 1994, HUM GENE THER, V5, P193, DOI 10.1089/hum.1994.5.2-193; BEVEC D, UNPUB; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; COCHRANE AW, 1990, P NATL ACAD SCI USA, V87, P1198, DOI 10.1073/pnas.87.3.1198; DALY TJ, 1993, BIOCHEMISTRY-US, V32, P10497, DOI 10.1021/bi00090a028; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DALY TJ, 1993, BIOCHEMISTRY-US, V32, P8945, DOI 10.1021/bi00085a028; DOBROVNIK M, UNPUB; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; HAMMERSCHMID M, 1994, J VIROL, V68, P7329, DOI 10.1128/JVI.68.11.7329-7335.1994; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KANG HA, 1994, J BIOL CHEM, V269, P3934; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; MAGDOLEN V, 1994, MOL GEN GENET, V244, P646, DOI 10.1007/BF00282755; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MALIM MH, 1992, J EXP MED, V176, P1197, DOI 10.1084/jem.176.4.1197; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; Pacher A, UNPUB; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1993, BIOFACTORS, V4, P95; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; SADAIE MR, 1988, SCIENCE, V239, P910, DOI 10.1126/science.3277284; SCHWELBERGER HG, 1993, J BIOL CHEM, V268, P14018; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; TERWILLIGER E, 1988, J VIROL, V62, P655, DOI 10.1128/JVI.62.2.655-658.1988; VENKATESH LK, 1990, VIROLOGY, V178, P327, DOI 10.1016/0042-6822(90)90414-M; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WOHL T, 1993, MOL GEN GENET, V241, P305; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	45	174	185	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1858	1860		10.1126/science.271.5257.1858	http://dx.doi.org/10.1126/science.271.5257.1858			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596953				2022-12-28	WOS:A1996UC77800044
J	Reuss, ML; Paneth, N; PintoMartin, JA; Lorenz, JM; Susser, M				Reuss, ML; Paneth, N; PintoMartin, JA; Lorenz, JM; Susser, M			The relation of transient hypothyroxinemia in preterm infants to neurologic development at two years of age	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS SYNDROME; WEIGHT PREMATURE-INFANTS; THYROID-FUNCTION; BIRTH-WEIGHT; TRIIODOTHYRONINE CONCENTRATIONS; FREE-THYROXINE; THYROTROPIN; REPLACEMENT; DEFICIENCY; LESS	Background. Transient hypothyroxinemia, a common finding in premature infants, is not thought to have long-term sequelae or to require treatment. We investigated whether hypothyroxinemia in premature infants is a cause of subsequent motor and cognitive abnormalities. Methods. In this historical cohort study, we retrieved blood thyroxine values, obtained on routine screening in the first week of life, from state screening records of children who weighed 2000 g or less at birth, who were born at 33 weeks' gestation or earlier, and who were enrolled in a population-based study of the late sequelae of neonatal brain hemorrhage. We investigated the relation of these values to the odds for disabling cerebral palsy among 463 subjects for whom data were available and to the mental-development score on the Bayley Scales of Infant Development or the Stanford-Binet Intelligence Scales for Children at the age of two years in 400 subjects. The effects of severe hypothyroxinemia, defined as a blood thyroxine value more than 2.6 SD below the mean for New Jersey newborns, were assessed before and after adjustment for gestational age and potentially confounding variables. Results. In analyses adjusted for gestational age, infants with severe hypothyroxinemia had a risk of disabling cerebral palsy that was nearly 11 times that of infants without hypothyroxinemia (odds ratio, 10.8; 95 percent confidence interval, 3.0 to 39.3) and a mean mental-development score at the age of two that was 15.4 points lower (95 percent confidence interval, 8.1 to 22.6 points) than the mean score of children with normal neonatal blood thyroxine concentrations. After adjustment for gestational age and multiple prenatal, perinatal, and early and late neonatal variables, severe hypothyroxinemia was still associated with an increased risk of disabling cerebral palsy (odds ratio, 4.4; 95 percent confidence interval, 1.0 to 18.6) and a reduction of nearly 7 points (95 percent confidence interval, 0.3 to 13.2 points) in the mental-development score. Conclusions. Severe hypothyroxinemia in preterm infants may be an important cause of problems in neurologic and mental development detected at the age of two years. (C) 1996, Massachusetts Medical Society.	COLUMBIA UNIV, SERGIEVSKY CTR, NEW YORK, NY USA; COLUMBIA UNIV, DEPT OBSTET & GYNECOL, NEW YORK, NY USA; MICHIGAN STATE UNIV, COLL HUMAN MED, PROGRAM EPIDEMIOL, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, COLL HUMAN MED, DEPT PEDIAT & HUMAN GENET, E LANSING, MI 48824 USA; UNIV PENN, SCH NURSING, PHILADELPHIA, PA 19104 USA	Columbia University; Columbia University; Michigan State University; Michigan State University College of Human Medicine; Michigan State University; Michigan State University College of Human Medicine; University of Pennsylvania			Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X	NICHD NIH HHS [HD-30278] Funding Source: Medline; NINDS NIH HHS [NS-20713] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020713] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMATO M, 1989, HORM RES, V32, P213, DOI 10.1159/000181292; Bayley N., 1969, BAYLEY SCALES INFANT; BURROW GN, 1994, NEW ENGL J MED, V331, P1072; CHOWDHRY P, 1984, PEDIATRICS, V73, P301; CUESTAS RA, 1979, J PEDIATR-US, V94, P643, DOI 10.1016/S0022-3476(79)80042-6; Delong G. Robeert, 1993, American Journal of Clinical Nutrition, V57, p286S, DOI 10.1093/ajcn/57.2.286S; DESCORBAR GM, 1987, HORM RES, V26, P12; EGGERMONT E, 1984, HELV PAEDIATR ACTA, V39, P209; ETLING N, 1984, HELV PAEDIATR ACTA, V39, P223; FABRIS N, 1987, J CLIN ENDOCR METAB, V65, P247, DOI 10.1210/jcem-65-2-247; FISHER DA, 1990, PEDIATR CLIN N AM, V37, P1297; FISHER DA, 1981, P SERONO S, V40, P225; FRANKLIN RC, 1986, ARCH DIS CHILD, V61, P589, DOI 10.1136/adc.61.6.589; FUSE Y, 1990, J DEV PHYSIOL, V14, P17; HACK M, 1994, NEW ENGL J MED, V331, P753, DOI 10.1056/NEJM199409223311201; HADEED AJ, 1981, PEDIATRICS, V68, P494; Harkavy K L, 1991, J Perinatol, V11, P117; HENNEMANN G, 1988, Acta Medica Austriaca, V15, P42; HETZEL BS, 1989, J NUTR, V119, P145, DOI 10.1093/jn/119.2.145; JOHN R, 1987, ANN CLIN BIOCHEM, V24, P461, DOI 10.1177/000456328702400506; KARNA P, 1991, AM J PERINAT, V8, P288, DOI 10.1055/s-2007-999399; KLEIN AH, 1979, PEDIATRICS, V63, P380; KOK JH, 1995, PEDIATR RES, V37, pA218; KOOISTRA L, 1994, J PEDIATR-US, V124, P903, DOI 10.1016/S0022-3476(05)83178-6; LEVITON A, 1990, EARLY HUM DEV, V24, P1, DOI 10.1016/0378-3782(90)90002-Z; LUCAS A, 1988, ARCH DIS CHILD, V63, P1201, DOI 10.1136/adc.63.10.1201; MEIJER WJ, 1992, ARCH DIS CHILD, V67, P944, DOI 10.1136/adc.67.7.944; MERCADO M, 1987, CLIN PEDIATR, V26, P343, DOI 10.1177/000992288702600704; MERCADO M, 1988, EARLY HUM DEV, V16, P131, DOI 10.1016/0378-3782(88)90093-X; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; OUDEN ALD, 1996, PEDIATR RES, V39, P142; PHAROAH P, 1981, DEV MED CHILD NEUROL, V23, P76; Pinto-Martin J, 1992, Paediatr Perinat Epidemiol, V6, P273, DOI 10.1111/j.1365-3016.1992.tb00767.x; PINTOMARTIN JA, 1995, PEDIATRICS, V95, P249; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; ROBERTSON CMT, 1992, PEDIATRICS, V90, P750; ROVET J, 1987, J PEDIATR-US, V110, P700, DOI 10.1016/S0022-3476(87)80005-7; SCHONBERGER W, 1981, EUR J PEDIATR, V135, P245, DOI 10.1007/BF00442098; STEIN SA, 1991, ADV EXP MED BIOL, V299, P47; TERM LM, 1972, STANFORD BINET INTEL; TILLOTSON SL, 1994, BRIT MED J, V309, P440, DOI 10.1136/bmj.309.6952.440; VANWASSENAER AG, 1993, ACTA ENDOCRINOL-COP, V129, P139, DOI 10.1530/acta.0.1290139; YUDKIN PL, 1987, EARLY HUM DEV, V15, P45, DOI 10.1016/0378-3782(87)90099-5	43	276	285	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1996	334	13					821	827		10.1056/NEJM199603283341303	http://dx.doi.org/10.1056/NEJM199603283341303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB950	8596548	Bronze			2022-12-28	WOS:A1996UB95000003
J	Staehlin, LA; Hepler, PK				Staehlin, LA; Hepler, PK			Cytokinesis in higher plants	CELL			English	Review							CELLS; TUBULIN		UNIV MASSACHUSETTS,DEPT BIOL,AMHERST,MA 01003; UNIV MASSACHUSETTS,PROGRAM MOLEC & CELLULAR BIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Staehlin, LA (corresponding author), UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309, USA.		Hepler, Peter/C-6320-2013	Hepler, Peter/0000-0003-0320-6912; Staehelin, Andrew/0000-0002-0611-4346				ASADA T, 1994, J CELL SCI, V107, P2249; ASADA T, 1991, NATURE, V350, P238, DOI 10.1038/350238a0; BASKIN TI, 1990, ANNU REV PLANT PHYS, V41, P277, DOI 10.1146/annurev.pp.41.060190.001425; CLEARY AL, 1995, PROTOPLASMA, V185, P152, DOI 10.1007/BF01272855; Gu XJ, 1996, EMBO J, V15, P695, DOI 10.1002/j.1460-2075.1996.tb00405.x; HUSH JM, 1994, J CELL SCI, V107, P775; JURGENS M, 1994, PROTOPLASMA, V183, P86, DOI 10.1007/BF01276816; KAKIMOTO T, 1992, PLANT CELL PHYSIOL, V33, P353; KAKIMOTO T, 1988, Protoplasma Supplementum, V2, P95; LIU B, 1993, J CELL SCI, V104, P1217; Liu B, 1996, PLANT CELL, V8, P119, DOI 10.1105/tpc.8.1.119; LLOYD C, 1995, CURR BIOL, V5, P1085, DOI 10.1016/S0960-9822(95)00216-8; PARKE J, 1986, EUR J CELL BIOL, V41, P9; PIERSON ES, 1996, IN PRESS DEV BIOL; SAMUELS AL, 1995, J CELL BIOL, V130, P1345, DOI 10.1083/jcb.130.6.1345; SAMUELS AL, 1996, IN PRESS PROTOPLASMA; TRAAS J, 1995, NATURE, V375, P676, DOI 10.1038/375676a0; VANTARD M, 1990, P NATL ACAD SCI USA, V87, P8825, DOI 10.1073/pnas.87.22.8825; Wick SM, 1991, CURR OPIN CELL BIOL, V3, P253, DOI 10.1016/0955-0674(91)90149-S; ZHANG D, 1993, CELL MOTIL CYTOSKEL, V24, P151, DOI 10.1002/cm.970240302	20	248	258	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					821	824		10.1016/S0092-8674(00)81060-0	http://dx.doi.org/10.1016/S0092-8674(00)81060-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601305	Bronze			2022-12-28	WOS:A1996UC38100003
J	Anderson, HR; deLeon, AP; Bland, JM; Bower, JS; Strachan, DP				Anderson, HR; deLeon, AP; Bland, JM; Bower, JS; Strachan, DP			Air pollution and daily mortality in London: 1987-92	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TIME-SERIES ANALYSIS; ASSOCIATIONS	Objective-To investigate whether outdoor air pollution levels in London influence daily mortality. Design-Poisson regression analysis of daily counts of deaths, with adjustment for effects of secular trend, seasonal and other cyclical factors, day of the week, holidays, influenza epidemic, temperature, humidity, and autocorrelation, from April 1987 to March 1992. Pollution variables were particles (black smoke), sulphur dioxide, ozone, and nitrogen dioxide, lagged 0-3 days. Setting-Greater London. Outcome measures-Relative risk of death from all causes (excluding accidents), respiratory disease, and cardiovascular disease. Results-Ozone levels (same day) were associated with a significant increase in all cause cardiovascular, and respiratory mortality; the effects were greater in the warm season (April to September) and were independent of the effects of other pollutants. In the warm season an increase of the eight hour ozone concentration from the 10th to the 90th centile of the seasonal range (7-36 ppb) was associated with an increase of 3.5% (95% confidence interval 1.7 to 5.3), 3.6% (1.04 to 6.1), and 5.4% (0.4 to 10.7) in all cause, cardiovascular, and respiratory mortality respectively. Black smoke concentrations on the previous day were significantly associated with all cause mortality, and this effect was also greater in the warm season and was independent of the effects of other pollutants. For black smoke an increase from the 10th to 90th centile in the warm season (7-19 mu g/m(3)) was associated with an increase of 2.5% (0.9 to 4.1) in all cause mortality. Significant but smaller and less consistent effects were also observed for nitrogen dioxide and sulphur dioxide. Conclusion-Daily variations in air pollution within the range currently occurring in London may have an adverse effect on daily mortality.	AEA TECHNOL, NATL ENVIRONM TECHNOL CTR, ABINGDON, OXON, ENGLAND		Anderson, HR (corresponding author), ST GEORGE HOSP, SCH MED, DEPT PUBL HLTH SCI, CRANMER TERRACE, LONDON SW17 0RE, ENGLAND.		de Leon, Antonio C M Ponce/G-5730-2012; Anderson, Hugh R/A-7417-2016	de Leon, Antonio C M Ponce/0000-0002-0704-5215; 				ANDERSON HR, 1995, THORAX, V50, P1188, DOI 10.1136/thx.50.11.1188; BUCK SF, 1960, J ROY STAT SOC B, V22, P302; DELEON AP, IN PRESS J EPIDMEIOL; *DEP HLTH, 1995, NONB PART HLTH; *DEP HLTH ADV GROU, 1992, SULPH DIOX AC AER PA; *DEPT HLTH ADV GRO, 1991, OZ; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72, DOI 10.1165/ajrcmb/4.1.72; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; DOCKERY DW, 1992, ENVIRON RES, V59, P362, DOI 10.1016/S0013-9351(05)80042-8; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; HARRISON RM, 1995, SCI TOTAL ENVIRON, V168, P195, DOI 10.1016/0048-9697(95)04536-A; Health Effects Institute, 1995, PART AIR POLL DAIL M; ITO K, 1993, ARCH ENVIRON HEALTH, V48, P213, DOI 10.1080/00039896.1993.9940362; KATSOUYANNI K, 1995, EUR RESPIR J, V8, P1030; KINNEY P L, 1992, American Review of Respiratory Disease, V145, pA95; KINNEY PL, 1995, INHAL TOXICOL, V7, P59, DOI 10.3109/08958379509014271; KINNEY PL, 1991, ENVIRON RES, V54, P99, DOI 10.1016/S0013-9351(05)80094-5; KUNST AE, 1993, AM J EPIDEMIOL, V137, P331, DOI 10.1093/oxfordjournals.aje.a116680; LAWTHER PJ, 1970, THORAX, V25, P525, DOI 10.1136/thx.25.5.525; LIPPMANN M, 1993, J EXPO ANAL ENV EPID, V3, P103; *LOND RES CTR, 1993, LOND EN STUD; MACFARLANE A, 1978, ENVIRON RES, V15, P332, DOI 10.1016/0013-9351(78)90115-9; MARTIN AE, 1964, P ROY SOC MED, V57, P969, DOI 10.1177/003591576405710P202; MAZUMDAR S, 1982, ARCH ENVIRON HEALTH, V37, P213, DOI 10.1080/00039896.1982.10667567; *MIN HLTH, 1954, REP PUBL HLTH MED SU, V95; MOOLGAVKAR SH, 1995, INHAL TOXICOL, V7, P35, DOI 10.3109/08958379509014269; OSTRO B, 1993, ARCH ENVIRON HEALTH, V48, P336, DOI 10.1080/00039896.1993.9936722; OSTRO B, IN PRESS J EXPO ANAL; POPE CA, 1992, ARCH ENVIRON HEALTH, V47, P211, DOI 10.1080/00039896.1992.9938351; *QUAL URB AIR REV, 1993, URB AIR QUAL UK; *SAS I, 1989, SAS STAT US GUID VER; SCHWARTZ J, 1994, ARCH ENVIRON HEALTH, V49, P366, DOI 10.1080/00039896.1994.9954989; SCHWARTZ J, 1992, AM J EPIDEMIOL, V135, P12, DOI 10.1093/oxfordjournals.aje.a116195; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; SCHWARTZ J, 1990, AM J EPIDEMIOL, V131, P185, DOI 10.1093/oxfordjournals.aje.a115473; SCHWARTZ J, 1992, AM REV RESPIR DIS, V145, P600, DOI 10.1164/ajrccm/145.3.600; SCHWARTZ J, 1993, AM J EPIDEMIOL, V137, P1136, DOI 10.1093/oxfordjournals.aje.a116617; SCHWARTZ J, IN PRESS HLTH CROSSR; SPIX C, 1993, ENVIRON HEALTH PERSP, V101, P518, DOI 10.2307/3431589; *WARR SPRING LAB, 1994, AIR POLL UK 1992 3; ZEGER SL, 1988, BIOMETRIKA, V75, P621	41	209	214	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 16	1996	312	7032					665	669						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597732				2022-12-28	WOS:A1996UB11000022
J	Bates, DW; Komaroff, AL				Bates, DW; Komaroff, AL			A cyberday in the life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1996	275	10					753	754						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY886	8598582				2022-12-28	WOS:A1996TY88600008
J	Macgregor, SH; Hamley, JG; Dunbar, JA; Dodd, TRP; Cromarty, JA				Macgregor, SH; Hamley, JG; Dunbar, JA; Dodd, TRP; Cromarty, JA			Evaluation of a primary care anticoagulant clinic managed by a pharmacist	BRITISH MEDICAL JOURNAL			English	Article									TAYSIDE HLTH BOARD,DUNDEE DD1 9NL,SCOTLAND; ROBERT GORDON UNIV,ABERDEEN AB1 1FR,SCOTLAND	Robert Gordon University	Macgregor, SH (corresponding author), DOWNFIELD SURG,DUNDEE DD3 8NE,SCOTLAND.		Dunbar, James A/G-3034-2012					HALL J, 1994, PHARM J, V252, P230; JENNINGS I, 1991, J CLIN PATHOL, V44, P950, DOI 10.1136/jcp.44.11.950; RADLEY AS, 1995, J CLIN PATHOL, V48, P545, DOI 10.1136/jcp.48.6.545; RADLEY AS, 1994, PHARM J, V252, P91; 1990, J CLIN PATHOL, V43, P177	5	29	31	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					560	560		10.1136/bmj.312.7030.560	http://dx.doi.org/10.1136/bmj.312.7030.560			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595288	Green Published			2022-12-28	WOS:A1996TY88500031
J	Monaghan, G; Ryan, M; Seddon, R; Hume, R; Burchell, B				Monaghan, G; Ryan, M; Seddon, R; Hume, R; Burchell, B			Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome	LANCET			English	Article							CRIGLER-NAJJAR SYNDROME; DRUG-METABOLISM; GLUCURONIDATION; POPULATION; TYPE-2; LIVER	Background The genetic basis of Gilbert's syndrome is ill-defined. This common mild hyperbilirubinaemia sometimes presents as an intermittent jaundice, A reduced hepatic bilirubin UDP-glucuronosyltransferase (UGT) is associated with this syndrome, We have examined variation in the gene encoding the UGT1*1 enzyme and serum bilirubin levels in a Scottish population. Methods Blood was collected from 12 patients with confirmed or suspected Gilbert's syndrome, from 6 members of a family with 4 Gilbert members, and from 77 non-smoking, alcohol-free, drug-free volunteers recruited from the staff of a teaching hospital in Dundee. Polymerase chain reaction amplification was used to examine sequence variation of the promoter upstream of the UGT1*1 exon I, Genotypes were assigned as follows: 6/6 (homozygous for a common allele bearing the sequence [TA](6)TAA), 7/7 (homozygous for a rarer allele with the sequence [TA](7)TAA), and 6/7 (heterozygous with one of each allele). Findings Individuals in the population with the 7/7 genotype had significantly higher bilirubin concentrations than those who had the 6/7 or 6/6 genotype, 14 volunteers underwent a 24 h fasting test to see if they had Gilbert's syndrome, and all four positives had the 7/7 genotype. One confirmed Gilbert's patient, two recurrent jaundice patients (with suspected Gilbert's syndrome), and nine clinically diagnosed cases had the 7/7 genotype. Segregation of the 7/7 genotype with the Gilbert phenotype was also demonstrated in the family with four affected members. The frequency of the 7/7 genotype in this eastern Scottish population was 10-13%. Interpretation In a healthy population there was an association between;variation in bilirubin concentration and a mutation within the gene encoding the enzyme bilirubin UGT, This and other findings suggest the existence of a mild and a more severe form of Gilbert's syndrome, depending on whether the gene defect lies in the promoter sequence upstream of UGT1*I exon I, as here (mild), or in the coding sequence (severe) of the gene.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT CHILD HLTH & OBSTET & GYNAECOL, DUNDEE DD1 9SY, SCOTLAND; N DEVON DIST HOSP, DEPT CHEM PATHOL, BARNSTAPLE, DEVON, ENGLAND	University of Dundee	Monaghan, G (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT BIOCHEM MED, DUNDEE DD1 9SY, SCOTLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AONO S, 1995, LANCET, V345, P958, DOI 10.1016/S0140-6736(95)90702-5; BAILEY A, 1977, LANCET, V1, P931; BOSMA P, 1994, HEPATOLOGY       OCT, pA226; CARULLI N, 1976, GUT, V17, P581, DOI 10.1136/gut.17.8.581; DEMORAIS SMF, 1992, GASTROENTEROLOGY, V102, P577, DOI 10.1016/0016-5085(92)90106-9; EBNER T, 1993, MOL PHARMACOL, V43, P649; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; FEVERY J, 1981, EUR J CLIN INVEST, V11, P417, DOI 10.1111/j.1365-2362.1981.tb02006.x; GOLLAN JL, 1975, GASTROENTEROLOGY, V68, P1543; IDEO G, 1971, EXPERIENTIA, V27, P24, DOI 10.1007/BF02137719; KOIWAI O, 1995, HUM MOL GENET, V4, P1183, DOI 10.1093/hmg/4.7.1183; LASCELLES PT, 1989, DIAGNOSTIC FUNCTION, P24; MACKLON AF, 1979, CLIN PHARMACOKINET, V4, P223, DOI 10.2165/00003088-197904030-00004; MOGHRABI N, 1993, GENOMICS, V18, P171, DOI 10.1006/geno.1993.1451; MOHRABI NN, 1994, THESIS U DUNDEE; OWENS D, 1973, BRIT MED J, V3, P559, DOI 10.1136/bmj.3.5880.559; OWENS D, 1975, J MED GENET, V12, P152, DOI 10.1136/jmg.12.2.152; REAVEN GM, 1994, J INTERN MED, V236, P13; ROSMA PJ, 1995, NEW ENGL J MED, V333, P1171; SUTHERLAND L, 1993, BIOCHEM PHARMACOL, V45, P295, DOI 10.1016/0006-2952(93)90064-4; Thompson R.P.H., 1981, FAMILIAL HYPERBILIRU, P91; WATSON KJR, 1989, BAILLIERE CLIN GASTR, V3, P337, DOI 10.1016/0950-3528(89)90004-3	22	507	528	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 2	1996	347	9001					578	581		10.1016/S0140-6736(96)91273-8	http://dx.doi.org/10.1016/S0140-6736(96)91273-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596320				2022-12-28	WOS:A1996TX69400011
J	Bujan, L; Mansat, A; Pontonnier, F; Mieusset, R				Bujan, L; Mansat, A; Pontonnier, F; Mieusset, R			Time series analysis of sperm concentration in fertile men in Toulouse, France between 1977 and 1992	BRITISH MEDICAL JOURNAL			English	Article							SEMEN CHARACTERISTICS	Objectives-To investigate whether sperm production has changed during the past 16 years in the Toulouse area of France. Design-Time series analysis of sperm donors' specimens between 1977 and 1992. Setting-Sperm bank of university hospital in Toulouse, France. Subjects-302 healthy fertile men candidate sperm donors more than 20 and up to 45 years old and without any infertile brothers. Main outcome measure-Spermatozoa concentration. Results-Donors' mean age at time of donation was 34.05 (SD 5.13), but this increased significantly (P<0.001) during the study, from 32.4 in 1977 to 36 in 1992. Mean sperm count of samples was 83.12 x 10(6)/ml (SD 68.42 x 10(6)/ml). Sperm concentration was positively linked to the year of donation (Pearson's coefficient r = 0.12, P < 0.05), but this correlation disappeared after adjustment for age of donors (r = 0.09, P > 0.05). Conclusion-Sperm concentration has not changed with time in the Toulouse area.	CHU LA GRAVE,CTR STERILITE MASCULINE,F-31052 TOULOUSE,FRANCE; CHU LA GRAVE,CECOS MIDI PYRENEES,F-31052 TOULOUSE,FRANCE	CHU de Toulouse; CHU de Toulouse				Bujan, Louis/0000-0003-1540-0536; Mieusset, Roger/0000-0001-9057-630X				ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; [Anonymous], 1992, ARCH DIS CHILD, V67, P892; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; COUZET P, 1994, ENV FRANCE EDITION 1, P9; DELAMASSA JP, 1994, DG 13 TELECOMMUNICAT, P5; GINSBURG J, 1994, LANCET, V343, P230, DOI 10.1016/S0140-6736(94)91012-X; JOUANNET P, 1981, INT J ANDROL, V4, P440, DOI 10.1111/j.1365-2605.1981.tb00728.x; LAVOUX T, 1994, ENV FRANCE EDITION 1, P216; MICHAL F, 1993, ENVIRON HEALTH PERSP, V101, P159, DOI 10.2307/3431390; MIEUSSET R, 1987, FERTIL STERIL, V48, P1006; MIEUSSET R, 1995, INT J ANDROL, V18, P169, DOI 10.1111/j.1365-2605.1995.tb00408.x; MOLLER H, 1993, EUR UROL, V23, P8; SCHWARTZ D, 1983, FERTIL STERIL, V39, P530; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; STEENO OP, 1984, ANDROLOGIA, V16, P5; TOPPARI J, 1995, MALE REPROD HLTH ENV	17	183	192	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					471	472		10.1136/bmj.312.7029.471	http://dx.doi.org/10.1136/bmj.312.7029.471			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597677	Green Published			2022-12-28	WOS:A1996TX38300021
J	Kenyon, C				Kenyon, C			Ponce d'elegans: Genetic quest for the fountain of youth	CELL			English	Review							CAENORHABDITIS-ELEGANS; MUTANTS; LIFE				Kenyon, C (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							AVERY L, 1993, GENETICS, V133, P897; DMELLO NP, 1994, J BIOL CHEM, V269, P15451; DORMAN JB, 1995, GENETICS, V141, P1399; Finch CE, 1990, LONGEVITY SENESCENCE; FRIEDMAN DB, 1988, GENETICS, V118, P75; GOTTLIEB S, 1994, GENETICS, V137, P107; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KLASS MR, 1983, MECH AGEING DEV, V22, P279, DOI 10.1016/0047-6374(83)90082-9; LARSEN PL, 1995, GENETICS, V139, P1567; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; Riddle DL., 1988, NEMATODE CAENORHABDI, P393; ROSE MR, 1984, CAN J ZOOL, V62, P1661, DOI 10.1139/z84-243; VOWELS JJ, 1992, GENETICS, V130, P105; WONG A, 1995, GENETICS, V139, P1247	16	48	54	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					501	504		10.1016/S0092-8674(00)81024-7	http://dx.doi.org/10.1016/S0092-8674(00)81024-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598036	Bronze			2022-12-28	WOS:A1996TX17600002
J	Kim, SS; Dallmann, HG; McHenry, CS; Marians, KJ				Kim, SS; Dallmann, HG; McHenry, CS; Marians, KJ			Coupling of a replicative polymerase and helicase: A tau-DnaB interaction mediates rapid replication fork movement	CELL			English	Article							COORDINATED LEADING-STRAND; ESCHERICHIA-COLI; III HOLOENZYME; PROTEIN; PURIFICATION; IDENTIFICATION; MECHANISM; SUBUNITS; TEMPLATE; SIZE	The E. coli replication fork synthesizes DNA at the rate of nearly 1000 nt/s. We show here that an interaction between the tau subunit of the replicative polymerase (the DNA polymerase III holoenzyme) and the replication fork DNA helicase (DnaB) is required to mediate this high rate of replication fork movement. In the absence of this interaction, the polymerase follows behind the helicase at a rate equal to the slow (similar to 35 nt/s) unwinding rate of the helicase alone, whereas upon establishing a tau-DnaB contact, DnaB becomes a more effective helicase, increasing its translocation rate by more than 10-fold. This finding establishes the existence of both a physical and communications link between the two major replication machines in the replisome: the DNA polymerase and the primosome.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,GRAD PROGRAM MOL BIOL,DENVER,CO 80262; MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Memorial Sloan Kettering Cancer Center	Kim, SS (corresponding author), CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOL BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036255, R37GM034557, R01GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34557, GM36255] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; CHANDLER M, 1975, J MOL BIOL, V94, P127, DOI 10.1016/0022-2836(75)90410-6; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DRAKE JW, 1969, NATURE, V221, P1128, DOI 10.1038/2211128a0; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; Kim S, 1996, J BIOL CHEM, V271, P4315; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6561; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MCMACKEN R, 1978, J BIOL CHEM, V253, P3313; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MOK M, 1987, J BIOL CHEM, V262, P16644; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; REEMS JA, 1995, J BIOL CHEM, V270, P5606, DOI 10.1074/jbc.270.10.5606; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TOUGU K, 1994, J BIOL CHEM, V269, P4675; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054	35	294	295	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					643	650		10.1016/S0092-8674(00)81039-9	http://dx.doi.org/10.1016/S0092-8674(00)81039-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598050	hybrid			2022-12-28	WOS:A1996TX17600016
J	Bobak, M; Marmot, M				Bobak, M; Marmot, M			East-West mortality divide and its potential explanations: Proposed research agenda	BRITISH MEDICAL JOURNAL			English	Article							AIR-POLLUTION; MEDICAL-CARE; TOBACCO; GERMANY; HEALTH; EUROPE; CANCER; POLAND; ERFURT; CZECH	There is a sharp divide in mortality between eastern and western Europe, which has largely developed over the past three decades and is caused mainly by chronic diseases in adulthood. The difference in life expectancy at birth between the best and worst European countries in this respect is more than 10 years for both sexes, The reasons for these differences in mortality are not clear and data currently available permit only speculation. The contributions of medical care and pollution are likely to be modest; health behaviour, diet, and alcohol consumption seem to be more important; smoking seems to have the largest impact. There is also evidence that psychosocial factors are less favourable in eastern Europe. Available data show socioeconomic gradients in all cause mortality within eastern European countries similar to those in the West. Determinants of the mortality gap between eastern and western Europe are probably related to the contrast in their social environments and may be similar to those underlying the social gradients in mortality within countries.	UCL, SCH MED, INT CTR HLTH & SOC, LONDON WC1E 6BT, ENGLAND	University of London; University College London; UCL Medical School	Bobak, M (corresponding author), UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, MORTIMER ST, LONDON WC1E 6BT, ENGLAND.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419; Bobak, Martin/0000-0002-2633-6851	Medical Research Council [G8802774] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		[Anonymous], 1989, WORLD HLTH STAT ANN, P27; BOBAK M, 1992, LANCET, V340, P1010, DOI 10.1016/0140-6736(92)93017-H; BOBAK M, 1992, HEALTH POLICY PLANN, V7, P234, DOI 10.1093/heapol/7.3.234; Bobak M, 1995, EUR J PUBLIC HEALTH, V5, P82; BOSMA JHA, 1994, CROSS CULTURAL COMP; BOYS RJ, 1991, BMJ-BRIT MED J, V303, P879, DOI 10.1136/bmj.303.6807.879; BRAJCZEWSKI C, 1993, AM J HUM BIOL, V5, P461, DOI 10.1002/ajhb.1310050410; CHENET L, IN PRESS EUROPEAN J; Doll R, 1981, THE CAUSES OF CANCER; GEY KF, 1991, AM J CLIN NUTR S, V53, P326; Hajdu P., 1995, EUR J PUBLIC HEALTH, V5, P259, DOI [DOI 10.1093/EURPUB/5.4.259, 10.1093/eurpub/5.4.259]; HERTZMAN C, 1995, 12270 ECA WORLD BANK; JAKUBOWSKI M, 1991, AIR POLLUTION CENTRA, P47; JEDRYCHOWSKI W, 1990, J EPIDEMIOL COMMUN H, V44, P114, DOI 10.1136/jech.44.2.114; Kingkade W. Ward, 1992, World Health Statistics Quarterly, V45, P15; KRZYZANOWSKI M, 1982, J EPIDEMIOL COMMUN H, V36, P262, DOI 10.1136/jech.36.4.262; Krzyzanowski Michal, 1991, Public Health Reviews, V19, P73; KUBIK AK, 1995, CANCER, V75, P2452, DOI 10.1002/1097-0142(19950515)75:10<2452::AID-CNCR2820751010>3.0.CO;2-E; LAVECCHIA C, 1993, CANCER DETECT PREV, V17, P495; Lehto J, 1993, World Health Stat Q, V46, P195; LIVESEY G, 1991, EUR J CLIN NUTR, V45, P1; Loewel H., 1993, Circulation, V88, P2524; Nanda A, 1993, World Health Stat Q, V46, P158; OSTRO B, 1993, ARCH ENVIRON HEALTH, V48, P336, DOI 10.1080/00039896.1993.9936722; Ostro B, 1994, 1301 WORLD BANK; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; Piha T, 1993, World Health Stat Q, V46, P188; PREKER A., 1994, LABOR MARKETS SOCIAL, P288; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; SALA J, 1995, EUR HEART J, V16, P779, DOI 10.1093/oxfordjournals.eurheartj.a060996; SHKOLNIKOV V, 1995, POPULATION, V4, P907; SPIX C, 1993, ENVIRON HEALTH PERSP, V101, P518, DOI 10.2307/3431589; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STERLING TD, 1993, AM J EPIDEMIOL, V138, P128, DOI 10.1093/oxfordjournals.aje.a116835; STEWART AW, 1994, INT J EPIDEMIOL, V23, P505; UEMURA K, 1988, World Health Statistics Quarterly, V41, P155; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; WINKLER G, 1992, ANN NUTR METAB, V36, P219, DOI 10.1159/000177721; WNUKLIPINSKI E, 1990, SOC SCI MED, V31, P833, DOI 10.1016/0277-9536(90)90019-O; 1993, 1993 WORLD BANK; 1994, 2 UNICEF UN CHILDR F; 1995, HLTH EUROPE; 1992, LANCET, V340, P821	43	267	270	0	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 17	1996	312	7028					421	425						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TW564	8601115				2022-12-28	WOS:A1996TW56400026
J	Carolei, A; Marini, C; Motolese, M				Carolei, A; Marini, C; Motolese, M			Multicentre Acute Stroke Trial - Italy	LANCET			English	Letter											Carolei, A (corresponding author), UNIV LAQUILA,DIPARTIMENTO MED INTERNA & SANITA PUBL,I-67100 LAQUILA,ITALY.		Marini, Carla/AAC-2413-2022	Marini, Carla/0000-0002-9212-2691				[Anonymous], 1986, Lancet, V1, P397; Multicentre Acute Stroke Trial-Italy Group, 1995, LANCET, V346, P1509; TOGNONI G, 1995, LANCET, V346, P1515, DOI 10.1016/S0140-6736(95)92050-1; 1995, NEW ENGL J MED, V333, P1581	4	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					392	392						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598713				2022-12-28	WOS:A1996TU69500040
J	Collinge, J; Rossor, M				Collinge, J; Rossor, M			A new variant of prion disease	LANCET			English	Editorial Material							CREUTZFELDT-JAKOB DISEASE		ST MARYS HOSP TRUST,DEPT NEUROL,LONDON,ENGLAND; NATL HOSP NEUROL & NEUROSURG,DEMENTIA RES GRP,LONDON WC1N 3BG,ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Collinge, J (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOL GENET,LONDON W2 1PG,ENGLAND.		Rossor, Martin/C-1598-2008	Rossor, Martin/0000-0001-8215-3120				BATEMAN D, 1995, LANCET, V346, P1155, DOI 10.1016/S0140-6736(95)91828-0; BRITTON TC, 1995, LANCET, V346, P1155, DOI 10.1016/S0140-6736(95)91827-2; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; SMITH PEM, 1995, LANCET, V346, P898, DOI 10.1016/S0140-6736(95)92734-4; Zeidler M, 1996, BRIT MED J, V312, P844	7	71	72	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1996	347	9006					916	917		10.1016/S0140-6736(96)91407-5	http://dx.doi.org/10.1016/S0140-6736(96)91407-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598749				2022-12-28	WOS:A1996UD59100002
J	RamirezLatorre, J; Yu, CR; Qu, X; Perin, F; Karlin, A; Role, L				RamirezLatorre, J; Yu, CR; Qu, X; Perin, F; Karlin, A; Role, L			Functional contributions of alpha 5 subunit to neuronal acetylcholine receptor channels	NATURE			English	Article							ANTISENSE OLIGONUCLEOTIDES; GENE FAMILY; EXPRESSION; SUBTYPES; LIGAND	LIGAND-GATED ion channels are multi-subunit complexes where each subunit-type is encoded by several related genes. Heterologous expression of any one of the neuronal nicotinic acetylcholine receptors (nAChR) alpha-type subunits, either alone or with any beta-type subunit, typically yields functional nAChR channels(1-5). A striking exception is the nAChR alpha 5 subunit: although apparently complexed with beta 2 and beta 4 nAChR subunits in neurons(6-8), and expressed in a subset of neurons within the central and peripheral nervous systems(9,10), heterologous expression of alpha 5, either alone or with any beta-type subunit has failed to yield functional channels(1.11). We demonstrate here that alpha 5 does participate in nAChRs expressed in heterologous systems and in primary neurons, and further that alpha 5 contributes to the lining of functionally unique nAChR channels, but only if coexpressed with both another alpha- and beta-type subunit. Furthermore, channels containing the alpha 5 subunit are potently activated and desensitized by nanomolar concentrations of nicotine.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,ECOLE NORMALE SUPER,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR MOL RECOGNIT,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University			Role, LW/Q-7371-2018	Role, LW/0000-0001-5851-212X; KARLIN, ARTHUR/0000-0002-4813-752X				ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; BALLIVET M, 1988, NEURON, V1, P847, DOI 10.1016/0896-6273(88)90132-8; BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763; BRUSSAARD AB, 1994, PFLUG ARCH EUR J PHY, V429, P27, DOI 10.1007/BF02584027; CHEN J, 1995, BIOPHYS J, V69, P849, DOI 10.1016/S0006-3495(95)79959-3; COHEN BN, 1992, J GEN PHYSIOL, V100, P373, DOI 10.1085/jgp.100.3.373; CONROY WG, 1992, NEURON, V9, P679, DOI 10.1016/0896-6273(92)90031-8; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; GERZANICH V, 1994, MOL PHARMACOL, V45, P212; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEINEMANN S, 1991, CLIN NEUROPHARMACOL, V14, pS45, DOI 10.1097/00002826-199114001-00007; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; LISTERUD M, 1991, SCIENCE, V254, P1518, DOI 10.1126/science.1720573; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; VERNALLIS AB, 1993, NEURON, V10, P451, DOI 10.1016/0896-6273(93)90333-M; VILLARROEL A, 1992, BIOPHYS J, V62, P196, DOI 10.1016/S0006-3495(92)81805-2; WADA E, 1990, BRAIN RES, V526, P45, DOI 10.1016/0006-8993(90)90248-A; WINKLER J, 1995, NATURE, V375, P484, DOI 10.1038/375484a0; YU C, 1993, DEV GENET, V14, P296, DOI 10.1002/dvg.1020140407	28	319	320	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					347	351		10.1038/380347a0	http://dx.doi.org/10.1038/380347a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598930				2022-12-28	WOS:A1996UC37900061
J	Lee, CG; Parikh, V; Itsukaichi, T; Bae, K; Edery, I				Lee, CG; Parikh, V; Itsukaichi, T; Bae, K; Edery, I			Resetting the Drosophila clock by photic regulation of PER and a PER-TIM complex	SCIENCE			English	Article							MESSENGER-RNA LEVELS; CIRCADIAN CLOCK; SUPRACHIASMATIC NUCLEUS; PROTEIN-SYNTHESIS; MOSAIC ANALYSIS; VISUAL-SYSTEM; GENE-PRODUCT; RHYTHMS; LIGHT; MELANOGASTER	Circadian clocks can be reset by light stimulation. To investigate the mechanism of this phase shifting, the effects of light pulses on the protein and messenger RNA products of the Drosophila clock gene period (per) were measured. Photic stimuli perturbed the timing of the PER protein and messenger RNA cycles in a manner consistent with the direction and magnitude of the phase shift. In addition, the recently identified clock protein TIM (for timeless) interacted with PER in vivo, and this association was rapidly decreased by light. This disruption of the PER-TIM complex in the cytoplasm was accompanied by a delay in PER phosphorylation and nuclear entry and disruption in the nucleus by an advance in PER phosphorylation and disappearance. These results suggest a mechanism for how a unidirectional environmental signal elicits a bidirectional clock response.	RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,DEPT MOLEC BIOL & BIOCHEM,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,GRAD PROGRAM MOLEC GENET & MICROBIOL,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,DEPT BIOL SCI,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick								ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; DUNLAP JC, 1988, P NATL ACAD SCI USA, V85, P1096, DOI 10.1073/pnas.85.4.1096; DUSHAY MS, 1990, GENETICS, V125, P557; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EWER J, 1992, J NEUROSCI, V12, P3321; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; HALL JC, 1987, TRENDS GENET, V3, P185, DOI 10.1016/0168-9525(87)90231-9; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HSTINGS JW, 1991, NEURAL INTEGRATIVE A, P435; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; KHALSA SBS, 1992, P NATL ACAD SCI USA, V89, P10862, DOI 10.1073/pnas.89.22.10862; KONOPKA R, 1983, MOL GEN GENET, V190, P284, DOI 10.1007/BF00330652; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; Lee C., UNPUB; LEVINE JD, 1994, NEURON, V13, P967, DOI 10.1016/0896-6273(94)90262-3; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; RUTILA JE, 1992, J NEUROGENET, V8, P101, DOI 10.3109/01677069209084155; SAUNDERS DS, 1994, J INSECT PHYSL, V40, P947; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; YOUNG MW, 1989, NEURONAL CELLULAR OS, P529; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZERR DM, 1990, J NEUROSCI, V10, P2749	39	229	236	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1740	1744		10.1126/science.271.5256.1740	http://dx.doi.org/10.1126/science.271.5256.1740			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596938				2022-12-28	WOS:A1996UB15100051
J	Hedstrom, J; Korvuo, A; Kenkimaki, P; Tikanoja, S; Haapiainen, R; Kivilaakso, E; Stenman, UH				Hedstrom, J; Korvuo, A; Kenkimaki, P; Tikanoja, S; Haapiainen, R; Kivilaakso, E; Stenman, UH			Urinary trypsinogen-2 test strip for acute pancreatitis	LANCET			English	Article							ENZYMES	Background A simple, rapid test that is specific and sensitive enough to distinguish, in patients with clinically suspected acute pancreatitis, those whose abdominal pain is indeed of pancreatic origin has proved elusive. Methods In two consecutive series of surgical patients in a teaching hospital, whose acute abdominal pain turned out to be due to acute pancreatitis (n=57) or extrapancreatic in origin (n=40), we studied urinary trypsinogen-2 in two ways. A test strip, incorporating monoclonal antibodies to two epitopes on trypsinogen-2, recorded a blue line when concentrations exceeded 50 mu g/L; we also measured trypsinogen-2 concentrations in the laboratory. Findings In the patients with acute pancreatitis the test strip was positive in 52 and negative in five, whereas in the 40 extrapancreatic controls there were four false positives. In a further set of 57 orthopaedic controls, one urine was strip-test positive. Concentrations of urinary trypsinogen-2 and the test-strip results were in good agreement and in only three of the 154 patients were the two approaches discrepant, at the 50 mu g/L cut-off. Interpretation These findings, in patients whose acute abdominal pain was known to be pancreatic in origin or not, are encouraging but need to be confirmed in a consecutive series of patients in whom the diagnosis of pancreatitis is in doubt.	UNIV HELSINKI,CENT HOSP,DEPT CLIN CHEM,SF-00290 HELSINKI,FINLAND; MEDIX BIOCHEM,HELSINKI,FINLAND; HELSINKI UNIV HOSP,DEPT SURG 2,SF-00170 HELSINKI,FINLAND	University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital								CLAVIEN PA, 1989, BRIT J SURG, V76, P1234, DOI 10.1002/bjs.1800761205; CORFIELD AP, 1985, LANCET, V2, P403; CORFIELD AP, 1985, GUT, V26, P724, DOI 10.1136/gut.26.7.724; GUNN IR, 1986, LANCET, V1, P1161; HEDSTROM J, 1994, CLIN CHEM, V40, P1761; HOLDSWORTH PJ, 1984, BRIT J SURG, V71, P958, DOI 10.1002/bjs.1800711215; ITKONEN O, 1990, J LAB CLIN MED, V115, P712; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MAYER AD, 1985, NEW ENGL J MED, V312, P399, DOI 10.1056/NEJM198502143120703; OHLSSON K, 1975, GASTROENTEROLOGY, V69, P668; Thomson H J, 1987, J R Coll Surg Edinb, V32, P348	11	65	70	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					729	731		10.1016/S0140-6736(96)90078-1	http://dx.doi.org/10.1016/S0140-6736(96)90078-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8602003				2022-12-28	WOS:A1996TZ98200011
J	Palmer, SR; Biffin, AH; Craig, PS; Walters, TM				Palmer, SR; Biffin, AH; Craig, PS; Walters, TM			Control of hydatid disease in Wales	BRITISH MEDICAL JOURNAL			English	Article							ECHINOCOCCUS-GRANULOSUS; CONTROL SCHEME; DOGS	Objectives-To evaluate the success of the south Powys hydatid control progamme by analysis of trends in cystic disease in humans and sheep and dog infestation. Design-A review of hospital admissions for human hydatid disease in 1984-90, abattoir prevalence surveys of hydatid cysts in adult sheep, arecoline acetarsol and coproantigen surveys of prevalence of Echinococcus infestation in dogs. Setting-All hospitals in England and Wales, three abattoirs, and dog populations in mid and south east Wales. Subjects-Residents of England and Wales admitted to hospital between 1984 and 1990 with a new diagnosis of human hydatid disease (International Classification of Diseases (ICD), ninth revision, code 122) acquired in the United Kingdom. Results-The average annual incidence of human hydatid disease in Powys, mid-Wales, fell from 3.9x10(-5) in 1974-83 to 2.3x10(-5) in 1984-90. Age specific incidence rates in Wales declined over this period only in children, and no cases occurred in children (<15 years) in Powys. Two Welsh children who lived in Gwent and mid-Glamorgan were infected. Prevalence of hydatid cysts in old sheep from south Wales declined during the control period, but in 1993 prevalence of cysts was 13%. Prevalence of E granulosus infestation was zero in the control area in 1993, but it was 2.4% in Powys dogs outside the control area in 1989 and 9.2% in dogs in Gwent in 1991. Conclusions-Human hydatid disease has been successfully controlled in south Powys but cystic echinococcosis is still endemic in sheep in mid-Wales, and there is a focus of infection in humans, sheep, and dogs in the bordering areas of Gwent and mid-Glamorgan. There is considerable potential for an upsurge in human cases if control measures are relaxed.	UNIV SALFORD,DEPT BIOL SCI,SALFORD M5 4WT,LANCS,ENGLAND; HLTH PROMOT UNIT,POWYS HLTH PROMOT,BRECON LD3 0LS,POWYS,WALES	University of Salford	Palmer, SR (corresponding author), CTR COMMUNICABLE DIS SURVEILLANCE,WELSH UNIT,PUBL HLTH LAB SERV,ABTON HOUSE,CARDIFF CF4 3QX,S GLAM,WALES.							ALLAN JC, 1992, PARASITOLOGY, V104, P347, DOI 10.1017/S0031182000061801; BARONET D, 1994, ANN TROP MED PARASIT, V88, P482; CRAIG PS, 1995, VET PARASITOL, V56, P293, DOI 10.1016/0304-4017(94)00680-B; FRNACIS B, 1993, GLIM SYSTEM RELEASE; GEMMELL MA, 1981, FAO UNEP WHO GUIDELI; LLOYD S, 1991, VET REC, V129, P73, DOI 10.1136/vr.129.4.73; PALMER SR, 1987, EPIDEMIOL INFECT, V99, P693, DOI 10.1017/S0950268800066553; SWAN AV, 1991, OXFORD TXB PUBLIC HL, V2; THOMAS TDL, 1966, THESIS LIVERPOOL U; WALTERS TMH, 1986, J SMALL ANIM PRACT, V27, P693, DOI 10.1111/j.1748-5827.1986.tb03769.x; WALTERS TMH, 1992, VET REC, V131, P39, DOI 10.1136/vr.131.2.39; WALTERS TMH, 1978, VET REC, V102, P257, DOI 10.1136/vr.102.12.257; WALTERS TMH, 1980, VET PARASITOL, V7, P185, DOI 10.1016/0304-4017(80)90022-9	13	32	33	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					674	675						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597734	Green Published			2022-12-28	WOS:A1996UB11000024
J	Mollon, JD; Perkins, AJ				Mollon, JD; Perkins, AJ			Errors of judgement at Greenwich in 1796	NATURE			English	Editorial Material									UNIV LIB,DEPT MANUSCRIPTS & UNIV ARCH,ROYAL GREENWICH OBSERV ARCH,CAMBRIDGE CB3 9DR,ENGLAND		Mollon, JD (corresponding author), UNIV CAMBRIDGE,DEPT EXPTL PSYCHOL,DOWNING ST,CAMBRIDGE CB2 3EB,ENGLAND.		Mollon, John/U-2631-2019; Mollon, John/C-3520-2009	Mollon, John/0000-0001-8533-033X; Mollon, John/0000-0001-8533-033X				Bessel FW, 1822, ASTRONOMISCHE BEOBAC; Boring E.G., 1950, CENTURY; BROOKS GP, 1979, J ROY ASTRON SOC CAN, V73, P9; Duncombe RL, 1945, POP ASTRON, V53, P63; Duncombe RL, 1945, POP ASTRON, V53, P110; Duncombe RL, 1945, POP ASTRON, V53, P2; Fodor J. A., 1974, PSYCHOL LANGUAGE; HESSEL PA, 1986, INT J EPIDEMIOL, V15, P122, DOI 10.1093/ije/15.1.122; MASKELYNE N, 1799, ASTRONOMICAL OSERVAT; *NORW CIT LIBR, 1736, BUR REG PAR ST PET M; REEVES A, 1986, PSYCHOL REV, V93, P180, DOI 10.1037/0033-295X.93.2.180; ROSE GA, 1964, LANCET, V1, P296; SAFFORD TH, 1896, MON NOT R ASTRON SOC, V57, P504; Sanford E. C., 1888, AM J PSYCHOL, V2, P3; Schaffer Simon, 1988, SCI CONTEXT, V2, P115, DOI DOI 10.1017/S026988970000051X; STERNBERG S, 1971, 71122117 BELL LAB; TITCHENER EB, 1908, LECT EL PSYCH FEEL A; VONLINDENAU BA, 1816, Z ASTR VERWANDTE WIS, V2, P199; Wundt W., 1880, GRUNDZUGE PHYSL PSYC; [No title captured]; 1802, BURY NORWICH POST NO	21	40	41	1	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					101	102		10.1038/380101a0	http://dx.doi.org/10.1038/380101a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600377				2022-12-28	WOS:A1996TZ97800020
J	Campbell, KHS; McWhir, J; Ritchie, WA; Wilmut, I				Campbell, KHS; McWhir, J; Ritchie, WA; Wilmut, I			Sheep cloned by nuclear transfer from a cultured cell line	NATURE			English	Article							EMBRYOS; TRANSPLANTATION	Nuclear transfer has been used in mammals as both a valuable tool in embryological studies(1) and as a method for the multiplication of 'elite' embryos(2-4). Offspring have only been reported when early embryos, or embryo-derived cells during primary culture, were used as nuclear donors(5,6). Here we provide the first report, to our knowledge, of live mammalian offspring following nuclear transfer from an established cell line. Lambs were born after cells derived from sheep embryos, which had been cultured for 6 to 13 passages, were induced to quiesce by serum starvation before transfer of their nuclei into enucleated oocytes. Induction of quiescence in the donor cells may modify the donor chromatin structure to help nuclear reprogramming and allow development. This approach will provide the same powerful opportunities for analysis and modification of gene function in livestock species that are available in the mouse through the use of embryonic stem cells(7).			Campbell, KHS (corresponding author), ROSLIN INST EDINBURGH, ROSLIN EH25 9PS, MIDLOTHIAN, SCOTLAND.							BONDIOLI KR, 1990, THERIOGENOLOGY, V33, P165, DOI 10.1016/0093-691X(90)90607-U; BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284; BUCHANAN FC, 1994, ANIM GENET, V25, P60, DOI 10.1111/j.1365-2052.1994.tb00069.x; CAMPBELL KHS, 1994, BIOL REPROD, V50, P1385, DOI 10.1095/biolreprod50.6.1385; CAMPBELL KHS, 1993, BIOL REPROD, V49, P933, DOI 10.1095/biolreprod49.5.933; CHESNE P, 1993, CR ACAD SCI III-VIE, V316, P487; COLLAS P, 1994, MOL REPROD DEV, V38, P264, DOI 10.1002/mrd.1080380306; Galli C., 1994, Zygote, V2, P385; Gerfen RW, 1995, ANIM BIOTECHNOL, V6, P1, DOI 10.1080/10495399509525828; HOOPER ML, 1992, EMBRYONAL STEM CELLS; MCGRATH J, 1983, SCIENCE, V220, P1300, DOI 10.1126/science.6857250; PIEDRAHITA JA, 1990, THERIOGENOLOGY, V34, P879, DOI 10.1016/0093-691X(90)90559-C; PRATHER RS, 1990, INT REV CYTOL, V120, P169; SIMS M, 1994, P NATL ACAD SCI USA, V91, P6143, DOI 10.1073/pnas.91.13.6143; SZOLLOSI D, 1988, J CELL SCI, V91, P603; WHITFIELD JF, 1985, CONTROL ANIMAL CELL, V1, P331; WHITTEN WK, 1968, J REPROD FERTIL, V17, P399, DOI 10.1530/jrf.0.0170399; WILLADSEN SM, 1986, NATURE, V320, P63, DOI 10.1038/320063a0	18	1254	1466	4	227	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1996	380	6569					64	66		10.1038/380064a0	http://dx.doi.org/10.1038/380064a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598906				2022-12-28	WOS:A1996TY87700056
J	Feher, MD; Simms, JP; Lant, AF				Feher, MD; Simms, JP; Lant, AF			History of chickenpox and steroid cards: A new warning?	BRITISH MEDICAL JOURNAL			English	Article									CHELSEA & WESTMINSTER HOSP,DEPT PHARM,LONDON SW10 9NH,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT PHARM,LONDON SW3 6LX,ENGLAND	Imperial College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Feher, MD (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT CLIN PHARMACOL & THERAPEUT,LONDON SW10 9NH,ENGLAND.							*COMM SAF MED, 1994, CURR PROBL PHARM, V20; *DEP HLTH, 1994, CORT VAR ZOST VIR CM; DOWELL SF, 1993, PEDIATRICS, V92, P223; RICE P, 1994, BRIT MED J, V309, P1069, DOI 10.1136/bmj.309.6961.1069	4	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					542	543		10.1136/bmj.312.7030.542	http://dx.doi.org/10.1136/bmj.312.7030.542			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595283	Green Published			2022-12-28	WOS:A1996TY88500023
J	Steuer, A; Seemungal, BM; Grenfell, A				Steuer, A; Seemungal, BM; Grenfell, A			A hot ankle	LANCET			English	Article											Steuer, A (corresponding author), CENT MIDDLESEX HOSP,DEPT DIABET,LONDON NW10 7NS,ENGLAND.			Seemungal, Barry/0000-0002-6578-0904				JACOBELLI S, 1973, ANN INTERN MED, V79, P340, DOI 10.7326/0003-4819-79-3-340; KATZ RS, 1977, MEDICINE, V56, P151, DOI 10.1097/00005792-197703000-00005; MCKOWN KM, 1994, SOUTHERN MED J, V87, P845, DOI 10.1097/00007611-199408000-00021; THOMPSON KS, 1989, J RHEUMATOL, V16, P166	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					586	586		10.1016/S0140-6736(96)91276-3	http://dx.doi.org/10.1016/S0140-6736(96)91276-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596323				2022-12-28	WOS:A1996TX69400014
J	Tucker, JS; Hall, MH; Howie, PW; Reid, ME; Barbour, RS; Florey, CD; McIlwaine, GM				Tucker, JS; Hall, MH; Howie, PW; Reid, ME; Barbour, RS; Florey, CD; McIlwaine, GM			Should obstetricians see women with normal pregnancies? A multicentre randomised controlled trial of routine antenatal care by general practitioners and midwives compared with shared care led by obstetricians	BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSION	Objective-To compare routine antenatal care provided by general practitioners and midwives with obstetrician led shared care. Design-Multicentre randomised controlled trial. Setting-51 general practices linked to nine Scottish maternity hospitals. Subjects-1765 women at low risk of antenatal complications. Intervention-Routine antenatal care by general practitioners and midwives according to a care plan and protocols for managing complications. Main outcome measures-Comparisons of health service use, indicators of quality of care, and women's satisfaction. Results-Continuity of carer was improved for the general practitioner and midwife group as the number of carers was less (median 5 carers v 7 for shared care group, P < 0.0001) and the number of routine visits reduced (10.9 v 11.7, P < 0.0001). Fewer women in the general practitioner and midwife group had antenatal admissions (27% (222/834) v 32% (266/840), P < 0.05), non-attendances (7% (57) v 11% (89), P < 0.01) and daycare (12% (102) v 7% (139), P < 0.05) but more were referred (49% (406) v 36% (305), P < 0.0001). Rates of antenatal diagnoses did not differ except that fewer women in the general practitioner and midwife group had hypertensive disorders (pregnancy induced hypertension, 5% (37) v 8% (70), P < 0.01) and fewer had labour induced (18% (149) v 24% (201), P < 0.01). Few failures to comply with the care protocol occurred, but more Rhesus negative women in the general practitioner and midwife group did not have an appropriate antibody check (2.5% (20) v 0.4% (3), P < 0.0001). Both groups expressed high satisfaction with care (68% (453/663) v 65% (430/656), P=0.5) and acceptability of allocated style of care (93% (618) v 94% (624), P=0.6). Access to hospital support before labour was similar (45% (302) v 48% (312) visited labour rooms before giving birth, P=0.6). Conclusion-Routine specialist visits for women initially at low risk of pregnancy complications offer little or no clinical or consumer benefit.	ABERDEEN MATERN HOSP,DEPT OBSTET & GYNAECOL,ABERDEEN AB9 2ZA,SCOTLAND; UNIV DUNDEE,DEPT OBSTET & GYNAECOL,DUNDEE,SCOTLAND; UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW G12 8RZ,LANARK,SCOTLAND; UNIV GLASGOW,DEPT SOCIAL & ECON RES,GLASGOW G12 8RZ,LANARK,SCOTLAND; UNIV HULL,DEPT PUBL HLTH MED,KINGSTON HULL HU6 7RX,N HUMBERSIDE,ENGLAND; GREATER GLASGOW HLTH BOARD,DEPT PUBL HLTH,GLASGOW G2 4JT,LANARK,SCOTLAND	University of Aberdeen; University of Dundee; University of Glasgow; University of Glasgow; University of Hull	Tucker, JS (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT EPIDEMIOL & PUBL HLTH,DUNDEE DD1 9SY,SCOTLAND.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				DAWSON A, 1994, HOME ANTENATAL CARE; Dean A. G., 1990, EPI INFO VERSION 5 W; *DEP HLTH SOC SERV, 1982, 1 DHSS MAT SERV ADV; *EXP MAT GROUP, 1993, CHANG CHILDB REP EXP; *GRAMP AR MAT SERV, 1989, GRAMP INT ANT CAR SC; HALL MH, 1980, LANCET, V2, P78; *HC HLTH COMM, 1992, 2 HC HLTH COMM MAT S, V1; Hill A M, 1993, Qual Health Care, V2, P152, DOI 10.1136/qshc.2.3.152; HOFMEYR GJ, 1991, BRIT J OBSTET GYNAEC, V98, P756, DOI 10.1111/j.1471-0528.1991.tb13479.x; JAMES JK, 1995, BRIT MED J, V310, P37; LITTLE BC, 1984, LANCET, V1, P865; MANCIA G, 1983, LANCET, V2, P695; Mason V., 1989, WOMENS EXPERIENCE MA; MCILWAINE GM, 1992, DHHS PUBLICATION PHS, P56; Ministry of Health, 1929, MAT MORT CHILDB ANT; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; Pocock SJ., 2013, CLIN TRIALS PRACTICA; PORTER M, 1984, SOC SCI MED, V19, P1197, DOI 10.1016/0277-9536(84)90370-8; REID M, 1983, COMP DELIVERY ANTENA; ROBERTSON WB, 1987, HYPERTENS PREGNANCY, P101; ROBSON J, 1986, J ROY COLL GEN PRACT, V36, P274; *ROYAL COLL OBST G, 1982, REP RCOG WORK PART A; *SCOTT OFF HOM HLT, 1993, PROV MAT SERV SCOTL; *SPSS INC, 1993, SPSS WIND REL 6; THOMAS H, 1987, J ROY COLL GEN PRACT, V37, P544; TUCKER J, 1994, J PUBLIC HEALTH MED, V16, P60, DOI 10.1093/oxfordjournals.pubmed.a042937; TURNBULL D, 1995, ESTABLISHMENT MIDWIF; WALKER P, 1995, BRIT MED J, V310, P36, DOI 10.1136/bmj.310.6971.36; WOOD J, 1991, BRIT J GEN PRACT, V41, P26	29	65	65	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					554	559		10.1136/bmj.312.7030.554	http://dx.doi.org/10.1136/bmj.312.7030.554			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595287	Green Published			2022-12-28	WOS:A1996TY88500029
J	Jewitt, D; Senay, M; Matthews, H				Jewitt, D; Senay, M; Matthews, H			Observations of carbon monoxide in comet Hale-Bopp	SCIENCE			English	Article							P/HALLEY	The recently discovered comet Hale-Bopp (C/1995 O1) sports a bright dust coma even though it is still far from the sun (presently 6 astronomical units). This feature has attracted considerable interest in the public and scientific arenas. The comet is headed toward perihelion at 0.92 astronomical unit in April 1997 and is widely expected to then become a spectacular naked-eye comet. With millimeter-wave observations, carbon monoxide (CO) has been identified as the driver for the early activity observed in Hale-Bopp.	JOINT ASTRON CTR,HILO,HI 96720; NATL RES COUNCIL CANADA,HERZBERG INST ASTROPHYS,OTTAWA,ON K1A 0R6,CANADA	National Research Council Canada	Jewitt, D (corresponding author), UNIV HAWAII,INST ASTRON,2680 WOODLAWN DR,HONOLULU,HI 96822, USA.							AHEARN MF, 1984, ASTRON J, V89, P579, DOI 10.1086/113552; BAILEY M, UNPUB; BOICE DC, 1993, P DISTANT COMET ACTI, P134; Brown G. N.  Jr., 1980, Advances in Cryogenic Engineering. Vol.25. Proceedings of the 1979 Cryogenic Engineering Conference, P662; CROVISIER J, 1995, ICARUS, V115, P213, DOI 10.1006/icar.1995.1091; CROVISIER J, 1995, 27 ANN M AM ASTR SOC; CROVISIER J, 1983, ASTRON ASTROPHYS, V1223, P61; DAVIES J, 1995, 6225 INT ASTR UN; EBERHARDT P, 1987, ASTRON ASTROPHYS, V187, P481; HICKS M, 1995, 6200 INT ASTR UN; HUEBNER WF, 1992, SOLAR PHOTO RATES PL, P273; Jewitt D., 1990, Astrophysical Journal, V351, P277, DOI 10.1086/168463; JEWITT DC, 1991, COMETS POST HALLEY E, P19; KELLER HU, 1987, ASTRON ASTROPHYS, V187, P807; LUU JX, 1990, ASTRON J, V100, P913, DOI 10.1086/115571; MATTHEWS H, 1995, 6234 INT ASTR UN; MCNAUGHT RH, 1995, 6198 INT ASTR UN; PRIALNIK D, 1989, ADV SPACE RES, V9, P25; RAUER H, 1995, 6236 INT ASTR UN; SAMARASINHA NH, 1994, ICARUS, V108, P103, DOI 10.1006/icar.1994.1044; SCHLOERB FP, 1987, ASTRON ASTROPHYS, V187, P469; SENAY MC, 1994, NATURE, V371, P229, DOI 10.1038/371229a0; WHIPPLE FL, 1950, ASTROPHYS J, V111, P375, DOI 10.1086/145272; WOMACK M, 1995, 6276 INT ASTRON UNIO	24	61	61	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1110	1113		10.1126/science.271.5252.1110	http://dx.doi.org/10.1126/science.271.5252.1110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599086				2022-12-28	WOS:A1996TW70100036
J	Barer, D				Barer, D			Multicentre Acute Stroke Trial - Italy	LANCET			English	Letter											Barer, D (corresponding author), NEWCASTLE GEN HOSP,DEPT GERIATR MED,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND.							BARER DH, IN PRESS EUROPEAN ME; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HORTON R, 1995, LANCET, V346, P1504, DOI 10.1016/S0140-6736(95)92043-9; Multicentre Acute Stroke Trial-Italy Group, 1995, LANCET, V346, P1509; SANDERCOCK P, 1995, LANCET, V346, P1504, DOI 10.1016/S0140-6736(95)92044-7	5	2	2	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					391	392						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598712				2022-12-28	WOS:A1996TU69500039
J	Bennett, JR				Bennett, JR			Altruism and the scientific congress	LANCET			English	Editorial Material									BRITISH SOC GASTROENTEROL,LONDON NW1 4LB,ENGLAND									LLEWELLYNJONES D, 1995, BRIT MED J, V311, P817, DOI 10.1136/bmj.311.7008.817; STANDAERT LO, 1993, GAST INT, P180	2	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					377	378		10.1016/S0140-6736(96)90543-7	http://dx.doi.org/10.1016/S0140-6736(96)90543-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598707				2022-12-28	WOS:A1996TU69500015
J	Offerhaus, GJA				Offerhaus, GJA			Molecular and epidemiological necropsy: Two or a pair?	LANCET			English	Editorial Material											Offerhaus, GJA (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT PATHOL,1105 AZ AMSTERDAM,NETHERLANDS.							AVRAHAMI R, 1995, ARCH SURG-CHICAGO, V130, P407; CALDAS C, 1994, CANCER RES, V54, P3568; CHANDRAMOHAN D, 1994, INT J EPIDEMIOL, V23, P213, DOI 10.1093/ije/23.2.213; DIGIUSEPPE JA, 1994, AM J PATHOL, V144, P889; DUMLER JS, 1991, JAMA-J AM MED ASSOC, V265, P718, DOI 10.1001/jama.265.6.718; HRUBAN RH, 1993, AM J PATHOL, V143, P545; KLEINER DE, 1995, LANCET, V346, P945, DOI 10.1016/S0140-6736(95)91561-3; MCFARLANE MJ, 1987, JAMA-J AM MED ASSOC, V258, P331, DOI 10.1001/jama.258.3.331; OFFERHAUS GJA, 1991, INT J CANCER, V49, P641, DOI 10.1002/ijc.2910490502; WAGNER BM, 1995, MODERN PATHOL, V8, P348	10	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					346	346						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598698				2022-12-28	WOS:A1996TU69500006
J	Collee, JG				Collee, JG			A dreadful challenge	LANCET			English	Editorial Material											Collee, JG (corresponding author), UNIV EDINBURGH,DEPT MED MICROBIOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.							BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; DEALLER S F, 1990, Food Microbiology (London), V7, P253, DOI 10.1016/0740-0020(90)90032-D; GAJDUSEK DC, 1957, NEW ENGL J MED, V257, P974, DOI 10.1056/NEJM195711142572005; KIMBERLIN RH, 1988, J GEN VIROL, V69, P2953, DOI 10.1099/0022-1317-69-12-2953; KIMBERLIN RH, 1990, TOPLEY WILSONS PRINC, V4, P671; PRUSINER SB, 1994, J R COLL PHYSICIAN S, V28, P1; TAYLOR DM, 1993, BRIT MED BULL, V49, P810, DOI 10.1093/oxfordjournals.bmb.a072648; Taylor DM, 1995, TRANSMISSIBLE SPONGI	8	10	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1996	347	9006					917	918						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598750				2022-12-28	WOS:A1996UD59100003
J	Allen, K; Blascovich, J				Allen, K; Blascovich, J			The value of service dogs for people with severe ambulatory disabilities - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SOCIAL ACKNOWLEDGMENTS; DEPRESSION; STRESS; CHILDREN; SUPPORT	Objective.-To assess the value of service dogs for people with ambulatory disabilities. Design.-Randomized, controlled clinical trial. Setting.-Environments of study participants. Participants.-Forty-eight individuals with severe and chronic ambulatory disabilities requiring use of wheelchairs who were recruited from advocacy and support groups for persons with muscular dystrophy, multiple sclerosis, traumatic brain injury, and spinal cord injury. Participants were matched on age, sex, marital status, race, and the nature and severity of the disability in order to create 24 pairs. Within each pair, participants were randomly assigned to either the experimental group or a wait-list control group. Intervention.-Experimental group members received trained-service dogs 1 month after the study began, and subjects in the wait-list control group received dogs in month 13 of the study. Main Outcome Measures.-Dependent variables evaluated were self-reported assessments of psychological well-being, internal locus of control, community integration, school attendance, part-time work status, self-esteem, marital status, living arrangements, and number of biweekly paid and unpaid assistance hours. Data collection occurred every 6 months over a 2-year period, resulting in five data collection points for all subjects. Results.-Significant positive changes in all but two dependent measures were associated with the presence of a service dog both between and within groups (P<.001). Psychologically, all participants showed substantial improvements in self-esteem, internal locus of control, and psychological well-being within 6 months after receiving their service dog. Socially, all participants showed similar improvements in community integration. Demographically, all participants showed increases in school attendance and/or part-time employment. Economically, all participants showed dramatic decreases in the number of both paid and unpaid assistance hours. Conclusions.-Trained service dogs can be highly beneficial and potentially cost-effective components of independent living for people with physical disabilities.	SUNY BUFFALO,DEPT MED,BUFFALO,NY; UNIV CALIF SANTA BARBARA,DEPT PSYCHOL,SANTA BARBARA,CA 93106	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of California System; University of California Santa Barbara								ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; ALLEN KM, 1991, J PERS SOC PSYCHOL, V61, P582, DOI 10.1037/0022-3514.61.4.582; Americans with Disabilities Act, SPRINGER REFERENCE, DOI [10.1007/springerreference_44126, DOI 10.1007/SPRINGERREFERENCE_44126]; BATAVIA AI, 1991, J HEALTH POLIT POLIC, V16, P523, DOI 10.1215/03616878-16-3-523; Bradburn N.M., 1969, STRUCTURE PSYCHOL WE, DOI DOI 10.1037/T10756-000; *CAN COMP IND, 1994, CAN COMP IND PROGR I; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; EATON L, 1994, NY TIMES        0911, P1; EDDY J, 1988, J PSYCHOL, V122, P39, DOI 10.1080/00223980.1988.10542941; EISENBERG MG, 1982, DISABLED PEOPLE 2 CL; FITZPATRICK R, 1991, SOC SCI MED, V33, P605, DOI 10.1016/0277-9536(91)90218-2; FRIEDLAND J, 1992, SOC SCI MED, V34, P395, DOI 10.1016/0277-9536(92)90299-6; HARTMANN C, 1988, Biofactors, V1, P41; KEENAN MP, 1989, CHANGING NEEDS LONG; KINNEY WB, 1992, ARCH PHYS MED REHAB, V73, P863; Kirk Roger, 1982, EXPT DESIGN PROCEDUR, V2nd; LAPLANTE MP, 1989, 1 U CAL I HLTH AG; LITVAK SIMI, 1987, ATTENDING AM PERSONA; MADER B, 1989, CHILD DEV, V60, P1529, DOI 10.1111/j.1467-8624.1989.tb04023.x; MARINELLI RP, 1977, PSYCHOL SOCIAL IMPAC; PAULHUS D, 1983, J PERS SOC PSYCHOL, V44, P1253, DOI 10.1037/0022-3514.44.6.1253; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI DOI 10.1515/9781400876136; TURNER RJ, 1990, J NERV MENT DIS, V178, P343, DOI 10.1097/00005053-199006000-00001; VALENTINE DP, 1993, SOC WORK HEALTH CARE, V19, P109, DOI 10.1300/J010v19n01_07; VARNI JW, 1991, ARCH PHYS MED REHAB, V72, P1053; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; *WORLD I DIS, 1988, REP NAT COUNC HAND M	27	106	107	1	53	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					1001	1006		10.1001/jama.275.13.1001	http://dx.doi.org/10.1001/jama.275.13.1001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UC123	8596231				2022-12-28	WOS:A1996UC12300027
J	Riddington, DW; Venkatesh, B; Boivin, CM; Bonser, RS; Elliot, TSJ; Marshall, T; Mountford, PJ; Bion, JF				Riddington, DW; Venkatesh, B; Boivin, CM; Bonser, RS; Elliot, TSJ; Marshall, T; Mountford, PJ; Bion, JF			Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFLAMMATORY BOWEL-DISEASE; TUMOR NECROSIS FACTOR; GASTROINTESTINAL COMPLICATIONS; CARDIAC OPERATIONS; INTRAMURAL PH; LUNG INJURY; MULTIPLE; ISCHEMIA; HYPOPERFUSION; ABSORPTION	Objective.-To examine the relationship between gastric intramucosal pH, intestinal permeability, endotoxemia, and oxygen delivery in patients undergoing cardiopulmonary bypass (CPB). Design.-Prospective, observational study. Setting.-Tertiary care center. Patients.-Fifty patients undergoing elective cardiac surgery and 10 patients awaiting elective cardiac surgery. Interventions.-Patients received chromium 51-labeled ethylenediaminetetraacetic acid (Cr-51-EDTA) as a marker of intestinal permeability; insertion of a nasogastric tonometer to measure intramucosal pH (pHi); insertion of a pulmonary artery catheter to measure systemic oxygen delivery and consumption variables; arterial blood sampling for plasma endotoxin by the Limulus amebocyte lysate assay; and blood and urine sampling for measurement of Cr-51-EDTA. Main Outcome Measures.-Systemic oxygen delivery, duration of gastric mucosal acidosis, absorption of Cr-51-EDTA, appearance of systemic endotoxemia, renal dysfunction, and duration of hospital stay. Results.-Median (range) 24-hour urinary recovery of Cr-51-EDTA in patients was 10.6% (2.1% to 40.2%) while that in controls was 1.2% (0.7% to 2.0%, P<.001). Intestinal permeability increased during CPB. The median (range) for the lowest pHi after bypass was 6.98 (6.74 to 7.17). The pHi did not decline until CPB was discontinued and the heart took over the load of the circulation. Endotoxin was detectable (>0.2 endotoxin unit per milliliter) in the plasma of 21 patients (42%) during the study, most of whom were endotoxemic by the end of CPB. There was no evident relationship between the degree of gut permeability, endotoxemia, gut ischemia, or systemic oxygen dynamics. Conclusions.-Cardiopulmonary bypass is associated with increases in gut permeability, which precede gut mucosal ischemia. In cardiac surgical patients, a low pHi is not necessarily indicative of an adverse clinical outcome. Endotoxemia as measured by the Limulus amebocyte lysate assay is common. The increased intestinal absorption of Cr-51-EDTA and gastric mucosal acidosis occur as independent phenomena and are not related in severity or time of onset.	UNIV BIRMINGHAM, DEPT ANAESTHESIA & INTENS CARE MED, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; QUEEN ELIZABETH HOSP, DEPT NUCL MED, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; QUEEN ELIZABETH HOSP, DEPT MED MICROBIOL, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; QUEEN ELIZABETH HOSP, CARDIOTHORAC SURG UNIT, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND	University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham			Venkatesh, Bala/F-4700-2010	Bion, Julian/0000-0003-0344-5403; Venkatesh, Bala/0000-0002-3234-5244				AABAKKEN L, 1989, SCAND J GASTROENTERO, V24, P351, DOI 10.3109/00365528909093059; Altman DG, 1991, PRACTICAL STAT MED R, P426; ANDERSEN LW, 1987, J THORAC CARDIOV SUR, V93, P115; BAUE AE, 1975, ARCH SURG-CHICAGO, V110, P779; BERTHIAUME F, 1994, CRIT CARE MED, V22, P455, DOI 10.1097/00003246-199403000-00016; BION JF, 1994, CRIT CARE MED, V22, P40, DOI 10.1097/00003246-199401000-00011; BJARNASON I, 1983, GASTROENTEROLOGY, V85, P318; CARRICO CJ, 1986, ARCH SURG-CHICAGO, V121, P196; DEITCH EA, 1990, ARCH SURG-CHICAGO, V125, P403; DINARELLO CA, 1986, J CLIN INVEST, V77, P1734, DOI 10.1172/JCI112495; ELIA M, 1987, CLIN SCI, V73, P197, DOI 10.1042/cs0730197; FIDDIANGREEN RG, 1987, CRIT CARE MED, V15, P153, DOI 10.1097/00003246-198702000-00015; FIDDIANGREEN RG, 1986, ARCH SURG-CHICAGO, V121, P654; FINE J, 1967, GASTROENTEROLOGY, V52, P454; FINK MP, 1991, ARCH SURG-CHICAGO, V126, P211; FONG YM, 1989, J IMMUNOL, V142, P2321; GIRAUD GD, 1984, J PHARMACOL EXP THER, V230, P214; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; HEARD SO, 1991, CRIT CARE MED, V19, P271, DOI 10.1097/00003246-199102000-00025; HOWDEN CW, 1991, AM J GASTROENTEROL, V86, P1445; KOIKE K, 1992, SURGERY, V112, P173; MARIK PE, 1993, CHEST, V104, P225, DOI 10.1378/chest.104.1.225; MARTINEZPELLUS AE, 1993, CRIT CARE MED, V21, P1684, DOI 10.1097/00003246-199311000-00017; METCHNIKOFF E, 1908, STUDIES OPPORTUNISTI, P309; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MONETA GL, 1985, AM J SURG, V149, P648, DOI 10.1016/S0002-9610(85)80148-3; NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823; OHRI SK, 1991, ANN THORAC SURG, V52, P826, DOI 10.1016/0003-4975(91)91219-L; OHRI SK, 1994, GASTROENTEROLOGY, V106, P318, DOI 10.1016/0016-5085(94)90588-6; PAPA M, 1983, J SURG RES, V35, P264, DOI 10.1016/S0022-4804(83)80013-4; PARSONNET V, 1989, CIRCULATION, V79, P3; PRINS JM, 1994, ANTIMICROB AGENTS CH, V38, P1211, DOI 10.1128/AAC.38.6.1211; RIDDINGTON D, 1994, CRIT CARE MED, V22, P96, DOI 10.1097/00003246-199401000-00019; RIDDINGTON D, 1992, LANCET, V340, P547, DOI 10.1016/0140-6736(92)91742-Q; RIDDINGTON DW, 1994, NUCL MED COMMUN, V15, P257; SOONG CV, 1995, BRIT J SURG, V82, P912, DOI 10.1002/bjs.1800820718; STJOHN RC, 1993, J APPL PHYSIOL, V74, P1994, DOI 10.1152/jappl.1993.74.4.1994; VANDERHULST RRWJ, 1993, LANCET, V341, P1363, DOI 10.1016/0140-6736(93)90939-E; WELLING RE, 1986, ARCH SURG-CHICAGO, V121, P1178; WYATT J, 1993, LANCET, V341, P1437, DOI 10.1016/0140-6736(93)90882-H	40	197	203	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					1007	1012		10.1001/jama.275.13.1007	http://dx.doi.org/10.1001/jama.275.13.1007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC123	8596232				2022-12-28	WOS:A1996UC12300028
J	Skaggs, WE; McNaughton, BL				Skaggs, WE; McNaughton, BL			Replay of neuronal firing sequences in rat hippocampus during sleep following spatial experience	SCIENCE			English	Article							LONG-TERM POTENTIATION; RABBIT FOLLOWING STIMULATION; COMPLEX-SPIKE CELLS; FREELY-MOVING RAT; LASTING POTENTIATION; SYNAPTIC TRANSMISSION; PERFORANT PATH; UNIT-ACTIVITY; THETA-RHYTHM; DENTATE GYRUS	The correlated activity of rat hippocampal pyramidal cells during sleep reflects the activity of those cells during earlier spatial exploration. Now the patterns of activity during sleep have also been found to reflect the order in which the cells fired during spatial exploration. this relation was reliably stronger for sleep after the behavioral session than before it; thus, the activity during sleep reflects changes produced by experience, This memory for temporal order of neuronal firing could be produced by an interaction between the temporal integration properties of long-term potentiation and the phase shifting of spike activity with respect to the hippocampal theta rhythm.			Skaggs, WE (corresponding author), UNIV ARIZONA, ARIZONA RES LABS, DIV NEURAL SYST MEMORY & AGING, TUCSON, AZ 85724 USA.				NIA NIH HHS [AG12609] Funding Source: Medline; NIMH NIH HHS [MH46823] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH046823, R37MH046823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012609, R37AG012609] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSEN P, 1977, NATURE, V266, P736, DOI 10.1038/266736a0; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BROWN TH, 1991, LONG TERM POTENTIATI, P357; BUZSAKI G, 1986, BRAIN RES, V398, P242, DOI 10.1016/0006-8993(86)91483-6; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; Cohen N. J., 1993, MEMORY AMNESIA HIPPO; COLINO A, 1992, J NEUROSCI, V12, P180; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; DOUGLAS RM, 1975, BRAIN RES, V86, P205, DOI 10.1016/0006-8993(75)90697-6; FOX SE, 1981, EXP BRAIN RES, V41, P399; GREENSTEIN YJ, 1988, BRAIN RES, V438, P331, DOI 10.1016/0006-8993(88)91358-3; GUSTAFSSON B, 1986, J NEUROSCI, V6, P1575; LARSON J, 1989, BRAIN RES, V489, P49, DOI 10.1016/0006-8993(89)90007-3; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; LEVY WB, 1979, BRAIN RES, V175, P233, DOI 10.1016/0006-8993(79)91003-5; LEVY WB, 1983, NEUROSCIENCE, V8, P791, DOI 10.1016/0306-4522(83)90010-6; LOMO T, 1966, ACTA PHYSIOL SCAND, VS 68, P128; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MCNAUGHTON BL, 1983, EXP BRAIN RES, V52, P41; MULLER RU, 1987, J NEUROSCI, V7, P1935; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE J, 1979, PROG NEUROBIOL, V13, P419, DOI 10.1016/0301-0082(79)90005-4; OKEEFE J, 1976, EXP NEUROL, V51, P78, DOI 10.1016/0014-4886(76)90055-8; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; OLTON DS, 1978, EXP NEUROL, V58, P387, DOI 10.1016/0014-4886(78)90096-1; PAVLIDES C, 1989, J NEUROSCI, V9, P2907; PAVLIDES C, 1988, BRAIN RES, V439, P383, DOI 10.1016/0006-8993(88)91499-0; RANCK JB, 1973, EXP NEUROL, V41, P462, DOI 10.1016/0014-4886(73)90290-2; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SKAGGS WE, IN PRESS HIPPOCAMPUS; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUZUKI SS, 1987, ELECTROENCEPHALOGR C, V69, P541; TEYLER TJ, 1986, BEHAV NEUROSCI, V100, P147, DOI 10.1037/0735-7044.100.2.147; TREVES A, 1994, HIPPOCAMPUS, V4, P374, DOI 10.1002/hipo.450040319; WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517; YLINEN A, 1995, J NEUROSCI, V15, P30	43	709	715	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1996	271	5257					1870	1873		10.1126/science.271.5257.1870	http://dx.doi.org/10.1126/science.271.5257.1870			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596957				2022-12-28	WOS:A1996UC77800048
J	Carlson, SJ; Yokoo, H; Vanagunas, A				Carlson, SJ; Yokoo, H; Vanagunas, A			Progression of gastritis to monoclonal B-cell lymphoma with resolution and recurrence following eradication of Helicobacter pylori	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAMPYLOBACTER-PYLORI; IMMUNE-RESPONSE; MUCOSA; FOLLICLES; TISSUE	Objective.-To follow a patient with Helicobacter pylori-associated gastritis by performing serial endoscopic biopsies to observe the histologic progression of the gastritis to a monoclonal B-cell lymphoma with resolution and subsequent reccurrence following eradication of H pylori organisms. Design.-A case report of a patient followed over 3 years. Main Outcome Measures.-Characteristics of the gastric mucosa as determined by histologic and gene rearrangement studies on multiple random biopsies obtained serially before and after the eradication of H pylori organisms. Results.-A progression from H pylori-associated gastritis through lymphoid hyperplasia to a monoclonal B-cell lymphoma was observed. With the techniques used, a resolution of the lymphoma was observed on eradication of H pylori organisms, with a subsequent reccurrence of the lymphoma 15 months later, despite the absence of H pylori organisms. Conclusion.-The observations made of this patient support an association between H pylori and the development of a gastric monoclonal B-cell lymphoma, This lesion appears to develop in the setting of gastritis and progresses through lymphoid hyperplasia followed subsequently by the lymphoma. We speculate that this process is initially antigen driven by the organism and may subsequently become autonomous as genetic damage is accumulated, so that eradication of H pylori organisms will lead to regression of the lesion to the degree that there are autonomously proliferating cells present.	NORTHWESTERN UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,CHICAGO,IL 60611	Northwestern University; Northwestern University								CALVERT R, 1995, LANCET, V345, P26, DOI 10.1016/S0140-6736(95)91154-5; Dukes C, 1926, J PATHOL BACTERIOL, V29, P111, DOI 10.1002/path.1700290113; GENTA RM, 1993, HUM PATHOL, V24, P577, DOI 10.1016/0046-8177(93)90235-9; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; ISAACSON PG, 1994, HUM PATHOL, V25, P1020, DOI 10.1016/0046-8177(94)90060-4; OKAZAKI K, 1994, LANCET, V343, P1636, DOI 10.1016/S0140-6736(94)93087-2; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; ROGGERO E, 1995, ANN INTERN MED, V122, P767, DOI 10.7326/0003-4819-122-10-199505150-00006; SIGAL SH, 1989, GASTROENTEROLOGY, V97, P195, DOI 10.1016/0016-5085(89)91435-2; SPENCER J, 1989, AM J PATHOL, V135, P7; STOLTE M, 1992, LANCET, V339, P745, DOI 10.1016/0140-6736(92)90645-J; STOLTE M, 1989, J CLIN PATHOL, V42, P1269, DOI 10.1136/jcp.42.12.1269; STOLTE M, 1993, LANCET, V342, P568, DOI 10.1016/0140-6736(93)91404-A; WEBER DM, 1994, GASTROENTEROLOGY, V107, P1835, DOI 10.1016/0016-5085(94)90828-1; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1994, LANCET, V343, P1503, DOI 10.1016/S0140-6736(94)92613-1; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; WYATT JI, 1988, SCAND J GASTROENTERO, V23, P44, DOI 10.3109/00365528809091712	18	41	42	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					937	939						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA563	8598622				2022-12-28	WOS:A1996UA56300034
J	Jones, DL; Kroenke, K; Landry, FJ; Tomich, DJ; Ferrel, RJ				Jones, DL; Kroenke, K; Landry, FJ; Tomich, DJ; Ferrel, RJ			Cost savings using a stepped-care prescribing protocol for nonsteroidal anti-inflammatory drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIINFLAMMATORY DRUGS; RHEUMATOID-ARTHRITIS; RISK; PHYSICIANS; IBUPROFEN; TOXICITY; THERAPY; ASPIRIN	Objective.-To lower nonsteroidal anti-inflammatory drug (NSAID) costs while maintaining quality patient care and clinician satisfaction. Design.-Before and after 21-month trial with one study site and two control sites and a questionnaire that was sent to 203 clinicians. Setting and Subjects.-Two military medical centers and two affiliated primary care clinics. All beneficiaries filling outpatient NSAID prescriptions. Interventions.-An NSAID prescribing protocol was implemented requiring a trial of either ibuprofen or indomethacin before new prescription of more expensive NSAIDs. One control center used an NSAID computer cost-prompt and the other had no intervention. Main Outcome Measures.-The proportion of expensive NSAIDs prescribed at each institution and total NSAID costs adjusted for prescription volume. Clinician acceptance and patient impact were assessed by the questionnaire. Results.-Study site clinicians (n=158) reported very few protocol-related patient care problems. A minority (9%) of study site clinicians considered the protocol very bothersome, and only 2% felt it should be discontinued. Quarterly use of expensive NSAIDs at the study site fell from 34% to 21%, decreasing costs by 30% (P<.001). In contrast, the site with a computer cost-prompt had only a 5% decrease in NSAID costs, while costs at the site with no intervention increased 2%. Conclusions.-For drugs with similar benefits and adverse effects, a ''stepped formulary'' approach requiring an initial trial of one of the less expensive agents can maintain physician prescribing choices and satisfaction while lowering costs.	UNIFORMED SERV UNIV HLTH SCI,DEPT MED,BETHESDA,MD 20814; MADIGAN ARMY MED CTR,DEPT PHARM,TACOMA,WA 98431	Uniformed Services University of the Health Sciences - USA; Madigan Army Medical Center	Jones, DL (corresponding author), WALTER REED ARMY MED CTR,INTERNAL MED SERV,6800 GEORGIA AVE NW,WASHINGTON,DC 20307, USA.		anand, amit/A-7222-2009	Kroenke, Kurt/0000-0002-0114-4669				BLECHMAN WJ, 1979, RHEUMATOL REHABIL, V18, P119, DOI 10.1093/rheumatology/18.2.119; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; DAY RO, 1988, DRUGS, V36, P643, DOI 10.2165/00003495-198836060-00001; EISEN SA, 1990, ARCH INTERN MED, V150, P1881, DOI 10.1001/archinte.150.9.1881; EPSTEIN AM, 1984, AM J MED, V77, P313, DOI 10.1016/0002-9343(84)90709-5; FRIES JF, 1991, ARTHRITIS RHEUM, V34, P1353; FRIES JF, 1993, ARCH INTERN MED, V153, P2465, DOI 10.1001/archinte.153.21.2465; FURST DE, 1994, ARTHRITIS RHEUM-US, V37, P1, DOI 10.1002/art.1780370102; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GREENE JM, 1992, ARCH INTERN MED, V152, P1995; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HELFGOTT SM, 1994, SEMIN ARTHRITIS RHEU, V23, P341, DOI 10.1016/0049-0172(94)90029-9; HELLER CA, 1985, PHARMACOTHERAPY, V5, P30; JAMALI S, 1986, CLIN EXP RHEUMATOL, V4, P91; JOHNSON JE, 1988, MIL MED, V153, P21; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; *MED EC DAT PROD I, 1994, 1994 RED BOOK; ORME M, 1981, SCANDINAVIAN J RHE S, V39, P19; RAY WA, 1993, NEW ENGL J MED, V329, P2029, DOI 10.1056/NEJM199312303292710; ROTH S, 1990, SEMIN ARTHRITIS RHEU, V19, P11; ROTH SH, 1993, ARCH INTERN MED, V153, P2565, DOI 10.1001/archinte.153.22.2565; SAFAVI KT, 1992, J GEN INTERN MED, V7, P32, DOI 10.1007/BF02599099; SCOTT DL, 1982, BRIT J CLIN PHARMACO, V14, P691, DOI 10.1111/j.1365-2125.1982.tb04958.x; SMALLEY WE, 1995, NEW ENGL J MED, V332, P1612, DOI 10.1056/NEJM199506153322406; SOUMERAI SB, 1989, MILBANK Q, V67, P269; TIERNEY WM, 1987, ANN INTERN MED, V107, P569, DOI 10.7326/0003-4819-107-4-569; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; [No title captured]; 1989, J RHEUMATOL, V16, P321; 1992, STAT B METROP INSUR, V73, P25	32	21	22	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					926	930		10.1001/jama.275.12.926	http://dx.doi.org/10.1001/jama.275.12.926			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA563	8598620				2022-12-28	WOS:A1996UA56300032
J	Saultz, JW				Saultz, JW			Reflections on internal medicine and family medicine	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PRIMARY CARE	The manner in which U.S. medical care is organized and paid for is rapidly changing. These political and financial changes have created an environment that favors collaboration and cooperation among the primary care specialties. Although their relationship was once that of referring physician and consultant, the family physician and general internist are becoming peers, and they increasingly have similar needs and interests. Improving collaboration between the practitioners in these two fields requires a respect for important differences in their respective cultures. All family physicians work closely with internists during residency, but many general internists have had little or no experience working with family physicians. This essay reviews the practice style and philosophy of the family physician and suggests ways to improve communication and collaboration between the two disciplines.			Saultz, JW (corresponding author), OREGON HLTH SCI UNIV, 3181 SW SAM JACKSON PK RD, L105, PORTLAND, OR 97201 USA.							ADKINSON NF, 1994, ANN INTERN MED, V121, P810, DOI 10.7326/0003-4819-121-10-199411150-00014; *AM MED ASS AD HOC, 1966, M CHALL FAM PRACT CH; ASCH DA, 1992, ANN INTERN MED, V117, P839, DOI 10.7326/0003-4819-117-10-839; BANKHEAD CD, 1990, MED WORLD NEWS   SEP, P36; BERTAKIS KD, 1987, J FAM PRACTICE, V24, P305; BERTAKIS KD, 1989, J FAM PRACTICE, V28, P91; Bowman M A, 1990, J Am Board Fam Pract, V3, P43; Citizens Commission on Graduate Medical Education, 1966, GRAD ED PHYS; Conry C M, 1991, J Am Board Fam Pract, V4, P399; Doherty W., 1983, FAMILY THERAPY FAMIL; Doherty William J., 1987, FAMILY MED MATURING; FITZGERALD FT, 1993, NEW ENGL J MED, V328, P654, DOI 10.1056/NEJM199303043280912; Fletcher R., 1982, CLIN EPIDEMIOLOGY ES; Kahn N B Jr, 1995, J Am Board Fam Pract, V8, P120; KASSIRER JP, 1993, NEW ENGL J MED, V328, P648, DOI 10.1056/NEJM199303043280910; KIMBALL HR, 1994, JAMA-J AM MED ASSOC, V271, P315, DOI 10.1001/jama.271.4.315; KIMBALL HR, 1995, JAMA-J AM MED ASSOC, V273, P320, DOI 10.1001/jama.273.4.320; MCGANN KP, 1990, J FAM PRACTICE, V31, P541; National Commission on Community Health Services, 1966, HLTH IS COMM AFF; NOLAN JP, 1992, ANN INTERN MED, V116, P1042, DOI 10.7326/0003-4819-116-12-1042; PAGE L, 1992, AM MED NEWS     0921, P31; PAGE L, 1992, AM MED NEWS     0921, P1; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; PETERSDORF RG, 1993, ANN INTERN MED, V119, P1130, DOI 10.7326/0003-4819-119-11-199312010-00011; RAMSEY CN, 1989, FAMILY SYSTEMS MED; SCHROEDER SA, 1986, ANN INTERN MED, V104, P554, DOI 10.7326/0003-4819-104-4-554; SOX HC, 1986, ANN INTERN MED, V104, P60, DOI 10.7326/0003-4819-104-1-60; SOX HC, 1994, ANN INTERN MED, V121, P616, DOI 10.7326/0003-4819-121-8-199410150-00011; Stephens G G, 1989, Fam Med, V21, P103; Stephens G. Gayle, 1982, INTELLECTUAL BASIS F; 1994, J GEN INTERN MED S, V9, pS1	31	14	14	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1996	124	6					600	603		10.7326/0003-4819-124-6-199603150-00009	http://dx.doi.org/10.7326/0003-4819-124-6-199603150-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ529	8597324				2022-12-28	WOS:A1996TZ52900010
J	Levin, JE; Miller, JP				Levin, JE; Miller, JP			Broadband neural encoding in the cricket cercal sensory system enhanced by stochastic resonance	NATURE			English	Article							PRIMARY INTERNEURONS; INFORMATION; REPRESENTATION	Sensory systems are often required to detect a small amplitude signal embedded in broadband background noise. Traditionally, ambient noise is regarded as detrimental to encoding accuracy. Recently, however, a phenomenon known as stochastic resonance has been described in which, for systems with a nonlinear threshold, increasing the input noise level can actually improve the output signal-to-noise ratio over a limited range of signal and noise strengths. Previous theoretical and experimental studies of stochastic resonance in physica(1-7) and biological(6-10) systems have dealt exclusively with single-frequency sine stimuli embedded in a broadband noise background. In the past year it has been shown in a theoretical and modelling study that stochastic resonance can be observed with broadband signals(11,12). Here we demonstrate that broadband stochastic resonance is manifest in the peripheral layers of neural processing in a simple sensory system, and that it plays a role over a wide range of biologically relevant stimulus parameters. Further, we quantify the functional significance of the phenomenon within the context of signal processing, using information theory.			Levin, JE (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							BENZI R, 1981, J PHYS A-MATH GEN, V14, pL453, DOI 10.1088/0305-4470/14/11/006; BIALEK W, 1993, PHYSICA A, V200, P581, DOI 10.1016/0378-4371(93)90563-J; BRAUN HA, 1994, NATURE, V367, P270, DOI 10.1038/367270a0; BULSARA A, 1991, J THEOR BIOL, V152, P531, DOI 10.1016/S0022-5193(05)80396-0; CAMHI JM, 1978, J COMP PHYSIOL, V128, P203, DOI 10.1007/BF00656853; COLLINS JJ, 1995, NATURE, V376, P236, DOI 10.1038/376236a0; COLLINS JJ, 1995, PHYS REV E, V52, pR3321, DOI 10.1103/PhysRevE.52.R3321; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; FAUUVE S, 1993, J POHYS LETT A, V97, P5; GNATZY W, 1990, J COMP PHYSIOL A, V167, P551, DOI 10.1007/BF00190826; KANOU M, 1984, J COMP PHYSIOL, V154, P357, DOI 10.1007/BF00605235; MCNAMARA B, 1988, PHYS REV LETT, V60, P2626, DOI 10.1103/PhysRevLett.60.2626; MCNAMARA B, 1989, PHYS REV A, V39, P4854, DOI 10.1103/PhysRevA.39.4854; MILLER JP, 1991, J NEUROPHYSIOL, V66, P1680, DOI 10.1152/jn.1991.66.5.1680; MOSS F, 1994, INT J BIFURCAT CHAOS, V4, P1383, DOI 10.1142/S0218127494001118; Shannon CE, 1949, MATH THEORY COMMUNIC, P64; THEUNISSEN FE, 1991, J NEUROPHYSIOL, V66, P1690, DOI 10.1152/jn.1991.66.5.1690; THEUNISSEN FE, IN OPRESS J NEUROPHY; THEUNISSEN FE, 1993, THESIS U CALIFORNIA; TOBIAS M, 1979, J COMP PHYSIOL, V129, P51, DOI 10.1007/BF00679911; VANSTEVENINCK RD, 1988, PROC R SOC SER B-BIO, V234, P379; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0; ZHOU T, 1990, PHYS REV A, V41, P4255, DOI 10.1103/PhysRevA.41.4255	23	599	615	2	45	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					165	168		10.1038/380165a0	http://dx.doi.org/10.1038/380165a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600392				2022-12-28	WOS:A1996TZ97800053
J	Dawson, C; Whitfield, H				Dawson, C; Whitfield, H			ABC of urology - Introduction to urology	BRITISH MEDICAL JOURNAL			English	Article									CENT MIDDLESEX HOSP,LONDON NW10 7NS,ENGLAND; INST UROL & NEPHROL,LONDON,ENGLAND	Imperial College London; University of London; University College London	Dawson, C (corresponding author), EDITH CAVELL HOSP,PETERBOROUGH,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					623	625						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595341				2022-12-28	WOS:A1996TZ84000031
J	DeRobertis, EM; Sasai, Y				DeRobertis, EM; Sasai, Y			A common plan for dorsoventral patterning in Bilateria	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; DORSAL-VENTRAL PATTERN; DROSOPHILA EMBRYO; XENOPUS MESODERM; MELANOGASTER; INDUCTION; NOGGIN; STAGE	Functional studies seem now to confirm, as first suggested by E. Geoffroy Saint-Hilaire in 1822, that there was an inversion of the dorsoventral axis during animal evolution. A conserved system of extracellular signals provides positional information for the allocation of embryonic cells to specific tissue types both in Drosophila and vertebrates; the ventral region of Drosophila is homologous to the dorsal side of the vertebrate. Developmental studies are now revealing some of the characteristics of the ancestral animal that gave rise to the arthropod and mammalian lineages, for which we propose the name Urbilateria.			DeRobertis, EM (corresponding author), UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT BIOL CHEM,LOS ANGELES,CA 90095, USA.			De Robertis, Edward/0000-0002-7843-1869				Appel Toby A., 1987, CUVIER GEOFFROY DEBA; ARENDT D, 1994, NATURE, V371, P26, DOI 10.1038/371026a0; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; CLEMENT JH, 1995, MECH DEVELOP, V52, P357, DOI 10.1016/0925-4773(95)00413-U; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; DALE L, 1992, DEVELOPMENT, V115, P573; De Robertis E.M., 1994, P11; DEROBERTIS EM, 1995, NATURE, V374, P407, DOI 10.1038/374407a0; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Geoffroy Saint-Hilaire E., 1822, MEMOIRES DU MUSEUM D, V9, P89; GRUNZ H, 1989, CELL DIFFER DEV, V28, P211, DOI 10.1016/0922-3371(89)90006-3; HAECKEL E, 1874, Q J MICROSC SCI, V14, P142; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HAWLEY SHB, 1995, GENE DEV, V9, P2913; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; HOGEN BLM, 1995, NATURE, V376, P210; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; JEFFERIES RPS, 1995, NATURE, V374, P22, DOI 10.1038/374022a0; JONES CM, 1995, CURR BIOL, V5, P574, DOI 10.1016/S0960-9822(95)00112-6; JONES CM, 1992, DEVELOPMENT, V115, P639; LACALLI TC, 1995, NATURE, V373, P110, DOI 10.1038/373110c0; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NUBLERJUNG K, 1994, ROUX ARCH DEV BIOL, V203, P357, DOI 10.1007/BF00188683; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PETERSON KJ, 1995, NATURE, V373, P111, DOI 10.1038/373111a0; PHILIPPE H, 1994, DEVELOPMENT, P15; PREOBRAZHENSKII AA, 1985, DOKL AKAD NAUK SSSR+, V284, P1489; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SATO SM, 1989, DEV BIOL, V134, P263, DOI 10.1016/0012-1606(89)90096-1; SCHIMDT JE, 1995, DEV BIOL, V169, P37; Schmidt J, 1995, DEVELOPMENT, V121, P4319; SCOTT MP, 1994, CELL, V79, P1121, DOI 10.1016/0092-8674(94)90001-9; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; STEINBEISSER H, 1995, EMBO J, V14, P5230, DOI 10.1002/j.1460-2075.1995.tb00208.x; SUZUKI A, 1995, GROWTH DIFFERENT, V35, P581; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; WILLMER CH, 1990, INVERTEBRATE RELATIO; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; XU RH, 1995, BIOCHEM BIOPH RES CO, V212, P212, DOI 10.1006/bbrc.1995.1958; YAMADA, 1995, J CELL BIOL, V130, P217; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7; ZUKER CS, 1994, SCIENCE, V265, P742, DOI 10.1126/science.8047881; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	57	555	568	4	92	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					37	40		10.1038/380037a0	http://dx.doi.org/10.1038/380037a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598900				2022-12-28	WOS:A1996TY87700047
J	Elon, RD				Elon, RD			Recent advances - Geriatric medicine	BRITISH MEDICAL JOURNAL			English	Article											Elon, RD (corresponding author), JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS GERIATR CTR,BALTIMORE,MD 21224, USA.							CHESTNUT CH, 1995, AM J MED, V99, P144, DOI 10.1016/S0002-9343(99)80134-X; COOPER C, 1995, NEW ENGL J MED, V332, P814, DOI 10.1056/NEJM199503233321210; CUMMINGS SR, 1994, NEW ENGL J MED, V331, P872, DOI 10.1056/NEJM199409293311310; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; Fries James F., 1994, Arthritis and Rheumatism, V37, pS198; FRIES JF, 1994, ANN INTERN MED, V121, P502, DOI 10.7326/0003-4819-121-7-199410010-00005; GREENDALE GA, 1995, AM J EPIDEMIOL, V141, P951, DOI 10.1093/oxfordjournals.aje.a117362; GRISSO JA, 1994, NEW ENGL J MED, V330, P155; Isaacs B., 1985, PRACTICAL GERIATRIC, P154; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008; NICHOL KL, 1995, NEW ENGL J MED, V333, P889, DOI 10.1056/NEJM199510053331401; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; OOMS ME, 1995, J CLIN ENDOCR METAB, V80, P1052, DOI 10.1210/jc.80.4.1052; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; WAGNER EH, 1994, AM J PUBLIC HEALTH, V84, P1800, DOI 10.2105/AJPH.84.11.1800	19	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					561	563		10.1136/bmj.312.7030.561	http://dx.doi.org/10.1136/bmj.312.7030.561			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595289	Green Published			2022-12-28	WOS:A1996TY88500032
J	Potts, M				Potts, M			USA aborts international family planning	LANCET			English	Editorial Material											Potts, M (corresponding author), UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720, USA.								0	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					556	556		10.1016/S0140-6736(96)91264-7	http://dx.doi.org/10.1016/S0140-6736(96)91264-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596311				2022-12-28	WOS:A1996TX69400002
J	Sato, H; Adachi, Y; Koiwai, O				Sato, H; Adachi, Y; Koiwai, O			The genetic basis of Gilbert's syndrome	LANCET			English	Editorial Material									KINKI UNIV,SCH MED,DEPT INTERNAL MED 2,OSAKA,OSAKA 577,JAPAN; AICHI CANC CTR,RES INST,DEPT BIOCHEM,NAGOYA,AICHI,JAPAN	Kindai University (Kinki University); Aichi Cancer Center	Sato, H (corresponding author), SHIGA UNIV MED SCI,DEPT BIOL,OTSU,SHIGA,JAPAN.							AONO S, 1995, LANCET, V345, P958, DOI 10.1016/S0140-6736(95)90702-5; BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802; KOIWAI O, 1995, HUM MOL GENET, V4, P1183, DOI 10.1093/hmg/4.7.1183; SCHMID R, 1995, NEW ENGL J MED, V333, P1217, DOI 10.1056/NEJM199511023331812; SOEDA Y, 1995, LANCET, V346, P1494, DOI 10.1016/S0140-6736(95)92514-7	5	97	99	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					557	558		10.1016/S0140-6736(96)91266-0	http://dx.doi.org/10.1016/S0140-6736(96)91266-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596313				2022-12-28	WOS:A1996TX69400004
J	Clark, DA				Clark, DA			Red-cell antibodies in pregnancy: Evidence overturned	LANCET			English	Editorial Material							NEWBORN; PATIENT				Clark, DA (corresponding author), MCMASTER UNIV,HAMILTON,ON,CANADA.							Dickersin K, 1993, ANN NY ACAD SCI, V703, P145; ENGELFRIET CP, 1994, TRANSFUSION, V34, P627; FROEHLICH P, 1995, LANCET, V346, P1039, DOI 10.1016/S0140-6736(95)91722-5; HADLEY AG, 1992, VOX SANG, V63, P291, DOI 10.1111/j.1423-0410.1992.tb01242.x; JUDD WJ, 1990, TRANSFUSION, V30, P175, DOI 10.1046/j.1537-2995.1990.30290162907.x; SOCOL ML, 1992, PRINCIPLES PRACTICE, P1046; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; VANDIJK BA, 1995, TRANSFUSION MED, V4, P199; 1992, JAMA-J AM MED ASSOC, V268, P2420; 1994, AM J REPROD IMMUNOL, V32, P55	10	4	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					485	486		10.1016/S0140-6736(96)91133-2	http://dx.doi.org/10.1016/S0140-6736(96)91133-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596262				2022-12-28	WOS:A1996TW69700004
J	Griffiths, C; Naish, J; Sturdy, P; Pereira, F				Griffiths, C; Naish, J; Sturdy, P; Pereira, F			Prescribing and hospital admissions for asthma in east London	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON QUEEN MARY & WESTFIELD COLL,DEPT EPIDEMIOL & MED STAT,LONDON,ENGLAND	University of London; Queen Mary University London	Griffiths, C (corresponding author), UNIV LONDON QUEEN MARY & WESTFIELD COLL,ST BARTHOLOMEWS & ROYAL LONDON SCH MED & DENT,LONDON E1 4NS,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CAMPBELL M, 1995, BRIT MED J, V310, P1069, DOI 10.1136/bmj.310.6986.1069b; NAISH J, 1995, BRIT MED J, V310, P97, DOI 10.1136/bmj.310.6972.97; SHINE C, 1995, BRIT MED J, V310, P1070, DOI 10.1136/bmj.310.6986.1070a; STURDY P, 1995, BRIT MED J, V311, P1547, DOI 10.1136/bmj.311.7019.1547; 1994, HLTH E ANN PUBLIC HL	5	37	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					481	482		10.1136/bmj.312.7029.481	http://dx.doi.org/10.1136/bmj.312.7029.481			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597680	Green Published			2022-12-28	WOS:A1996TX38300024
J	Winkens, RAG; Pop, P; Grol, RPTM; BugterMaessen, AMA; Kester, ADM; Beusmans, GHMI; Knottnerus, JA				Winkens, RAG; Pop, P; Grol, RPTM; BugterMaessen, AMA; Kester, ADM; Beusmans, GHMI; Knottnerus, JA			Effects of routine individual feedback over nine years on general practitioners' requests for tests	BRITISH MEDICAL JOURNAL			English	Article							PHYSICIANS		CTR RES QUAL GEN PRACTICE,6200 MD MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT METHODOL & STAT,6200 MD MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT GEN PRACTICE,6200 MD MAASTRICHT,NETHERLANDS	Hasselt University; Hasselt University; Maastricht University	Winkens, RAG (corresponding author), DIAGNOST COORDINATING CTR MAASTRICHT,POB 5800,6202 AZ MAASTRICHT,NETHERLANDS.		Knottnerus, Andre/F-4866-2013; Grol, Richard/C-8523-2013; Knottnerus, Johannes A/A-3829-2009					EISENBERG JM, 1985, MED CARE, V23, P461, DOI 10.1097/00005650-198505000-00010; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; WINKENS RAG, 1995, LANCET, V345, P498, DOI 10.1016/S0140-6736(95)90588-X; WINKENS RAG, 1992, BRIT MED J, V304, P1093, DOI 10.1136/bmj.304.6834.1093	5	35	35	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					490	490		10.1136/bmj.312.7029.490	http://dx.doi.org/10.1136/bmj.312.7029.490			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597685	Green Submitted, Green Published			2022-12-28	WOS:A1996TX38300030
J	Rubin, RA; Levine, MS				Rubin, RA; Levine, MS			Images in clinical medicine - Giant esophageal ulcers	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									HOSP UNIV PENN,PHILADELPHIA,PA 19104	University of Pennsylvania	Rubin, RA (corresponding author), THOMAS JEFFERSON UNIV HOSP,PHILADELPHIA,PA 19107, USA.		Rubin, Raymond/AAI-2579-2021						0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1996	334	16					1029	1029		10.1056/NEJM199604183341605	http://dx.doi.org/10.1056/NEJM199604183341605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE733	8598841				2022-12-28	WOS:A1996UE73300005
J	Shaw, BA				Shaw, BA			Pott's disease with paraparesis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Shaw, BA (corresponding author), VALLEY CHILDRENS HOSP,FRESNO,CA 93703, USA.		Shaw, Brian/AAA-6843-2019	Shaw, Brian/0000-0002-0125-9327					0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1996	334	15					958	959		10.1056/NEJM199604113341505	http://dx.doi.org/10.1056/NEJM199604113341505			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD596	8596597				2022-12-28	WOS:A1996UD59600005
J	Goldman, M				Goldman, M			Cancer risk of low-level exposure	SCIENCE			English	Editorial Material											Goldman, M (corresponding author), UNIV CALIF DAVIS,DEPT SURG & RADIOL SCI,DAVIS,CA 95616, USA.							AMES BN, 1993, ENVIRON HEALTH PERSP, V101, P35, DOI 10.2307/3431840; [Anonymous], 1994, SOURC EFF ION RAD, P16; COHEN BL, 1995, HEALTH PHYS, V68, P157, DOI 10.1097/00004032-199502000-00002; EVANS R, 1974, HEALTH PHYS, V17, P497; GOLDMAN M, 1971, RADIAT RES, V47, P305; KITCHIN KT, 1994, TOXICOLOGY, V88, P31, DOI 10.1016/0300-483X(94)90109-0; Kondo S., 1993, HLTH EFFECTS LOW LEV; LEWIS EB, 1957, SCIENCE, V125, P965, DOI 10.1126/science.125.3255.965; Muller H J, 1927, Science, V66, P84, DOI 10.1126/science.66.1699.84; *NATL RES COUNC, 1990, HLTH EFF EXP LOW LEV; ROSENBLATT LS, 1971, HEALTH PHYS, V21, P869; WOLFF S, 1988, INT J RADIAT BIOL, V53, P39, DOI 10.1080/09553008814550401	12	56	59	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1821	1822		10.1126/science.271.5257.1821	http://dx.doi.org/10.1126/science.271.5257.1821			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596947				2022-12-28	WOS:A1996UC77800031
J	Reddy, MM; Quinton, PM; Haws, C; Wine, JJ; Grygorczyk, R; Tabcharani, JA; Hanrahan, JW; Gunderson, KL; Kopito, RR				Reddy, MM; Quinton, PM; Haws, C; Wine, JJ; Grygorczyk, R; Tabcharani, JA; Hanrahan, JW; Gunderson, KL; Kopito, RR			Failure of the cystic fibrosis transmembrane conductance regulator to conduct ATP	SCIENCE			English	Article							GENE; CFTR; IDENTIFICATION; SELECTIVITY; CHANNEL; CELLS	The cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride ion channel regulated by protein kinase A and adenosine triphosphate (ATP). Loss of CFTR-mediated chloride ion conductance from the apical plasma membrane of epithelial cells is a primary physiological lesion in cystic fibrosis. CFTR has also been suggested to function as an ATP channel, although the size of the ATP anion is much larger than the estimated size of the CFTR pore. ATP was not conducted through CFTR in intact organs, polarized human lung cell lines, stably transfected mammalian cell lines, or planar lipid bilayers reconstituted with CFTR protein. These findings suggest that ATP permeation through the CFTR is unlikely to contribute to the normal function of CFTR or to the pathogenesis of cystic fibrosis.	STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA; UNIV CALIF RIVERSIDE, DIV BIOMED SCI, RIVERSIDE, CA 92521 USA; STANFORD UNIV, DEPT PSYCHOL, CYST FIBROSIS RES LAB, STANFORD, CA 94305 USA; MCGILL UNIV, DEPT PHYSIOL, MONTREAL, PQ H3G 1Y6, CANADA	Stanford University; University of California System; University of California Riverside; Stanford University; McGill University			Hanrahan, John/AGG-1926-2022	Hanrahan, John/0000-0001-9080-2039; Grygorczyk, Ryszard/0000-0002-9798-7651	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045913, R01DK043994] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42368] Funding Source: Medline; NIDDK NIH HHS [DK45913, DK43994] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BULL HB, 1972, INTRO PHYSICAL BIOCH; GREGER R, 1981, PFLUG ARCH EUR J PHY, V390, P30, DOI 10.1007/BF00582707; GRYGORCZYK R, IN PRESS J MEMBR BIO; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; GUNDERSON KL, UNPUB; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanrahan John W., 1993, P93; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; NEHER E, 1992, METHOD ENZYMOL, V207, P123; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; QUINTON PM, 1982, FLUID ELECTROLYTE AB, P53; REDDY MM, 1994, AM J PHYSIOL-CELL PH, V267, pC1136, DOI 10.1152/ajpcell.1994.267.4.C1136; REISIN IL, 1994, J BIOL CHEM, V269, P20584; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698	25	165	166	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1996	271	5257					1876	1879		10.1126/science.271.5257.1876	http://dx.doi.org/10.1126/science.271.5257.1876			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596959				2022-12-28	WOS:A1996UC77800050
J	Duchosal, MA; Rothermel, AL; McConahey, PJ; Dixon, FJ; Altieri, DC				Duchosal, MA; Rothermel, AL; McConahey, PJ; Dixon, FJ; Altieri, DC			In vivo immunosuppression by targeting a novel protease receptor	NATURE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; VERSUS-HOST DISEASE; B-CELL LYMPHOMAS; PBL-SCID MICE; LYMPHOPROLIFERATIVE DISEASE; T-CELLS; ACTIVATION; PATHOGENESIS; GENERATION; MECHANISM	MEMBRANE receptors for blood proteases govern the clotting(1) and fibrinolytic(2) cascades, regulate signal transduction(3,4), and control the growth of mesenchymal cells(5,6). Despite their importance in the development of vascular injury(7), it is unclear whether these mechanisms participate in the generation of an immune response. Here we report that targeting a factor Xa receptor, designated effector cell protease receptor-1 (EPR-1), with antisense oligonucleotide or with a monoclonal antibody (mAb 2E1)(8) inhibited CD3/T-cell receptor-dependent lymphocyte proliferation. Immunosuppression was mediated by abolishing cytokine production and down-modulating membrane expression of the interleukin (IL)-2 receptor. In vivo administration of mAb 2E1 to severe-combined-immunodeficient mice injected with human peripheral blood leukocytes suppressed production of human immunoglobulin, abolished graft-versus-host disease, and protected these xenochimaeric mice from Epstein-Barr-virus-induced human lymphoproliferative disease. These observations indicate a new role for protease receptors in the regulation of the immune response, and identify a potential target for therapeutic immunosuppression in humans.	RW JOHNSON PHARMACEUT RES INST, RARITAN, NJ 08869 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; YALE UNIV, BOYER CTR MOLEC MED, DEPT PATHOL, NEW HAVEN, CT 06536 USA	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute; Yale University	Duchosal, MA (corresponding author), CHU VAUDOIS, DEPT INTERNAL MED, DIV HAEMATOL, CH-1011 LAUSANNE, SWITZERLAND.							ALTIERI DC, 1994, J BIOL CHEM, V269, P3139; ALTIERI DC, 1994, CELL IMMUNOL, V155, P372, DOI 10.1006/cimm.1994.1130; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DUCHOSAL MA, 1990, J EXP MED, V172, P985, DOI 10.1084/jem.172.3.985; DUCHOSAL MA, 1992, AM J PATHOL, V141, P1097; DUCHOSAL MA, 1992, NATURE, V355, P258, DOI 10.1038/355258a0; FREEMAN GJ, 1993, SCIENCE, V262, P907, DOI 10.1126/science.7694362; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GLENN KC, 1979, NATURE, V278, P711, DOI 10.1038/278711a0; JANEWAY CA, 1993, CURR OPIN IMMUNOL, V5, P313, DOI 10.1016/0952-7915(93)90048-W; JENKINS MK, 1993, CURR OPIN IMMUNOL, V5, P361, DOI 10.1016/0952-7915(93)90054-V; MERKENSCHLAGER M, 1990, J IMMUNOL, V145, P2839; MOSIER DE, 1989, NATURE, V338, P211, DOI 10.1038/338211b0; MOSIER DE, 1989, CURR TOP MICROBIOL, V152, P195; MOSIER DE, 1991, NATURE, V353, P509, DOI 10.1038/353509c0; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; OKANO M, 1990, AM J PATHOL, V137, P517; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PICCHIO GR, 1992, CANCER RES, V52, P2468; PIRRUCCELLO SJ, 1992, AM J PATHOL, V140, P1187; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROTHMAN BL, 1991, J IMMUNOL, V147, P2493; ROWE M, 1991, J EXP MED, V173, P147, DOI 10.1084/jem.173.1.147; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; VERONESE ML, 1992, J EXP MED, V176, P1763, DOI 10.1084/jem.176.6.1763; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALKER C, 1987, EUR J IMMUNOL, V17, P873, DOI 10.1002/eji.1830170622	28	26	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 28	1996	380	6572					352	356		10.1038/380352a0	http://dx.doi.org/10.1038/380352a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598931				2022-12-28	WOS:A1996UC37900062
J	Mengaud, J; Ohayon, H; Gounon, P; Mege, RM; Cossart, P				Mengaud, J; Ohayon, H; Gounon, P; Mege, RM; Cossart, P			E-cadherin is the receptor for internalin, a surface protein required for entry of L-monocytogenes into epithelial cells	CELL			English	Article							CULTURED MAMMALIAN-CELLS; GRAM-POSITIVE COCCI; ADHESION MOLECULES; LISTERIA-MONOCYTOGENES; MEDIATED-IMMUNITY; INVASIN PROTEIN; IDENTIFICATION; UVOMORULIN; BACTERIA; DOMAIN	We report the first identification of a cellular receptor mediating entry of a gram-positive bacterium into nonphagocytotic cells. By an affinity chromatography approach, we identified E-cadherin as the ligand for internalin, an L. monocytogenes protein essential for entry into epithelial cells. Expression of the chicken homolog of E-cadherin (L-CAM) in transfected fibroblasts dramatically increases entry of L. monocytogenes and promotes that of a recombinant L. innocua strain expressing internalin but does not promote entry of the wild-type noninvasive L. innocua or that of an internalin-deficient mutant of L. monocytogenes. Furthermore, L-CAM-specific antibodies block internalin-mediated entry. In contrast to Salmonella, Listeria enters cells by a mechanism of induced phagocytosis occurring without membrane ruffling. This work reveals a novel type of heterophilic interactions for E-cadherin.	INST PASTEUR, UNITE INTERACT BACTERIES CELLULES, F-75724 PARIS 15, FRANCE; INST PASTEUR, STN CENT MICROSCOPIE ELECT, F-75724 PARIS 15, FRANCE; INSERM, U440, F-75005 PARIS, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)			Mege, Rene Marc/M-9569-2013	Mege, Rene-Marc/0000-0001-8128-5543				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BOLLER K, 1985, J CELL BIOL, V100, P327, DOI 10.1083/jcb.100.1.327; BRAY DF, 1993, MICROSC RES TECHNIQ, V26, P489, DOI 10.1002/jemt.1070260603; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; DRAMSI S, 1995, MOL MICROBIOL, V16, P251, DOI 10.1111/j.1365-2958.1995.tb02297.x; DRAMSI S, 1993, MOL MICROBIOL, V9, P931, DOI 10.1111/j.1365-2958.1993.tb01223.x; DUNHAM LJ, 1953, JNCI-J NATL CANCER I, V13, P1299; EDELMAN GM, 1983, P NATL ACAD SCI-BIOL, V80, P4384, DOI 10.1073/pnas.80.14.4384; FALKOW S, 1992, ANNU REV CELL BIOL, V8, P333, DOI 10.1146/annurev.cb.08.110192.002001; Finlay B B, 1994, Curr Top Microbiol Immunol, V192, P163; FINLAY BB, 1991, J CELL SCI, V99, P283; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; FISCHETTI VA, 1985, J EXP MED, V161, P1384, DOI 10.1084/jem.161.6.1384; FRANCIS CL, 1992, MOL MICROBIOL, V6, P3077, DOI 10.1111/j.1365-2958.1992.tb01765.x; GAILLARD JL, 1987, INFECT IMMUN, V55, P2822, DOI 10.1128/IAI.55.11.2822-2829.1987; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; GAILLARD JL, 1994, METHOD ENZYMOL, V236, P551; GALLIN WJ, 1983, P NATL ACAD SCI-BIOL, V80, P1038, DOI 10.1073/pnas.80.4.1038; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Isberg Ralph R., 1994, Trends in Microbiology, V2, P10, DOI 10.1016/0966-842X(94)90338-7; ISBERG RR, 1988, P NATL ACAD SCI USA, V85, P6682, DOI 10.1073/pnas.85.18.6682; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; KAPLAN G, 1977, SCAND J IMMUNOL, V6, P797, DOI 10.1111/j.1365-3083.1977.tb02153.x; KARECLA PI, 1995, EUR J IMMUNOL, V25, P852, DOI 10.1002/eji.1830250333; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KIRKPATRICK C, 1995, CURR OPIN GENET DEV, V5, P56, DOI 10.1016/S0959-437X(95)90054-3; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LEPAY DA, 1985, J EXP MED, V161, P1503, DOI 10.1084/jem.161.6.1503; MACDONALD TT, 1980, INFECT IMMUN, V28, P516; MARCO AJ, 1992, J COMP PATHOL, V107, P1, DOI 10.1016/0021-9975(92)90090-H; MASON I, 1994, CURR BIOL, V4, P1158, DOI 10.1016/S0960-9822(00)00263-3; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MILLER VL, 1994, INVASION GENES YERSI, P213; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Parsot C, 1994, Curr Top Microbiol Immunol, V192, P217; RACZ P, 1972, LAB INVEST, V26, P694; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P89, DOI 10.1016/S0962-8924(00)88956-4; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TANG P, 1994, MOL BIOL CELL, V5, P455, DOI 10.1091/mbc.5.4.455; TEMMGROVE CJ, 1994, J CELL SCI, V107, P2951; VELGE P, 1994, MICROB PATHOGENESIS, V17, P37, DOI 10.1006/mpat.1994.1050; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; WILLEMS J, 1995, FEBS LETT, V363, P289, DOI 10.1016/0014-5793(95)00334-6; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; YOUNG VB, 1992, J CELL BIOL, V116, P197, DOI 10.1083/jcb.116.1.197	63	667	687	1	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1996	84	6					923	932		10.1016/S0092-8674(00)81070-3	http://dx.doi.org/10.1016/S0092-8674(00)81070-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601315	Bronze			2022-12-28	WOS:A1996UC38100013
J	Fagon, JY; Chastre, J; Vuagnat, A; Trouillet, JL; Novara, A; Gibert, C				Fagon, JY; Chastre, J; Vuagnat, A; Trouillet, JL; Novara, A; Gibert, C			Nosocomial pneumonia and mortality among patients in intensive care units	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTINUOUS MECHANICAL VENTILATION; PROTECTED SPECIMEN BRUSH; ATTRIBUTABLE MORTALITY; INFECTION; RISK; FATALITY; FAILURE; DEATHS; SYSTEM; STAY	Objective.-To evaluate the role that nosocomial pneumonia plays in the outcome of intensive care unit (ICU) patients. Design.-Cohort study. Setting.-Medical ICU, Hospital Bichat, Paris, France, an academic tertiary care center. Patients.-A total of 1978 consecutive patients admitted to the ICU for at least 48 hours. Main Outcome Measures.-Various parameters known to be strongly associated with death of ICU patients were recorded: age, location before admission to the ICU, diagnostic categories, Acute Physiology and Chronic Health Evaluation (APACHE) II score, Simplified Acute Physiologic Score, McCabe score, number and type of dysfunctional organs, and the development of nosocomial bacteremia and nosocomial urinary tract infection. These variables and the presence or absence of nosocomial pneumonia were compared between survivors and nonsurvivors and entered into a stepwise logistic regression model to evaluate their independent prognostic roles. Results.-Nosocomial pneumonia developed in 328 patients (16.6%) whose mortality rate was 52.4% compared with 22.4% for patients without ICU-acquired pneumonia (P<.001). APACHE II score (odds ratio [OR]=1.08; 95% confidence interval [CI], 1.06 to 1.10; P<.001), number of dysfunctional organs (OR=1.54; 95% CI, 1.36 to 1.74; P<.001), nosocomial pneumonia (OR=2.08; 95% CI, 1.55 to 2.80; P<.001), nosocomial bacteremia (OR=2.51; 95% CI, 1.78 to 3.55; P<.001), ultimately or rapidly fatal underlying disease (OR=1.76; 95% CI, 1.38 to 2.25; P<.001), and admission from another ICU (OR=1.30; 95% CI, 1.01 to 1.68; P=.04) were significantly associated with mortality. Conclusion.-These data suggest that, in addition to the severity of underlying medical conditions and nosocomial bacteremia, nosocomial pneumonia independently contributes to ICU patient mortality.			Fagon, JY (corresponding author), HOP BICHAT,SERV REANIMAT MED,46 RUE HENRI HUCHARD,F-75877 PARIS 18,FRANCE.							BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BUENOCAVANILLAS A, 1994, CRIT CARE MED, V22, P55, DOI 10.1097/00003246-199401000-00013; CHASTRE J, 1994, AM J RESP CRIT CARE, V150, P570, DOI 10.1164/ajrccm.150.2.8049850; CHASTRE J, 1995, AM J RESP CRIT CARE, V152, P231, DOI 10.1164/ajrccm.152.1.7599829; CHASTRE J, 1988, AM J MED, V85, P499; CRAIG CP, 1984, AM J INFECT CONTROL, V12, P233, DOI 10.1016/0196-6553(84)90114-7; CRAVEN DE, 1988, ARCH INTERN MED, V148, P1161, DOI 10.1001/archinte.148.5.1161; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; FAGON JY, 1993, INTENS CARE MED, V19, P137, DOI 10.1007/BF01720528; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FAGON JY, 1993, CHEST, V103, P547, DOI 10.1378/chest.103.2.547; GROSS PA, 1983, AM J MED, V75, P658, DOI 10.1016/0002-9343(83)90453-9; GROSS PA, 1980, AM J MED, V68, P219, DOI 10.1016/0002-9343(80)90357-5; HALEY RW, 1985, AM J EPIDEMIOL, V121, P159, DOI 10.1093/oxfordjournals.aje.a113988; HURLEY JC, 1995, ANTIMICROB AGENTS CH, V39, P941, DOI 10.1128/AAC.39.4.941; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LEU HS, 1989, AM J EPIDEMIOL, V129, P1258, DOI 10.1093/oxfordjournals.aje.a115245; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; MEDURI GU, 1990, CHEST, V97, P1208, DOI 10.1378/chest.97.5.1208; NIEDERMAN MS, 1994, AM J RESP CRIT CARE, V150, P565, DOI 10.1164/ajrccm.150.2.8049849; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; SPILKER B, 1991, GUIDE CLIN TRIALS, P134; TEASDALE G, 1974, LANCET, V2, P81; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523	28	333	349	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					866	869		10.1001/jama.275.11.866	http://dx.doi.org/10.1001/jama.275.11.866			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ971	8596225				2022-12-28	WOS:A1996TZ97100030
J	Schieber, RA; Switzer, DW				Schieber, RA; Switzer, DW			Injuries from propane gas grills	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									US CONSUMER PROD SAFETY COMMISS,BETHESDA,MD		Schieber, RA (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA 30341, USA.							*US CONS PROD SAF, 1992, NEISS SAMPL DES IMPL	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					886	886		10.1001/jama.275.11.886	http://dx.doi.org/10.1001/jama.275.11.886			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ971	8596229				2022-12-28	WOS:A1996TZ97100035
J	Craig, NL				Craig, NL			Update - V(D)J recombination and transposition: Closer than expected	SCIENCE			English	Editorial Material											Craig, NL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.							CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; WWEVER DT, 1995, TRENDS GENET, V11, P388	5	18	67	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1512	1512		10.1126/science.271.5255.1512	http://dx.doi.org/10.1126/science.271.5255.1512			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599105				2022-12-28	WOS:A1996TZ98300025
J	Crossley, PH; Martinez, S; Martin, GR				Crossley, PH; Martinez, S; Martin, GR			Midbrain development induced by FGF8 in the chick embryo	NATURE			English	Article							EXPRESSION PATTERNS; INT-1 PROTOONCOGENE; MOUSE-BRAIN; HOMEO BOX; EN-2; PHENOTYPE; REGION; WNT-1; GENES	Vertebrate midbrain development depends on an organizing centre located at the isthmus, a constriction in the embryonic mid/hindbrain region-(1-3,28). Isthmic tissue grafts transform chick caudal forebrain into an ectopic midbrain that is the mirror image of the normal midbrain(4). Here we report that FGF8 protein has the same midbrain-inducing and polarizing effect as isthmic tissue. Moreover, FGF8 induces ectopic expression in the forebrain of genes normally expressed in the isthmus, suggesting that the ectopic midbrain forms under the influence of signals from a new 'isthmus-like' organizing centre induced in the forebrain. Because Fgf8 itself is expressed in the isthmus, our results identify FGF8 as an important signalling molecule in normal midbrain development.	UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV ALICANTE,INST NEUROSCI,ALACANT,SPAIN; UNIV MURCIA,FAC MED,DEPT MORPHOL SCI,E-30001 MURCIA,SPAIN	University of California System; University of California San Francisco; Universitat d'Alacant; University of Murcia	Crossley, PH (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.		Mratinez, Salvador/L-4896-2014	Mratinez, Salvador/0000-0002-9320-4103; Martinez, Salvador/0000-0002-2910-8926				ANG SL, 1993, DEVELOPMENT, V118, P139; BALLYCUIF L, 1992, DEVELOPMENT, V115, P999; BALLYCUIF L, 1994, DEVELOPMENT, V120, P3379; BALLYCUIF L, 1995, CURR OPIN GENET DEV, V5, P450, DOI 10.1016/0959-437X(95)90048-L; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; GARDNER CA, 1992, DEV DYNAM, V193, P370, DOI 10.1002/aja.1001930410; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; HOLLYDAY M, 1995, MECH DEVELOP, V52, P9, DOI 10.1016/0925-4773(95)00385-E; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; MARIN F, 1994, DEV BIOL, V163, P19, DOI 10.1006/dbio.1994.1120; MARIN F, 1995, EUR J NEUROSCI, V7, P1714, DOI 10.1111/j.1460-9568.1995.tb00693.x; MARTINEZ S, 1991, NEURON, V6, P971, DOI 10.1016/0896-6273(91)90237-T; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; RUBENSTEIN J, 1995, SCIENCE, V266, P578; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; WILKINSON D, 1992, IN SITU HYBRIDISATIO; WURST W, 1994, DEVELOPMENT, V120, P2065	28	597	604	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					66	68		10.1038/380066a0	http://dx.doi.org/10.1038/380066a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598907				2022-12-28	WOS:A1996TY87700057
J	Mendelson, JH; Mello, NK				Mendelson, JH; Mello, NK			Drug therapy: Management of cocaine abuse and dependence	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ADRENOCORTICOTROPIN ACTH SECRETION; METHADONE-MAINTENANCE; INTRAVENOUS COCAINE; ANTERIOR-PITUITARY; ALCOHOL DEPENDENCE; OPIOID DEPENDENCE; CONTROLLED TRIAL; RHESUS-MONKEYS; HIV INFECTION; BROMOCRIPTINE		HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Harvard Medical School	Mendelson, JH (corresponding author), MCLEAN HOSP, 115 MILL ST, BELMONT, MA 02178 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R18DA006116, K05DA000064, K05DA000101] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 06116, KO5-DA 00101, KO5-DA 00064] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALTERMAN AI, 1992, DRUG ALCOHOL DEPEN, V31, P19, DOI 10.1016/0376-8716(92)90004-V; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Anker A L, 1982, NIDA Res Monogr, V41, P452; [Anonymous], 1978, ARCH GEN PSYCHIAT, V35, P335; BATKI SL, 1993, J CLIN PSYCHOPHARM, V13, P243; Bergman J., 1990, Behav Pharmacol, V1, P355; Bickel WK, 1995, EXP CLIN PSYCHOPHARM, V3, P477, DOI 10.1037/1064-1297.3.4.477; CARRERA MRA, 1995, NATURE, V378, P727, DOI 10.1038/378727a0; CARROLL KM, 1991, AM J DRUG ALCOHOL AB, V17, P229, DOI 10.3109/00952999109027549; CARROLL KM, 1994, ARCH GEN PSYCHIAT, V51, P177; CHADWICK MJ, 1990, AM J DRUG ALCOHOL AB, V16, P275, DOI 10.3109/00952999009001589; CHAISSON RE, 1989, JAMA-J AM MED ASSOC, V261, P561, DOI 10.1001/jama.261.4.561; CONDELLI WS, 1991, J SUBST ABUSE TREAT, V8, P203, DOI 10.1016/0740-5472(91)90040-H; CORNISH JW, 1995, DRUG ALCOHOL DEPEN, V38, P221, DOI 10.1016/0376-8716(95)01102-5; COVI L, 1994, CLIN PHARMACOL THER, V55, P132; CRAINE SB, 1993, SCIENCE, V260, P1814; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; DACKIS CA, 1985, NEUROSCI BIOBEHAV R, V9, P469, DOI 10.1016/0149-7634(85)90022-3; DACKIS CA, 1987, PSYCHIAT RES, V20, P261, DOI 10.1016/0165-1781(87)90086-2; DACKIS CA, 1988, PSYCHIAT ANN, V18, P528, DOI 10.3928/0048-5713-19880901-09; DONAHOE RM, 1988, ADV BIOCHEM PSYCHOPH, V44, P145; FOLTIN RW, 1991, J PHARMACOL EXP THER, V257, P247; FREUD S, 1974, COCAINE PAPERS; GASTFRIEND DR, IN PRESS NIDA RES MO; Gastfriend DR, 1993, AM J ADDICTION, V2, P269; GAWIN F, 1985, AM J DRUG ALCOHOL AB, V11, P193, DOI 10.3109/00952998509016861; GAWIN F, 1986, PSYCHIAT CLIN N AM, V9, P573; GAWIN FH, 1989, ARCH GEN PSYCHIAT, V46, P322; GAWIN FH, 1989, ARCH GEN PSYCHIAT, V46, P117; GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107; GAWIN FH, 1989, PSYCHOPHARMACOLOGY, V97, P402, DOI 10.1007/BF00439458; GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806; GAWIN FH, 1988, J CLIN PSYCHIAT, V49, P11; GAWIN FH, 1984, ARCH GEN PSYCHIAT, V41, P903; GFROERER JC, 1993, AM J PUBLIC HEALTH, V83, P1149, DOI 10.2105/AJPH.83.8.1149; GIANNINI AJ, 1987, J CLIN PHARMACOL, V27, P267, DOI 10.1002/j.1552-4604.1987.tb03011.x; GIANNINI AJ, 1989, PSYCHIAT RES, V29, P11, DOI 10.1016/0165-1781(89)90182-0; GOLD MS, 1983, SOC NEUR ABSTR, V9, P157; GRABOWSKI J, 1995, J CLIN PSYCHOPHARM, V15, P163, DOI 10.1097/00004714-199506000-00004; HALIKAS J, 1989, LANCET, V1, P623; Halikas James A., 1993, Journal of Addictive Diseases, V12, P129, DOI 10.1300/J069v12n02_09; HIGGINS ST, 1994, AM J DRUG ALCOHOL AB, V20, P47, DOI 10.3109/00952999409084056; HIGGINS ST, 1994, DRUG ALCOHOL DEPEN, V34, P87, DOI 10.1016/0376-8716(94)90128-7; HIGGINS ST, 1994, ARCH GEN PSYCHIAT, V51, P568; HIGGINS ST, 1993, AM J PSYCHIAT, V150, P763; HOLLANDER JE, 1995, NEW ENGL J MED, V333, P1267, DOI 10.1056/NEJM199511093331907; HOLMAN BL, 1991, J NUCL MED, V32, P1206; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; Jaffe J.H., 1990, PHARMACOL BASIS THER, P522; JOHANSON CE, 1995, DRUG ALCOHOL DEPEN, V38, P201, DOI 10.1016/0376-8716(95)98131-L; JOHANSON CE, 1989, PHARMACOL REV, V41, P3; JOHNSON RE, 1992, JAMA-J AM MED ASSOC, V267, P2750, DOI 10.1001/jama.267.20.2750; Jones R T, 1986, NIDA Res Monogr, V68, P142; KLEBER H, 1986, AM J DRUG ALCOHOL AB, V12, P235, DOI 10.3109/00952998609007393; Kleber H D, 1984, NIDA Res Monogr, V50, P111; KOLAR AF, 1992, INT J ADDICT, V27, P849, DOI 10.3109/10826089209068770; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; KOSTEN TR, 1988, AM J PSYCHIAT, V145, P381; KOSTEN TR, 1992, ARCH GEN PSYCHIAT, V49, P894; KOSTEN TR, 1993, J NERV MENT DIS, V181, P358, DOI 10.1097/00005053-199306000-00004; KOSTEN TR, 1989, LIFE SCI, V44, P887, DOI 10.1016/0024-3205(89)90589-4; KOSTEN TR, 1987, J CLIN PSYCHIAT, V48, P442; KRANZLER HR, 1995, DRUG ALCOHOL DEPEN, V38, P203, DOI 10.1016/0376-8716(95)01100-D; Kreek M.J., 1987, PSYCHOPHARMACOLOGY 3, P1597; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; KUHAR MJ, 1993, PHARMACOLOGIST, V35, P28; LANDRY DW, 1993, SCIENCE, V259, P1899, DOI 10.1126/science.8456315; Margolin A, 1995, DRUG ALCOHOL DEPEN, V40, P125, DOI 10.1016/0376-8716(95)01198-6; MARLOWE DB, 1995, AM J ADDICTION, V4, P70; MARZUK PM, 1995, NEW ENGL J MED, V332, P1753, DOI 10.1056/NEJM199506293322606; MCCANCE EF, 1995, J PHARMACOL EXP THER, V274, P215; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; MELLO NK, 1990, J PHARMACOL EXP THER, V254, P815; MELLO NK, 1993, HARVARD REV PSYCHIAT, V1, P168, DOI 10.3109/10673229309017075; MELLO NK, 1993, J PHARMACOL EXP THER, V266, P804; MELLO NK, 1989, SCIENCE, V245, P859, DOI 10.1126/science.2772637; MELLO NK, IN PRESS NEUROPSYCHO; MELLO NK, 1983, PATHOGENESIS ALCOHOL, V7, P133; Mendelson J. H., 1994, HARRISONS PRINCIPLES, P2429; MENDELSON JH, 1989, J CLIN ENDOCR METAB, V69, P1256, DOI 10.1210/jcem-69-6-1256; MENDELSON JH, 1992, J PHARMACOL EXP THER, V263, P505; MENDELSON JH, 1992, NEUROPSYCHOPHARMACOL, V7, P157; MENDELSON JH, 1979, NEW ENGL J MED, V301, P912, DOI 10.1056/NEJM197910253011704; MENDELSON JH, 1978, P 39 ANN SCI M COMM, P572; MILLMAN RB, 1988, J CLIN PSYCHIAT, V49, P27; MOLITERNO DJ, 1994, NEW ENGL J MED, V330, P454, DOI 10.1056/NEJM199402173300702; MONTOYA ID, 1995, DRUG ALCOHOL DEPEN, V38, P213, DOI 10.1016/0376-8716(95)01101-4; MUSTO DF, 1973, AM DISEASE ORIGINS N; NAJAVITS LM, 1994, HARVARD REV PSYCHIAT, V2, P84, DOI 10.3109/10673229409017121; *NAT COMM ACQ IMM, 1991, 5 NAT COMM ACQ IMM D; *NAT I DRUG AB, 1995, NIH PUBL; NESTLER EJ, 1994, NEUROPSYCHOPHARMACOL, V11, P77, DOI 10.1038/npp.1994.37; OBRIEN CP, 1990, ADDICT BEHAV, V15, P355, DOI 10.1016/0306-4603(90)90045-Y; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; PILLAI R, 1991, ARCH TOXICOL, V65, P609, DOI 10.1007/BF02098025; PRESTON KL, 1993, J PHARMACOL EXP THER, V267, P296; Rawson R A, 1991, J Subst Abuse, V3, P457; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; RITZ MC, 1994, PSYCHOPHARMACOLOGY, V114, P47, DOI 10.1007/BF02245443; RIVIER C, 1987, BRAIN RES, V422, P403, DOI 10.1016/0006-8993(87)90953-X; SARNYAI Z, IN PRESS J PHARM EXP; SATEL SL, 1991, AM J PSYCHIAT, V148, P1712; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; SCHOTTENFELD RS, 1993, BIOL PSYCHIAT, V34, P66, DOI 10.1016/0006-3223(93)90258-F; SPEALMAN RD, 1992, NEUROCHEM INT, V20, pS147; *SUBST AB MENT HLT, 1994, 7 SUBST AB MENT HLTH, P29; *SUBST AB MENT HLT, 1993, 2 SUBST AB MENT HLTH; TAYLOR D, 1977, J NEUROSCI RES, V3, P95, DOI 10.1002/jnr.490030203; TELLER DW, 1988, INT J ADDICT, V23, P1197, DOI 10.3109/10826088809056194; TENNANT FS, 1987, ARCH INTERN MED, V147, P109, DOI 10.1001/archinte.147.1.109; Tennant FS, 1985, NIDA RES MONOGR, V55, P159; TENNANT FS, 1986, MED WITHDRAWAL COCAI, P1; TEOH SK, 1993, J CLIN PSYCHOPHARM, V13, P87; TIMS FM, 1993, NIDA RES MONOGR, V135, P266; Tutton Craig S., 1993, Journal of Addictive Diseases, V12, P109, DOI 10.1300/J069v12n02_08; VANDENABEELE P, 1983, J ECON PSYCHOL, V3, P1; VIEDERMAN M, 1995, AM J PSYCHIAT, V152, P1; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; WEDDINGTON WW, 1990, ARCH GEN PSYCHIAT, V47, P861; WOLFSOHN R, 1993, NEUROPSYCHOPHARMACOL, V9, P49, DOI 10.1038/npp.1993.42; WOOLVERTON WL, 1992, TRENDS PHARMACOL SCI, V13, P193, DOI 10.1016/0165-6147(92)90063-C; [No title captured]	122	232	235	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 11	1996	334	15					965	972		10.1056/NEJM199604113341507	http://dx.doi.org/10.1056/NEJM199604113341507			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD596	8596599				2022-12-28	WOS:A1996UD59600007
J	Gomi, H; Kawato, M				Gomi, H; Kawato, M			Equilibrium-point control hypothesis examined by measured arm stiffness during multijoint movement	SCIENCE			English	Article							HUMAN ELBOW JOINT; TRAJECTORY FORMATION; VOLUNTARY MOVEMENTS; POSTURE; MODEL; COORDINATION; MAINTENANCE; CEREBELLUM; POSITION	For the last 20 years, it has been hypothesized that well-coordinated, multijoint movements are executed without complex computation by the brain, with the use of springlike muscle properties and peripheral neural feedback loops. However, it has been technically and conceptually difficult to examine this ''equilibrium-point control'' hypothesis directly in physiological or behavioral experiments. A high-performance manipulandum was developed and used here to measure human arm stiffness, the magnitude of which during multijoint movement is important for this hypothesis. Here, the equilibrium-point trajectory was estimated from the measured stiffness, the actual trajectory, and the generated torque. Its velocity profile differed from that of the actual trajectory. These results argue against the hypothesis that the brain sends as a motor command only an equilibrium-point trajectory similar to the actual trajectory.	ATR HUMAN INFORMAT PROC RES LABS, SEIKA, KYOTO, JAPAN		Gomi, H (corresponding author), NIPPON TELEGRAPH & TEL PUBL CORP, BASIC RES LABS, INFORMAT SCI RES LAB, WAKAMIYA 3-1, ATSUGI, KANAGAWA, JAPAN.		Gomi, Hiroaki/C-5269-2013; Gomi, Hiroaki/AEL-2645-2022	Gomi, Hiroaki/0000-0003-3541-2251				ABEND W, 1982, BRAIN, V105, P331, DOI 10.1093/brain/105.2.331; BENNETT DJ, 1992, EXP BRAIN RES, V88, P433, DOI 10.1007/BF02259118; BENNETT DJ, 1993, EXP BRAIN RES, V95, P488; BIZZI E, 1976, J NEUROPHYSIOL, V39, P435, DOI 10.1152/jn.1976.39.2.435; BIZZI E, 1984, J NEUROSCI, V4, P2738; DOLAN JM, 1993, IEEE T SYST MAN CYB, V23, P698, DOI 10.1109/21.256543; FELDMAN AG, 1966, BIOPHYS-USSR, V11, P565; FELDMAN AG, 1986, J MOTOR BEHAV, V18, P17; FLANAGAN JR, 1993, J MOTOR BEHAV, V25, P140, DOI 10.1080/00222895.1993.9942045; FLASH T, 1985, J NEUROSCI, V5, P1688, DOI 10.1523/jneurosci.05-07-01688.1985; FLASH T, 1987, BIOL CYBERN, V57, P257, DOI 10.1007/BF00338819; FLASH T, 1990, EXP BRAIN RES, V82, P315; GOMI H, 1992, P 14 IEEE ENG MED BI, V4, P1628; GOMI H, 1995, ISRL954 NTT BAS RES; HOGAN N, 1985, BIOL CYBERN, V52, P315, DOI 10.1007/BF00355754; HOGAN N, 1984, J NEUROSCI, V4, P2745; HOLLERBACH JM, 1989, ROBOTICS SCI, P378; KATAYAMA M, 1993, BIOL CYBERN, V69, P353, DOI 10.1007/BF01185407; KAWATO M, 1987, BIOL CYBERN, V57, P169, DOI 10.1007/BF00364149; KAWATO M, 1992, TRENDS NEUROSCI, V15, P445, DOI 10.1016/0166-2236(92)90008-V; KAWATO M, 1992, ATTENTION PERFORM, V14, P821; KELSO JAS, 1979, SCIENCE, V203, P1029, DOI 10.1126/science.424729; LACQUANITI F, 1993, J NEUROPHYSIOL, V69, P1443, DOI 10.1152/jn.1993.69.5.1443; MCINTYRE J, 1993, J MOTOR BEHAV, V25, P193, DOI 10.1080/00222895.1993.9942049; MORASSO P, 1981, EXP BRAIN RES, V42, P223; MUSSAIVALDI FA, 1985, J NEUROSCI, V5, P2732; NICHOLS TR, 1976, J NEUROPHYSIOL, V39, P119, DOI 10.1152/jn.1976.39.1.119; Paul R.P., 1981, ROBOT MANIPULATORS M; POLIT A, 1979, J NEUROPHYSIOL, V42, P183, DOI 10.1152/jn.1979.42.1.183; SCHWEIGHOFER N, 1995, THESIS SO CALIFORNIA; SHIDARA M, 1993, NATURE, V365, P50, DOI 10.1038/365050a0; TSUJI T, 1995, BIOL CYBERN, V72, P475, DOI 10.1007/BF00199890; UNO Y, 1989, BIOL CYBERN, V61, P89, DOI 10.1007/BF00204593; WITNERS JM, 1990, MULTIPLE MUSCLE SYST, P69; 1993, J MOT BEHAV, V25; 1992, BEHAV BRAIN SCI, V15	36	342	347	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1996	272	5258					117	120		10.1126/science.272.5258.117	http://dx.doi.org/10.1126/science.272.5258.117			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UD597	8600521				2022-12-28	WOS:A1996UD59700053
J	Bucher, HC; Cook, RJ; Guyatt, GH; Lang, JD; Cook, DJ; Hatala, R; Hunt, DL				Bucher, HC; Cook, RJ; Guyatt, GH; Lang, JD; Cook, DJ; Hatala, R; Hunt, DL			Effects of dietary calcium supplementation on blood pressure - A meta-analysis of randomized controlled trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ORAL CALCIUM; ESSENTIAL-HYPERTENSION; DOUBLE-BLIND; NORMOTENSIVE SUBJECTS; MILD HYPERTENSION; VEGETARIAN DIET; CONTROLLED INTERVENTION; CROSSOVER TRIAL; NUTRIENT INTAKE; MEN	Objective.-To review the effect of supplemental calcium on blood pressure. Data Source. We searched MEDLINE and EMBASE for 1966 to May 1994. We contacted authors of eligible trials to ensure accuracy and completeness of data and to identify unpublished trials. Study Selection.-We included any study in which investigators randomized people to calcium supplementation or placebo and measured blood pressure for at least 2 weeks. Fifty-six articles met the inclusion criteria, and 33 were eligible for analysis, involving a total of 2412 patients. Data Extraction.-Two pairs of independent reviewers abstracted data and assessed validity according to six quality criteria. Data Synthesis.-We calculated the differences in blood pressure change between the calcium supplementation group and the control group and pooled the estimates, with each trial weighted with the inverse of the variance using a random-effects model, Predictors of blood pressure reduction that we examined included method of supplementation, baseline blood pressure, and the methodological quality of the studies. The pooled analysis showed a reduction in systolic blood pressure of -1.27 mm Hg (95% confidence interval [CI], -2.25 to -0.29 mm Hg; P=.01) and in diastolic blood pressure of -0.24 mm Hg (95% CI, -0.92 to 0.44 mm Hg; P=.49). None of the possible mediators of blood pressure reduction explained differences in treatment effects. Conclusions.-Calcium supplementation may lead to a small reduction in systolic but not diastolic blood pressure. The results do not exclude a larger, important effect of calcium on blood pressure in subpopulations. In particular, further studies should address the hypothesis that inadequate calcium intake is associated with increased blood pressure that can be corrected with calcium supplementation.	MCMASTER UNIV,MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON,ON L8N 3Z5,CANADA; MCMASTER UNIV,DEPT MED,HAMILTON,ON L8N 3Z5,CANADA; UNIV WATERLOO,FAC APPL HLTH SCI,DEPT HLTH STUDIES & GERONTOL,KITCHENER,ON,CANADA	McMaster University; McMaster University; University of Waterloo				Cook, Richard/0000-0002-1414-4908				APPEL LJ, 1993, ARCH INTERN MED, V153, P1429, DOI 10.1001/archinte.153.12.1429; BELIZAN JM, 1983, JAMA-J AM MED ASSOC, V249, P1161, DOI 10.1001/jama.249.9.1161; BIERENBAUM ML, 1988, AM J HYPERTENS, V1, pS149, DOI 10.1093/ajh/1.3.149S; BLOOMFIELD RL, 1986, J HYPERTENS, V4, pS351; BUCHER HC, IN PRESS JAMA; CAPPUCCIO FP, 1995, AM J EPIDEMIOL, V142, P935, DOI 10.1093/oxfordjournals.aje.a117741; CAPPUCCIO FP, 1991, J HYPERTENS, V9, P465, DOI 10.1097/00004872-199105000-00011; CAPPUCCIO FP, 1986, CLIN SCI, V71, P453, DOI 10.1042/cs0710453; CAPPUCCIO FP, 1989, J HYPERTENS, V7, P941, DOI 10.1097/00004872-198912000-00003; CAPPUCCIO FP, 1987, J HYPERTENS, V5, P67, DOI 10.1097/00004872-198702000-00010; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; CUTLER JA, 1990, AM J HYPERTENS, V3, pS137, DOI 10.1093/ajh/3.8.137; CUTLER JA, 1992, JAMA-J AM MED ASSOC, V267, P1213; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; DUMAS P, 1995, AM J MED SCI S1, V307, pS130; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; GALLOE AM, 1993, J HUM HYPERTENS, V7, P43; GILLMAN MW, 1995, J PEDIATR-US, V127, P186, DOI 10.1016/S0022-3476(95)70293-8; GROBBEE DE, 1986, LANCET, V2, P703; HAKALA P, 1989, EUR J CLIN NUTR, V43, P421; HAMET P, 1993, EVALUATION SCI EVIDE, pA1; INSUA JT, 1994, ANN INTERN MED, V121, P355, DOI 10.7326/0003-4819-121-5-199409010-00008; JESPERSEN B, 1993, J HUM HYPERTENS, V7, P103; JOHNSON NE, 1985, AM J CLIN NUTR, V42, P12, DOI 10.1093/ajcn/42.1.12; KARANJA N, 1987, AM J CLIN NUTR, V5, P60; KYNASTGALES S, 1992, J AM DIET ASSOC, V92, P1497; LASARIDIS AN, 1987, J HYPERTENS       S5, V5, pS307; LIND L, 1988, AM J HYPERTENS, V1, P397, DOI 10.1093/ajh/1.4.397; LUFT FC, 1989, AM J HYPERTENS, V2, P14, DOI 10.1093/ajh/2.1.14; LYLE RM, 1988, AM J CLIN NUTR, V47, P1030, DOI 10.1093/ajcn/47.6.1030; LYLE RM, 1992, NETH J MED, V41, P48; LYLE RM, 1987, JAMA-J AM MED ASSOC, V257, P1772, DOI 10.1001/jama.257.13.1772; MARGETTS BM, 1986, BRIT MED J, V293, P1468, DOI 10.1136/bmj.293.6560.1468; MCCARRON DA, 1987, ANN INTERN MED, V107, P919, DOI 10.7326/0003-4819-107-6-919; MCCARRON DA, 1985, ANN INTERN MED, V103, P825, DOI 10.7326/0003-4819-103-6-825; MEESE RB, 1986, CLIN RES, V34, pA218; MEESE RB, 1987, AM J MED SCI, V294, P219, DOI 10.1097/00000441-198710000-00001; MORRIS CD, 1988, CLIN RES, V36, pA139; NOWSON C, 1989, HYPERTENSION, V13, P630, DOI 10.1161/01.HYP.13.6.630; NOWSON C, 1986, J HYPERTENS, V4, pS673; NOWSON C, 1988, J HYPERTENS, V6, pS637, DOI 10.1097/00004872-198812040-00200; NOWSON C, 1988, 12 SCI M INT SOC HYP; ORWOLL ES, 1990, AM J CLIN NUTR, V52, P717, DOI 10.1093/ajcn/52.4.717; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B; Pan W H, 1993, Chin J Physiol, V36, P85; RESNICK LM, 1985, ANN INTERN MED, V103, P944, DOI 10.7326/0003-4819-103-6-944; RESNICK LM, 1986, ANN INTERN MED, V105, P649, DOI 10.7326/0003-4819-105-5-649; RESNICK LM, 1986, J HYPERTENS, V4, pS679; ROUSE IL, 1983, LANCET, V1, P5; ROUSE IL, 1986, J HYPERTENS, V4, P241, DOI 10.1097/00004872-198604000-00016; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SAITO K, 1989, HYPERTENSION, V13, P219, DOI 10.1161/01.HYP.13.3.219; Satterfield S, 1991, Ann Epidemiol, V1, P455; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SIANI A, 1988, J HYPERTENS, V6, P253, DOI 10.1097/00004872-198803000-00011; SIANI A, 1987, J HYPERTENS       S5, V5, pS311; SINGH RB, 1993, J HUM HYPERTENS, V7, P33; STAMLER J, 1989, HYPERTENSION S5, V13, pI33; STRAZZULLO P, 1986, HYPERTENSION, V8, P1084, DOI 10.1161/01.HYP.8.11.1084; SUNDERRAJAN S, 1984, CIRCULATION, V70, P130; TAKAGI Y, 1991, AM J HYPERTENS, V4, P836, DOI 10.1093/ajh/4.10.836; Tanji J L, 1991, J Am Board Fam Pract, V4, P145; TERASAWA F, 1976, YOKUFUKAI GERIATR J, V1, P15; THOMSEN K, 1987, ACTA MED SCAND, V222, P51; VANBERESTEIJN ECH, 1990, J INTERN MED, V228, P477, DOI 10.1111/j.1365-2796.1990.tb00266.x; VANBERESTEYN ECH, 1986, AM J CLIN NUTR, V44, P883, DOI 10.1093/ajcn/44.6.883; VILLAR J, 1984, ANN NY ACAD SCI, V435, P509, DOI 10.1111/j.1749-6632.1984.tb13868.x; VINSON JA, 1987, NUTR REP INT, V36, P497; WAALMANNING HJ, 1987, NEW ZEAL MED J, V100, P252; WEINBERGER MH, 1993, AM J HYPERTENS, V6, P799, DOI 10.1093/ajh/6.9.799; ZHOU CY, 1994, AM J HYPERTENS, V7, P363, DOI 10.1093/ajh/7.4.363; ZOCCALI C, 1986, J HYPERTENS, V4, pS676; ZOCCALI C, 1988, J HYPERTENS, V6, P451, DOI 10.1097/00004872-198806000-00004; ZOCCALI C, 1987, J HYPERTENS       S5, V5, pS267; ZOCCALI C, 1985, P EUR DIAL TRANSPL A, V22, P884; [No title captured]; 1994, JAMA-J AM MED ASSOC, V272, P1942; 1986, JAMA-J AM MED ASSOC, V256, P70	81	233	240	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					1016	1022		10.1001/jama.275.13.1016	http://dx.doi.org/10.1001/jama.275.13.1016			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC123	8596234				2022-12-28	WOS:A1996UC12300030
J	Axelrod, JD; Matsuno, K; ArtavanisTsakonas, S; Perrimon, N				Axelrod, JD; Matsuno, K; ArtavanisTsakonas, S; Perrimon, N			Interaction between wingless and notch signaling pathways mediated by dishevelled	SCIENCE			English	Article							SEGMENT-POLARITY GENE; CELL-FATE; DROSOPHILA-MELANOGASTER; PATTERN-FORMATION; IMAGINAL DISKS; PROTEIN; EXPRESSION; RECEPTOR; PRODUCT; LOCUS	In Drosophila, the Wingless and Notch signaling pathways function in many of the same developmental patterning events. Genetic analysis demonstrates that the dishevelled gene, which encodes a molecule previously implicated in implementation of the Wingless signal, interacts antagonistically with Notch and one of its known ligands, Delta. A direct physical interaction between Dishevelled and the Notch carboxyl terminus, distal to the cdc10/ankyrin repeats, suggests a mechanism for this interaction. it is proposed that Dishevelled, in addition to transducing the Wingless signal, blocks Notch signaling directly, thus providing a molecular mechanism for the inhibitory cross talk observed between these pathways.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; YALE UNIV, SCH MED, BOYER CTR MOLEC MED, DEPT CELL BIOL, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, BOYER CTR MOLEC MED, DEPT BIOL, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06536 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Yale University; Yale University; Howard Hughes Medical Institute; Yale University			Perrimon, Norbert/F-9766-2011	Perrimon, Norbert/0000-0001-7542-472X				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; AXELROD JD, UNPUB; BAKER NE, 1988, DEVELOPMENT, V102, P489; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BLAIR SS, 1992, DEV BIOL, V152, P263, DOI 10.1016/0012-1606(92)90134-3; BOULIANNE GL, 1991, EMBO J, V10, P2975, DOI 10.1002/j.1460-2075.1991.tb07848.x; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHOU TB, 1992, GENETICS, V131, P643; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, CELL, V79, P259, DOI 10.1016/0092-8674(94)90195-3; COUSO JP, 1994, DEVELOPMENT, V120, P621; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DECELIS JF, 1994, MECH DEVELOP, V46, P109, DOI 10.1016/0925-4773(94)90080-9; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GONZALEZGAITAN M, 1995, DEVELOPMENT, V121, P2313; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HING HK, 1994, MECH DEVELOP, V47, P261, DOI 10.1016/0925-4773(94)90044-2; HUANG F, 1991, DEVELOPMENT, V111, P1087; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; LYMAN D, 1993, P NATL ACAD SCI USA, V90, P10395, DOI 10.1073/pnas.90.21.10395; MARTINEZARIAS A, 1993, DEV DROSOPHILA MELAN, V1, P517; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PEIFER M, 1993, DEVELOPMENT, P163; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; RAMAKRISHNA NR, 1993, DEVELOPMENT, P95; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; ROBERTSON HM, 1988, GENETICS, V118, P461; RUEL L, 1993, EMBO J, V12, P1657, DOI 10.1002/j.1460-2075.1993.tb05811.x; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; THEISEN H, 1994, DEVELOPMENT, V120, P347; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; Thummel CS, 1992, DROS INF SERV, V71, P150; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WILDER EL, 1995, DEVELOPMENT, V121, P477; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; WOODS DF, 1993, J CELL SCI, P171; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087	68	368	375	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1996	271	5257					1826	1832		10.1126/science.271.5257.1826	http://dx.doi.org/10.1126/science.271.5257.1826			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596950				2022-12-28	WOS:A1996UC77800035
J	Nightingale, SL				Nightingale, SL			First product available for preventing serious RSV disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					902	902						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA563	8598604				2022-12-28	WOS:A1996UA56300009
J	Goldberg, J; Nairn, AC; Kuriyan, J				Goldberg, J; Nairn, AC; Kuriyan, J			Structural basis for the autoinhibition of calcium calmodulin-dependent protein kinase I	CELL			English	Article							LIGHT CHAIN KINASE; CATALYTIC SUBUNIT; INTRASTERIC REGULATION; INHIBITOR PEPTIDE; CRYSTAL-STRUCTURE; BINDING; COMPLEX; RECOGNITION; REFINEMENT; SEQUENCE	The crystal structure of calcium/calmodulin-dependent protein kinase I has been determined in the autoinhibited form. The C-terminal regulatory region of the enzyme forms a helix-loop-helix segment that extends across the two domains of the catalytic core, making multiple inhibitory interactions. Elements of the first regulatory alpha helix and the loop interfere with the binding site for peptide substrates, while the loop and the second helix interact with the ATP-binding domain to induce conformational changes that obstruct the nucleotide binding pocket. lane part of the calmodulin recognition element protrudes away from the catalytic domain and is potentially available for an initial interaction with calmodulin. The structure provides a view of an intact calmodulin target and suggests that substantial structural changes will accompany kinase activation by calmodulin binding to the regulatory region.	ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Rockefeller University	Goldberg, J (corresponding author), HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA.			Nairn, Angus/0000-0002-7075-0195				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BRAGG WL, 1954, ACTA CRYSTALLOGR, V7, P409, DOI 10.1107/S0365110X54001235; Brunger A.T., 1992, X PLOR VERSION 3 1 M; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CHO FS, 1994, BBA-MOL CELL RES, V1224, P156, DOI 10.1016/0167-4889(94)90123-6; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; DAVIS TN, 1992, CELL, V71, P557, DOI 10.1016/0092-8674(92)90590-9; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; FINDLAY WA, 1995, PROTEIN SCI, V4, P2375, DOI 10.1002/pro.5560041116; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GRUNER SM, 1994, CURR OPIN STRUC BIOL, V4, P765, DOI 10.1016/S0959-440X(94)90177-5; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; HUTTNER WB, 1981, J BIOL CHEM, V256, P1482; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KEMP BE, 1994, STRUCTURAL ASPECTS P, P30; KEMP BE, 1991, PSEUDOSUBSTRATE BASE; KENNEDY MB, 1981, P NATL ACAD SCI-BIOL, V78, P1293, DOI 10.1073/pnas.78.2.1293; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE JC, 1995, BIOCHEM BIOPH RES CO, V210, P631, DOI 10.1006/bbrc.1995.1705; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; LEE JSC, 1994, J BIOL CHEM, V269, P2158; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MOCHIZUKI H, 1993, BIOCHEM BIOPH RES CO, V197, P1595, DOI 10.1006/bbrc.1993.2661; NALM AC, 1987, J BIOL CHEM, V262, P7273; NALM AC, 1994, SEMIN CANCER BIOL, V5, P295; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLAH GA, 1993, BIOCHEMISTRY-US, V32, P3649, DOI 10.1021/bi00065a018; PARKER PJ, 1994, PROTEIN KINASES, P68; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PICKERSGILL RW, 1987, ACTA CRYSTALLOGR A, V43, P502, DOI 10.1107/S0108767387099112; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SMITH MK, 1992, J BIOL CHEM, V267, P1761; WILSON AJC, 1949, ACTA CRYSTALLOGR, V2, P318, DOI 10.1107/S0365110X49000813; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	69	265	273	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1996	84	6					875	887		10.1016/S0092-8674(00)81066-1	http://dx.doi.org/10.1016/S0092-8674(00)81066-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601311	Bronze			2022-12-28	WOS:A1996UC38100009
J	Grieco, D; Porcellini, A; Avvedimento, EV; Gottesman, ME				Grieco, D; Porcellini, A; Avvedimento, EV; Gottesman, ME			Requirement for cAMP-PKA pathway activation by M phase-promoting factor in the transition from mitosis to interphase	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; XENOPUS-LAEVIS-OOCYTES; CELL-CYCLE; CATALYTIC SUBUNIT; AMPHIBIAN EGGS; CDC2; DEGRADATION; EXTRACTS; MPF; INACTIVATION	Cell cycle progression in cycling Xenopus egg extracts is accompanied by fluctuations in the concentration of adenosine 3',5'-monophosphate (cAMP) and in the activity of the cAMP-dependent protein kinase (PKA). The concentration of cAMP and the activity of PKA decrease at the onset of mitosis and increase at the transition between mitosis and interphase. Blocking the activation of PKA at metaphase prevented the transition into interphase; the activity of M phase-promoting factor (MPF; the cyclin B-p34(cdc2) complex) remained high, and mitotic cyclins were not degraded. The arrest in mitosis was reversed by the reactivation of PKA. The inhibition of protein synthesis prevented the accumulation of cyclin and the oscillations of MPF, PKA, and cAMP. Addition of recombinant nondegradable cyclin B activated p34(cdc2) and PKA and induced the degradation of full-length cyclin B. Addition of cyclin A activated p34(cdc2) but not PKA, nor did it induce the degradation of full-length cyclin B. These findings suggest that cyclin degradation and exit from mitosis require MPF-dependent activation of the cAMP-PKA pathway.	UNIV NAPLES,SCH MED 2,CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; COLUMBIA UNIV,INST CANC RES,NEW YORK,NY 10032; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE,SCH MED,CATANZARO,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Columbia University; Universita Mediterranea di Reggio Calabria	Grieco, D (corresponding author), UNIV NAPLES,SCH MED 2,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC L CAL,VIA S PANSINI 5,I-80131 NAPLES,ITALY.		Porcellini, Antonio/AAC-6097-2019; Porcellini, Antonio/E-1900-2011	Porcellini, Antonio/0000-0001-6882-9518; GRIECO, Domenico/0000-0002-7131-5742				CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; COSTA M, 1976, J BIOL CHEM, V251, P3313; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FINIDORILEPICARD J, 1981, NATURE, V292, P255, DOI 10.1038/292255a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRIECO D, 1994, P NATL ACAD SCI USA, V91, P9896, DOI 10.1073/pnas.91.21.9896; GRIECO D, UNPUB; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LORCA T, 1992, J CELL SCI, V102, P55; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MALLER JL, 1977, J BIOL CHEM, V252, P1712; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PORCELLINI A, UNPUB; SCHORDERETSLATKINE S, 1978, CELL, V15, P1269, DOI 10.1016/0092-8674(78)90052-1; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682	31	127	131	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1718	1723		10.1126/science.271.5256.1718	http://dx.doi.org/10.1126/science.271.5256.1718			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596931				2022-12-28	WOS:A1996UB15100044
J	Ridge, JP; Fuchs, EJ; Matzinger, P				Ridge, JP; Fuchs, EJ; Matzinger, P			Neonatal tolerance revisited: Turning on newborn T cells with dendritic cells	SCIENCE			English	Article							ANTIGEN-PRESENTING FUNCTION; SMALL B-CELLS; TRANSPLANTATION TOLERANCE; SELF-TOLERANCE; PROTEIN ANTIGENS; IMMUNE-SYSTEM; LYMPHOCYTE-T; INDUCTION; MICE; INVIVO	For some time it has been thought that antigenic challenge in neonatal life is a tolerogenic rather than immunogenic event. Reexamination of the classic neonatal tolerance experiments of Billingham, Brent, and Medawar showed that tolerance is not an intrinsic property of the newborn immune system, but that the nature of the antigen-presenting cell determines whether the outcome is neonatal tolerance or immunization.			Ridge, JP (corresponding author), NIAID,CELLULAR & MOLEC IMMUNOL LAB,SECT T CELL TOLERANCE & MEMORY,GHOST LAB,BETHESDA,MD 20892, USA.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257				ARNOLD B, 1991, ANNU REV IMMUNOL, V9, P297, DOI 10.1146/annurev.iy.09.040191.001501; BAL V, 1990, EUR J IMMUNOL, V20, P1893, DOI 10.1002/eji.1830200904; BANDEIRA A, 1989, P NATL ACAD SCI USA, V86, P272, DOI 10.1073/pnas.86.1.272; BELLGRAU D, 1981, J EXP MED, V153, P1660, DOI 10.1084/jem.153.6.1660; BILLINGHAM R, 1956, P ROY SOC LONDON, V239, P44; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BILLINGHAM RE, 1960, J IMMUNOL, V85, P14; BONNEY EA, UNPUB; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BURNET FM, 1950, AUST J EXP BIOL MED, V28, P291, DOI 10.1038/icb.1950.29; Burnet FM, 1949, PRODUCTION ANTIBODIE; BURNET FM, 1959, CLONAL SELECTION THE; BUSKER AE, 1990, CELL IMMUNOL, V125, P225, DOI 10.1016/0008-8749(90)90076-4; CHEN NX, 1995, TRANSPLANTATION, V59, P933, DOI 10.1097/00007890-199504150-00002; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHIAK J, 1978, IMMUNOLOGY, V34, P265; COBBOLD SP, 1990, EUR J IMMUNOL, V20, P2747, DOI 10.1002/eji.1830201232; DONOHOE JA, 1983, TRANSPLANTATION, V35, P62, DOI 10.1097/00007890-198301000-00012; EYNON EE, 1991, TRANSPLANT P, V23, P729; EYNON EE, 1992, J EXP MED, V175, P131, DOI 10.1084/jem.175.1.131; FINKLEMAN F, UNPUB; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; GERSHON RK, 1971, IMMUNOLOGY, V21, P903; GOLLOB KJ, 1993, J IMMUNOL, V150, P3705; GUERDER S, 1992, J EXP MED, V176, P553, DOI 10.1084/jem.176.2.553; GUERDER S, 1989, COLD SPRING HARB SYM, V54, P799; HOFFMAN PM, 1984, J VIROL, V52, P734, DOI 10.1128/JVI.52.3.734-738.1984; INABA M, 1991, J EXP MED, V173, P549, DOI 10.1084/jem.173.3.549; ISHIZAKA ST, 1986, J IMMUNOL, V137, P2093; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JOHNSON LL, 1988, TRANSPLANTATION, V46, P167; JOHNSON LL, 1988, TRANSPLANTATION, V46, P170; Lafferty K J, 1986, Prog Clin Biol Res, V224, P87; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LASSILA O, 1988, NATURE, V334, P253, DOI 10.1038/334253a0; LAUCHART W, 1980, TRANSPLANTATION, V29, P259, DOI 10.1097/00007890-198003000-00020; LECHLER RI, 1982, J EXP MED, V156, P1835, DOI 10.1084/jem.156.6.1835; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LU CY, 1979, NATURE, V282, P327, DOI 10.1038/282327a0; MACATONIA SE, 1989, J EXP MED, V169, P1255, DOI 10.1084/jem.169.4.1255; MARKMANN J, 1988, NATURE, V336, P476, DOI 10.1038/336476a0; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MILLER A, 1994, EUR J IMMUNOL, V24, P1026, DOI 10.1002/eji.1830240503; MORRISSEY PJ, 1983, J EXP MED, V158, P365, DOI 10.1084/jem.158.2.365; NOSSAL G. J. V., 1957, AUSTRALIAN JOUR EXPTL BIOL AND MED SCI, V35, P549, DOI 10.1038/icb.1957.57; POWELL TJ, 1990, J IMMUNOL, V144, P854; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; RAMMENSEE HG, 1984, J IMMUNOL, V133, P2390; REES MA, 1990, P NATL ACAD SCI USA, V87, P2765, DOI 10.1073/pnas.87.7.2765; RIDGE JP, UNPUB; ROSER BJ, 1989, IMMUNOL REV, V107, P179, DOI 10.1111/j.1600-065X.1989.tb00009.x; Sarzotti M, 1996, SCIENCE, V271, P1726, DOI 10.1126/science.271.5256.1726; SCHURMANS S, 1990, J IMMUNOL, V145, P2465; SHEHADEH NN, 1993, SPRINGER SEMIN IMMUN, V14, P203; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; UMLAUF SW, 1993, IMMUNOL REV, V133, P177, DOI 10.1111/j.1600-065X.1993.tb01516.x	62	638	659	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1723	1726		10.1126/science.271.5256.1723	http://dx.doi.org/10.1126/science.271.5256.1723			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596932	Green Submitted			2022-12-28	WOS:A1996UB15100045
J	Welch, HG; Albertsen, PC; Nease, RF; Bubolz, TA; Wasson, JH				Welch, HG; Albertsen, PC; Nease, RF; Bubolz, TA; Wasson, JH			Estimating treatment benefits for the elderly: The effect of competing risks	ANNALS OF INTERNAL MEDICINE			English	Article							ABDOMINAL AORTIC-ANEURYSMS; LIFE-EXPECTANCY; CONVENIENT APPROXIMATION; CANCER; DEALE	To fully involve patients in treatment decisions, physicians need to communicate future health prospects that patients will have both with and without newly diagnosed disease. These prospects depend not only on the risks patients face from the new disease but also on the risks they face from other causes. Nowhere is an understanding of these competing risks more relevant than in the care of the elderly. In this study, we use the declining exponential approximation for life expectancy (DEALE) to provide a framework to help clinicians gauge the effect of competing risks as a function of age. Because older patients have many competing risks for death, the absolute effect of a new diagnosis on life expectancy is often relatively small. Consequently, the potential gain in survival even from perfect therapy may also be small. Moreover, no therapy is perfect, and the risks of therapy often increase with age. In the elderly, the combination of a high burden of competing risks and high rates of treatment-related complications conspires to reduce the net benefit of numerous interventions. We conclude that, compared with younger patients, the elderly should request only the more clearly effective treatments and should be willing to tolerate fewer associated complications before they agree to initiate therapy.	DARTMOUTH COLL, SCH MED, DEPT COMMUNITY & FAMILY MED, HANOVER, NH 03755 USA; DEPT VET AFFAIRS MED CTR, WHITE RIVER JCT, VT USA; WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, DIV GEN MED SCI, ST LOUIS, MO 63110 USA; UNIV CONNECTICUT, CTR HLTH, DIV UROL, FARMINGTON, CT 06032 USA	Dartmouth College; Washington University (WUSTL); University of Connecticut								BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; BURKE L, 1992, ANN REV GERONTOLOGY, V12; CHALFIN DB, 1994, CLIN GERIATR MED, V10, P51, DOI 10.1016/S0749-0690(18)30359-8; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; DESCH CE, 1993, J CLIN ONCOL, V11, P777, DOI 10.1200/JCO.1993.11.4.777; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; FORROW L, 1992, AM J MED, V92, P121, DOI 10.1016/0002-9343(92)90100-P; GUYETT GH, 1994, JAMA-J AM MED ASSOC, V291, P59; IDLER EL, 1991, J GERONTOL, V46, pS55, DOI 10.1093/geronj/46.2.S55; KAHNEMAN D, 1984, AM PSYCHOL, V39, P341, DOI 10.1037/0003-066X.39.4.341; KATZ DA, 1992, JAMA-J AM MED ASSOC, V268, P2678, DOI 10.1001/jama.268.19.2678; KEELER E, 1992, MED DECIS MAKING, V12, P307, DOI 10.1177/0272989X9201200410; KUNTZ KM, 1995, MED DECIS MAKING, V15, P158, DOI 10.1177/0272989X9501500209; Leslie W T, 1992, Oncology (Williston Park), V6, P74; MANTON KG, 1993, J GERONTOL, V48, pS153, DOI 10.1093/geronj/48.4.S153; MOR V, 1994, AM J PUBLIC HEALTH, V84, P1274, DOI 10.2105/AJPH.84.8.1274; *NAT CTR HLTH STAT, 1994, 1991 VIT STAT US, V2; National Research Council, 1989, IMPR RISK COMM; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; RICHARDSON JD, 1991, ARCH SURG-CHICAGO, V126, P614	21	228	232	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1996	124	6					577	584		10.7326/0003-4819-124-6-199603150-00007	http://dx.doi.org/10.7326/0003-4819-124-6-199603150-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TZ529	8597322				2022-12-28	WOS:A1996TZ52900008
J	Baker, DW; Parker, RM; Williams, MV; Coates, WC; Pitkin, K				Baker, DW; Parker, RM; Williams, MV; Coates, WC; Pitkin, K			Use and effectiveness of interpreters in an emergency department	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPEAKING PATIENTS; HEALTH-CARE	Objective.-To determine how often interpreters were used for Spanish-speaking patients, patients' perceived need for an interpreter, and the impact of interpreter use on patients' subjective and objective knowledge of their diagnosis and treatment. Design.-Cross-sectional survey. Setting.-Public hospital emergency department. Patients.-A total of 467 native Spanish-speaking and 63 English-speaking Latino patients presenting with nonurgent medical problems. Main Outcome Measures.-Patients' report of whether an interpreter was used, whether one was needed, self-perceived understanding of diagnosis and treatment, and objective knowledge of discharge instructions. Results.-An interpreter was used for 26% of Spanish-speaking patients, For 52%, an interpreter was not used but was not thought to be necessary by the patient. A total of 22% said an interpreter was not used but should have been used, When both the patient's English and the examiner's Spanish were poor, an interpreter was not called 34% of the time, and 87% of the patients who did not have an interpreter thought one should have been used, Nurses and physicians interpreted most frequently (49%), and professional interpreters were used for only 12% of patients. Patients who said an interpreter was not necessary rated their understanding of their disease as good to excellent 67% of the time, compared with 57% of those who used an interpreter and 38% of those who thought an interpreter should have been used (P<.001). For understanding of treatment, the figures were 86%, 82%, and 58%, respectively (P<.001), However, when objective measures of understanding diagnosis and treatment were used, the differences between these groups were smaller and generally not statistically significant, There were no differences between English-speaking Latinos and native Spanish-speakers who said they did not need an interpreter. Conclusions.-Interpreters are often not used despite a perceived need by patients, and the interpreters who are used usually lack formal training in this skill. Language concordance and interpreter use greatly affected patients' perceived understanding of their disease, but a high proportion of patients in all groups had poor knowledge of their diagnosis and recommended treatment.	UNIV CALIF LOS ANGELES,HARBOR MED CTR,DEPT EMERGENCY MED,TORRANCE,CA 90509	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Baker, DW (corresponding author), EMORY UNIV,SCH MED,DEPT MED,DIV GEN INTERNAL MED,ATLANTA,GA 30303, USA.		Coates, Wendy/M-1165-2019; Parker, Ruth M/S-4583-2017	Coates, Wendy/0000-0002-3305-8802; Parker, Ruth M/0000-0001-9685-6396; Williams, Mark V/0000-0001-6107-0457				DOWNING BT, 1992, PROFESSIONAL TRAININ; EBDEN P, 1988, LANCET, V1, P347, DOI 10.1016/S0140-6736(88)91133-6; GINZBERG E, 1991, JAMA-J AM MED ASSOC, V265, P238, DOI 10.1001/jama.265.2.238; MANSON A, 1988, MED CARE, V26, P1119, DOI 10.1097/00005650-198812000-00003; MARCOS LR, 1979, AM J PSYCHIAT, V136, P171; PARKER RM, 1995, J GEN INTERN MED, V10, P537, DOI 10.1007/BF02640361; PUTSCH RW, 1985, JAMA-J AM MED ASSOC, V254, P3344, DOI 10.1001/jama.254.23.3344; *US BUR CENS, 1993, 1990 STAT ABSTR US; VASQUEZ C, 1991, HOSP COMMUNITY PSYCH, V42, P163; WILLIAMS MV, 1995, JAMA-J AM MED ASSOC, V274, P1677; WOLOSHIN S, 1995, JAMA-J AM MED ASSOC, V273, P724, DOI 10.1001/jama.273.9.724; 1991, JAMA-J AM MED ASSOC, V265, P248	12	265	267	1	40	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1996	275	10					783	788		10.1001/jama.275.10.783	http://dx.doi.org/10.1001/jama.275.10.783			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY886	8598595				2022-12-28	WOS:A1996TY88600026
J	Wallentin, L; Ohlsson, J; Swahn, E; Karlsson, E; Lundin, L; Landgren, F; Saetre, H; Adren, B; Enghoff, E; Lundstrom, T; Hjalmarsson, A; Nordlander, R; Andren, B; Blomstrand, P; Venge, P; Siegbahn, A; Almroth, G; Johansson, C; Normark, A; Wiklund, K; Logander, E; Lindstrom, G; Svensson, E; Undeland, S; Neiger, K; Perers, G; Irving, P; Andersson, I; Hammarstrom, E; Bastani, H; Eng, E; Lundin, P; Rehnqvist, N; Ambrant, B; Oblack, P; Holmstrand, M; Ekdahl, S; Nyman, I; Pantzar, Y; Ahlberg, G; Hagstrom, L; Sundqvist, C; Pihl, E; Gustafsson, G; Larsson, L; Gustavsson, PE; Lofmark, R; Lundqvist, IB; Lundqvist, L; Angman, K; Karlsson, JE; Svensson, O; Malmberg, C; Holmberg, B; Ryden, S; Bjurling, E; Abjorn, C; Wahlfors, AL; Malmros, B; Nicol, P; Rowa, M; Nielsen, N; Safstrom, K; Frisell, JE; Hedman, A; Sandstom, M; Ahlstrom, P; Rosenqvist, U; Ryden, BO; Gustavsson, SB; Almen, I; Fjelstad, B; Aronson, D; Ostberg, S; Falk, SA; Friden, J; Nilsson, O; Ronnhagen, K; AbouZeid, L; Hedback, B; Perk, J; OssianssonPettersson, L; Ellstrom, J; Brodersson, H; vonHolst, M; KjellinWiberg, A; Hulting, J; Hojier, J; Amanullah, A; Samad, B; Steinbruck, I; Ekblom, M; Toss, H; Lindahl, B; Alsjo, G; Sinnerstad, B; Larsson, LE; Nilsson, G; Agert, G; Wiberg, S; Pihlstrom, B; Johansson, PA; Lind, O; Thorsen, S; Ekberg, K				Wallentin, L; Ohlsson, J; Swahn, E; Karlsson, E; Lundin, L; Landgren, F; Saetre, H; Adren, B; Enghoff, E; Lundstrom, T; Hjalmarsson, A; Nordlander, R; Andren, B; Blomstrand, P; Venge, P; Siegbahn, A; Almroth, G; Johansson, C; Normark, A; Wiklund, K; Logander, E; Lindstrom, G; Svensson, E; Undeland, S; Neiger, K; Perers, G; Irving, P; Andersson, I; Hammarstrom, E; Bastani, H; Eng, E; Lundin, P; Rehnqvist, N; Ambrant, B; Oblack, P; Holmstrand, M; Ekdahl, S; Nyman, I; Pantzar, Y; Ahlberg, G; Hagstrom, L; Sundqvist, C; Pihl, E; Gustafsson, G; Larsson, L; Gustavsson, PE; Lofmark, R; Lundqvist, IB; Lundqvist, L; Angman, K; Karlsson, JE; Svensson, O; Malmberg, C; Holmberg, B; Ryden, S; Bjurling, E; Abjorn, C; Wahlfors, AL; Malmros, B; Nicol, P; Rowa, M; Nielsen, N; Safstrom, K; Frisell, JE; Hedman, A; Sandstom, M; Ahlstrom, P; Rosenqvist, U; Ryden, BO; Gustavsson, SB; Almen, I; Fjelstad, B; Aronson, D; Ostberg, S; Falk, SA; Friden, J; Nilsson, O; Ronnhagen, K; AbouZeid, L; Hedback, B; Perk, J; OssianssonPettersson, L; Ellstrom, J; Brodersson, H; vonHolst, M; KjellinWiberg, A; Hulting, J; Hojier, J; Amanullah, A; Samad, B; Steinbruck, I; Ekblom, M; Toss, H; Lindahl, B; Alsjo, G; Sinnerstad, B; Larsson, LE; Nilsson, G; Agert, G; Wiberg, S; Pihlstrom, B; Johansson, PA; Lind, O; Thorsen, S; Ekberg, K			Low-molecular-weight heparin during instability in coronary artery disease	LANCET			English	Article							UNSTABLE ANGINA; MYOCARDIAL-INFARCTION; ASPIRIN; ISCHEMIA; EPISODE; TRIAL	Background Intravenous heparin is at least as effective as aspirin in preventing new cardiac events after an episode of unstable coronary artery disease (CAD), though the benefits are short-lived. Low-molecular-weight heparin has similar antithrombotic properties but can be given subcutaneously and is therefore suitable for long-term treatment. We have investigated whether subcutaneous low-molecular-weight heparin, in addition to aspirin and antianginal drugs, is protective against new cardiac events in unstable CAD. Methods 1506 patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) took part in a double-blind trial and were randomly assigned subcutaneous dalteparin (Fragmin; 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days then 7500 IU once daily for the next 35-45 days) or placebo injections. The primary endpoint was the rate of death and new myocardial infarction during the first 6 days. Secondary endpoints were the rates of death and new myocardial infarction after 40 and 150 days, the frequency of revascularisation procedures and need for heparin infusion, and a composite endpoint. Findings During the first 6 days the rate of death and new myocardial infarction was lower in the dalteparin group than in the placebo group (13 [1.8%] vs 36 [4.8%]; risk ratio 0.37 [95% CI 0.20-0.68]), as were the frequencies of need for intravenous heparin (28 [3.8%] vs 58 [7.7%]; 0.49 [0.32-0.75]) and need for revascularisation (3 [0.4%] vs 9 [1.2%]; 0.33 [0.10-1.10]). The composite endpoint(death, myocardial infarction, revascularisation, intravenous heparin) also showed a significant difference in favour of dalteparin (40 [5.4%] vs 78 [10.3%]; 0.52 [0.37-0.75]). At 40 days the differences in rates of death and myocardial infarction and the composite endpoint persisted, although subgroup analysis showed that the effect was confined to non-smokers (80% of sample), Survival analysis showed a risk of reactivation and reinfarction when the dose was decreased, more pronounced in smokers. 4-5 months after the end of treatment, there were no significant differences in the rates of death, new myocardial infarction, or revascularisation. The regimen was safe and compliance was adequate. Interpretation We recommend that treatment with a combination of dalteparin and aspirin for at least 6 days should be considered in patients with unstable CAD to reduce the risk of new cardiac events and to allow time for risk stratification and selection of a long-term treatment strategy. Long-term dalteparin treatment instead of or in addition to early invasive procedures warrants further assessment.	SODER SJUKHUSET,STOCKHOLM,SWEDEN	Sodersjukhuset Hospital	Wallentin, L (corresponding author), UNIV UPPSALA HOSP,DEPT CARDIOL,S-78185 UPPSALA,SWEDEN.		Lundqvist, Lars-Olov/M-8547-2014; Wiberg, Sebastian/AAX-9062-2021; Blomstrand, Peter/AAZ-4842-2020; Mikhailidis, Dimitri P/A-1869-2013	Lundqvist, Lars-Olov/0000-0002-6703-7575; Wiberg, Sebastian/0000-0002-7062-7189; Mikhailidis, Dimitri P/0000-0002-9566-2263				BADIMON L, 1994, HAEMOSTASIS, V24, P69; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; CHEN LJ, 1995, CIRCULATION, V91, P2319, DOI 10.1161/01.CIR.91.9.2319; COHEN M, 1994, CIRCULATION, V89, P81, DOI 10.1161/01.CIR.89.1.81; ERIKSSON BI, 1995, THROMB HAEMOSTASIS, V73, P398; FUSTER V, 1994, CIRCULATION, V90, P2126, DOI 10.1161/01.CIR.90.4.2126; GREEN D, 1994, AM SOC PHARM EXP THE, V46, P89; HIRSH J, 1992, BLOOD, V79, P1; HOFFMEISTER HM, 1995, CIRCULATION, V91, P2520, DOI 10.1161/01.CIR.91.10.2520; HOLDRIGHT D, 1994, J AM COLL CARDIOL, V24, P39, DOI 10.1016/0735-1097(94)90539-8; KIMURA S, 1994, AM HEART J, V128, P7, DOI 10.1016/0002-8703(94)90003-5; LEIZOROVICZ A, 1994, BMJ-BRIT MED J, V309, P299, DOI 10.1136/bmj.309.6950.299; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; MERLINI PA, 1994, CIRCULATION, V90, P61, DOI 10.1161/01.CIR.90.1.61; MONREAL M, 1994, THROMB HAEMOSTASIS, V71, P7; NYMAN I, 1992, AM HEART J, V123, P324, DOI 10.1016/0002-8703(92)90642-9; NYMAN I, 1993, INT J CARDIOL, V39, P131, DOI 10.1016/0167-5273(93)90024-B; SAMAMA MM, 1994, HAEMOSTASIS, V24, P105; SERNERI GG, 1987, LANCET, V1, P37; SERNERI GGN, 1990, LANCET, V335, P615; SERNERI GGN, 1995, LANCET, V345, P1201; SWAHN E, 1989, SCAND J CLIN LAB INV, V49, P49, DOI 10.3109/00365518909089077; TELFORD AM, 1981, LANCET, V1, P1225; THEROUX P, 1992, NEW ENGL J MED, V327, P141, DOI 10.1056/NEJM199207163270301; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; THEROUX P, 1993, CIRCULATION, V88, P2045, DOI 10.1161/01.CIR.88.5.2045; THEROUX P, 1995, CIRCULATION, V91, P2295, DOI 10.1161/01.CIR.91.9.2295; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; 1994, CIRCULATION, V89, P1545; 1990, LANCET, V36, P827	30	616	623	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					561	568						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596317				2022-12-28	WOS:A1996TX69400008
J	Muir, KW				Muir, KW			Multicentre Acute Stroke Trial - Italy	LANCET			English	Letter											Muir, KW (corresponding author), SO GEN HOSP,INST NEUROL SCI,DEPT NEUROL,GLASGOW G51 4TF,LANARK,SCOTLAND.		Muir, Keith W/A-7670-2011	Muir, Keith W/0000-0001-9535-022X; Ciccone, Alfonso/0000-0002-4590-3575				MORRIS AD, 1993, J NEUROL NEUROSUR PS, V56, P352, DOI 10.1136/jnnp.56.4.352; Multicentre Acute Stroke Trial-Italy Group, 1995, LANCET, V346, P1509; SANDERCOCK P, 1995, LANCET, V346, P1504, DOI 10.1016/S0140-6736(95)92044-7; TOGNONI G, 1995, LANCET, V346, P1515, DOI 10.1016/S0140-6736(95)92050-1; 1995, NEW ENGL J MED, V333, P1581	5	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					391	391		10.1016/S0140-6736(96)90568-1	http://dx.doi.org/10.1016/S0140-6736(96)90568-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598711				2022-12-28	WOS:A1996TU69500038
J	Kawashima, T; BerthetColominas, C; Wulff, M; Cusack, S; Leberman, R				Kawashima, T; BerthetColominas, C; Wulff, M; Cusack, S; Leberman, R			The structure of the Escherichia coli EF-Tu center dot EF-Ts complex at 2.5 angstrom resolution	NATURE			English	Article							POLYPEPTIDE ELONGATION-FACTOR; QBETA-REPLICASE; PURIFICATION; SEQUENCE; DOMAIN; RAS	The crystal structure of the EF-Tu . EF-Ts complex from Escherichia coli has been determined to a resolution of 2.5 Angstrom. The complex contains two subunits of each of the elongation factors. The two EF-Ts molecules form a tight dimer, but there is little contact between the two EF-Tu molecules. The interaction of EF-Ts with EF-Tu results principally in the disruption of the Mg2+ ion binding site, thereby reducing the affinity of EF-Tu for guanine nucleotides.	EUROPEAN MOLEC BIOL LAB, GRENOBLE OUTSTN, F-38042 GRENOBLE, FRANCE; EUROPEAN SYNCHROTRON RADIAT FACIL, F-38043 GRENOBLE, FRANCE	European Molecular Biology Laboratory (EMBL); European Synchrotron Radiation Facility (ESRF)				Cusack, Stephen/0000-0002-9324-0796				AN G, 1981, NUCLEIC ACIDS RES, V9, P4163, DOI 10.1093/nar/9.16.4163; ARAI KI, 1972, J BIOL CHEM, V247, P7029; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BLUMENTHAL T, 1972, P NATL ACAD SCI USA, V69, P1313, DOI 10.1073/pnas.69.5.1313; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; ERTEL R, 1968, ARCH BIOCHEM BIOPHYS, V128, P331, DOI 10.1016/0003-9861(68)90039-8; JANSSEN GMC, 1994, J BIOL CHEM, V269, P31410; JOHN J, 1993, J BIOL CHEM, V268, P923; JONES MD, 1980, EUR J BIOCHEM, V108, P507, DOI 10.1111/j.1432-1033.1980.tb04748.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jones TA, 1992, MOL REPLACEMENT, P92; KABSCH W, 1977, J MOL BIOL, V117, P999, DOI 10.1016/S0022-2836(77)80009-0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAWASHIMA T, IN PRESS ACTA CRYSTA; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEBERMAN R, 1980, ANAL BIOCHEM, V104, P29, DOI 10.1016/0003-2697(80)90272-9; LEBERMAN R, 1981, FEBS LETT, V124, P279, DOI 10.1016/0014-5793(81)80155-X; LESLIE AGW, 1987, P CCP4 STUD WEEK SER, P39; LUCUSLENARD J, 1966, P NATN ACAD SCIUS, V55, P1562; MILLER DL, 1970, ARCH BIOCHEM BIOPHYS, V141, P26, DOI 10.1016/0003-9861(70)90102-5; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; SCHICK B, 1994, ACTA CRYSTALLOGR D, V50, P563, DOI 10.1107/S0907444994001976; SCHNEIDER U, 1983, THESIS U FREIBURG GE; WEISSBACH H, 1970, ARCH BIOCHEM BIOPHYS, V137, P262, DOI 10.1016/0003-9861(70)90433-9; 1979, SERC4 DAR LAB COLL C	30	276	283	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 8	1996	379	6565					511	518		10.1038/379511a0	http://dx.doi.org/10.1038/379511a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596629				2022-12-28	WOS:A1996TU69300041
J	Culotta, E				Culotta, E			Maintaining diversity in science	SCIENCE			English	Editorial Material																			0	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1901	1901		10.1126/science.271.5257.1901	http://dx.doi.org/10.1126/science.271.5257.1901			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596960				2022-12-28	WOS:A1996UC77800054
J	Fukasawa, K; Choi, T; Kuriyama, R; Rulong, S; VandeVoude, GF				Fukasawa, K; Choi, T; Kuriyama, R; Rulong, S; VandeVoude, GF			Abnormal centrosome amplification in the absence of p53	SCIENCE			English	Article							WILD-TYPE P53; HAMSTER OVARY CELLS; GENE AMPLIFICATION; FRIEND-VIRUS; CYCLE; EXPRESSION; TRANSCRIPTION; PROTEIN; BINDING; CANCER	The centrosome plays a vital role in mitotic fidelity, ensuring establishment of bipolar spindles and balanced chromosome segregation. Centrosome duplication occurs only once during the cell cycle and is therefore highly regulated. Here, it is shown that in mouse embryonic fibroblasts (MEFs) lacking the p53 tumor suppressor protein, multiple copies of functionally competent centrosomes are generated during a single cell cycle. In contrast, MEFs prepared from normal mice or mice deficient in the retinoblastoma tumor suppressor gene product do not display these abnormalities. The abnormally amplified centrosomes profoundly affect mitotic fidelity, resulting in unequal segregation of chromosomes. These observations implicate p53 in the regulation of centrosome duplication and suggest one possible mechanism by which the loss of p53 may cause genetic instability.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; UNIV MINNESOTA,SCH MED,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Minnesota System; University of Minnesota Twin Cities								AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BLAIRZAJDEL ME, 1988, ONCOGENE, V2, P579; BOMENS M, 1992, CENTROSOME, P1; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; CALARCO PD, 1983, J CELL BIOL, V101, P319; CARDER P, 1993, ONCOGENE, V8, P1397; CLAYTON L, 1985, CELL, V35, P621; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FUKASAWA K, 1995, ONCOGENE, V10, P1; FUKASAWA K, UNPUB; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, ONCOGENE, V8, P2457; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOSHI HC, 1994, CURR OPIN CELL BIOL, V6, P55, DOI 10.1016/0955-0674(94)90116-3; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KURIYAMA R, 1986, CELL MOTIL CYTOSKEL, V6, P355, DOI 10.1002/cm.970060402; KURIYAMA R, 1981, J CELL BIOL, V91, P814, DOI 10.1083/jcb.91.3.814; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE JM, 1994, ONCOGENE, V9, P3731; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE DS, 1991, P NATL ACAD SCI USA, V88, P6427, DOI 10.1073/pnas.88.15.6427; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANIOTIS A, 1991, CELL, V67, P495, DOI 10.1016/0092-8674(91)90524-3; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Oakley B R, 1992, Trends Cell Biol, V2, P1, DOI 10.1016/0962-8924(92)90125-7; ORREN DK, 1995, MOL CELL BIOL, V15, P3722; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROBBINS E, 1968, J CELL BIOL, V36, P329, DOI 10.1083/jcb.36.2.329; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHAEFER DI, 1993, CANCER RES, V53, P4946; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TUFFANELLI DL, 1983, ARCH DERMATOL, V119, P560, DOI 10.1001/archderm.119.7.560; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	57	722	743	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1744	1747		10.1126/science.271.5256.1744	http://dx.doi.org/10.1126/science.271.5256.1744			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596939	Green Submitted			2022-12-28	WOS:A1996UB15100052
J	Leach, DR; Krummel, MF; Allison, JP				Leach, DR; Krummel, MF; Allison, JP			Enhancement of antitumor immunity by CTLA-4 blockade	SCIENCE			English	Article							RECEPTOR; CELLS; CD28; MOLECULES; MOUSE; COSTIMULATION; EXPRESSION; REJECTION; ANTIGEN	One reason for the poor immunogenicity of many tumors may be that they cannot provide signals for CD28-mediated costimulation necessary to fully activate T cells. It has recently become apparent that CTLA-4, a second counterreceptor for the B7 family of costimulatory molecules, is a negative regulator of T cell activation. Here, in vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors. Furthermore, this rejection resulted in immunity to a secondary exposure to tumor cells. These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells.	UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley				Allison, James/0000-0001-8980-5697	NATIONAL CANCER INSTITUTE [T32CA009179, R01CA057986, R37CA040041, R01CA040041] Funding Source: NIH RePORTER; NCI NIH HHS [CA40041, CA09179, CA57986] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON JP, 1995, CURR OPIN IMMUNOL, V7, P682, DOI 10.1016/0952-7915(95)80077-8; ALLISON JP, 1995, SCIENCE, V270, P932, DOI 10.1126/science.270.5238.932; ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; BASKAR S, 1993, P NATL ACAD SCI USA, V90, P5687, DOI 10.1073/pnas.90.12.5687; BASKAR S, 1995, J EXP MED, V181, P619, DOI 10.1084/jem.181.2.619; BLUESTONE JA, 1995, IMMUNITY, V2, P555, DOI 10.1016/1074-7613(95)90000-4; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FLAMAND V, 1994, EUR J IMMUNOL, V24, P605, DOI 10.1002/eji.1830240317; GRABBE S, 1995, IMMUNOL TODAY, V16, P117, DOI 10.1016/0167-5699(95)80125-1; GRIBBEN JG, 1995, P NATL ACAD SCI USA, V92, P811, DOI 10.1073/pnas.92.3.811; GROSS JA, 1992, J IMMUNOL, V149, P380; HARPER K, 1991, J IMMUNOL, V147, P1037; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; JENKINS MK, 1994, IMMUNITY, V1, P443, DOI 10.1016/1074-7613(94)90086-8; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KEARNEY ER, 1995, J IMMUNOL, V155, P1033; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; KRUMMEL MF, IN PRESS INT IMMUNOL; LEACH DR, 1995, J IMMUNOL, V154, P738; LEACH DRF, UNPUB; LEVITSKY HI, 1994, J EXP MED, V179, P1215, DOI 10.1084/jem.179.4.1215; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1995, J EXP MED, V182, P289, DOI 10.1084/jem.182.2.289; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; OSTRANDROSENBERG S, 1990, J IMMUNOL, V144, P4068; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TOWNSEND SE, 1994, CANCER RES, V54, P6477; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985	33	2500	2689	25	402	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1734	1736		10.1126/science.271.5256.1734	http://dx.doi.org/10.1126/science.271.5256.1734			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596936				2022-12-28	WOS:A1996UB15100049
J	Bowling, A				Bowling, A			Health care rationing: The public's debate	BRITISH MEDICAL JOURNAL			English	Article								Objective-To elicit the views of a large nationally representative sample of adults on priorities for health services. Design-An interview survey based on a random sample of people aged 16 and over in Great Britain taken by the Office of Population Censuses and Surveys. Subjects-The response rate to the survey was 75%, and the total number of adults interviewed was 2005. Main outcome measures-A priority ranking exercise of health services supplemented with attitude questions about priorities, who should set priorities, and budget allocation. Results-The results of the main priority ranking exercise of 12 health services showed that the highest priority (rank 1) was accorded to ''treatments for children with life threatening illness,'' the next highest priority (rank 2) was accorded to ''special care and pain relief for people who are dying.'' The lowest priorities (11 and 12) were given to ''treatment for infertility'' and ''treatment for people aged 75 and over with life threatening illness.'' Most respondents thought that surveys like this one should be used in the planning of health services. Conclusions-The public prioritise treatments specifically for younger rather than older people. There is some public support for people with self inflicted conditions (for example, through tobacco smoking) receiving lower priority for care, which raises ethical issues.			Bowling, A (corresponding author), UCL, SCH MED, WHITTINGTON HOSP, CTR HLTH INFORMAT & MULTIPROFESS EDUC, MORTIMER ST, LONDON N19 5NF, ENGLAND.							BOWLING A, 1993, WHAT PEOPLE SAY PRIO; *CIT COMM BIOM ETH, 1988, YOUR HLTH YOUR CHOIC; *DEP HLTH, 1995, CMND2826; FOSTER K, 1995, GENERAL HOUSEHOLD SU; HAM C, 1995, BRIT MED J, V310, P1483, DOI 10.1136/bmj.310.6993.1483; HEGINBOTHAM C, 1993, RATIONING ACTION; *HLTH COMM, 1995, REP PR SETT NHS PURC, V1; HONIGSBAUM F, 1995, PRIORITY SETTING HLT; HUNTER D, 1993, RATIONING DILEMMAS H; LUTTON G, 1991, 4 PUBL HLTH FOR 25 A; MURRAY SA, 1994, BRIT MED J, V308, P698, DOI 10.1136/bmj.308.6930.698; *NAT HLTH MED RES, 1990, DISC PAP ETH RES ALL; NICHOLSON R, 1995, WORLD TONIGHT   0524; *OFF POP CENS SURV, 1994, MIDT POP EST; *OR HLTH SERV COMM, 1991, HLTH CAR COMM; REDMAYNE S, 1995, RESHAPING NHS STRATE; RICHARDSON A, 1992, BRIT MED J, V304, P680, DOI 10.1136/bmj.304.6828.680; WHITTY P, 1992, PRIORITIES HLTH CARE; 1995, NEW SCI         0318, P3	19	137	138	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					670	674						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597733				2022-12-28	WOS:A1996UB11000023
J	Gilks, CF; Ojoo, SA; Ojoo, JC; Brindle, RJ; Paul, J; Batchelor, BIF; Kimari, JN; Newnham, R; Bwayo, J; Plummer, FA; Warrell, DA				Gilks, CF; Ojoo, SA; Ojoo, JC; Brindle, RJ; Paul, J; Batchelor, BIF; Kimari, JN; Newnham, R; Bwayo, J; Plummer, FA; Warrell, DA			Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya	LANCET			English	Article							BACTEREMIA; DIAGNOSIS; PNEUMONIA; SINUSITIS; ADULTS	Background HIV infection is a major risk factor for pneumococcal disease in industrialised countries. Although both are common infections in sub-Saharan Africa, few studies have investigated the importance of this interaction. We have followed up a cohort of female sex-workers in Nairobi and report here on the extent of invasive pneumococcal disease. Methods A well-established cohort of low-class female sex-workers, based around a community clinic, was followed up from October, 1989, to September, 1992. 587 participants were HIV positive and 132 remained HIV negative. Set protocols were used to investigate common presentations. Cases were identified clinically and radiographically. and other pathogens were identified clinically and radiographically. Streptococcus pneumoniae and other pathogens were diagnosed by culture. Findings Seventy-nine episodes of invasive pneumococcal disease were seen in the 587 HIV-positive women compared with one episode in the 132 seronegative women (relative risk 17.8, 95% CI 2.5 to 126.5). In seropositive women the incidence rate was 42.5 per 1000 person-years and the recurrence rate was 264 per 1000 person-years. By serotyping, most recurrent events were re-infection. A wide spectrum of HIV-related pneumococcal disease was seen: only 56% of cases were pneumonia; sinusitis was seen in 30% of cases, and occult bacteraemia, a novel adult presentation, in 11%. Despite forty-two bacteraemic episodes, no deaths were attributable to Strep pneumoniae. At first presentation the mean CD4 cell count was 302/mu L (SD 191) and was 171/mu L (105) for recurrent episodes. During acute Strep pneumoniae infection the CD4 cell count was reversibly suppressed (mean fall in sixteen episodes, 105/mu L [123]). The neutrophil response to acute infection was blunted and was correlated with CD4 count (r=0.50, 95% CI 0.29 to 0.66). Strep pneumoniae caused more disease, at an earlier stage of HIV immunosuppression, than Mycobacterium tuberculosis or non-typhi salmonellae. Interpretation Our study highlights the importance of the pneumococcus as an early but readily treatable complication of HIV infection in sub-Saharan Africa.	KENYA GOVT MED RES CTR,CLIN RES CTR,NAIROBI,KENYA; KENYA GOVT MED RES CTR,CTR MICROBIOL RES,NAIROBI,KENYA; UNIV NAIROBI,DEPT MED MICROBIOL,NAIROBI,KENYA; UNIV WINNIPEG,WINNIPEG,MB R3B 2E9,CANADA; UNIV OXFORD,CTR TROP MED,OXFORD,ENGLAND	Kenya Medical Research Institute; Kenya Medical Research Institute; University of Nairobi; University of Winnipeg; University of Oxford			Gilks, Charles/B-4184-2012	Gilks, Charles/0000-0002-8953-3123	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADERAYE G, 1994, TUBERCLE LUNG DIS, V75, P308, DOI 10.1016/0962-8479(94)90138-4; ANZALA OA, 1995, J INFECT DIS, V171, P686, DOI 10.1093/infdis/171.3.686; AUSTRIAN R, 1986, SA MED J, V77, P46; BARNES DJ, 1988, AUST NZ J MED, V18, P754, DOI 10.1111/j.1445-5994.1988.tb00174.x; BARRETTC.E, 1971, AM REV RESPIR DIS, V103, P845; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; GILKS C, 1993, 9 INT C AIDS BERL; GILKS CF, 1993, LANCET, V342, P1037, DOI 10.1016/0140-6736(93)92885-W; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; GODOFSKY EW, 1992, AM J MED, V93, P163, DOI 10.1016/0002-9343(92)90046-E; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; JANOFF EN, 1992, ANN INTERN MED, V117, P314, DOI 10.7326/0003-4819-117-4-314; JORDENS JZ, 1995, J INFECT DIS, V172, P983, DOI 10.1093/infdis/172.4.983; KELL CM, 1993, INFECT IMMUN, V61, P4382, DOI 10.1128/IAI.61.10.4382-4391.1993; MARTIN DJ, 1995, J ACQ IMMUN DEF SYND, V8, P386; MIENTJES GHC, 1993, BRIT MED J, V306, P371, DOI 10.1136/bmj.306.6874.371; NUNN P, 1993, TUBERC LUND DIS, V7, P273; PALLANGYO K, 1992, AIDS, V6, P971, DOI 10.1097/00002030-199209000-00010; REDD SC, 1990, J INFECT DIS, V162, P1012, DOI 10.1093/infdis/162.5.1012; SCHUCHAT A, 1991, JAMA-J AM MED ASSOC, V265, P3275, DOI 10.1001/jama.265.24.3275; SIMANI P, 1992, 8 INT C AIDS AMST; SIMONSEN JN, 1990, AIDS, V4, P139, DOI 10.1097/00002030-199002000-00007; SPITALNY KC, 1982, JOHNS HOPKINS MED J, V150, P35; TAELMAN H, 1990, 5 INT C AIDS AFR KIN; TAELMAN H, 1992, 8 INT C AIDS AMST; TEKLU B, 1984, PRINCIPLES MED AFRIC, P761; VONREYN CF, 1993, J CLIN MICROBIOL, V31, P3247; WALLACE JM, 1993, AM REV RESPIR DIS, V148, P1523, DOI 10.1164/ajrccm/148.6_Pt_1.1523; *WHO, 1994, WHOGPATCOSEF944; 1987, MMWR-MORBID M      S, V36, pS1; 1992, MMWR-MORBID MORTAL W, V41, P1	31	163	163	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					718	723		10.1016/S0140-6736(96)90076-8	http://dx.doi.org/10.1016/S0140-6736(96)90076-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8602001				2022-12-28	WOS:A1996TZ98200009
J	Dietrich, WF; Miller, J; Steen, R; Merchant, MA; DamronBoles, D; Husain, Z; Dredge, R; Daly, MJ; Ingalls, KA; OConnor, TJ; Evans, CA; DeAngelis, MM; Levinson, DM; Kruglyak, L; Goodman, N; Copeland, NG; Jenkins, NA; Hawkins, TL; Stein, L; Page, DC; Lander, ES				Dietrich, WF; Miller, J; Steen, R; Merchant, MA; DamronBoles, D; Husain, Z; Dredge, R; Daly, MJ; Ingalls, KA; OConnor, TJ; Evans, CA; DeAngelis, MM; Levinson, DM; Kruglyak, L; Goodman, N; Copeland, NG; Jenkins, NA; Hawkins, TL; Stein, L; Page, DC; Lander, ES			A comprehensive genetic map of the mouse genome	NATURE			English	Article							LINKAGE MAP	The availability of dense genetic linkage maps of mammalian genomes makes feasible a wide range of studies, including positional cloning of monogenic traits, genetic dissection of polygenic traits, construction of genome-wide physical maps, rapid marker-assisted construction of congenic strains, and evolutionary comparisons(1,2). We have been engaged for the past five years in a concerted effort to produce a dense genetic map of the laboratory mouse(3-6). Here we present the final report of this project. The map contains 7,377 genetic markers, consisting of 6,580 highly informative simple sequence length polymorphisms integrated with 797 restriction fragment length polymorphisms in mouse genes. The average spacing between markers is about 0.2 centimorgans or 400 kilobases.	WHITEHEAD INST BIOMED RES, WHITEHEAD MIT CTR GENOME RES, CAMBRIDGE, MA 02142 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, MAMMALIAN GENET LAB, FREDERICK, MD 21702 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)			DeAngelis, e/J-7863-2015; Daly, Mark J/B-2453-2017	Daly, Mark J/0000-0002-0949-8752; Merchant, Mark/0000-0003-0690-8581				BREEN M, 1994, HUM MOL GENET, V3, P621, DOI 10.1093/hmg/3.4.621; BUCHBERG AM, 1989, GENETICS, V122, P153; CECI JD, 1989, GENOMICS, V5, P699, DOI 10.1016/0888-7543(89)90111-0; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DIETRICH WF, 1992, GENETIC MAPS 1992; EVANS E, 1994, GENETIC VARIANTS STR; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JACOB HJ, 1995, NAT GENET, V9, P63, DOI 10.1038/ng0195-63; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LINCOLN SE, 1992, GENOMICS, V14, P604, DOI 10.1016/S0888-7543(05)80158-2; MILLER JC, 1994, GENETIC VARIANTS STR; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178	19	738	778	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 14	1996	380	6570					149	152		10.1038/380149a0	http://dx.doi.org/10.1038/380149a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600386				2022-12-28	WOS:A1996TZ97800047
J	Bindels, PJE; Krol, A; vanAmeijden, E; MulderFolkerts, DKF; vandenHoek, JAR; vanGriensven, GPJ; Coutinho, RA				Bindels, PJE; Krol, A; vanAmeijden, E; MulderFolkerts, DKF; vandenHoek, JAR; vanGriensven, GPJ; Coutinho, RA			Euthanasia and physician-assisted suicide in homosexual men with AIDS	LANCET			English	Article							IMMUNODEFICIENCY-SYNDROME AIDS; LONGITUDINAL DATA-ANALYSIS; RESPONSIVENESS; SURVIVAL	Background In the Netherlands a nationwide study has shown that, in 38% of deaths, there have been medical decisions concerning the end of life (MDEL); 2.1% of all deaths were brought about by euthanasia or physician-assisted suicide (PAS). We investigated the incidence of MDEL in homosexual men with AIDS, suspecting that it might be higher, and studied the effect of euthanasia/PAS on survival time. Methods The patients were 131 male homosexual participants in a cohort study in Amsterdam, diagnosed between 1985 and 1992 as having AIDS; all had died before Jan 1, 1995. Clinical and laboratory data and information on mode of death were obtained from their physicians and by review of hospital records. Those who died by euthanasia/PAS or in whom there had been other MDEL were then compared with those who died naturally. Findings 29 men (22%) had died by euthanasia/PAS and in 17 (13%) another MDEL had been made; thus, more than one-third of these men had made medical decisions concerning the end of life. The greatest difference between the groups was in age at time of diagnosis-72% aged 40 or more in the euthanasia/PAS group compared with 38% in the natural death group. The likelihood (relative risk) of euthanasia/PAS increased with duration of survival after AIDS diagnosis. Comparison of the groups in terms of three laboratory markers (CD4+ and CD8+ cells and phytohaemagglutinin responses) in the two years before death, and estimates of these markers at the time of death, did not indicate any substantial shortening of life by euthanasia/PAS; in the judgment of the physicians, most of these patients would have died naturally within one month. Interpretation A possible reason for the high incidence of MDEL in this cohort was a good knowledge of the characteristics of AIDS acquired through long-term awareness of HIV infection. The higher rate of euthanasia in those with long survival from AIDS diagnosis could reflect either additional suffering or the greater opportunity to discuss this option with friends and physicians. Our findings indicate that euthanasia and other MDEL did little to shorten life; rather, they were an extreme form of palliation, applied in the terminal phase of a lethal disease.			Bindels, PJE (corresponding author), DEPT PUBL HLTH,MUNICIPAL HLTH SERV,NIEUWE ACHTERGRACHT 100,POB 20244,1000 HE AMSTERDAM,NETHERLANDS.							Anderson PK, 1993, STAT MODELS BASED CO; BINDELS PJE, 1995, J INFECT DIS, V172, P97, DOI 10.1093/infdis/172.1.97; BLOEMENA E, 1989, J IMMUNOL METHODS, V122, P161, DOI 10.1016/0022-1759(89)90260-3; CHANG HGH, 1993, AM J EPIDEMIOL, V138, P341, DOI 10.1093/oxfordjournals.aje.a116864; FAHEY JL, 1989, NEW ENGL J MED, V321, P673; GRIENSVEN GP, 1987, AM J EPIDEMIOL, V125, P1048; JACOBSON LP, 1993, AM J EPIDEMIOL, V138, P952, DOI 10.1093/oxfordjournals.aje.a116815; KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LUNDGREN JD, 1994, BMJ-BRIT MED J, V308, P1068, DOI 10.1136/bmj.308.6936.1068; PIJNENBORG L, 1995, END LIFE DECISIONS M; SCHELLEKENS PTA, 1990, J CLIN IMMUNOL, V10, P121, DOI 10.1007/BF00918194; SEAGE GR, 1993, AM J PUBLIC HEALTH, V83, P72, DOI 10.2105/AJPH.83.1.72; SORGDRAGER W, 1995, MED CONTACT, V50, P381; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; VANDERWAL G, 1991, MED CONTACT, V46, P174; VANLIER RAW, 1987, J IMMUNOL, V139, P2873; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1987, MMWR-MORBID M      S, V36, pS1	21	27	27	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					499	504		10.1016/S0140-6736(96)91138-1	http://dx.doi.org/10.1016/S0140-6736(96)91138-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TW697	8596267				2022-12-28	WOS:A1996TW69700009
J	Little, P; Smith, L; Cantrell, T; Chapman, J; Langridge, J; Pickering, R				Little, P; Smith, L; Cantrell, T; Chapman, J; Langridge, J; Pickering, R			General practitioners' management of acute back pain: A survey of reported practice compared with clinical guidelines	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SPINAL MANIPULATION; CONTROLLED TRIAL; EXERCISE; PHYSIOTHERAPY; THERAPY; REST	Objective-To compare general practitioners' reported management of acute back pain with ''evidence based'' guidelines for its management. Design-Confidential postal questionnaire. Setting-One health district in the South and West region. Subjects-236 general practitioners; 166 (70%) responded. Outcome measures-Examination routinely performed, ''danger'' symptoms and signs warranting urgent referral, advice given, and satisfaction with management. Results-A minority of general practitioners do not examine reflexes routinely (27%, 95% confidence interval 20% to 34%), and a majority do not examine routinely for muscle weakness or sensation. Although most would refer patients with danger signs, some would not seek urgent advice for saddle anaesthesia (6%, 3% to 11%), extensor plantar response (45%, 37% to 53%), or neurological signs at multiple levels (15%, 10% to 21%). A minority do not give advice about back exercises (42%, 34% to 49%), fitness (34%, 26% to 41%), or everyday activities. A minority performed manipulation (20%) or acupuncture (6%). One third rated their satisfaction with management of back pain as 4 out of 10 or less. Conclusions-The management of back pain by general practitioners does not match the guidelines, but there is little evidence from general practice for many of the recommendations, including routine examination, activity modification, educational advice, and back exercises. General practitioners need to be more aware of danger symptoms and of the benefits of early mobilisation and possibly of manipulation for persisting symptoms. Guidelines should reference each recommendation and discuss study methodology and the setting of evidence.	SOUTHAMPTON HOSP, NHS TRUST, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND; UNIV SOUTHAMPTON, SCH OCCUPAT THERAPY & PHYSIOTHERAPY, SOUTHAMPTON SO17 1BJ, HANTS, ENGLAND; UNIV SOUTHAMPTON, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND	University of Southampton; University of Southampton	Little, P (corresponding author), UNIV SOUTHAMPTON, FAC MED HLTH & BIOL SCI, SOUTHAMPTON SO16 5ST, HANTS, ENGLAND.			Little, Paul/0000-0003-3664-1873	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND S1, V70, P1; CAREY TS, 1995, NEW ENGL J MED, V333, P913, DOI 10.1056/NEJM199510053331406; CHOLER U, 1985, ONT RUGGEN FORSCH ME; COSTE J, 1994, BRIT MED J, V308, P577, DOI 10.1136/bmj.308.6928.577; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; DEYO RA, 1992, JAMA-J AM MED ASSOC, V268, P760, DOI 10.1001/jama.268.6.760; FAAS A, 1995, SPINE, V20, P941, DOI 10.1097/00007632-199504150-00012; FAAS A, 1993, SPINE, V18, P1388; FEDER G, 1994, BRIT MED J, V309, P1457, DOI 10.1136/bmj.309.6967.1457; FRANK A, 1993, BMJ-BRIT MED J, V306, P901, DOI 10.1136/bmj.306.6882.901; FROST H, 1995, BRIT MED J, V310, P151, DOI 10.1136/bmj.310.6973.151; GARDNER SB, 1989, CIA CONFIDENCE INTER; GILBERT JR, 1985, BRIT MED J, V291, P791, DOI 10.1136/bmj.291.6498.791; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GUNDEWALL B, 1993, SPINE, V18, P587, DOI 10.1097/00007632-199304000-00011; JONES SL, 1988, SPINE, V13, P553, DOI 10.1097/00007632-198805000-00020; KELLETT KM, 1991, PHYS THER, V71, P283, DOI 10.1093/ptj/71.4.283; KOES BW, 1992, BRIT MED J, V304, P601, DOI 10.1136/bmj.304.6827.601; KOES BW, 1995, SPINE, V20, P228, DOI 10.1097/00007632-199501150-00021; KOES BW, 1991, BRIT MED J, V303, P1298, DOI 10.1136/bmj.303.6813.1298; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; LINDSTROM I, 1992, PHYS THER, V72, P279, DOI 10.1093/ptj/72.4.279; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; Management of cancer pain, 1994, AGENCY HLTH CARE POL; MANNICHE C, 1991, PAIN, V47, P53, DOI 10.1016/0304-3959(91)90011-L; MEADE TW, 1992, BRIT MED J, V304, P1310, DOI 10.1136/bmj.304.6837.1310; Morrell D C, 1976, J R Coll Gen Pract, V26, P398; Postacchini F, 1988, NEURO-ORTHOPEDICS, V6, P28; ROLAND M, 1989, J ROY COLL GEN PRACT, V39, P244; ROLAND MO, 1983, BRIT MED J, V286, P523, DOI 10.1136/bmj.286.6364.523; ROLAND MO, 1983, PRACTITIONER, V227, P1119; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; STUBBS DA, 1983, ERGONOMICS, V26, P767, DOI 10.1080/00140138308963398; VALAT JP, 1994, RHEUMATOLOGY EUROPE, V23, P55; WADDELL G, 1993, ANN RHEUM DIS, V52, P317, DOI 10.1136/ard.52.5.317; WADDELL G, 1992, BAILLIERE CLIN RHEUM, V6, P523, DOI 10.1016/S0950-3579(05)80126-8; WADSWORTH MEJ, 1971, HLTH SICKNESS CHOICE; 1994, MANAGEMENT GUIDELINE; 1994, EFFECTIVE HLTH CARE, P8; 1987, SPINE, V12, pS9; 1993, BETTER LIVING BETTER; 1994, GUIDE MANAGEMENT LOW	42	61	61	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 24	1996	312	7029					485	488		10.1136/bmj.312.7029.485	http://dx.doi.org/10.1136/bmj.312.7029.485			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597683	Green Published			2022-12-28	WOS:A1996TX38300028
J	Taylor, IK; Hill, AA; Hayes, M; Rhodes, CG; OShaughnessy, KM; OConnor, BJ; Jones, HA; Hughes, JMB; Jones, T; Pride, NB; Fuller, RW				Taylor, IK; Hill, AA; Hayes, M; Rhodes, CG; OShaughnessy, KM; OConnor, BJ; Jones, HA; Hughes, JMB; Jones, T; Pride, NB; Fuller, RW			Imaging allergen-invoked airway inflammation in atopic asthma with [F-18]-fluorodeoxyglucose and positron emission tomography	LANCET			English	Article							BRONCHOALVEOLAR LAVAGE; GLUCOSE-UTILIZATION; LOBAR PNEUMONIA; CHALLENGE; LUNG; METABOLISM; DENSITY; HUMANS	Background Airway inflammation is a feature of asthma and can be quantified invasively with bronchial lavage and endobronchial histology. Inflammatory foci can be imaged non-invasively with positron emission tomography (PET) and [F-18]-fluorodeoxyglucose ((18)FDG) to quantify glucose uptake in activated granulocytes. We used this technique to study airway inflammation in asthma. Methods Nine men with mild atopic asthma were studied. In five, we studied the effect of bronchoscopic segmental allergen challenge on (18)FDG uptake. Allergen was instilled into the posterior segment of the right upper lobe; a similar volume (20 mL) of isotonic saline was instilled into the posterior segment of the left upper lobe. At 1-32 h after instillation, PET with (18)FDG was done. In the other four patients, we administered aerosolised allergen. Findings (18)FDG uptake was increased four-fold in the right compared with the left upper lobe (geometric mean of ratios 4.30, 95% Cl 2.39-7.72, p=0.002). Aerosolised administration of allergen did not significantly increase (18)FDG uptake. Interpretation These data show that local allergen-invoked airway inflammation can be visualised with (18)FDG and PET in asthma. The cellular localisation of the (18)FDG signal remains to be determined.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT RESP MED,LONDON W12,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CLIN PHARMACOL,LONDON W12,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,CYCLOTRON UNIT,LONDON W12,ENGLAND; GLAXO RES & DEV,GREENFORD,MIDDX,ENGLAND	Imperial College London; Imperial College London; Imperial College London; GlaxoSmithKline				Hill, Anthony/0000-0002-7605-9274				BRUDIN LH, 1994, EUR J NUCL MED, V21, P297, DOI 10.1007/BF00947964; DECHATELET LR, 1977, BLOOD, V50, P525; DUPUIS R, 1992, J ALLERGY CLIN IMMUN, V89, P850, DOI 10.1016/0091-6749(92)90441-4; GRATZIOU C, 1992, AM REV RESPIR DIS, V145, P1259, DOI 10.1164/ajrccm/145.6.1259; HASLETT C, 1989, AM REV RESPIR DIS, V140, P756, DOI 10.1164/ajrccm/140.3.756; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; JONES HA, 1994, AM J RESP CRIT CARE, V149, P1635, DOI 10.1164/ajrccm.149.6.7516252; JONES HA, 1995, AM J RESP CRIT CARE, V151, pA343; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; NOLOP KB, 1987, CANCER, V60, P2682, DOI 10.1002/1097-0142(19871201)60:11<2682::AID-CNCR2820601118>3.0.CO;2-H; PANTIN CF, 1988, AM REV RESPIR DIS, V138, P1234, DOI 10.1164/ajrccm/138.5.1234; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; REISS M, 1978, J CLIN INVEST, V61, P480, DOI 10.1172/JCI108959; RHODES CG, 1981, J COMPUT ASSIST TOMO, V5, P783, DOI 10.1097/00004728-198112000-00001; ROBB R A, 1991, Australasian Physical and Engineering Sciences in Medicine, V14, P9; SAVERYMUTTU SH, 1985, THORAX, V40, P925, DOI 10.1136/thx.40.12.925; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; UEKI J, 1993, J APPL PHYSIOL, V75, P559, DOI 10.1152/jappl.1993.75.2.559; WASHAWSKI FJ, 1986, AM REV RESPIR DIS, V133, P797; WOLLMER P, 1982, LANCET, V2, P1361	23	59	61	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1996	347	9006					937	940		10.1016/S0140-6736(96)91416-6	http://dx.doi.org/10.1016/S0140-6736(96)91416-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598758				2022-12-28	WOS:A1996UD59100011
J	Glass, RI; Gentsch, JR; Ivanoff, B				Glass, RI; Gentsch, JR; Ivanoff, B			New lessons for rotavirus vaccines	SCIENCE			English	Editorial Material							YOUNG-CHILDREN; PROTECTION; IMMUNIZATION; INFECTION; IMMUNITY		CTR DIS CONTROL & PREVENT,GASTROENTEROL SECT,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333; WHO,GLOBAL PROGRAMME VACCINES,VACCINE RES & DEV,CH-1211 GENEVA,SWITZERLAND	Centers for Disease Control & Prevention - USA; World Health Organization								Ball JM, 1996, SCIENCE, V272, P101, DOI 10.1126/science.272.5258.101; BERNSTEIN DI, 1995, JAMA-J AM MED ASSOC, V273, P1191, DOI 10.1001/jama.273.15.1191; BHAN MK, 1993, J INFECT DIS, V168, P282, DOI 10.1093/infdis/168.2.282; BISHOP RF, 1983, NEW ENGL J MED, V309, P72, DOI 10.1056/NEJM198307143090203; Burns JW, 1996, SCIENCE, V272, P104, DOI 10.1126/science.272.5258.104; COOK SM, 1990, B WORLD HEALTH ORGAN, V68, P171; COOK SM, 1986, NEW VACCINE DEV DISE, V2; DAVIDSON GP, 1979, ACTA PAEDIATR SCAND, V68, P181, DOI 10.1111/j.1651-2227.1979.tb04986.x; DEZOYSA I, 1985, B WORLD HEALTH ORGAN, V63, P569; GLASS RI, 1994, SCIENCE, V265, P1389, DOI 10.1126/science.8073280; GREENBERG HB, 1994, ROTAVIRUSES, P255; HO MS, 1988, J INFECT DIS, V158, P1112, DOI 10.1093/infdis/158.5.1112; JIN S, IN PRESS PED INFECT; KAPIKIAN AZ, 1996, FIELDS VIROLOGY, V2, P1657; KAPIKIAN AZ, 1994, VIRAL INFECTIONS GAS, P409; KOHLER VT, 1990, KINDERARZTL PRAX, V58, P323; Rennels MB, 1996, PEDIATRICS, V97, P7; SATO K, 1981, ARCH VIROL, V69, P155, DOI 10.1007/BF01315159; SMITH JC, 1995, PEDIATRICS, V96, P609; TREANOR JJ, 1995, PEDIATR INFECT DIS J, V14, P301, DOI 10.1097/00006454-199504000-00010; URASAWA T, 1981, MICROBIOL IMMUNOL, V25, P1025, DOI 10.1111/j.1348-0421.1981.tb00109.x; WARD RL, 1992, VIROLOGY, V188, P57, DOI 10.1016/0042-6822(92)90734-7; WARD RL, 1990, J VIROL, V64, P5070, DOI 10.1128/JVI.64.10.5070-5075.1990; WARD RL, 1994, J INFECT DIS, V169, P900, DOI 10.1093/infdis/169.4.900; *WORLD BANK, 1993, 1993 WORLD BANK; WYATT RG, 1980, SCIENCE, V207, P189, DOI 10.1126/science.6243190; WYATT RG, 1979, SCIENCE, V203, P548, DOI 10.1126/science.216077	27	50	53	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					46	48		10.1126/science.272.5258.46	http://dx.doi.org/10.1126/science.272.5258.46			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600533				2022-12-28	WOS:A1996UD59700032
J	Sorrell, MF; Delbanco, TL				Sorrell, MF; Delbanco, TL			A 47-year-old man with asymptomatic hepatitis C infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							NON-B-HEPATITIS; RECOMBINANT INTERFERON-ALFA; OUTPATIENT LIVER-BIOPSY; NON-A; CONTROLLED TRIAL; TRANSFUSION; VIRUS; ALPHA		UNIV NEBRASKA, MED CTR, LIVER TRANSPLANT PROGRAM, OMAHA, NE USA	University of Nebraska System; University of Nebraska Medical Center								AKAHANE Y, 1994, ANN INTERN MED, V120, P748, DOI 10.7326/0003-4819-120-9-199405010-00005; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259; Bennett W. G., 1995, Hepatology, V22, p290A; BRILLANTI S, 1994, GASTROENTEROLOGY, V107, P812, DOI 10.1016/0016-5085(94)90131-7; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DEMEDINA M, 1995, SEMIN LIVER DIS, V15, P33, DOI 10.1055/s-2007-1007261; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; Dusheiko GM, 1995, HEPATOLOGY, V22, P1863, DOI 10.1016/0270-9139(95)90216-3; FRIED MW, 1995, SEMIN LIVER DIS, V15, P82, DOI 10.1055/s-2007-1007265; GARCIATSAO G, 1993, ANN INTERN MED, V118, P150, DOI 10.7326/0003-4819-118-2-199301150-00013; JANES CH, 1993, ANN INTERN MED, V118, P96, DOI 10.7326/0003-4819-118-2-199301150-00003; JANSSEN HLA, 1994, J HEPATOL, V21, P241, DOI 10.1016/S0168-8278(05)80402-7; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KLEINMAN S, 1992, TRANSFUSION, V32, P805, DOI 10.1046/j.1537-2995.1992.32993110750.x; LAU JYN, 1993, LANCET, V342, P1208, DOI 10.1016/0140-6736(93)92187-X; MARCELLIN P, 1995, GASTROENTEROLOGY, V109, P156, DOI 10.1016/0016-5085(95)90281-3; MARCELLIN P, 1991, HEPATOLOGY, V13, P393, DOI 10.1002/hep.1840130302; MARTIN P, 1995, ANN INTERN MED, V122, P227, DOI 10.7326/0003-4819-122-3-199502010-00012; McCashland T M, 1995, Liver Transpl Surg, V1, P358, DOI 10.1002/lt.500010604; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; REINUS JF, 1992, ANN INTERN MED, V117, P881, DOI 10.7326/0003-4819-117-11-881; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; Serfaty L, 1996, GASTROENTEROLOGY, V110, P291, DOI 10.1053/gast.1996.v110.pm8536870; TERRAULT N, 1995, NEW ENGL J MED, V332, P1509, DOI 10.1056/NEJM199506013322211; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; VANTHIEL DH, 1995, J HEPATOL, V23, P503, DOI 10.1016/0168-8278(95)80054-9; VANTHIEL DH, 1994, J HEPATOL, V20, P410, DOI 10.1016/S0168-8278(94)80017-0; Wright T L, 1995, Liver Transpl Surg, V1, P30, DOI 10.1002/lt.500010108	31	6	6	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					1023	1029		10.1001/jama.275.13.1023	http://dx.doi.org/10.1001/jama.275.13.1023			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC123	8596235				2022-12-28	WOS:A1996UC12300031
J	Busettini, C; Masson, GS; Miles, FA				Busettini, C; Masson, GS; Miles, FA			A role for stereoscopic depth cues in the rapid visual stabilization of the eyes	NATURE			English	Article							OCULAR-FOLLOWING RESPONSES; DEPENDENCE	PRIMATES have visual tracking systems that help stabilize the eyes on the surroundings by responding to retinal image motion at ultra-short latencies(1,2). However, as the observer moves through the environment, the image motion on the retina depends on the three-dimensional structure of the scene(3,4). We report here that the very earliest of these tracking responses is elicited only by objects moving in the immediate vicinity of the plane of fixation: objects nearer or farther are ignored. This selectivity is achieved by means of a stereoscopic depth mechanism which uses the fact that the two eyes have differing viewpoints, so only objects in the plane of fixation have images that occupy corresponding positions on the two retinae. Such behaviour is readily explained by the known binocular properties of some motion-selective neurons in the visual cortex(5). Some (stereoanomalous) subjects showed highly specific tracking deficits as though lacking one subtype of these neurons.	NEI,SENSORIMOTOR RES LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)			MASSON, Guillaume S/G-4615-2012	MASSON, Guillaume S/0000-0001-9227-0777				BUSETTINI C, 1991, J NEUROPHYSIOL, V66, P865, DOI 10.1152/jn.1991.66.3.865; BUSETTINI C, 1994, CONTEMPORARY OCULAR MOTOR AND VESTIBULAR RESEARCH: A TRIBUTE TO DAVID A. ROBINSON, P312; FUCHS AF, 1966, J APPL PHYSIOL, V21, P1068, DOI 10.1152/jappl.1966.21.3.1068; GELLMAN RS, 1990, VISUAL NEUROSCI, V5, P107, DOI 10.1017/S0952523800000158; Gibson JJ, 1950, PERCEPTION VISUAL WO; HOWARD IP, 1989, EXP BRAIN RES, V78, P309; MILES FA, 1986, J NEUROPHYSIOL, V56, P1321, DOI 10.1152/jn.1986.56.5.1321; MILES FA, 1992, HEAD NECK SENSORY MO, P471; MILES FA, 1991, REPRESENTATIONS VISI, P185; MORGAN MJ, 1995, NATURE, V378, P380, DOI 10.1038/378380a0; POGGIO GF, 1995, CEREB CORTEX, V5, P193, DOI 10.1093/cercor/5.3.193	11	46	46	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					342	345		10.1038/380342a0	http://dx.doi.org/10.1038/380342a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598928				2022-12-28	WOS:A1996UC37900059
J	vanderSchouw, YT; vanderGraaf, Y; Steyerberg, EW; Eijkemans, MJC; Banga, JD				vanderSchouw, YT; vanderGraaf, Y; Steyerberg, EW; Eijkemans, MJC; Banga, JD			Age at menopause as a risk factor for cardiovascular mortality	LANCET			English	Article							CORONARY HEART-DISEASE; WOMEN; ESTROGEN	Background Although an association of occurrence of menopause and subsequent oestrogen deficiency with increased cardiovascular disease has been postulated, studies on this association have not shown convincing results. We investigated whether age at menopause is associated with cardiovascular mortality risk. Methods We studied a cohort of 12 115 postmenopausal women living in Utrecht, Netherlands, aged 50-65 years at enrolment in a breast cancer screening project. During follow-up of up to 20 years the women attended screening rounds at which we asked questions on menopausal status, age at menopause, medication use, cardiovascular risk factors, and ovarian function. Deaths were ascertained from the patient's family physicians. Life-table analysis and Cox regression analysis were used to investigate the association between age at menopause and cardiovascular mortality. All analyses were adjusted for biological age. Findings 824 women died of cardiovascular causes. 1459 women had left the study area. The risk of cardiovascular mortality was higher for women with early menopauses than for those with late menopauses. The age-adjusted hazard ratio of age at menopause was 0.982 (95% CI 0.968-0.996, p=0.01)-ie, for each year's delay in the menopause the cardiovascular mortality risk decreased by 2%. The extra risk of early menopause seemed to decrease with biological age (p for interaction 0.07); at biological age 60 the reduction of the annual hazard was 3%, but at age 80 there was no reduction. Adjustment for known cardiovascular risk factors and indicators of ovarian function did not significantly alter the risk estimate. Interpretation These results support the hypothesis that longer exposure to endogenous oestrogens protects against cardiovascular diseases. The effect of an early menopause may be more important at younger biological ages.	ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, CTR CLIN DECIS SCI, ROTTERDAM, NETHERLANDS; ACAD HOSP, DEPT INTERNAL MED, UTRECHT, NETHERLANDS	Erasmus University Rotterdam	vanderSchouw, YT (corresponding author), UNIV UTRECHT, DEPT EPIDEMIOL, POB 80035, 3508 TA UTRECHT, NETHERLANDS.		van der Schouw, Yvonne T./F-8327-2014; Eijkemans, Marinus J/D-8214-2013; Steyerberg, Ewout/C-1509-2018	van der Schouw, Yvonne T./0000-0002-4605-435X; Steyerberg, Ewout/0000-0002-7787-0122				BARRETTCONNOR E, 1995, BRIT MED J, V311, P1193, DOI 10.1136/bmj.311.7014.1193; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BEARD CM, 1984, AM J EPIDEMIOL, V120, P108, DOI 10.1093/oxfordjournals.aje.a113859; BENGTSSON C, 1973, ACTA MED SCAND S, V89, P75; BRAMBILLA DJ, 1989, J CLIN EPIDEMIOL, V42, P1031, DOI 10.1016/0895-4356(89)90044-9; BRESLOW NE, 1987, STAT METHODS CANCER, V2, P195; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; CORRAO JM, 1990, CARDIOLOGY, V77, P8, DOI 10.1159/000174649; DENTONKELAAR I, 1994, BRIT J CANCER, V69, P352, DOI 10.1038/bjc.1994.64; DEWAARD F, 1984, J CHRON DIS, V47, P41; GORDON T, 1978, ANN INTERN MED, V89, P157, DOI 10.7326/0003-4819-89-2-157; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; HELLER RF, 1978, BRIT MED J, V1, P472, DOI 10.1136/bmj.1.6111.472; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; LUOTO R, 1994, AM J EPIDEMIOL, V139, P64, DOI 10.1093/oxfordjournals.aje.a116936; Midgette A S, 1990, Epidemiology, V1, P474, DOI 10.1097/00001648-199011000-00010; PARRISH HM, 1967, AM J OBSTET GYNECOL, V99, P155; RIVIN AU, 1954, CIRCULATION, V9, P533, DOI 10.1161/01.CIR.9.4.533; ROBINSON RW, 1959, ARCH INTERN MED, V104, P908, DOI 10.1001/archinte.1959.00270120064010; ROSENBERG L, 1981, AM J OBSTET GYNECOL, V139, P47, DOI 10.1016/0002-9378(81)90410-5; STAMPFER MJ, 1990, ANN NY ACAD SCI, V592, P193; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STANFORD JL, 1987, J CHRON DIS, V40, P995, DOI 10.1016/0021-9681(87)90113-5; TRACY RE, 1966, J CHRON DIS, V19, P1245, DOI 10.1016/0021-9681(66)90022-1; WINKELSTEIN W Jr, 1958, J Chronic Dis, V7, P273, DOI 10.1016/0021-9681(58)90085-7; WUEST JH, 1953, CIRCULATION, V7, P801, DOI 10.1161/01.CIR.7.6.801	27	481	486	1	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 16	1996	347	9003					714	718		10.1016/S0140-6736(96)90075-6	http://dx.doi.org/10.1016/S0140-6736(96)90075-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8602000	Green Submitted			2022-12-28	WOS:A1996TZ98200008
J	Perelson, AS; Neumann, AU; Markowitz, M; Leonard, JM; Ho, DD				Perelson, AS; Neumann, AU; Markowitz, M; Leonard, JM; Ho, DD			HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1	A new mathematical model was used to analyze a detailed set of human immunodeficiency virus-type 1 (HIV-1) viral load data collected from five infected individuals after the administration of a potent inhibitor of HIV-1 protease. Productively infected cells were estimated to have, on average, a life-span of 2.2 days (half-life t(1/2) = 1.6 days), and plasma virions were estimated to have a mean life-span of 0.3 days (t(1/2) = 0.24 days). The estimated average total HIV-1 production was 10.3 x 10(9) virions per day, which is substantially greater than previous minimum estimates. The results also suggest that the minimum duration of the HIV-1 life cycle in vivo is 1.2 days on average, and that the average HIV-1 generation time-defined as the time from release of a virion until it infects another cell and causes the release of a new generation of viral particles-is 2.6 days, These findings on viral dynamics provide not only a kinetic picture of HIV-1 pathogenesis, but also theoretical principles to guide the development of treatment strategies.	AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016; LOS ALAMOS NATL LAB,DIV THEORET,LOS ALAMOS,NM 87545; ABBOTT LABS,DIV PHARMACEUT PROD,ABBOTT PK,IL 60064	United States Department of Energy (DOE); Los Alamos National Laboratory; Abbott Laboratories			Perelson, Alan S/Z-1959-2019; Yang, Chen/G-1379-2010	Perelson, Alan S/0000-0002-2455-0002; 	NCRR NIH HHS [RR06555] Funding Source: Medline; NIAID NIH HHS [N01 AI45218, AI27742] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027742, N01AI045218] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CAO YZ, 1995, AIDS RES HUM RETROV, V11, P353, DOI 10.1089/aid.1995.11.353; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; NATHANSON N, 1966, AM J EPIDEMIOL, V85, P494; NOWAK MA, 1995, NATURE, V375, P193, DOI 10.1038/375193a0; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Winslow D L, 1995, AIDS, V9 Suppl A, pS183	15	2628	2723	6	211	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1582	1586		10.1126/science.271.5255.1582	http://dx.doi.org/10.1126/science.271.5255.1582			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599114				2022-12-28	WOS:A1996TZ98300041
J	Messite, J; Stellman, SD				Messite, J; Stellman, SD			Accuracy of death certificate completion - The need for formalized physician training	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER MORTALITY STATISTICS	Objective.-To assess the extent to which accuracy of death certificate completion varies with level of physician training and experience. Design and Setting.-In a classroom setting, subjects were presented with six written cases of hospital deaths adapted from materials from the National Center for Health Statistics and were asked to complete the cause-of-death section of the New York City death certificate. Participants.-A total of 12 practicing general internists, 21 internal medicine residents, and 35 senior medical students. Outcome Measures.-The underlying cause of death recorded by each participant was compared with the correct cause determined by a nosologist. Agreement and disagreement were classified as major or minor depending on concordance within the 17 International Classification of Diseases categories. Results.-Only one internist and five residents had received formal training in death certificate completion. The overall level of agreement between underlying cause of death reported by the three groups of participants and the correct cause was 56.9% for internists, 56.0% for residents, and 55.7% for medical students, although agreement varied with the type of case, ranging from 15% to 99%. Conclusions.-If the misclassification observed in this pilot study were widespread, it would imply a substantial underreporting of mortality from both circulatory diseases and diabetes. These data strongly support the need to include training in death certificate completion as part of physician education.	AMER HLTH FDN,NEW YORK,NY 10017	American Health Foundation	Messite, J (corresponding author), NEW YORK ACAD MED,OFF PUBL HLTH,1216 5TH AVE,NEW YORK,NY 10029, USA.				NCI NIH HHS [CA-17613, CA-68384, CA-32617] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA068384, P30CA017613, P01CA032617] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COMSTOCK GW, 1986, AM J EPIDEMIOL, V124, P180, DOI 10.1093/oxfordjournals.aje.a114376; COTE TR, 1992, JAMA-J AM MED ASSOC, V268, P2066, DOI 10.1001/jama.268.15.2066; CURB JD, 1983, AM J EPIDEMIOL, V118, P122, DOI 10.1093/oxfordjournals.aje.a113613; ENGEL LW, 1980, AM J EPIDEMIOL, V111, P99, DOI 10.1093/oxfordjournals.aje.a112879; GAY G, 1989, NAT CTR HLTH STAT WO; GITTELSOHN A, 1982, 821363 PHS DHHS; GOODMAN RA, 1982, JAMA-J AM MED ASSOC, V247, P793, DOI 10.1001/jama.247.6.793; HANZLICK R, 1993, JAMA-J AM MED ASSOC, V269, P47; Hanzlick R, 1994, MED CAUSE DEATH MANU; ISRAEL R A, 1990, World Health Statistics Quarterly, V43, P259; ISRAEL RA, 1986, AM J EPIDEMIOL, V124, P161, DOI 10.1093/oxfordjournals.aje.a114375; KELSON M, 1987, INT J EPIDEMIOL, V16, P411, DOI 10.1093/ije/16.3.411; KIRCHER T, 1987, JAMA-J AM MED ASSOC, V258, P349, DOI 10.1001/jama.258.3.349; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; KIRCHER T, 1987, P BIENN C REC STAT, P188; *NAT CTR HLTH STAT, 1987, PHYS HDB MED CERT DE; *NAT CTR HLTH STAT, 1985, VIT STAT INSTR MA 20; *NAT CTR HLTH STAT, 1982, VIT STAT INSTR MA 18; PERCY C, 1981, AM J PUBLIC HEALTH, V71, P242, DOI 10.2105/AJPH.71.3.242; STEENLAND K, 1992, AM J EPIDEMIOL, V136, P855, DOI 10.1093/aje/136.7.855; STEHBENS WE, 1987, LANCET, V2, P606; WHO (World Health Organization), 1977, MAN INT STAT CLASS D	22	183	183	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1996	275	10					794	796		10.1001/jama.275.10.794	http://dx.doi.org/10.1001/jama.275.10.794			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY886	8598597	Green Submitted			2022-12-28	WOS:A1996TY88600028
J	Calltorp, J				Calltorp, J			Health care with equity and cost containment	LANCET			English	Article											Calltorp, J (corresponding author), NORD SCH PUBL HLTH,GOTHENBURG,SWEDEN.								0	40	39	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					587	588		10.1016/S0140-6736(96)91278-7	http://dx.doi.org/10.1016/S0140-6736(96)91278-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596324				2022-12-28	WOS:A1996TX69400016
J	Mok, A; Nelson, EAS				Mok, A; Nelson, EAS			Children on hunger strike: Child abuse or legitimate protest?	BRITISH MEDICAL JOURNAL			English	Article								The issue of children on hunger strike (voluntary total fasting) has not been reported before. The World Medical Association Declaration of Tokyo 1975 and the Declaration of Malta 1991 (revised 1992) provide clinicians with guidelines for the management of adult patients on hunger strike(12) but do not mention children. We report the management of 14 Vietnamese children, aged 1 to 12 years, who took part in a hunger strike at a refugee detention centre in Hong Kong.	CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT PAEDIAT,SHA TIN,HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital			Nelson, E Anthony S/ABF-4238-2020	Nelson, E Anthony S/0000-0002-2521-3403				[Anonymous], 1989, CONV RIGHTS CHILD 20; DEVEREUX JA, 1993, BRIT MED J, V306, P1459, DOI 10.1136/bmj.306.6890.1459; KALK WJ, 1991, LANCET, V337, P660, DOI 10.1016/0140-6736(91)92465-E; SHIELD JP, 1994, BRIT MED J, V308, P1182, DOI 10.1136/bmj.308.6938.1182; 1994, S CHINA MORNING 0914; 1975, WORLD MED J, V22, P87; 1992, 44 WORLD MED ASS MAR; 1991, 43 WORLD MED ASS MAL	8	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					501	502		10.1136/bmj.312.7029.501	http://dx.doi.org/10.1136/bmj.312.7029.501			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597690	Green Published			2022-12-28	WOS:A1996TX38300037
J	Taylor, M; Kerr, D				Taylor, M; Kerr, D			Diabetes control and complications: A coming of AGE	LANCET			English	Editorial Material											Taylor, M (corresponding author), ROYAL BOURNEMOUTH HOSP,METAB UNIT,BOURNEMOUTH,DORSET,ENGLAND.							BAYNES JW, 1994, J CLIN INVEST, V94, P2, DOI 10.1172/JCI117307; BROWNLEE M, 1994, DIABETES, V43, P836, DOI 10.2337/diab.43.6.836; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; GABBAY KH, 1976, NEW ENGL J MED, V295, P443, DOI 10.1056/NEJM197608192950810; GOLDSTEIN DE, 1995, DIABETES CARE, V18, P896, DOI 10.2337/diacare.18.6.896; KLEIN R, 1995, DIABETES CARE, V18, P258, DOI 10.2337/diacare.18.2.258; 1993, NEW ENGL J MED, V329, P977	7	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					485	485		10.1016/S0140-6736(96)91132-0	http://dx.doi.org/10.1016/S0140-6736(96)91132-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596261				2022-12-28	WOS:A1996TW69700003
J	VanDaele, PLA; Seibel, MJ; Burger, H; Hofman, A; Grobbee, DE; VanLeeuwen, JPTM; Birkenhager, JC; Pols, HAP				VanDaele, PLA; Seibel, MJ; Burger, H; Hofman, A; Grobbee, DE; VanLeeuwen, JPTM; Birkenhager, JC; Pols, HAP			Case-control analysis of bone resorption markers, disability, and hip fracture risk: The Rotterdam study	BRITISH MEDICAL JOURNAL			English	Article									ERASMUS UNIV ROTTERDAM,SCH MED,DEPT INTERNAL MED 3,3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS; UNIV HEIDELBERG,DEPT ENDOCRINOL & METAB,HEIDELBERG,GERMANY	Erasmus University Rotterdam; Erasmus University Rotterdam; Ruprecht Karls University Heidelberg			Grobbee, Diederick/C-7651-2014; van Leeuwen, Johannes/D-5015-2014	Grobbee, Diederick/0000-0003-4472-4468; van Leeuwen, Johannes/0000-0002-2282-4006; Seibel, Markus J/0000-0002-2701-378X				CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; JOHNSTON CC, 1994, OSTEOPOROSIS INT, V4, P43; LIPS P, 1990, BONE MINER, V9, P49, DOI 10.1016/0169-6009(90)90099-2; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107	5	154	156	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					482	483		10.1136/bmj.312.7029.482	http://dx.doi.org/10.1136/bmj.312.7029.482			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597681	Green Submitted, Green Published			2022-12-28	WOS:A1996TX38300025
J	Wang, TW; Danielson, PD; Li, BY; Shah, PC; Kim, SD; Donahoe, PK				Wang, TW; Danielson, PD; Li, BY; Shah, PC; Kim, SD; Donahoe, PK			The p21(RAS) farnesyltransferase alpha subunit in TGF-beta and activin signaling	SCIENCE			English	Article							GROWTH-FACTOR-BETA; PROTEIN FARNESYLTRANSFERASE; II RECEPTOR; P21RAS; CLONING; RECOGNITION; EXPRESSION; ACTIVATION	The alpha subunit of p21(RAS) farnesyltransferase (FNTA), which is also shared by geranylgeranyltransferase, was isolated as a specific cytoplasmic interactor of the transforming growth factor-beta (TGF-beta) and activin type I receptors with the use of the yeast two-hybrid system. FNTA interacts specifically with ligand-free TGF-beta type I receptor but is phosphorylated and released upon ligand binding. Furthermore, the release is dependent on the kinase activity of the TGF-beta type II receptor. Thus, the growth inhibitory and differentiative pathways activated by TGF-beta and activin involve novel mechanisms of serine-threonine receptor phosphorylation-dependent release of cytoplasmic interactors and regulation of the activation of small G proteins, such as p21(RAS).			Wang, TW (corresponding author), MASSACHUSETTS GEN HOSP,PEDIAT SURG RES LAB,BOSTON,MA 02114, USA.				NICHD NIH HHS [R01 HD3081, R01 HD32112, HD28138] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032112, P30HD028138] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDRES DA, 1993, GENOMICS, V18, P105, DOI 10.1006/geno.1993.1432; ANDRES DA, 1993, J BIOL CHEM, V268, P1383; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MULDER KM, 1992, J BIOL CHEM, V267, P5029; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1993, ONCOGENE, V8, P2879; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WANG TW, UNPUB; WARANA JL, 1994, MOL CELL BIOL, V14, P944; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	34	109	111	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1120	1122		10.1126/science.271.5252.1120	http://dx.doi.org/10.1126/science.271.5252.1120			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599089				2022-12-28	WOS:A1996TW70100039
J	Farrell, AM; Roberts, NM; Walsh, JC; Staughton, RCD				Farrell, AM; Roberts, NM; Walsh, JC; Staughton, RCD			A painful rash with AIDS	LANCET			English	Article									CHELSEA & WESTMINSTER HOSP,DEPT GENITOURINARY MED,LONDON SW10 9NH,ENGLAND	Imperial College London	Farrell, AM (corresponding author), CHELSEA & WESTMINSTER HOSP,DEPT DERMATOL,369 FULHAM RD,LONDON SW10 9NH,ENGLAND.							MORRISON JG, 1974, BRIT J DERMATOL, V91, P263, DOI 10.1111/j.1365-2133.1974.tb12894.x; SLOAN JB, 1990, PEDIATR DERMATOL, V7, P191, DOI 10.1111/j.1525-1470.1990.tb00280.x; VICTOR T, 1992, AM J DERMATOPATH, V14, P491; WILLIAMS JT, 1994, INT J DERMATOL, V33, P109, DOI 10.1111/j.1365-4362.1994.tb01537.x; WILSONJONES E, 1986, J AM ACAD DERMATOL, V14, P815, DOI 10.1016/S0190-9622(86)70099-6	5	6	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					372	372		10.1016/S0140-6736(96)90541-3	http://dx.doi.org/10.1016/S0140-6736(96)90541-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598705				2022-12-28	WOS:A1996TU69500013
J	Daltry, JC; Wuster, W; Thorpe, RS				Daltry, JC; Wuster, W; Thorpe, RS			Diet and snake venom evolution	NATURE			English	Article							RATTLESNAKE VENOM; RUSSELL VIPER; ISLAND; PREY	VENOM composition within snake species can show considerable geographical variation(1), an important consideration because bites by conspecific populations may differ in symptomatology and require different treatments(2-5). The underlying causes of this phenomenon have never been explained, Here we present evidence that the variation in the venom of the pitviper Calloselasma rhodostoma (Serpentes: Viperidae) is closely associated with its diet, We also evaluated other possible causes of geographic variation in venom using partial Mantel tests(6-10) and independent contrasts(11), but rejected both contemporary gene flow (estimated from geographical proximity) and the phylogenetic relationships (assessed by analysis of mitochondrial DNA) among populations as important influences upon venom evolution, As the primary function of viperid venom is to immobilize and digest prey(12-14) and prey animals vary in their susceptibility to venom(15,16), we suggest that geographical variation in venom composition reflects natural selection for feeding on local prey.	UNIV COLL N WALES, SCH BIOL SCI, BANGOR LL57 2UW, GWYNEDD, WALES	Bangor University			Wuster, Wolfgang/B-2879-2008	Wuster, Wolfgang/0000-0002-4890-4311; Daltry, Jennifer C./0000-0003-0364-9465				BARRIO AVELINO, 1951, ACTA PHYSIOL LATINOAMER, V1, P291; BOCHE J, 1981, B SOC PATHOL EXOT, V74, P356; BROWN RP, 1991, NATURE, V352, P60, DOI 10.1038/352060a0; CASTELLANO S, 1994, BIOL J LINN SOC, V52, P365, DOI 10.1006/bijl.1994.1057; CHEN YC, 1984, TOXICON, V22, P53, DOI 10.1016/0041-0101(84)90138-7; CHIPPAUX JP, 1991, TOXICON, V29, P1279, DOI 10.1016/0041-0101(91)90116-9; ELLIOTT WB, 1978, BIOL REPTILIA, V8, P163; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FELSENSTEIN J, 1990, PHYLIP VERSION 3 3; FOOTE R, 1977, COMP BIOCHEM PHYS B, V57, P235, DOI 10.1016/0305-0491(77)90150-X; GREGORYDWYER VM, 1986, TOXICON, V24, P995, DOI 10.1016/0041-0101(86)90005-X; HAYES WK, 1991, TOXICON, V29, P867, DOI 10.1016/0041-0101(91)90223-E; JAYANTHI GP, 1988, TOXICON, V26, P257, DOI 10.1016/0041-0101(88)90216-4; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; MACKESSY SP, 1988, COPEIA, P92, DOI 10.2307/1445927; MCELROY D, 1992, RESTRICTION ENZYME A; Minton S. A., 1969, VENOMOUS REPTILES; MORITZ C, 1992, SYST BIOL, V41, P273, DOI 10.2307/2992567; POUGH FH, 1983, AM ZOOL, V23, P443; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; Tan N.-H., 1991, Tropical Biomedicine, V8, P91; THOMAS RG, 1979, TOXICON, V17, P221, DOI 10.1016/0041-0101(79)90211-3; Thorpe R.S., 1994, Linnean Society Symposium Series, V17, P189; THORPE RS, 1995, PHILOS T ROY SOC B, V349, P61, DOI 10.1098/rstb.1995.0091; THORPE RS, 1993, BIOL J LINN SOC, V48, P75, DOI 10.1111/j.1095-8312.1993.tb00878.x; TU AT, 1978, J HERPETOL, V12, P105, DOI 10.2307/1563515; TU AT, 1968, NATURE, V217, P761; WARRELL DA, 1986, NATURAL TOXINS ANIMA, P00025; WUSTER W, 1992, BIOL J LINN SOC, V47, P97, DOI 10.1111/j.1095-8312.1992.tb00658.x	29	486	498	1	149	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					537	540		10.1038/379537a0	http://dx.doi.org/10.1038/379537a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596631				2022-12-28	WOS:A1996TU69300049
J	Kwan, JTC; Marsh, FP				Kwan, JTC; Marsh, FP			Bilateral nephrocalcinosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Kwan, JTC (corresponding author), ROYAL LONDON HOSP,LONDON E1 1BB,ENGLAND.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	1996	334	17					1105	1105		10.1056/NEJM199604253341706	http://dx.doi.org/10.1056/NEJM199604253341706			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG457	8598870				2022-12-28	WOS:A1996UG45700006
J	Nightingale, SL				Nightingale, SL			New cancer therapy initiatives	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1224	1224		10.1001/jama.275.16.1224	http://dx.doi.org/10.1001/jama.275.16.1224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF478	8601942				2022-12-28	WOS:A1996UF47800009
J	Ball, JM; Tian, P; Zeng, CQY; Morris, AP; Estes, MK				Ball, JM; Tian, P; Zeng, CQY; Morris, AP; Estes, MK			Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein	SCIENCE			English	Article							HEAT-STABLE ENTEROTOXIN; ESCHERICHIA-COLI; GUANYLATE-CYCLASE; MURINE ROTAVIRUS; GNOTOBIOTIC PIGS; PATHOGENESIS; INFECTION; MICE; SITES; SEQUENCE	The rotavirus nonstructural glycoprotein NSP4 is an intracellular receptor that mediates the acquisition of a transient membrane envelope as subviral particles bud into the endoplasmic reticulum. NSP4 also causes an increase in intracellular calcium in insect cells. Purified NSP4 or a peptide corresponding to NSP4 residues 114 to 135 induced diarrhea in young (6 to 10 days old) CD1 mice. This disease response was age-dependent, dose-dependent, and specific. Electrophysiologic data from intestinal mucosa showed that the NSP4 114-135 peptide potentiates chloride secretion by a calcium-dependent signaling pathway. Diarrhea is induced when NSP4, acting as a viral enterotoxin, triggers a signal transduction pathway.	BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,DEPT INTEGRAT BIOL,HOUSTON,TX 77030	Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston					NIDDK NIH HHS [DK 30144] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030144, R56DK030144] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALL JM, 1994, J IMMUNOL METHODS, V171, P37, DOI 10.1016/0022-1759(94)90226-7; BOTH GW, 1983, J VIROL, V48, P335, DOI 10.1128/JVI.48.2.335-339.1983; BURGESS MN, 1978, INFECT IMMUN, V21, P526, DOI 10.1128/IAI.21.2.526-531.1978; BURNS JW, 1995, VIROLOGY, V207, P143, DOI 10.1006/viro.1995.1060; CARPINO LA, 1970, J AM CHEM SOC, V92, P5748, DOI 10.1021/ja00722a043; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLLINS J, 1988, J PEDIATR GASTR NUTR, V7, P264, DOI 10.1097/00005176-198803000-00017; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; ESTES MK, 1983, CURR TOP MICROBIOL, V105, P123; FENG NG, 1994, J VIROL, V68, P7766, DOI 10.1128/JVI.68.12.7766-7773.1994; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; GIANNELLA RA, 1983, AM J PHYSIOL, V245, pG492, DOI 10.1152/ajpgi.1983.245.4.G492; GIANNELLA RA, 1981, ANNU REV MED, V32, P341, DOI 10.1146/annurev.me.32.020181.002013; GRAHAM DY, 1984, DIGEST DIS SCI, V29, P1028, DOI 10.1007/BF01311255; Greenberg H B, 1994, Curr Top Microbiol Immunol, V185, P255; GRUBB BR, 1995, AM J PHYSIOL-GASTR L, V268, pG505, DOI 10.1152/ajpgi.1995.268.3.G505; HALVORSRUD J, 1980, SCAND J INFECT DIS, V12, P161, DOI 10.3109/inf.1980.12.issue-3.01; HOLZEL H, 1980, J INFECTION, V2, P33, DOI 10.1016/S0163-4453(80)91750-8; HOSHINO Y, 1995, VIROLOGY, V209, P274, DOI 10.1006/viro.1995.1255; JIANG X, 1990, Science (Washington D C), V250, P1580; JOHNSON GP, 1986, ANAL CHEM, V58, P1084; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KAPIKIAN AC, 1996, VIROLOGY, pCH55; KRAUSE WJ, 1990, CELL TISSUE RES, V260, P387, DOI 10.1007/BF00318641; LEVIN J, 1968, THROMB DIATH HAEMOST, V19, P186; LITTLE LM, 1982, INFECT IMMUN, V38, P755, DOI 10.1128/IAI.38.2.755-763.1982; MARGALIT H, 1987, J IMMUNOL, V138, P2213; MCADARAGH JP, 1980, AM J VET RES, V41, P1572; MEBUS CA, 1976, AM J DIG DIS, V21, P592, DOI 10.1007/BF01464768; MORRIS AP, 1994, AM J PHYSIOL, V266, pC254, DOI 10.1152/ajpcell.1994.266.1.C254; NOVITSKY TJ, 1984, OCEANUS, V27, P13; OSBORNE MP, 1988, J PEDIATR GASTR NUTR, V7, P236, DOI 10.1097/00005176-198803000-00014; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; RAMIG RF, 1988, MICROB PATHOGENESIS, V4, P189, DOI 10.1016/0882-4010(88)90069-1; REED L. J., 1938, AMER JOUR HYG, V27, P493; SAIF LJ, IN PRESS P SAPP INT; SEARS CL, 1995, INFECTIONS GASTROINT, pCH44; STARKEY WG, 1986, J GEN VIROL, V67, P2625, DOI 10.1099/0022-1317-67-12-2625; THEIL KW, 1978, AM J VET RES, V39, P213; TIAN P, 1995, J VIROL, V69, P5763, DOI 10.1128/JVI.69.9.5763-5772.1995; TIAN P, 1994, J VIROL, V68, P251, DOI 10.1128/JVI.68.1.251-257.1994; WARD RL, 1990, J VIROL, V64, P5070, DOI 10.1128/JVI.64.10.5070-5075.1990; ZENG CQY, IN PRESS J VIROL; [No title captured]	45	479	509	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					101	104		10.1126/science.272.5258.101	http://dx.doi.org/10.1126/science.272.5258.101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600515				2022-12-28	WOS:A1996UD59700047
J	Goodrich, JA; Cutler, G; Tjian, R				Goodrich, JA; Cutler, G; Tjian, R			Contacts in context: Promoter specificity and macromolecular interactions in transcription	CELL			English	Review							TATA BOX; ACTIVATION; INITIATOR; MECHANISM; ELEMENT; SP1				Goodrich, JA (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.							BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; DIKSTEIN R, 1996, IN PRESS CELL, V84; GILMOUR DS, 1990, MOL CELL BIOL, V10, P4233, DOI 10.1128/MCB.10.8.4233; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; PURNELL BA, 1993, MOL CELL BIOL, V13, P2593, DOI 10.1128/MCB.13.4.2593; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TAN SY, 1994, P NATL ACAD SCI USA, V91, P9808, DOI 10.1073/pnas.91.21.9808; TANSEY WP, 1995, P NATL ACAD SCI USA, V92, P10550, DOI 10.1073/pnas.92.23.10550; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	37	180	186	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1996	84	6					825	830		10.1016/S0092-8674(00)81061-2	http://dx.doi.org/10.1016/S0092-8674(00)81061-2			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601306	Bronze			2022-12-28	WOS:A1996UC38100004
J	Seiwert, SD; Heidmann, S; Stuart, K				Seiwert, SD; Heidmann, S; Stuart, K			Direct visualization of uridylate deletion in vitro suggests a mechanism for kinetoplastid RNA editing	CELL			English	Article							MITOCHONDRIAL EXTRACTS; LEISHMANIA-TARENTOLAE; MESSENGER-RNAS; MOLECULES; INVITRO; SITES	Deletion of uridylates from the 3'-most editing site of synthetic ATPase 6 pre-mRNA can be visualized directly by coincubation of a radiolabeled substrate RNA and a synthetic gRNA in 20S fractions of T. brucei mitochondrial lysates. Substrate RNA cleavage is gRNA directed and occurs 3' to the uridylates to be deleted. U residues appear to be sequentially removed from the 3' end of the 5' cleavage product prior to religation of the two pre-mRNA halves. gRNA/mRNA chimeric molecules are also produced. Time course experiments indicate that chimeras appear after cleavage intermediates and edited product. Furthermore, a mutant gRNA promotes formation of edited product but not detectable chimeras. Our results suggest a model for kinetoplastid RNA editing in which chimeric molecules are nonproductive end products of editing and not intermediates that serve as a repository for deleted U's.	UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	Seiwert, SD (corresponding author), SEATTLE BIOMED RES INST,4 NICKERSON ST,SEATTLE,WA 98109, USA.				NIGMS NIH HHS [GM42188] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTS GJ, 1993, EMBO J, V12, P1523, DOI 10.1002/j.1460-2075.1993.tb05796.x; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1994, EUR J BIOCHEM, V221, P9, DOI 10.1111/j.1432-1033.1994.tb18710.x; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1992, P NATL ACAD SCI USA, V89, P11944, DOI 10.1073/pnas.89.24.11944; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CORELL RA, 1996, MOL CELL BIOL, V16; GORINGER HU, 1994, P NATL ACAD SCI USA, V91, P1776, DOI 10.1073/pnas.91.5.1776; HARRIS M, 1992, MOL CELL BIOL, V12, P2591, DOI 10.1128/MCB.12.6.2591; HARRIS ME, 1992, CELL, V68, P1091, DOI 10.1016/0092-8674(92)90080-V; KOLLER J, 1994, NUCLEIC ACIDS RES, V22, P1988, DOI 10.1093/nar/22.11.1988; KOSLOWSKY DJ, 1992, NATURE, V356, P807, DOI 10.1038/356807a0; KOSLOWSKY DJ, 1991, CELL, V67, P637; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PERIS M, 1994, EMBO J, V13, P1664, DOI 10.1002/j.1460-2075.1994.tb06430.x; PILLER KJ, 1995, MOL CELL BIOL, V15, P2916; PILLER KJ, 1995, MOL CELL BIOL, V15, P2925; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; READ LK, 1992, NUCLEIC ACIDS RES, V20, P2341, DOI 10.1093/nar/20.9.2341; READ LK, 1994, MOL CELL BIOL, V14, P2629, DOI 10.1128/MCB.14.4.2629; RILEY GR, 1995, NUCLEIC ACIDS RES, V23, P708, DOI 10.1093/nar/23.4.708; RUSCHE LN, 1995, MOL CELL BIOL, V15, P2933; SABATINI R, 1995, J BIOL CHEM, V270, P7233, DOI 10.1074/jbc.270.13.7233; SEIWERT SD, 1994, SCIENCE, V266, P114, DOI 10.1126/science.7524149; SEIWERT SD, 1995, PARASITOL TODAY, V11, P362, DOI 10.1016/0169-4758(95)80004-2; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SIMPSON AM, 1992, J BIOL CHEM, V267, P6782; SIMPSON L, 1995, CELL, V81, P837, DOI 10.1016/0092-8674(95)90003-9; STURM NR, 1992, CELL, V70, P469, DOI 10.1016/0092-8674(92)90171-8; TERNS MP, 1992, MOL CELL BIOL, V12, P3032, DOI 10.1128/MCB.12.7.3032; WHITE TC, 1987, NUCLEIC ACIDS RES, V15, P3276	33	177	179	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					831	841		10.1016/S0092-8674(00)81062-4	http://dx.doi.org/10.1016/S0092-8674(00)81062-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601307	Bronze			2022-12-28	WOS:A1996UC38100005
J	Elmer, GW; Surawicz, CM; McFarland, LV				Elmer, GW; Surawicz, CM; McFarland, LV			Biotherapeutic agents - A neglected modality for the treatment and prevention of selected intestinal and vaginal infections	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ANTIBIOTIC-ASSOCIATED DIARRHEA; CLOSTRIDIUM-DIFFICILE COLITIS; HUMAN LACTOBACILLUS STRAIN; ENTEROTOXIGENIC ESCHERICHIA-COLI; HEALTHY-HUMAN VOLUNTEERS; SACCHAROMYCES-BOULARDII; DOUBLE-BLIND; PREMATURE-INFANTS; CONTROLLED TRIAL; GG	Objective.-To evaluate the potential of biotherapeutic agents (microorganisms with therapeutic properties) for the prevention and/or treatment of selected intestinal and vaginal infections. Data Sources.-The MEDLINE database was searched for all relevant articles published between 1966 and September 1995. Search terms used were biotherapeutic agent, probiotic, Lactobacillus, Saccharomyces, Bifidobacterium, Candida, gastrointestinal-system, vaginitis, vaginosis-bacterial, and related terms. The bibliographies of obtained articles were also reviewed. Study Selection and Data Extraction.-All placebo-controlled human studies on biotherapeutic agents were reviewed, English-language open trials, case series and reports, and animal studies were reviewed only if they were especially relevant to providing information on the potential efficacy, adverse effects, or mechanisms of action of these agents. Data Synthesis.-Placebo-controlled studies have shown that biotherapeutic agents have been used successfully to prevent antibiotic-associated diarrhea (Lactobacillus casei GG, Bifidobacterium longum, B longum with L acidophilus, and Saccharomyces boulardii), to prevent acute infantile diarrhea (Bifidobacterium bifidum with Streptococcus thermophilus), to treat recurrent Clostridium difficile disease (S bouiardii), and to treat various other diarrheal illnesses (Enterococcus faecium SF68, L casei GG, and S boulardii), There is also limited evidence for Lactobacillus acidophilus in the prevention of candidal vaginitis, Few adverse effects have been reported, However, many of the studies tested only small numbers of patients or volunteers. Conclusions.-There is now evidence that administration of selected microorganisms is beneficial in the prevention and treatment of certain intestinal and, possibly, treatment of vaginal infections. In an effort to decrease the reliance on antimicrobials, the time has come to carefully explore the therapeutic applications of biotherapeutic agents.	UNIV WASHINGTON,DIV GASTROENTEROL,DEPT MED,SCH MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	Elmer, GW (corresponding author), UNIV WASHINGTON,DEPT MED CHEM,SCH PHARM,POB 357610,SEATTLE,WA 98195, USA.							Adam J, 1977, GAZ MED FR, V84, P2072; Axelsson L.T., 1989, MICROB ECOL HEALTH D, V2, P131, DOI [DOI 10.3109/08910608909140210, 10.3109/08910608909140210]; BARTLETT JG, 1992, CLIN INFECT DIS, V15, P573, DOI 10.1093/clind/15.4.573; BELITSOS PC, 1992, J INFECT DIS, V166, P277, DOI 10.1093/infdis/166.2.277; BERNET MF, 1994, GUT, V35, P483, DOI 10.1136/gut.35.4.483; BILLER JA, 1995, J PEDIATR GASTR NUTR, V21, P224, DOI 10.1097/00005176-199508000-00016; BLATZ R, 1987, MICROECOL T, V17, P191; BLEHAUT H, 1989, BIOPHARM DRUG DISPOS, V10, P353, DOI 10.1002/bdd.2510100403; BLOMBERG L, 1993, APPL ENVIRON MICROB, V59, P34, DOI 10.1128/AEM.59.1.34-39.1993; BOUHNIK Y, 1992, GASTROENTEROLOGY, V102, P875, DOI 10.1016/0016-5085(92)90172-U; BOWDEN TA, 1982, AM SURGEON, V4, P178; BUTS JP, 1986, PEDIATR RES, V20, P192, DOI 10.1203/00006450-198602000-00020; BUTS JP, 1990, DIGEST DIS SCI, V35, P251, DOI 10.1007/BF01536771; BUTS JP, 1994, PEDIATR RES, V36, P522, DOI 10.1203/00006450-199410000-00019; CAETANO JAM, 1986, INT J IMMUNOPHARMACO, V8, P245; CETINASAURI G, 1989, TRIBUNA MED, V56, P111; CHAPOY P, 1985, ANN PEDIATR-PARIS, V32, P561; CLEMENTS ML, 1981, ANTIMICROB AGENTS CH, V20, P104, DOI 10.1128/AAC.20.1.104; COCONNIER MH, 1993, FEMS MICROBIOL LETT, V110, P299, DOI 10.1016/0378-1097(93)90119-M; COLOMBEL JF, 1987, LANCET, V2, P43; CZERUCKA D, 1994, GASTROENTEROLOGY, V106, P65, DOI 10.1016/S0016-5085(94)94403-2; de dios Pozo-Olano J, 1978, Gastroenterology, V74, P829; DUCLUZEAU R, 1982, ANN INST PASTEUR MIC, VB133, P491; ELMER GW, IN PRESS MICROECOLOG; FEKETY R, 1993, JAMA-J AM MED ASSOC, V269, P71, DOI 10.1001/jama.269.1.71; FULLER R, 1991, GUT, V32, P439, DOI 10.1136/gut.32.4.439; GOLDIN BR, 1992, DIGEST DIS SCI, V37, P121, DOI 10.1007/BF01308354; GORBACH SL, 1987, LANCET, V2, P1519; GOTZ V, 1979, AM J HOSP PHARM, V36, P754, DOI 10.1093/ajhp/36.6.754; HILLIER SL, 1993, CLIN INFECT DIS, V16, pS273, DOI 10.1093/clinids/16.Supplement_4.S273; HILTON E, 1992, ANN INTERN MED, V116, P353, DOI 10.7326/0003-4819-116-5-353; HILTON E, 1995, J CLIN MICROBIOL, V33, P1433, DOI 10.1128/JCM.33.5.1433-1433.1995; HOCHTER W, 1990, MUNCHEN MED WOCHEN, V132, P188; HUGHES VL, 1990, OBSTET GYNECOL, V75, P244; ISOLAURI E, 1991, PEDIATRICS, V88, P90; KAILA M, 1992, PEDIATR RES, V32, P141, DOI 10.1203/00006450-199208000-00002; KLEIN SM, 1993, PHARMACEUT RES, V10, P1615, DOI 10.1023/A:1018924820333; Kollaritsch H, 1993, FORTSCHR MED, V11, P153; Kotler D P, 1995, Adv Intern Med, V40, P197; LARSEN B, 1993, CLIN OBSTET GYNECOL, V36, P107, DOI 10.1097/00003081-199303000-00016; LIDBECK A, 1987, SCAND J INFECT DIS, V19, P531, DOI 10.3109/00365548709032419; LIMA NL, 1990, J INFECT DIS, V161, P948, DOI 10.1093/infdis/161.5.948; MAHE S, 1987, INFECT IMMUN, V55, P1801, DOI 10.1128/IAI.55.8.1801-1805.1987; MCCONNELL M A, 1991, Microbial Ecology in Health and Disease, V4, P343; MCFARLAND LV, 1995, AM J GASTROENTEROL, V90, P439; MCFARLAND LV, 1994, JAMA-J AM MED ASSOC, V271, P1913, DOI 10.1001/jama.271.24.1913; McFarland LV, 1995, MICROECOL T, V23, P46; MCFARLAND LV, 1991, GASTROENTEROLOGY INT, V4, P82; MCFARLAND LV, 1993, ACUTE INFECT DIARRHE, P563; MCGROARTY JA, 1993, FEMS IMMUNOL MED MIC, V6, P251, DOI 10.1111/j.1574-695X.1993.tb00337.x; MICHELICH VJ, 1981, LAB ANIM SCI, V31, P259; MILLAR MR, 1993, ARCH DIS CHILD-FETAL, V69, P483, DOI 10.1136/adc.69.5_Spec_No.483; MITRA AK, 1990, GASTROENTEROLOGY, V99, P1149, DOI 10.1016/0016-5085(90)90638-H; MYNOTT TL, 1991, INFECT IMMUN, V59, P3708, DOI 10.1128/IAI.59.10.3708-3714.1991; OKSANEN PJ, 1990, ANN MED, V22, P53, DOI 10.3109/07853899009147242; ORRHAGE K, 1994, MICROB ECOL HEALTH D, V7, P17, DOI 10.3109/08910609409141570; PERDIGON G, 1986, INFECT IMMUN, V53, P404, DOI 10.1128/IAI.53.2.404-410.1986; PLETINCX M, 1995, J PEDIATR GASTR NUTR, V21, P113, DOI 10.1097/00005176-199507000-00022; POTHOULAKIS C, 1993, GASTROENTEROLOGY, V104, P1108, DOI 10.1016/0016-5085(93)90280-P; RAMARE F, 1993, APPL ENVIRON MICROB, V59, P2876, DOI 10.1128/AEM.59.9.2876-2883.1993; REID G, 1990, CLIN MICROBIOL REV, V3, P335, DOI 10.1128/CMR.3.4.335-344.1990; REID G, 1992, CLIN THER, V14, P11; REINKE CM, 1994, AM J HOSP PHARM, V51, P1771, DOI 10.1093/ajhp/51.14.1771; REUMAN PD, 1986, PEDIATR INFECT DIS J, V5, P663, DOI 10.1097/00006454-198611000-00013; RIGOTHIER MC, 1990, ANN PARASIT HUM COMP, V65, P51, DOI 10.1051/parasite/1990652051; RIGOTHIER MC, 1994, PARASITOL RES, V80, P10, DOI 10.1007/BF00932617; SAAVEDRA JM, 1994, LANCET, V344, P1046, DOI 10.1016/S0140-6736(94)91708-6; SAINTMARC T, 1991, ANN MED INTERNE, V142, P64; SCHWAN A, 1983, LANCET, V2, P845; SIITONEN S, 1990, ANN MED, V22, P57, DOI 10.3109/07853899009147243; SILVA M, 1987, ANTIMICROB AGENTS CH, V31, P1231, DOI 10.1128/AAC.31.8.1231; SURAWICZ CM, 1989, AM J GASTROENTEROL, V84, P1285; SURAWICZ CM, 1989, GASTROENTEROLOGY, V96, P981, DOI 10.1016/0016-5085(89)91613-2; TANKANOW RM, 1990, DICP ANN PHARMAC, V24, P382, DOI 10.1177/106002809002400408; TOUHAMI M, 1992, ANN PEDIATR-PARIS, V39, P79; TVEDE M, 1989, LANCET, V1, P1156; VANDENBERGH PA, 1993, FEMS MICROBIOL REV, V12, P221, DOI [10.1016/0168-6445(93)90065-H, 10.1111/j.1574-6976.1993.tb00020.x]; VIDON N, 1986, GASTROEN CLIN BIOL, V10, P13; WILSON KH, 1988, INFECT IMMUN, V56, P2610, DOI 10.1128/IAI.56.10.2610-2614.1988; WUNDERLICH PF, 1989, J INT MED RES, V17, P333, DOI 10.1177/030006058901700405; ZAIDI M, 1991, INFECT CONT HOSP EP, V12, P349, DOI 10.2307/30145210	81	267	300	1	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					870	876		10.1001/jama.275.11.870	http://dx.doi.org/10.1001/jama.275.11.870			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ971	8596226				2022-12-28	WOS:A1996TZ97100031
J	Johnson, MB				Johnson, MB			Three pictures, one child	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					834	834		10.1001/jama.275.11.834	http://dx.doi.org/10.1001/jama.275.11.834			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ971	8596210				2022-12-28	WOS:A1996TZ97100008
J	OConnor, GT; Plume, SK; Olmstead, EM; Morton, JR; Maloney, CT; Nugent, WC; Hernandez, F; Clough, R; Leavitt, BJ; Coffin, LH; Marrin, CAS; Wennberg, D; Birkmeyer, JD; Charlesworth, DC; Malenka, DJ; Quinton, HB; Kasper, JF				OConnor, GT; Plume, SK; Olmstead, EM; Morton, JR; Maloney, CT; Nugent, WC; Hernandez, F; Clough, R; Leavitt, BJ; Coffin, LH; Marrin, CAS; Wennberg, D; Birkmeyer, JD; Charlesworth, DC; Malenka, DJ; Quinton, HB; Kasper, JF			A regional intervention to improve the hospital mortality associated with coronary artery bypass graft surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE; RISK	Objective.-To determine whether an organized intervention including data feedback, training in continuous quality improvement techniques, and site visits to other medical centers could improve the hospital mortality rates associated with coronary artery bypass graft (CABG) surgery. Design.-Regional intervention study. Patient demographic and historical data, body surface area, cardiac catheterization results, priority of surgery, comorbidity, and status at hospital discharge were collected on CABG patients in Northern New England between July 1, 1987, and July 31, 1993. Setting.-This study included all 23 cardiothoracic surgeons practicing in Maine, New Hampshire, and Vermont during the study period. Patients.-Data were collected on 15 095 consecutive patients undergoing isolated CABG procedures in Maine, New Hampshire, and Vermont during the study period. Interventions.-A three-component intervention aimed at reducing CABG mortality was fielded in 1990 and 1991. The interventions included feedback of outcome data, training in continuous quality improvement techniques, and site visits to other medical centers. Main Outcome Measure.-A comparison of the observed and expected hospital mortality rates during the postintervention period. Results.-During the postintervention period, we observed the outcomes for 6488 consecutive cases of CABG surgery, There were 74 fewer deaths than would have been expected. This 24% reduction in the hospital mortality rate was statistically significant (P=.001). This reduction in mortality rate was relatively consistent across patient subgroups and was temporally associated with the interventions. Conclusion.-We conclude that a multi-institutional, regional model for the continuous improvement of surgical care is feasible and effective. This model may have applications in other settings.	DARTMOUTH HITCHCOCK MED CTR, HANOVER, NH USA; MAINE MED CTR, PORTLAND, ME 04102 USA; CATHOLIC MED CTR, MANCHESTER, NH USA; EASTERN MAINE MED CTR, BANGOR, ME USA; FLETCHER ALLEN HLTH CARE, BURLINGTON, VT USA; MAINE MED ASSESSMENT FDN, BELFAST, ME USA; DARTMOUTH COLL SCH MED, DEPT FAMILY & COMMUNITY MED, HANOVER, NH USA	Dartmouth College; Maine Medical Center; Eastern Maine Medical Center; University of Vermont Medical Center; Dartmouth College					AHRQ HHS [HS 06503, HS 06813] Funding Source: Medline; NLM NIH HHS [LM-04667] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS006813] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R29LM004667] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ARMITAGE P, 1987, STATISTICAL METHODS; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; Camp R. C., 1989, BENCHMARKING SEARCH; CLARK RE, 1995, ANN THORAC SURG, V59, P1376, DOI 10.1016/0003-4975(95)00288-V; Cornfield J, 1961, B INT STAT I, V38, P97; Deming EW., 1986, OUT CRISIS; DISCH DL, 1994, ANN THORAC SURG, V57, P416, DOI 10.1016/0003-4975(94)91008-1; FREEDMAN J, 1970, SOCIAL PSYCHOL; HAMMERMEISTER KE, 1994, ANN SURG, V219, P281, DOI 10.1097/00000658-199403000-00008; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; HENNEKENS CH, 1988, EPIDEMIOLOGY MED; Imai M., 1986, KEY JAPANS COMPETITI; Kasper J F, 1992, QRB Qual Rev Bull, V18, P129; KENNEDY JW, 1980, J THORAC CARDIOV SUR, V80, P876; Kralovec O J 3rd, 1991, Nurs Adm Q, V15, P1; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869, DOI DOI 10.1001/JAMA.1989.03430200113036; New York State Department of Health, 1992, COR ART BYP GRAFT SU; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; OCONNOR GT, 1992, CIRCULATION, V85, P2110, DOI 10.1161/01.CIR.85.6.2110; *PA HLTH CAR COST, 1991, CONS GUID COR ART BY; *PA HLTH CAR COST, 1995, COR ART BYP GRAFT SU, V4; *PA HLTH CAR COST, 1992, RES PLAN DET METH RE; PARSONNET V, 1989, CIRCULATION, V79, P3; PETERSON ED, 1994, ANN INTERN MED, V121, P919, DOI 10.7326/0003-4819-121-12-199412150-00003; PIERPONT GL, 1985, J THORAC CARDIOV SUR, V89, P673; *PRES HLTH SEC PLA, 1993, COMPL DRAFT FIN REP; Principal Investigators of CASS and Associates, 1981, CIRCULATION S1, V63, pI1; *SAS I INC, 1986, STAT AN SYST; Spendolini MJ., 1992, BENCHMARKING BOOK, V2; TOPOL EJ, 1994, ANN INTERN MED, V120, P65, DOI 10.7326/0003-4819-120-1-199401010-00011; *US DEP HHS, 1987, DHHS PUBL; WALLACE AG, 1973, CIRCULATION, V47, P439, DOI 10.1161/01.CIR.47.3.439; Walton Mary, 1986, DEMING MANAGEMENT ME; WENNBERG JE, 1994, HEALTH AFFAIR, V13, P257, DOI 10.1377/hlthaff.13.1.257; 1988, ANN THORAC SURG, V46, P348	36	564	565	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					841	846		10.1001/jama.275.11.841	http://dx.doi.org/10.1001/jama.275.11.841			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ971	8596221				2022-12-28	WOS:A1996TZ97100026
J	Bland, JM; Altman, DG				Bland, JM; Altman, DG			Statistics notes - Logarithms .16.	BRITISH MEDICAL JOURNAL			English	Article									INST HLTH SCI,CTR STAT MED,IMPERIAL CANC RES FUND,MED STAT GRP,OXFORD OX1 7LF,ENGLAND	University of Oxford	Bland, JM (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.								0	50	52	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					700	700						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597743				2022-12-28	WOS:A1996UB11000036
J	Jones, L				Jones, L			Letter form Bosnia-Hercegovina - Signs of hope	BRITISH MEDICAL JOURNAL			English	Article											Jones, L (corresponding author), INST FAMILY PSYCHIAT,IPSWICH IP1 3TF,SUFFOLK,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					698	700						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597742				2022-12-28	WOS:A1996UB11000035
J	Thomas, DHV; Noyce, PR				Thomas, DHV; Noyce, PR			Over the counter drugs - The interface between self medication and the NHS	BRITISH MEDICAL JOURNAL			English	Article								Cost and convenience seem to be major factors in determining whether, given the choice, patients purchase a medicine over the counter or obtain it on prescription. With current arrangements, exemption from prescription charges provides an incentive to continue to obtain products on NHS prescription even when they are available over the counter. There is therefore no simple relation between the availability of over the counter medicines and the level of prescribing of deregulated products. The appropriate use of over the counter medicines-particularly those that have only recently been deregulated-places a burden of care on community pharmacists and calls for closer working relationships with general practitioners. In particular, systems for referral and for recording details of both prescribed and over the counter medicines need to be developed, and a direct route needs to be established for community pharmacists to report adverse drug reactions to over the counter products.	UNIV MANCHESTER,DEPT PHARM,MANCHESTER M13 9PL,LANCS,ENGLAND; ST JOHNS HLTH CTR,WOKING GU21 1TD,SURREY,ENGLAND	University of Manchester								BAHRA MS, 1994, PHARM J, V253, pR10; BLENKINSOPP A, 1991, BRIT J GEN PRACT, V41, P116; BRADLEY C, 1995, PRESCRIBER      0305, P75; *BRIT MARK RES BUR, 1987, EVERYDAY HLTH CARE C; COLWELL J, 1993, PHARM J, V251, P194; Consumers' Association, 1991, WHICH WAY HLTH, P191; HEAD S, 1994, BRIT MED J, V309, P957, DOI 10.1136/bmj.309.6959.957a; HEATH I, 1994, BRIT MED J, V309, P623, DOI 10.1136/bmj.309.6955.623; NOYCE PR, 1992, INT J PHARM PRACT, V1, P122; NOYCE PR, 1995, PARLIAMENTARY BREIF, V3, P85; *PROPR ASS GREAT B, 1995, OTC DIR 1995 6; Rogers PJ, 1994, INT J PHARM PRACT, V3, P6; ROGERS PJ, 1992, PHARM J, V248, P193; RYAN M, 1990, HEALTH POLICY, V16, P233, DOI 10.1016/0168-8510(90)90424-C; SCHAFHEUTLE EL, 1994, THESIS U MANCHESTER; TERMIN P, 1983, J HLTH EC, V2, P187; THOM C, 1994, PHARM J, V253, P616; 1994, OTG BUSINESS NE 0706, P13; 1994, READERS DIGEST	19	31	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					688	691						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597739				2022-12-28	WOS:A1996UB11000032
J	Grimm, S; Pflugfelder, GO				Grimm, S; Pflugfelder, GO			Control of the gene optomotor-blind in Drosophila wing development by decapentaplegic and wingless	SCIENCE			English	Article							SEGMENT-POLARITY GENE; PATTERN-FORMATION; IMAGINAL DISKS; BETA HOMOLOG; MELANOGASTER; EXPRESSION; MUTATIONS; TRANSCRIPT; DIRECTS; SYSTEM	Diffusible factors of several protein families control appendage outgrowth and patterning in both insects and vertebrates. In Drosophila wing development, the gene decapentaplegic (dpp) is expressed along the anteroposterior compartment boundary. Early wingless (wg) expression is involved in setting up the dorsoventral boundary. Interaction between dpp- and wg-expressing cells promotes appendage outgrowth. Here, it is shown that optomotor-blind (omb) expression is required for distal wing development and is controlled by both dpp and wg. Ectopic omb expression can lead to the growth of additional wings. Thus, omb is essential for wing development and is controlled by two signaling pathways.	UNIV WURZBURG,THEODOR BOVERI INST,BIOZENTRUM,LEHRSTUHL GENET,D-97074 WURZBURG,GERMANY	University of Wurzburg			Pflugfelder, Gert/ABG-9562-2021					BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BALLES J, UNPUB; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BAUSENWEIN B, 1994, GENE DEV, V8, P2137; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BOLLAG RJ, 1994, NAT GENET, V7, P383, DOI 10.1038/ng0794-383; BOWNES M, 1981, DIFFERENTIATION, V18, P89, DOI 10.1111/j.1432-0436.1981.tb01108.x; BRYANT PJ, 1988, DEV BIOL, V128, P386, DOI 10.1016/0012-1606(88)90300-4; BRYANT PJ, 1993, SCIENCE, V259, P471, DOI 10.1126/science.8424169; Bryant PJ., 1978, GENET BIOL DROSOPHIL, P229; BURATOVICH MA, 1995, DEV BIOL, V168, P452, DOI 10.1006/dbio.1995.1094; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, DEVELOPMENT, V120, P621; CUNLIFFE V, 1994, EMBO J, V13, P349, DOI 10.1002/j.1460-2075.1994.tb06268.x; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FRISTROM D, 1969, MOL GEN GENET, V103, P363, DOI 10.1007/BF00383486; GELBART WM, 1989, DEVELOPMENT, V107, P65; HELD LI, 1994, ROUX ARCH DEV BIOL, V203, P310, DOI 10.1007/BF00457802; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; JAMES AA, 1981, DEV BIOL, V85, P39, DOI 10.1016/0012-1606(81)90234-7; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MEINHARDT H, 1994, BIOESSAYS, V16, P627, DOI 10.1002/bies.950160906; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PFLUGFELDER GO, 1995, COMP BIOCHEM PHYS A, V110, P185, DOI 10.1016/0300-9629(94)00159-Q; PFLUGFELDER GO, 1992, P NATL ACAD SCI USA, V89, P1199, DOI 10.1073/pnas.89.4.1199; POECK B, 1993, DEVELOPMENT, V117, P1017; POECK B, 1993, MOL GEN GENET, V238, P325, DOI 10.1007/BF00291990; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; SMITH JC, 1991, CELL, V67, P1; STAEHLINGHAMPTON K, 1994, CELL GROWTH DIFFER, V5, P585; SUN YH, 1995, GENETICS, V141, P1075; TABATA T, 1995, DEVELOPMENT, V121, P3359; WILDER EL, 1995, DEVELOPMENT, V121, P477; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; ZECCA M, 1995, DEVELOPMENT, V121, P2265	52	188	193	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1601	1604		10.1126/science.271.5255.1601	http://dx.doi.org/10.1126/science.271.5255.1601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599120				2022-12-28	WOS:A1996TZ98300047
J	Orteu, CH; Rustin, MHA				Orteu, CH; Rustin, MHA			20 thickened, fragile nails	LANCET			English	Article											Orteu, CH (corresponding author), ROYAL FREE HOSP,DEPT DERMATOL,LONDON NW3 2QG,ENGLAND.							BLUMENBERG M, 1992, J INVEST DERMATOL, V98, pS42, DOI 10.1111/1523-1747.ep12462194; CARAVATI CM, 1969, SOUTH MED J, V62, P1127, DOI 10.1097/00007611-196909000-00020; DAWBER PRP, 1992, TXB DERMATOLOGY, V4, P2531; DIVEN DG, 1989, DERMATOL CLIN, V7, P547, DOI 10.1016/S0733-8635(18)30584-9; KEIPERT JA, 1978, AUSTRALAS J DERMATOL, V19, P89, DOI 10.1111/j.1440-0960.1978.tb00202.x	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					662	662		10.1016/S0140-6736(96)91207-6	http://dx.doi.org/10.1016/S0140-6736(96)91207-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596383				2022-12-28	WOS:A1996TZ28500015
J	Males, MA				Males, MA			Putting child abuse back on the political agenda	LANCET			English	Editorial Material											Males, MA (corresponding author), UNIV CALIF IRVINE,SCH SOCIAL ECOL,IRVINE,CA 92717, USA.							ANGELINI PJ, 1995, RELATIONSHIP CHILDHO; BOYER D, 1992, FAM PLANN PERSPECT, V24, P4, DOI 10.2307/2135718; BOYER D, 1992, FAMILY PLANNING PERS, V24, P19; Finkelhor D, 1995, AM J PUBLIC HEALTH, V85, P1684, DOI 10.2105/AJPH.85.12.1684; RIVERA C, 1995, LOS ANGELES TIM 0426, pA1; RIVERA C, 1995, LOS ANGELES TIM 0426, pA23; VANZI M, 1996, LOS ANGELES TIM 0106, pA31; Widom C. S, 1992, CYCLE VIOLENCE NATL, P1; 1992, RAPE AM, P2; 1995, GREAT TRANSITIONS PR, P103; 1995, 1994 US DEP JUST FED; 1995, CHILD MALTREATMENT 1	12	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					488	488		10.1016/S0140-6736(96)91135-6	http://dx.doi.org/10.1016/S0140-6736(96)91135-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TW697	8596264				2022-12-28	WOS:A1996TW69700006
J	Neal, KR; Scott, HM; Slack, RCB; Logan, RFA				Neal, KR; Scott, HM; Slack, RCB; Logan, RFA			Omeprazole as a risk factor for campylobacter gastroenteritis: Case-control study	BRITISH MEDICAL JOURNAL			English	Article									NOTTINGHAM HLTH AUTHOR,NOTTINGHAM NG1 6GN,ENGLAND		Neal, KR (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT PUBL HLTH MED,NOTTINGHAM NG7 2UH,ENGLAND.							GIANNELLA RA, 1972, GUT, V13, P251, DOI 10.1136/gut.13.4.251; GLYNN JR, 1992, EPIDEMIOL INFECT, V109, P371, DOI 10.1017/S0950268800050366; NEAL KR, 1994, BRIT MED J, V308, P176; NORDBRING F, 1962, ACTA MED SCAND, V171, P783; 1993, INTERIM REPORT CAMPY	5	111	111	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	1996	312	7028					414	415						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601113				2022-12-28	WOS:A1996TW56400022
J	Moher, D; Fortin, P; Jadad, AR; Juni, P; Klassen, T; LeLorier, J; Liberati, A; Linde, K; Penna, A				Moher, D; Fortin, P; Jadad, AR; Juni, P; Klassen, T; LeLorier, J; Liberati, A; Linde, K; Penna, A			Completeness of reporting of trials published in languages other than English: Implications for conduct and reporting of systematic reviews	LANCET			English	Article							CLINICAL-TRIALS; QUALITY; THERAPY; BIAS	Background Lately, the number of systematic reviews published has increased substantially. Many systematic reviews exclude trials published in languages other than English. However, there is little empirical evidence to support this action. We looked for differences in the completeness of reporting between trials published in other languages and those published in English, to see whether the exclusion of trials published in other languages is justified. Methods We compared completeness of reporting, design characteristics, and analytical approaches of 133 randomised controlled trials (RCTs) published in English between 1989 and 1994 and 96 published in French, German, Italian, or Spanish during the same time. RCTs were identified by hand searching of journals (seven in English and six in the other languages). Findings We found no significant differences between trials published in English and other-language trials for any single item in the completeness of reporting scale (randomisation, double-blinding, withdrawals), or for the overall score (percentage of maximum possible score 51.0% for trials in English, 46.2% for trials in other languages, 95% CI for difference -1.1 to 10.5). Other-language trials were more likely than English-language trials to have adult participants, to use two or more interventions, and to compare two or more active treatments without an untreated control group. Trials in other languages were less likely to report a clearly prespecified primary outcome or any rationale for sample size estimation. Interpretation These results provide evidence for inclusion of all trial reports, irrespective of the language in which they are published, in systematic reviews, Their inclusion is likely to increase precision and may reduce systematic errors. We hope that our findings will prove useful to those developing guidelines and policies for the conduct of reporting of systematic reviews.	UNIV OTTAWA,DEPT MED,OTTAWA,ON K1Y 4E9,CANADA; MCGILL UNIV,DIV RHEUMATOL,DEPT MED,MONTREAL GEN HOSP RES INST,MONTREAL,PQ H3A 2T5,CANADA; MCGILL UNIV,DIV CLIN EPIDEMIOL,DEPT MED,MONTREAL GEN HOSP RES INST,MONTREAL,PQ H3A 2T5,CANADA; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON,ON,CANADA; CLIN EPIDEMIOL STUDY GRP,OLTEN,SWITZERLAND; UNIV MANITOBA,DEPT PEDIAT,WINNIPEG,MB R3T 2N2,CANADA; UNIV MANITOBA,DEPT COMMUNITY HLTH SCI,WINNIPEG,MB R3T 2N2,CANADA; UNIV MONTREAL,DEPT MED & PHARMACOL,MONTREAL,PQ,CANADA; MARIO NEGRI INST PHARMACOL RES,LAB CLIN EPIDEMIOL,MILAN,ITALY; UNIV MUNICH,MUNCHENER MODELL,D-81377 MUNICH,GERMANY	University of Ottawa; McGill University; McGill University; McMaster University; University of Manitoba; University of Manitoba; Universite de Montreal; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Munich	Moher, D (corresponding author), UNIV OTTAWA,CLIN EPIDEMIOL UNIT,LOEB MED RES INST,1053 CARLING AVE,OTTAWA,ON K1Y 4E9,CANADA.		Juni, Peter/Q-8700-2016	Juni, Peter/0000-0002-5985-0670; Moher, David/0000-0003-2434-4206; Linde, Klaus/0000-0002-2902-970X; Fortin, Paul R./0000-0002-7278-2596				ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; ANDREW E, 1990, EUR J RADIOL, V10, P92, DOI 10.1016/0720-048X(90)90114-Q; CHALMERS I, 1993, ANN NY ACAD SCI, V703, P156, DOI 10.1111/j.1749-6632.1993.tb26345.x; Chalmers T C, 1993, Stat Methods Med Res, V2, P161; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; GREGOIRE G, 1995, J CLIN EPIDEMIOL, V48, P159, DOI 10.1016/0895-4356(94)00098-B; JADAD AR, IN PRESS CONTROL CLI; LIBERATI A, 1986, J CLIN ONCOL, V4, P942, DOI 10.1200/JCO.1986.4.6.942; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; OTTENBACHER K, 1985, SPINE, V10, P833, DOI 10.1097/00007632-198511000-00010; ROSSETTI L, 1993, ONLINE J CURR CLIN T, P93; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; 1991, SCI J CITATION REPOR; 1994, JAMA-J AM MED ASSOC, V272, P1926; 1994, ANN INTERN MED, V121, P894	21	403	407	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					363	366		10.1016/S0140-6736(96)90538-3	http://dx.doi.org/10.1016/S0140-6736(96)90538-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598702				2022-12-28	WOS:A1996TU69500010
J	tenWolde, S; Breedveld, FC; Hermans, J; Vandenbroucke, JP; vandeLaar, MAFJ; Markusse, HM; Janssen, M; vandenBrink, HR; Dijkmans, BAC				tenWolde, S; Breedveld, FC; Hermans, J; Vandenbroucke, JP; vandeLaar, MAFJ; Markusse, HM; Janssen, M; vandenBrink, HR; Dijkmans, BAC			Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis	LANCET			English	Article							LOW-DOSE METHOTREXATE; DOUBLE-BLIND; CONTROLLED TRIAL; GOLD THERAPY; PENICILLAMINE; DISCONTINUATION; REMISSION; CRITERIA	Background A favourable benefit/risk ratio for treatment of rheumatoid arthritis (RA) with second-line drugs has been established only in short-term studies, The present investigation addresses the question of whether RA patients with a good response to long-term treatment with second-line drugs benefit from continuation of such treatment. Methods A 52-week randomised double-blind placebo-controlled multicentre study was conducted to assess the effect of stopping second-line therapy in 285 RA patients with a good long-term therapeutic response, The patients either continued the second-line drug (n=142) or received a placebo (n=143). The endpoint was a flare, defined as recurrence of synovitis. Findings At entry into the study median duration of second-line drug therapy was 5 years (range 2-33). At 52 weeks the cumulative incidence of a flare was 38% for the placebo group and 22% for the continued therapy group (p=0.002). The risk of a flare was 2.0 times higher for patients receiving placebo than for those continuing the second-line drug (95% CI 1.27 to 3.17). The same trend was found for each second-line drug separately, with the exception of d-penicillamine. Side-effects that necessitated dose reduction or discontinuation occurred in 2 patients in each group. Interpretation Second-line drugs continue to be effective in RA patients who have responded well to initial treatment.	UNIV LEIDEN HOSP, DEPT RHEUMATOL, 2300 RC LEIDEN, NETHERLANDS; UNIV LEIDEN HOSP, DEPT MED STAT, 2300 RC LEIDEN, NETHERLANDS; UNIV LEIDEN HOSP, DEPT CLIN EPIDEMIOL, 2300 RC LEIDEN, NETHERLANDS; MED SPECTRUM TWENTE, DEPT RHEUMATOL, ENSCHEDE, NETHERLANDS; DR DANIEL HOED KLIN, ROTTERDAM, NETHERLANDS; ZIEKENHUIS RIJNSTATE, ARNHEM, NETHERLANDS; MED CENTRUM ALKMAAR, ALKMAAR, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Medical Spectrum Twente; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Rijnstate Hospital; Medical Center Of Alkmaar			Vandenbroucke, Jan/AAM-3928-2020; Janssen, Matthijs/AAZ-2784-2020	Vandenbroucke, Jan/0000-0001-5668-6716; 				AHERN MJ, 1984, ANN RHEUM DIS, V43, P213, DOI 10.1136/ard.43.2.213; American Rheumatism Association, 1973, ARTHRITIS RHEUM, V16, P353; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BAX DE, 1986, DRUGS, V32, P73, DOI 10.2165/00003495-198600321-00016; CADE R, 1976, SOUTH MED J, V69, P388, DOI 10.1097/00007611-197604000-00003; CASH JM, 1994, NEW ENGL J MED, V330, P1368; CATS A, 1976, AGENTS ACTIONS, V6, P355, DOI 10.1007/BF01972255; CATS A, 1970, ANN RHEUM DIS, V29, P254, DOI 10.1136/ard.29.3.254; CLARK P, 1993, ANN INTERN MED, V119, P1067, DOI 10.7326/0003-4819-119-11-199312010-00002; DESILVA M, 1981, ANN RHEUM DIS, V40, P560, DOI 10.1136/ard.40.6.560; GABRIEL SE, 1988, MAYO CLIN PROC, V63, P58, DOI 10.1016/S0025-6196(12)62665-2; GRINDULIS KA, 1984, ANN RHEUM DIS, V43, P398, DOI 10.1136/ard.43.3.398; HANNONEN P, 1993, ARTHRITIS RHEUM-US, V36, P1501, DOI 10.1002/art.1780361104; HAWLEY DJ, 1991, J RHEUMATOL, V18, P1008; KREMER JM, 1987, AM J MED, V82, P781, DOI 10.1016/0002-9343(87)90015-5; PAULUS HE, 1982, ANN RHEUM DIS, V41, P26, DOI 10.1136/ard.41.Suppl_1.26; PINALS RS, 1981, ARTHRITIS RHEUM, V24, P1308, DOI 10.1002/art.1780241012; PINCUS T, 1988, J CLIN EPIDEMIOL, V41, P1037, DOI 10.1016/0895-4356(88)90072-8; PINCUS T, 1992, J RHEUMATOL, V19, P1885; PORTER DR, 1994, ANN RHEUM DIS, V53, P812, DOI 10.1136/ard.53.12.812; RITCHIE DM, 1968, Q J MED, V37, P393; SCULL E, 1962, ARTHRITIS RHEUM-US, V5, P30, DOI 10.1002/art.1780050105; SIEGERT CEH, 1984, CLIN RHEUMATOL, V3, P305, DOI 10.1007/BF02032335; SINGH G, 1991, J RHEUMATOL, V18, P188; SZANTO E, 1986, SCAND J RHEUMATOL, V15, P97, DOI 10.3109/03009748609102072; UROWITZ MD, 1976, ARTHRITIS RHEUM, V16, P411; VANDERLEEDEN H, 1986, CLIN RHEUMATOL, V5, P56, DOI 10.1007/BF02030968; VANDESTADT RJ, 1980, ANN RHEUM DIS, V39, P31, DOI 10.1136/ard.39.1.31; VANZEBEN D, 1992, ANN RHEUM DIS, V51, P1029, DOI 10.1136/ard.51.9.1029; VANZEBEN D, 1993, J RHEUMATOL, V20, P1288; WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303; WIJNANDS MJH, 1992, BRIT J RHEUMATOL, V31, P253, DOI 10.1093/rheumatology/31.4.253; WILLIAMS HJ, 1983, ARTHRITIS RHEUM, V26, P581, DOI 10.1002/art.1780260502; WOLFE F, 1985, J RHEUMATOL, V12, P245; WOLFE F, 1990, J RHEUMATOL, V17, P994	35	127	131	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 10	1996	347	8998					347	352		10.1016/S0140-6736(96)90535-8	http://dx.doi.org/10.1016/S0140-6736(96)90535-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598699				2022-12-28	WOS:A1996TU69500007
J	Fiore, MC; Wetter, DW; Bailey, WC; Bennett, G; Cohen, SJ; Dorfman, SF; Goldstein, MG; Gritz, ER; Hasselblad, V; Henningfield, JE; Heyman, RB; Holbrook, J; Husten, C; Jaen, CR; Kohler, C; Kottke, TE; Lando, HA; Manley, M; Mecklenburg, R; Melvin, C; Mullen, PD; Nett, LM; Piasecki, TM; Robinson, L; Rothstein, D; Schriger, DL; Stitzer, ML; Stachenko, S; Tommasello, A; Villejo, L; Wewers, ME; Baker, TB				Fiore, MC; Wetter, DW; Bailey, WC; Bennett, G; Cohen, SJ; Dorfman, SF; Goldstein, MG; Gritz, ER; Hasselblad, V; Henningfield, JE; Heyman, RB; Holbrook, J; Husten, C; Jaen, CR; Kohler, C; Kottke, TE; Lando, HA; Manley, M; Mecklenburg, R; Melvin, C; Mullen, PD; Nett, LM; Piasecki, TM; Robinson, L; Rothstein, D; Schriger, DL; Stitzer, ML; Stachenko, S; Tommasello, A; Villejo, L; Wewers, ME; Baker, TB			The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WEIGHT-GAIN; NICOTINE REPLACEMENT; CIGARETTE-SMOKING; UNITED-STATES; QUIT SMOKING; BODY-WEIGHT; WOMEN; INTERVENTION; POPULATION; PHYSICIAN	Objective.-To summarize the Smoking Cessation Clinical Practice Guideline that provides recommendations for 3 groups of professionals: primary care clinicians, smoking cessation specialists, and health care administrators, insurers, and purchasers. Participants.-An independent panel of scientists, clinicians, consumers, and methodologists selected by the US Agency for Health Care Policy and Research. Evidence.-English-language, peer-reviewed literature published between 1975 and 1994 that addresses the assessment and treatment of tobacco dependence, nicotine addiction, and clinical practice. Consensus Process.-Four panel meetings were held over 2 years to evaluate meta-analytic and other results, to synthesize the results, and to develop recommendations. The Guideline was repeatedly reviewed and revised. Conclusions.-The panel recommendations address 3 audiences, Major recommendations for primary care clinicians are to use officewide systems to identify smokers, treat every smoker with a cessation or motivational intervention, offer nicotine replacement except in special circumstances, and schedule follow-up contact to occur after cessation, Major recommendations to smoking cessation specialists are to use multiple individual or group counseling sessions lasting at least 20 minutes each with sessions spanning multiple weeks, offer nicotine replacement, and provide problem-solving and social support counseling, Major recommendations for health care administrators, insurers, and purchasers are that tobacco-user identification systems be used in all clinics and that smoking cessation treatment be supported through staff education and training, dedicated staff, changes in hospital policies, and the provision of reimbursement for tobacco-dependence treatment.	UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX; UNIV ALABAMA,BIRMINGHAM,AL; NHLBI,NIH,BETHESDA,MD 20892; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC; BROWN UNIV,SCH MED,MIRIAM HOSP,PROVIDENCE,RI 02912; DUKE UNIV,DURHAM,NC; NIDA,NIH,BALTIMORE,MD; AMER ACAD PEDIAT,CINCINNATI,OH; UNIV UTAH,SCH MED,SALT LAKE CITY,UT; CTR DIS CONTROL & PREVENT,OFF SMOKING & HLTH,ATLANTA,GA 30341; SUNY BUFFALO,CTR URBAN RES PRIMARY CARE,BUFFALO,NY; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905; UNIV MINNESOTA,MINNEAPOLIS,MN 55455; NCI,NIH,ROCKVILLE,MD; NCI,POTOMAC,MD; UNIV TEXAS,CTR HLTH PROMOT RES & DEV,HOUSTON,TX; CTR HLTH SCI STUDIES,PSL HLTH ONE,DENVER,CO; UNIV WISCONSIN,SCH MED,CTR TOBACCO RES & INTERVENT,MADISON,WI; OFF DIS PREVENT & HLTH PROMOT,WASHINGTON,DC; DEPT PUBL HLTH,WASHINGTON,DC; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA; JOHNS HOPKINS UNIV HOSP,BAYVIEW MED CTR,BALTIMORE,MD; HLTH CANADA,OTTAWA,ON,CANADA; UNIV MARYLAND,SCH PHARM,BALTIMORE,MD 21201; OHIO STATE UNIV,COLL NURSING,COLUMBUS,OH 43210	University of Texas System; UTMD Anderson Cancer Center; University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Wake Forest University; Wake Forest Baptist Medical Center; Brown University; Lifespan Health Rhode Island; Miriam Hospital; Duke University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA); Utah System of Higher Education; University of Utah; Centers for Disease Control & Prevention - USA; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Mayo Clinic; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Johns Hopkins University; Johns Hopkins Medicine; Health Canada; University System of Maryland; University of Maryland Baltimore; University System of Ohio; Ohio State University	Fiore, MC (corresponding author), UNIV WISCONSIN,SCH MED,CTR TOBACCO RES & INTERVENT,1300 UNIV AVE,MADISON,WI 53706, USA.							ABRAMS DB, 1993, TOBACCO CONTROL S, V2, P17; ABRAMS DB, IN PRESS ANN BEHAV M; *AM MED ASS, 1994, AM MED ASS GUID DIAG; ANDA RF, 1987, JAMA-J AM MED ASSOC, V257, P1916; BENOWITZ NL, 1991, JAMA-J AM MED ASSOC, V266, P3174, DOI 10.1001/jama.266.22.3174; BROWMAN GP, 1993, NEW ENGL J MED, V328, P159, DOI 10.1056/NEJM199301213280302; BROWNSON RC, 1992, AM J PUBLIC HEALTH, V82, P99, DOI 10.2105/AJPH.82.1.99; COULTAS DB, 1994, AM J RESP CRIT CARE, V149, pS93, DOI 10.1164/ajrccm/149.3_Pt_2.S93; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; EMONT SL, 1987, ADDICT BEHAV, V12, P151, DOI 10.1016/0306-4603(87)90021-9; FIORE MC, 1990, JAMA-J AM MED ASSOC, V263, P2760, DOI 10.1001/jama.263.20.2760; FIORE MC, 1989, JAMA-J AM MED ASSOC, V261, P49, DOI 10.1001/jama.261.1.49; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; FIORE MC, 1995, AM J PUBLIC HEALTH, V85, P161, DOI 10.2105/AJPH.85.2.161; FIORE MC, 1996, SMOKING CESSATION CL; FRANK E, 1991, JAMA-J AM MED ASSOC, V266, P3139, DOI 10.1001/jama.266.22.3139; GELB BD, 1985, HARVARD BUS REV, V64, P12; GILCHRIST V, 1993, J FAM PRACTICE, V37, P555; GLYNN TJ, 1990, NIH PUBL; GRITZ E R, 1989, Annals of Behavioral Medicine, V11, P144, DOI 10.1207/s15324796abm1104_4; GROSS J, 1989, J CONSULT CLIN PSYCH, V57, P87, DOI 10.1037/0022-006X.57.1.87; *GROUP HLTH ASS AM, 1993, HMO IND PROF 1993 ED; HALL SM, 1994, J CONSULT CLIN PSYCH, V62, P141, DOI 10.1037/0022-006X.62.1.141; HALL SM, 1992, AM J PUBLIC HEALTH, V82, P799, DOI 10.2105/AJPH.82.6.799; HATSUKAMI D, 1993, HEALTH PSYCHOL, V12, P499, DOI 10.1037/0278-6133.12.6.499; HATZIANDREU EJ, 1990, J NATL CANCER I, V82, P1402, DOI 10.1093/jnci/82.17.1402; HAYWARD RA, 1989, J PUBLIC HEALTH DENT, V49, P147, DOI 10.1111/j.1752-7325.1989.tb02051.x; Hedges L, 1985, STATISTICAL METHODS; HUGHES JR, 1995, PSYCHIATR SERV, V46, P435; HURT RD, 1991, CLIN RES, V39, pA636; JAEN CR, 1994, J FAM PRACTICE, V38, P166; JONES RM, 1985, BRIT MED J, V290, P1763, DOI 10.1136/bmj.290.6484.1763; KAPLAN RM, 1995, ANN BEHAV MED, V17, P3, DOI 10.1007/BF02888801; KENFORD SL, 1994, JAMA-J AM MED ASSOC, V271, P589, DOI 10.1001/jama.271.8.589; KLESGES RC, 1989, PSYCHOL BULL, V106, P204, DOI 10.1037/0033-2909.106.2.204; KLESGES RC, 1988, INT J EAT DISORDER, V7, P413, DOI 10.1002/1098-108X(198805)7:3<413::AID-EAT2260070314>3.0.CO;2-D; KLESGES RC, 1992, HEALTH PSYCHOL, V11, P1, DOI 10.1037/h0090339; KOTTKE TE, 1995, MAYO CLIN PROC, V70, P303, DOI 10.4065/70.3.303; LICHTENSTEIN E, 1992, J FAM PRACTICE, V34, P739; MARCUS AC, 1989, NCI MONOGRAPHS, V0008; MULLEN PD, 1991, AM J OBSTET GYNECOL, V165, P409, DOI 10.1016/0002-9378(91)90105-Z; MULLEN PD, 1994, AM J OBSTET GYNECOL, V171, P1328; NIDES M, 1994, HEALTH PSYCHOL, V13, P354, DOI 10.1037/0278-6133.13.4.354; NOPPA H, 1980, PREV MED, V9, P534, DOI 10.1016/0091-7435(80)90048-1; OCKENE JK, 1987, AM J PUBLIC HEALTH, V77, P782, DOI 10.2105/AJPH.77.7.782; ORLEANS CT, 1989, AM J PUBLIC HEALTH, V79, P176, DOI 10.2105/AJPH.79.2.176; ORLEANS CT, 1993, NICOTINE ADDICTION P, P145; PEDERSON LL, 1982, PREV MED, V11, P71, DOI 10.1016/0091-7435(82)90006-8; Perkins Kenneth A., 1994, Annals of Behavioral Medicine, V16, P46; PIRIE PL, 1992, AM J PUBLIC HEALTH, V82, P1238, DOI 10.2105/AJPH.82.9.1238; PROCHASKA JO, 1991, CLIN CHEST MED, V12, P727; ROYCE JM, 1993, AM J PUBLIC HEALTH, V83, P220, DOI 10.2105/AJPH.83.2.220; SACHS DPL, 1993, ARCH INTERN MED, V153, P1881, DOI 10.1001/archinte.153.16.1881; STAMFORD BA, 1986, AM J CLIN NUTR, V43, P486, DOI 10.1093/ajcn/43.4.486; STEVENS VJ, 1993, MED CARE, V31, P65, DOI 10.1097/00005650-199301000-00005; Stotts R C, 1991, J Health Care Poor Underserved, V2, P307; Tomar SL, 1996, J AM DENT ASSOC, V127, P259, DOI 10.14219/jada.archive.1996.0179; *US DEPT HHS, 1993, NIH PUBL; *US DEPT HHS, 1980, HLTH CONS SMOK WOM R; *US DEPT HHS, 1995, HLTH PEOPL 2000 MIDC; *US DEPT HHS, 1990, DHHS PUBL; *US DEPT HHS, 1994, PREV TOB US YOUNG PE; WILLIAMSON DF, 1991, NEW ENGL J MED, V324, P789; ZELMAN DC, 1992, J CONSULT CLIN PSYCH, V60, P943, DOI 10.1037/0022-006X.60.6.943; 1990, JAMA-J AM MED ASSOC, V263, P1795; 1993, MMWR-MORBID MORTAL W, V42, P854; 1987, MMWR-MORBID MORTAL W, V36, P405; 1994, NATL CANCER I MONOGR, V5, P1	68	259	262	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1270	1280		10.1001/jama.1996.03530400058039	http://dx.doi.org/10.1001/jama.1996.03530400058039			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF478	8601960				2022-12-28	WOS:A1996UF47800032
J	Pirkle, JL; Flegal, KM; Bernert, JT; Brody, DJ; Etzel, RA; Maurer, KR				Pirkle, JL; Flegal, KM; Bernert, JT; Brody, DJ; Etzel, RA; Maurer, KR			Exposure of the US population to environmental tobacco smoke - The Third National Health and Nutrition Examination Survey, 1988 to 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SCOTTISH HEART HEALTH; PASSIVE SMOKING; NONSMOKING WOMEN; URINARY COTININE; DIETARY NICOTINE; SERUM COTININE; LUNG-CANCER; BODY-FLUIDS; SALIVA	Objective.-To estimate the extent of exposure of the US population to environmental tobacco smoke and the contribution of the home and workplace environment to environmental tobacco smoke exposure. Design.-Nationally representative cross-sectional survey including questionnaire information from persons aged 2 months and older (n=16818) and measurements of serum cotinine (a metabolite of nicotine) from persons aged 4 years and older (n=10642). Setting/Participants.-Participants in the Third National Health and Nutrition Examination Survey, October 25, 1988, to October 21, 1991. Results.-Of US children aged 2 months to 11 years, 43% lived in a home with at least 1 smoker, and 37% of adult non-tobacco users lived in a home with at least 1 smoker or reported environmental tobacco smoke exposure at work. Serum cotinine levels indicated more widespread exposure to nicotine. Of non-tobacco users, 87.9% had detectable levels of serum cotinine, Both the number of smokers in the household and the hours exposed at work were significantly and independently associated (P<.001, multiple regression t test) with increased serum cotinine levels. Serum cotinine levels of children, non-Hispanic blacks, and males indicated that these groups had higher exposure to environmental tobacco smoke. Dietary variables showed no consistent association with serum cotinine levels, and dietary contribution to serum cotinine level, if any, appeared to be extremely small. Conclusions.-The high proportion of the population with detectable serum cotinine levels indicates widespread exposure to environmental tobacco smoke in the US population, Both the home and workplace environments significantly contribute to environmental tobacco smoke exposure in the United States.	CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,HYATTSVILLE,MD 20782	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Pirkle, JL (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,MAILSTOP F20,ATLANTA,GA 30341, USA.		Etzel, Ruth A./N-5700-2019	Etzel, Ruth A./0000-0002-5236-3976; Flegal, Katherine/0000-0002-0838-469X				BENOWITZ NL, 1983, CLIN PHARMACOL THER, V34, P604, DOI 10.1038/clpt.1983.222; BENOWITZ NL, 1995, CLIN PHARMACOL THER, V57, P159; Bernert John T. Jr., 1994, Clinical Chemistry, V40, P1075; BORLAND R, 1992, JAMA-J AM MED ASSOC, V268, P749, DOI 10.1001/jama.268.6.749; CASTRO A, 1986, BIOCHEM ARCH, V2, P91; CUMMINGS KM, 1990, ARCH ENVIRON HEALTH, V45, P74, DOI 10.1080/00039896.1990.9935929; CUMMINGS SR, 1988, AM J PUBLIC HEALTH, V78, P574, DOI 10.2105/AJPH.78.5.574; DAVIS RA, 1991, FOOD CHEM TOXICOL, V29, P821, DOI 10.1016/0278-6915(91)90109-K; DOMINO EF, 1993, NEW ENGL J MED, V329, P437, DOI 10.1056/NEJM199308053290619; EMMONS KM, 1994, PREV MED, V23, P35, DOI 10.1006/pmed.1994.1005; ETZEL RA, 1990, PREV MED, V19, P190, DOI 10.1016/0091-7435(90)90020-K; EZZATI TM, 1992, VITAL HLTH STAT, V113; FLEGAL KM, 1987, DIABETES, V36, P523; FONTHAM ETH, 1994, JAMA-J AM MED ASSOC, V271, P1752, DOI 10.1001/jama.271.22.1752; FORTHOFER RN, 1983, AM J EPIDEMIOL, V117, P507, DOI 10.1093/oxfordjournals.aje.a113568; GREENBERG RA, 1984, NEW ENGL J MED, V310, P1075, DOI 10.1056/NEJM198404263101703; HALEY NJ, 1983, AM J PUBLIC HEALTH, V73, P1204, DOI 10.2105/AJPH.73.10.1204; HAMMOND SK, 1995, JAMA-J AM MED ASSOC, V274, P956, DOI 10.1001/jama.274.12.956; HINDS WC, 1975, NEW ENGL J MED, V292, P844, DOI 10.1056/NEJM197504172921606; JARVIS M, 1984, J EPIDEMIOL COMMUN H, V38, P335, DOI 10.1136/jech.38.4.335; JARVIS MJ, 1987, AM J PUBLIC HEALTH, V77, P1435, DOI 10.2105/AJPH.77.11.1435; JARVIS MJ, 1988, AM J PUBLIC HEALTH, V78, P696, DOI 10.2105/AJPH.78.6.696; JARVIS MJ, 1994, BRIT MED J, V308, P62; JENKINS PL, 1992, ATMOS ENVIRON A-GEN, V26, P2141, DOI 10.1016/0960-1686(92)90402-7; KABAT GC, 1984, CANCER, V53, P1214, DOI 10.1002/1097-0142(19840301)53:5<1214::AID-CNCR2820530532>3.0.CO;2-8; LANGONE JJ, 1973, BIOCHEMISTRY-US, V12, P5025, DOI 10.1021/bi00748a032; LONG GL, 1983, ANAL CHEM, V55, pA712, DOI 10.1021/ac00258a001; MATSUKURA S, 1984, NEW ENGL J MED, V311, P828, DOI 10.1056/NEJM198409273111305; MURAMATSU M, 1984, ENVIRON RES, V35, P218, DOI 10.1016/0013-9351(84)90130-0; National Research Council Committee on Passive Smoking, 1986, ENV TOB SMOK MEAS EX; OVERPECK MD, 1991, ADV DATA VITAL HLTH, V202; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086; PATTISHALL EN, 1985, AM J DIS CHILD, V139, P1101, DOI 10.1001/archpedi.1985.02140130039026; REPACE JL, 1994, BRIT MED J, V308, P61, DOI 10.1136/bmj.308.6920.61c; RIBOLI E, 1990, CANCER CAUSE CONTROL, V1, P243, DOI 10.1007/BF00117476; SAS Institute Inc., 1990, SAS LANG REF VERS 6; SHAH BV, 1991, SUDAAN USERS MANUAL; SHEEN SJ, 1988, J FOOD SCI, V53, P1572, DOI 10.1111/j.1365-2621.1988.tb09328.x; STOCKWELL HG, 1992, J NATL CANCER I, V84, P1417, DOI 10.1093/jnci/84.18.1417; TAYLOR JK, 1987, QUALITY CONTROL CHEM; TUNSTALLPEDOE H, 1991, J CLIN EPIDEMIOL, V44, P1411, DOI 10.1016/0895-4356(91)90102-F; *US DEPT HHS, 1986, PUBL PHS; WAGENKNECHT LE, 1993, ENVIRON RES, V63, P39, DOI 10.1006/enrs.1993.1124; WALL MA, 1988, AM J PUBLIC HEALTH, V78, P699, DOI 10.2105/AJPH.78.6.699; WATTS RR, 1990, ENVIRON HEALTH PERSP, V84, P173, DOI 10.2307/3430719; WILCOX RG, 1979, BRIT MED J, V2, P1026, DOI 10.1136/bmj.2.6197.1026; WOODWARD M, 1991, J CLIN EPIDEMIOL, V44, P1405, DOI 10.1016/0895-4356(91)90101-E; WOODWARD M, 1992, PREV MED, V21, P88, DOI 10.1016/0091-7435(92)90008-6; 1992, EPA600690006F OFF AI; 1994, VITAL HLTH STAT, V1	50	511	518	1	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1233	1240						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF478	8601954				2022-12-28	WOS:A1996UF47800026
J	Shilatifard, A; Lane, WS; Jackson, KW; Conaway, RC; Conaway, JW				Shilatifard, A; Lane, WS; Jackson, KW; Conaway, RC; Conaway, JW			An RNA polymerase II elongation factor encoded by the human ELL gene	SCIENCE			English	Article							ACUTE LEUKEMIAS; CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA-TRITHORAX; TRANSCRIPTION FACTOR; SEQUENCE	The human ELL gene on chromosome 19 undergoes frequent translocations with the trithorax-like MLL gene on chromosome 11 in acute myeloid leukemias. Here, ELL was shown to encode a previously uncharacterized elongation factor that can increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by polymerase at multiple sites along the DNA. Functionally, ELL resembles Elongin (SIII), a transcription elongation factor regulated by the product of the von Hippel-Lindau (VHL) tumor suppressor gene. The discovery of a second elongation factor implicated in oncogenesis provides further support for a close connection between the regulation of transcription elongation and cell growth.	OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104; HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138; UNIV OKLAHOMA,HLTH SCI CTR,WILLIAM K WARREN MED RES INST,OKLAHOMA CITY,OK 73190	Oklahoma Medical Research Foundation; Harvard University; University of Oklahoma System; University of Oklahoma Health Sciences Center				Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; BERNARD OA, 1994, ONCOGENE, V9, P1039; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; PRASAD R, 1993, CANCER RES, V53, P5624; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SHILATIFARD A, UNPUB; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; TAN SY, 1994, BIOTECHNIQUES, V16, P824; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9	25	288	294	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1873	1876		10.1126/science.271.5257.1873	http://dx.doi.org/10.1126/science.271.5257.1873			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596958				2022-12-28	WOS:A1996UC77800049
J	Nightingale, SL				Nightingale, SL			Nicorette gum approved for over-the-counter marketing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					902	902						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA563	8598604				2022-12-28	WOS:A1996UA56300010
J	Ramirez, AJ; Graham, J; Richards, MA; Cull, A; Gregory, WM				Ramirez, AJ; Graham, J; Richards, MA; Cull, A; Gregory, WM			Mental health of hospital consultants: The effects of stress and satisfaction at work	LANCET			English	Article								Background Burnout and psychiatric morbidity among gastroenterologists, surgeons, radiologists, and oncologists in the UK have been estimated by means of a questionnaire-based survey. The relationship between consultants' mental health and their job stress and satisfaction, as well as their job and demographic characteristics, were also examined. Methods Psychiatric morbidity was estimated using the 12-item General Health Questionnaire. The three components of burnout-emotional exhaustion, depersonalisation, and low personal accomplishment-were assessed using the Maslach Burnout Inventory. Job stress and satisfaction were measured using study-specific questions. Findings Of 1133 consultants, 882 (78%) returned questionnaires. The estimated prevalence of psychiatric morbidity was 27%, with no significant differences between the four specialist groups. Radiologists reported the highest level of burnout in terms of low personal accomplishment. Job satisfaction significantly protected consultants' mental health against job stress. Three sources of stress were associated with both burnout and psychiatric morbidity: feeling overloaded, and its effect on home life; feeling poorly managed and resourced; and dealing with patients' suffering. Burnout was also associated with low satisfaction in three domains: relationships with patients, relatives, and staff; professional status/esteem; intellectual stimulation. In addition, being aged 55 years or less and being single were independent risk factors for burnout. Burnout was also more prevalent among consultants who felt insufficiently trained in communication and management skills. Interpretation Consultants' mental health is likely to be protected against the high demands of medical practice by maintaining or enhancing job satisfaction, and by providing training in communication and management skills.	UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,LONDON SE1 9RT,ENGLAND; WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Edinburgh								BANKS MH, 1980, J OCCUP PSYCHOL, V53, P187, DOI 10.1111/j.2044-8325.1980.tb00024.x; BLENKIN H, 1995, BRIT MED J, V310, P534, DOI 10.1136/bmj.310.6978.534; *BMA, 1992, STRESS MED PROF; *BMA, 1993, MORB MORT MED PROF; CAPLAN RP, 1994, BRIT MED J, V309, P1261, DOI 10.1136/bmj.309.6964.1261; Charlton J., 1993, POPULATION TRENDS, V71, P34; FIRTHCOZENS J, 1987, BRIT MED J, V295, P533, DOI 10.1136/bmj.295.6597.533; FREUDENBERGER HJ, 1974, J SOC ISSUES, V30, P159, DOI 10.1111/j.1540-4560.1974.tb00706.x; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; KARASEK RA, 1979, ADMIN SCI QUART, V24, P285, DOI 10.2307/2392498; Maslach C, 2016, MASLACH BURNOUT INVE; SILVEY S, 1970, STAT INFERENCE, P108; SIMON R, 1986, ANN INTERN MED, V105, P49; 1994, LANCET, V344, P1583	14	613	629	1	112	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					724	728		10.1016/S0140-6736(96)90077-X	http://dx.doi.org/10.1016/S0140-6736(96)90077-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TZ982	8602002	Bronze			2022-12-28	WOS:A1996TZ98200010
J	DeCamilli, P; Emr, SD; McPherson, PS; Novick, P				DeCamilli, P; Emr, SD; McPherson, PS; Novick, P			Phosphoinositides as regulators in membrane traffic	SCIENCE			English	Review							ASSEMBLY PROTEIN AP-2; LYSOSOME-LIKE VACUOLE; PHOSPHATIDYLINOSITOL 3-KINASE; KINASE; CLATHRIN; BINDING; RECEPTOR; PATHWAY; VPS34; INTERNALIZATION	Phosphorylated products of phosphatidylinositol play critical roles in the regulation of membrane traffic, in addition to their classical roles as second messengers in signal transduction at the cell surf ace. Growing evidence suggests that phosphorylation-dephosphorylation of the polar heads of phosphoinositides (polyphosphorylated inositol lipids) in specific intracellular locations signals either the recruitment or the activation of proteins essential for vesicular transport. Cross talk between phosphatidylinositol metabolites and guanosine triphosphatases is an important feature of these regulatory mechanisms.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; UNIV CALIF SAN DIEGO, SCH MED, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA; MCGILL UNIV, MONTREAL NEUROL INST, DEPT NEUROL & NEUROSURG, MONTREAL, PQ H3A 2B4, CANADA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA	Yale University; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; McGill University; Yale University	DeCamilli, P (corresponding author), YALE UNIV, SCH MED, HOWARD HUGHES MED INST, 295 CONGRESS AVE, NEW HAVEN, CT 06510 USA.				NATIONAL CANCER INSTITUTE [P01CA046128, P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032703] Funding Source: NIH RePORTER; NCI NIH HHS [CA-46128, CA-58689] Funding Source: Medline; NIGMS NIH HHS [GM-32703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON F, 1995, J BIOL CHEM, V270, P214; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; AUNIS D, 1988, J EXP BIOL, V139, P253; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BARKER SA, 1995, MOL BIOL CELL, V6, P1145, DOI 10.1091/mbc.6.9.1145; BARSAGI D, 1987, J CELL PHYSIOL, P69; BECK KA, 1991, J BIOL CHEM, V266, P4442; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CLAGUE MJ, 1995, FEBS LETT, V367, P272, DOI 10.1016/0014-5793(95)00576-U; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DECAMILLI P, 1995, CURR OPIN NEUROBIOL, V5, P559, DOI 10.1016/0959-4388(95)80059-X; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; FRY MJ, 1993, PHILOS T ROY SOC B, V340, P337, DOI 10.1098/rstb.1993.0076; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; GAIDAROV IO, 1995, MOL BIOL CELL, V6, P2368; Gips Sanford J., 1994, Seminars in Cell Biology, V5, P201, DOI 10.1006/scel.1994.1025; GOUT I, 1996, J MOL BIOL, V255, P14; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HARTWIN JH, 1995, CELL, V82, P642; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAVANAUGH M, IN RPESS CURR BIOL; KTISTAKIS NT, 1995, MOL BIOL CELL, V6, P135, DOI 10.1091/mbc.6.2.135; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; OLIVOSGLANDER IM, 1995, AM J HUM GENET, V57, P817; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; PHILLIPS JH, 1973, BIOCHEM J, V136, P579, DOI 10.1042/bj1360579; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; SCHMID SL, 1995, FASEB J, V9, P1445, DOI 10.1096/fasebj.9.14.7589986; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P535, DOI 10.1006/bbrc.1995.1846; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SPIRO DJ, IN PRESS MOL BIOL CE; STACK JH, 1994, J BIOL CHEM, V269, P31552; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; SUCHY SF, 1995, HUM MOL GENET, V4, P2245, DOI 10.1093/hmg/4.12.2245; TERUI T, 1994, J BIOL CHEM, V269, P28130; TIMERMAN AP, 1992, P NATL ACAD SCI USA, V89, P8976, DOI 10.1073/pnas.89.19.8976; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WIEDEMANN T, 1995, SOC NEUR ABSTR, V21, P330; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; YU FX, 1992, J BIOL CHEM, V267, P14616; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	114	640	649	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1996	271	5255					1533	1539		10.1126/science.271.5255.1533	http://dx.doi.org/10.1126/science.271.5255.1533			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599109				2022-12-28	WOS:A1996TZ98300029
J	Biver, N; Rauer, H; Despois, D; Moreno, R; Paubert, G; BockeleeMorvan, D; Colom, P; Crovisier, J; Gerard, E; Jorda, L				Biver, N; Rauer, H; Despois, D; Moreno, R; Paubert, G; BockeleeMorvan, D; Colom, P; Crovisier, J; Gerard, E; Jorda, L			Substantial outgassing of CO from comet Hale-Bopp at large heliocentric distance	NATURE			English	Article								When comet C/1995 O1 (Hale-Bopp) was discovered(1), at a distance of seven astronomical units from the Sun, it was more than one hundred times brighter than comet Halley at the same distance. A comet's brightness is derived from the reflection of sunlight from dust grains driven away from the nucleus by the sublimation of volatile ices. Near the Sun, sublimation of water ice (a main constituent of comet nuclei) is the source of cometary activity; but at its current heliocentric distance, Hale-Bopp is too cold for this process to operate. Other comets have shown activity at large distances(2), and in the case of comet Schwassmann-Wachmann 1, carbon monoxide has been detected in quantities sufficient to generate its observed coma(3,4). Here we report the detection of CO emission from Hale-Bopp, at levels indicating a very large rate of outgassing. Several other volatile species were searched for, but not detected. Sublimation of CO therefore appears to be responsible for the present activity of this comet, and we anticipate that future observations will reveal the onset of sublimation of other volatile species as the comet continues its present journey towards the Sun.	OBSERV BORDEAUX, F-33270 FLOIRAC, FRANCE; IRAM, E-18012 GRANADA, SPAIN		Biver, N (corresponding author), OBSERV PARIS, F-92195 MEUDON, FRANCE.		Jorda, Laurent/AAA-1718-2021					AHEARN MF, 1984, ASTRON J, V89, P579, DOI 10.1086/113552; AHEARN MF, 1995, 6244 IAU; BOCKELEEMORVAN D, 1990, ASTRON ASTROPHYS, V238, P382; BOCKELEEMORVAN D, 1994, ASTRON ASTROPHYS, V287, P647; COLOM P, 1992, ASTRON ASTROPHYS, V264, P710; CROVISIER J, 1995, ICARUS, V115, P213, DOI 10.1006/icar.1995.1091; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; CROVISIER J, 1994, IAU SYMP, P313; DAVIES J, 1995, 6225 IAU; DESPOIS D, IN PRESS PLANET SPAC; Fitzsimmons A, 1996, MON NOT R ASTRON SOC, V278, pL37, DOI 10.1093/mnras/278.2.L37; FULLE M, 1992, NATURE, V359, P42, DOI 10.1038/359042a0; HALE A, 1995, 6187 IAU; HUEBNER WF, 1992, WORKSH ACT DIST COM; Jewitt D., 1990, Astrophysical Journal, V351, P277, DOI 10.1086/168463; KIDGER M, 1995, 6240 IAU; MATTHEWS HE, 1995, 6234 IAU; RAUER H, 1995, 6236 IAU; SENAY MC, 1994, NATURE, V371, P229, DOI 10.1038/371229a0; WILD W, 1995, 30M MANUAL HDB IRAM; WOMACK M, 1995, 6276 IAU	21	63	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 14	1996	380	6570					137	139		10.1038/380137a0	http://dx.doi.org/10.1038/380137a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600385				2022-12-28	WOS:A1996TZ97800042
J	Gale, CR; Martyn, CN; Cooper, C				Gale, CR; Martyn, CN; Cooper, C			Cognitive impairment and mortality in a cohort of elderly people	BRITISH MEDICAL JOURNAL			English	Article							NUTRITIONAL-STATUS; ASSOCIATION; ATHEROSCLEROSIS; POPULATION	Objectives-To investigate the relation between cognitive function and cause specific mortality in people aged 65 and over. Design-A 20 year follow up study of a cohort of randomly selected elderly people living in the community who in 1973-4 had taken part in a nutritional survey funded by the Department of Health and Social Security. Setting-Eight areas in Britain (five in England, two in Scotland, and one in Wales). Subjects-921 men and women whose cognitive function was assessed by a geriatrician in 1973-4 and for whom data on health, socioeconomic circumstances, and diet had been recorded. Results-Cognitive impairment was associated with increased mortality, in particular death from ischaemic stroke. Those who scored 7 or less on the Hodkinson mental test had a relative risk of dying from stroke of 2.8 (95% confidence interval 1.4 to 5.5), compared with those who gained the maximum score (10), after adjustment for age, sex, blood pressure, serum cholesterol concentration, and vitamin C intake. These associations were independent of illness or social class. At the time of the nutritional survey, cognitive function was poorest in those with the lowest vitamin C status, whether measured by dietary intake or plasma ascorbic acid concentration. The relation between vitamin C status and cognitive function was independent of age, illness, social class, or other dietary variables. Conclusion-The relation between cognitive function and risk of death from stroke suggests that cerebrovascular disease is an important cause of declining cognitive function. Vitamin C status may be a determinant of cognitive function in elderly people through its effect on atherogenesis. A high vitamin C intake may protect against both cognitive impairment and cerebrovascular disease.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND	University of Southampton			Gale, Catharine R/B-1653-2012					ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; BORNSTEIN RA, 1991, NEUROBEHAVIORAL ASPE, P182; BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604; DEEG DJH, 1990, AM J EPIDEMIOL, V132, P973, DOI 10.1093/oxfordjournals.aje.a115740; DESMOND DW, 1993, ARCH NEUROL-CHICAGO, V50, P162, DOI 10.1001/archneur.1993.00540020040015; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; GOODWIN JS, 1983, JAMA-J AM MED ASSOC, V249, P2917, DOI 10.1001/jama.249.21.2917; HACHINSKI V, 1992, LANCET, V340, P645; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; LIU IY, 1990, AM J EPIDEMIOL, V132, P136, DOI 10.1093/oxfordjournals.aje.a115625; MARTYN CN, 1988, J EPIDEMIOL COMMUN H, V42, P134, DOI 10.1136/jech.42.2.134; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; STRINGER MD, 1989, BRIT MED J, V298, P281, DOI 10.1136/bmj.298.6669.281; SWAN GE, 1995, AM J EPIDEMIOL, V141, P32, DOI 10.1093/oxfordjournals.aje.a117342; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; WOO J, 1989, RES COMMUN PSYCH PSY, V14, P85	16	225	231	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					608	611						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595334				2022-12-28	WOS:A1996TZ84000024
J	Hull, HF; Lee, JW				Hull, HF; Lee, JW			Sabin, Salk, or sequential?	LANCET			English	Editorial Material											Hull, HF (corresponding author), WHO,CH-1211 GENEVA,SWITZERLAND.							ANDRUS JK, 1995, B WORLD HEALTH ORGAN, V73, P33; BART KJ, IN PRESS B WHO; FRANKEL DH, 1995, LANCET, V346, P1151, DOI 10.1016/S0140-6736(95)91812-4; GHENDON Y, 1994, B WORLD HEALTH ORGAN, V72, P973; HEYMANN DL, 1987, B WORLD HEALTH ORGAN, V65, P495; HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4; WARD NA, 1995, LANCET, V345, P318, DOI 10.1016/S0140-6736(95)90305-4; 1995, WEEKLY EPIDEMIOL REC, V70, P169; 1994, WEEKLY EPIDEMIOL REC, V69, P293; 1995, WEEKLY EPIDEMIOL REC, V70, P341; 1995, WEEKLY EPIDEMIOL REC, V79, P325; 1994, WEEKLY EPIDEMIOL REC, V69, P377	12	14	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					630	630		10.1016/S0140-6736(96)91194-0	http://dx.doi.org/10.1016/S0140-6736(96)91194-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596370				2022-12-28	WOS:A1996TZ28500002
J	Turpie, AGG				Turpie, AGG			Hirudin and thrombosis prophylaxis	LANCET			English	Editorial Material							HEPARIN; INHIBITORS				Turpie, AGG (corresponding author), HGH MCMASTER CLIN,HAMILTON,ON,CANADA.							CLAGETT GP, 1995, CHEST, V108, P371; HARKER LA, 1994, HEMOSTASIS THROMBOSI; HIRSH J, 1992, BLOOD, V79, P1; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; KLEMENT P, 1992, THROMB HAEMOSTASIS, V68, P64; NEUHAUS KL, 1994, CIRCULATION, V90, P1632; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; 1994, CIRCULATION, V90, P1631; 1992, BRIT MED J, V305, P567; 1994, CIRCULATION, V90, P1624; 1992, INT ANGIOL, V11, P151	11	2	2	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					632	633		10.1016/S0140-6736(96)91197-6	http://dx.doi.org/10.1016/S0140-6736(96)91197-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596373				2022-12-28	WOS:A1996TZ28500005
J	Chao, DM; Gadbois, EL; Murray, PJ; Anderson, SF; Sonu, MS; Parvin, JD; Young, RA				Chao, DM; Gadbois, EL; Murray, PJ; Anderson, SF; Sonu, MS; Parvin, JD; Young, RA			A mammalian SRB protein associated with an RNA polymerase II holoenzyme	NATURE			English	Article							TATA-BINDING PROTEIN; TRANSCRIPTION; PURIFICATION; YEAST; CTD	A large multisubunit complex containing RNA polymerase II, general transcription factors and SRB regulatory proteins initiates transcription of class II genes in yeast cells(1-4). The SRB proteins are a hallmark of this RNA polymerase II holoenzyme as they are found only in this complex, where they contribute to the response to regulators(4-8). We have now isolated a human homologue of the yeast SRB7 gene and used antibodies against human SRB7 protein to purify and characterize a mammalian RNA polymerase II holoenzyme containing the general transcription factors TFIIE and TFIIH. This holoenzyme is more responsive to transcriptional activators than core RNA polymerase II when assayed in the presence of coactivators.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; BRIGHAM & WOMENS HOSP, DIV MOLEC ONCOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Chao, DM (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Young, Richard A/F-6495-2012; Murray, Peter J/K-4725-2018; Parvin, Jeffrey D/C-8955-2009	Young, Richard A/0000-0001-8855-8647; Murray, Peter J/0000-0001-6329-9802; Chao, David/0000-0001-9198-337X				BASSET DE, 1995, TRENDS GENET, V11, P372, DOI 10.1016/S0168-9525(00)89109-X; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; INOSTROZA JA, 1992, CELL, V70, P477; KIM TK, 1995, J BIOL CHEM, V270, P10976, DOI 10.1074/jbc.270.18.10976; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KOLESKE AJ, IN PRESS METH ENZYM; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; KRETZSCHMAR M, 1994, MOL CELL BIOL, V14, P3927, DOI 10.1128/MCB.14.6.3927; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; STELZER G, 1994, MOL CELL BIOL, V14, P4712, DOI 10.1128/MCB.14.7.4712; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069	27	130	132	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1996	380	6569					82	85		10.1038/380082a0	http://dx.doi.org/10.1038/380082a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598913				2022-12-28	WOS:A1996TY87700062
J	Froster, UG; Jackson, L				Froster, UG; Jackson, L			Limb defects and chorionic villus sampling: Results from an international registry, 1992-94	LANCET			English	Article							PRENATAL-DIAGNOSIS; CONGENITAL-DEFECTS; REDUCTION DEFECTS; ABNORMALITIES; POPULATION; CVS; MALFORMATIONS; ANOMALIES; AMNIOCENTESIS	Background Several reports of limb defects occurring among infants exposed to chorionic villus sampling (CVS) during pregnancy resulted in concern about the safety of this procedure for prenatal diagnosis. To avoid publication bias and evaluate the true risk of limb defects in a CVS cohort, the World Health Organization initiated international registration of post-CVS limb defects in 1992. Methods From May, 1992, to May, 1994, 77 infants or fetuses with limb defects from 138 996 pregnancies having CVS were reported to the WHO CVS Registry. These cases were analysed by standardised methods-ie, exclusion of syndromes, inherited disorders, and defects occurring in previable fetuses. The included limb deficiencies were studied by pattern analysis. Findings Defects of the upper limbs were reported in 64.6%, of the lower limbs in 12.5%, and of both upper and lower limbs in 20.8% of cases, These figures are in agreement with the distribution of limb defects in several large population-based studies. Transverse limb defects occurred in 40.8% and longitudinal defects in 59.2%, compared with 42.7% and 57.3% in an unexposed population. Interpretation The analysis of this cohort did not show any differences from the background population in the overall frequency or pattern distribution of limb deficiencies. There was also no correlation between gestational age at CVS and severity of defects. Therefore these results do not indicate any increased risk of limb defects after CVS.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DIV MED GENET,PHILADELPHIA,PA 19107	Jefferson University	Froster, UG (corresponding author), UNIV SPITAL ZURICH,KLIN & POLIKLIN GEBURTSHILFE,DEPT FRAUENHEILKUNDE,FRAUENKLIN STR 10,CH-8091 ZURICH,SWITZERLAND.							[Anonymous], 1991, LANCET, V337, P1491; ARO T, 1982, INT J EPIDEMIOL, V3, P239; BAMFORTH JS, 1992, AM J MED GENET, V44, P281; BRAMBATI B, 1983, LANCET, V1, P586; BRAMBATI B, 1992, PRENATAL DIAG, V12, P789, DOI 10.1002/pd.1970121004; BURTON BK, 1992, OBSTET GYNECOL, V79, P726; BURTON BK, 1993, PEDIATRICS, V91, P989; Canadian Collaborative CVS-Amniocentesis Clinical Trial Group, 1989, LANCET, V1, P1; DOLK H, 1992, LANCET, V339, P876, DOI 10.1016/0140-6736(92)90325-W; FIRTH HV, 1994, LANCET, V343, P1069, DOI 10.1016/S0140-6736(94)90182-1; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; FROSTER UG, 1993, AM J MED GENET, V45, P60, DOI 10.1002/ajmg.1320450116; FROSTER UG, 1993, AM J MED GENET, V46, P479, DOI 10.1002/ajmg.1320460502; FROSTER UG, 1993, AM J MED GENET, V46, P497, DOI 10.1002/ajmg.1320460507; FROSTER UG, 1992, LANCET, V339, P66, DOI 10.1016/0140-6736(92)90198-C; FROSTERISKENIUS UG, 1990, TERATOLOGY, V41, P23, DOI 10.1002/tera.1420410104; FROSTERISKENIUS UG, 1989, TERATOLOGY, V39, P127, DOI 10.1002/tera.1420390205; GOLBUS MT, 1992, PRENATAL DIAG, V12, P313, DOI 10.1002/pd.1970120502; HOLZGREVE W, 1990, GYNAKOLOGE, V23, P261; HSIEH FJ, 1991, LANCET, V337, P1091; JAHODA MGJ, 1991, PRENATAL DIAG, V11, P559, DOI 10.1002/pd.1970110811; KALLEN B, 1984, TERATOLOGY, V29, P73, DOI 10.1002/tera.1420290109; KAPLAN P, 1990, AM J MED GENET, V37, P366, DOI 10.1002/ajmg.1320370315; KULIEV AM, 1993, PRENATAL DIAG, V13, P197, DOI 10.1002/pd.1970130307; KULIEV AM, 1992, LANCET, V340, P668, DOI 10.1016/0140-6736(92)92197-N; KULIEV AM, 1992, J ASSIST REPROD GEN, V9, P299, DOI 10.1007/BF01203947; LIN SP, 1992, J MED GENET, V51, pA261; LIPPMAN A, 1992, PRENATAL DIAG, V12, P385, DOI 10.1002/pd.1970120508; MAHONEY MJ, 1991, LANCET, V337, P1422, DOI 10.1016/0140-6736(91)93117-R; MASTROIACOVO P, 1992, AM J MED GENET, V44, P856, DOI 10.1002/ajmg.1320440639; MONNI G, 1991, LANCET, V337, P1091; OLNEY RS, 1995, TERATOLOGY, V51, P20, DOI 10.1002/tera.1420510104; RHOADS GG, 1989, NEW ENGL J MED, V320, P609, DOI 10.1056/NEJM198903093201001; SCHLOO R, 1992, AM J MED GENET, V42, P404, DOI 10.1002/ajmg.1320420338; Stoll C, 1992, Paediatr Perinat Epidemiol, V6, P323, DOI 10.1111/j.1365-3016.1992.tb00773.x; Wapner R., 1996, American Journal of Obstetrics and Gynecology, V174, P310; 1993, PRENATAL DIAG, V13, P1051	37	69	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					489	494		10.1016/S0140-6736(96)91136-8	http://dx.doi.org/10.1016/S0140-6736(96)91136-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596265				2022-12-28	WOS:A1996TW69700007
J	Wainwright, RB				Wainwright, RB			The US arctic investigations program: Infectious disease prevention and control research in Alaska	LANCET			English	Review							HEPATITIS-B VACCINE; INFLUENZAE TYPE-B; PRESUMPTIVE PNEUMOCOCCAL PNEUMONIA; YUPIK ESKIMO POPULATION; HEPATOCELLULAR-CARCINOMA; ENZYME-IMMUNOASSAY; ANTICAPSULAR ANTIBODY; C POLYSACCHARIDE; VIRUS-INFECTION; NATIVE INFANTS				Wainwright, RB (corresponding author), CTR DIS CONTROL & PREVENT,PUBL HLTH SERV,US DEPT HHS,NATL CTR INFECT DIS,ARCTIC INVEST PROGRAM,ANCHORAGE,AK, USA.							ALBERTS SR, 1991, GENET EPIDEMIOL, V8, P127, DOI 10.1002/gepi.1370080206; ALWARD WLM, 1986, J INFECT DIS, V153, P171, DOI 10.1093/infdis/153.1.171a; BELLER M, 1993, BORULISM ALASKA GUID; BRENNEMAN G, 1987, PEDIATR INFECT DIS J, V6, P388, DOI 10.1097/00006454-198704000-00009; Bulkow L R, 1993, Arctic Med Res, V52, P118; BULKOW LR, 1993, PEDIATR INFECT DIS J, V12, P484, DOI 10.1097/00006454-199306000-00006; Cruz A, 1990, Arctic Med Res, V49, P175; DAVIDSON M, 1994, J INFECT DIS, V169, P792, DOI 10.1093/infdis/169.4.792; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; DAVIDSON M, 1993, PUBLIC HEALTH REP, V108, P439; DAVIDSON M, 1994, J INFECT DIS, V170, P368, DOI 10.1093/infdis/170.2.368; DAVIDSON M, 1994, ARCH INTERN MED, V154, P2209, DOI 10.1001/archinte.154.19.2209; DAVIDSON M, 1944, INT J EPIDEMIOL, V23, P238; FINDLEY JC, 1992, ARCH INTERN MED, V152, P1641; HALL DB, 1987, AM J EPIDEMIOL, V126, P1190, DOI 10.1093/oxfordjournals.aje.a114758; LANIER AP, 1987, AM J TROP MED HYG, V37, P609, DOI 10.4269/ajtmh.1987.37.609; LANIER AP, 1987, CANCER, V60, P1915, DOI 10.1002/1097-0142(19871015)60:8<1915::AID-CNCR2820600841>3.0.CO;2-5; MCMAHON BJ, 1992, GASTROENTEROLOGY, V103, P590, DOI 10.1016/0016-5085(92)90851-O; MCMAHON BJ, 1993, AM J MED, V95, P589, DOI 10.1016/0002-9343(93)90354-R; MCMAHON BJ, 1989, HEPATOLOGY, V9, P97, DOI 10.1002/hep.1840090116; MCMAHON BJ, 1993, AM J EPIDEMIOL, V138, P544; MCMAHON BJ, 1987, LANCET, V2, P1134; MCMAHON BJ, 1992, AM J MED, V92, P254, DOI 10.1016/0002-9343(92)90073-K; MCMAHON BJ, 1990, ARCH INTERN MED, V150, P1051, DOI 10.1001/archinte.150.5.1051; MCMAHON BJ, 1990, AM J MED, V88, P460, DOI 10.1016/0002-9343(90)90423-B; MCMAHON BJ, 1991, J NATL CANCER I, V83, P916, DOI 10.1093/jnci/83.13.916; MCMAHON BJ, 1993, HEPATITIS B VACCINES; MCMAHON BJ, 1988, HEPATOLOGY, V8, P976; MCMAHON BJ, 1991, ETIOLOGY PATHOLOGY T; MCMAHON BJ, 1990, PROGR LIVER DIS HEPA; MCMAHON BJ, 1990, PROGR HEPATITIS B IM; MUNOZ R, 1992, CLIN INFECT DIS, V15, P112, DOI 10.1093/clinids/15.1.112; PARKINSON AJ, 1994, J INFECT DIS, V170, P461, DOI 10.1093/infdis/170.2.461; PARKINSON AJ, 1994, AM J CLIN NUTR, V59, P384, DOI 10.1093/ajcn/59.2.384; PARKINSON AJ, 1992, J CLIN MICROBIOL, V30, P318, DOI 10.1128/JCM.30.2.318-322.1992; PARKINSON AJ, 1990, J MED VIROL, V30, P253, DOI 10.1002/jmv.1890300405; PARKINSON AJ, 1990, SERODIAG IMMUN INF D, V4, P495, DOI 10.1016/0888-0786(90)90064-U; PETERSEN GM, 1986, J PEDIATR, V110, P228; POPPER H, 1988, ARCH PATHOL LAB MED, V112, P498; RUDOLPH KM, 1993, J CLIN MICROBIOL, V31, P2661, DOI 10.1128/JCM.31.10.2661-2666.1993; SCHANTZ PM, 1991, PARASITOL TODAY, V7, P35, DOI 10.1016/0169-4758(91)90185-Q; SHAFFER N, 1990, WESTERN J MED, V153, P390; SINGLETON RJ, 1994, PEDIATR INFECT DIS J, V13, P362, DOI 10.1097/00006454-199405000-00006; STEHRGREEN JK, 1988, AM J TROP MED HYG, V38, P380, DOI 10.4269/ajtmh.1988.38.380; THIELE M, 1988, MMWR-MORBID MORTAL W, V37, P200; TUOMANEN E, 1988, J INFECT DIS, V158, P36, DOI 10.1093/infdis/158.1.36; WAINWRIGHT RB, 1989, JAMA-J AM MED ASSOC, V261, P2362, DOI 10.1001/jama.261.16.2362; WAINWRIGHT RB, 1988, J INFECT DIS, V157, P1158, DOI 10.1093/infdis/157.6.1158; WAINWRIGHT RB, 1991, ARCH INTERN MED, V151, P1634, DOI 10.1001/archinte.151.8.1634; WAINWRIGHT RB, 1992, CLOSTRIDIUM BOTULINU; WARD JI, 1988, J INFECT DIS, V158, P719, DOI 10.1093/infdis/158.4.719; WARD JI, 1986, J INFECT DIS, V153, P17, DOI 10.1093/infdis/153.1.17	52	14	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					517	520		10.1016/S0140-6736(96)91143-5	http://dx.doi.org/10.1016/S0140-6736(96)91143-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596272				2022-12-28	WOS:A1996TW69700014
J	Miyazaki, T; Wolf, P; Tourne, S; Waltzinger, C; Dierich, A; Barois, N; Ploegh, H; Benoist, C; Mathis, D				Miyazaki, T; Wolf, P; Tourne, S; Waltzinger, C; Dierich, A; Barois, N; Ploegh, H; Benoist, C; Mathis, D			Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway	CELL			English	Article							ANTIGEN-PROCESSING MUTANT; MAJOR HISTOCOMPATIBILITY COMPLEX; INVARIANT CHAIN PEPTIDES; HLA-DR MOLECULES; SELECTION; GENES; EXPRESSION	We have generated mice lacking H2-M complexes, critical facilitators of peptide loading onto major histocompatibility complex class II molecules. Ab molecules in these mice matured into stable complexes and were efficiently expressed at the cell surface. Most carried a single peptide derived from the class II-associated invariant chain; the diverse array of peptides normally displayed by class II molecules was absent. Cells from mutant mice presented both whole proteins and short peptides very poorly. Surprisingly, positive selection of CD4(+) T cells was quite efficient, yielding a large and broad repertoire. Peripheral T cells reacted strongly to splenocytes from syngeneic wild-type mice, no doubt reflecting the unique peptide complement carried by class II molecules in mutant animals.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; CTR IMMUNOL MARSEILLE LUMINY,F-13288 MARSEILLE 9,FRANCE	Massachusetts Institute of Technology (MIT); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Miyazaki, T (corresponding author), UNIV STRASBOURG 1,INSERM,CNRS,INST GENET & BIOL MOL & CELLULAIRE,CU STRASBOURG,F-67404 ILLKIRCH GRAFFENS,FRANCE.				NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NCI NIH HHS [2-P30-CA14051-24] Funding Source: Medline; PHS HHS [5-R01-AL34893, T32-AL07463] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BROOKS AG, 1994, J IMMUNOL, V153, P5382; CEMAN S, 1992, J IMMUNOL, V149, P754; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; CHO SG, 1991, P NATL ACAD SCI USA, V88, P5197, DOI 10.1073/pnas.88.12.5197; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; EASTMAN S, 1996, IN PRESS EUR J IMMUN; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; KROPSHOFER H, 1995, SCIENCE, V270, P1357, DOI 10.1126/science.270.5240.1357; LANDAIS D, 1986, J IMMUNOL, V137, P3002; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LIANG MN, 1995, INT IMMUNOL, V7, P1397, DOI 10.1093/intimm/7.9.1397; MALCHEREK G, 1995, J EXP MED, V181, P527, DOI 10.1084/jem.181.2.527; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MIYAZAKI T, 1996, IN PRESS SCIENCE; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NAUJOKAS MF, 1995, IMMUNITY, V3, P359, DOI 10.1016/1074-7613(95)90120-5; RADLEY E, 1994, J BIOL CHEM, V269, P18834; REGNIERVIGOUROX A, 1988, J IMMUNOL, V140, P1069; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SETTE A, 1995, J EXP MED, V181, P677, DOI 10.1084/jem.181.2.677; SHACHAR I, 1995, IMMUNITY, V3, P373, DOI 10.1016/1074-7613(95)90121-3; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; TOUME S, 1995, EUR J IMMUNOL, V25, P1851; URBAN RG, 1995, J EXP MED, V180, P1851; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WHITE J, 1989, J IMMUNOL, V143, P1822; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411	44	300	305	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					531	541		10.1016/S0092-8674(00)81029-6	http://dx.doi.org/10.1016/S0092-8674(00)81029-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598040	Bronze			2022-12-28	WOS:A1996TX17600006
J	Beale, J				Beale, J			Reconsidering an attenuated vaccine for AIDS	LANCET			English	Editorial Material																		ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BEALE J, 1995, LANCET, V345, P1318, DOI 10.1016/S0140-6736(95)92532-5; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; HILLEMAN MR, 1995, NAT MED, V1, P1126, DOI 10.1038/nm1195-1126; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; RUD EW, 1994, VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P217; SABIN AB, 1993, NATURE, V362, P212, DOI 10.1038/362212a0	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					344	345		10.1016/S0140-6736(96)90532-2	http://dx.doi.org/10.1016/S0140-6736(96)90532-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598696				2022-12-28	WOS:A1996TU69500004
J	Bjarnason, GA				Bjarnason, GA			Menstrual cycle chronobiology: Is it important in breast cancer screening and therapy?	LANCET			English	Editorial Material											Bjarnason, GA (corresponding author), TORONTO SUNNYBROOK REG CANC CTR,DIV MED ONCOL,TORONTO,ON,CANADA.		Bjarnason, Georg A/L-6032-2019	Bjarnason, Georg A/0000-0001-6903-5357				BOYD NF, 1995, J NATL CANCER I, V87, P670, DOI 10.1093/jnci/87.9.670; FENTIMAN IS, 1994, LANCET, V344, P402, DOI 10.1016/S0140-6736(94)91428-1; GOING JJ, 1988, AM J PATHOL, V130, P193; Graham SJ, 1995, JMRI-J MAGN RESON IM, V5, P695, DOI 10.1002/jmri.1880050613; GRAHAM SJ, IN PRESS BR J CANCER; HRUSHESKY WJM, 1993, J CLIN ONCOL, V11, P1403, DOI 10.1200/JCO.1993.11.7.1403; HRUSHESKY WJM, 1993, J SURG ONCOL, V53, P1, DOI 10.1002/jso.2930530103; KRZANOWSKI M, 1985, CHRONOBIOLOGIA, V12, P254; LEVI F, 1995, P ANN M AM SOC CLIN, V493; MILLIGAN D, 1975, BRIT MED J, V4, P494, DOI 10.1136/bmj.4.5995.494; SIMPSON HW, 1993, BREAST CANCER RES TR, V27, P239, DOI 10.1007/BF00665693; SIMPSON HW, 1995, EUR J CANCER, V31A, P1768, DOI 10.1016/0959-8049(95)00379-W; SMYTH CM, 1988, BREAST CANCER RES TR, V11, P45, DOI 10.1007/BF01807557; WETTERBERG L, 1976, J CLIN ENDOCR METAB, V42, P185, DOI 10.1210/jcem-42-1-185; WHITE D, 1982, BRIT J CANCER, V46, P611, DOI 10.1038/bjc.1982.245	15	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					345	346		10.1016/S0140-6736(96)90533-4	http://dx.doi.org/10.1016/S0140-6736(96)90533-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598697				2022-12-28	WOS:A1996TU69500005
J	Schmitz, N; Linch, DC; Dreger, P; Goldstone, AH; Boogaerts, MA; Ferrant, A; Demuynck, HMS; Link, H; Zander, A; Barge, A; Borkett, K				Schmitz, N; Linch, DC; Dreger, P; Goldstone, AH; Boogaerts, MA; Ferrant, A; Demuynck, HMS; Link, H; Zander, A; Barge, A; Borkett, K			Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients	LANCET			English	Article							COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM-CELLS; HIGH-DOSE CHEMOTHERAPY; PLATELET RECOVERY; G-CSF; GRANULOCYTE; THERAPY	Background A randomised trial comparing filgrastim-mobilised peripheral blood progenitor cell (PBPC) transplants with autologous bone marrow transplantation (ABMT) for haematopoietic stem cell support has not been done. We compared the effects of filgrastim-mobilised PBPC or autologous bone marrow reinfused to lymphoma patients after high-dose chemotherapy in a prospective randomised multicentre trial. Methods The trial was done at six centres in three European countries. After high-dose chemotherapy (carmustine, etoposide, cytarabine, and melphalan [BEAM protocol]) 58 patients with advanced Hodgkin's disease or high-grade non-Hodgkin lymphoma received either filgrastim-mobilised PBPC (n=27) or bone marrow (n=31) for haemopoietic reconstitution. Findings The median number of days with platelet transfusions after grafting was 6 in the PBPC transplantation group and 10 in the ABMT group (estimate of treatment difference 5 days, 95% CI 3-7 days). Time to platelet recovery above 20x10(9)/L was 16 days in the PBPC transplantation group and 23 days in the ABMT group (p=0.02). Time to neutrophil recovery above 0.5x10(9)/L was also reduced in the PBPC transplantation group (11 vs 14 days, p=0.005). Patients randomised to PBPC transplantation needed fewer red blood cell transfusions (two vs three, p=0.002) and spent less time in hospital (17 vs 23 days, p=0.002). Early post-transplant morbidity and mortality as well as overall survival (median follow-up 311 days) were similar in both groups. There was no notable toxicity ascribed to filgrastim administration or the leucapheresis procedures. Interpretation In patients with lymphoma treated with high-dose chemotherapy, reinfusing filgrastim-mobilised PBPC instead of autologous bone marrow significantly reduced the number of platelet transfusions, the time to platelet and neutrophil recovery, and led to earlier discharge from hospital.	UCL HOSP, LONDON, ENGLAND; UNIV LEUVEN, MED CTR, DEPT HAEMATOL, LOUVAIN, BELGIUM; CLIN UNIV ST LUC, DEPT HAEMATOL, BRUSSELS, BELGIUM; UNIV HAMBURG, BONE MARROW TRANSPLANTAT UNIT, D-20246 HAMBURG, GERMANY; HANNOVER MED SCH, DEPT HAEMATOL & ONCOL, HANNOVER, GERMANY; AMGEN LTD, CAMBRIDGE, ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; University College London; KU Leuven; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Hamburg; Hannover Medical School; Amgen; Amgen Limited	Schmitz, N (corresponding author), CHRISTIAN ALBRECHTS UNIV KIEL, DEPT INTERNAL MED 2, CHEMNITZSTR 33, D-24116 KIEL, GERMANY.							BENSINGER W, 1993, BLOOD, V81, P3158; BISHOP MR, 1994, BLOOD, V83, P610; CHAO NJ, 1993, BLOOD, V81, P2031; DREGER P, 1993, BRIT J CANCER, V68, P950, DOI 10.1038/bjc.1993.460; DREGER P, 1995, BLOOD, V86, P3970, DOI 10.1182/blood.V86.10.3970.bloodjournal86103970; DUHRSEN U, 1988, BLOOD, V72, P2074; GIANNI AM, 1989, LANCET, V2, P580; GISSELBRECHT C, 1994, LANCET, V343, P696, DOI 10.1016/S0140-6736(94)91579-2; GOODMAN JOAN WRIGHT, 1962, BLOOD JOUR HEMATOL, V19, P702; GRATWOHL A, 1995, CLIN TRANSPLANT, V9, P355; GRIBBEN JG, 1989, BLOOD, V73, P340; HAAS R, 1993, PERIPHERAL BLOOD STE, P155; HAYLOCK DN, 1992, BLOOD, V80, P1405; KESSINGER A, 1988, BLOOD, V71, P723; KORBLING M, 1986, BLOOD, V67, P529; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; MCCREDIE KB, 1971, SCIENCE, V171, P293, DOI 10.1126/science.171.3968.293; PHILIP T, 1987, NEW ENGL J MED, V316, P1493, DOI 10.1056/NEJM198706113162401; RICHMAN CM, 1976, BLOOD, V47, P1031; SCHMITZ N, 1995, BONE MARROW TRANSPL, V15, P261; SCHMITZ N, 1995, BLOOD, V85, P1666, DOI 10.1182/blood.V85.6.1666.bloodjournal8561666; SHERIDAN WP, 1992, LANCET, V339, P640, DOI 10.1016/0140-6736(92)90795-5; SMITH TJ, 1995, P AN M AM SOC CLIN, V14, P314; SOCINSKI MA, 1988, LANCET, V1, P1194; STAHEL RA, 1994, J CLIN ONCOL, V12, P1931, DOI 10.1200/JCO.1994.12.9.1931; TO LB, 1984, BRIT J HAEMATOL, V58, P399, DOI 10.1111/j.1365-2141.1984.tb03987.x	26	546	553	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					353	357		10.1016/S0140-6736(96)90536-X	http://dx.doi.org/10.1016/S0140-6736(96)90536-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598700				2022-12-28	WOS:A1996TU69500008
J	Friedman, EA				Friedman, EA			End-stage renal disease therapy - An American success story	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEMODIALYSIS; ADEQUACY; SURVIVAL				Friedman, EA (corresponding author), SUNY HLTH SCI CTR, DEPT MED, 450 CLARKSON AVE, BROOKLYN, NY 11203 USA.							ALTER MJ, 1991, T AM SOC ART INT ORG, V37, P97; BERLYNE GM, 1982, NEPHRON, V31, P189, DOI 10.1159/000182644; BERNHEIM J, 1995, NEPHROL DIAL TRANSPL, V10, P431, DOI 10.1093/ndt/10.4.431; BLOEMBERGEN WE, 1995, J AM SOC NEPHROL, V6, P177; CHAZAN JA, 1992, AM J KIDNEY DIS, V19, P523, DOI 10.1016/S0272-6386(12)80829-8; CIESLINSKI DA, 1994, BIOTECHNOL BIOENG, V43, P678, DOI 10.1002/bit.260430718; FRIEDMAN EA, 1994, DEV NEPHROL, V35, P1; FRIEDMAN EA, 1994, NEPHROL DIAL TRANSPL, V9, P242; HAKIM RM, 1992, AM J KIDNEY DIS, V20, P107, DOI 10.1016/S0272-6386(12)80538-5; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; IKEGAMI N, 1995, NEW ENGL J MED, V333, P1295, DOI 10.1056/NEJM199511093331922; KJELLSTRAND CM, 1994, DEV NEPHROL, V35, P55; KJELLSTRAND CM, 1994, CAN MED ASSOC J, V150, P1067; KJELLSTRAND CM, 1988, ACTA MED SCAND, V224, P149; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; Levin N, 1991, ANNA J, V18, P269; LEVIT KR, 1994, HEALTH CARE FINANC R, V16, P247; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; LOWRIE EG, 1983, KIDNEY INT, pS113; MAKOWKA L, 1987, ANN SURG, V206, P482, DOI 10.1097/00000658-198710000-00009; MANTON KG, 1995, NEW ENGL J MED, V333, P1232, DOI 10.1056/NEJM199511023331824; MARWICK C, 1995, JAMA-J AM MED ASSOC, V273, P10; MESSANA A, 1994, AM J KIDNEY DIS, V24, P334, DOI 10.1016/S0272-6386(12)80199-5; NEUMANN M, 1994, NEPHROL NEWS ISSUES, V8, P9; POWE NR, 1994, J AM SOC NEPHROL, V4, P1455; Rettig RA, 1991, KIDNEY FAILURE FEDER; SETALA K, 1978, KIDNEY INT S, V8, pS194; SHALDON S, 1994, DEV NEPHROL, V35, P95; SHALDON S, 1991, NEPHRON, V59, P353, DOI 10.1159/000186591; SHALDON S, 1993, KIDNEY NT S, V41, P5274; TEEHAN BP, 1995, J AM SOC NEPHROL, V6, P139; THOMAS B, 1995, JAMA-J AM MED ASSOC, V274, P276; THOMAS WM, 1995, ROLL CALL       0619, P1; *US REN DAT SYST, 1993, 1993 USRDS NIH NAT I; *US REN DAT SYST, 1995, 1995 USRDS NIH NAT I; WILLIAMSON K, 1965, Hospitals, V39, P39; 1993, NIH CONSENSUS STATE, V11, P1; 1995, DIABETES CARE S1, V18, P8; 1995, NEPHROL DIAL TRAN S5, V10, P1; 1995, ANN INTERN MED, V121, P62	40	31	31	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1996	275	14					1118	1122		10.1001/jama.275.14.1118	http://dx.doi.org/10.1001/jama.275.14.1118			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD027	8601932				2022-12-28	WOS:A1996UD02700029
J	McDuffie, RS; Beck, A; Bischoff, K; Cross, J; Orleans, M				McDuffie, RS; Beck, A; Bischoff, K; Cross, J; Orleans, M			Effect of frequency of prenatal care visits on perinatal outcome among low-risk women - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIRTH-WEIGHT; PREGNANCY; HEALTH	Objectives.-In 1989, the Expert Panel on the Content of Prenatal Care established guidelines on the timing and content of prenatal care, including a schedule consisting of fewer prenatal visits than traditionally provided, for women at low risk of adverse perinatal outcomes. We tested the hypothesis that there are no significant increases in adverse perinatal outcomes when low-risk women are seen in a prenatal care visit schedule of fewer visits than routinely advised. Design.-Randomized controlled trial. Setting.-Group-model health maintenance organization. Patients.-A total of 2764 pregnant women, judged to be at low risk of adverse perinatal outcomes. Interventions.-following risk assessment, participants were randomly assigned to an experimental schedule (nine visits) or a control schedule (14 visits) with additional visits as indicated or as desired by the patient. Main Outcome Measures.-Preterm delivery, preeclampsia, cesarean delivery, low birth weight, and patients' satisfaction with care. Results.-On average, there were 2.7 fewer visits observed in the experimental group than in the control group. There were no significant increases in the main outcomes of the experimental group: preterm delivery (relative risk [RR], 1.08; 95% confidence interval [CI], 0.92 to 1.27; P=.19), preeclampsia (RR, 0.94; 95% CI, 0.78 to 1.14; P=.74), cesarean delivery (RR, 1.04; 95% CI, 0.93 to 1.17, P=.25), and low birth weight (RR, 0.94; 95% CI, 0.78 to 1.12; P=.76). There were no differences between the two groups in patients' satisfaction with quality of prenatal care. Conclusion.-In this study, good perinatal outcomes and patient satisfaction were maintained when the prenatal visit schedule proposed by the Expert Panel on the Content of Prenatal Care was observed.	KAISER PERMANENTE,DEPT RES & DEV,DENVER,CO 80205; UNIV COLORADO,HLTH SCI CTR,DEPT PREVENT MED & BIOMETR,DENVER,CO 80262	Kaiser Permanente; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	McDuffie, RS (corresponding author), KAISER PERMANENTE,DEPT OBSTET & GYNECOL,2045 FRANKLIN ST,DENVER,CO 80205, USA.							*AM COLL OBST GYN, 1989, STAND OBST GYN SERV, P16; BINSTOCK MA, 1994, J REPROD MED, V39, P1; BLONDEL B, 1985, BRIT J OBSTET GYNAEC, V92, P565, DOI 10.1111/j.1471-0528.1985.tb01393.x; Cohen J., 1977, STATISTICAL POWER AN, P179, DOI [10.1016/b978-0-12-179060-8.50011-6, DOI 10.1016/B978-0-12-179060-8.50011]; GORTMAKER SL, 1979, AM J PUBLIC HEALTH, V69, P653, DOI 10.2105/AJPH.69.7.653; HEMMINKI E, 1988, MED CARE, V26, P199, DOI 10.1097/00005650-198802000-00010; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V271, P1340, DOI 10.1001/jama.271.17.1340; LUBCHENCO LO, 1963, PEDIATRICS, V32, P793; MALLOY MH, 1992, AM J PUBLIC HEALTH, V82, P448, DOI 10.2105/AJPH.82.3.448; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; MUSTARD CA, 1994, AM J PUBLIC HEALTH, V84, P1450, DOI 10.2105/AJPH.84.9.1450; *PHS, 1989, CAR OUT FUT CONT PRE; SCHOLL TO, 1987, OBSTET GYNECOL, V69, P312; SCHRAMM WF, 1992, PUBLIC HEALTH REP, V107, P647; SHIONO PH, 1986, JAMA-J AM MED ASSOC, V255, P48, DOI 10.1001/jama.255.1.48; THOMPSON JE, 1993, NEW PERSPECTIVES PRE, P9; TYSON J, 1990, PEDIATRICS, V85, P195; 1995, MONTHLY VITAL STAT R, V43, P1	18	102	104	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					847	851		10.1001/jama.275.11.847	http://dx.doi.org/10.1001/jama.275.11.847			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ971	8596222				2022-12-28	WOS:A1996TZ97100027
J	Gorlich, D; Mattaj, IW				Gorlich, D; Mattaj, IW			Protein kinesis - Nucleocytoplasmic transport	SCIENCE			English	Article							PRE-MESSENGER-RNA; NUCLEAR TRANSPORT; T-ANTIGEN; 2 STEPS; IMPORT; TRANSLOCATION; BINDING; NUCLEOPLASMIN; SIGNALS; ACCUMULATION	Active transport of proteins and RNAs between the nucleus and cytoplasm is a major process in eukaryotic cells. Recently, factors that recognize transport substrates and mediate nuclear import or export have been characterized, revealing interactions that target substrates to the nuclear pore complexes, through which translocation occurs. Translocation requires energy, and for the import process this energy is at least partly consumed by the action of the small guanosine triphosphatase Ran. In the first half of the review, some of the well-established general background information on nucleocytoplasmic transport is discussed. The second half describes recent information on the mechanistic details of nuclear import and export as well as major unresolved issues such as how directionality is conferred on either import or export. The whole review is slanted toward discussion of metazoan cells.	WELLCOME CANC RES CAMPAIGN INST, CAMBRIDGE CB2 1QR, ENGLAND; UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE, ENGLAND; EUROPEAN MOLEC BIOL LAB, D-69117 HEIDELBERG, GERMANY	University of Cambridge; European Molecular Biology Laboratory (EMBL)			Görlich, Dirk/B-8296-2017	Görlich, Dirk/0000-0002-4343-5210; Mattaj, Iain/0000-0002-5537-8284	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; Bonner W.M., 1978, CELL NUCLEUS, V6, P97; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; CULLEN BR, 1991, TRENDS BIOCHEM SCI, V16, P346, DOI 10.1016/0968-0004(91)90141-H; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1995, P NATL ACAD SCI USA, V92, P7525, DOI 10.1073/pnas.92.16.7525; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FABRE E, 1994, CURR OPIN CELL BIOL, V6, P335, DOI 10.1016/0955-0674(94)90023-X; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FELDHERR CM, 1993, EXP CELL RES, V205, P179, DOI 10.1006/excr.1993.1073; FELDHERR CM, 1962, J CELL BIOL, V14, P65, DOI 10.1083/jcb.14.1.65; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FRIDELL RA, IN PRESS P NATL ACAD; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; GORLICH D, IN PRESS EMBO J; GORLICH D, UNPUB; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; IOVINE MK, J CELL BIOL, V1319, P95; Izaurralde E, 1992, Semin Cell Biol, V3, P279, DOI 10.1016/1043-4682(92)90029-U; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; KUSSEL P, 1995, J CELL BIOL, V129, P1491, DOI 10.1083/jcb.129.6.1491; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LIU XD, 1995, GENE DEV, V9, P1766, DOI 10.1101/gad.9.14.1766; MEICHIOR F, 1995, J CELL BIOL, V131, P571; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAEL WM, 1995, CELL, V83, P415; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POKRYWKA NJ, 1995, J BIOL CHEM, V270, P3619, DOI 10.1074/jbc.270.8.3619; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TOROK I, 1995, J CELL BIOL, V129, P1473, DOI 10.1083/jcb.129.6.1473; VISA N, IN PRESS J CELL BIOL; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WARE VC, 1991, RIBOSOME STRUCTURE F; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WEIS K, IN PRESS EMBO J; WEIS K, UNPUB; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	94	1073	1104	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1996	271	5255					1513	1518		10.1126/science.271.5255.1513	http://dx.doi.org/10.1126/science.271.5255.1513			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599106	Green Submitted			2022-12-28	WOS:A1996TZ98300026
J	Pascher, T; Chesick, JP; Winkler, JR; Gray, HB				Pascher, T; Chesick, JP; Winkler, JR; Gray, HB			Protein folding triggered by electron transfer	SCIENCE			English	Article							THERMODYNAMICS; HYDRATION	Rapid photochemical electron injection into unfolded ferricytochrome c titrated with 2.3 to 4.6 M guanidine hydrochloride (GuHCl) at pH 7 and 40 degrees C produced unfolded ferrocytochrome, which then converted to the folded protein. Two folding phases were observed: a fast process with a time constant of 40 microseconds (4.6 M GuHCl), and a slower phase with a rate constant of 90 +/- 20 per second (2.3 M GuHCl). The activation free energy for the slow step varied linearly with GuHCl concentration; the rate constant, extrapolated to aqueous solution, was 7600 per second, Electron-transfer methods can bridge the nanosecond to millisecond measurement time gap for protein folding.	CALTECH, BECKMAN INST, PASADENA, CA 91125 USA; HAVERFORD COLL, HAVERFORD, PA 19041 USA	California Institute of Technology; Haverford College								BABUL J, 1971, BIOPOLYMERS, V10, P2359, DOI 10.1002/bip.360101125; BABUL J, 1972, BIOCHEMISTRY-US, V11, P1195, DOI 10.1021/bi00757a013; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; BALDWIN RL, 1994, BIOESSAYS, V16, P207, DOI 10.1002/bies.950160312; BALLEW RM, IN PRESS P NATL ACAD; BEALS JM, 1991, BIOCHEMISTRY-US, V30, P7680, DOI 10.1021/bi00245a004; BERTRAND P, 1995, BIOCHEMISTRY-US, V34, P11071, DOI 10.1021/bi00035a012; BIXLER J, 1992, J AM CHEM SOC, V114, P6938, DOI 10.1021/ja00043a062; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; CHEN BL, 1992, BIOCHEMISTRY-US, V31, P1464, DOI 10.1021/bi00120a025; CHEN LXQ, 1987, CHEM PHYS LETT, V139, P55, DOI 10.1016/0009-2614(87)80150-1; COHEN DS, 1995, J AM CHEM SOC, V117, P1675, DOI 10.1021/ja00111a001; ELOVE GA, 1994, BIOCHEMISTRY-US, V33, P6925, DOI 10.1021/bi00188a023; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.biophys.21.1.243; FERSHT AR, 1995, CURR OPIN STRUC BIOL, V5, P79, DOI 10.1016/0959-440X(95)80012-P; GUTIN AM, 1995, P NATL ACAD SCI USA, V92, P1282, DOI 10.1073/pnas.92.5.1282; JONES CM, 1993, P NATL ACAD SCI USA, V90, P11860, DOI 10.1073/pnas.90.24.11860; KARPLUS M, 1994, PROTEIN SCI, V3, P650; KUWAJIMA K, 1987, FEBS LETT, V221, P115, DOI 10.1016/0014-5793(87)80363-0; MAKHATADZE GI, 1993, J MOL BIOL, V232, P639, DOI 10.1006/jmbi.1993.1416; MCLENDON G, 1978, J BIOL CHEM, V253, P4004; NOTLING B, 1995, P NATL ACAD SCI USA, V92, P10668; ONUCHIC JN, 1995, P NATL ACAD SCI USA, V92, P3626, DOI 10.1073/pnas.92.8.3626; PHILLIPS CM, 1995, P NATL ACAD SCI USA, V92, P7292, DOI 10.1073/pnas.92.16.7292; PRIVALOV PL, 1993, J MOL BIOL, V232, P660, DOI 10.1006/jmbi.1993.1417; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; SANTUCCI R, 1988, J AM CHEM SOC, V110, P8536, DOI 10.1021/ja00233a035; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; Sutin N, 1978, ADV CHEM SER, V168, P1; TANIGUCHI VT, 1980, PURE APPL CHEM, V52, P2275, DOI 10.1351/pac198052102275; WOODRUFF WH, 1994, BIOPHYS J, V66, pA397; YEE EL, 1979, J AM CHEM SOC, V101, P1131, DOI 10.1021/ja00499a013	32	317	318	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1996	271	5255					1558	1560		10.1126/science.271.5255.1558	http://dx.doi.org/10.1126/science.271.5255.1558			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599112				2022-12-28	WOS:A1996TZ98300033
J	Thomas, T; Thomas, G; McLendon, C; Sutton, T; Mullan, M				Thomas, T; Thomas, G; McLendon, C; Sutton, T; Mullan, M			beta-Amyloid-mediated vasoactivity and vascular endothelial damage	NATURE			English	Article							ALZHEIMERS-DISEASE; PROTEIN	Deposits of beta-amyloid are apparent in ageing and Alzheimer's disease(1), but the role of this peptide in neurodegeneration is unclear(2). The free-radical theory of ageing may also account for Alzheimer-type degeneration and consequently links between free-radical generation and beta-amyloid have been sought(3). We demonstrate here that beta-amyloid interacts with endothelial cells on blood vessels to produce an excess of superoxide radicals, with attendant alterations in endothelial structure and function. The superoxide radical can scavenge endothelium-derived relaxing factor and produce potent oxidizing agents, which can cause lipid peroxidation and other degenerative changes(4). The alterations in vascular tone and endothelial damage are prevented by the oxygen-radical-scavenging enzyme superoxide dismutase. These observations suggest a normal vasoactive role for beta-amyloid as well as a mechanism by which beta-amyloid may play a role in vascular abnormalities and neurodegeneration mediated by free radicals.	UNIV S FLORIDA,COLL MED,DEPT PHYSIOL & BIOPHYS,TAMPA,FL 33613	State University System of Florida; University of South Florida	Thomas, T (corresponding author), UNIV S FLORIDA,ROSKAMP LABS,INST PSYCHIAT RES,TAMPA,FL 33613, USA.			Mullan, Michael/0000-0002-1473-7527				BUEE L, 1994, ACTA NEUROPATHOL, V87, P469; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; ETCHEBERRIGARAY R, 1994, SCIENCE, V264, P276, DOI 10.1126/science.8146663; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1992, JAP J PHARM S2, V58, P185; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MATTSON MP, 1995, NAT STRUCT BIOL, V2, P926, DOI 10.1038/nsb1195-926; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; PRICE DL, 1992, NEUROBIOL AGING, V13, P623, DOI 10.1016/0197-4580(92)90069-A; Scholz W, 1938, Z GESAMTE NEUROL PSY, V162, P694, DOI 10.1007/BF02890989; TOMIMOTO H, 1994, J CEREB BLOOD FLOW M, V14, P563; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	14	625	648	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					168	171		10.1038/380168a0	http://dx.doi.org/10.1038/380168a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600393				2022-12-28	WOS:A1996TZ97800054
J	Tallis, RC				Tallis, RC			Burying Freud	LANCET			English	Editorial Material											Tallis, RC (corresponding author), HOPE HOSP,DEPT GERIATR MED,SALFORD M6 8HD,LANCS,ENGLAND.							CHAPMAN AH, 1994, LANCET, V344, P1752, DOI 10.1016/S0140-6736(94)92892-4; CREWS F, 1994, NEW YORK REV BO 1201, P49; CREWS F, 1994, NEW YORK REV BO 1117, P54; ESTERSON A, 1993, SEDUCTIVE MIRAGE EXP, P254; Freud S., 1954, ORIGINS PSYCHOANALYS; FREYNMAN R, 1985, SURELY YOURE JOKING; Gellner E, 1985, PSYCHOANALYTIC MOVEM; GRUNBAUM A, 1984, F PSYCHOANALYSIS PHI; JONES E, 1953, S FREUD LIFE WORKS; MALCOLM J, 1985, FREUD ARCH; Malcolm Janet, 1982, PSYCHOANALYSIS IMPOS; Masson J. M., 1985, ASSAULT TRUTH; Medawar P.B., 1975, NEW YORK REV BO 0123, P17; ROUDINESCO E, 1993, J LACAN ESQUISSE UNE; SARTRE JP, 1957, BEING NOTHINGNESS, P557; TALLIS R, 1987, PN REV, V14, P23; TALLIS R, 1991, EXPLICIT ANIMAL; THORNTON EM, 1983, FREUD COCAINE FREUDI; Webster Richard., 1995, WHY FREUD WAS WRONG; Wilcocks Robert, 1994, MAELZELS CHESS PLAYE; STANDARD EDITION, V2, P279	21	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					669	671		10.1016/S0140-6736(96)91210-6	http://dx.doi.org/10.1016/S0140-6736(96)91210-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596386				2022-12-28	WOS:A1996TZ28500018
J	MacLennan, AH; Wilson, DH; Taylor, AW				MacLennan, AH; Wilson, DH; Taylor, AW			Prevalence and cost of alternative medicine in Australia	LANCET			English	Article								Background To determine the prevalence and cost of alternative medicines and alternative practitioner use in an Australian population. Methods We conducted a representative population survey of persons aged 15 or older living in South Australia, which required 3004 personal interviews, We assessed the rates of use and types of alternative medicine and therapists used by this population in 1993, and correlations with other demographic and medical variables. Findings The overall use of at least one non-medically prescribed alternative medicine (excluding calcium, iron and prescribed vitamins) was 48.5%. The users were more likely to be perimenopausal females, better educated, have a higher alcohol intake, be of normal weight and more likely to be employed than non-users, 20.3% of respondents had visited at least one alternative practitioner, most commonly chiropractors (15%). The users of alternative practitioners were more likely to be younger, live in the country and be overweight, Women were more likely to consult naturopaths, iridiologists, and reflexologists than men. Interpretation Extrapolation of the costs to the Australian population gives a natural expenditure in 1993, for alternative medicines, of $621 million (Australian dollars) and for alternative therapists of $AU309 million per annum. This compares to the $AU360 million of patient contributions for all classes of pharmaceutical drugs purchased in Australia in 1992/93, The public health and economic ramifications of these huge costs are questioned in view of the paucity of sound safety and efficacy data for many of the therapies and products of the alternative medicine industry.	S AUSTRALIAN HLTH COMMISS,PUBL & ENVIRONM HLTH SERV,ADELAIDE,SA,AUSTRALIA		MacLennan, AH (corresponding author), UNIV ADELAIDE,DEPT OBSTET & GYNAECOL,ADELAIDE,SA 5000,AUSTRALIA.		Taylor, Anne w/F-5708-2010	Taylor, Anne w/0000-0002-4422-7974				CHENOY R, 1994, BRIT MED J, V308, P501, DOI 10.1136/bmj.308.6927.501; CUI J, 1994, LANCET, V344, P134, DOI 10.1016/S0140-6736(94)91322-6; DESMET PAGM, 1995, BRIT MED J, V310, P1023, DOI 10.1136/bmj.310.6986.1023; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; ERNST E, 1993, LANCET, V341, P1626, DOI 10.1016/0140-6736(93)90763-7; KELLY JL, 1988, USING ASCO SOCIO EC; LLOYD P, 1993, AUST J PUBLIC HEALTH, V17, P135; LOHR SL, 1994, J QUANT CRIMINOL, V10, P343, DOI 10.1007/BF02221280; MOULDS RFW, 1988, MED J AUSTRALIA, V149, P572, DOI 10.5694/j.1326-5377.1988.tb120789.x; ONEILL A, 1994, SOC SCI MED, V38, P497, DOI 10.1016/0277-9536(94)90246-1; PERHARIC L, 1993, LANCET, V342, P180, DOI 10.1016/0140-6736(93)91389-4; STARK DJ, 1981, MED J AUSTRALIA, V2, P676, DOI 10.5694/j.1326-5377.1981.tb113049.x; SWAYNE JMD, 1989, J ROY COLL GEN PRACT, V39, P503; TORO T, 1992, NEW SCI, V1831, P10; WIESNER D, 1995, AUSTR DOCT       MAR, P44; 1994, AUSTR HLTH; 1990, 12220 AUSTR BUR STAT; 1986, INQUIRY ALTERNATIVE; 1990, 27100 AUSTR BUR STAT	19	664	672	0	29	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					569	573		10.1016/S0140-6736(96)91271-4	http://dx.doi.org/10.1016/S0140-6736(96)91271-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596318				2022-12-28	WOS:A1996TX69400009
J	Sikorski, J; Wilson, J; Clement, S; Das, S; Smeeton, N				Sikorski, J; Wilson, J; Clement, S; Das, S; Smeeton, N			A randomised controlled trial comparing two schedules of antenatal visits: The antenatal care project	BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY	Objective-To compare the clinical and psychosocial effectiveness of the traditional British antenatal visit schedule (traditional care) with a reduced schedule of visits (new style care) for low risk women, together with maternal and professional satisfaction with care. Design-Randomised controlled trial. Setting-Places in south east London providing antenatal care for women receiving shared care and planning to deliver in one of three hospitals or at home. Subjects-2794 women at low risk fulfilling the trial's inclusion criteria between June 1993 and July 1994. Main outcome measures-Measures of fetal and maternal morbidity, health service use, psychosocial outcomes, and maternal and professional satisfaction. Results-Pregnant women allocated to new style care had fewer day admissions (0.8 v 1.0; P=0.002) and ultrasound scans (1.6 v 1.7; P=0.003) and were less often suspected of carrying fetuses that were small for gestational age (odds ratio 0.73; 95% confidence interval 0.54 to 0.99). They also had some poorer psychosocial outcomes: for example, they were more worried about fetal wellbeing antenatally and coping with the baby postnatally, and they had more negative attitudes to their babies, both in pregnancy and postnatally. These women were also more dissatisfied with the number of visits they received (odds ratio 2.50; 2.00 to 3.11). Conclusions Patterns of antenatal care involving fewer routine visits for women at low risk may lead to reduced psychosocial effectiveness and dissatisfaction with frequency of visits. The number of antenatal day admissions and ultrasound scans performed may also be reduced. For the variables reported, the visit schedules studied are similar in their clinical effectiveness. Uncertainty remains as to the clinical effectiveness of reduced visit schedules for rare pregnancy problems.	UNITED MED & DENT SCH,GUYS HOSP,DEPT PUBL HLTH MED,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Sikorski, J (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,DEPT GEN PRACTICE,ANTENATAL CARE PROJECT,LONDON SE11 6SP,ENGLAND.		Clement, Sarah/E-9601-2010					BINSTOCK MA, 1995, J REPROD MED, V40, P507; BLONDEL B, 1985, BRIT J OBSTET GYNAEC, V92, P565, DOI 10.1111/j.1471-0528.1985.tb01393.x; *CDC, 1991, EP INF VERS 5 01; CHITTY LS, 1994, BRIT J OBSTET GYNAEC, V101, P125, DOI 10.1111/j.1471-0528.1994.tb13077.x; Cochran WG, 1957, EXPT DESIGNS; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; DAVEY DA, 1988, AM J OBSTET GYNECOL, V158, P892, DOI 10.1016/0002-9378(88)90090-7; Department of Health, 1993, CHANGING CHILDBIRTH; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; Fleiss JL, 1981, STAT METHODS RATES P; FRANCOME C, 1993, CAESAREAN BIRTH BRIT; GARDNER J, 1992, CONFIDENCE INTERVAL; GREEN JM, 1988, GREAT EXPECTATIONS P; HALL M, 1985, ANTENATAL CARE ASSES; HALL MH, 1980, LANCET, V2, P78; Kaminski M, 1988, Paediatr Perinat Epidemiol, V2, P13, DOI 10.1111/j.1365-3016.1988.tb00177.x; MARSH GN, 1985, BRIT MED J, V29, P646; MASON V, 1989, WOMENS EXPERIENCES M; Murray D, 1990, J REPROD INFANT PSYC, V8, P99, DOI DOI 10.1080/02646839008403615; PORTER M, 1984, SOC SCI MED, V19, P1197, DOI 10.1016/0277-9536(84)90370-8; READING AE, 1984, HEALTH PSYCHOL, V3, P211, DOI 10.1037/0278-6133.3.3.211; *ROYAL COLL OBST G, 1982, REP RCOG WORK PART A; SIKORSKI J, 1993, BRIT MED J, V307, P1064, DOI 10.1136/bmj.307.6911.1064; SIKORSKI J, 1995, MIDWIFERY, V11, P61, DOI 10.1016/0266-6138(95)90068-3; *SPSS INC, 1990, SPSS PC PLUS VERS 4; THOMAS P, 1991, SOC SCI MED, V32, P715, DOI 10.1016/0277-9536(91)90151-2; THORLEY K, 1993, BR J MIDWIFERY, V1, P216; WALLENBURG HCS, 1989, EFFECTIVE CARE PREGN, P382	28	135	137	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					546	553		10.1136/bmj.312.7030.546	http://dx.doi.org/10.1136/bmj.312.7030.546			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595286	Green Published			2022-12-28	WOS:A1996TY88500027
J	BenArush, M; Berant, M				BenArush, M; Berant, M			Lesson of the week - Retention of drugs in venous access port chamber: A note of caution	BRITISH MEDICAL JOURNAL			English	Article							CATHETERS; DEVICES; SYSTEM		TECHNION ISRAEL INST TECHNOL,RAMBAM MED CTR,IL-31096 HAIFA,ISRAEL; TECHNION ISRAEL INST TECHNOL,FAC MED,IL-31096 HAIFA,ISRAEL	Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine								BROVIAC JW, 1974, SURG GYNECOL OBSTET, V139, P24; DAWSON S, 1991, AM J PEDIAT HEMATOL, V13, P126; GROEGER JS, 1993, ANN INTERN MED, V119, P1168, DOI 10.7326/0003-4819-119-12-199312150-00003; HICKMAN RO, 1979, SURG GYNECOL OBSTET, V148, P871; STRUM S, 1986, J CLIN ONCOL, V4, P596, DOI 10.1200/JCO.1986.4.4.596; WURZEL CL, 1988, AM J DIS CHILD, V142, P536, DOI 10.1001/archpedi.1988.02150050074036	6	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					496	497		10.1136/bmj.312.7029.496	http://dx.doi.org/10.1136/bmj.312.7029.496			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597688	Green Published			2022-12-28	WOS:A1996TX38300034
J	Amakawa, R; Hakem, A; Kundig, TM; Matsuyama, T; Simard, JJL; Timms, E; Wakeham, A; Mittruecker, HW; Griesser, H; Takimoto, H; Schmits, R; Shahinian, A; Ohashi, PS; Penninger, JM; Mak, TW				Amakawa, R; Hakem, A; Kundig, TM; Matsuyama, T; Simard, JJL; Timms, E; Wakeham, A; Mittruecker, HW; Griesser, H; Takimoto, H; Schmits, R; Shahinian, A; Ohashi, PS; Penninger, JM; Mak, TW			Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice	CELL			English	Article							VESICULAR STOMATITIS-VIRUS; X-LINKED IMMUNODEFICIENCY; NECROSIS-FACTOR RECEPTOR; STERNBERG-REED CELLS; HYPER-IGM SYNDROME; KI-1 ANTIGEN; CD40 LIGAND; CD30 ANTIGEN; SELF-TOLERANCE; LYMPHOID-CELLS	CD30 is found on Reed-Sternberg cells of Hodgkin's disease and on a variety of non-Hodgkin's lymphoma cells and is up-regulated on cells after Epstein-Barr virus, human T cell leukemia virus, and HIV infections. We report here that the thymus in CD30-deficient mice contains elevated numbers of thymocytes. Activation-induced death of thymocytes after CD3 cross-linking is impaired both in vitro and in vivo. Breeding the CD30 mutation separately into alpha beta TCR- or gamma delta TCR-transgenic mice revealed a gross defect in negative but not positive selection. Thus, like TNF-receptors and Fas/Apo-1, the CD30 receptor is involved in cell death signaling. It is also an important coreceptor that participates in thymic deletion.	UNIV TORONTO, AMGEN INST, TORONTO, ON M5G 2C1, CANADA; UNIV TORONTO, ONTARIO CANC INST, DEPT MED BIOPHYS, TORONTO, ON M5G 2C1, CANADA; UNIV TORONTO, ONTARIO CANC INST, DEPT IMMUNOL, TORONTO, ON M5G 2C1, CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto			Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777; Ohashi, Pamela S./0000-0003-2915-9317				ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ALZONA M, 1994, J IMMUNOL, V153, P2861; ANDREESEN R, 1984, BLOOD, V63, P1299; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BACHMANN MF, 1994, CURR OPIN IMMUNOL, V6, P320, DOI 10.1016/0952-7915(94)90108-2; BINDER D, 1991, J IMMUNOL, V146, P4301; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; CALIGARISCAPPIO F, 1995, CLIN EXP RHEUMATOL, V13, P339; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DELPRETE G, 1995, FASEB J, V9, P81, DOI 10.1096/fasebj.9.1.7821763; DENT AL, 1990, NATURE, V343, P714, DOI 10.1038/343714a0; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ELLIS TM, 1993, J IMMUNOL, V151, P2380; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FONATSCH C, 1992, GENOMICS, V14, P825, DOI 10.1016/S0888-7543(05)80203-4; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FOY TM, 1995, J EXP MED, V182, P1377, DOI 10.1084/jem.182.5.1377; FROESE P, 1987, J IMMUNOL, V139, P2081; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GAUSE A, 1991, BLOOD, V77, P1983; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GRUSS HJ, 1994, BLOOD, V83, P2045; KEMPER O, 1991, HUM GENET, V87, P623; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KUNDIG TM, 1993, J VIROL, V67, P3680; KUNDIG TM, 1993, J IMMUNOL, V150, P4450; LATZA U, 1994, EUR J IMMUNOL, V24, P677, DOI 10.1002/eji.1830240329; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MAGGI E, 1994, J EXP MED, V180, P489, DOI 10.1084/jem.180.2.489; MANETTI R, 1994, J EXP MED, V180, P2407, DOI 10.1084/jem.180.6.2407; MCDONALD PP, 1995, EUR J IMMUNOL, V25, P2870, DOI 10.1002/eji.1830251024; MECHTERSHEIMER G, 1990, CANCER, V66, P1732, DOI 10.1002/1097-0142(19901015)66:8<1732::AID-CNCR2820660815>3.0.CO;2-5; Merkenschlager M, 1989, Int Immunol, V1, P450, DOI 10.1093/intimm/1.4.450; NAWROCKI JF, 1988, J IMMUNOL, V141, P672; PALLESEN G, 1990, HISTOPATHOLOGY, V16, P409, DOI 10.1111/j.1365-2559.1990.tb01151.x; PALLESEN G, 1988, AM J PATHOL, V133, P446; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PIRIS M, 1990, HISTOPATHOLOGY, V17, P211, DOI 10.1111/j.1365-2559.1990.tb00709.x; PIZZOLO G, 1990, BRIT J HAEMATOL, V75, P282, DOI 10.1111/j.1365-2141.1990.tb02664.x; PIZZOLO G, 1994, AIDS, V8, P741, DOI 10.1097/00002030-199406000-00003; PUDDINGTON L, 1986, J VIROL, V60, P708, DOI 10.1128/JVI.60.2.708-717.1986; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SCHUURMAN HJ, 1989, THYMUS, V14, P43; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SCHWARTING R, 1989, BLOOD, V74, P1678; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SHI YF, 1991, J IMMUNOL, V146, P3340; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SKEEN MJ, 1993, J EXP MED, V178, P971, DOI 10.1084/jem.178.3.971; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPRENT J, 1988, IMMUNOL REV, V101, P173, DOI 10.1111/j.1600-065X.1988.tb00737.x; SPRENT J, 1995, CURR OPIN IMMUNOL, V7, P196, DOI 10.1016/0952-7915(95)80004-2; STEIN H, 1982, INT J CANCER, V30, P445, DOI 10.1002/ijc.2910300411; STEIN H, 1985, BLOOD, V66, P848; SUCHI T, 1987, J CLIN PATHOL, V40, P995, DOI 10.1136/jcp.40.9.995; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TATSUMI Y, 1993, J IMMUNOL, V151, P3030; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WALLACE VA, 1992, J EXP MED, V176, P1657, DOI 10.1084/jem.176.6.1657; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	74	284	295	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 23	1996	84	4					551	562		10.1016/S0092-8674(00)81031-4	http://dx.doi.org/10.1016/S0092-8674(00)81031-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598042	Bronze			2022-12-28	WOS:A1996TX17600008
J	Leopold, DA; Logothetis, NK				Leopold, DA; Logothetis, NK			Activity changes in early visual cortex reflect monkeys' percepts during binocular rivalry	NATURE			English	Article								WHEN the two eyes view dissimilar images, we experience binocular rivalry, in which one eye's view dominates for several seconds and is then replaced by that of the other eye(1,2). What causes these perceptual changes in the absence of any change in the stimulus? We showed previously that some neurons in monkey cortical area MT show changes in activity during motion rivalry that reflect the perceived direction of motion(3). To determine whether perception-related modulation of activity occurs in other visual cortical areas, we recorded from individual neurons in V1, V2 and V4 while monkeys reported the perceived orientation of rival gratings of two orthogonal orientations. Many cells, particularly in V4, showed patterns of activity that correlated with the perceptual dominance and suppression of one stimulus. The majority were orientation-selective and could be driven equally well from either eye. It has been previously suggested that binocular rivalry involves reciprocal inhibition between monocular neurons within V1 (for example, see ref, 4), but our results do not support this view; rather, we propose that binocular rivalry arises through interactions between binocular neurons at several levels in the visual pathways, and that similar mechanisms may underlie other multistable perceptual states that occur when viewing ambiguous images.	BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine			Logothetis, Nikos/U-9282-2019	Leopold, David/0000-0002-1345-6360				BLAKE R, 1989, PSYCHOL REV, V96, P145, DOI 10.1037/0033-295X.96.1.145; BLAKE R, 1974, NATURE, V249, P488, DOI 10.1038/249488a0; BORSELLINO A, 1972, KYBERNETIK, V10, P139, DOI 10.1007/BF00290512; Breese BB., 1899, PSYCHOL REV-MONOGR S, V3, DOI [10.1037/h0092990, DOI 10.1037/H0092990]; CAMPBELL FW, 1972, J PHYSIOL-LONDON, V225, pP19; FOX R, 1967, PERCEPT PSYCHOPHYS, V2, P432, DOI 10.3758/BF03208783; Helmholtz H.von., 1924, PHYSL OPTICS; Levelt WJM, 1965, BINOCULAR RIVALRY; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; LOGOTHETIS NK, 1995, CURR BIOL, V5, P552, DOI 10.1016/S0960-9822(95)00108-4; WALKER P, 1975, PERCEPT PSYCHOPHYS, V18, P467, DOI 10.3758/BF03204122; WHITTLE P, 1968, PERCEPT PSYCHOPHYS, V4, P183, DOI 10.3758/BF03210465	12	646	652	2	61	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					549	553		10.1038/379549a0	http://dx.doi.org/10.1038/379549a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TU693	8596635				2022-12-28	WOS:A1996TU69300053
J	Majzoub, JA; Muglia, LJ				Majzoub, JA; Muglia, LJ			Molecular medicine - Knockout mice	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Majzoub, JA (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV ENDOCRINOL,BOSTON,MA 02115, USA.							CAPECCHI MR, 1994, SCI AM, V270, P52, DOI 10.1038/scientificamerican0394-52; MUGLIA L, 1995, NATURE, V373, P427, DOI 10.1038/373427a0; ROSENTHAL N, 1994, NEW ENGL J MED, V331, P315, DOI 10.1056/NEJM199408043310508; ROSENTHAL N, 1994, NEW ENGL J MED, V331, P931, DOI 10.1056/NEJM199410063311408	4	62	68	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	1996	334	14					904	907		10.1056/NEJM199604043341407	http://dx.doi.org/10.1056/NEJM199604043341407			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD374	8596575				2022-12-28	WOS:A1996UD37400007
J	McKee, M; Figueras, J				McKee, M; Figueras, J			For debate - Setting priorities: Can Britain learn from Sweden?	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE	The Swedish government recently published a report on priorities in health care. It was written by a cross party group of politicians and drew extensively on the views of the public, health professionals, experience of earlier local exercises in priority setting, and research based evidence. It laid down an ethical framework for approaching issues of health care rationing. Underpinning the framework are the principles of human dignity, need and solidarity, and cost efficiency. The Swedish approach thus contrasts with the British experience of many local initiatives but an absence of national political guidance. The absence of political consensus on many aspects of social policy in the United Kingdom is a major obstacle to developing an agreed ethical framework within which decision makers in the National Health Service can work.			McKee, M (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,HLTH SERV RES UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Mckee, Martin/E-6673-2018; McKee, Marc D/E-2187-2011; Embrett, Mark G./H-4466-2014	Mckee, Martin/0000-0002-0121-9683; McKee, Marc D/0000-0001-8349-965X; Embrett, Mark G./0000-0002-3969-0219				Abel-Smith Brian, 1995, CHOICES HLTH POLICY; BOTTOMLEY V, 1993, RATIONING ACTION, P25; BOWLING A, 1993, SOC SCI MED, V37, P851, DOI 10.1016/0277-9536(93)90138-T; CARRHILL RA, 1991, INT J HEALTH SERV, V21, P351, DOI 10.2190/HPLM-EGXV-BWKY-5XBN; CHADWICK R, 1993, RATIONING ACTION, P85; HAM C, 1993, RATIONING ACTION, P59; *HC HLTH COMM, 1995, PRIOR SETT NHS PURCH; HONIGSBAUM F, 1995, PRIORITY SETTING PRO; JENKINS S, 1995, ACCOUNTABLE NONE TOR; KLEIN R, 1991, BRIT MED J, V302, P1, DOI 10.1136/bmj.302.6767.1; *LAB PART, 1995, REN NHS LAB AG HLTH; MCKEE M, 1995, BRIT MED J, V310, P101, DOI 10.1136/bmj.310.6972.101; *MIN HLTH SOC AFF, 1993, NO EAS CHOIC DIFF PR, P93; *MIN HLTH WELF CUL, 1992, CHOIC HLTH CAR REP G; *NAT ADV COMM, 1992, COR SERV 1993 4; *ROYAL MIN HLTH SO, 1987, RETN PRIOR INN NORSK, P23; SMITH R, 1993, RATIONING ACTION, pR7; SMITH R, 1993, RATIONING ACTION; Swedish Parliamentary Priorities Commission, 1995, PRIOR HLTH CAR ETH E, P5; 1995, J COLLP HYSICIANS LO, V29, P379	20	28	30	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					691	694						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597740				2022-12-28	WOS:A1996UB11000033
J	Davis, AW; Roote, J; Morley, T; Sawamura, K; Herrmann, S; Ashburner, M				Davis, AW; Roote, J; Morley, T; Sawamura, K; Herrmann, S; Ashburner, M			Rescue of hybrid sterility in crosses between D-melanogaster and D-simulans	NATURE			English	Article							TRANSPOSABLE ELEMENT MARINER; DROSOPHILA-MELANOGASTER; SPECIES COMPLEX; LETHAL SYSTEMS; GENETIC-BASIS; SUBGROUP	The genetic analysis of reproductive isolation between species of Drosophila has now reached the resolution necessary(1,2) to start answering one of the fundamental questions of evolution: what is the genetic basis of species differences? (ref. 3). A. H. Sturtevant, one of the founders of Drosophila genetics, was fascinated by this question(4) and thought he had found a way to analyse it when he realized that 'Drosophila melanogaster' was actually two species: D. melanogaster and D. simulans(5). By passing genes between these two species he hoped to investigate their genetic differences directly. No doubt he was disappointed to find that the D. melanogaster/D. simulans hybridization resulted only in unisexual sterile hybrids(6), a disappointment appreciated all the more by modern evolutionary biologists. Seventy-five years after Sturtevant's description of D. melanogaster/D. simulans hybrid sterility, we have discovered a strain of D. simulans that produces fertile female hybrids in crosses with D. melanogaster. Our discovery promises to bring the enormous resolution of D. melanogaster genetics to the study of reproductive isolation and species differences.			Davis, AW (corresponding author), UNIV CAMBRIDGE,DEPT GENET,DOWNING ST,CAMBRIDGE CB2 3EH,ENGLAND.							ASHBURNER M, 1989, DROSOPHILA LABORATOR; CACCONE A, 1988, GENETICS, V118, P671; COYNE JA, 1983, EVOLUTION, V37, P1101, DOI 10.1111/j.1558-5646.1983.tb00225.x; COYNE JA, 1994, SCIENCE, V265, P1461, DOI 10.1126/science.8073292; Dobzhansky T., 1937; GARZA D, 1991, GENETICS, V128, P303; HEY J, 1993, MOL BIOL EVOL, V10, P804; HUTTER P, 1990, GENETICS, V124, P909; HUTTER P, 1987, NATURE, V327, P331, DOI 10.1038/327331a0; JEFFS PS, 1994, MOL BIOL EVOL, V11, P287; LEMEUNIER F, 1976, PROC R SOC SER B-BIO, V193, P275, DOI 10.1098/rspb.1976.0046; LEMEUNIER F, 1984, GENET BIOL DROSOPHIL, P147; MARUYAMA K, 1991, GENETICS, V128, P319; MULLER HJ, 1940, NATURE, V146, P1969; PEREZ DE, 1995, GENETICS, V140, P201; PONTECORVO G, 1943, P R SOC EDINB B, V61, P385; PROVINE WB, 1991, GENETICS, V129, P1; Sambrook J, 1989, MOL CLONING LABORATO; SAWAMURA K, 1993, GENETICA, V88, P175, DOI 10.1007/BF02424474; SAWAMURA K, 1993, GENETICS, V133, P307; SAWAMURA K, 1993, GENETICS, V133, P299; Sturtevant A. H., 1919, Psyche Boston, V26, DOI 10.1155/1919/97402; Sturtevant AH, 1920, GENETICS, V5, P488; WATANABE TK, 1979, JPN J GENET, V54, P325, DOI 10.1266/jjg.54.325; WU CI, 1994, ANNU REV GENET, V28, P283, DOI 10.1146/annurev.ge.28.120194.001435	25	78	79	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					157	159		10.1038/380157a0	http://dx.doi.org/10.1038/380157a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600389				2022-12-28	WOS:A1996TZ97800050
J	Zeng, HK; Qian, ZW; Myers, MP; Rosbash, M				Zeng, HK; Qian, ZW; Myers, MP; Rosbash, M			A light-entrainment mechanism for the Drosophila circadian clock	NATURE			English	Article							MESSENGER-RNA LEVELS; PERIOD; GENE; MELANOGASTER; MUTANTS; PRODUCT; PROTEIN	Biochemical studies indicate that the Drosophila timeless protein (Tim) is a stoichiometric partner of the period protein (Per) in fly head extracts. A Per-Tim heterodimeric complex explains the reciprocal autoregulation of the proteins on transcription. The complex is under clock control, and many circadian features of the Tim cycle resemble those of the Per cycle. However, Tim is rapidly degraded in the early morning or in response to light, releasing Per from the complex. The Per-Tim complex is a functional unit of the Drosophila circadian clock, and Tim degradation may be the initial response of the clock to light.	BRANDEIS UNIV,HOWARD HUGHES MED INST,NATL SCI FDN SCI,WALTHAM,MA 02254; BRANDEIS UNIV,TECHNOL CTR BIOL TIMING,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NATL SCI FDN SCI,NEW YORK,NY 10021; ROCKEFELLER UNIV,TECHNOL CTR BIOL TIMING,NEW YORK,NY 10021; ROCKEFELLER UNIV,GENET LAB,NEW YORK,NY 10021	Brandeis University; Howard Hughes Medical Institute; Brandeis University; Brandeis University; Howard Hughes Medical Institute; Rockefeller University; Rockefeller University; Rockefeller University								CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KAY SA, 1995, CELL, V83, P361, DOI 10.1016/0092-8674(95)90113-2; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LOROS J, 1995, NEUROSCIENCES, V7, P3; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PITTENDRIGH CS, 1976, MOL BASIS CIRCADIAN, P11; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; REPPERT SM, 1995, NEURON, V15, P983, DOI 10.1016/0896-6273(95)90086-1; ROSBASH M, 1995, CURR OPIN GENET DEV, V5, P662, DOI 10.1016/0959-437X(95)80037-9; RUTILA JE, 1992, J NEUROGENET, V8, P101, DOI 10.3109/01677069209084155; SAUNDERS DS, 1994, J INSECT PHYSIOL, V40, P957, DOI 10.1016/0022-1910(94)90134-1; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZERR DM, 1990, J NEUROSCI, V10, P2749; ZWIEBEL LJ, 1991, P NATL ACAD SCI USA, V88, P3882, DOI 10.1073/pnas.88.9.3882	34	390	396	1	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					129	135		10.1038/380129a0	http://dx.doi.org/10.1038/380129a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600384				2022-12-28	WOS:A1996TZ97800041
J	Hvass, U; Juliard, JM; Assayag, P; Laperche, T; Pansard, Y; Chatel, D				Hvass, U; Juliard, JM; Assayag, P; Laperche, T; Pansard, Y; Chatel, D			Tricuspid autograft for mitral-valve repair	LANCET			English	Article							REPLACEMENT	Background Transferring the posterior leaflet of the patient's own tricuspid Valve with its subvalvular apparatus to the mitral valve is a new technique that allows a conservative approach to mitral-valve repair. The technique is based on the knowledge that the tricuspid valve can be remodelled from tricuspid to bicuspid, with a very low risk of significant dysfunction. Methods We describe six patients (age range 20-70 years) with mitral insufficiency in whom we have used the technique. Findings All patients survived the operation and were in sinus rhythm. Transoesophageal echocardiography before discharge showed trivial or no regurgitation at the site of mitral repair. Before operation, all patients were in New York Heart Association class Ill-IV; at follow-up after 6-13 months all patients were in class I-II Interpretation Compared with using segments of mitral homografts in similar situations, the intraoperative availability of the tricuspid's viable natural chordae and valvular leaflet means that there are no immunological disadvantages to the procedure. With this new operation, the patient is his own tissue bank.	HOP BEAUJON, DEPT CARDIOL, CLICHY, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Hvass, U (corresponding author), HOP BICHAT, DEPT CARDIOL, F-75018 PARIS, FRANCE.		Assayag, Patrick/GPS-4910-2022	Assayag, Patrick/0000-0001-9406-4555				ACAR C, 1994, ANN THORAC SURG, V57, P746, DOI 10.1016/0003-4975(94)90582-7; CARPENTIER A, 1983, J THORAC CARDIOV SUR, V86, P323; CHAUVAUD S, 1991, J THORAC CARDIOV SUR, V102, P171; DAVID TE, 1991, J THORAC CARDIOV SUR, V101, P495; ELKINS RC, 1995, ANN THORAC SURG, V59, P269, DOI 10.1016/0003-4975(94)00974-C; Horskotte D, 1993, J Heart Valve Dis, V2, P150; HVASS U, 1986, ARCH MAL COEUR VAISS, V79, P103; KIRKLIN JW, 1993, CARDIAC SURG, P589; MATSUKI O, 1988, J THORAC CARDIOV SUR, V95, P705; OKADA Y, 1995, ANN THORAC SURG, V59, P658, DOI 10.1016/0003-4975(94)01008-0; 1967, LANCET, V2, P956	11	9	11	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	1996	347	9002					659	661		10.1016/S0140-6736(96)91206-4	http://dx.doi.org/10.1016/S0140-6736(96)91206-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596382				2022-12-28	WOS:A1996TZ28500014
J	McMillan, TJ				McMillan, TJ			Gene manipulation in radiotherapy	LANCET			English	Editorial Material											McMillan, TJ (corresponding author), UNIV LANCASTER,INST ENVIRONM & BIOL SCI,DIV BIOL SCI,LANCASTER LA1 4YQ,ENGLAND.							HALLAHAN DE, 1994, NATURE MED, V1, P85; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SURESH A, 1994, CANCER GENE THER, V1, P85; VILE RG, 1993, CANCER RES, V53, P962; WEISCHELBAUM RR, 1991, EUR J CANCER, V27, P405	6	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					632	632		10.1016/S0140-6736(96)91196-4	http://dx.doi.org/10.1016/S0140-6736(96)91196-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596372				2022-12-28	WOS:A1996TZ28500004
J	Banner, DW; DArcy, A; Chene, C; Winkler, FK; Guha, A; Konigsberg, WH; Nemerson, Y; Kirchhofer, D				Banner, DW; DArcy, A; Chene, C; Winkler, FK; Guha, A; Konigsberg, WH; Nemerson, Y; Kirchhofer, D			The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor	NATURE			English	Article							EGF-LIKE DOMAIN; HUMAN FACTOR-IX; ACTIVE-SITE; FACTOR-X; CALCIUM-BINDING; CA2+ ION; RESOLUTION; SURFACE; LOCALIZATION; FLUORESCENCE	Blood coagulation is initiated when tissue factor binds to coagulation factor VIIa to give an enzymatically active complex which then activates factors IX and X, leading too thrombin generation and clot formation. We have determined the crystal structure at 2.0-Angstrom resolution of active-site-inhibited factor VIIa complexed with the cleaved extracellular domain of tissue factor. In the complex, factor VIIa adopts an extended conformation. This structure provides a basis for understanding many molecular aspects of the initiation of coagulation.	CUNY MT SINAI SCH MED, DEPT MED, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA; YALE UNIV, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Yale University	Banner, DW (corresponding author), F HOFFMANN LA ROCHE & CO LTD, DIV PHARMA, GRENZACHERSTR 124, CH-4002 BASEL, SWITZERLAND.							BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1991, J BIOL CHEM, V266, P20085; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BJOERN S, 1991, J BIOL CHEM, V266, P11051; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLARKE BJ, 1992, FEBS LETT, V298, P206, DOI 10.1016/0014-5793(92)80058-O; DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FREEDMAN SJ, 1995, BIOCHEMISTRY-US, V34, P12126, DOI 10.1021/bi00038a005; GIBBS CS, 1994, BIOCHEMISTRY-US, V33, P14003, DOI 10.1021/bi00251a007; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KAZAMA Y, 1993, J BIOL CHEM, V268, P16231; KELLEY RF, 1995, BIOCHEMISTRY-US, V34, P10383, DOI 10.1021/bi00033a009; KIRCHHOFER D, 1995, PROTEINS, V22, P419, DOI 10.1002/prot.340220412; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARTIN DMA, 1995, FASEB J, V9, P852, DOI 10.1096/fasebj.9.10.7615155; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEMERSON Y, 1988, BLOOD, V71, P1; OBRIEN DP, 1994, BIOCHEMISTRY-US, V33, P14162, DOI 10.1021/bi00251a027; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PETERSEN LC, 1994, FEBS LETT, V347, P73, DOI 10.1016/0014-5793(94)00513-3; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; RUF W, 1995, BIOCHEMISTRY-US, V34, P6310, DOI 10.1021/bi00019a008; RUF W, 1994, BIOCHEMISTRY-US, V33, P1565, DOI 10.1021/bi00172a037; SABHARWAL AK, 1995, J BIOL CHEM, V270, P15523, DOI 10.1074/jbc.270.26.15523; SAKAI T, 1990, J BIOL CHEM, V265, P1890; SCHIODT J, 1992, FEBS LETT, V306, P265, DOI 10.1016/0014-5793(92)81014-D; SCHULLEK JR, 1994, J BIOL CHEM, V269, P19399; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; TUDDENHAM EGD, 1995, THROMB HAEMOSTASIS, V74, P313; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290	51	665	698	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1996	380	6569					41	46		10.1038/380041a0	http://dx.doi.org/10.1038/380041a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598903				2022-12-28	WOS:A1996TY87700048
J	Berger, SP; Hall, S; Mickalian, JD; Reid, MS; Crawford, CA; Delucchi, K; Carr, K; Hall, S				Berger, SP; Hall, S; Mickalian, JD; Reid, MS; Crawford, CA; Delucchi, K; Carr, K; Hall, S			Haloperidol antagonism of cue-elicited cocaine craving	LANCET			English	Article							NUCLEUS-ACCUMBENS; EXTRACELLULAR DOPAMINE; DEPENDENT PATIENTS; HOMOVANILLIC-ACID; ABSTINENCE; ABUSERS; PLASMA; BROMOCRIPTINE; REACTIVITY; ADDICTION	Background Studies of cocaine-dependent subjects have shown that re-exposure to environmental cues previously associated with cocaine use produces a strong conditioned response characterised by autonomic hyperarousal and increases in subjective measures of cocaine craving. Methods To evaluate the role of dopamine release by such cues, 20 cocaine-dependent inpatients were randomised in a single-dose, crossover, placebo-controlled design, to haloperidol (4 mg by mouth) and placebo. Plasma homovanillic acid (HVA, a dopamine metabolite), adrenocorticotropic hormone (ACTH), and cortisol were assayed before and after cue exposure, Craving and anxiety were measured before and after cues with visual analogue scales for desire to use cocaine now and for mood changes. Findings Cocaine cues significantly increased anxiety, ACTH, cortisol, and HVA. Increases in anxiety and craving resulting from cue exposure were significantly antagonised by pretreatment with haloperidol. Interpretation It has long been hypothesised that increases in extracellular concentrations of dopamine mediate the acute reinforcing effects of cocaine. Our data suggest that dopamine release may also mediate some of the conditioned responses to cocaine cues.	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; PACIFIC MED CTR,DEPT PSYCHIAT,SAN FRANCISCO,CA; VET AFFAIRS MED CTR,SAN FRANCISCO,CA 94121; UNIV CALIF LOS ANGELES,BRAIN RES INST,PROGRAM NEUROSCI,LOS ANGELES,CA	University of California System; University of California San Francisco; California Pacific Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Los Angeles			Crawford, cynthia/G-2603-2012	Carr, Kenneth/0000-0001-6567-6376; Crawford, Cynthia/0000-0001-8884-562X				AMIN F, 1992, SCHIZOPHRENIA BULL, V18, P123, DOI 10.1093/schbul/18.1.123; BREIER A, 1992, BIOL PSYCHIAT, V32, P880, DOI 10.1016/0006-3223(92)90177-2; CHANG WH, 1983, ACTA PHARMACOL TOX, V53, P275; Childress A R, 1993, NIDA Res Monogr, V137, P73; Childress A R, 1987, NIDA Res Monogr, V76, P137; CHILDRESS AR, 1986, BRIT J ADDICT, V81, P655; CRAWFORD CA, 1995, PSYCHOPHARMACOLOGY, V120, P392, DOI 10.1007/BF02245810; DACKIS CA, 1987, PSYCHIAT RES, V20, P261, DOI 10.1016/0165-1781(87)90086-2; FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538; FONTANA DJ, 1993, BRAIN RES, V629, P31, DOI 10.1016/0006-8993(93)90477-5; GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107; KALIVAS PW, 1990, SYNAPSE, V5, P48, DOI 10.1002/syn.890050104; KNOBLICH G, 1992, BIOL PSYCHIAT, V32, P96, DOI 10.1016/0006-3223(92)90146-Q; KRANZLER HR, 1992, BRIT J ADDICT, V87, P1537; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; LEYTON M, 1992, NEUROREPORT, V3, P1127, DOI 10.1097/00001756-199212000-00024; MARGOLIN A, 1991, ARCH GEN PSYCHIAT, V48, P87; MARTIN SD, 1989, BIOL PSYCHIAT, V26, P356, DOI 10.1016/0006-3223(89)90051-6; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; NICHOLSON WE, 1984, CLIN CHEM, V30, P259; OBRIEN CP, 1990, ADDICT BEHAV, V15, P355, DOI 10.1016/0306-4603(90)90045-Y; PARSONS LH, 1991, SYNAPSE, V9, P60, DOI 10.1002/syn.890090109; PLEIM ET, 1990, BRAIN RES, V524, P160, DOI 10.1016/0006-8993(90)90507-8; ROBBINS SJ, 1992, ADDICT BEHAV, V17, P491, DOI 10.1016/0306-4603(92)90009-K; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; SEEMAN P, 1994, TRENDS PHARMACOL SCI, V15, P264, DOI 10.1016/0165-6147(94)90323-9	26	155	155	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					504	508		10.1016/S0140-6736(96)91139-3	http://dx.doi.org/10.1016/S0140-6736(96)91139-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596268				2022-12-28	WOS:A1996TW69700010
J	Ammala, C; Moorhouse, A; Gribble, F; Ashfield, R; Proks, P; Smith, PA; Sakura, H; Coles, B; Ashcroft, SJH; Ashcroft, FM				Ammala, C; Moorhouse, A; Gribble, F; Ashfield, R; Proks, P; Smith, PA; Sakura, H; Coles, B; Ashcroft, SJH; Ashcroft, FM			Promiscuous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels	NATURE			English	Article							K+ CHANNEL; ATP	SULPHONYLUREAS are a class of drugs widely used to treat non-insulin-dependent diabetes mellitus. These drugs act by binding to a sulphonylurea receptor (SUR) in the pancreatic beta-cell membrane which inhibits an ATP-sensitive potassium (K-ATP) channel and thereby stimulates insulin secretion. There has been much debate as to whether SUR and the K-ATP channel are the same or separate proteins, whether SUR confers ATP-sensitivity on an ATP-insensitive pore-forming subunit, and whether sulphonylureas can also modulate other types of K-channel. We show here that SUR itself does not possess intrinsic channel activity but that it endows sulphonylurea sensitivity on several types of inwardly-rectifying K-channels. It does not necessarily confer ATP-sensitivity on these channels.	UNIV OXFORD,PHYSIOL LAB,OXFORD OX1 3PT,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN BIOCHEM,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford			Moorhouse, Andrew J/B-8526-2011	Moorhouse, Andrew J/0000-0001-7957-2498; Proks, Peter/0000-0001-6097-3646; Smith, Paul/0000-0002-8710-6830; Gribble, Fiona/0000-0002-4232-2898	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT SJH, 1992, BIOCHIM BIOPHYS ACTA, V1175, P45, DOI 10.1016/0167-4889(92)90008-Y; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; THOMAS PM, 1995, SCIENCE, V268, P425; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; TSUCHIYA K, 1992, P NATL ACAD SCI USA, V89, P6418, DOI 10.1073/pnas.89.14.6418; ZUNCKLER BJ, 1988, N-S ARCH PHARMACOL, V337, P225	14	152	158	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					545	548		10.1038/379545a0	http://dx.doi.org/10.1038/379545a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596634				2022-12-28	WOS:A1996TU69300052
J	Warner, KE; Fulton, GA; Nicolas, P; Grimes, DR				Warner, KE; Fulton, GA; Nicolas, P; Grimes, DR			Employment implications of declining tobacco product sales for the regional economies of the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To determine whether declines in tobacco product sales significantly reduce employment in the United States, as the tobacco industry claims. Design.-Computer simulation of the economies of the Southeast Tobacco region and 8 nontobacco regions of the United States, with domestic tobacco expenditures eliminated or reduced and the equivalent spending redistributed, according to consumers' normal spending patterns, We compared these results with baseline forecasts of the regional economies that include normal tobacco expenditures. Main Outcome Measure.-Number of jobs. Results.-Had there been no spending on tobacco products in the United States in 1993, the Southeast Tobacco region would have had 303 000 fewer jobs. Collectively, however, the 8 nontobacco regions would have gained enough employment to completely offset losses in the Southeast Tobacco region, with every nontobacco region gaining jobs. By the year 2000, the absence of tobacco spending would mean a loss of 222 000 jobs in the Southeast Tobacco region, but a gain of 355 000 throughout the rest of the country. In the more realistic scenario of doubling the downward trend in tobacco consumption, the Southeast Tobacco region would lose 6300 jobs in 1993 (0.03% of regional employment) and 36 600 jobs by 2000 (0.2%). The 8 nontobacco regions would gain 6400 jobs in 1993 and 56 300 jobs in 2000, with each of the nontobacco regions gaining employment in every year. Conclusions.-Contrary to the tobacco industry's claims, reductions in spending on tobacco products will boost employment in every one of the 8 nontobacco regions and will not diminish employment in the Southeast Tobacco region by as much as the industry estimates. The primary concern about tobacco should be the enormity of its toll on health and not its impact on employment.	UNIV MICHIGAN,INST LABOR & IND RELAT,ANN ARBOR,MI; UNIV MICHIGAN,DEPT ECON,ANN ARBOR,MI	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Warner, KE (corresponding author), UNIV MICHIGAN,SCH PUBL HLTH,DEPT HLTH MANAGEMENT & POLICY,109 S OBSERV,ANN ARBOR,MI 48109, USA.			Warner, Kenneth/0000-0002-8214-1776				ALLEN RC, 1993, FALSE DILEMMA IMPACT; Bartlett J. C., 1994, Morbidity and Mortality Weekly Report, V43, P469; Buck D, 1995, TOBACCO AND JOBS; HODGSON TA, 1992, MILBANK Q, V70, P81, DOI 10.2307/3350086; KOOP CE, 1984, JM JON LECT ANN M AM; SCHELLING TC, 1986, PREV MED, V15, P549, DOI 10.1016/0091-7435(86)90030-7; *TOB I, 1995, TAX BURD TOB HIST CO, V29; *TOB MERCH ASS, 1995, TOB CONTR NAT EC; Treyz G. I., 1993, REGIONAL EC MODELING; TREYZ GI, 1992, INT REGIONAL SCI REV, V14, P221, DOI 10.1177/016001769201400301; *U MI, 1994, EC OUTL 1995; *U PA, 1979, STUD TOB IND EC CONT; *US BUR CENS, 1992, GEOGR AR SER 1992 CE; *US BUR EC AN, 1995, STAT PERS INC 1929 9; *US BUR LAB STAT, 1993, AM WORKF 1992 2005; WARNER KE, 1994, JAMA-J AM MED ASSOC, V271, P771, DOI 10.1001/jama.271.10.771; WARNER KE, 1987, JAMA-J AM MED ASSOC, V258, P2080, DOI 10.1001/jama.258.15.2080; 1986, ROCHESTER CITY  1016, V1, P6; 1985, EC IMPACT TOBACCO IN, V1, pV3; 1990, EC IMPACT TOBACCO IN; 1992, EC IMPACT TOBACCO IN; 1993, MON LABOR REV, V11, P3	22	38	40	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1241	1246		10.1001/jama.275.16.1241	http://dx.doi.org/10.1001/jama.275.16.1241			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF478	8601955				2022-12-28	WOS:A1996UF47800027
J	Sancar, A				Sancar, A			No ''end of history'' for photolyases	SCIENCE			English	Editorial Material							REPAIR; ENZYME; GENE				Sancar, A (corresponding author), UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.							AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; BATSCHAUER A, 1993, PLANT J, V4, P705, DOI 10.1046/j.1365-313X.1993.04040705.x; BEGLEY TP, 1994, ACCOUNTS CHEM RES, V27, P394, DOI 10.1021/ar00048a002; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; Fukuyama F., 1992, END HIST LAST MAN, P418; HEARST JE, 1995, SCIENCE, V268, P1858, DOI 10.1126/science.7604259; HEELIS PF, 1995, CHEM SOC REV, P289; KATO T, 1994, NUCLEIC ACIDS RES, V22, P4119, DOI 10.1093/nar/22.20.4119; KIM ST, 1994, J BIOL CHEM, V269, P8535; Kim ST, 1996, PHOTOCHEM PHOTOBIOL, V63, P292, DOI 10.1111/j.1751-1097.1996.tb03028.x; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PRAKASH G, 1995, J AM CHEM SOC, V117, P11375, DOI 10.1021/ja00150a050; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; TAYLOR JS, 1995, PURE APPL CHEM, V67, P183, DOI 10.1351/pac199567010183; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; TODO T, 1993, NATURE, V361, P371, DOI 10.1038/361371a0; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x	20	94	95	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					48	49		10.1126/science.272.5258.48	http://dx.doi.org/10.1126/science.272.5258.48			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600535				2022-12-28	WOS:A1996UD59700034
J	Hengst, L; Reed, SI				Hengst, L; Reed, SI			Translational control of p27(Kip1) accumulation during the cell cycle	SCIENCE			English	Article							KINASES; TUMOR	Cell cycle phase transitions in eukaryotic cells are driven by regulation of the activity of protein kinases known as cyclin-dependent kinases (Cdks). A broad spectrum Cdk-inhibitory activity associated with a 28-kilodalton protein (p28(lck1)) was induced in cells treated with the drug lovastatin or upon density-mediated growth arrest and was periodic in the cell cycle, with peak activity in G(1). The p28(lck1) protein was shown to be identical to p27(Kip1), and the periodic or induced inhibitory activity resulted from a periodic accumulation of the protein. Variations in the amount of p27 protein occurred, whereas the abundance of the p27 messenger RNA remained unchanged. In every instance investigated, the posttranscriptional alteration of p27 protein levels was achieved in part by a mechanism of translational control, although in density-arrested fibroblasts and thymidine-arrested HeLa cells the half-life of the protein was also changed.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				Hengst, Ludger/0000-0002-0605-0223	NIGMS NIH HHS [GM46006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM046006] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUNCE CM, 1994, LEUKEMIA, V8, P595; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1994, MOL CELL BIOL, V14, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HENGST L, UNPUB; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MATRSUOKA S, 1995, GENE DEV, V9, P650; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	28	814	840	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1861	1864		10.1126/science.271.5257.1861	http://dx.doi.org/10.1126/science.271.5257.1861			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596954				2022-12-28	WOS:A1996UC77800045
J	Cane, EJ; Portmann, BC; Naoumov, NV; Smith, HM; Underhill, JA; Donaldson, PT; Maertens, G; Williams, R				Cane, EJ; Portmann, BC; Naoumov, NV; Smith, HM; Underhill, JA; Donaldson, PT; Maertens, G; Williams, R			Long-term outcome of hepatitis C infection after liver transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; NON-A; VIRUS	Background. End-stage cirrhosis related to hepatitis C virus (HCV) is a common reason for liver transplantation, although viremia is known to persist in most cases. We investigated the impact of persistent HCV infection after liver transplantation on patient and graft survival and the effects of the HCV genotype and the degree of HLA matching between donor and recipient on the severity of recurrent hepatitis. Methods. A group of 149 patients with HCV infection who received liver transplants between January 1982 and April 1994 were followed for a median of 36 months; 623 patients without HCV infection who underwent liver transplantation for end-stage chronic liver disease were used as a control group, A total of 528 liver-biopsy specimens from the HCV-infected recipients were reviewed, including 82 obtained one year after transplantation as scheduled and 39 obtained at five years as scheduled. In addition, biopsy specimens were obtained from 91 of the HCV-negative patients five years after transplantation. Results. Cumulative survival rates for the 149 patients with HCV infection were 79 percent after one year, 74 percent after three years, and 70 percent after five years, as compared with rates of 75 percent, 71 percent, and 69 percent, respectively, in the HCV-negative transplant recipients (P = 0.12). Of the 130 patients with hepatitis C infection who survived more than 6 months after transplantation, 15 (12 percent) had no evidence of chronic hepatitis on their most recent liver biopsy (median followup, 20 months), 70 (54 percent) had mild chronic hepatitis (median, 35 months), 35 (27 percent) had moderate chronic hepatitis (median, 35 months), and 10 (8 percent) had cirrhosis (median, 51 months). Graft loss occurred after a median of 303 days in 27 of the 149 patients, including 5 with HCV-related cirrhosis and 3 with HCV-related cholestatic hepatitis. Infection with HCV genotype Ib was associated with more severe graft injury, whereas the primary immunosuppressive regimen used and the extent of HLA mismatching between donors and recipients had no significant effect on this variable. Conclusions. After liver transplantation for HCV-related cirrhosis, persistent HCV infection can cause severe graft damage, and such damage is more frequent in patients infected with HCV genotype 1b than with other genotypes. After five years, the rates of graft and overall survival are similar between patients with and those without HCV infection. (C) 1996, Massachusetts Medical Society.	UNIV LONDON KINGS COLL, SCH MED & DENT, INST LIVER STUDIES, LONDON SE5 9PJ, ENGLAND; IMMUNOGENET, GHENT, BELGIUM	University of London; King's College London			Yang, Chen/G-1379-2010					ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; [Anonymous], 1994, Lancet, V344, P423; Armitage P., 2001, STAT METHODS MED RES; ASCHER NL, 1994, HEPATOLOGY, V20, pS24; BALLARDINI G, 1995, J CLIN INVEST, V95, P2067, DOI 10.1172/JCI117893; BOTARELLI P, 1993, GASTROENTEROLOGY, V104, P580, DOI 10.1016/0016-5085(93)90430-K; BUSUTTIL RW, 1994, NEW ENGL J MED, V331, P1110; CASAVILLA A, 1994, HEPATOLOGY, V20, pA133; CHAZOUILLERES O, 1994, GASTROENTEROLOGY, V106, P994, DOI 10.1016/0016-5085(94)90759-5; Cox D. R., 1984, ANAL SURVIVAL DATA; DAVIES SE, 1991, HEPATOLOGY, V13, P150, DOI 10.1002/hep.1840130122; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; DONALDSON P, 1993, HEPATOLOGY, V17, P1008, DOI 10.1002/hep.1840170611; DUSHEIKO G, 1994, HEPATOLOGY, V19, P13, DOI 10.1016/0270-9139(94)90046-9; FERAY C, 1995, GASTROENTEROLOGY, V108, P1088, DOI 10.1016/0016-5085(95)90207-4; FERAY C, 1994, HEPATOLOGY, V20, P1137, DOI 10.1016/0270-9139(94)90748-X; FERRARI C, 1994, HEPATOLOGY, V19, P286; Gane EJ, 1996, GASTROENTEROLOGY, V110, P167, DOI 10.1053/gast.1996.v110.pm8536853; GRETCH D, 1993, HEPATOLOGY, V18, pA108, DOI 10.1016/0270-9139(93)91960-Z; IZOPET J, 1994, HEPATOLOGY, V20, pA241; KONIG V, 1992, HEPATOLOGY, V16, P1137, DOI 10.1016/0270-9139(92)90005-T; KOZIEL MJ, 1993, J VIROL, V67, P7522, DOI 10.1128/JVI.67.12.7522-7532.1993; LIM HL, 1994, GASTROENTEROLOGY, V106, P248, DOI 10.1016/S0016-5085(94)95829-7; MAGRIN S, 1994, HEPATOLOGY, V19, P273; MCHUTCHISON G, 1993, HEPATOLOGY, V18, pA87; MONDELLI M, 1986, CLIN EXP IMMUNOL, V63, P147; NAGAYAMA R, 1993, J CLIN INVEST, V92, P1529, DOI 10.1172/JCI116731; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; POZZATO G, 1994, J MED VIROL, V43, P291, DOI 10.1002/jmv.1890430318; QU D, 1994, J HEPATOL, V21, P70, DOI 10.1016/S0168-8278(94)80139-8; Rosen H. R., 1995, Hepatology, V22, p132A; SCHLUGER LK, 1994, GASTROENTEROLOGY, V106, pA978; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SHAH GJ, 1992, GASTROENTEROLOGY, V103, P323, DOI 10.1016/0016-5085(92)91130-V; SHEINER PA, 1995, HEPATOLOGY, V21, P30, DOI 10.1016/0270-9139(95)90404-2; TANAKA T, 1994, HEPATOLOGY, V19, P1347, DOI 10.1016/0270-9139(94)90226-7; TERASAKI PI, 1974, DHEW NIH75545 PUBL, P67; TILSTON P, 1994, LANCET, V344, P201, DOI 10.1016/S0140-6736(94)92809-6; VANDOORN LJ, 1994, J HEPATOL, V21, P122, DOI 10.1016/S0168-8278(94)80148-7; WEINSTEIN JS, 1994, HEPATOLOGY, V20, pA133; WILLEMS M, 1994, J MED VIROL, V44, P266, DOI 10.1002/jmv.1890440310; WRIGHT TL, 1992, GASTROENTEROLOGY, V103, P317, DOI 10.1016/0016-5085(92)91129-R; YUKI N, 1995, J HEPATOL, V22, P457, DOI 10.1016/0168-8278(95)80109-X; ZHOU S, 1994, HEPATOLOGY, V20, pA134	45	775	781	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1996	334	13					815	820		10.1056/NEJM199603283341302	http://dx.doi.org/10.1056/NEJM199603283341302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB950	8596547	Bronze			2022-12-28	WOS:A1996UB95000002
J	Xie, XL; Kokubo, T; Cohen, SL; Mirza, UA; Hoffmann, A; Chait, BT; Roeder, RG; Nakatani, Y; Burley, SK				Xie, XL; Kokubo, T; Cohen, SL; Mirza, UA; Hoffmann, A; Chait, BT; Roeder, RG; Nakatani, Y; Burley, SK			Structural similarity between TAFs and the heterotetrameric core of the histone octamer	NATURE			English	Article							TRANSCRIPTION FACTOR; PREINITIATION COMPLEX; CRYSTAL-STRUCTURE; NUCLEOSOME; RESOLUTION; INITIATION; INTERACTS; DOMAIN; DNA	A complex of two TFIID TATA hox-binding protein-associated factors (TAF(II)s) is described at 2.0 Angstrom resolution. The amino-terminal portions of dTAF(II)42 and dTAF(II)62 from Drosophila adopt the canonical histone fold, consisting of two short alpha-helices flanking a long central alpha-helix. Like histones H3 and H4, dTAF(II)42 and dTAF(II)62 form an intimate heterodimer by extensive hydrophobic contacts between the paired molecules. In solution and in the crystalline state, the dTAF(II)42/dTAF(II)62 complex exists as a heterotetramer, resembling the (H3/H4), heterotetrameric core of the histone octamer, suggesting that TFIID contains a histone octamer-like substructure.	ROCKEFELLER UNIV,LAB MOLEC BIOPHYS,NEW YORK,NY 10021; ROCKEFELLER UNIV,MASS SPECTROMETRY & GASEOUS ION CHEM LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; NICHHD,NIH,BETHESDA,MD 20892	Rockefeller University; Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Burley, Stephen K./0000-0002-2487-9713				ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Brunger AT, 1992, XPLOR VERSION 3 1 MA; BURLEY SK, IN PRESS A REV BIOCH, V65; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; DARCY A, 1994, ACTA CRYSTALLOGR D, V50, P469, DOI 10.1107/S0907444993014362; FERREDAMARE AR, 1994, STRUCTURE, V2, P357, DOI 10.1016/S0969-2126(00)00037-X; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JANIN J, 1995, PROTEINS, V21, P30, DOI 10.1002/prot.340210105; KARANTZA V, IN PRESS BIOCHEMISTR, V35; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KLUG A, 1980, NATURE, V287, P509, DOI 10.1038/287509a0; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LATTMAN E, 1982, SCIENCE, V216, P1016, DOI 10.1126/science.7079748; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	50	226	231	2	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					316	322		10.1038/380316a0	http://dx.doi.org/10.1038/380316a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598927				2022-12-28	WOS:A1996UC37900050
J	Deng, CX; WynshawBoris, A; Zhou, F; Kuo, A; Leder, P				Deng, CX; WynshawBoris, A; Zhou, F; Kuo, A; Leder, P			Fibroblast growth factor receptor 3 is a negative regulator of bone growth	CELL			English	Article							EXPRESSION PATTERN; MOUSE; FAMILY; MUTATION; PROTEINS; ORGANOGENESIS; DISRUPTION; CARTILAGE; ONCOGENE; MEMBER	Endochondral ossification is a major mode of bone formation that occurs as chondrocytes undergo proliferation, hypertrophy, cell death, and osteoblastic replacement. We have identified a role for fibroblast growth factor receptor 3 (FGFR-3) in this process by disrupting the murine Fgfr-3 gene to produce severe and progressive bone dysplasia with enhanced and prolonged endochondral bone growth. This growth is accompanied by expansion of proliferating and hypertrophic chondrocytes within the cartilaginous growth plate. Thus, FGFR-3 appears to regulate endochondral ossification by an essentially negative mechanism, limiting rather than promoting osteogenesis. In light of these mouse results, certain human disorders, such as achondroplasia, can be interpreted as gain-of-function mutations that activate the fundamentally negative growth control exerted by the FGFR-3 kinase.	HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT GENET, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute			deng, chuxia/N-6713-2016		NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001393] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC01393] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHITAYAT D, 1995, AM J MED GENET, V55, P147, DOI 10.1002/ajmg.1320550203; DENG CX, 1992, MOL CELL BIOL, V12, P3365, DOI 10.1128/MCB.12.8.3365; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; GILBERT SF, 1994, DEV BIOL; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; LONGO N, 1993, P NATL ACAD SCI USA, V90, P60, DOI 10.1073/pnas.90.1.60; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MCKUSICK VA, 1973, J MED GENET, V10, P11, DOI 10.1136/jmg.10.1.11; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; NILSSON A, 1986, SCIENCE, V233, P571, DOI 10.1126/science.3523759; OBERKLAID F, 1979, J MED GENET, V16, P140, DOI 10.1136/jmg.16.2.140; ORIOLI I, 1979, J MED GENET, V23, P328; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; PETERS KG, 1992, DEVELOPMENT, V114, P233; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; ROUSSEAU F, 1995, NAT GENET, V10, P11, DOI 10.1038/ng0595-11; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; STARK KL, 1991, DEVELOPMENT, V113, P641; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693	43	852	885	1	55	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1996	84	6					911	921		10.1016/S0092-8674(00)81069-7	http://dx.doi.org/10.1016/S0092-8674(00)81069-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601314	Bronze			2022-12-28	WOS:A1996UC38100012
J	Muslin, AJ; Tanner, JW; Allen, PM; Shaw, AS				Muslin, AJ; Tanner, JW; Allen, PM; Shaw, AS			Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine	CELL			English	Article							BIOSPECIFIC INTERACTION ANALYSIS; SURFACE-PLASMON RESONANCE; KINASE-C; PHOSPHORYLATION; TYROSINE; RAF-1; IDENTIFICATION; PURIFICATION; MATURATION; TECHNOLOGY	The highly conserved and ubiquitously expressed 14-3-3 family of proteins bind to a variety of proteins involved in signal transduction and cell cycle regulation. The nature and specificity of 14-3-3 binding is, however, not known. Here we show that 14-3-3 is a specific phosphoserine-binding protein. Using a panel of phosphorylated peptides based on Raf-1, we have defined the 14-3-3 binding motif and show that most of the known 14-3-3 binding proteins contain the motif. Peptides containing the motif could disrupt 14-3-3 complexes and inhibit maturation of Xenopus laevis oocytes. These results suggest that the interactions of 14-3-3 with signaling proteins are critical for the activation of signaling proteins. Our findings also suggest novel roles for serine/threonine phosphorylation in the assembly of protein-protein complexes.	WASHINGTON UNIV, SCH MED, DEPT PHYSIOL & CELL BIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, CTR IMMUNOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Muslin, AJ (corresponding author), WASHINGTON UNIV, JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,DIV CARDIOL, 216 S KINGSHIGHWAY BLVD, ST LOUIS, MO 63110 USA.			Shaw, Andrey/0000-0001-5685-0272	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034094] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-34094] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; JONSSON U, 1993, ANN BIOL CLIN-PARIS, V51, P19; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LORENZ RG, 1989, J EXP MED, V170, P203, DOI 10.1084/jem.170.1.203; MACNICOL AM, 1995, MOL CELL BIOL, V15, P6686; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; TANJI M, 1994, J NEUROCHEM, V63, P1908; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723	44	1183	1221	1	53	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1996	84	6					889	897		10.1016/S0092-8674(00)81067-3	http://dx.doi.org/10.1016/S0092-8674(00)81067-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601312	Bronze			2022-12-28	WOS:A1996UC38100010
J	OHare, JP; Hopper, A; Madhaven, C; Charny, M; Purewal, TS; Harney, B; Griffiths, J				OHare, JP; Hopper, A; Madhaven, C; Charny, M; Purewal, TS; Harney, B; Griffiths, J			Adding retinal photography to screening for diabetic retinopathy: A prospective study in primary care	BRITISH MEDICAL JOURNAL			English	Article							NONMYDRIATIC FUNDUS PHOTOGRAPHY; OPHTHALMOSCOPY	Objective-To evaluate whether adding retinal photography improved community screening for diabetic retinopathy. Setting-Mobile screening unit at rural and urban general practices in south west England. Subjects-1010 diabetic patients from primary care. Design-Prospective study; patients were examined by ophthalmoscopy by general practitioners or opticians without fundal photographs and again with photographs, and assessments were compared to those of an ophthalmologist. Main outcome measures-Whether fundal photography improved the sensitivity of detection of retinopathy and referrable diabetic retinopathy, and whether this sensitivity could be improved by including a review of the films by the specialist. Results-Diabetic retinopathy was detected by the ophthalmologist in 205 patients (20.5%) and referrable retinopathy in 49 (4.9%). The sensitivity of the general practitioners and opticians for referrable retinopathy with ophthalmoscopy was 65% and improved to 84% with retinal photographs. General practitioners' sensitivity in detecting background retinopathy improved with photographs from 22% to 65%; opticians' sensitivity in detecting background retinopathy improved from 43% to 71%. The sensitivity of detecting referrable retinopathy by general practitioners improved from 56% to 80% with photographs; for opticians it improved from 75% to 88%. Conclusion-Combining modalities of screening by providing photography with specialist review of all films in addition to direct ophthalmoscopy through dilated pupils improves assessment and referral for diabetic retinopathy by general practitioners and opticians. With further training and experience, primary care screeners should be able to achieve a sensitivity that will achieve an effective, acceptable, and economical community based screening programme for this condition.	ROYAL UNITED HOSP,DEPT OPHTHALMOL,BATH BA1 3NG,AVON,ENGLAND; WILTSHIRE & BATH HLTH COMMISS,DEVIZES SN10 5EQ,WILTS,ENGLAND		OHare, JP (corresponding author), ROYAL UNITED HOSP,DEPT MED,COMBE PK,BATH BA1 3NG,AVON,ENGLAND.							[Anonymous], 1981, OPHTHALMOLOGY, V88, P583; BUXTON MJ, 1991, DIABETIC MED, V8, P371, DOI 10.1111/j.1464-5491.1991.tb01612.x; CLARK JB, 1994, BRIT J OPHTHALMOL, V78, P741, DOI 10.1136/bjo.78.10.741; FINLAY R, 1991, HLTH TRENDS, V23, P104; Government Statistical Service, 1988, CAUS BLINDN PART SIG; GREY RHB, 1989, BRIT J OPHTHALMOL, V73, P88, DOI 10.1136/bjo.73.2.88; KLEIN R, 1985, OPHTHALMOLOGY, V92, P485; LEE VS, 1993, OPHTHALMOLOGY, V100, P1504; LEESE GP, 1992, DIABETIC MED, V9, P459, DOI 10.1111/j.1464-5491.1992.tb01817.x; MOLLENTZE WF, 1990, S AFR MED J, V78, P248; OWENS DR, 1991, DIABETIC MED, V8, pS4, DOI 10.1111/j.1464-5491.1991.tb02148.x; ROHAN T, 1989, BRIT MED J, V289, P1192; RYDER REJ, 1995, BRIT MED J, V331, P207; RYDER REJ, 1994, DIABETIC MED S2, V11, pS44; TAYLOR R, 1990, BRIT MED J, V301, P1243, DOI 10.1136/bmj.301.6763.1243; WAREHAM N, 1991, DIABETIC MED, V8, P607, DOI 10.1111/j.1464-5491.1991.tb01665.x; WHO/IDF Europe, 1990, DIABETIC MED, V7, P360; 1983, DIABETES, V32, P1010; 1993, NEW ENGL J MED, V329, P977	19	45	45	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					679	682						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597737				2022-12-28	WOS:A1996UB11000029
J	Vallee, RB; Sheetz, MP				Vallee, RB; Sheetz, MP			Targeting of motor proteins	SCIENCE			English	Review							MICROTUBULE-ASSOCIATED PROTEIN; BETA-HEAVY CHAIN; OUTER ARM DYNEIN; CYTOPLASMIC DYNEIN; AXONAL-TRANSPORT; MOLECULAR MOTORS; RETROGRADE TRANSPORT; ENDOCYTIC VESICLES; INTERMEDIATE CHAIN; FLAGELLAR DYNEIN	Microtubules are responsible for chromosome segregation and the movement and reorganization of membranous organelles. Many aspects of microtubule-based motility can be attributed to the action of motor proteins, producing force directed toward either end of microtubules. How these proteins are targeted to the appropriate organellar sites within the cell, however, has remained a mystery. Recent work has begun to define the targeting mechanism for two well-studied motor proteins, kinesin and cytoplasmic dynein.	DUKE UNIV,DEPT CELL BIOL,DURHAM,NC 27710	Duke University	Vallee, RB (corresponding author), WORCESTER FDN BIOMED RES,222 MAPLE AVE,SHREWSBURY,MA 01545, USA.							ALLAN V, 1995, J CELL BIOL, V128, P879, DOI 10.1083/jcb.128.5.879; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; Beck K. A., 1994, Molecular Biology of the Cell, V5, p240A; BECK KA, 1994, J CELL BIOL, V127, P707, DOI 10.1083/jcb.127.3.707; BERLIN V, 1990, J CELL BIOL, V111, P2573, DOI 10.1083/jcb.111.6.2573; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; Burkhardt J. K., 1995, Molecular Biology of the Cell, V6, p266A; CLARK SW, 1992, NATURE, V359, P246, DOI 10.1038/359246a0; CLARK SW, 1994, J CELL BIOL, V127, P129, DOI 10.1083/jcb.127.1.129; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Collins C. A., 1995, Molecular Biology of the Cell, V6, p265A; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; CORTHESYTHEULAZ I, 1992, J CELL BIOL, V118, P1333, DOI 10.1083/jcb.118.6.1333; DABORA SL, 1988, CELL, V54, P24; DEMEY J, COMMUNICATION; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; ENDOW SA, 1992, ANNU REV CELL BIOL, V8, P29; ENDOW SA, 1993, TRENDS GENET, V9, P52, DOI 10.1016/0168-9525(93)90187-M; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; FATH KR, 1994, J CELL BIOL, V126, P661, DOI 10.1083/jcb.126.3.661; FERRO KL, 1995, J BIOL CHEM, V270, P4492, DOI 10.1074/jbc.270.9.4492; FUTTERER A, 1995, MOL BIOL CELL, V6, P161; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; GIBBONS BH, 1994, MOL BIOL CELL, V5, P57, DOI 10.1091/mbc.5.1.57; GIBBONS IR, 1991, NATURE, V352, P640, DOI 10.1038/352640a0; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; GOODENOUGH UW, 1987, J MOL BIOL, V194, P481, DOI 10.1016/0022-2836(87)90676-0; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HAMMALVAREZ SF, 1993, J CELL SCI, V106, P955; HERMAN B, 1984, J CELL BIOL, V98, P565, DOI 10.1083/jcb.98.2.565; HIROKAWA N, 1993, NEUROSCI RES, V18, P1, DOI 10.1016/0168-0102(93)90099-C; HOLLENBECK PJ, 1993, J NEUROCHEM, V60, P2265, DOI 10.1111/j.1471-4159.1993.tb03513.x; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; HOYT MA, 1994, CURR OPIN CELL BIOL, V6, P63, DOI 10.1016/0955-0674(94)90117-1; HUGHES SM, 1995, J CELL SCI, V108, P17; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; JELLALI A, 1994, CELL MOTIL CYTOSKEL, V28, P79, DOI 10.1002/cm.970280108; JIANG MY, 1995, BIOPHYS J, V68, P2835; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; KING SM, 1990, J BIOL CHEM, V265, P19807; KING SM, 1991, J BIOL CHEM, V266, P8401; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; KOONCE MP, 1992, J CELL BIOL, V119, P1597, DOI 10.1083/jcb.119.6.1597; KUMAR J, 1995, SCIENCE, V267, P1834, DOI 10.1126/science.7892610; KUMAR J, UNPUB; Kumar Janardan, 1995, Molecular Biology of the Cell, V6, p292A; KUZNETSOV SA, 1992, NATURE, V356, P722, DOI 10.1038/356722a0; LACEY ML, 1992, J BIOL CHEM, V267, P4793; LAFONT F, 1994, NATURE, V372, P801; LANGFORD GM, 1995, CURR OPIN CELL BIOL, V7, P82, DOI 10.1016/0955-0674(95)80048-4; LEESMILLER JP, 1992, NATURE, V359, P244, DOI 10.1038/359244a0; LI MG, 1994, J CELL BIOL, V126, P1475, DOI 10.1083/jcb.126.6.1475; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; LILLIE SH, 1994, J CELL BIOL, V125, P825, DOI 10.1083/jcb.125.4.825; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; LIN SXH, 1992, J CELL SCI, V101, P125; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; LYE RJ, 1995, CELL MOTIL CYTOSKEL, V32, P26, DOI 10.1002/cm.970320104; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MCGRAIL M, 1995, J CELL BIOL, V131, P411, DOI 10.1083/jcb.131.2.411; MCILVAIN JM, 1994, J BIOL CHEM, V269, P19176; MIKAMI A, 1993, NEURON, V10, P787, DOI 10.1016/0896-6273(93)90195-W; MITCHELL DR, 1991, J CELL BIOL, V113, P835, DOI 10.1083/jcb.113.4.835; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MUHUA L, 1994, CELL, V78, P669, DOI 10.1016/0092-8674(94)90531-2; OGAWA K, 1991, NATURE, V352, P643, DOI 10.1038/352643a0; PASCHAL BM, 1993, J BIOL CHEM, V268, P15318; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PASCHAL BM, 1992, J CELL BIOL, V118, P1133, DOI 10.1083/jcb.118.5.1133; PATEL N, 1993, P NATL ACAD SCI USA, V90, P9181, DOI 10.1073/pnas.90.19.9181; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PIPERNO G, 1990, J CELL BIOL, V110, P379, DOI 10.1083/jcb.110.2.379; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; RASMUSSON K, 1994, MOL BIOL CELL, V5, P45, DOI 10.1091/mbc.5.1.45; REIDER CL, 1990, J CELL BIOL, V110, P81; ROGALSKI AA, 1984, J CELL BIOL, V99, P1092, DOI 10.1083/jcb.99.3.1092; ROZDZIAL MM, 1986, CELL, V47, P1061, DOI 10.1016/0092-8674(86)90821-4; SADHU A, 1992, J BIOL CHEM, V267, P11352; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; SCHAFER DA, 1994, J CELL BIOL, V126, P403, DOI 10.1083/jcb.126.2.403; SCHMITZ F, 1994, EUR J CELL BIOL, V63, P77; SCHNAPP BJ, 1986, TRENDS NEUROSCI, V9, P155, DOI 10.1016/0166-2236(86)90052-4; SCHOLEY JM, 1980, NATURE, V287, P233, DOI 10.1038/287233a0; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; SHAKIR MA, 1993, NEUROREPORT, V4, P891, DOI 10.1097/00001756-199307000-00013; SHEETZ MP, IN PRESS CELL BIOL; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; Skoufias DA, 1993, CURR OPIN CELL BIOL, V5, P95, DOI 10.1016/S0955-0674(05)80014-6; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; TANAKA Y, 1995, J CELL SCI, V108, P1883; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; Trivifios-Lagos L., 1994, Molecular Biology of the Cell, V5, p286A; Vaisberg E. A., 1995, Molecular Biology of the Cell, V6, p153A; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; VALE RD, 1988, J CELL BIOL, V107, P2233, DOI 10.1083/jcb.107.6.2233; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; VALLEE RB, 1989, TRENDS NEUROSCI, V12, P66, DOI 10.1016/0166-2236(89)90138-0; VALLEE RB, 1988, NATURE, V332, P561, DOI 10.1038/332561a0; VALLEE RB, IN PRESS COLD SPRING; Vaughan K. T., 1995, Molecular Biology of the Cell, V6, p154A; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; WILKERSON CG, 1995, J CELL BIOL, V129, P169, DOI 10.1083/jcb.129.1.169; WILKERSON CG, 1994, J CELL SCI, V107, P497; WORDEMAN L, 1991, J CELL BIOL, V114, P285, DOI 10.1083/jcb.114.2.285; XIANG X, 1995, MOL BIOL CELL, V6, P297, DOI 10.1091/mbc.6.3.297; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100; YU H, 1995, MOL BIOL CELL, V6, P171, DOI 10.1091/mbc.6.2.171; YU H, 1992, J BIOL CHEM, V267, P20457; ZHANG ZZ, 1993, P NATL ACAD SCI USA, V90, P7928, DOI 10.1073/pnas.90.17.7928; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	122	261	267	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1539	1544		10.1126/science.271.5255.1539	http://dx.doi.org/10.1126/science.271.5255.1539			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599110				2022-12-28	WOS:A1996TZ98300030
J	Luepker, RV; Perry, CL; McKinlay, SM; Nader, PR; Parcel, GS; Stone, EJ; Webber, LS; Elder, JP; Feldman, HA; Johnson, CC; Kelder, SH; Wu, M				Luepker, RV; Perry, CL; McKinlay, SM; Nader, PR; Parcel, GS; Stone, EJ; Webber, LS; Elder, JP; Feldman, HA; Johnson, CC; Kelder, SH; Wu, M			Outcomes of a field trial to improve children's dietary patterns and physical activity - The Child and Adolescent Trial for Cardiovascular Health (CATCH)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTE-SMOKING; EDUCATION-PROGRAM; PREVENTION; PROMOTION; ATHEROSCLEROSIS; LIPOPROTEINS; INTERVENTION; TRACKING; BEHAVIOR; LIPIDS	Objective.-To assess the outcomes of health behavior interventions, focusing on the elementary school environment, classroom curricula, and home programs, for the primary prevention of cardiovascular disease. Design.-A randomized, controlled field trial at four sites with 56 intervention and 40 control elementary schools. Outcomes were assessed using prerandomization measures (fall 1991) and follow-up measures (spring 1994). Participants.-A total of 5106 initially third-grade students from ethnically diverse backgrounds in public schools located in California, Louisiana, Minnesota, and Texas. Intervention.-Twenty-eight schools participated in a third-grade through fifth-grade intervention including school food service modifications, enhanced physical education (PE), and classroom health curricula. Twenty-eight additional schools received these components plus family education. Main Outcome Measures.-At the school level, the two primary end points were changes in the fat content of food service lunch offerings and the amount of moderate-to-vigorous physical activity in the PE programs. At the level of the individual student, serum cholesterol change was the primary end point and was used for power calculations for the study. individual level secondary end points included psychosocial factors, recall measures of eating and physical activity patterns, and other physiologic measures. Results.-In intervention school lunches, the percentage of energy intake from fat fell significantly more (from 38.7% to 31.9%) than in control lunches (from 38.9% to 36.2%)(P<.001). The intensity of physical activity in PE classes during the Child and Adolescent Trial for Cardiovascular Health (CATCH) intervention increased significantly in the intervention schools compared with the control schools (P<.02). Self-reported daily energy intake from fat among students in the intervention schools was significantly reduced (from 32.7% to 30.3%) compared with that among students in the control schools (from 32.6% to 32.2%)(P<.001). Intervention students reported significantly more daily vigorous activity than controls (58.6 minutes vs 46.5 minutes; P<.003). Blood pressure, body size, and cholesterol measures did not differ significantly between treatment groups. No evidence of deleterious effects of this intervention on growth or development was observed. Conclusion.-The CATCH intervention was able to modify the fat content of school lunches, increase moderate-to-vigorous physical activity in PE, and improve eating and physical activity behaviors in children during 3 school years.	NEW ENGLAND RES INST, WATERTOWN, MA 02172 USA; UNIV CALIF SAN DIEGO, DEPT PEDIAT, COMMUNITY PEDIAT DIV, LA JOLLA, CA 92093 USA; UNIV TEXAS, HLTH SCI CTR, CTR HLTH PROMOT RES & DEV, HOUSTON, TX USA; NHLBI, PROJECT OFF, BETHESDA, MD 20892 USA; TULANE UNIV, SCH PUBL HLTH & TROP MED, NEW ORLEANS, LA 70118 USA	HealthCore, Inc; University of California System; University of California San Diego; University of Texas System; University of Texas Health Science Center Houston; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Tulane University	Luepker, RV (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55455 USA.		Feldman, Henry/M-2302-2013; Fahimifar, Sepideh/M-5303-2019	Williams, Colleen Kelly/0000-0001-9416-2489	NHLBI NIH HHS [U01-HL-39880, U01-HL-39852, U01-HL-39906] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL039852, U01HL039880, U01HL039906] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; Allan R., 1992, CARDIOVASC REV REP, V13, P13; BERENSON GS, 1981, AM J EPIDEMIOL, V113, P157, DOI 10.1093/oxfordjournals.aje.a113080; CLARKE WR, 1978, CIRCULATION, V58, P626, DOI 10.1161/01.CIR.58.4.626; *COUNC PHYS ED CHI, 1994, GUID EL SCH PHYS ED; CROCKETT SJ, 1988, J SCHOOL HEALTH, V58, P53, DOI 10.1111/j.1746-1561.1988.tb05822.x; EBZERY MK, IN PRESS SCH FOOD SE; EDMUNDSON E, IN PRESS J HLTH PROM; EDMUNDSON EW, 1994, HEALTH EDUC QUART, pS27, DOI 10.1177/10901981940210S104; ELDER JP, 1994, HEALTH EDUC QUART, pS107; EVANS RI, 1976, PREV MED, V5, P122, DOI 10.1016/0091-7435(76)90015-3; FESKANICH D, 1988, J AM DIET ASSOC, V88, P1263; FLYNN BS, 1992, AM J PUBLIC HEALTH, V82, P827, DOI 10.2105/AJPH.82.6.827; Food and Nutrition Board Commission on Life Sciences National Research Council, 1989, REC DIET ALL; HAINLINE A, 1986, CLIN CHEM, V32, P611; JOHNSON CC, 1994, HLTH ED Q S2, V21, pS91; KANNEL WB, 1972, J PEDIATR-US, V80, P544, DOI 10.1016/S0022-3476(72)80049-0; KELDER SH, 1994, AM J PUBLIC HEALTH, V84, P1121, DOI 10.2105/AJPH.84.7.1121; KELDER SH, 1995, HEALTH EDUC RES, V10, P119, DOI 10.1093/her/10.2.119-a; KEYS A, 1965, METABOLIS, V14, P776, DOI 10.1016/0026-0495(65)90004-1; KOEPSELL TD, 1991, J CLIN EPIDEMIOL, V44, P701, DOI 10.1016/0895-4356(91)90030-D; LAUER RM, 1995, JAMA-J AM MED ASSOC, V273, P1429, DOI 10.1001/jama.273.18.1429; LENFANT C, 1995, J HLTH ED, V26, P6; LLOYD DM, 1983, INT J EPIDEMIOL, V12, P51, DOI 10.1093/ije/12.1.51; LUEPKER RV, 1983, J BEHAV MED, V6, P53, DOI 10.1007/BF00845276; LYTLE LA, 1994, J SCHOOL HEALTH, V64, P405, DOI 10.1111/j.1746-1561.1994.tb03261.x; LYTLE LA, 1993, J AM DIET ASSOC, V93, P1431, DOI 10.1016/0002-8223(93)92247-U; MCGRAW SA, 1994, HEALTH EDUC QUART, pS5, DOI 10.1177/10901981940210S103; McKenzie T.L., 1991, J TEACH PHYS EDUC, V11, P195; MCKENZIE TL, 1995, RES Q EXERCISE SPORT, V66, P184, DOI 10.1080/02701367.1995.10608832; MCKENZIE TL, 1994, HEALTH EDUC QUART, pS73, DOI 10.1177/10901981940210S106; MURRAY DM, 1994, J COMMUNITY PSYCHOL, P140; NADER PR, 1992, FAM COMMUNITY HEALTH, V15, P57, DOI DOI 10.1097/00003727-199204000-00007; *NAT CHOL ED PROGR, 1991, NIH PUBL; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; Nicklas TA, 1994, J HLTH ED, V25, P299; OSGANIAN SK, IN PRESS PREV MED; PARCEL GS, 1989, HEALTH EDUC QUART, V16, P181, DOI 10.1177/109019818901600204; PARCEL GS, 1995, J SCHOOL HEALTH, V65, P23, DOI 10.1111/j.1746-1561.1995.tb03335.x; Perry C., 1992, CARDIOVASC RISK FACT, V2, P36; PERRY CL, 1988, AM J PUBLIC HEALTH, V78, P1156, DOI 10.2105/AJPH.78.9.1156; PERRY CL, 1990, J SCHOOL HEALTH, V60, P406, DOI 10.1111/j.1746-1561.1990.tb05960.x; PERRY CL, 1992, AM J PUBLIC HEALTH, V82, P1210, DOI 10.2105/AJPH.82.9.1210; PERRY CL, 1985, J SCHOOL HEALTH, V55, P399, DOI 10.1111/j.1746-1561.1985.tb01163.x; RAIZMAN DJ, 1994, HEALTH EDUC QUART, pS51; SALLIS JS, IN PRESS MED SCI SPO; *SAS I INC, 1992, P229 SAS I INC, P289; Siedentop D., 1991, DEV TEACHING SKILLS; Smiciklas-Wright HA, 1991, J AM DIET ASSOC, V91, pA28; STONE EJ, 1989, HEALTH EDUC QUART, V16, P155, DOI 10.1177/109019818901600202; STONE EJ, 1995, J HLTH ED S, V26, pS9; STONE EJ, 1994, HLTH ED Q S2, V21, P1; SUSSER M, 1995, AM J PUBLIC HEALTH, V85, P156, DOI 10.2105/AJPH.85.2.156; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; TURLEY KR, 1994, PEDIATR EXERC SCI, V6, P178; *US DEP HHS, 1994, NAT HEART LUNG BLOOD; *US PHS, 1990, DHHS PUBL; WALTER HJ, 1989, J NATL CANCER I, V81, P995, DOI 10.1093/jnci/81.13.995; WEBBER LS, 1995, AM J EPIDEMIOL, V141, P428, DOI 10.1093/oxfordjournals.aje.a117445; WEBBER LS, 1991, AM J EPIDEMIOL, V133, P884, DOI 10.1093/oxfordjournals.aje.a115968; ZUCKER DM, 1995, CONTROL CLIN TRIALS, V16, P96, DOI 10.1016/0197-2456(94)00026-Y	61	759	768	0	143	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1996	275	10					768	776		10.1001/jama.275.10.768	http://dx.doi.org/10.1001/jama.275.10.768			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY886	8598593				2022-12-28	WOS:A1996TY88600024
J	Todd, JS				Todd, JS			Remarks of the AMA executive vice president	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Todd, JS (corresponding author), AMER MED ASSOC,OFF EXECUT VICE PRESIDENT,515 N STATE ST,CHICAGO,IL 60610, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1996	275	10					802	802						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY886	8598599				2022-12-28	WOS:A1996TY88600030
J	Berwick, DM				Berwick, DM			A primer on leading the improvement of systems	BRITISH MEDICAL JOURNAL			English	Article											Berwick, DM (corresponding author), INST HEALTHCARE IMPROVEMENT,BOSTON,MA 02215, USA.							Argyris C., 1990, OVERCOMING ORG DEFEN; AXELROD R, 1974, EVOLUTION COOPERATIO; Batalden P B, 1993, Jt Comm J Qual Improv, V19, P424; BERWICK DM, 1994, JAMA-J AM MED ASSOC, V272, P797, DOI 10.1001/jama.272.10.797; EISENBERG J, 1986, DOCTORS DECISIONS CO; Ohno T., 2019, TOYOTA PRODUCTION SY, V1st ed., DOI [10.4324/9780429273018, DOI 10.4324/9780429273018]; Roberts Harry, 1993, QUALITY IS PERSONAL; ROBERTS HV, 1993, QUALITY IMPROVEMENT; Senge, 1980, 5 DISCIPLINE ART PRA; Shewhart WA., 1931, EC CONTROL QUALITY M; Watzlawick P., 1974, CHANGE PRINCIPLES PR; [No title captured]	12	436	436	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					619	622		10.1136/bmj.312.7031.619	http://dx.doi.org/10.1136/bmj.312.7031.619			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595340	Green Published			2022-12-28	WOS:A1996TZ84000030
J	Erwin, J; Britten, N; Jones, R				Erwin, J; Britten, N; Jones, R			General practitioners' views on over the counter sales by community pharmacists	BRITISH MEDICAL JOURNAL			English	Article									UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,DEPT GEN PRACTICE,LONDON SE11 6SP,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London								BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; Department of Health, 1994, HLTH PERS SOC SERV S; FORD S, 1995, BRIT MED J, V310, P1620, DOI 10.1136/bmj.310.6995.1620; SPENCER JA, 1992, BRIT MED J, V304, P1670, DOI 10.1136/bmj.304.6843.1670; WILSON RPH, 1995, BRIT MED J, V311, P1347, DOI 10.1136/bmj.311.7016.1347	5	27	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					617	618						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595339				2022-12-28	WOS:A1996TZ84000029
J	Pharoah, P				Pharoah, P			A golden jubilee	LANCET			English	Editorial Material											Pharoah, P (corresponding author), UNIV LIVERPOOL,DEPT PUBL HLTH,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							Butler N.R., 1963, PERINATAL MORTALITY; CHAMBERLAIN R, 1975, BRIT BIRTHS 1970; DALY C, 1955, LANCET, V1, P445; HEADY JA, 1955, LANCET, V1, P499; HEADY JA, 1955, LANCET, V1, P395; MORRIS JN, 1955, LANCET, V1, P554; MORRIS JN, 1955, LANCET, V1, P343; SPENCE JC, 1954, 1000 FAMILIES NEWCAS	8	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					557	557		10.1016/S0140-6736(96)91265-9	http://dx.doi.org/10.1016/S0140-6736(96)91265-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596312				2022-12-28	WOS:A1996TX69400003
J	Berg, JM; Shi, YG				Berg, JM; Shi, YG			The galvanization of biology: A growing appreciation for the roles of zinc	SCIENCE			English	Article							TRANSCRIPTION FACTOR-IIIA; FINGER DNA RECOGNITION; ACID BINDING-PROTEIN; NUCLEOCAPSID PROTEIN; CRYSTAL-STRUCTURE; GLUCOCORTICOID RECEPTOR; DEPENDENT STRUCTURE; IRON-METABOLISM; METAL-BINDING; 5S RNA	Zinc ions are key structural components of a large number of proteins. The binding of zinc stabilizes the folded conformations of domains so that they may facilitate interactions between the proteins and other macromolecules such as DNA. The modular nature of some of these zinc-containing proteins has allowed the rational design of site-specific DNA binding proteins. The ability of zinc to be bound specifically within a range of tetrahedral sites appears to be responsible for the evolution of the wide range of zinc-stabilized structural domains now known to exist. The lack of redox activity for the zinc ion and its binding and exchange kinetics also may be important in the use of zinc for specific functional roles.			Berg, JM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOPHYS & BIOPHYS CHEM, BALTIMORE, MD 21205 USA.		Berg, Jeremy/GRY-6706-2022	Berg, Jeremy/0000-0002-2444-8139; Berg, Jeremy/0000-0003-3022-0963; Shi, Yigong/0000-0003-2030-168X				ANDERSON GJ, 1994, ADV EXP MED BIOL, V356, P81; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BERG JM, 1989, J AM CHEM SOC, V111, P3759, DOI 10.1021/ja00192a050; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; CRICHTON RR, 1992, BIOCHEMISTRY-US, V31, P11255, DOI 10.1021/bi00161a001; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1994, P NATL ACAD SCI USA, V91, P11099, DOI 10.1073/pnas.91.23.11099; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; EIGEN M, 1963, PURE APPL CHEM, V6, P105; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Figgis BN., 1966, INTRO LIGAND FIELDS; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GABIG TG, 1994, J BIOL CHEM, V269, P29515; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GREEN LM, 1990, P NATL ACAD SCI USA, V87, P6403, DOI 10.1073/pnas.87.16.6403; GREEN LM, 1989, P NATL ACAD SCI USA, V86, P4047, DOI 10.1073/pnas.86.11.4047; HANAS JS, 1983, J BIOL CHEM, V258, P4120; HECHT SM, 1986, ACCOUNTS CHEM RES, V19, P383, DOI 10.1021/ar00132a002; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOOVERS JMN, 1992, GENOMICS, V12, P254, DOI 10.1016/0888-7543(92)90372-Y; HU HM, 1994, J BIOL CHEM, V269, P30069; HUANG RC, 1993, P NATL ACAD SCI USA, V90, P11806, DOI 10.1073/pnas.90.24.11806; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; JOHO KE, 1990, CELL, V61, P293, DOI 10.1016/0092-8674(90)90809-S; Keilin D, 1940, BIOCHEM J, V34, P1163, DOI 10.1042/bj0341163; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRIZEK BA, 1991, J AM CHEM SOC, V113, P4518, DOI 10.1021/ja00012a021; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MORIUCHI H, 1994, VIROLOGY, V205, P238, DOI 10.1006/viro.1994.1639; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NELBACH ME, 1972, BIOCHEMISTRY-US, V11, P315, DOI 10.1021/bi00753a002; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PEARSON RG, 1969, SURVERY PROGR CHEM, V1, pCH1; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; Raulin J., 1869, ANN SCI NAT BOT BIOL, V11, P93; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; RICE WG, 1995, SCIENCE, V270, P1194, DOI 10.1126/science.270.5239.1194; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; ROBERTS WJ, 1989, BIOCHEMISTRY-US, V28, P10043, DOI 10.1021/bi00452a024; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SHI YG, 1995, SCIENCE, V268, P282, DOI 10.1126/science.7536342; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SOUTH TL, 1990, BIOCHEMISTRY-US, V29, P7786, DOI 10.1021/bi00486a002; SOUTH TL, 1989, J AM CHEM SOC, V111, P395, DOI 10.1021/ja00183a074; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; SUMMERS MF, 1991, J CELL BIOCHEM, V45, P41, DOI 10.1002/jcb.240450110; SUZUKI M, 1994, NUCLEIC ACIDS RES, V22, P3397, DOI 10.1093/nar/22.16.3397; THUKRAL SK, 1992, MOL CELL BIOL, V12, P2784, DOI 10.1128/MCB.12.6.2784; TULLIUS TD, 1987, TRENDS BIOCHEM SCI, V12, P297, DOI 10.1016/0968-0004(87)90145-9; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344	81	1619	1743	6	280	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 23	1996	271	5252					1081	1085		10.1126/science.271.5252.1081	http://dx.doi.org/10.1126/science.271.5252.1081			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599083				2022-12-28	WOS:A1996TW70100028
J	Festenstein, R; Tolaini, M; Corbella, P; Mamalaki, C; Parrington, J; Fox, M; Miliou, A; Jones, M; Kioussis, D				Festenstein, R; Tolaini, M; Corbella, P; Mamalaki, C; Parrington, J; Fox, M; Miliou, A; Jones, M; Kioussis, D			Locus control region function and heterochromatin-induced position effect variegation	SCIENCE			English	Article							HUMAN CD2 GENE; TRANSGENIC MICE; GLOBIN GENE; MONOCLONAL-ANTIBODIES; DEPENDENT EXPRESSION; FAR UPSTREAM; HIGH-LEVEL; DROSOPHILA; BOUNDARIES; SEQUENCES	Human CD2 locus control region (LCR) sequences are shown here to be essential for establishing an open chromatin configuration. Transgenic mice carrying an hCD2 minigene attached only to the 3' CD2 transcriptional enhancer exhibited variegated expression when the transgene integrated in the centromere. In contrast, mice carrying a transgene with additional 3' sequences showed no variegation even when the latter integrated in centromeric positions. This result suggests that LCRs operate by ensuring an open chromatin configuration and that a short region, with no enhancer activity, functions in the establishment, maintenance, or both of an open chromatin domain.	UNIV LONDON UNIV COLL, MRC, HUMAN BIOCHEM GENET UNIT, GALTON LAB, LONDON NW1 2HE, ENGLAND; JOHN RADCLIFFE HOSP, DEPT PATHOL, OXFORD OX3 9DU, ENGLAND	University of London; University College London; University of Oxford	Festenstein, R (corresponding author), NATL INST MED RES, DIV MOLEC IMMUNOL, RIDGEWAY, MILL HILL, LONDON NW7 1AA, ENGLAND.				Telethon [TGT95000, TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; CARSON S, 1993, NUCLEIC ACIDS RES, V21, P2065, DOI 10.1093/nar/21.9.2065; CATTANACH BM, 1974, GENET RES, V23, P291, DOI 10.1017/S0016672300014932; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DIAZ P, 1994, IMMUNITY, V1, P207, DOI 10.1016/1074-7613(94)90099-X; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; EISSENBERG JC, 1989, BIOESSAYS, V11, P14, DOI 10.1002/bies.950110105; ELLIOTT JI, 1995, EMBO J, V14, P575, DOI 10.1002/j.1460-2075.1995.tb07033.x; FESTENSTEIN R, UNPUB; GHARIB B, 1993, ANN HUM GENET, V57, P9, DOI 10.1111/j.1469-1809.1993.tb00882.x; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; KARPEN GH, 1992, GENETICS, V132, P737; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LANG G, 1991, NUCLEIC ACIDS RES, V19, P5851, DOI 10.1093/nar/19.21.5851; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; MORETTA A, 1986, EUR J IMMUNOL, V16, P1427, DOI 10.1002/eji.1830161118; PALMITER RD, 1993, MOL CELL BIOL, V13, P5266, DOI 10.1128/MCB.13.9.5266; PARRINGTON J, UNPUB; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PRAVTCHEVA DD, 1994, J EXP ZOOL, V268, P452, DOI 10.1002/jez.1402680606; REITMAN M, 1990, NATURE, V348, P749, DOI 10.1038/348749a0; ROBERTSON G, 1995, P NATL ACAD SCI USA, V92, P5371, DOI 10.1073/pnas.92.12.5371; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPANOPOULOU E, 1990, THESIS U LONDON; VERBI W, 1982, EUR J IMMUNOL, V12, P81, DOI 10.1002/eji.1830120115; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; WEINTRAUB H, 1988, P NATL ACAD SCI USA, V85, P5819, DOI 10.1073/pnas.85.16.5819	39	303	313	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 23	1996	271	5252					1123	1125		10.1126/science.271.5252.1123	http://dx.doi.org/10.1126/science.271.5252.1123			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599090				2022-12-28	WOS:A1996TW70100040
J	Martin, WD; Hicks, GG; Mendiratta, SK; Leva, HI; Ruley, HE; VanKaer, L				Martin, WD; Hicks, GG; Mendiratta, SK; Leva, HI; Ruley, HE; VanKaer, L			H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection	CELL			English	Article							HLA-DR MOLECULES; INVARIANT CHAIN PEPTIDES; PROCESSING MUTANT; POSITIVE SELECTION; MHC; GENES; COMPLEX; SELF	H2-M is a nonconventional major histocompatibility complex (MHC) class II molecule that has been implicated in the loading of peptides onto conventional class II molecules. We generated mice with a targeted mutation in the H2-Ma gene, which encodes a subunit for H2-M. Although the mutant mice express normal class II cell surface levels, these are structurally distinct from the compact SDS-resistant complexes expressed by wild-type cells and are predominantly bound by class II-associated invariant chain peptides (CLIPs). Cells from these animals are unable to present intact protein antigens to class II-restricted T cells and show reduced capacity to present exogenous peptides. Numbers of mature CD4(+) T lymphocytes in mutant mice are reduced 3- to 4-fold and exhibit altered reactivities. Overall, this phenotype establishes an important role for H2-M in regulating MHC class II function in vivo and supports the notion that self-peptides contribute to the specificity of T cell positive selection.	VANDERBILT UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232	Vanderbilt University	Martin, WD (corresponding author), VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,221 KIRKLAND HALL,NASHVILLE,TN 37232, USA.		Van Kaer, Luc/H-1033-2015	Van Kaer, Luc/0000-0001-5275-2309; Hicks, Geoffrey/0000-0003-4688-2312				ALDRICH CJ, 1994, P NATL ACAD SCI USA, V91, P6525, DOI 10.1073/pnas.91.14.6525; ASHTONRICKARDT PG, 1994, IMMUNOL TODAY, V15, P362, DOI 10.1016/0167-5699(94)90174-0; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P1464; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BROOKS AG, 1994, J IMMUNOL, V153, P5382; CEMAN S, 1992, J IMMUNOL, V149, P754; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; EASTMAN S, 1996, IN PRESS EUR J IMMUN; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; GLAS R, 1994, J EXP MED, V179, P661, DOI 10.1084/jem.179.2.661; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; KROPSHOFER H, 1995, SCIENCE, V270, P1357, DOI 10.1126/science.270.5240.1357; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; MURPHY DB, 1992, J IMMUNOL, V148, P3483; NEWCOMB JR, 1993, J IMMUNOL, V150, P499; NOSSAL GJV, 1994, CELL, V76, P219; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; Sanderson F, 1996, IMMUNITY, V4, P87, DOI 10.1016/S1074-7613(00)80301-5; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SCHMID SL, 1994, NATURE, V369, P103, DOI 10.1038/369103a0; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STEBBINS CC, 1995, J EXP MED, V181, P223, DOI 10.1084/jem.181.1.223; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411	42	269	272	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					543	550		10.1016/S0092-8674(00)81030-2	http://dx.doi.org/10.1016/S0092-8674(00)81030-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598041	Bronze			2022-12-28	WOS:A1996TX17600007
J	Seehra, H; MacDermott, N; Lascelles, RG; Taylor, TV				Seehra, H; MacDermott, N; Lascelles, RG; Taylor, TV			Lesson of the week - Wernicke's encephalopathy after vertical banded gastroplasty for morbid obesity	BRITISH MEDICAL JOURNAL			English	Article									MANCHESTER ROYAL INFIRM,DEPT NEUROL,MANCHESTER M13 9WL,LANCS,ENGLAND	University of Manchester	Seehra, H (corresponding author), MANCHESTER ROYAL INFIRM,DEPT SURG,OXFORD RD,MANCHESTER M13 9WL,LANCS,ENGLAND.							ALBINA JE, 1988, JPEN-PARENTER ENTER, V12, P619, DOI 10.1177/0148607188012006619; FEIT H, 1982, ANN INTERN MED, V96, P453, DOI 10.7326/0003-4819-96-4-453; FERRARA J, 1982, JPEN-PARENTER ENTER, V6, P140, DOI 10.1177/0148607182006002140; HAID RW, 1982, JAMA-J AM MED ASSOC, V247, P2566, DOI 10.1001/jama.247.18.2566; PAULSON GW, 1985, ARCH NEUROL-CHICAGO, V42, P675, DOI 10.1001/archneur.1985.04060070065017	5	65	67	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	1996	312	7028					434	434						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601118				2022-12-28	WOS:A1996TW56400029
J	Arno, PS; Brandt, AM; Gostin, LO; Morgan, J				Arno, PS; Brandt, AM; Gostin, LO; Morgan, J			Tobacco industry strategies to oppose federal regulation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH		HARVARD UNIV,SCH MED,DEPT SOCIAL MED,BOSTON,MA 02115; GEORGETOWN UNIV,CTR LAW,WASHINGTON,DC	Harvard University; Harvard Medical School; Georgetown University	Arno, PS (corresponding author), YESHIVA UNIV,ALBERT EINSTEIN COLL MED,MONTEFIORE MED CTR,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10467, USA.							ALBRIGHT CL, 1988, HEALTH EDUC QUART, V15, P225, DOI 10.1177/109019818801500207; CALIFANO JA, 1994, JAMA-J AM MED ASSOC, V272, P1217; CARTER B, 1995, NY TIMES        1111, pA39; Carter Bill, 1995, NY TIMES        1109, pA1; *CDCP, 1996, CDCP PUBL; COHEN SE, 1964, ADVERTISING AGE, V35, P82; COHEN SE, 1964, ADVERTISING AGE, V35, P1; COLLINS G, 1995, NY TIMES        0218, pD4; FEDER BJ, 1996, NY TIMES        0107; FRANKEL A, 1995, AM LAWYER        JUL, P68; FRITSCHLER AL, 1969, SMOKING POLITICS POL; GLANTZ SA, 1994, JAMA-J AM MED ASSOC, V272, P1176, DOI 10.1001/jama.272.15.1176; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; Goodin R. E., 1989, NO SMOKING ETHICAL I; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P904, DOI 10.1001/jama.269.7.904; GOSTIN LO, 1991, JAMA-J AM MED ASSOC, V266, P3178, DOI 10.1001/jama.266.22.3178; HOVENKAMP H, 1995, YALE J REGUL, V12, P549; JACOBSON PD, 1993, J HEALTH POLIT POLIC, V18, P787; KANDEL DB, 1984, AM J PUBLIC HEALTH, V74, P660, DOI 10.2105/AJPH.74.7.660; KENT C, 1995, AM MED NEWS     0911, P2; KENT C, 1996, AM MED NEWS, V39, P3; MOORE S, 1994, JAMA-J AM MED ASSOC, V272, P1171, DOI 10.1001/jama.272.15.1171; NELSON DE, 1995, AM J PUBLIC HEALTH, V85, P34, DOI 10.2105/AJPH.85.1.34; NEWBERGER MB, 1963, SMOKE SCREEN TOBACCO; POSNER RA, 1971, BELL J ECON, V2, P22, DOI 10.2307/3003161; Quirk PJ, 1981, IND INFLUENCE FEDERA; SHEPARD AC, 1995, AM JOURNALISM REV, V17, P28; SHEPARD AC, 1995, AM JOURNALISM REV, V17, P47; SHEPARD AM, 1965, AM JOURNALISM REV, V17, P30; SLADE J, 1995, JAMA-J AM MED ASSOC, V274, P225, DOI 10.1001/jama.274.3.225; *TOB I, 1990, ITS LAW TOB PROD RET; *TOB I, 1993, TAX BURD TOB; *US DEPT HHS, 1994, PREV TOB US AM YOUNG; *US DEPT HHS, 1995, PUBL PHS; *US DEPT HHS, 1988, HLTH CONS SMOK NIC A; *US DHEW, 1964, US PHS PUBL, V1103; Warner K, 1995, TOB CONTROL, V4, P180; WATERHOUSE P, 1992, EC IMPACT TOBACCO IN; 1994, MMWR-MORBID MORTAL W, V43, P925; 1964, FED REGISTER, V29, P530; 1984, TIMES           0409, P91; 1995, CANT KICK HABIT TOBA; PUBL L, V8992; 1965, CONSUM REP, V30, P488; 1995, FED REG         1016, V60, P41313	45	22	23	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1258	1262		10.1001/jama.275.16.1258	http://dx.doi.org/10.1001/jama.275.16.1258			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF478	8601958				2022-12-28	WOS:A1996UF47800030
J	Nightingale, SL				Nightingale, SL			Important new safety information for tramadol hydrochloride	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1224	1224		10.1001/jama.275.16.1224	http://dx.doi.org/10.1001/jama.275.16.1224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF478	8601942				2022-12-28	WOS:A1996UF47800008
J	Kuipers, EJ; Lundell, L; KlinkenbergKnol, EC; Havu, N; Festen, HPM; Liedman, B; Lamers, CBHW; Jansen, JBMJ; Dalenback, J; Snel, P; Nelis, GF; Meuwissen, SGM				Kuipers, EJ; Lundell, L; KlinkenbergKnol, EC; Havu, N; Festen, HPM; Liedman, B; Lamers, CBHW; Jansen, JBMJ; Dalenback, J; Snel, P; Nelis, GF; Meuwissen, SGM			Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOLLOW-UP; DUODENAL-ULCER; VAGOTOMY; MUCOSA; THERAPY; DISEASE; RISK	Background. Helicobacter pylori infection plays an important part in the development of atrophic gastritis and intestinal metaplasia, conditions that predispose patients to gastric cancer. Profound suppression of gastric acid is associated with increased severity of gastritis caused by H. pylori, but it is not known whether acid suppression increases the risk of atrophic gastritis. Methods. We studied patients from two separate cohorts who were being treated for reflux esophagitis: 72 patients treated with fundoplication in Sweden and 105 treated with omeprazole (20 to 40 mg once daily) in the Netherlands. In both cohorts, the patients were followed for an average of five years (range, three to eight). After fundoplication, the patients did not receive acid-suppressive therapy. The presence of H. pylori was assessed at the first visit by histologic evaluation in the fundoplication group and by histologic and serologic evaluation in the omeprazole group. The patients were not treated for H. pylori infection. Before treatment and during follow-up, the patients underwent repeated gastroscopy, with biopsy sampling for histologic evaluation. Results. Among the patients treated with fundoplication, atrophic gastritis did not develop in any of the 31 who were infected with H. pylori at base line or the 41 who were not infected; 1 patient infected with H. pylori had atrophic gastritis before treatment that persisted after treatment. Among the patients treated with omeprazole, none of whom had atrophic gastritis at base line, atrophic gastritis developed in 18 of the 59 infected with H. pylori (P<0.001) and 2 of the 46 who were not infected (P=0.62). Conclusions. Patients with reflux esophagitis and H. pylori infection who are treated with omeprazole are at increased risk of atrophic gastritis.	UNIV LEIDEN HOSP,2300 RC LEIDEN,NETHERLANDS; UNIV NIJMEGEN HOSP,6500 HB NIJMEGEN,NETHERLANDS; SLOTERVAART HOSP,AMSTERDAM,NETHERLANDS; SOPHIA HOSP,ZWOLLE,NETHERLANDS; GOTHENBURG UNIV,SAHLGRENS HOSP,DEPT SURG,S-41345 GOTHENBURG,SWEDEN; ASTRA AB,SODERTALJE,SWEDEN	Leiden University; Leiden University Medical Center (LUMC); Radboud University Nijmegen; Slotervaart Hospital; Sahlgrenska University Hospital; University of Gothenburg; AstraZeneca	Kuipers, EJ (corresponding author), FREE UNIV AMSTERDAM HOSP,DEPT GASTROENTEROL,POB 7057,1007 MB AMSTERDAM,NETHERLANDS.		Kuipers, Ernst J/H-3293-2019	Kuipers, Ernst J/0000-0002-0633-3098				Armitage P., 1987, STAT METHODS MED RES; CORREA P, 1975, LANCET, V2, P58; CORREA P, 1990, CANCER RES, V50, P4737; DANON SJ, 1995, GASTROENTEROLOGY, V108, P1386, DOI 10.1016/0016-5085(95)90686-X; GARVEY W, 1985, Journal of Histotechnology, V8, P15; GRIMELIUS L, 1980, INVEST CELL PATHOL, V3, P3; HAVU N, 1991, SCAND J GASTROENTE S, V186, P90; IHAMAKI T, 1978, SCAND J GASTROENTERO, V13, P771, DOI 10.3109/00365527809182189; International Agency for Research on Cancer, 1994, IARC MON EV CARC RIS, V61; JONSSON KA, 1988, SCAND J GASTROENTERO, V23, P433, DOI 10.3109/00365528809093891; KLINKENBERGKNOL EC, 1994, ANN INTERN MED, V121, P161, DOI 10.7326/0003-4819-121-3-199408010-00001; KUIPERS EJ, 1995, AM J GASTROENTEROL, V90, P1401; KUIPERS EJ, 1995, LANCET, V345, P1525, DOI 10.1016/S0140-6736(95)91084-0; KUIPERS EJ, 1993, SCAND J GASTROENTERO, V28, P978, DOI 10.3109/00365529309098295; LAMBERTS R, 1993, GASTROENTEROLOGY, V104, P1356, DOI 10.1016/0016-5085(93)90344-C; LOGAN RPH, 1995, GUT, V36, P12, DOI 10.1136/gut.36.1.12; LUNDELL L, IN PRESS BR J SURG; MAAROOS HI, 1985, SCAND J GASTROENTERO, V20, P198, DOI 10.3109/00365528509089657; MEIKLE DD, 1976, GUT, V17, P719, DOI 10.1136/gut.17.9.719; MODLIN IM, 1994, AM J GASTROENTEROL, V89, P308; PENA AS, 1989, DIGESTION, V44, P131, DOI 10.1159/000199902; PRICE AB, 1991, J GASTROEN HEPATOL, V6, P209, DOI 10.1111/j.1440-1746.1991.tb01468.x; ROLAND M, 1975, SCAND J GASTROENTERO, V10, P181; SAVARY M, 1987, ESOPHAGUS HDB ATLAS; SEVIER AC, 1965, J NEUROPATH EXP NEUR, V24, P130, DOI 10.1097/00005072-196501000-00012; SIPPONEN P, 1985, INT J CANCER, V35, P173; SOLCIA E, 1994, SCAND J GASTROENTERO, V29, P28, DOI 10.3109/00365529409105357; SOLCIA E, 1992, DIGESTION, V51, P82, DOI 10.1159/000200921; SOLCIA E, 1988, DIGESTION, V41, P185, DOI 10.1159/000199786; STOLTE M, 1992, IR J MED SCI S10, V161, P6; VILLAKO K, 1991, SCAND J GASTROENTE S, V186, P135	31	659	680	3	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1996	334	16					1018	1022		10.1056/NEJM199604183341603	http://dx.doi.org/10.1056/NEJM199604183341603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE733	8598839	Bronze			2022-12-28	WOS:A1996UE73300003
J	Ahmed, R; Gray, D				Ahmed, R; Gray, D			Immunological memory and protective immunity: Understanding their relation	SCIENCE			English	Review							T-CELL MEMORY; CENTER B-CELLS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; GERMINAL-CENTERS; PRIMARY VACCINATION; ANTIGEN RECEPTOR; LIFE-SPAN; DEATH; MICE; INFECTION	The immune system can remember, sometimes for a lifetime, the identity of a pathogen. Understanding how this is accomplished has fascinated immunologists and microbiologists for many years, but there is still considerable debate regarding the mechanisms by which long-term immunity is maintained. Some of the controversy stems from a failure to distinguish between effector and memory cells and to define their roles in conferring protection against disease. Here the current understanding of the cellular basis of immune memory is reviewed and the relative contributions made to protective immunity by memory and effector T and B cells are examined.	EMORY UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, ATLANTA, GA 30322 USA; HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT IMMUNOL, LONDON W12 0HS, ENGLAND	Emory University; Imperial College London	Ahmed, R (corresponding author), EMORY UNIV, SCH MED, EMORY VACCINE CTR, ATLANTA, GA 30322 USA.		Gray, David/L-8295-2013	Gray, David/0000-0003-3785-4934	NIAID NIH HHS [AI-30048] Funding Source: Medline; NINDS NIH HHS [NS-21496] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030048, R37AI030048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021496] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHMED R, 1994, SEMIN VIROL, V5, P319, DOI 10.1006/smvy.1994.1035; AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; AKBAR AN, 1993, IMMUNOL TODAY, V14, P526, DOI 10.1016/0167-5699(93)90181-J; ALLEN PM, 1994, CELL, V76, P593, DOI 10.1016/0092-8674(94)90497-9; ASANO M, IN PRESS J EXP MED; BACHMANN MF, 1994, J IMMUNOL, V153, P3386; BARTH RK, 1985, NATURE, V316, P517, DOI 10.1038/316517a0; BATTEGAY M, 1994, J VIROL, V68, P4700, DOI 10.1128/JVI.68.7.4700-4704.1994; BELL EB, 1987, J IMMUNOL, V139, P1379; BENNER R, 1981, CLIN EXP IMMUNOL, V46, P1; BEREK C, 1985, NATURE, V316, P412, DOI 10.1038/316412a0; BEREK C, 1988, IMMUNOL REV, V105, P5, DOI 10.1111/j.1600-065X.1988.tb00763.x; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BEVAN MJ, 1995, J EXP MED, V182, P639, DOI 10.1084/jem.182.3.639; BEVERLEY PCL, 1990, CURR TOP MICROBIOL, V159, P111; BEVERLEY PCL, 1990, IMMUNOL TODAY, V11, P203, DOI 10.1016/0167-5699(90)90083-L; BRUNO L, 1995, IMMUNITY, V2, P37, DOI 10.1016/1074-7613(95)90077-2; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CARTER LL, 1995, J IMMUNOL, V155, P1028; CELADA F, 1971, PROG ALLERGY, V15, P223; CEROTTINI JC, 1989, ANNU REV IMMUNOL, V7, P77, DOI 10.1146/annurev.iy.07.040189.000453; CEROTTINI JC, 1974, J EXP MED, V140, P703, DOI 10.1084/jem.140.3.703; CHIEN YH, 1984, NATURE, V309, P322, DOI 10.1038/309322a0; COHEN D, 1994, EUR J EPIDEMIOL, V10, P267, DOI 10.1007/BF01719348; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; DEMKOWICZ WE, IN PRESS J VIROL; DIROSA F, IN PRESS J EXP MED; DOHERTY P, COMMUNICATION; DOHERTY PC, 1992, ANNU REV IMMUNOL, V10, P123; DULLFORCE P, UNPUB; FELDBUSH TL, 1973, CELL IMMUNOL, V8, P435, DOI 10.1016/0008-8749(73)90134-2; Fields BN, 1996, VIROLOGY; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; Finley John H., 1951, COMPLETE WRITINGS TH; FOY TM, 1994, J EXP MED, V180, P157, DOI 10.1084/jem.180.1.157; FRANCO MA, 1995, J VIROL, V69, P7800, DOI 10.1128/JVI.69.12.7800-7806.1995; FREER G, 1995, EUR J IMMUNOL, V25, P1410, DOI 10.1002/eji.1830250541; GALVAN M, UNPUB; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GESSNER A, 1989, J IMMUNOL, V142, P1293; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; GRAY D, 1988, NATURE, V336, P70, DOI 10.1038/336070a0; GRAY D, 1994, J EXP MED, V180, P141, DOI 10.1084/jem.180.1.141; GRAY D, 1991, INT IMMUNOL, V3, P141, DOI 10.1093/intimm/3.2.141; HO F, 1986, EUR J IMMUNOL, V16, P1297, DOI 10.1002/eji.1830161018; HOTCHIN J, 1971, MONOGR VIROL, V3; HOU S, 1994, NATURE, V369, P652, DOI 10.1038/369652a0; HYLAND L, 1994, J VIROL, V68, P6083, DOI 10.1128/JVI.68.9.6083-6086.1994; JACOB J, 1993, J EXP MED, V178, P1293, DOI 10.1084/jem.178.4.1293; JACOB J, 1992, J EXP MED, V176, P679, DOI 10.1084/jem.176.3.679; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; JOHNSON ED, 1975, J EXP MED, V141, P866; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; KELSO A, 1991, IMMUNOL REV, V123, P85, DOI 10.1111/j.1600-065X.1991.tb00607.x; KIRBERG J, 1993, EUR J IMMUNOL, V23, P1963, DOI 10.1002/eji.1830230835; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KJELDSEN K, 1985, LANCET, V1, P900; KLAUS GGB, 1977, IMMUNOLOGY, V33, P31; KORSMEYER SJ, 1992, BLOOD, V80, P879; KOSCOVILBOIS MH, UNPUB; KRAAL G, 1982, NATURE, V298, P377, DOI 10.1038/298377a0; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; KULKARNI AB, 1993, J VIROL, V67, P1044, DOI 10.1128/JVI.67.2.1044-1049.1993; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LAU LL, UNPUB; LEVY JA, 1993, AIDS, V7, P1401, DOI 10.1097/00002030-199311000-00001; Linton P J, 1992, Semin Immunol, V4, P3; LINTON PJ, 1992, EUR J IMMUNOL, V22, P1293, DOI 10.1002/eji.1830220526; LINTON PJ, 1989, CELL, V59, P1049, DOI 10.1016/0092-8674(89)90761-7; LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1995, IMMUNITY, V2, P239, DOI 10.1016/1074-7613(95)90048-9; LIU YJ, 1991, EUR J IMMUNOL, V21, P1107, DOI 10.1002/eji.1830210504; LIVINGSTONE A, UNPUB; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MANDEL TE, 1980, IMMUNOL REV, V53, P29, DOI 10.1111/j.1600-065X.1980.tb01039.x; Maryanski JL, 1996, IMMUNITY, V4, P47, DOI 10.1016/S1074-7613(00)80297-6; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; MATZINGER P, 1994, NATURE, V369, P605, DOI 10.1038/369605a0; MCHEYZERWILLIAMS MG, 1995, SCIENCE, V268, P106, DOI 10.1126/science.7535476; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Miller J F, 1969, Transplant Rev, V1, P3; MILLER JJ, 1964, J IMMUNOL, V92, P673; MOSKOPHIDIS D, 1987, EUR J IMMUNOL, V17, P937, DOI 10.1002/eji.1830170707; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MULLBACHER A, 1994, J EXP MED, V179, P317, DOI 10.1084/jem.179.1.317; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEURATH MF, 1995, P NATL ACAD SCI USA, V92, P5336, DOI 10.1073/pnas.92.12.5336; NOSSAL GJ, 1971, ANTIGENS LYMPHOID CE; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; Panum PL, 1847, VIRCHOWS ARCH PATH A, V1, P492, DOI [DOI 10.1007/BF02114472, 10.1007/BF02114472]; PANUM PL, 1939, MED CLASSICS, V3, P829; PAUL JR, 1951, AM J HYG, V54, P275, DOI 10.1093/oxfordjournals.aje.a119485; Plotkin Stanley A., 1994, VACCINES; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; RAZVI ES, 1995, J IMMUNOL, V154, P620; RAZVI ES, 1995, ADV VIRUS RES, V45, P1, DOI 10.1016/S0065-3527(08)60057-3; RENNO T, 1995, J EXP MED, V181, P2283, DOI 10.1084/jem.181.6.2283; ROCHA B, 1989, EUR J IMMUNOL, V19, P905, DOI 10.1002/eji.1830190518; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; Rock KL, 1996, IMMUNOL TODAY, V17, P131, DOI 10.1016/0167-5699(96)80605-0; RUSSELL JH, 1991, P NATL ACAD SCI USA, V88, P2151, DOI 10.1073/pnas.88.6.2151; SALMON M, 1994, EUR J IMMUNOL, V24, P892, DOI 10.1002/eji.1830240417; SAWYER W. A., 1931, JOUR PREV MED, V5, P413; SCHEIBEL I, 1966, ACTA PATHOL MIC SC, V67, P380, DOI 10.1111/apm.1966.67.3.380; SCHITTEK B, 1990, NATURE, V346, P749, DOI 10.1038/346749a0; SELIN LK, 1994, J EXP MED, V179, P1933, DOI 10.1084/jem.179.6.1933; SIMONSEN O, 1984, LANCET, V2, P1240; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SLIFKA MK, 1995, J VIROL, V69, P1895, DOI 10.1128/JVI.69.3.1895-1902.1995; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282; SPRENT J, COMMUNICATION; STUBER E, 1995, IMMUNITY, V2, P507, DOI 10.1016/1074-7613(95)90031-4; Swain S L, 1992, Semin Immunol, V4, P59; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; SWAIN SL, 1994, IMMUNITY, V1, P543, DOI 10.1016/1074-7613(94)90044-2; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TOUGH DF, 1995, STEM CELLS, V13, P242, DOI 10.1002/stem.5530130305; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; TRIPP RA, 1995, J IMMUNOL, V155, P3719; TRIPP RA, 1995, J IMMUNOL, V154, P6013; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; UEHARA T, 1992, BLOOD, V80, P452; UNUTMAZ D, 1994, J EXP MED, V180, P1159, DOI 10.1084/jem.180.3.1159; VIEIRA P, 1990, INT IMMUNOL, V2, P487, DOI 10.1093/intimm/2.6.487; VITETTA ES, 1991, ANNU REV IMMUNOL, V9, P193, DOI 10.1146/annurev.iy.09.040191.001205; VOLKERT M, 1974, J EXP MED, V139, P1329, DOI 10.1084/jem.139.5.1329; VONBOEHMER H, 1993, J EXP MED, V177, P891, DOI 10.1084/jem.177.4.891; WALSH CM, 1994, P NATL ACAD SCI USA, V91, P10854, DOI 10.1073/pnas.91.23.10854; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WURZBURG U, 1973, EUR J IMMUNOL, V3, P762, DOI 10.1002/eji.1830031205; ZHENG B, 1994, NATURE, V372, P556, DOI 10.1038/372556a0; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0; ZINKERNAGEL RM, 1990, CURR TOP MICROBIOL, V159, P65	143	1382	1404	4	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1996	272	5258					54	60		10.1126/science.272.5258.54	http://dx.doi.org/10.1126/science.272.5258.54			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600537				2022-12-28	WOS:A1996UD59700036
J	Burns, JW; SiadatPajouh, M; Krishnaney, AA; Greenberg, HB				Burns, JW; SiadatPajouh, M; Krishnaney, AA; Greenberg, HB			Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity	SCIENCE			English	Article							INTESTINAL M-CELLS; RHESUS ROTAVIRUS; IMMUNOGLOBULIN-A; INFECTION; RESPONSES; DIARRHEA; PROTEINS; DEFENSE; VIRUS; MODEL	Rotaviruses are the leading cause of severe gastroenteritis and dehydrating diarrhea in young children and animals worldwide. A murine model and ''backpack tumor'' transplantatio n were used to determine the protective effect of anti bod ies against VP4 (an outer capsid viral protein) and VP6 (a major inner capsid viral protein). Only two non-neutralizing immunoglobulin A (IgA) antibodies to VP6 were capable of preventing primary and resolving chronic murine rotavirus infections. These antibodies were not active, however, when presented directly to the luminal side of the intestinal tract. These findings support the hypothesis that in vivo intracellular viral inactivation by secretory IgA during transcytosis is a mechanism of host defense against rotavirus infection.	STANFORD UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA; VET ADM, PALO ALTO HLTH CARE SYST, PALO ALTO, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Burns, JW (corresponding author), STANFORD UNIV, SCH MED, DEPT MED, MED SCH LAB SURGE BLDG, ROOM P304, STANFORD, CA 94305 USA.			greenberg, harry/0000-0002-2128-9080	NIAID NIH HHS [R37AI21362] Funding Source: Medline; NIDDK NIH HHS [DK38707] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burns JK., UNPUB; BURNS JW, 1988, J VIROL, V62, P2164, DOI 10.1128/JVI.62.6.2164-2172.1988; BURNS JW, 1995, VIROLOGY, V207, P143, DOI 10.1006/viro.1995.1060; CHIBA S, 1986, LANCET, V2, P417; CHILDERS NK, 1989, ANNU REV MICROBIOL, V43, P503, DOI 10.1146/annurev.mi.43.100189.002443; DHARAKUL T, 1990, J VIROL, V64, P4375, DOI 10.1128/JVI.64.9.4375-4382.1990; ESTES MK, 1989, MICROBIOL REV, V53, P410, DOI 10.1128/MMBR.53.4.410-449.1989; FENG NG, 1994, J VIROL, V68, P7766, DOI 10.1128/JVI.68.12.7766-7773.1994; GLASS RI, 1994, SCIENCE, V265, P1389, DOI 10.1126/science.8073280; HERRMANN JE, IN PRESS ARCH VIROL; KRAEHENBUHL JP, 1992, PHYSIOL REV, V72, P853, DOI 10.1152/physrev.1992.72.4.853; MACKOW ER, 1988, VIROLOGY, V165, P511, DOI 10.1016/0042-6822(88)90595-8; MACKOW ER, 1988, P NATL ACAD SCI USA, V85, P645, DOI 10.1073/pnas.85.3.645; MATSON DO, 1993, J INFECT DIS, V167, P577, DOI 10.1093/infdis/167.3.577; MATSUI SM, 1989, ADV VIRUS RES, V36, P181; MAZANEC MB, 1992, P NATL ACAD SCI USA, V89, P6901, DOI 10.1073/pnas.89.15.6901; MAZANEC MB, 1995, J VIROL, V69, P1339, DOI 10.1128/JVI.69.2.1339-1343.1995; MAZANEC MB, 1993, IMMUNOL TODAY, V14, P430, DOI 10.1016/0167-5699(93)90245-G; McGhee J R, 1990, Infect Dis Clin North Am, V4, P315; MCNEAL MM, 1995, VIROLOGY, V211, P474, DOI 10.1006/viro.1995.1429; OFFIT PA, 1986, J VIROL, V58, P700, DOI 10.1128/JVI.58.2.700-703.1986; PADILLANORIEGA L, 1992, J CLIN MICROBIOL, V30, P1392, DOI 10.1128/JCM.30.6.1392-1397.1992; SHAW RD, 1986, VIROLOGY, V155, P434, DOI 10.1016/0042-6822(86)90205-9; TAGGART RT, 1983, SCIENCE, V219, P1228, DOI 10.1126/science.6402815; WARD RL, 1990, J VIROL, V64, P5070, DOI 10.1128/JVI.64.10.5070-5075.1990; WARD RL, 1992, J INFECT DIS, V166, P1251, DOI 10.1093/infdis/166.6.1251; WELTZIN R, 1989, J CELL BIOL, V108, P1673, DOI 10.1083/jcb.108.5.1673; WINNER L, 1991, INFECT IMMUN, V59, P977, DOI 10.1128/IAI.59.3.977-982.1991; WOLF JL, 1981, SCIENCE, V212, P471, DOI 10.1126/science.6259737	29	399	428	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1996	272	5258					104	107		10.1126/science.272.5258.104	http://dx.doi.org/10.1126/science.272.5258.104			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600516				2022-12-28	WOS:A1996UD59700048
J	Frankel, SS; Wenig, BM; Burke, AP; Mannan, P; Thompson, LDR; Abbondanzo, SL; Nelson, AM; Pope, M; Steinman, RM				Frankel, SS; Wenig, BM; Burke, AP; Mannan, P; Thompson, LDR; Abbondanzo, SL; Nelson, AM; Pope, M; Steinman, RM			Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid	SCIENCE			English	Article							EPIDERMAL LANGERHANS CELLS; LYMPH-NODES; INFECTED PATIENTS; VIRUS; EXPRESSION; AIDS; LYMPHADENOPATHY; DISEASE; RNA; RESERVOIRS	Human immunodeficiency virus-type 1 (HIV-1) replicates actively in infected individuals, yet cells with intracellular depots of viral protein are observed only infrequently. Many cells expressing the HIV-1 Gag protein were detected at the surface of the nasopharyngeal tonsil or adenoid. This infected mucosal surface contained T cells and dendritic cells, two cell types that together support HIV-1 replication in culture. The infected cells were multinucleated syncytia and expressed the S100 and p55 dendritic cell markers. Eleven of the 13 specimens analyzed were from donors who did not have symptoms of acquired immunodeficiency syndrome (AIDS). The interaction of dendritic cells and T cells in mucosa may support HIV-1 replication, even in subclinical stages of infection.	ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021; ARMED FORCES INST PATHOL,DEPT INFECT & PARASIT DIS PATHOL,DIV AIDS,WASHINGTON,DC 20306; ARMED FORCES INST PATHOL,DEPT OTOLARYNG & ENDOCRINE PATHOL,WASHINGTON,DC 20306; ARMED FORCES INST PATHOL,DEPT CARDIOVASC PATHOL,WASHINGTON,DC 20306; ARMED FORCES INST PATHOL,DEPT HEMATOL & LYMPHAT PATHOL,WASHINGTON,DC 20306	Rockefeller University; United States Department of Defense; United States Department of Defense; United States Department of Defense; United States Department of Defense			Steinman, Ralph/F-7729-2012; Thompson, Lester D. R./J-8404-2016	Thompson, Lester D. R./0000-0003-3714-1432	NIAID NIH HHS [AI24775] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024775] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG JA, 1984, LANCET, V2, P370; BIBERFELD P, 1986, AM J PATHOL, V125, P436; CAMERON PU, 1987, CLIN EXP IMMUNOL, V68, P465; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAWCETT DW, 1986, TXB HIST; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; FRANKEL S, UNPUB; GIANNETTI A, 1993, J ACQ IMMUN DEF SYND, V6, P329; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; KAHN HJ, 1983, AM J CLIN PATHOL, V79, P341, DOI 10.1093/ajcp/79.3.341; KALTER DC, 1991, J IMMUNOL, V146, P3396; KANITAKIS J, 1989, AIDS RES HUM RETROV, V5, P293, DOI 10.1089/aid.1989.5.293; KLEIN J, 1990, IMMUNOLOGY, P52; Mosialos G, 1996, AM J PATHOL, V148, P593; MULLER H, 1993, RES VIROLOGY, V144, P59, DOI 10.1016/S0923-2516(06)80013-0; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; POPE M, 1995, J INVEST DERMATOL, V104, P11, DOI 10.1111/1523-1747.ep12613452; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; RACZ KT, 1988, AIDS, V2, P299; RACZ KT, 1985, LANCET, V1, P105; RUCO LP, 1995, J PATHOL, V176, P391, DOI 10.1002/path.1711760410; SCHUURMAN HJ, 1988, AM J PATHOL, V133, P516; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; TAKAHASHI K, 1984, AM J PATHOL, V116, P497; TENNERRACZ K, 1986, AM J PATHOL, V123, P9; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WEISER B, 1990, P NATL ACAD SCI USA, V87, P3997, DOI 10.1073/pnas.87.10.3997	29	269	270	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					115	117		10.1126/science.272.5258.115	http://dx.doi.org/10.1126/science.272.5258.115			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600520				2022-12-28	WOS:A1996UD59700052
J	Fazio, S; Sabatini, D; Capaldo, B; Vigorito, C; Giordano, A; Guida, R; Pardo, F; Biondi, B; Sacca, L				Fazio, S; Sabatini, D; Capaldo, B; Vigorito, C; Giordano, A; Guida, R; Pardo, F; Biondi, B; Sacca, L			A preliminary study of growth hormone in the treatment of dilated cardiomyopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VENTRICULAR MECHANICAL EFFICIENCY; HEART-DISEASE; MYOCARDIAL ENERGETICS; RAT; HYPERSECRETION; DEFICIENCY; VALIDATION; STRESS	Background. Cardiac hypertrophy is a physiologic response that allows the heart to adapt to an excess hemodynamic load. We hypothesized that inducing cardiac hypertrophy with recombinant human growth hormone might be an effective approach to the treatment of idiopathic dilated cardiomyopathy, a condition in which compensatory cardiac hypertrophy is believed to be deficient. Methods. Seven patients with idiopathic dilated cardiomyopathy and moderate-to-severe heart failure were studied at base line, after three months of therapy with human growth hormone, and three months after the discontinuation of growth hormone. Standard therapy for heart failure was continued throughout the study. Cardiac function was evaluated with Doppler echocardiography, right-heart catheterization, and exercise testing. Results. When administered at a dose of 14 IU per week, growth hormone doubled the serum concentrations of insulin-like growth factor I. Growth hormone increased left-ventricular-wall thickness and reduced chamber size significantly. Consequently, end-systolic wall stress (a function of both wall thickness and chamber size) fell markedly (from a mean [+/-SE] of 144+/-11 to 85+/-8 dyn per square centimeter, P<0.001). Growth hormone improved cardiac output, particularly during exercise (from 7.4+/-0.7 to 9.7+/-0.9 liters per minute, P=0.003), and enhanced ventricular work, despite reductions in myocardial oxygen consumption (from 56+/-6 to 39+/-5 ml per minute, P=0.005) and energy production (from 1014+/-100 to 701+/-80 J per minute, P=0.002). Thus, ventricular mechanical efficiency rose from 9+/-2 to 21+/-5 percent (P=0.006). Growth hormone also improved clinical symptoms, exercise capacity, and the patients' quality of life. The changes in cardiac size and shape, systolic function, and exercise tolerance were partially reversed three months after growth hormone was discontinued. Conclusions. Recombinant human growth hormone administered for three months to patients with idiopathic dilated cardiomyopathy increased myocardial mass and reduced the size of the left ventricular chamber, resulting in improvement in hemodynamics, myocardial energy metabolism, and clinical status. (C) 1996, Massachusetts Medical Society.	UNIV NAPLES FEDERICO II,DEPT INTERNAL MED,I-80131 NAPLES,ITALY	University of Naples Federico II			Capaldo, Brunella/AAC-6437-2022; Biondi, Bernadette/AAH-7664-2020	Capaldo, Brunella/0000-0001-5222-1524; Biondi, Bernadette/0000-0001-8360-4464				AMATO G, 1993, J CLIN ENDOCR METAB, V77, P1671, DOI 10.1210/jc.77.6.1671; Armitage P., 1987, STAT METHODS MED RES; BAXLEY WA, 1977, CIRCULATION, V55, P564, DOI 10.1161/01.CIR.55.4.564; CHANSON P, 1990, ANN INTERN MED, V113, P921, DOI 10.7326/0003-4819-113-12-921; CITTADINI A, 1994, AM J PHYSIOL, V267, pE219, DOI 10.1152/ajpendo.1994.267.2.E219; DEC GW, 1994, NEW ENGL J MED, V331, P1564, DOI 10.1056/NEJM199412083312307; DEMARCO T, 1988, AM HEART J, V115, P809; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; FAZIO S, 1993, EUR HEART J, V14, P26, DOI 10.1093/eurheartj/14.1.26; FRUSTACI A, 1992, AM J CLIN PATHOL, V97, P503, DOI 10.1093/ajcp/97.4.503; GORLIN R, 1965, CIRCULATION, V32, P361, DOI 10.1161/01.CIR.32.3.361; HAMMAN BL, 1995, AM J PHYSIOL-HEART C, V269, pH1030, DOI 10.1152/ajpheart.1995.269.3.H1030; HARDY CJ, 1991, AM HEART J, V122, P795, DOI 10.1016/0002-8703(91)90527-O; HASENFUSS G, 1989, CIRCULATION, V80, P51, DOI 10.1161/01.CIR.80.1.51; INGWALL JS, 1993, CIRCULATION, V87, P58; KASPER EK, 1994, J AM COLL CARDIOL, V23, P586, DOI 10.1016/0735-1097(94)90740-4; LOMBARDO TA, 1953, CIRCULATION, V7, P71, DOI 10.1161/01.CIR.7.1.71; MAYOUX E, 1993, CIRC RES, V72, P57, DOI 10.1161/01.RES.72.1.57; MEROLA B, 1993, J CLIN ENDOCR METAB, V77, P1658, DOI 10.1210/jc.77.6.1658; MOLLER J, 1991, J CLIN ENDOCR METAB, V72, P768, DOI 10.1210/jcem-72-4-768; NEUBAUER S, 1995, J CLIN INVEST, V95, P1092, DOI 10.1172/JCI117756; NICHOLS AB, 1986, J AM COLL CARDIOL, V7, P270, DOI 10.1016/S0735-1097(86)80490-9; NOZAWA T, 1994, CIRCULATION, V90, P3047, DOI 10.1161/01.CIR.90.6.3047; PEPINE CJ, 1978, CIRCULATION, V58, P795, DOI 10.1161/01.CIR.58.5.795; REICHEK N, 1982, CIRCULATION, V65, P99, DOI 10.1161/01.CIR.65.1.99; ROSS J, 1976, PROG CARDIOVASC DIS, V18, P225; RUBIN SA, 1990, J MOL CELL CARDIOL, V22, P429, DOI 10.1016/0022-2828(90)91478-P; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; Sacca L, 1996, NAT MED, V2, P29, DOI 10.1038/nm0196-29; SACCA L, 1994, ENDOCR REV, V15, P555, DOI 10.1210/er.15.5.555; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SIMONSON DC, 1990, AM J PHYSIOL, V258, pE399, DOI 10.1152/ajpendo.1990.258.3.E399; STRAUER BE, 1979, AM J CARDIOL, V44, P730, DOI 10.1016/0002-9149(79)90295-9; SUGA H, 1990, PHYSIOL REV, V70, P247, DOI 10.1152/physrev.1990.70.2.247; TANDON PK, 1989, J CLIN EPIDEMIOL, V42, P955, DOI 10.1016/0895-4356(89)90160-1; THUESEN L, 1988, ACTA MED SCAND, V223, P337; TIMSIT J, 1990, J CLIN INVEST, V86, P507, DOI 10.1172/JCI114737; YANG RH, 1995, CIRCULATION, V92, P262, DOI 10.1161/01.CIR.92.2.262; ZHANG JY, 1995, CIRCULATION, V92, P1011, DOI 10.1161/01.CIR.92.4.1011	39	405	420	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1996	334	13					809	814		10.1056/NEJM199603283341301	http://dx.doi.org/10.1056/NEJM199603283341301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB950	8596546				2022-12-28	WOS:A1996UB95000001
J	Chen, ZJ; Parent, L; Maniatis, T				Chen, ZJ; Parent, L; Maniatis, T			Site-specific phosphorylation of I kappa B alpha by a novel ubiquitination-dependent protein kinase activity	CELL			English	Article							DEGRADATION; ACTIVATION; LIGASE	Signal-induced activation of the transcription factor NF-kappa B requires specific phosphorylation of the inhibitor I kappa B alpha and its subsequent proteolytic degradation. Phosphorylation of serine residues 32 and 36 targets I kappa B alpha to the ubiquitin (Ub)-proteasome pathway. Here we report the identification of a large, multisubunit kinase (molecular mass similar to 700 kDa) that phosphorylates I kappa B alpha at S32 and S36. Remarkably, the activity of this kinase requires the Uh-activating enzyme (E1), a specific Ub carrier protein (E2) of the Ubc4/Ubc5 family, and Ub. We also show that a ubiquitination event in the kinase complex is a prerequisite for specific phosphorylation of I kappa B alpha. Thus, ubiquitination serves a novel regulatory function that does not involve proteolysis.	HARVARD UNIV,DEPT CELLULAR & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University	Chen, ZJ (corresponding author), PROSCRIPT INC,38 SIDNEY ST,CAMBRIDGE,MA 02139, USA.		Chen, Zhijian/C-6039-2012	Chen, Zhijian/0000-0002-8475-8251				ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; BROOKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Clechanover A., 1994, CELL, V79, P13; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; KUNO K, 1995, J BIOL CHEM, V270, P27914, DOI 10.1074/jbc.270.46.27914; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MENON SD, 1993, J BIOL CHEM, V268, P26805; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PICKART CM, 1985, J BIOL CHEM, V260, P1573; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	48	851	889	1	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					853	862		10.1016/S0092-8674(00)81064-8	http://dx.doi.org/10.1016/S0092-8674(00)81064-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601309	Bronze			2022-12-28	WOS:A1996UC38100007
J	Chang, RW; Pellissier, JM; Hazen, GB				Chang, RW; Pellissier, JM; Hazen, GB			A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STOCHASTIC TREES; REPLACEMENT; ARTHRITIS; REVISION	Objective.-To quantify the trade-off between the expected increased short- and long-term costs and the expected increase in quality-adjusted life expectancy (QALE) associated with total hip arthroplasty (THA) for persons with functionally significant hip osteoarthritis. Design.-A cost-effectiveness study was performed from the societal perspective by constructing stochastic tree, decision analytic models designed to estimate lifetime functional outcomes and costs of THA and nonoperative managements. Main Outcome Measures.-A modified four-state American College of Rheumatology functional status classification was used to measure effectiveness. These functional classes were assigned utility values to allow the relative effectiveness of THA to be expressed in quality-adjusted life years (QALYs), Lifetime costs included costs associated with primary and potential revision surgeries and long-term care costs associated with the functionally dependent class. Data Used in the Cost-effectiveness Model.-Probability and incidence rate data were summarized from the literature. The THA hospital cost data were obtained from local teaching hospitals' cost accounting systems, Estimates of recurring medical costs for functionally significant hip osteoarthritis and for custodial care were derived from the literature. Results.-The THA cost-effectiveness ratio increases with age and is higher for men than for women, In the base-case scenario for 60-year-old white women who have functionally significant but not dependent hip osteoarthritis, the model predicts that THA is cost saving because of the high costs of custodial care associated with dependency due to worsening hip osteoarthritis and that the procedure increases QALE by about 6.9 years. In the base-case scenario for men aged 85 years and older, the average lifetime cost associated with THA is $9100 more than nonoperative management, with an average increase in QALE of about 2 years. Thus, the THA cost-effectiveness ratio for men aged 85 years and older is $4600 per QALY gained, less than that of procedures intended to extend life such as coronary artery bypass surgery or renal dialysis, Worst-case analysis suggests that THA remains minimally cost-effective for this oldest age category ($80 000/QALY) even if probabilities, rates, utilities, costs, and the discount rate are simultaneously varied to extreme values that bias the analysis against surgery. Conclusions.-For persons with hip osteoarthritis associated with significant functional limitation, THA can be cost saving or, at worst, cost-effective in improving QALE when both short- and long-term outcomes are considered, Further research is needed to determine whether this procedure is actually being used in this cost-effective manner, especially in older age categories.	NORTHWESTERN UNIV, INST HLTH SERV RES & POLICY STUDIES, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, DEPT PREVENT MED, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, DEPT MED, ARTHRITIS DIV, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, DEPT PHYS MED & REHABIL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, DEPT IND ENGN, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, INST HLTH SERV RES & POLICY STUDIES, EVANSTON, IL USA; NORTHWESTERN UNIV, DEPT PREVENT MED, EVANSTON, IL USA; NORTHWESTERN UNIV, DEPT MED, ARTHRITIS DIV, EVANSTON, IL USA; NORTHWESTERN UNIV, DEPT PHYS MED & REHABIL, EVANSTON, IL USA; NORTHWESTERN UNIV, DEPT IND ENGN, EVANSTON, IL USA; LOYOLA UNIV, DEPT MANAGEMENT SCI, CHICAGO, IL 60611 USA	Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Loyola University Chicago	Chang, RW (corresponding author), NORTHWESTERN UNIV, MULTIPURPOSE ARTHRITIS & MUSCULOSKELETAL DIS CTR, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.		Hazen, Gordon/B-7463-2009		NIAMS NIH HHS [AR30692] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR030692] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		*AM AC ORTH SURG, 1993, ORTH KNOWL UPD, V4; *AM ASS HOM SERV A, 1994, BACKGR FACTS AG SERV; AMSTUTZ HC, 1982, CLIN ORTHOP RELAT R, V170, P21; ANDERSON M A, 1981, Orthopaedic Transactions, V5, P75; [Anonymous], 1995, JAMA, V273, P1950; BARBER TC, 1993, J BONE JOINT SURG AM, V75A, P321, DOI 10.2106/00004623-199303000-00002; BECKENBAUGH RD, 1978, J BONE JOINT SURG AM, V60, P306, DOI 10.2106/00004623-197860030-00005; BOOTH RE, 1988, TOTAL HIP ARTHROPLAS; BROUGHTON NS, 1982, ACTA ORTHOP SCAND, V53, P923, DOI 10.3109/17453678208992850; Cameron H U, 1981, Acta Orthop Belg, V47, P49; COLLIS DK, 1988, ORTHOP CLIN N AM, V19, P541; COVENTRY MB, 1974, J BONE JOINT SURG AM, VA 56, P273, DOI 10.2106/00004623-197456020-00005; COX DR, 1955, P CAMBRIDGE PHILOS S, V51, P313; DANIELSSON L, 1964, ACTA ORTHOP SCAND S, V66, P9; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ESSES S, 1983, CAN J SURG, V26, P345; ESTOCK DM, 1994, CLIN ORTHOP RELAT R, P190; ETCHASON J, 1995, NEW ENGL J MED, V332, P719, DOI 10.1056/NEJM199503163321106; FOWLER JL, 1988, ORTHOP CLIN N AM, V19, P477; FRIEDMAN B, 1993, MED CARE, V31, P581, DOI 10.1097/00005650-199307000-00002; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; GUSTILO RB, 1984, P 12 ANN M HIP SOC S, P342; GUSTILO RB, 1988, CLIN ORTHOPAEDICS, V0235, P00111; HARRIS WH, 1990, NEW ENGL J MED, V323, P725, DOI 10.1056/NEJM199009133231106; HARRIS WH, 1969, J BONE JOINT SURG AM, VA 51, P737, DOI 10.2106/00004623-196951040-00012; HAZEN GB, 1993, MED DECIS MAKING, V13, P227, DOI 10.1177/0272989X9301300309; HAZEN GB, 1992, MED DECIS MAKING, V12, P163, DOI 10.1177/0272989X9201200302; HERBERTS P, 1989, CLIN ORTHOP RELAT R, V249, P48; HOOGLAND T, 1981, CLIN ORTHOP RELAT R, V161, P180; HUNTER GA, 1979, J BONE JOINT SURG BR, V61, P419, DOI 10.1302/0301-620X.61B4.500750; JAMES ETR, 1982, CLIN ORTHOP RELAT R, V170, P88; JINNAH RH, 1986, CLIN ORTHOP RELAT R, V211, P164; JONES JM, 1979, J BONE JOINT SURG AM, V61, P1029, DOI 10.2106/00004623-197961070-00010; KAPLAN RM, 1976, HEALTH SERV RES, V11, P478; KATZ JN, 1994, MED CARE, V32, P183, DOI 10.1097/00005650-199402000-00009; KAVANAGH BF, 1989, J BONE JOINT SURG AM, V71A, P1496, DOI 10.2106/00004623-198971100-00007; KAVANAGH BF, 1985, J BONE JOINT SURG AM, V67A, P517, DOI 10.2106/00004623-198567040-00003; KAVANAGH BF, 1987, J BONE JOINT SURG AM, V69A, P1144, DOI 10.2106/00004623-198769080-00006; KAVANAGH BF, 1985, CLIN ORTHOP RELAT R, V193, P133; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; LAUPACIS A, 1994, J ARTHROPLASTY, V9, P481, DOI 10.1016/0883-5403(94)90093-0; LAUPACIS A, 1993, J BONE JOINT SURG AM, V75A, P1619, DOI 10.2106/00004623-199311000-00006; LIANG MH, 1986, ARTHRITIS RHEUM, V29, P937, DOI 10.1002/art.1780290801; MARTI RK, 1990, J BONE JOINT SURG AM, V72A, P346, DOI 10.2106/00004623-199072030-00005; MCCOY TH, 1988, ORTHOP CLIN N AM, V19, P467; MULROY RD, 1990, J BONE JOINT SURG BR, V72, P757, DOI 10.1302/0301-620X.72B5.2211749; MUSHLIN AI, 1992, CANCER, V69, P1957, DOI 10.1002/1097-0142(19920401)69:7+<1957::AID-CNCR2820691716>3.0.CO;2-T; *NAT CTR HLTH STAT, 1993, VIT STAT US, V2, P12; PELLICCI PM, 1985, J BONE JOINT SURG AM, V67A, P513, DOI 10.2106/00004623-198567040-00002; PELLICCI PM, 1982, CLIN ORTHOP RELAT R, V170, P34; PELLISSIER JM, 1994, SOCIO ECON PLAN SCI, V28, P251, DOI 10.1016/0038-0121(94)90030-2; PELLISSIER JM, 1994, MED DECIS MAKING, V14, P439; REIGSTAD A, 1984, ARCH ORTHOP TRAUM SU, V103, P152, DOI 10.1007/BF00435545; Retpen J B, 1989, J Arthroplasty, V4, P311, DOI 10.1016/S0883-5403(89)80032-4; SANZEN L, 1988, CLIN ORTHOP RELAT R, P165; SCHULMAN KA, 1991, ANN INTERN MED, V114, P798, DOI 10.7326/0003-4819-114-9-798; SCHULTE KR, 1993, J BONE JOINT SURG AM, V75A, P961, DOI 10.2106/00004623-199307000-00002; SCHURMAN DJ, 1989, CLIN ORTHOP RELAT R, V240, P172; SCHUTZER SF, 1988, J BONE JOINT SURG AM, V70A, P724, DOI 10.2106/00004623-198870050-00013; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; WHITE RH, 1990, J GEN INTERN MED, V5, P304, DOI 10.1007/BF02600396; WHITTLE J, 1993, CLIN ORTHOP RELAT R, V295, P119; [No title captured]; [No title captured]; [No title captured]; [No title captured]; 1994, EC INDICATORS, P23; [No title captured]	70	406	410	3	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					858	865		10.1001/jama.275.11.858	http://dx.doi.org/10.1001/jama.275.11.858			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ971	8596224				2022-12-28	WOS:A1996TZ97100029
J	Inouye, SK; Charpentier, PA				Inouye, SK; Charpentier, PA			Precipitating factors for delirium in hospitalized elderly persons - Predictive model and interrelationship with baseline vulnerability	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE CONFUSIONAL STATES; MINI-MENTAL STATE; MEDICAL PATIENTS; RISK-FACTORS; SEVERITY; ILLNESS	Objectives.-To prospectively develop and validate a predictive model for delirium based on precipitating factors during hospitalization, and to examine the interrelationship of precipitating factors and baseline vulnerability. Design.-Two prospective cohort studies, in tandem. Setting.-General medical wards, university teaching hospital. Patients.-For the development cohort, 196 patients aged 70 years and older with no delirium at baseline, and for the validation cohort, 312 comparable patients. Main Outcome Measure.-New-onset delirium by hospital day 9, defined by the Confusion Assessment Method diagnostic criteria. Results.-Delirium developed in 35 patients (18%) in the development cohort. Five independent precipitating factors for delirium were identified: use of physical restraints (adjusted relative risk [RR], 4.4; 95% confidence interval [CI], 2.5 to 7.9), malnutrition (RR, 4.0; 95% CI, 2.2 to 7.4), more than three medications added (RR, 2.9; 95% CI, 1.6 to 5.4), use of bladder catheter (RR, 2.4; 95% CI, 1.2 to 4.7), and any iatrogenic event (RR, 1.9; 95% CI, 1.1 to 3.2). Each precipitating factor preceded the onset of delirium by more than 24 hours. A risk stratification system was developed by adding 1 point for each factor present. Rates of delirium for low-risk (0 points), intermediate-risk (1 to 2 points), and high-risk groups (greater than or equal to 3 points) were 3%, 20%, and 59%, respectively (P<.001). The corresponding rates in the validation cohort, in which 47 patients (15%) developed delirium, were 4%, 20%, and 35%, respectively (P<.001). When precipitating and baseline factors were analyzed in cross-stratified format, delirium rates increased progressively from low-risk to high-risk groups in all directions (double-gradient phenomenon). The contributions of baseline and precipitating factors were documented to be independent and statistically significant. Conclusions.-A simple predictive model based on the presence of five precipitating factors can be used to identify elderly medical patients at high risk for delirium. Precipitating and baseline vulnerability factors are highly interrelated and contribute to delirium in independent, substantive, and cumulative ways.	YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510	Yale University; Yale University			Inouye, Sharon/R-7216-2019		NIA NIH HHS [P60AG10469] Funding Source: Medline; PHS HHS [K08AB00524] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P60AG010469] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BECK S, RAND PUBLICATION; BECKER PM, 1987, JAMA-J AM MED ASSOC, V257, P2313, DOI 10.1001/jama.257.17.2313; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; CHARLSON ME, 1986, J CHRON DIS, V39, P439, DOI 10.1016/0021-9681(86)90111-6; FEINSTEIN AR, 1987, CLINIMETRICS, P57; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOREMAN MD, 1989, RES NURS HEALTH, V12, P21, DOI 10.1002/nur.4770120105; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P525, DOI 10.1111/j.1532-5415.1988.tb04023.x; Hodkinson H M, 1973, J R Coll Physicians Lond, V7, P305; HOSMER DW, 1989, APPL LOGISTIC REGRES, P131; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; INOUYE SK, 1994, AM J MED, V97, P278, DOI 10.1016/0002-9343(94)90011-6; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; INOUYE SK, 1993, J GEN INTERN MED, V8, P645, DOI 10.1007/BF02598279; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; MCCULLAGH P, 1983, GEN LINEAR MODELS MO, P79; POMPEI P, 1994, J AM GERIATR SOC, V42, P809, DOI 10.1111/j.1532-5415.1994.tb06551.x; ROCKWOOD K, 1989, J AM GERIATR SOC, V37, P150, DOI 10.1111/j.1532-5415.1989.tb05874.x; ROGERS MP, 1989, INT J PSYCHIAT MED, V19, P109; ROSIN AJ, 1966, J CHRON DIS, V19, P307, DOI 10.1016/0021-9681(66)90134-2; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; TINETTI ME, 1995, JAMA-J AM MED ASSOC, V273, P1348, DOI 10.1001/jama.273.17.1348; UHLMANN RF, 1987, J GERONTOL, V42, P33, DOI 10.1093/geronj/42.1.33; VENTRY IM, 1982, EAR HEARING, V3, P128, DOI 10.1097/00003446-198205000-00006; WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174, DOI 10.1093/oxfordjournals.aje.a114212; WILLIAMS MA, 1985, RES NURS HEALTH, V8, P31, DOI 10.1002/nur.4770080107; WILLIAMSRUSSO P, 1992, J AM GERIATR SOC, V40, P759, DOI 10.1111/j.1532-5415.1992.tb01846.x	31	862	885	2	53	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					852	857		10.1001/jama.275.11.852	http://dx.doi.org/10.1001/jama.275.11.852			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TZ971	8596223				2022-12-28	WOS:A1996TZ97100028
J	Cuskelly, GJ; McNulty, H; Scott, JM				Cuskelly, GJ; McNulty, H; Scott, JM			Effect of increasing dietary folate on red-cell folate: Implications for prevention of neural tube defects	LANCET			English	Article							RISK	Background Recommendations by the UK Department of Health suggest that protection from neural tube defects (NTD) can be achieved through intakes of an extra 400 mu g daily of folate/folic acid as natural food, foods fortified with folic acid, or supplements. The assumption is that all three routes of intervention would have equal effects on folate status. Methods We assessed the effectiveness of these suggested routes of intervention in optimising folate status. 62 women were recruited from the University staff and students to take part in a 3-month intervention study. Participants were randomly assigned to one of the following five groups: folic acid supplement (400 mu g/day; I); folic-acid-fortified foods (an additional 400 mu g/day; II); dietary folate (an additional 400 mu g/day; III); dietary advice (IV), and control (V). Responses to intervention were assessed as changes in red-cell folate between preintervention and postintervention values. Findings 41 women completed the intervention study. Red-cell folate concentrations increased significantly over the 3 months in the groups taking folic acid supplements (group I) or food fortified with folic acid (group II) only (p<0.01 for both groups). By contrast, although aggressive intervention with dietary folate (group III) or dietary advice (group IV) significantly increased intake of food folate (p<0.001 and p<0.05, respectively), there was no significant change in folate status. Interpretation We have shown that compared with supplements and fortified food, consumption of extra folate as natural food folate is relatively ineffective at increasing folate status. We believe that advice to women to consume folate-rich foods as a means to optimise folate status is misleading.	UNIV ULSTER,SCH BIOMED SCI,COLERAINE BT52 1SA,LONDONDERRY,NORTH IRELAND; TRINITY COLL DUBLIN,DEPT BIOCHEM,DUBLIN,IRELAND	Ulster University; Trinity College Dublin				McNulty, Helene/0000-0002-4366-6457; Cuskelly, Geraldine/0000-0003-1645-7243				BLACK AE, 1991, P NUTR SOC, V50, pA108; BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; CRAWLEY H, 1988, FOOD PORTION SIZES; DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; Department of Health, 1992, FOL AC PREV NEUR TUB; Gregory JF, 1995, FOLATE HLTH DIS, P195; National Health and Medical Research Council, 1993, REV STAT REL DIET FO; OBROIN S, 1992, J CLIN PATHOL, V45, P344, DOI 10.1136/jcp.45.4.344; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; 1992, MMWR MORBID MORTAL W, V41, P1; 1991, LANCET, V338, P132	11	226	230	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					657	659		10.1016/S0140-6736(96)91205-2	http://dx.doi.org/10.1016/S0140-6736(96)91205-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596381				2022-12-28	WOS:A1996TZ28500013
J	Klemperer, F				Klemperer, F			How to do it - Work in the European Union	BRITISH MEDICAL JOURNAL			English	Article								Continental Europe is now only 20 minutes away by train from mainland Britain, and moving ever closer politically. Mutual recognition of medical qualifications within the European Union is well established: working in other parts of Europe is, in principle, straightforward. Working in different health care systems can offer new perspectives on British medical practice and the NHS. But the cultural differences and practical difficulties are not always easy to overcome.			Klemperer, F (corresponding author), COMMUNITY HELP SERV,RUE ST GEORGES 102,BOX 20,B-1050 BRUSSELS,BELGIUM.							ADAMSONTAYLOR S, 1994, CULTURE SHOCK FRANCE; BELCHER JP, 1995, EUROPEAN PUBLIC HLTH; BOCHNER A, 1986, CULTURE SHOCK PSYCHO, P157; BREARLEY S, 1992, BRIT MED J, V305, P661, DOI 10.1136/bmj.305.6855.661; CHRISTENSEN SM, 1991, SURPLUS DEFICIT MED, P8; European Union, 1993, OFFICIAL J EURO 0405; GOZAN G, 1994, DAILY TELEGRAPH GUID; HINDLE A, 1993, HLTH CARE SYSTEMS EU; *INT HOSP FED, 1990, GUID HLTH SERV WORLD; MEBAZAN A, 1992, GUIDE HLTH EUROPE; NICHOLAS S, 1994, EUROPEAN UNION GENER, P156; PASCOE R., 1994, CULTURE SHOCK PARENT; TWINN B, 1993, EXPATRIATES HDB; VEALE D, 1992, BRIT MED J, V305, P482	14	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					567	570		10.1136/bmj.312.7030.567	http://dx.doi.org/10.1136/bmj.312.7030.567			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595291	Green Published			2022-12-28	WOS:A1996TY88500035
J	Faham, S; Hileman, RE; Fromm, JR; Linhardt, RJ; Rees, DC				Faham, S; Hileman, RE; Fromm, JR; Linhardt, RJ; Rees, DC			Heparin structure and interactions with basic fibroblast growth factor	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; MITOGENIC ACTIVITY; FACTOR FAMILY; BINDING; RECEPTOR; OLIGOSACCHARIDES; REFINEMENT; RESOLUTION; AFFINITY; CELLS	Crystal structures of heparin-derived tetra- and hexasaccharides complexed with basic fibroblast growth factor (bFGF) were determined at resolutions of 1.9 and 2.2 angstroms, respectively. The heparin structure may be approximated as a helical polymer with a disaccharide rotation of 174 degrees and a translation of 8.6 angstroms along the helix axis. Both molecules bound similarly to a region of the bFGF surface containing residues asparagine-28, arginine-121, lysine-126, and glutamine-135; the hexasaccharide also interacted with an additional binding site formed by lysine-27, asparagine-102, and lysine-136. No significant conformational change in bFGF occurred upon heparin oligosaccharide binding, which suggests that heparin primarily serves to juxtapose components of the FGF signal transduction pathway.	CALTECH,DIV CHEM & CHEM ENGN 14775CH,PASADENA,CA 91125; UNIV IOWA,COLL PHARM,DIV MED & NAT PROD CHEM,IOWA CITY,IA 52242	California Institute of Technology; University of Iowa					NIGMS NIH HHS [GM45162, GM38060, T32 GM08346] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM045162, R01GM038060, R01GM045162, T32GM008346] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGO H, 1991, J BIOCHEM-TOKYO, V110, P360, DOI 10.1093/oxfordjournals.jbchem.a123586; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BARZU T, 1989, J CELL PHYSIOL, V140, P538, DOI 10.1002/jcp.1041400320; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BENHARROCH D, 1990, ISRAEL J MED SCI, V26, P212; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COX JM, 1967, J MOL BIOL, V28, P151, DOI 10.1016/S0022-2836(67)80083-4; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; ERIKSSON AE, 1993, PROTEIN SCI, V2, P1274, DOI 10.1002/pro.5560020810; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GAMBARINI AG, 1993, MOL CELL BIOCHEM, V124, P121, DOI 10.1007/BF00929204; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HARPER JW, 1988, BIOCHEMISTRY-US, V27, P671, DOI 10.1021/bi00402a027; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LANE DA, 1989, HEPARIN; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lindahl, 1989, HEPARIN CHEM BIOL PR, P51; LOBB RR, 1988, BIOCHEMISTRY-US, V27, P2572, DOI 10.1021/bi00407a045; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Stoddart J.F., 1971, STEREOCHEMISTRY CARB; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; WALKER A, 1994, J BIOL CHEM, V269, P931; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	39	708	728	2	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1116	1120		10.1126/science.271.5252.1116	http://dx.doi.org/10.1126/science.271.5252.1116			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599088				2022-12-28	WOS:A1996TW70100038
J	Ignatowicz, L; Kappler, J; Marrack, P				Ignatowicz, L; Kappler, J; Marrack, P			The repertoire of T cells shaped by a single MHC/peptide ligand	CELL			English	Article							RECEPTOR TRANSGENIC MICE; INVARIANT CHAIN; MONOCLONAL-ANTIBODY; POSITIVE SELECTION; ANTIGEN RECEPTOR; THYMUS; TOLERANCE; RECOGNITION; PEPTIDES; LACKING	Although the thymus produces many immature thymocytes, few of these cells mature. Positive selection has been thought to limit thymocyte development. In thymuses expressing a single MHC/peptide combination, however, surprisingly large numbers of thymocytes are selected to mature. Many of these react with the selecting MHC, bound to other self-peptides. Therefore, the number of thymocytes that mature is limited by the fact that positively selected cells die because they react too well with MHC bound to self-peptides that are not identical to those involved in positive selection. T cells that mature in thymuses expressing a single MHC/peptide ligand react frequently with foreign MHC, suggesting that the repertoire of alpha beta receptors may be more biased toward reaction with MHC than was previously thought.	NATL JEWISH CTR IMMUNOL & RESP MED,HOWARD HUGHES MED INST,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT IMMUNOL,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80206	Howard Hughes Medical Institute; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Ignatowicz, L (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,1400 JACKSON ST,DENVER,CO 80206, USA.		Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687	PHS HHS [AL18785, AL22295, AL17134] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BLACKMAN M, 1986, CELL, V47, P349, DOI 10.1016/0092-8674(86)90591-X; BODMER H, 1994, SCIENCE, V263, P1284, DOI 10.1126/science.7510069; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; CARDELL S, 1995, J EXP MED, V182, P993, DOI 10.1084/jem.182.4.993; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DIANZANI U, 1992, J IMMUNOL, V148, P678; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; ELLIOTT EA, 1994, J EXP MED, V179, P681, DOI 10.1084/jem.179.2.681; FISCHERLINDAHL K, 1977, J EXP MED, V145, P508; GLAS R, 1994, J EXP MED, V179, P661, DOI 10.1084/jem.179.2.661; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HUMBLET C, 1994, INT IMMUNOL, V6, P1949, DOI 10.1093/intimm/6.12.1949; HUNIG T, 1980, J EXP MED, V151, P1288, DOI 10.1084/jem.151.5.1288; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; IGNATOWICZ L, 1995, J IMMUNOL, V154, P3852; JERNE N K, 1971, European Journal of Immunology, V1, P1, DOI 10.1002/eji.1830010102; Kabat EA, 1991, SEQUENCES PROTEINS I; KAPPLER JW, 1976, NATURE, V262, P797, DOI 10.1038/262797a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KELLY KA, 1993, EUR J IMMUNOL, V23, P1922, DOI 10.1002/eji.1830230829; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUSOFF U, 1993, J IMMUNOL METHODS, V166, P287; LAMB CA, 1992, J IMMUNOL, V148, P3478; LERNER EA, 1980, J EXP MED, V152, P1085, DOI 10.1084/jem.152.4.1085; LO D, 1986, IMMUNOL RES, V5, P221, DOI 10.1007/BF02919203; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MATHIS DJ, 1983, P NATL ACAD SCI-BIOL, V80, P273, DOI 10.1073/pnas.80.1.273; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; NAUJOKAS MF, 1995, IMMUNITY, V3, P359, DOI 10.1016/1074-7613(95)90120-5; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; SCHERER MT, 1995, J EXP MED, V182, P1493, DOI 10.1084/jem.182.5.1493; SCHUMACHER TNM, 1994, IMMUNITY, V1, P721, DOI 10.1016/S1074-7613(94)80013-8; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHACHAR I, 1995, IMMUNITY, V3, P373, DOI 10.1016/1074-7613(95)90121-3; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WHITE J, 1983, J IMMUNOL, V130, P1033; WHITE J, 1989, J IMMUNOL, V143, P1822; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882; ZINKERNAGEL RM, 1975, J EXP MED, V141, P1427, DOI 10.1084/jem.141.6.1427	55	381	392	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					521	529		10.1016/S0092-8674(00)81028-4	http://dx.doi.org/10.1016/S0092-8674(00)81028-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598039	Bronze			2022-12-28	WOS:A1996TX17600005
J	Chatellier, G; Zapletal, E; Lemaitre, D; Menard, J; Degoulet, P				Chatellier, G; Zapletal, E; Lemaitre, D; Menard, J; Degoulet, P			The number needed to treat: A clinically useful nomogram in its proper context	BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; TRIAL	The number needed to treat is a meaningful way of expressing the benefit of an active treatment over a control. It can be used either for summarising the results of a therapeutic trial or for medical decision making about an individual patient, but its use at the bedside has been impeded by the need for time consuming calculations. A nomogram has therefore been devised that will greatly simplify the calculations. Since calculations are now easy, the number needed to treat can be used to assess the value of several interventions, although it does have its limitations. In particular it should not be used when it is not known whether the relative risk reduction associated with an intervention is constant for all levels of risk, or for periods of time longer than that studied in the original trials.	HOP BROUSSAIS,CLIN INVEST CTR,F-75674 PARIS 14,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Chatellier, G (corresponding author), HOP BROUSSAIS,DEPT MED INFORMAT,F-75674 PARIS 14,FRANCE.			Degoulet, Patrice/0000-0002-5574-9428				Anderson K, 1990, AM HEART J, V121, P293; [Anonymous], 1992, Arch Intern Med, V152, P1399; [Anonymous], 1995, LANCET, V345, P669; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; BUCHER HC, 1994, BRIT MED J, V309, P761, DOI 10.1136/bmj.309.6957.761; CHATELLIER G, 1995, MEDINFO 95 P, P876; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; FORROW L, 1992, AM J MED, V92, P121, DOI 10.1016/0002-9343(92)90100-P; GROVER A, 1995, BRIT MED J, V310, P975; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; Morgenstern H, 1982, EPIDEMIOLOGIC RES PR, P403; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; PEDERSEN TR, 1985, NEW ENGL J MED, V313, P1055; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; VISCOLI CM, 1993, ANN INTERN MED, V118, P99, DOI 10.7326/0003-4819-118-2-199301150-00004; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; 1988, JAMA-J AM MED ASSOC, V259, P2113	20	160	169	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	1996	312	7028					426	429						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601116				2022-12-28	WOS:A1996TW56400027
J	Amir, S; Stewart, J				Amir, S; Stewart, J			Resetting of the circadian clock by a conditioned stimulus	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; PHASE RESPONSE CURVES; SUPRACHIASMATIC NUCLEUS; GENE-EXPRESSION; SYRIAN-HAMSTER; C-FOS; RAT; RHYTHMS; IMMUNOREACTIVITY; PROJECTIONS	ENVIRONMENTAL, light is the dominant temporal cue for the entrainment of circadian rhythms. In mammals, light entrains circadian rhythms by daily resetting a pacemaker located in the hypothalamic suprachiasmatic nucleus (SCN)(1,2). Although it is widely held that phase resetting by light involves cellular elements within the SCN that are uniquely responsive to photic cues(1,3), we now report that non-photic cues that reliably precede the onset of light can, through associative learning, come to activate these elements. In rats, a neutral non-photic stimulus paired with light in pavlovian conditioning trials was capable of eliciting cellular and behavioural effects characteristic of phase-dependent resetting of the pacemaker by light, the expression of the transcription factor Fos in SCN cells, and phase shifts in free-running activity and temperature rhythms(4-7). Thus an associative learning process, pavlovian conditioning, provides a means whereby environmental cues that predict light onset can come to mimic the effect of light on the SCN pacemaker and thereby bring about entrainment of circadian rhythms.			Amir, S (corresponding author), CONCORDIA UNIV,DEPT PSYCHOL,CTR STUDIES BEHAV NEUROBIOL,1455 MAISONNEUVE BLVD,MONTREAL,PQ H3G 1M8,CANADA.		Amir, Shimon/AAE-4635-2022					AMIR S, 1995, NEUROSCIENCE, V69, P1005, DOI 10.1016/0306-4522(95)00393-W; CARD JP, 1982, J COMP NEUROL, V206, P390, DOI 10.1002/cne.902060407; CARD JP, 1989, J COMP NEUROL, V284, P135, DOI 10.1002/cne.902840110; CUTRERA RA, 1993, BRAIN RES, V602, P14, DOI 10.1016/0006-8993(93)90235-F; DAAN S, 1976, J COMP PHYSIOL, V106, P253, DOI 10.1007/BF01417857; DAVIDOWA H, 1992, BEHAV BRAIN RES, V50, P127, DOI 10.1016/S0166-4328(05)80294-3; EDELSTEIN K, 1995, BRAIN RES, V690, P254, DOI 10.1016/0006-8993(95)00736-A; Harrington M E, 1986, J Biol Rhythms, V1, P309, DOI 10.1177/074873048600100405; HARRINGTON ME, 1987, BRAIN RES, V410, P275, DOI 10.1016/0006-8993(87)90325-8; HICKEY TL, 1976, EXP BRAIN RES, V24, P523; JANIK D, 1992, NEUROREPORT, V3, P575, DOI 10.1097/00001756-199207000-00007; JOHNSON RF, 1988, BRAIN RES, V462, P301, DOI 10.1016/0006-8993(88)90558-6; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; MEAD S, 1992, J NEUROSCI, V12, P2516; MOGA MM, 1995, J COMP NEUROL, V359, P221, DOI 10.1002/cne.903590204; MOORE RY, 1972, J COMP NEUROL, V146, P1, DOI 10.1002/cne.901460102; MOORE RY, 1994, J COMP NEUROL, V344, P403, DOI 10.1002/cne.903440306; MORIN LP, 1994, BRAIN RES REV, V67, P102; MROSOVSKY N, 1988, J COMP PHYSIOL A, V162, P35, DOI 10.1007/BF01342701; PICARD GE, 1985, NEUROSCI LETT, V55, P211; PITTENDRIGH CS, 1981, HDB BEHAVIORAL NEURO, V4, P95; RUSAK B, 1989, BRAIN RES, V493, P283, DOI 10.1016/0006-8993(89)91163-3; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; SCHWARTZ WJ, 1994, NEUROSCIENCE, V58, P573, DOI 10.1016/0306-4522(94)90082-5; SHINOHARA K, 1993, NEUROSCIENCE, V56, P813, DOI 10.1016/0306-4522(93)90129-4; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; VANREETH O, 1989, NATURE, V339, P49, DOI 10.1038/339049a0; WICKLAND CR, 1991, AM J PHYSIOL, V261, pR1109, DOI 10.1152/ajpregu.1991.261.5.R1109; ZHANG Y, 1993, NEUROSCI LETT, V164, P203, DOI 10.1016/0304-3940(93)90892-O	29	72	72	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					542	545		10.1038/379542a0	http://dx.doi.org/10.1038/379542a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596633				2022-12-28	WOS:A1996TU69300051
J	Iglehart, JK				Iglehart, JK			The struggle to reform Medicare	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Aaron HJ, 1995, HEALTH AFFAIR, V14, P8, DOI 10.1377/hlthaff.14.4.8; AM MED ASS, 1995, 31 AM MED ASS BOARD; BLENDON RJ, 1995, JAMA-J AM MED ASSOC, V274, P1645, DOI 10.1001/jama.274.20.1645; BURDA D, 1996, MODERN HEALTHCA 0108, P40; CALMES J, 1995, WALL STREET J   1006, pA16; EMMONS DW, 1996, SOCIOECONOMIC CHARAC, P15; *GEN ACC OFF, 1995, GAOHEHS9621; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; GRAMM P, 1994, NEW ENGL J MED, V330, P1752, DOI 10.1056/NEJM199406163302411; IGLEHART JK, 1980, MILBANK FUND Q, V58, P656, DOI 10.2307/3349809; IGLEHART JK, 1995, NEW ENGL J MED, V333, P1019, DOI 10.1056/NEJM199510123331525; IGLEHART JK, 1982, NEW ENGL J MED, V307, P451, DOI 10.1056/NEJM198208123070734; IGLEHART JK, 1994, NEW ENGL J MED, V331, P63, DOI 10.1056/NEJM199407073310129; KASSIRER JP, 1995, J ENGL J MED, V333, P50; MCCORMICK B, 1994, AM MED NEWS     1212, P4; PAGE L, 1996, AM MED NEWS     0219, P5; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; SEWARD PJ, 1995, 27A95 AM MED ASS; Wilensky GR, 1995, NEW ENGL J MED, V333, P1774, DOI 10.1056/NEJM199512283332612; WINSLOW R, 1995, WALL STREET J   0721, pB1; WOOLHANDLER S, 1995, NEW ENGL J MED, V333, P1706, DOI 10.1056/NEJM199512213332510; 1995, NY TIMES        1015, pE14	22	7	7	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1996	334	16					1071	1075		10.1056/NEJM199604183341621	http://dx.doi.org/10.1056/NEJM199604183341621			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE733	8598864				2022-12-28	WOS:A1996UE73300034
J	Despres, JP; Lamarche, B; Mauriege, P; Cantin, B; Dagenais, GR; Moorjani, S; Lupien, PJ				Despres, JP; Lamarche, B; Mauriege, P; Cantin, B; Dagenais, GR; Moorjani, S; Lupien, PJ			Hyperinsulinemia as an independent risk factor for ischemic heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADIPOSE-TISSUE DISTRIBUTION; HIGH-DENSITY LIPOPROTEIN; INSULIN RESISTANCE; GLUCOSE-TOLERANCE; PLASMA-INSULIN; FOLLOW-UP; ABDOMINAL FAT; OBESE WOMEN; BODY-FAT; CORONARY	Background. Prospective studies suggest that hyperinsulinemia may be an important risk factor for ischemic heart disease. However, it has not been determined whether plasma insulin levels are independently related to ischemic heart disease after adjustment for other risk factors, including plasma lipoprotein levels. Methods. In 1985 we collected blood samples from 2103 men from suburbs of Quebec City, Canada, who were 45 to 75 years of age and who did not have ischemic heart disease. A first ischemic event (angina pectoris, acute myocardial infarction, or death from coronary heart disease) occurred in 114 men (case patients) between 1985 and 1990. Each case patient was matched for age, body-mass index, smoking habits, and alcohol consumption with a control selected from among the 1989 men who remained free of ischemic heart disease during follow-up. After excluding men with diabetes, we compared fasting plasma insulin and lipoprotein concentrations at base line in 91 case patients and 105 controls. Results. Pasting insulin concentrations at base line were 18 percent higher in the case patients than in the controls (P<0.001). Logistic-regression analysis showed that the insulin concentration remained associated with ischemic heart disease (odds ratio for ischemic heart disease with each increase of 1 SD in the insulin concentration, 1.7; 95 percent confidence interval, 1.3 to 2.4) after adjustment for systolic blood pressure, use of medications, and family history of ischemic heart disease. Further adjustment by multivariate analysis for plasma triglyceride, apolipoprotein B, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol concentrations did not significantly diminish the association between the insulin concentration and the risk of ischemic heart disease (odds ratio, 1.6; 95 percent confidence interval, 1.1 to 2.3). Conclusions. High fasting insulin concentrations appear to be an independent predictor of ischemic heart disease in men. (C) 1996, Massachusetts Medical Society.	UNIV MONTREAL,DEPT MED,MONTREAL,PQ H3C 3J7,CANADA	Universite de Montreal	Despres, JP (corresponding author), CHU LAVAL,RES CTR,LIPID RES CTR,2705 LAURIER BLVD,ST FOY,PQ G1V 4G2,CANADA.		Lamarche, Benoit/ABA-4785-2021	Lamarche, Benoit/0000-0002-4443-5378				ALBERS JJ, 1978, CLIN CHEM, V24, P853; BIERMAN EL, 1992, ARTERIOSCLER THROMB, V12, P647, DOI 10.1161/01.ATV.12.6.647; CASASSUS P, 1992, ARTERIOSCLER THROMB, V12, P1387, DOI 10.1161/01.ATV.12.12.1387; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; DAGENAIS GR, 1990, CAN J CARDIOL, V6, P274; DESPRES JP, 1989, ARTERIOSCLEROSIS, V9, P203, DOI 10.1161/01.ATV.9.2.203; DESPRES JP, 1989, DIABETES, V38, P304, DOI 10.2337/diabetes.38.3.304; DESPRES JP, 1994, BAILLIERE CLIN ENDOC, V8, P629, DOI 10.1016/S0950-351X(05)80289-7; DESPRES JP, 1990, ARTERIOSCLEROSIS, V10, P497, DOI 10.1161/01.ATV.10.4.497; ESCHWEGE E, 1985, HORM METAB RES, V15, P41; FONTBONNE A, 1994, DIABETOLOGIA, V37, P953, DOI 10.1007/s001250050203; FONTBONNE A, 1989, DIABETOLOGIA, V32, P300, DOI 10.1007/BF00265546; FONTBONNE A, 1991, DIABETOLOGIA, V34, P356, DOI 10.1007/BF00405009; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; HAFFNER SM, 1993, DIABETES, V42, P1297, DOI 10.2337/diabetes.42.9.1297; JUHANVAGUE I, 1991, DIABETOLOGIA, V34, P457, DOI 10.1007/BF00403280; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; LAMARCHE B, 1995, AM J CARDIOL, V75, P1189, DOI 10.1016/S0002-9149(99)80760-7; LAURELL CB, 1972, SCAND J CLIN LAB INV, V29, P21, DOI 10.3109/00365517209102748; LAWS A, 1992, J INTERN MED, V231, P25, DOI 10.1111/j.1365-2796.1992.tb00494.x; MARMOT MG, 1984, INT J EPIDEMIOL, V13, P160, DOI 10.1093/ije/13.2.160; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MOORJANI S, 1987, METABOLISM, V36, P244, DOI 10.1016/0026-0495(87)90183-1; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; ORCHARD TJ, 1983, AM J EPIDEMIOL, V118, P326, DOI 10.1093/oxfordjournals.aje.a113639; POULIOT MC, 1992, DIABETES, V41, P826, DOI 10.2337/diabetes.41.7.826; Pyorala K, 1979, Diabetes Care, V2, P131, DOI 10.2337/diacare.2.2.131; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; WINGARD DL, 1995, DIABETES CARE, V18, P1299, DOI 10.2337/diacare.18.9.1299; YARNELL JWG, 1994, BRIT HEART J, V171, P293; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	33	1401	1453	0	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1996	334	15					952	957		10.1056/NEJM199604113341504	http://dx.doi.org/10.1056/NEJM199604113341504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD596	8596596				2022-12-28	WOS:A1996UD59600004
J	Ham, C				Ham, C			Learning from the tigers: Stakeholder health care	LANCET			English	Article											Ham, C (corresponding author), UNIV BIRMINGHAM,HLTH SERV MANAGEMENT CTR,PK HOUSE,40 EDGBASTON PK RD,BIRMINGHAM B15 2RT,W MIDLANDS,ENGLAND.							HSIAO WC, 1995, HLTH AFFAIRS, P261; MASSARO T, 1995, HLTH AFFAIRS     SUM, P267; *MIN HLTH SING, 1994, ANN REP; *REP SING MIN COMM, 1993, AFF HLTH CAR WHIT PA	4	14	14	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1996	347	9006					951	953		10.1016/S0140-6736(96)91421-X	http://dx.doi.org/10.1016/S0140-6736(96)91421-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598763				2022-12-28	WOS:A1996UD59100016
J	Tabrizi, SJ; Scaravilli, F; Howard, RS; Collinge, J; Rossor, M				Tabrizi, SJ; Scaravilli, F; Howard, RS; Collinge, J; Rossor, M			Creutzfeldt-Jakob disease in a young woman	LANCET			English	Editorial Material							PRION PROTEIN GENE; FEATURES		ST THOMAS HOSP, GUYS & ST THOMAS HOSP TRUST, DEPT NEUROL, LONDON SE1 7EH, ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP, SCH MED, DEPT BIOCHEM & MOLEC GENET, LONDON W2 1PG, ENGLAND; ST MARYS HOSP, DEPT NEUROL, LONDON, ENGLAND; INST NEUROL, LONDON WC1N 3BG, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Imperial College London; Imperial College London; University of London; University College London			Rossor, Martin/C-1598-2008	Tabrizi, Sarah/0000-0003-2716-2045; Rossor, Martin/0000-0001-8215-3120				BATEMAN D, 1995, LANCET, V346, P1155, DOI 10.1016/S0140-6736(95)91828-0; BRITTON TC, 1995, LANCET, V346, P1155, DOI 10.1016/S0140-6736(95)91827-2; BROWN P, 1994, NEUROLOGY, V44, P291, DOI 10.1212/WNL.44.2.291; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; BROWN P, 1984, ANN NEUROL, V16, P295, DOI 10.1002/ana.410160305; BROWN P, 1986, ANN NEUROL, V20, P597, DOI 10.1002/ana.410200507; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; COLLINGE J, 1994, PHILOS T R SOC B, V343, P371, DOI 10.1098/rstb.1994.0031; COLLINGE J, 1992, BRAIN, V115, P687, DOI 10.1093/brain/115.3.687; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; COLLINGE J, 1995, NATURE, V378, P779, DOI 10.1038/378779a0; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; GOLDFARB LG, 1995, ANNU REV MED, V46, P57; HOROUPIA.DS, 1972, ARCH NEUROL-CHICAGO, V27, P555, DOI 10.1001/archneur.1972.00490180091018; OWEN F, 1990, AM J HUM GENET, V46, P1215; PALMER MS, 1993, HUM MUTAT, V2, P168, DOI 10.1002/humu.1380020303; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; Pattison I. H., 1965, NINDB MONOGRAPH, V2, P249; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1994, ANNU REV NEUROSCI, V17, P311, DOI 10.1146/annurev.ne.17.030194.001523; ROOS R, 1973, BRAIN, V96, P1; ROSSOR MN, 1995, J ROY COLL PHYS LOND, V29, P412; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; WILL RG, 1984, J NEUROL NEUROSUR PS, V47, P134, DOI 10.1136/jnnp.47.2.134	24	24	25	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	1996	347	9006					945	948		10.1016/S0140-6736(96)91419-1	http://dx.doi.org/10.1016/S0140-6736(96)91419-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598761				2022-12-28	WOS:A1996UD59100014
J	Baglin, T				Baglin, T			Fortnightly review - Disseminated intravascular coagulation: Diagnosis and treatment	BMJ-BRITISH MEDICAL JOURNAL			English	Review							COAGULOPATHY; MANAGEMENT; HEPARIN; TRIAL				Baglin, T (corresponding author), ADDENBROOKS NHS TRUST, DEPT HAEMATOL, CAMBRIDGE CB2 2QQ, ENGLAND.							ALPERIN JB, 1987, JAMA-J AM MED ASSOC, V258, P1916, DOI 10.1001/jama.258.14.1916; BELL WR, 1985, AM J MED, V79, P423, DOI 10.1016/0002-9343(85)90028-2; CARR JM, 1989, AM J CLIN PATHOL, V91, P280, DOI 10.1093/ajcp/91.3.280; COLMAN RW, 1974, NEW ENGL J MED, V291, P509, DOI 10.1056/NEJM197409052911008; COLMAN RW, 1972, AM J MED, V52, P679, DOI 10.1016/0002-9343(72)90058-7; ESMON CT, 1994, BAILLIERE CLIN HAEM, V7, P453, DOI 10.1016/S0950-3536(05)80093-9; FEINSTEIN DI, 1982, BLOOD, V60, P284; FOURRIER F, 1993, CHEST, V104, P882, DOI 10.1378/chest.104.3.882; GORDON SG, 1985, BLOOD, V66, P1261; HAMILTON KK, 1990, J BIOL CHEM, V265, P3809; HARPER PL, 1994, BRIT J HOSP MED, V52, P571; HEMKER HC, 1994, HAEMOSTASIS THROMBOS, V1, P477; HOYLE CF, 1988, BRIT J HAEMATOL, V68, P283, DOI 10.1111/j.1365-2141.1988.tb04204.x; KREGER BE, 1980, AM J MED, V68, P344, DOI 10.1016/0002-9343(80)90102-3; LATALLO ZS, 1983, THROMB HAEMOSTASIS, V50, P604; MANNUCCI PM, 1969, BLOOD-J HEMATOL, V33, P207, DOI 10.1182/blood.V33.2.207.207; MOMBELLI G, 1993, J LAB CLIN MED, V121, P83; OKAMURA T, 1993, ACTA HAEMATOL-BASEL, V90, P120, DOI 10.1159/000204391; RICHARDS EM, 1995, BRIT J HAEMATOL, V91, P445, DOI 10.1111/j.1365-2141.1995.tb05320.x; RODEGHIERO F, 1990, BLOOD, V75, P2112; SAITO M, 1995, BLOOD COAGUL FIBRIN, V6, P60, DOI 10.1097/00001721-199502000-00010; SIEGAL T, 1978, THROMB HAEMOSTASIS, V39, P122; SPERO JA, 1980, THROMB HAEMOSTASIS, V43, P28; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; VICTOR J., 1994, HEMOSTASIS THROMBOSI, P1023; WARR TA, 1990, BLOOD, V75, P1481; Williams E, 1994, THROMBOSIS HEMORRHAG, P921; WILLIAMS EC, 1989, ARCH INTERN MED, V149, P1769, DOI 10.1001/archinte.149.8.1769	28	82	85	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 16	1996	312	7032					683	687						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597738				2022-12-28	WOS:A1996UB11000031
J	Buchdahl, R; Parker, A; Stebbings, T; Babiker, A				Buchdahl, R; Parker, A; Stebbings, T; Babiker, A			Association between air pollution and acute childhood wheezy episodes: Prospective observational study	BRITISH MEDICAL JOURNAL			English	Article							LUNG-FUNCTION; ASTHMA; OZONE; CHILDREN; REGRESSION; EXPOSURES; BACTERIA; VIRUSES; VISITS	Objective-To examine the association between the air pollutants ozone, sulphur dioxide, and nitrogen dioxide and the incidence of acute childhood wheezy episodes. Design-Prospective observational study over one year. Setting-District general hospital. Subjects-1025 children attending the accident and emergency department with acute wheezy episodes; 4285 children with other conditions as the control group. Main outcome measures-Daily incidence of acute wheezy episodes. Results-After seasonal adjustment, day to day variations in daily average concentrations of ozone and sulphur dioxide were found to have significant associations with the incidence of acute wheezy episodes. The strongest association was with ozone, for which a non-linear U shaped relation was seen. In terms of the incidence rate ratio (1 at a mean 24 hour ozone concentration of 40 Alpha mu g/m(3) (SD=19.1)), children were more likely to attend when the concentration was two standard deviations below the mean (incidence rate ratio=3.01; 95% confidence interval 2.17 to 4.18) or two standard deviations above the mean (1.34; 1.09 to 1.66). Sulphur dioxide had a weaker log-linear relation with incidence (1.12; 1.05 to 1.19 for each standard deviation (14.1) increase in sulphur dioxide concentration). Further adjustment for temperature and wind speed did not significantly alter these associations. Conclusions-Independent of season, temperature, and wind speed, fluctuations in concentrations of atmospheric ozone and sulphur dioxide are strongly associated with patterns of attendance at accident and emergency departments for acute childhood wheezy episodes. A critical ozone concentration seems to exist in the atmosphere above or below which children are more likely to develop symptoms.	LONDON BOROUGH HILLINGDON, ENVIRONM PROTECT UNIT, UXBRIDGE UB8 1UN, MIDDX, ENGLAND; UCL, SCH MED, MRC, HIV CLIN TRIALS CTR, LONDON WC1E 6AU, ENGLAND	Medical Research Council Clinical Trials Unit; University of London; University College London; UCL Medical School	Buchdahl, R (corresponding author), HILLINGDON HOSP, UXBRIDGE UB8 3NN, MIDDX, ENGLAND.							ANDERSON HR, 1994, BRIT MED J, V308, P1600, DOI 10.1136/bmj.308.6944.1600; BATES DV, 1990, ENVIRON RES, V51, P51, DOI 10.1016/S0013-9351(05)80182-3; BRIDGMAN HA, 1990, GLOBAL AIR POLLUTION; BURLESON GR, 1975, APPL MICROBIOL, V29, P340, DOI 10.1128/AEM.29.3.340-344.1975; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; CODY RP, 1992, ENVIRON RES, V58, P184, DOI 10.1016/S0013-9351(05)80214-2; COX CS, 1989, SCI PROG, V73, P469; *DEP HLTH ADV GROU, 1991, 1 DEP HLTH ADV GROUP; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; GIRSH LS, 1967, J ALLERGY, V39, P347, DOI 10.1016/0021-8707(67)90047-0; GODLEE F, 1991, BRIT MED J, V303, P1539, DOI 10.1136/bmj.303.6816.1539; HIGGINS ITT, 1990, AM REV RESPIR DIS, V141, P1136, DOI 10.1164/ajrccm/141.5_Pt_1.1136; HYNDMAN SJ, 1994, BRIT MED J, V308, P1596, DOI 10.1136/bmj.308.6944.1596; KHOT A, 1984, BRIT MED J, V289, P235, DOI 10.1136/bmj.289.6439.235; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; PARTRIDGE RH, 1995, QU109 NAT PHYS LAB; PHELAN PD, 1994, BRIT MED J, V308, P1584, DOI 10.1136/bmj.308.6944.1584; READ C, 1991, AIR POLLUTION CHILD; RICHARDS W, 1981, ANN ALLERGY, V47, P348; ROSSI OVJ, 1993, THORAX, V48, P244, DOI 10.1136/thx.48.3.244; SCHWARTZ J, 1989, ENVIRON RES, V50, P309, DOI 10.1016/S0013-9351(89)80012-X; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; SOUKUP J, 1993, ENVIRON RES, V60, P178, DOI 10.1006/enrs.1993.1025; SPEKTOR DM, 1991, ENVIRON RES, V55, P107, DOI 10.1016/S0013-9351(05)80167-7; *STAT CORP, 1993, STAT REF MAN 3 1; TSENG RYM, 1990, ANN ALLERGY, V65, P379; VONZIEMSSEN H, 1875, CYCLOPAEDIA PRACTICE, V2; WALTERS S, 1994, THORAX, V49, P133, DOI 10.1136/thx.49.2.133	32	49	49	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					661	665						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597731				2022-12-28	WOS:A1996UB11000021
J	Christensen, JH; Gustenhoff, P; Korup, E; Aaroe, J; Toft, E; Moller, J; Rasmussen, K; Dyerberg, J; Schmidt, EB				Christensen, JH; Gustenhoff, P; Korup, E; Aaroe, J; Toft, E; Moller, J; Rasmussen, K; Dyerberg, J; Schmidt, EB			Effect of fish oil on heart rate variability in survivors of myocardial infarction: A double blind randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article											Christensen, JH (corresponding author), AALBORG HOSP, DEPT ENDOCRINOL, REBERBANSGADE, POB 561, DK-9100 AALBORG, DENMARK.							BURR ML, 1989, LANCET, V2, P757; CHARNOCK JS, 1994, PROG LIPID RES, V33, P355, DOI 10.1016/0163-7827(94)90023-X; DYERBERG J, 1978, LANCET, V2, P117, DOI 10.1016/s0140-6736(78)91505-2; STEIN PK, 1994, AM HEART J, V127, P1376, DOI 10.1016/0002-8703(94)90059-0; Vanravenswaaijarts CMA, 1993, ANN INTERN MED, V118, P436, DOI 10.7326/0003-4819-118-6-199303150-00008	5	185	253	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 16	1996	312	7032					677	678						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597736	Green Published			2022-12-28	WOS:A1996UB11000027
J	Nantel, F; Monaco, L; Foulkes, NS; Masquilier, D; LeMeur, M; Henriksen, K; Dierich, A; Parvinen, M; SassoneCorsi, P				Nantel, F; Monaco, L; Foulkes, NS; Masquilier, D; LeMeur, M; Henriksen, K; Dierich, A; Parvinen, M; SassoneCorsi, P			Spermiogenesis deficiency and germ-cell apoptosis in CREM-mutant mice	NATURE			English	Article							NUCLEOTIDE-SEQUENCE; MOUSE PROTAMINE-1; PROTEIN; SPERMATOGENESIS; TRANSCRIPTION; EXPRESSION; ACTIVATOR; DIRECTS; SWITCH; GENES	Spermiogenesis is a complex process by which postmeiotic male germ cells differentiate into mature spermatozoa. This process involves remarkable structural and biochemical changes including nuclear DNA compaction and acrosome formation(1,2). Transcriptional activator CREM (cyclic AMP-responsive element modulator) is highly expressed in postmeiotic cells(3-5), and CREM may be responsible for the activation of several haploid germ cell-specific genes involved in the structuring of the spermatozoon(5-7). The specific role of CREM in spermiogenesis was addressed using CREM-mutant mice generated by homologous recombination. Analysis of the seminiferous epithelium in mutant male mice reveals postmeiotic arrest at the first step of spermiogenesis. Late spermatids are completely absent, and there is a significant increase in apoptotic germ cells. We show that CREM deficiency results in the lack of postmeiotic cell-specific gene expression. The complete lack of spermatozoa in the mutant mice is reminiscent of cases of human infertility.	INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE; TURKU UNIV,DEPT ANAT,SF-20520 TURKU,FINLAND	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Turku			Foulkes, Nicholas S/K-7003-2013; Monaco, Lucia/A-4031-2010	Foulkes, Nicholas S/0000-0002-1794-9891; 				BABA T, 1994, J BIOL CHEM, V269, P10133; CHAGANTI RSK, 1979, AM J HUM GENET, V31, P634; CHEVRIER P, 1988, EMBO J, V7, P29; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; HENRIKSEN K, 1995, INT J ANDROL, V18, P256, DOI 10.1111/ijan.1995.18.5.256; HENRIKSEN K, 1995, ENDOCRINOLOGY, V136, P3285, DOI 10.1210/en.136.8.3285; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; KISTLER MK, 1994, BIOL REPROD, V51, P1322, DOI 10.1095/biolreprod51.6.1322; KLEENE KC, 1985, BIOCHEMISTRY-US, V24, P719, DOI 10.1021/bi00324a027; KLEENE KC, 1988, BIOCHIM BIOPHYS ACTA, V950, P215, DOI 10.1016/0167-4781(88)90013-9; KLEENE KC, 1987, J BIOL CHEM, V262, P17272; LALLI E, 1994, J BIOL CHEM, V269, P17356; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; MICIC M, 1992, HUM REPROD, V7, P1118, DOI 10.1093/oxfordjournals.humrep.a137804; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; OAKBERG EF, 1956, AM J ANAT, V99, P507, DOI 10.1002/aja.1000990307; PARVINEN M, 1981, HISTOCHEMISTRY, V71, P567, DOI 10.1007/BF00508382; PARVINEN M, 1982, ENDOCR REV, V3, P404, DOI 10.1210/edrv-3-4-404; PEREY B, 1961, AM J ANAT, V108, P47, DOI 10.1002/aja.1001080105; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Rubin M R, 1991, DNA Seq, V1, P329, DOI 10.3109/10425179109020787; Santen R. J., 1987, ENDOCRINOL METAB, P821; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418	30	477	494	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					159	162		10.1038/380159a0	http://dx.doi.org/10.1038/380159a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600390				2022-12-28	WOS:A1996TZ97800051
J	Northridge, D				Northridge, D			Frusemide or nitrates for acute heart failure?	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; FUROSEMIDE; RESPONSES; THERAPY; VOLUME				Northridge, D (corresponding author), WESTERN GEN HOSP,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BAYLISS J, 1987, BRIT HEART J, V57, P17; BIAGI RW, 1967, LANCET, V1, P849; BRAUNWALD E, 1994, AM HEART J, V72, pS68; CHATTERJEE K, 1973, CIRCULATION, V48, P1183, DOI 10.1161/01.CIR.48.6.1183; DIKSHIT K, 1973, NEW ENGL J MED, V288, P1087, DOI 10.1056/NEJM197305242882102; FRANCIOSA JA, 1982, CLIN PHARMACOL THER, V32, P62, DOI 10.1038/clpt.1982.127; FRANCIS GS, 1985, ANN INTERN MED, V103, P1, DOI 10.7326/0003-4819-103-1-1; Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico, 1994, LANCET, V343, P1115; Hampton J. R., 1994, British Heart Journal, V72, pS68; IKRAM H, 1980, CLIN SCI, V59, P443, DOI 10.1042/cs0590443; JOHNSTON GD, 1983, CIRC RES, V53, P630, DOI 10.1161/01.RES.53.5.630; KIELY J, 1973, CIRCULATION, V48, P581, DOI 10.1161/01.CIR.48.3.581; Kruck F, 1991, Drugs, V41 Suppl 3, P60; LAL S, 1969, BRIT HEART J, V31, P711; LARSEN FF, 1988, EUR HEART J, V9, P125, DOI 10.1093/oxfordjournals.eurheartj.a062465; MOND H, 1974, BRIT HEART J, V36, P44; NELSON GIC, 1983, LANCET, V1, P730; NELSON GIC, 1983, EUR HEART J, V4, P706, DOI 10.1093/oxfordjournals.eurheartj.a061382; NISHIMURA M, 1981, CRIT CARE MED, V9, P829; VALETTE H, 1983, EUR J CLIN PHARMACOL, V24, P163, DOI 10.1007/BF00613811; VERMA SP, 1987, BRIT J CLIN PHARMACO, V24, P21, DOI 10.1111/j.1365-2125.1987.tb03131.x	21	25	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					667	668		10.1016/S0140-6736(96)91209-X	http://dx.doi.org/10.1016/S0140-6736(96)91209-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596385				2022-12-28	WOS:A1996TZ28500017
J	Stensvold, I; Tverdal, A; Jacobsen, BK				Stensvold, I; Tverdal, A; Jacobsen, BK			Cohort study of coffee intake and death from coronary heart disease over 12 years	BRITISH MEDICAL JOURNAL			English	Article							BOILED COFFEE		UNIV TROMSO,INST COMMUNITY MED,TROMSO,NORWAY	UiT The Arctic University of Tromso	Stensvold, I (corresponding author), NATL HLTH SCREENING SERV,POB 8155,N-0033 OSLO,NORWAY.			Tverdal, Aage/0000-0002-2909-5678				AHOLA I, 1991, J INTERN MED, V230, P293, DOI 10.1111/j.1365-2796.1991.tb00447.x; GREENLAND S, 1993, EPIDEMIOLOGY, V4, P366, DOI 10.1097/00001648-199307000-00013; KAWACHI I, 1994, BRIT HEART J, V72, P269; TVERDAL A, 1990, BRIT MED J, V300, P566, DOI 10.1136/bmj.300.6724.566; ZOCK PL, 1990, LANCET, V335, P1235, DOI 10.1016/0140-6736(90)91302-Q	5	28	28	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					544	545		10.1136/bmj.312.7030.544	http://dx.doi.org/10.1136/bmj.312.7030.544			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595285	Green Published			2022-12-28	WOS:A1996TY88500025
J	Desai, CJ; Gindhart, JG; Goldstein, LSB; Zinn, K				Desai, CJ; Gindhart, JG; Goldstein, LSB; Zinn, K			Receptor tyrosine phosphatases are required for motor axon guidance in the Drosophila embryo	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; P ELEMENTS; KINASE; TRANSPOSITION; CLONING; NEURONS; SUBSET; GENES; CNS	The receptor tyrosine phosphatases DPTP69D and DPTP99A are expressed on motor axons in Drosophila embryos. In mutant embryos lacking DPTP69D protein, motor neuron growth cones stop growing before reaching their muscle targets, or follow incorrect pathways that bypass these muscles. Mutant embryos lacking DPTP99A are indistinguishable from wild type. Motor axon defects in dptp69D dptp99A double mutant embryos, however, are much more severe than in embryos lacking only DPTP69D. Our results demonstrate that DPTP69D and DPTP99A are required for motor axon guidance and that they have partially redundant functions during development of the neuromuscular system.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,DIV CELLULAR & MOLEC MED,DEPT PHARMACOL,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego	Desai, CJ (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.				NIGMS NIH HHS [GM35252] Funding Source: Medline; NINDS NIH HHS [NS28182] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028182] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BATE M, 1995, NEURON, V15, P513, DOI 10.1016/0896-6273(95)90141-8; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; DALBY B, 1995, GENETICS, V139, P757; DESAI CJ, 1994, J NEUROSCI, V14, P7272; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FITZPATRICK KA, 1995, MECH DEVELOP, V53, P171, DOI 10.1016/0925-4773(95)00432-Z; GAUGER AK, 1993, J BIOL CHEM, V268, P13657; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; HALPERN ME, 1991, J NEUROSCI, V11, P3227; HAMILTON BA, 1995, ROUX ARCH DEV BIOL, V204, P187, DOI 10.1007/BF00241271; HAMILTON BA, 1994, DROSOPHILA MELANOGAS, P81; HARIHARAN IK, 1991, P NATL ACAD SCI USA, V88, P11266, DOI 10.1073/pnas.88.24.11266; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; KRUEGER NX, 1996, CELL, V84; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LITTLETON JT, 1993, CELL, V74, P1124; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PATEL NH, 1994, DROSOPHILA MELANOGAS, P446; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SINK H, 1991, DEVELOPMENT, V112, P307; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STOKER AW, 1995, DEVELOPMENT, V121, P1833; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TOWER J, 1993, GENETICS, V133, P347; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; Zinn Kai, 1993, Seminars in Cell Biology, V4, P397, DOI 10.1006/scel.1993.1047	36	252	255	1	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					599	609		10.1016/S0092-8674(00)81035-1	http://dx.doi.org/10.1016/S0092-8674(00)81035-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598046	Bronze			2022-12-28	WOS:A1996TX17600012
J	Hurt, EC				Hurt, EC			Importins/karyopherins meet nucleoporins	CELL			English	Editorial Material							NUCLEAR-PORE COMPLEX; SACCHAROMYCES-CEREVISIAE; PROTEIN IMPORT; TRANSPORT; INVITRO; SEARCH				Hurt, EC (corresponding author), UNIV HEIDELBERG,INST BIOCHEM 1,NEUENHEIMER FELD 328,D-69120 HEIDELBERG,GERMANY.		Ed Hurt, Dr./AAE-8874-2019	Ed Hurt, Dr./0000-0002-4535-8255				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Aitchison JD, 1995, J CELL BIOL, V131, P1659, DOI 10.1083/jcb.131.6.1659; AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DOYE V, 1995, TRENDS GENET, V11, P193; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; JARNIK M, 1991, J STRUCT BIOL, V107, P291, DOI 10.1016/1047-8477(91)90054-Z; KADOWAKI T, 1992, P NATL ACAD SCI USA, V89, P2312, DOI 10.1073/pnas.89.6.2312; MEIER E, 1995, J CELL BIOL, V129, P1459, DOI 10.1083/jcb.129.6.1459; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; ROUT MP, 1993, J CELL BIOL, V123, P771, DOI 10.1083/jcb.123.4.771; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; ULLMAN KS, 1995, MOL CELL BIOL, V15, P4873; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WILKEN N, 1995, EUR J CELL BIOL, V68, P211; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Xue Zhixiong, 1994, Trends in Cell Biology, V4, P414, DOI 10.1016/0962-8924(94)90095-7; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	39	25	25	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					509	515		10.1016/S0092-8674(00)81026-0	http://dx.doi.org/10.1016/S0092-8674(00)81026-0			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598038	Bronze			2022-12-28	WOS:A1996TX17600004
J	Johnson, AE; Gordon, C; Hobbs, FDR; Bacon, PA				Johnson, AE; Gordon, C; Hobbs, FDR; Bacon, PA			Undiagnosed systemic lupus erythematosus in the community	LANCET			English	Article							POPULATION	Background Systemic lupus erythematosus (SLE) produces a wide range of symptoms, some of them mild; therefore it may be underdiagnosed. In a pilot study we tested the ability of a screening questionnaire to identify undiagnosed cases in the community. Methods A 10-item questionnaire was mailed to 3500 women aged 18-65 randomly selected from a general practice list in Birmingham, UK. A random sample of 300 non-respondents were sent two further mailings, Women returning the questionnaire with three positive answers were to attend for an antinuclear antibody (ANA) test; and those testing positive were to be referred to a rheumatologist for standard clinical assessment. Findings 1153 (30%) of the women responded, and 307 of these gave three or more positive answers on the questionnaire, The survey disclosed three women with previously undiagnosed SLE; and, in addition, it picked up all four of the women whose SLE had been diagnosed previously. Interpretation The prevalence of SLE revealed by this survey in Birmingham women is 200/100 000 (95% confidence interval 80 to 412), whereas the prevalence of diagnosed SLE in this age group is 54/100 000 (95% CI 47-62). Thus, a substantial number of undiagnosed cases exist, and further work needs to focus on the prevalence in different ethnic groups and the benefits of early diagnosis and treatment.	UNIV BIRMINGHAM,FAC MED & DENT,DEPT RHEUMATOL,BIRMINGHAM,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,FAC MED & DENT,DEPT GEN PRACTICE,BIRMINGHAM,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham				hobbs, richard/0000-0001-7976-7172; Gordon, Caroline/0000-0002-1244-6443				Balarajan R, 1991, Health Trends, V23, P90; CHANG NC, 1983, J RHEUMATOL, V10, P41; CHOU CT, 1986, J RHEUMATOL, V13, P806; HAYNES RB, 1988, CAN MED ASSOC J, V124, P703; HOCHBERG MC, 1983, CLIN EXP RHEUMATOL, V1, P67; JOHNSON AE, 1995, ARTHRITIS RHEUM, V38, P551, DOI 10.1002/art.1780380415; JOHNSON AE, 1993, BRIT J RHEUMATOL, V32, P30; LIANG MH, 1980, ARTHRITIS RHEUM-US, V23, P153, DOI 10.1002/art.1780230204; MCINNES PM, 1994, ARTHRITIS RHEUM, V37, P1000, DOI 10.1002/art.1780370704; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101	10	45	46	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					367	369		10.1016/S0140-6736(96)90539-5	http://dx.doi.org/10.1016/S0140-6736(96)90539-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598703				2022-12-28	WOS:A1996TU69500011
J	Dickson, D				Dickson, D			... as ethics report clears xenografts	NATURE			English	News Item																			0	2	2	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					6	6						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598904				2022-12-28	WOS:A1996TY87700011
J	Dickson, D				Dickson, D			Britain may set up genetics advisory body ...	NATURE			English	News Item																		1996, NATURE, V379, P195	1	2	2	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					6	6						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598904				2022-12-28	WOS:A1996TY87700010
